<SEC-DOCUMENT>0001558370-24-003161.txt : 20240314
<SEC-HEADER>0001558370-24-003161.hdr.sgml : 20240314
<ACCEPTANCE-DATETIME>20240314070311
ACCESSION NUMBER:		0001558370-24-003161
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240314
DATE AS OF CHANGE:		20240314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		24747895

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>plx-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:plx="http://www.protalix.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" xs:nil="true" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_OpKEeYznFEKbgT9Kjt0XEg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" xs:nil="true" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_V_gQmWVwdkeibqOYS8aNww"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityCentralIndexKey" id="Tc_7GU4zUGp-kq0GCi9ny_hRQ_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:CurrentFiscalYearEndDate" id="Tc_z-cwl7ehlk6oy6m3dNTBiw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:DocumentFiscalYearFocus" id="Tc_InmwRDTt_UK6YEzUdHKfjw_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:DocumentFiscalPeriodFocus" id="Tc_qMskS9TJVE-lOo17bm2ryg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:AmendmentFlag" id="Tc_lMaB9GvyH0OSPDZ8tyRe7Q_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_ZD3tFDQGbkK4hFZHJfpYSQ">72952124</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_KfS7JDB3k06YGo1S5puwCg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_8ZPqFDiPQU29lutivXBeTw">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_7_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_vB9y4DT3xkGRfePGVkNqMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gcdiHe0OrkaRgPsieHDsIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-07</xbrli:startDate><xbrli:endDate>2021-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2021_To_2_17_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RTfbrWi6qkSb5DrbSpC38w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-17</xbrli:startDate><xbrli:endDate>2021-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KoWXKKVDCUWPZuUT1WTDdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whY022XGs0KlMAyNJFGWMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U3XBnkC7qEm6XPK7cp3CoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sJB3yn3mr0CwfBJ5isgHEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1TbW1rn7nUeqCRQw6xQlRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eyEfL7MvJkeQsA4M6v4ywA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HElXUIExK0aOC5Db-v7aeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SjXBySsIy0OVSVIytRlcHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EvqBctZ660eMWfEw45p_Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2lHvWBXaM0q4Oy29CWa4tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oMdnHc9qbkOrXZVbmGVf1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A-V99KoI40mufi3_2xy4zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2021_CVbxW9emMEyG2cHIMoZs5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_LrNNiJqQIkSf1ulC8PfLpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69To5.60Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_1p-co_pHGEWdS066RgFFvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55To3.73Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_9pTD0HcQLEO_MTuojw_G6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_4fFw3SaWjU-j0D-jbfOafA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.03To2.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69To5.60Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55To3.73Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_Z5ILinr5pki5oFoOTXqaOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.03To2.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N8BFMU2rM0W5-sfr4UsdRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_-Wf9gnqOa0O0OwdXouHwAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YMVeyD2j70y4VdJ42iD_fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Jd93bicWJk-u0ptZ1qcGrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_rJLQx2leAEWZ1CL6p85CcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_upSNdbkvUk60NSUBUbvSBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YujFqI1i2U-sAYFqgp2Lmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_dzHxfLYBE0qT2A92CcAQaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_KfS7JDB3k06YGo1S5puwCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_NF1mOzE5nku6qIeb4j6l4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_0fEP6-_4Uk2cQqZDJ9ix_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_04wyWQKORk-L7RWyITxn_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_sDnT6zVWrUuhi2kasN2_WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Fqn4nOxM00S03kAdCXfsqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_weEzKGUPDUudnECpvmaZ4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_W_ciO9dfwEyGfy9D31WFzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_FCBox10Ye0O87jYJEc-ybw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dFI_S2Cmw0uvW76jwBJ16Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_FK1NoKYDfkC6DWFfd-k4ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_5MUpU_iFQUS9Zerkh9wIMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_aTbJ73vbwU-Xj9MZr0N5Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pFUzP2PhrEGGo1GT6PZxWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kkqXot9cn0WBAMEZIGa-PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_1gt-ZUM87U6djr_4A5S4_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_siXWryuQpU285WNgy45APw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_UjTGHkbY20CN6fqj_cqXNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_e9UvRO3aE0mfSCcsC-dTvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U-GkrbLvEEer06wV3cdFkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_IzrnD5jt5UGo5H0UZZIy6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-29</xbrli:startDate><xbrli:endDate>2021-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b6xXIxG3uUumtk0da2OG_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vv13STm1FEiXvwnu0lUpEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_H8gaQjdU40-YdEqUm0lstA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bJsWGX3NvUKW3gZlGPknpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_6DVEbvAY4UqBUIIBPTkpNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_8yYtim8BTk2lBe258_oMnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_K8BonSjLn02SgJ1mtQ59Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7N3JOpLANkCpswk4FsO4uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_WRnbeAQqwEefX40snBbQkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_x3Te36hAu0S8PmYz5LK19g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Upra0nCWlkODQtvrYRKqGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_bgO50fNA_kW_vKYNh3YVMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_zYIwEllr5UaT82dnyTwL4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oUGb2yHFvkmftb5K_Hd41w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rB-wUzmla0SlVO0p8Yda1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rhLqZfwsikKgSa9TtspiSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ssnGYhUhj0KL7KcjrJIBKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_qEwfUVZLKEeMlUabO-wb4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2021_To_2_17_2021_SJuIvsv5bUOxBNrdkJQFqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-17</xbrli:startDate><xbrli:endDate>2021-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_8C7y4du30EGx7NNV_qKuMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_EyG0dq2VUECJScHNcRo4pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_vtfaP8TfsEyMcbIsM1oBkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_HOk8TyvPSkmZaIMc922oBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_u3-UCxFuAUOj3iNBJvmi2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_rYb5LIKYEU-DUI4F45twMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_Uh0a4pl7bU-2Tnjx_lqtJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_o34DNclg302qjFkTJ9TCVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_96dVppJwckClqojVBy1Ycw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_YBmOU2lAJUOBzWtk50UFrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g52wVaMHREOxVOaAH1rbeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lwt4ua-FPk6WAW-XMj40PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wHGv4XDWOkqx4oPOB_i_5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_eAbAHtoxYkGir02r071VSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_6gBeWpquBkO5DzLdfEEOMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_VZDiVAJYeUq_J3J-EliWwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qMG5qS3iLEyHdybWijdG5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_C5zBNMbhSkObSb6Xa-cZ3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_SkKeGJpZk0ix9VIXIl82bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_OISz_geoOEqDePVi3rhqJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_Rc3FfJee6ka0ZRjX--HI1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_XzqK5SZYk0uC0x8Ph1LJBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_jJGc7jy940K8Qw9jBJ_iPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_iZ27SMRREEmvpe0JdqEXIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_4iW3B1WCqECY6mC8PZcRJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementLifeInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_4ij6hzi0rkmx1gwIssCBgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">plx:ContributionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_3I09XpnwBUK1eNxQSTeoEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_XwrlUpDhVkulphV17M8Jmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_251HtAiKnEG6Q7qnPV5dYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_wE9yb5vMiUiXD8b4zFAFDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_QVm3W7ty10eUY0pOqxsecQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5BUHKipIbUSYH07fhT7fxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3ifThMNCrkuKLL1kdLaJ9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_BZLsajDjiEe6-0mciWg6Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_sNa-abEf9kq7MgbpeppqKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_YD_U8HfQWUOjf8ZrXymgNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_57ZK5w5WGUyALypMdLvZ_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_a9FL0cjM4UWj0kWAe34-9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_2IMzGamN40K0qlSWNrY3Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WlO3JuHosU66SIYEqogVsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_CON_DW57J06LCucDdq1I-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_iAqmHavoc0y6aGWMensHBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rTPd6I7xUkGiNNPDC-sQZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u1l6Q7eIvEKTQP9MPBmN9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_RSywV91c8EyVXNBMXvKebA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dFp5G0LNJUya7KtQK3pNQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2023_tpab9C7-pEeEaYxfCF7NUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_24_2023_JDfUxPdHikKEo3CybT518w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_D3oeVDNTUUiUr-_FfN-zLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1Yw2nKGMb0-CWAUOtRv76w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_BND5mOCuk0aUwO4j88CGJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_eCN7L55gSkWPyF5sZKKtCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_p8gLt_bw0EKb2iCn7NXpJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_sxPvfKZ4_E6nZxOZsSDnVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_A6SB-KSPHUOpgmPJyNMoXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_3JYAY1fui0OUhP6pQk-C8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5Lw9SAW0v0e805cbfkLdFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Pg3HBbrQE0O-vf2piO-deg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_4cbqNYW9bkqJeKPztiOARQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_VhZ8eBzgxUiYQec9RnyolA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7jCMuUnJUkiYu615rQJzSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_nUUou62YI0uMyf3Ceo-SDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Wq2H6c6tw0WzLJeQe0xOnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_pPMvRU8ZMk2uuux3HO2TYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_G-5RnTikyEe9kMD0HS9VgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_b5QnVZ12wk6qJy-jCttpIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_sjRoIJCFyUScH2Tf8mBsdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_fA3_XWjL2kiVo9BcdeEmJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_PfizerMember_p6MbltwMMEWI2aMxFJC3uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_rEiciTruOUm2wOSIAx_19Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_ChiesiMember_JefjA3XnO0-mFmgSL6r5WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I7HBPUkpYkG4hv_N2994ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nJOVwAxjsk22aPDfa4pnSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_XwwI97cnr0imfvHx08Av8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y7utRnms1UOqtqZVB3Km0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_46WI__Tnm0OEDK5uErsfzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZMEMUOBNoUyTMPRQ3bJFUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_GvuRJaXm1UWlbfDR82Bxug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_4-jgrc8-u0GNmkLJxYHkRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_QWELD20hJUCp7BaaLVXfkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_nqKCRd69hEOEP6D4HvRrJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuM681TIWk-KXTzBvFq0cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_w5_kliyzhkCBaXvHO4GYkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_T3JAfM2fWECmvcQSRXd74g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_LrxACSzPi0yrQT4i01lIRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_vr63tArlm0-q0bAYY5jS7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_MJT48I74nkqfkLgGf8DWVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_YYAL7Hdl_U-pTxkWB5nOeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iyt1XR_TI0OMpk9KrJ5mlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_ssAFEpgqrkqUmuHATgmJXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_T8vMq4SkD0iHfguhY8hxzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_MGXDBj87K0SGVdw9QsCN6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_vo-_yyTgdUqcdD8bTMOyuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_DxZ7yiKloEeYPqjWugRpiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_KSEwWosZJU6bgW9NBu3j-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_21_2023_MSmaAEySeUOElBXVq6cGkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_p6jVivnBs0mBGLiQhyt5oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0jdO8xpKLUGP05OvtmHFoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_wxdHXaWGJUe-pHkKaGr9qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_IoUaetkJx0G8wYJ_o32Cpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-29</xbrli:startDate><xbrli:endDate>2022-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I6KOw7CYo0-cs1kRCGYA5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-29</xbrli:startDate><xbrli:endDate>2022-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7tsfGy4RVUWLVfK_0YWXpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-25</xbrli:startDate><xbrli:endDate>2021-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CPzVDrt_wUy8VbkR5mm3YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_yi4pzduSA0iPeEkKzhrW3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_BusinessDevelopmentConsultantMember_yVKHJHqyLk-Kh4whSboFgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:BusinessDevelopmentConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ymHVK27wsk-xnzEuafVJJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_U62DmPC_4E27mSZiUh7v1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YTSB_ILxnkmbVEy0yW3LuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_eJ-H8KcFkESIM5aPrjQhMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5MEdadDSM0SF5R2b_ZDHTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_pZvuo2NuB0adTw1Fuq0XEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2024_JH8KKO0890u2Q8I5mpLHzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_5yXfmzhLaEC9tEJVIkFchA"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_hWE00M5FlEez7fUfIQ-eZg"><xbrli:measure>plx:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_hZumu6sr7UyT0mvTxrhElw"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q"><xbrli:measure>plx:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_EpjUeGM08kCkStcWvhYgyg"><xbrli:measure>plx:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_LtAR6Q5w6kqJ8CT_46DuZA"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_eeb79153_e86a_4b49_8094_ea881bd9bf4b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:DocumentType" id="Narr_RW89Mir6n0mz11Dd4IZuvA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><a id="_d3cfb9af_6096_4d8c_be73_3670c88bd207"></a><a id="Tc_8dR_jfpoZ0-bjzPYecW4cg_1_2"></a><a id="Tc_hUh6eddr206DP3UG5vFSpQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:DocumentAnnualReport" id="Tc_wZFXYU2HdkGUrSURuz6zgg_1_1"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:DocumentPeriodEndDate" id="Narr_cZc0ntATQE2obdGSt6QRPQ"><b style="font-size:7pt;font-weight:bold;">December&#160;31, 2023</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_363c4b72_8c99_4fe4_8cf1_fef7ba3a7dcb"></a><a id="Tc_XqjpP5OmJUSKyMmMUx021A_1_2"></a><a id="Tc_gZHxdSzz5UC8jX5cTX8rYg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:DocumentTransitionReport" id="Tc__M7dixhhn0eSTFYiAfCH1Q_1_1"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;"> </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityFileNumber" id="Narr_yeB201uaQEeY7WQyY7VrpA"><b style="font-size:7pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityRegistrantName" id="Narr_kObjhsCvhEeycWMReGnKbg"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a6c241f7_1ec8_4187_a30c_8be39e61aefa"></a><a id="Tc_6Pb958Ent02TkiQMIECL7A_2_0"></a><a id="Tc_y17Nr30akU2TXB5UO1C3Tg_2_1"></a><a id="Tc_W0qsBaAUpkGHG1g6ASyeFw_4_0"></a><a id="Tc_5ZYvyDbZ9EmJL8qDLocvKg_6_0"></a><a id="Tc_Dfv2yUpyQkmiRdCkeR7i3g_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.51%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityIncorporationStateCountryCode" id="Tc_tEJRTPcEN0OFV2q3F6zq2A_1_0"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityTaxIdentificationNumber" id="Tc_nBbbX1AK_UC7SVzWzSb_iQ_1_1"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization</b></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:middle;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityAddressAddressLine1" id="Narr_Fm8BwX3TG0ieljEHFl9zKA"><b style="font-size:7pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityAddressAddressLine2" id="Narr_qiYduSWNeUyBg7BZwwvSog"><b style="font-size:7pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityAddressCityOrTown" id="Narr_uLBjY25G70m_7S08M1nARA"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityAddressStateOrProvince" id="Narr_zvfoPaEzOkuUclz6JeLFqQ"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityAddressPostalZipCode" id="Tc_vrnSGa0HXEO8KCHNA0BbgQ_4_1"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:CityAreaCode" id="Narr_L-ZiQLDr00Cm7s5neiVLIg"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:LocalPhoneNumber" id="Narr_AWJoKHRmOUeAkE4bvB-Qmw"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_6ead232e_1582_40d9_b92c_15f6a55d95c5"></a><a id="Tc_yzqOXx64gk-mXB8rMZp2Ew_0_0"></a><a id="Tc_cn03XvK53E-8yQb0uBs3mw_0_2"></a><a id="Tc_MjHgs8AS1E2ACZhv_lfo5g_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:29.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:top;width:2.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:36.34%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:1.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:29.49%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:29.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:Security12bTitle" id="Tc_xdX5xLUVOEqyWDw7wDLKAg_1_0"><span style="font-size:7pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.34%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:TradingSymbol" id="Tc_mkEn8JqG_0y5r4he0xf8wQ_1_2"><span style="font-size:7pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.49%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:SecurityExchangeName" id="Tc_yQurpyev0ECM0g9bh0CNQg_1_4"><span style="font-size:7pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_GlCR980F1USaljEfYxRD9Q"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityVoluntaryFilers" id="Narr_Ciaiug8xNU-O6it0Aae_Hg"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityCurrentReportingStatus" id="Narr_i4OrfMutNkuNB0x61mjcgQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityInteractiveDataCurrent" id="Narr_kpxX3q234kK2nS64laq8_A"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_69b1fb3e_fd77_4713_8a3b_720977774d44"></a><a id="Tc_hxY3glvbcku1O9CKUdMnaQ_1_0"></a><a id="Tc_83SGGToSPEatekykjeHGjw_1_1"></a><a id="Tc_bcXhBDfXOUOpKuoexEJRXQ_1_2"></a><a id="Tc_qGkH4RbCZkmPacg13Vsf8w_1_3"></a><a id="Tc_FbRX0uJ0M0KoPKhthjdrfA_2_1"></a><a id="Tc_uiGlvaojuUu7OaHZll6iPg_2_2"></a><a id="Tc_-wZGqzz1BUSINvtpCf1jwg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityFilerCategory" id="Tc_2dCLZK4vs0yN6DtXDuzR2g_2_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntitySmallBusiness" id="Tc_GzpjK7eMREm-_MnhhV3TiQ_2_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityEmergingGrowthCompany" id="Tc_r1nWpqRsU0Ki94ClOluOww_3_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:IcfrAuditorAttestationFlag" id="Narr_ILk5fn1Ssky9axt5s7NObw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_WcPMnVeDHk6kPRHBQB80Ow"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="white-space:pre-wrap;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:EntityShellCompany" id="Narr_2BIxCQhv8E27zx0aYh_fKg"><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">The aggregate market value of the voting common stock held by non-affiliates of the Registrant as of June&#160;30, 2023 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2023_pZvuo2NuB0adTw1Fuq0XEQ" decimals="-5" name="dei:EntityPublicFloat" id="Narr_wynfjtxW1kSShqmB4kd1tQ">139.3</ix:nonFraction>&#160;million, based on the closing price for shares of the Registrant&#8217;s common stock reported by the NYSE American for such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt;">On March 1, 2024, approximately <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_1_2024_JH8KKO0890u2Q8I5mpLHzw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_oJcZgTII9UuHSmssmyTVwQ">73,052,124</ix:nonFraction> shares of the Registrant&#8217;s common stock, par value $0.001 per share, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 2pt 0pt;">Portions of the registrant&#8217;s proxy statement related to its 2024 Annual Stockholders&#8217; Meeting to be filed subsequently are incorporated by reference into Part III of this Annual Report on Form 10-K. Except as expressly incorporated by reference, the registrant&#8217;s proxy statement shall not be deemed to be part of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:36pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ef4577d9_75ab_4582_b50b_02eb3f98d26b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">2023 FORM&#160;10-K ANNUAL REPORT</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#CAUTIONARY_STATEMENT_REGARDING_FORWARD"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a><b style="font-weight:bold;"> </b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CAUTIONARY_STATEMENT_REGARDING_FORWARD"><span style="font-style:normal;font-weight:normal;">Cautionary Statement Regarding Forward-Looking Statements</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_89253"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_89253"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_626044"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_626044"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Item&#160;1C.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_907582"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_907582"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_932888"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_932888"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_147620"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_147620"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII_453527"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_730194"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_730194"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_882944"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_882944"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII_463758"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_376320"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_376320"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIV_377623"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_450405"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_450405"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_579077"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f1c3332e_b596_4f59_ad76_abf8fea6ae17"></a><a id="PARTI_803173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PART&#160;I</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Except where the context otherwise requires, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or &#8220;the Company,&#8221; refer to the business of Protalix BioTherapeutics,&#160;Inc. and its consolidated subsidiaries, and &#8220;Protalix&#8221; or &#8220;Protalix&#160;Ltd.&#8221; refers to the business of Protalix&#160;Ltd., our wholly-owned subsidiary and sole operating unit.</i></p><a id="S1_002"></a><a id="CAUTIONARY_STATEMENT_REGARDING_FORWARD"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The statements set forth under the sections entitled &#8220;Business,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Risk Factors,&#8221; and other statements included elsewhere in this Annual Report on Form&#160;10-K, particularly with respect to our plans and strategy for our business and related financing, include forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words or phrases of similar import, as they relate to our company, our subsidiaries or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the U.S.&#160;Food and Drug Administration, or FDA, approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible disruption of our operations due to the war declared by Israel&#8217;s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the potential commercial value of our products and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, European Medicines Agency, or EMA, or other health regulatory authorities for our other product candidates, and other risks relating to the review process;</div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents and short-term bank deposits;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, top-line or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Funda&#231;&#227;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These and other risks and uncertainties are detailed under the &#8220;<a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a>&#8221; section of this Annual Report and are described from time to time in the reports we file with the U.S.&#160;Securities and Exchange Commission, or the Commission.</p><a id="_bcd062e3_f970_45f4_84cd_09804ad52a9c"></a><a id="Item1Business_89253"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;1.</b></span>Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a commercial stage biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced via our proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have successfully developed two commercial products. On May&#160;5, 2023, the European Commission, or EC, announced that it had approved the Marketing Authorization Application, or MAA, for Elfabrio and on May&#160;9, 2023, the FDA announced that it had approved the Biologics License Application, or BLA, for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed indication (Fabry disease). Elfabrio has also been approved for marketing in Great Britain, Switzerland and Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA publicly released the internal review documents for Elfabrio. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (our phase&#160;I\II clinical trial of Fabry Disease, Study PB-102-F01/02) with confirmatory evidence provided by our phase III BALANCE clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our first product, Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa, except in Brazil where it is marketed as BioManguinhos alfataliglicerase), an ERT for the treatment of patients with Gaucher disease was first approved by the FDA in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we are developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase&#160;I, or PRX-119, for the treatment of NETs-related diseases, and a number of other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our proprietary ProCellEx platform is being used to manufacture both of our approved and marketed products as well as PRX-115 and PRX-119.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our strategy moving forward is to develop proprietary recombinant proteins designed to address high, unmet needs in the genetic and non-genetic rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, we have a number of product candidates in varying stages of the clinical development process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:147.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20231231x10k001.jpg" alt="Graphic" style="display:inline-block;height:132.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:432pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expression in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins. We plan to execute on our strategy by developing tailored complex recombinant therapeutic proteins primarily produced through ProCellEx while genetically engineering and/or chemically modifying the proteins pre- and/or post-production. We intend such engineering and modifications to provide added clinical benefits by improving the biological characteristics (e.g., glycosylation, half-life, immunogenicity) of the therapeutic proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We developed ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins which are the essential foundation of modern biotechnology. We develop new, recombinant therapeutic proteins by using the natural capability of agrobacterium to transfer a DNA fragment into the plant chromosome, allowing the genome of the plant cell to code for specific proteins of interest. The agrobacterium-mediated transformed cells are then able to produce specific proteins, which are extracted and purified and can be used as therapies to treat a variety of diseases. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression, and with the recent approval of Elfabrio, we now have two commercial proteins produced through our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20231231x10k002.jpg" alt="Graphic" style="display:inline-block;height:147.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.47pt;"/></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:183.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology can be utilized to express complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines. The entire protein expression process, from initial nucleotide cloning to large-scale production of the protein product, occurs under Current Good Manufacturing Practice-, or cGMP-, compliant, controlled processes. Our plant cell culture technology uses cells, such as carrot and tobacco (BY-2) cells, which undergo advanced genetic engineering and/or chemical modifications, and are grown on an industrial scale in a disposable, flexible bioreactor system. Our system does not involve mammalian or animal-derived components or transgenic field-grown or whole plants at any point in the production process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell growth, from initiating scale-up steps from a cell-bank through large-scale production takes place in a clean-room environment in flexible, sterile, custom-designed polyethylene bioreactors, and does not require the use of large stainless-steel bioreactors commonly used in mammalian-based systems for recombinant protein production. The ProCellEx reactors are easy to use and maintain, allow for rapid horizontal scale-up and do not involve the risk of mammalian viral contamination. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive, chemically defined growth medium. The reactors, which are custom-designed and optimized for plant cell cultures, require low initial capital investment and are rapidly scalable at a low cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20231231x10k003.jpg" alt="Graphic" style="display:inline-block;height:183.75pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:431.83pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20231231x10k004.jpg" alt="Graphic" style="display:inline-block;height:180.54pt;width:432pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Business Highlights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have two commercial products, each of which is an ERT; Elelyso and Elfabrio. Our pipeline of product candidates includes PEGylated uricase for the treatment of severe gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup><i style="font-style:italic;">(taliglucerase alfa)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso for the treatment of Gaucher disease is currently approved and marketed in 23 countries including the United States, Australia, Canada, Israel, Brazil, Russia and Turkey. In June&#160;2012, the EMA&#8217;s Committee for Medicinal Products for Human Use, or the CHMP, issued a positive opinion regarding the benefit of Elelyso but did not immediately grant marketing authorization because of the ten-year market exclusivity granted to Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Takeda Shire) in August&#160;2010 for the same condition, which was extended for an additional two&#160;years, and expired in August 2022. We have granted the marketing rights to Elelyso globally, excluding Brazil, to Pfizer through an exclusive licensing agreement. We maintain the distribution rights to Elelyso in Brazil, where it is currently marketed as BioManguinhos alfataliglicerase, through the Supply and Technology Transfer Agreement, or the Brazil Agreement, we entered into on June&#160;18, 2013, with Fiocruz, an arm of the Brazilian MoH. In 202<span style="direction:rtl;">3</span>, we generated $12.5&#160;million from sales of Elelyso to Pfizer and $10.4&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><i style="font-style:italic;"> (pegunigalsidase alfa orPRX</i>-<i style="font-style:italic;">102)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elfabrio for the treatment of adult patients with Fabry disease, is our proprietary, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a lysosomal enzyme. Elfabrio has been approved by the FDA for marketing in the United States, the European Union, Great Britain, Switzerland and Israel. In 2023, we generated $17.5&#160;million from sales of Elfabrio to Chiesi. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd., our wholly-owned subsidiary, has entered into two exclusive licensing and supply agreements with Chiesi for Elfabrio, one global excluding the United States and the second for the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PEGylated </span><span style="font-style:italic;font-weight:bold;">Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated Uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of severe gout. Gout is the most common inflammatory arthritis, affecting an estimated 14.0&#160;million adults in the United States, 2.0&#160;million in France, 2.0&#160;million in United Kingdom, 0.7 &#160;million in Italy, 1.5&#160;million in Germany, 0.7&#160;million in Spain and over 190.0 million in China. An estimated approximately 5% of the gout population is considered to have chronic refractory disease. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals, tophi, in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate which we are designing to have an elongated half-life in the circulation for the potential treatment of NETs-related diseases. NETs, or Neutrophil extracellular traps, are web-like structures released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase&#160;I treatment reduce NETs toxicity. Our proprietary modified DNase&#160;I may potentially enable effective treatment for these conditions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2023 and Recent Company Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Recent Developments</i></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In January 2024, the Israeli Ministry of Health granted principle approval of Elfabrio for adult patients with a confirmed diagnosis of Fabry disease. </div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">2023 Developments</i></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;21, 2023, we announced our participation in the 19th Annual WORLD<i style="font-style:italic;">Symposium</i>&#8482; 2023, which took place on February&#160;22-26, 2023 at the Hilton Orlando in Orlando, Florida. We hosted an informational booth at the symposium.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On March&#160;21, 2023, the first patient was dosed in our phase I First-in-Human (FIH) clinical trial of PRX-115.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Our decision to voluntarily delist our common stock from the Tel Aviv Stock Exchange took effect on March&#160;22, 2023. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On May&#160;5, 2023, we announced that the EC had granted marketing authorization to Elfabrio in the European Union for the treatment of adult patients with Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On May&#160;10, 2023, we announced that the FDA had approved Elfabrio in the United States for the treatment of adult patients with Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On June&#160;28, 2023, we held our Annual Meeting of Stockholders at which our stockholders: (1)&#160;elected the seven persons nominated by our Board of Directors to serve as directors of our Company; (2)&#160;approved, on a non-binding, advisory basis, the compensation of our named executive officers; (3)&#160;approved, on a non-binding, advisory basis, one year as the frequency at which we will solicit stockholder approval of the compensation of our named executive officers; (4)&#160;adopted amendments to our <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2006 Stock Incentive Plan, as amended</span></a>, to increase the number of shares of common stock available under such plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of the plan; and (5)&#160;ratified the appointment of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2023. The meeting was adjourned until July&#160;13, 2023 to allow us to continue to solicit stockholder approval for the proposal to increase the amount of shares of common stock authorized for issuance under our Certificate of Incorporation, as amended, or the Amended Charter, from 144,000,000 shares to 185,000,000 shares.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On July&#160;13, 2023, our stockholders approved an amendment to our Amended Charter to increase the amount of shares of common stock authorized for issuance thereunder from 144,000,000 shares to 185,000,000 shares.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;15, 2023, Chiesi announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing authorization for Elfabrio in Great Britain for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On September&#160;11, 2023, Swissmedic, the national authorization and supervisory authority for drugs and medical products in Switzerland, announced the approval of Elfabrio in Switzerland for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On September&#160;14, 2023, Eliot Richard Forster, Ph.D. commenced his tenure as Chairman of our Board of Directors. Zeev Bronfeld, the former Chairman of our Board retired for personal reasons, effective as of the same date.</div><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Marketed Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in 23&#160;markets including the United States, Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; Recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1&#160;in 400 to 1&#160;in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.6&#160;billion in 2023, is forecasted to be approximately $1.6&#160;billion in 2024 and is forecasted to grow at a CAGR of approximately 1% from 2023-2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">The current standard of care for Gaucher disease is ERT, which is a medical treatment where recombinant enzymes are injected into patients to replace the lacking or dysfunctional enzyme. In Gaucher disease, recombinant GCD is infused to replace the mutated or deficient natural GCD enzyme. Elelyso is the only alternative ERT treatment of Gaucher disease to Sanofi Genzyme&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Takeda&#8217;s (Shire) Vpriv.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Elfabrio, our second commercial product, was approved by the EC for marketing in the EU and by the FDA for marketing in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed indication (Fabry disease). The FDA publicly released the internal review documents for Elfabrio. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study, our phase&#160;I\II clinical trial of Fabry disease, with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study. The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support the non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">In August and September of 2023, Elfabrio was approved in Great Britain and Switzerland, respectively, and by the Israeli Ministry of Health in January 2024, for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">, in blood vessel walls throughout their body. The ultimate consequences of Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">&#160;deposition </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The standard of care for Fabry disease is ERT. Currently, the ERTs for Fabry disease are agalsidase alfa, agalsidase beta, and now Elfabrio. Through an ERT, the missing &#945;-galactosidase-A is replaced with a recombinant form of the protein via intravenous, or IV, infusion once every two weeks. Fabry disease, if left untreated, will progress from a less severe condition to a more serious one. It can have a significant impact on quality of life due to presence of serious, chronic and debilitating complications, including cardiovascular and renal complications, and comorbid conditions such as pain can have a significant impact on the psychological well-being of Fabry patients and their social functioning. Fabry disease involves substantial reduction in life expectancy. Causes of death are most often cardiovascular disease and, to a lesser extent, cerebrovascular disease and renal disease. The life expectancy of Fabry patients is significantly shorter compared to the general population. Untreated male Fabry patients may experience shortened lifespans to approximately 50&#160;years, and 70&#160;years for untreated female patients with Fabry disease. This represents a 20- and 10-year reduction of their respective lifespans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes agalsidase beta, Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, agalsidase alfa, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $2.0&#160;billion in 2023 and is forecasted to grow at a CAGR of 6.8% from 2023-2029 reaching approximately $3.1&#160;billion in annual sales at the end of the decade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Background</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On November&#160;9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and the submission was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a complete response letter, or CRL, in response to the initial BLA. In preparation for the BLA resubmission, we and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission had the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, included the final two-year analyses of our&#160;<i style="font-style:italic;">BALANCE&#160;</i>study, which were completed in July 2022, and long-term data from our open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102. The initial BLA included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase&#160;I/II clinical trial of PRX-102, including the related extension study, interim clinical data from our phase III BRIDGE clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BRIDGE</i>&#160;study, and safety data from our then on-going clinical studies of PRX-102 in adult patients receiving 1&#160;mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a new drug. Due to travel restrictions during the COVID-19 pandemic, the FDA was unable to conduct the required pre-approval inspection during the review cycle. In addition to the foregoing, the FDA noted that agalsidase beta had recently been converted to full approval, a change in regulatory circumstances which had to be addressed in the resubmitted BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On February&#160;7, 2022, the PRX-102 MAA was submitted to, and subsequently validated by, the EMA. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission. The MAA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease. The submission was supported by the 12&#8211;month interim data analysis generated from our <i style="font-style:italic;">BALANCE</i> study, which was released in June 2021. Data generated from the completed&#160;<i style="font-style:italic;">BRIDGE</i>&#160;study, the phase&#160;I/II clinical trial in naive or untreated patients, and from the extension studies with 1&#160;mg/kg every two weeks were also included in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:187.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">submission. In addition, the MAA included data from the completed 12&#8211;month switch&#8211;over phase&#160;III BRIGHT clinical trial of PRX-102 for the treatment of Fabry disease for adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage, or the <i style="font-style:italic;">BRIGHT</i> study. As part of the EMA review process, we and Chiesi received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year&#160;<i style="font-style:italic;">BALANCE</i>&#160;study (the final Clinical Study Report), and an interim analysis of the long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 4.3pt 10pt 0pt;">On February&#160;24, 2023, we, together with Chiesi, announced that the CHMP had adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was then referred for final action to the EC. As disclosed above, Elfabrio was subsequently approved by the EC for marketing in the EU and in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our PRX-102 clinical development program was designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to the then marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;III clinical program included three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study the <i style="font-style:italic;">BRIGHT</i> study, all of which have been completed. In the phase&#160;III clinical program overall, two potential dosing regimens for PRX-102 were analyzed; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks. The phase&#160;III program was preceded by the phase&#160;I/II clinical trial, a dose range finding study in ERT-na&#239;ve adult patients with Fabry disease, which was completed in 2016.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;"><img src="plx-20231231x10k005.jpg" alt="Graphic" style="display:inline-block;height:186.79pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:388.71pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Phase&#160;III BALANCE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20, NCT02795676) was a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study was completed in July 2022. The final analysis confirmed the positive top-line results (announced in April 2022) and favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -2&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77&#160;patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100&#160;years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">TEAEs were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11&#160;(21.2%)&#160;patients in the PRX-102 arm experienced a total of 13&#160;events compared to six (24.0%) patients experiencing a total of 51&#160;events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients that received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in-line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial from both the PRX-102 and agalsidase beta treatment arms, 69 opted, with the advice of the treating physician, to receive PRX-102 1&#160;mg/kg every two weeks in the long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Phase&#160;III BRIDGE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30, NCT03018730) was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">agalsidase alfa for at least two years and on a stable dose for at least six months. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment. The study was completed in December 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea. An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 18 opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every two weeks in a long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Phase&#160;III BRIGHT Study</i><i style="direction:rtl;font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50, NCT03180840) was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The study was completed in June 2020. The 2&#160;mg/kg every four weeks dosage has not been approved by the EMA, FDA or any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12 months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The final results from the <i style="font-style:italic;">BRIGHT</i> study indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the applicable Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every two weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four weeks as an effective and tolerable alternative treatment option. Additional long term data is being collected as part of the ongoing long term extension study (PB-102-F51, NCT03614234) of the 2&#160;mg/kg PRX-102 every four weeks dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 29 opted, with the advice of the treating physician, to continue receiving PRX-102 2&#160;mg/kg every four weeks in a long-term open-label extension study which is now sponsored by Chiesi. Two of such patients are being treated with 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Phase I/II Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;I/II clinical trial of PRX-102 (NCT01678898) was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. It was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We initiated the phase&#160;I\II study after PRX-102, in preclinical studies, showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the phase&#160;I/II study, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial, 10 patients opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Extension Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Overall, 126 subjects who participated in our PRX-102 clinical program initially opted, with the advice of the treating physician, to enroll in one of our long-term, open label, extension studies of PRX-102: 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60, NCT03566017) (10 subjects who completed an extension study from the phase&#160;I/II study, 18 subjects who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 subjects who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 subjects who completed the <i style="font-style:italic;">BRIGHT</i> study in the 2&#160;mg/kg every four weeks extension study (PB-102-F51, NCT03614234). Two of the subjects in the PB-102-F51 study are being treated with 1&#160;mg/kg every two weeks. As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the open-label extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Over time, and as Elfabrio is approved for marketing in different jurisdictions, participants switch-out of the open-label extension studies. Most of them have transferred to a commercial setting; others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Pediatric FLY Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The pediatric FLY study, to be sponsored by Chiesi with our collaborative efforts, is currently in the start-up phase. The study is planned to be a multi-center, open-label trial to assess the safety, pharmacodynamics, efficacy and pharmacokinetics of Elfabrio in patients from two years to less than 18 years of age with confirmed Fabry disease. The design of the study is based on the Initial Pediatric Study Plan (iPSP) agreed to with the FDA and the paediatric investigation plan (PIP) for Elfabrio, which has been accepted, as amended, by the Paediatric Committee (PDCO) of the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Japanese RISE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is currently enrolling patients in its Japanese RISE clinical trial of PRX-102 for the treatment of Fabry disease in Japan.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PEGylated Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of severe gout patients. The uricase enzyme converts uric acid to allantoin, which is easily eliminated through urine and does not exist naturally in humans. This recombinant enzyme, expressed via our ProCellEx system, is designed to lower uric acid levels and improve clinical manifestation of the disease while having low immunogenicity and increased half-life of the drug in the blood. Pre-clinical data demonstrates long half-life, reduced immunogenic risk and high specific activity which supports the potential of PRX-115 to be a safe and effective treatment for patients with gout. One-month multiple dosing toxicity studies in two species and 6-month multiple dosing toxicity study in one species were conducted to support single and multiple dose studies is humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A phase&#160;I First in Human (FIH) single ascending dose (SAD) double-blind, placebo-controlled study designed to evaluate the safety, pharmacokinetics, pharmacodynamics (reduction of uric acid) and immunogenicity of PRX-115 in patients with elevated uric acid levels (NCT05745727) was commenced in March 2023. The study is being conducted at </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines. Fifty-six patients with no previous exposure to PEGylated uricase have been enrolled in the study. We anticipate announcing preliminary results in the second quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis, affecting an estimated 14.0&#160;million adults in the United States, 2.0&#160;million in France, 2.0&#160;million in United Kingdom, 0.7 &#160;million in Italy, 1.5&#160;million in Germany, 0.7&#160;million in Spain and over 190.0 million in China. An estimated approximately 5% of the gout population is considered to have chronic refractory disease. The risk of gout increases with age, and it is thus more common in ageing populations. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals and\or tophi in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Severe gout is generally described as a state of gout in which there is a presence of monosodium urate crystals with any of the following: frequent recurrent gout flares, chronic gouty arthritis, subcutaneous tophi or disease elements of gout seen via imaging. Currently available urate-lowering therapies, can be effective in treating gout. However, low adherence, under dosing and disease progression that cause high patient burden require new, effective and safe therapies to treat these severe, underserved gout patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering uric acid treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. In particular, 89% of patients treated with Krystexxa developed an immunogenic response associated with a failure to maintain normalization of serum uric acid levels over a 6-month therapy cycle. The FDA label of krystexxa was amended in 2022 to include co-treatment of metrotrexate to prolong efficacy and increases tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons. We believe that new effective, safe therapies are needed to treat severe gout, chronic refractory and uncontrolled<b style="font-weight:bold;"> </b>gout, regardless of treatment history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase&#160;I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of these conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The administration of PRX-119 resulted in a decrease in circulating of DNA levels and significantly enhanced the survival of mice in both a CLP-induced sepsis model and an ARDS model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have a robust patent portfolio, which is a key element of our overall strategy. We work to continually enhance, strengthen, and protect our intellectual property and now hold a broad portfolio of approximately 90 patents globally, including in Europe, the United States, Israel and additional countries worldwide. Our patents are designed to protect our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">proprietary technology, proprietary products and product candidates, and their methods of use. Additionally, we have approximately 50 pending patent applications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2023, we received the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New patents in each of New Zealand and the Russian Federation for the patent family named &#8220;Therapeutic Regimen For The Treatment of Fabry Using Stabilized Alpha-galactosidase, adding to the single previously granted patent in such family.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A new patent in Brazil for the patent family named &#8220;DNase I Polypeptides, Polynucleotides Encoding Same, Methods of Producing DNase&#160;I and uses thereof in Therapy, adding to the two previously granted patents in such family.</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A new patent in Brazil for the patent family named &#8220;Nucleic Acid Construct for Expression of Alpha-Galactosidase in Plants and Plant Cells,&#8221; adding to the nine previously granted patents in such family.</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New patents in each of the USA, New Zealand, Israel and South Africa for the patent family named &#8220;Modified DNase and uses thereof,&#8221; adding to the three previously granted patents in such family.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our competitive position and future success depend, in part, on our ability, and that of our licensees, to obtain and leverage the intellectual property rights covering our product candidates, know-how, methods, processes and other technologies, to protect our trade secrets, to prevent others from using our intellectual property and to operate without infringing on the intellectual property rights of third parties. We seek to protect our competitive position by filing United States, European Union, Israeli and other foreign patent applications covering our technology, including both new technology and improvements to existing technology. Our patent strategy includes obtaining patents on methods of production, compositions of matter and methods of use. We also rely on know-how, continuing technological innovation, licensing and partnership opportunities to develop and maintain our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our outstanding 7.50% Senior Secured Convertible Notes due 2024, or the 2024 Notes, are guaranteed by our subsidiaries and secured by perfected liens on all of our material assets, primarily consisting of our intellectual property assets, including a stock pledge of our foreign subsidiaries in favor of the holders of outstanding 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2023, our patent portfolio consisted of several patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and system and product candidates, as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:22.7pt;"><td style="vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:22.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Name/Int. App. No.</b></p></div></div></td><td style="vertical-align:bottom;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:22.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Pending Jurisdictions</b></p></div></div></td><td style="vertical-align:bottom;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:22.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Granted Jurisdictions</b></p></div></div></td><td style="vertical-align:bottom;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:22.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nominal Expiry</b></p></div></div></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Production of High Mannose Proteins in Plant Culture/PCT/ Il2004 000181</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Japan, Israel, Canada, Russian Federation, Mexico, India, Australia, South Africa, Republic of Korea, Singapore, Europe, Hong Kong, Ukraine, China, USA, Brazil</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024(1)<br/>(3)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plant Cell/Tissue Culturing Device, System and Method/PCT/Il2005/ 000228</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2025</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Large Scale Disposable Bioreactor/PCT/Il2008/000614</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A </p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Australia, Canada, China, Europe, Hong Kong, India, Israel, Republic of Korea, Russian Federation, Singapore, South Africa, USA, Brazil</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2028(2)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stabilized Alpha-galactosidase and uses thereof/PCT/Il2011/ 000209</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Brazil</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Canada, South Africa, Russian Federation, Singapore, Israel, India, New Zealand, <br/>Republic of Korea, Australia, </p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2031(3)</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">China, Japan, USA, Europe,<br/>Hong Kong, India, Brazil</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nucleic Acid Construct for Expression of Alpha-galactosidase in Plants and Plant Cells/PCT/ Il2011/000719</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">India, China, Republic of Korea, Japan, Israel, Europe, Hong Kong, USA, Brazil</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024(2)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Therapeutic Regimen For The Treatment of Fabry Using Stabilized Alpha-galactosidase/ PCT/Il2018/050018</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA, Europe, Brazil, Japan, Canada, Australia, Chile, Israel, Republic of Korea, China, Mexico, Hong Kong</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">South Africa, New Zealand, Russian Federation</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2038</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dry Powder Formulations of DNase&#160;1/PCT/Il2013/050094</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, USA</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2033</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DNase I Polypeptides, Polynucleotides Encoding Same, Methods of Producing DNase&#160;I and uses thereof in Therapy/PCT/ Il2013/050097</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Europe, Israel, Brazil</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2033</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inhalable Liquid Formulations of DNase I/PCT/Il2013/050096</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, USA</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2033</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Modified DNase and uses thereof/ PCT/Il2016/050003</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Europe, Canada, China, <br/>Hong Kong</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA, Australia, Mexico, Israel,<br/>New Zealand, South Africa</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2036</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use of Plant Cells Expressing a TNF Alpha Polypeptide Inhibitor in Therapy/PCT/IL2014/050231</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2034</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Removal of Constructs from Transformed Cells/PCT/IL2019/ 051266</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA, Israel, Japan, New Zealand, Australia</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-Acting DNase/PCT/IL2021/051207</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Canada, Israel, USA, Japan, Europe, Hong Kong, Republic of Korea, China</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dicer-Like Knock-Out Plant Cells/ PCT/IL2021/051194</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, USA, Japan, Europe, Hong Kong, Republic of Korea, China</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Modified Uricase and Uses Thereof/PCT/IL2021/051305</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Japan, Canada, Brazil, USA, Israel, Mexico, Europe, Republic of Korea, China</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Methods of treating diseases associated with elevated uric acid</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent granted in Australia expires in 2029.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent granted in the United States expires in 2032.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PTE/SPC applications were submitted for some of the patents.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are aware of U.S. patents, and corresponding international counterparts of such patents, owned by third parties that contain claims covering methods of producing glucocerebrosidase. We do not believe that, if any claim of infringement were to be asserted against us based upon such patents, taliglucerase alfa would be found to infringe any valid claim under such patents. However, there can be no assurance that a court would find in our favor or that, if we choose or are required to seek a license to any one or more of such patents, a license would be available to us on acceptable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In April&#160;2005, Protalix&#160;Ltd. entered into a license agreement with Icon Genetics AG, or Icon, pursuant to which we received an exclusive worldwide license to develop, test, use and commercialize Icon&#8217;s technology to express certain proteins in our ProCellEx protein expression system. We are also entitled to a non-exclusive worldwide license to make and have made other proteins expressed by using Icon&#8217;s technology. As consideration for the license, we are obligated to make royalty payments equal to varying low, single-digit&#160;percentages of net sales of products by us, our affiliates, or any </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">sublicensees under the agreement. In addition, we are obligated to make milestone payments equal to $350,000, in the aggregate, for each product developed under the license, upon the achievement of certain milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our license agreement with Icon remains in effect until the earlier of the expiration of the last patent under the agreement or, if all of the patents under the agreement expire, 20&#160;years after the first commercial sale of any product under the agreement. Icon may terminate the agreement upon written notice to us that we are in material breach of our obligations under the agreement and we are unable to remedy such material breach within 30&#160;days after we receive such notice. Further, Icon may terminate the agreement in connection with certain events relating to a wind up or bankruptcy, if we make a general assignment for the benefit of our creditors, or if we cease to conduct operations for a certain period. Icon may also terminate the exclusivity granted to us by written notice if we fail to reach certain milestones within a designated period of time. Notwithstanding the termination date of the agreement, our obligation to pay royalties to Icon under the agreement may expire prior to the termination of the agreement, subject to certain conditions.</p><a id="_Competition"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the fields in which we operate is intense and expected to increase. Most of these companies have substantially greater research and development, manufacturing, marketing, financial, technological personnel and managerial resources than we do. In addition, many specialized biotechnology companies have formed collaborations with large, established companies to support research, development and commercialization of products that may be competitive with our current and future product candidates and technologies. Acquisitions of competing companies by large pharmaceutical or biotechnology companies could further enhance such competitors&#8217; financial, marketing and other resources. Academic institutions, governmental agencies and other public and private research organizations are also conducting research activities and seeking patent protection and may commercialize competitive products or technologies on their own through collaborations with pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to Gaucher disease, we face competition primarily from two ERTs, Sanofi Genzyme&#8217;s Cerezyme and Takeda&#8217;s (Shire) Vpriv. In addition, Actelion markets a small molecule drug for the treatment of mild to moderate Type&#160;1 Gaucher disease (Zavesca or miglustat), an oral treatment approved by the FDA only for patients for whom ERT is not a therapeutic option. In addition, Sanofi Genzyme markets a small molecule oral drug, Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, approved for Gaucher patients with certain CYP2D6 metabolizer status. We are aware of other treatments and gene therapies in early clinical development and later stage clinical development for the treatment of Gaucher disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to Fabry disease, we face competition primarily from Sanofi Genzyme (Fabrazyme), Takeda (Replagal) and Amicus (Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>). In addition, we are aware of other late clinical stage, early clinical stage and experimental drugs that are being developed by other companies for the treatment of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to severe gout, we face competition from Horizon Therapeutics Public Limited Company (Krsytexxa), which is indicated for treatment of chronic gout in adult patients refractory to conventional therapy. In addition, we are aware of other clinical stage, early clinical stage and experimental refractory or chronic gout treatments. For example, we are aware of a product candidate for chronic refractory gout that recently completed a phase&#160;III clinical trial and has met the primary endpoints of the trial, and of another product candidate that is the subject of a phase&#160;II clinical trial for hyperuricemia in gout patients with advanced CKD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;"> We also face potential competition to our ProCellEx system from companies that are developing other platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed proteins. A number of companies have developed or are developing alternative expression technologies. Examples include Crucell N.V.&#8217;s (acquired by Johnson&#160;&amp;&#160;Johnson) expression system based on human-cell technology, Dyadic International Inc.&#8217;s expression system based on a fungus, Pfenex Inc.&#8217;s (acquired by Ligand Pharmaceuticals Incorporated) bacteria-based expression system, and others. Companies developing alternate plant-based technologies include iBio,&#160;Inc., Medicago,&#160;Inc., and eleva. Unlike ProCellEx, these alternate technologies are not cell-based. These companies base their product development on transgenic plants or whole plants.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Agreements and Partnerships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Elelyso &#8211; Pfizer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets, excluding Brazil, pursuant to an Amended and Restated Exclusive License and Supply Agreement, or the Amended Pfizer Agreement, which we entered into with Pfizer in October&#160;2015 to amend and restate our initial Exclusive License and Supply Agreement with Pfizer, or the Pfizer Agreement. Pursuant to the Amended Pfizer Agreement, Pfizer retains 100% of revenue and reimburses 100% of direct costs. For the first 10-year period after the execution of the Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, subject to certain terms and conditions, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods, subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period. Any failure to comply with our supply commitments may subject us to substantial financial penalties. The Amended Pfizer Agreement includes customary provisions regarding cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements. We retain distribution rights to taliglucerase alfa in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Elelyso &#8211; Funda&#231;&#227;o Oswaldo Cruz (Fiocruz)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso, marketed as BioManguinhos alfataliglicerase in Brazil, is commercialized in Brazil through the Brazil Agreement with Fiocruz, which became effective in January&#160;2014. Gaucher patients in Brazil are entitled to receive ERT paid for by the Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicerase is currently estimated to be used by approximately 25% of Gaucher patients in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Brazil Agreement provides for a staged technology transfer which is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of BioManguinhos alfataliglicerase. Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement. Accordingly, we and Fiocruz discuss on a continuous basis, potential steps to maximize sales of BioManguinhos alfataliglicerase sales to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><i style="white-space:pre-wrap;">Elfabrio (pegunigalsidase alfa\PRX-102)  &#8211; Chiesi Farmaceutici</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi; the Exclusive License and Supply Agreement dated as of October&#160;17, 2017, made by and between Protalix&#160;Ltd. and Chiesi, or the Chiesi Ex-US Agreement, and the <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418013053/tv486893_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License and Supply Agreement dated as of </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">July&#160;23, 2018</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, made by and between Protalix&#160;Ltd. and </span></a>Chiesi, or the Chiesi US Agreement. The Chiesi Ex-US Agreement and the Chiesi US Agreement are referred to herein collectively as the Chiesi Agreements. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45&#160;million, and is entitled to more than $1.0&#160;billion in potential milestone payments tiered payments for drug product purchased from Protalix Ltd. equal to 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US), depending on the amount of annual net sales in the applicable territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Chiesi Ex-US Agreement, we granted to Chiesi an exclusive license for all markets outside of the United States to commercialize PRX-102. Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The exclusive license to develop and commercialize PRX-102 in the United States were granted to Chiesi under the Chiesi US Agreement. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement will expire December&#160;31, 2025, unless terminated earlier in accordance with its terms and may be extended by mutual agreement in writing for an additional period of seven years. The Letter Agreement changed the obligations of both us and Chiesi under the Chiesi Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the Chiesi Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We use our current manufacturing facility in Carmiel, Israel, which has approximately 14,700&#160;sq/ft of clean rooms built according to industry standards, to manufacture drug substance for Elfabrio and Elelyso for commercial purposes and, with respect to Elfabrio, in connection with clinical trials. We maintain an approximately 3,400&#160;sq/ft pilot plant for protein development and to manufacture supplies for clinical trials (phase&#160;I and phase&#160;II). Elelyso, Elfabrio and our drug product candidates must be manufactured in a clean environment and in compliance with cGMPs set by the FDA and other relevant foreign regulatory authorities. We intend to use our manufacturing space to produce all of the drug substance needed in connection with the clinical trials for our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In 2017, the FDA approved the supplemental New Drug Application (sNDA) we submitted to allow us to convert our manufacturing facility from a single dedicated product facility to a multi-product facility. This conversion allows us to realize potentially significant operational savings. Our facility&#8217;s current capacity can serve all of our current and expected commercial and clinical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our manufacturing facilities are subject to inspections by various regulatory authorities from time to time. We have undergone successful inspections by the FDA, the Irish Medicines Board (under the EMA&#8217;s centralized marketing authorization procedure), the Brazilian National Health Surveillance Agency (ANVISA), the Israeli Ministry of Health, the Turkish Ministry of Health, the Australian Therapeutic Goods Administration (TGA) and Health Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our current facility in Israel was granted &#8220;Approved Enterprise&#8221; status, and we have elected to participate in the alternative benefits program. Our facility is located in a top priority location, or &#8220;Zone A,&#8221; location, and, therefore, our income from the Approved Enterprise will be tax exempt in Israel for a 10-year period, commencing with the&#160;year in which we first generate taxable income from the relevant Approved Enterprise and after we use our net operating loss carryforwards, or NOLs. We expect to be entitled to similar tax benefits for a number of&#160;years thereafter. To remain eligible for these tax benefits, we must continue to meet certain conditions, and if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs. In addition, our technology is subject to certain restrictions with respect to the transfer of technology and manufacturing rights.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Raw Materials and Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that the raw materials that we require throughout the manufacturing process of Elfabrio and Elelyso, and our current and potential drug product candidates, are widely available from numerous suppliers and are generally considered to be generic industrial biological supplies. We rely on a single, approved supplier for certain materials relating to the current expression of our proprietary biotherapeutic proteins through ProCellEx. We have identified additional suppliers for most of the materials required for the production of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Development and regulatory approval of our pharmaceutical products are dependent upon our ability to procure active ingredients (DS) and certain packaging materials from sources approved by the FDA and other regulatory authorities. The FDA and other regulatory approval processes require manufacturers to specify their proposed suppliers of active ingredients (which is not relevant to our company), intermediate material and certain packaging materials in their applications. From time to time, we intend to continue to identify alternative approved suppliers to ensure the uninterrupted supply of necessary raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Government Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">U.S. Drug Development Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA regulates drugs under the U.S.&#160;Federal Food, Drug, and Cosmetic Act, or the FFDCA, and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. Biologics are subject to regulation by the FDA under the FFDCA, the Public Health Service Act, and related regulations and other federal, state and local laws and regulations. Biological products include a wide variety of products including vaccines, blood and blood components, gene therapies, tissue and proteins. Unlike most prescription products made through chemical processes, biological products generally are made from human and/or animal materials. To be lawfully marketed in interstate commerce, a biologic product must be the subject of a BLA issued by the FDA on the basis of a demonstration that the product is safe, pure and potent, and that the facility in which the product is manufactured meets standards to assure that the product continues to be safe, pure and potent. The FDA has developed, and is continuously updating, the requirements with respect to cell and gene therapy products and has issued documents concerning the regulation of cellular and tissue-based products. Manufacturers of cell and tissue-based products must comply with the FDA&#8217;s current good tissue practices, or cGTP, which are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of such products. The primary intent of the cGTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The process of obtaining regulatory approvals and ensuring compliance with appropriate federal, state and local statutes and regulations in the United States, and foreign statutes and regulations, requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, product detention, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The process required by the FDA before a biological product or drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well-controlled clinical trials according to Good Clinical Practices, or GCP, to establish the safety and efficacy of the proposed biological product or drug for its intended use;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of a BLA for a new biological product or a new drug application, or NDA, for a new drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA or NDA.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These regulations include the requirement that all subjects participating in the clinical trial provide their informed consent regarding the trial. Further, an institutional review board, or IRB, must review and approve the plan for any clinical trial before it commences at any institution. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the information regarding the clinical trial and the consent form that must be provided to each clinical trial subject, or his or her legal representative, and must monitor the clinical trial until completed. Once an IND is in effect, each new clinical protocol and any amendments to the protocol must be submitted to the FDA for review, and to the IRBs for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase I.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted in patients having the specific disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase II. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase II clinical trials involve investigations in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and the optimal dosage and schedule.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase III.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Phase III clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for regulatory approval and product labeling.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Post-approval studies, also called Phase&#160;IV trials, may be conducted after initial marketing approvals. These studies are used to obtain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected side effects. Phase&#160;I, Phase&#160;II and Phase&#160;III testing may not be completed successfully within any specified period, if at all. The FDA or the trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the study subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the applicable product candidate does not undergo unacceptable deterioration over its shelf life.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the product candidate, proposed labeling and other relevant information, are submitted to the FDA as part of an NDA or BLA, requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees which may be waived under certain limited circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The testing and approval processes require substantial time and effort, and may not result in an approval on a timely basis, if at all. The FDA may refuse to approve a BLA or NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Generally, it takes one to three&#160;years to obtain approval. If questions arise during the FDA review process, approval may take a significantly longer period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase&#160;IV testing which involves clinical trials designed to further assess a drug&#8217;s or biologic&#8217;s safety and effectiveness after BLA or NDA approval and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Orphan Drug Act of 1983, the FDA may grant orphan drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 persons in the United States but that sales in the United States are not expected to recover the costs of developing and marketing a treatment drug. Orphan product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Among the benefits of orphan drug designation are possible funding and tax savings to support clinical trials, other financial incentives and a waiver of the marketing application user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same treatment for the same indication for seven&#160;years, except in limited circumstances, such as (i)&#160;the drug&#8217;s orphan designation is revoked; (ii)&#160;its marketing approval is withdrawn; (iii)&#160;the orphan exclusivity holder consents to the approval of another applicant&#8217;s product; (iv)&#160;the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v)&#160;a showing of clinical superiority to the product with orphan exclusivity by a competitor product. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan drug status in the European Union has similar but not identical benefits in the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between (a)&#160;the effective date of an IND and the submission date of a BLA or an NDA plus (b)&#160;the time between the submission date of a BLA or an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the extension must be requested prior to expiration of the patent. The U.S. Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. We anticipate that we will apply for restorations of the patent term for certain of patents covering our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Fast Track Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA has a fast track program that is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, the purpose being to make important new drugs available to patients earlier. A drug candidate that receives Fast Track designation from the FDA is eligible for some or all of the following: more frequent meetings with the FDA to discuss the drug&#8217;s development plan and ensure collection of appropriate data needed to support drug approval; more frequent written communication from the FDA about such things as the design of the proposed clinical trials; eligibility for the FDA&#8217;s Accelerated Approval and Priority Review, if relevant criteria are met; and eligibility for Rolling Review, which allows a drug company to submit completed sections of its BLA or NDA for review by the FDA, rather than waiting until every section of the BLA or NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. We used the Rolling Review option for our taliglucerase alfa NDA, which we completed in April&#160;2010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Accelerated Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Section&#160;901 of the U.S.&#160;Food and Drug Administration Safety Innovations Act amends the FFDCA to allow the FDA to base Accelerated Approval for drugs for serious conditions that fill an unmet medical need on whether the drug has an effect on a surrogate or an intermediate clinical endpoint. A surrogate endpoint used for Accelerated Approval is a marker; that is, a laboratory measurement, radiographic image, physical sign or other measure, that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a measure of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on irreversible morbidity and mortality. The FDA bases its decision on whether to accept the proposed surrogate or intermediate clinical endpoint on the scientific support for that endpoint. Studies that demonstrate a drug&#8217;s effect on a surrogate or intermediate clinical endpoint must be &#8220;adequate and well controlled&#8221; as required by the FFDCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Accelerated Approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Under subpart H of the Accelerated Approval pathway, the FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. The Accelerated Approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;IV or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Any drugs for which we receive FDA approval are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse effects with the product, reporting of changes in distributed products which would require field alert reports (FARs), drugs and biological product deviation reports (BPDRs) providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. In September&#160;2007, the Food and Drug Administration Amendments Act of 2007 was enacted, giving the FDA enhanced post-marketing authority, including the authority to require post marketing studies and clinical trials (PMRs and PMCs), labeling changes based on new safety information, and compliance with risk evaluations and mitigation strategies (REMS), approved by the FDA. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. Further, manufacturers of drugs and biologics must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process generally </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Drug and biologic manufacturers and other entities involved in the manufacturing and distribution of approved drugs and biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, GTP applicable to biologics, and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the drug. Manufacturers must establish validated systems to ensure that products meet specifications and regulatory standards, and test each product batch or lot prior to its release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA may withdraw a product approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Discovery of previously unknown problems with a product subsequent to its approval may result in restrictions on the product or even complete withdrawal of the product from the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, warning letters, holds on clinical trials, product recalls or seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, the FDA regulations and policies are often revised or reinterpreted by the agency in ways that may significantly affect our business and our development efforts. It is impossible to predict whether further legislative or FDA regulation or policy changes will be enacted or implemented and what the impact of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Foreign Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are subject to regulations and product registration requirements in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements, labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements for licensing a product in a foreign country may differ significantly from FDA requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pharmaceutical products may not be imported into, or manufactured or marketed in, the State of Israel absent drug registration. The three basic criteria for the registration of pharmaceuticals in Israel is quality, safety and efficacy of the pharmaceutical product and the Israeli Ministry of Health requires pharmaceutical companies to conform to international developments and standards. Regulatory requirements are constantly changing in accordance with scientific advances as well as social and ethical values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The relevant legislation of the European Union requires that medicinal products, including generic versions of previously approved products, and new strengths, dosage forms and formulations, of previously approved products, shall have a marketing authorization before they are placed on the market in the European Union. Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities. In order to obtain an authorization, an application must be made to the competent authority of the member state concerned or in a centralized procedure to the EMA. Besides various formal requirements, the application must contain the results of pharmaceutical (physico-chemical, biological or microbiological) tests, of preclinical (toxicological and pharmacological) tests as well as of clinical trials. All of these tests must have been conducted in accordance with relevant EU regulations and must allow the reviewer to evaluate the quality, safety and efficacy of the medicinal product. Orphan drug designation in the European Union is granted to medicinal products intended for the diagnosis, prevention and treatment of life-threatening diseases and very serious conditions that affect not more than five in 10,000 people in the European Union. Orphan drug designation is generally given to medicinal products that treat conditions for which no current therapy exists or are expected to bring a significant benefit to patients over existing therapies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Third Party Payor Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Coverage and reimbursement status of any approved therapy carries uncertainty and risk. In both the United States and foreign markets, our ability to commercialize our product and product candidates successfully, and to attract commercialization partners, depends in significant part on the availability of adequate financial coverage and reimbursement from third party payors, including, in the United States, governmental payors such as Medicare, Medicaid and the Veterans Affairs Health programs, and private health insurers. Medicare is a federally funded program managed by the Centers for Medicare and Medicaid Services, or CMS, through local fiscal intermediaries and carriers that administer coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are otherwise uninsured that is both federally and state funded and managed by each state. The federal government sets general guidelines for Medicaid and each state creates specific regulations that govern its individual program. Each payor has its own process and standards for determining whether it will cover and reimburse a procedure or particular product. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant gating issue for successful introduction of a new product. The competitive position of some of our products will depend, in part, upon the extent of coverage and adequate reimbursement for such products and for the procedures in which such products are used. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by the government and other payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Possible legislation at the federal and state levels in the United States focused on cost containment and price transparency may impact our ability to sell our product and product candidates for maximum profitably. It appears likely that the pressure on pharmaceutical pricing will continue, especially under the Medicare program, which may also increase our regulatory burdens and operating costs. Moreover, additional changes could be made to governmental healthcare programs that could significantly impact the success of our product and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Some third party payors also require pre-approval of coverage for new or innovative devices, biologics or drug therapies before they will reimburse healthcare providers that use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our product candidates and operate profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules&#160;and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs and biologics, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S.&#160;Department of Health and Human Services (e.g., the Office of Inspector General), the U.S.&#160;Department of Justice and individual U.S.&#160;Attorney General offices within the Department of Justice, and state and local governments. These regulations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal transparency requirements under the Health Care Reform Law requires manufacturers of drugs, devices, biologics, and medical supplies to report to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FFDCA, which among other things, strictly regulates drug and biologic product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Compliance with Environmental, Health and Safety Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to FDA regulations, we are also subject to evolving federal, state and local environmental, health and safety laws and regulations. In the past, compliance with environmental, health and safety laws and regulations has not had a material effect on our capital expenditures. Compliance with environmental, health and safety laws and regulations in the future may require additional capital expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Israeli Government Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following is a brief summary of the current principal Israeli tax laws applicable to us and Protalix&#160;Ltd., and of the Israeli Government programs from which Protalix&#160;Ltd. benefits. Some parts of this discussion are based on new tax legislation that has not been subject to judicial or administrative interpretation. Therefore, the views expressed in the discussion may not be accepted by the tax authorities in question. This summary is based on laws and regulations in effect as of the date hereof, and should not be construed as legal or professional tax advice and does not cover all possible tax considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">General Corporate Tax Structure in Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The income of Protalix&#160;Ltd., other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at regular rates. Pursuant to the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget&#160;Year), 2016, the corporate tax rate in 2018 and thereafter is 23%. Capital gains on the sale of assets are subject to capital gains tax according to the corporate tax rate in effect in the&#160;year which the assets are sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Law for the Encouragement of Capital Investments, 1959</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Law for the Encouragement of Capital Investments, 1959, as amended, or the Investment Law, provides certain incentives for capital investments in a production facility (or other eligible assets). Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, referred to as an &#8220;Approved Enterprise,&#8221; is entitled to benefits. These benefits may include cash grants from the Israeli government and tax benefits, based upon, among other things, the location within Israel of the facility in which the investment is made and specific elections made by the grantee. In order to qualify for these incentives, an Approved Enterprise is required to comply with the requirements of the Investment Law, and Letter of approval received by Protalix&#160;Ltd.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd. will continue to enjoy the tax benefits under the pre-revision provisions of the Investment Law. If any new benefits are granted to Protalix&#160;Ltd. in the future, Protalix&#160;Ltd. will be subject to the provisions of the amended Investment Law with respect to these new benefits. Therefore, the following discussion is a summary of the Investment Law prior to its amendment as well as the relevant changes contained in the new legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Investment Law prior to its amendment, a company that wished to receive benefits had to receive approval from the Authority for the Investment and Development of the Industry and Economy, or the Investment Center. Each certificate of approval for an Approved Enterprise relates to a specific investment program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the asset, e.g., the equipment to be purchased and utilized pursuant to the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">An Approved Enterprise may elect to forego any entitlement to the grants otherwise available under the Investment Law and, instead, participate in an alternative benefits program under which the undistributed income (after deductions and offsets) from the Approved Enterprise is exempt from corporate tax for a defined period of time. Under the alternative package of benefits, a company&#8217;s undistributed income derived from an Approved Enterprise will be exempt from corporate tax for a period of between two and 10&#160;years from the first&#160;year of taxable income, depending upon the geographic location within Israel of the Approved Enterprise. Upon expiration of the exemption period, the Approved Enterprise is eligible for the reduced tax rates otherwise applicable under the Investment Law for any remainder of the otherwise applicable benefits period (up to an aggregate benefits period of either seven or 10&#160;years, depending on the location of the company or its definition as a foreign investors&#8217; company). If a company has more than one Approved Enterprise program or if only a portion of its capital investments are approved, its effective tax rate is the result of a weighted combination of the applicable rates. The tax benefits from any certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise and are contingent upon meeting the criteria set out in the certificate of approval. Income derived from activity that is not integral to the activity of the Approved Enterprises (including capital gain) does not enjoy these tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A company that has an Approved Enterprise program is eligible for further tax benefits, as an alternative to exemption, if it qualifies as a foreign investors&#8217; company. A foreign investors&#8217; company eligible for benefits is essentially a company in which more than 25% of the share capital (in terms of shares, rights to profit, voting and appointment of directors) is owned (measured by both share capital and combined share and loan capital) by non-Israeli residents. A company that qualifies as a foreign investors&#8217; company and has an Approved Enterprise program is eligible for tax benefits for a 10-year benefit period and may enjoy a reduced corporate tax rate of 10% to 23%, depending on the amount of the company&#8217;s shares held by non-Israeli shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a company that has an Approved Enterprise program is a wholly-owned subsidiary of another company, the&#160;percentage of foreign investments is determined based on the&#160;percentage of foreign investment in the parent company. The tax rates and related levels of foreign investments with respect to a foreign investor&#8217;s company that has an Approved Enterprise program are set forth in the following table:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of Foreign Ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rate&#160;of&#160;Reduced&#160;Tax</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Over 25% but less than 49%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">23%</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">49% or more but less than 74%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">20%</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">74% or more but less than 90%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15%</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">90% or more</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our original facility in Israel has been granted &#8220;Approved Enterprise&#8221; status, and it has elected to participate in the alternative benefits program. Under the terms of its Approved Enterprise program, the facility is located in a Zone A area and, therefore, the undistributed income from that Approved Enterprise will be tax exempt in Israel for a period of 10&#160;years, commencing with the&#160;year in which taxable income is first generated from the relevant Approved Enterprise. The current benefits program may not continue to be available and Protalix&#160;Ltd. may not continue to qualify for its benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A company that has elected to participate in the alternative benefits program and that subsequently pays a dividend out of the income derived from the portion of its facilities that have been granted Approved Enterprise status during the tax exemption period will be subject to corporate tax in respect of the amount of dividend distributed at the rate that would </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">have been applicable had the company not elected the alternative benefits program (generally 10% to 23%, depending on the extent to which non-Israeli shareholders hold such company&#8217;s shares). If the dividend is distributed within 12&#160;years after the end of the benefits period (or, in the case of a foreign investor&#8217;s company, without time limitation), the dividend recipient is taxed at the reduced withholding tax rate of 20% applicable to dividends from approved enterprises, or at the lower rate under an applicable tax treaty. After this period, the withholding tax rate is 25% to 30%, or at the lower rate under an applicable tax treaty. In the case of a company with a foreign investment level (as defined by the Investment Law) of 25% or more, the 12-year limitation on reduced withholding tax on dividends does not apply. The company must withhold this tax at its source, regardless of whether the dividend is converted into foreign currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Investment Law also provides that an Approved Enterprise is entitled to accelerated depreciation on its property and equipment that are included in an approved investment program. This benefit is an incentive granted by the Israeli government regardless of whether the alternative benefits program is elected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The benefits available to an Approved Enterprise are conditioned upon terms stipulated in the Investment Law and its regulations and the criteria set forth in the applicable certificate of approval. If Protalix&#160;Ltd. does not fulfill these conditions in whole or in part, the benefits can be canceled and Protalix&#160;Ltd. may be required to refund the benefits received, linked to the Israeli consumer price index with interest. We believe that Protalix&#160;Ltd. currently operates in compliance with all applicable conditions and criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Amendment No.&#160;60 to the Investment Law introduced a tax benefits regime referred to as &#8220;Benefitted Enterprises.&#8221; Under the Investment Law, the approval of the Investment Center is required only for Benefitted Enterprises that receive cash grants. Benefitted Enterprises that do not receive benefits in the form of governmental cash grants, but only tax benefits, are no longer required to obtain this approval. Instead, these Benefitted Enterprises are required to make certain investments as specified in the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The amended Investment Law specifies certain conditions for a Benefitted Enterprise to be entitled to benefits. These conditions include, inter alia, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Benefitted Enterprise&#8217;s revenues from any single country or a separate customs territory may not exceed 75% of the Benefitted Enterprise&#8217;s total revenues; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least 25% of the Benefitted Enterprise&#8217;s revenues during the benefits period must be derived from sales into a single country or a separate customs territory with a population of at least 14 million people (starting from January 1, 2012, 1.4% must be added for each year).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that Protalix&#160;Ltd. will comply with the above conditions in the future or that Protalix&#160;Ltd. will be entitled to any additional benefits under the Investment Law. In addition, it is possible that Protalix&#160;Ltd. may not be able to operate in a manner that maximizes utilization of the potential benefits available under the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the future there may be changes in the law, subject to the preservation of benefits, which may affect the benefits available to companies under the Investment Law. The termination or substantial reduction of any of the benefits available under the Investment Law could impact our tax expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Amendment of the Law for the Encouragement of Capital Investments, 1959</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In recent&#160;years, several amendments have been made to the Investments Law which have enabled new alternative benefit tracks, subject to certain conditions. The Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Investments Law. On December&#160;29, 2016, Amendment 73 to the Investments Law, or the Investments Law Amendment, was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise.&#8221; To date, we have elected not to have the Investments Law Amendment apply to our company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Encouragement of Industrial Research, Development and Technology Innovation Law, 1984</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, Protalix&#160;Ltd. has received grants from the Office of the Chief Scientist of the Israeli Department of Labor, or the OCS, under the Israeli Law for the Encouragement of Industrial Research, Development and Technology Innovation, 1984, and related regulations, or the Research Law. On January&#160;1, 2016, the Israeli government established the National Authority for Technological Innovation, or NATI, which replaced many of the functions of the OCS. For purposes of clarity, references to NATI will include the OCS. NATI grants may be made available, from time to time, to finance a portion of Protalix&#160;Ltd.&#8217;s research and development expenditures in Israel. As of December&#160;31, 2023, NATI approved grants in respect of Protalix&#160;Ltd.&#8217;s continuing operations totaling approximately $53.2&#160;million (before interest, as described below), measured from inception. Protalix&#160;Ltd. is required to repay up to 100% of grants actually received (plus interest at the LIBOR rate applied to the grants received on or after January&#160;1, 1999) to NATI through payments of royalties at a rate of 3% to 6% of the revenues generated from NATI-funded project, depending on the period in which revenues were generated. As of December&#160;31, 2023, Protalix Ltd. either paid or accrued royalties payable of $17.7&#160;million, and Protalix&#160;Ltd.&#8217;s contingent liability to NATI with respect to grants received was approximately $35.5&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Research Law, recipients of grants from NATI are prohibited from manufacturing products developed using these grants outside of the State of Israel without special approvals, although the Research Law does enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased royalties. If Protalix Ltd. receives approval to manufacture the products developed with government grants outside of Israel, it will be required to pay an increased total amount of royalties (possibly up to 150% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, under the Research Law, Protalix&#160;Ltd. is prohibited from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix&#160;Ltd. may not receive the required approvals for any proposed transfer and, if received, Protalix&#160;Ltd. may be required to pay NATI a portion of the consideration that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that Protalix&#160;Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to NATI. The payments to NATI may result in up to 600% of the grant amounts plus interest. Approval of the transfer of technology to residents of the State of Israel is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested, will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Research Law and the regulations promulgated thereunder, the NATI Council may allow the transfer outside of Israel of know-how derived from an approved program and the related manufacturing rights in limited circumstances which are currently as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of a sale of know-how itself to a non-affiliated third party, provided that upon such sale the owner of the know-how pays to NATI an amount, in cash, as set forth in the Research Law (and the regulations promulgated thereunder). In addition, the amendment provides that if the purchaser of the know-how gives the selling Israeli company the right to exploit the know-how by way of an exclusive, irrevocable and unlimited license, the research committee may approve such transfer in special cases without requiring a cash payment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of a sale of a company which is the owner of know-how, pursuant to which the company ceases to be an Israeli company, provided that upon such sale, the owner of the know-how makes a cash payment to NATI as set forth in the Research Law (and the regulations promulgated thereunder).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of an exchange of know-how such that in exchange for the transfer of know-how outside of Israel, the recipient of the know-how transfers other know-how to the company in Israel in a manner in </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which NATI is convinced that the Israeli economy realizes a greater, overall benefit from the exchange of know-how.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Research Committee may, in special cases, approve the transfer of manufacture or of manufacturing rights of a product developed within the framework of the approved program or which results therefrom, outside of Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The State of Israel does not own intellectual property rights in technology developed with NATI funding and there is no restriction on the export of products manufactured using technology developed with NATI funding. The technology is, however, subject to transfer of technology and manufacturing rights restrictions as described above. For a description of such restrictions, please see &#8220;<a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Risk Factors&#8212;Risks Relating to Our Operations in Israel</span></a>.&#8221; NATI approval is not required for the export of any products resulting from the research or development or for the licensing of any technology in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Law for the Encouragement of Industry (Taxes), 1969</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that Protalix&#160;Ltd. currently qualifies as an &#8220;Industrial Company&#8221; within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law. The Industry Encouragement Law defines &#8220;Industrial Company&#8221; as a company resident in Israel and incorporated in Israel, that derives 90% or more of its income in any tax&#160;year (other than specified kinds of passive income such as capital gains, interest and dividends) from an &#8220;Industrial Enterprise&#8221; operating in Israel (including Judea&#160;&amp; Samaria territories and the Gaza strip), that it owns. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose major activity in a given tax&#160;year is industrial production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following corporate tax benefits, among others, are available to Industrial Companies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amortization of the cost of purchased know-how and patents over an eight-year period for tax purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accelerated depreciation rates on equipment and buildings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under specified conditions, an election to file consolidated tax returns with other related Israeli Industrial Companies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses related to a public offering are deductible in equal amounts over three&#160;years.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Eligibility for the benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority. It is possible that Protalix&#160;Ltd. may fail to qualify or may not continue to qualify as an &#8220;Industrial Company&#8221; or that the benefits described above will not be available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Tax Benefits for Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under specified conditions, Israeli tax laws allow a tax deduction by a company for research and development expenditures, including capital expenditures, for the&#160;year in which such expenditures are incurred. These expenditures must relate to scientific research and development projects and must be approved by NATI. Furthermore, the research and development projects must be for the promotion of the company and carried out by or on behalf of the company seeking such tax deduction. However, the amount of such deductible expenditures is reduced by the sum of any funds received through government grants for the finance of such scientific research and development projects. Research and development expenses which were not approved shall be deductible over a period of three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December&#160;31, 2023, we had <span style="direction:rtl;">208</span> employees of whom <span style="direction:rtl;">208</span> are full time employees and <span style="direction:rtl;">16</span> have a Ph.D. or an M.D. in their respective scientific fields. We believe that our relations with our employees are good. We believe that our success will greatly depend on our ability to identify, attract and retain capable employees. The Israeli Ministry of Labor and Welfare is authorized to make certain industry-wide collective bargaining agreements, or Expansion Orders, that apply to types of industries or employees including ours. These agreements affect matters such as cost of living adjustments to salaries, length of working hours and week, recuperation, travel expenses, and pension rights. Otherwise, our employees are not represented by a labor union or represented under a collective bargaining agreement. See &#8220;<a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Risk </span></a></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Factors&#8212;We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.<a href="#Item1ARiskFactors_654735"></a>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Company Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We were originally incorporated in the State of Florida in April&#160;1992, and reincorporated in the State of Delaware in March&#160;2016. Protalix&#160;Ltd., our wholly-owned subsidiary and sole operating unit, is an Israeli company and was incorporated in Israel in 1993.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is our registered trademark. Each of the other trademarks, trade names or service marks appearing in this Annual Report on Form&#160;10-K belongs to its respective holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Our main corporate website address is </span><span style="background:#ffffff;">http://www.protalix.com</span><span style="background:#ffffff;">. </span>We make available on our website, free of charge, our Commission filings, including our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and any amendments to these reports, as soon as reasonably practicable after we electronically file these documents with, or furnish them to, the Commission. <span style="background:#ffffff;">The </span>Commission<span style="background:#ffffff;"> maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the </span>Commission<span style="background:#ffffff;"> at </span><span style="background:#ffffff;">www.sec.gov</span><span style="background:#ffffff;">. </span>Additionally, from time to time, we provide notifications of material news including press releases and conferences on our website. Webcasts of presentations made by our company at certain conferences may also be available from time to time on our website, to the extent the webcasts are available. The content of our website is not intended to be incorporated by reference into this report or in any other report or document we file and any references to these websites are intended to be inactive textual references only. Interested persons may sign up on our website to automatically receive e-mail alerts when we post financial information and issue press releases, and to receive information about upcoming events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our website also includes printable versions of our Code of Business Conduct and Ethics and the charters for each of the Audit, Compensation and Nominating Committees of our Board of Directors. Each of these documents is also available in print, free of charge, to any stockholder who requests a copy by addressing a request to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Protalix BioTherapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;University Plaza, Suite&#160;100</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">Hackensack, NJ  07601</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Attn: Mr.&#160;Eyal Rubin, Sr.&#160;Vice President and Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ac107459_d1c4_43c4_bfde_43564c3febc6"></a><a id="Item1ARiskFactors_654735"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should carefully consider the risks described below together with the other information included in this Annual Report on Form&#160;10-K. Our business, financial condition and results of operations could be adversely affected by any of these risks. The risks described below include forward-looking statements, and actual events and our actual results may differ materially from these forward-looking statements. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also impair our business, results of operations and financial condition. Furthermore, additional risks and uncertainties are described under other captions in this Annual Report on Form&#160;10-K. If any of these risks occur, the value of our common stock could decline. A summary of the risk factors included in this Item&#160;1A are set forth below followed by a full set of risk factors described in greater detail. For further details on our forward-looking statements, see &#8220;</i><a href="#S1_002"><i style="font-style:italic;font-weight:normal;">Cautionary Statement Regarding Forward-Looking Statements</i></a><i style="font-style:italic;">&#8221; on page&#160;1.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Summary of Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Commercialization and Continued Approval of our Products</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We currently depend heavily on the generation of revenues from the sales of our products.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Any current products or future product candidates may cause serious adverse events or undesirable side effects.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">There may be safety issues regarding our products that were not known at the time of approval are discovered.</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Physicians, patients, third party payors and others in the medical community might not accept and use our current or future products.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Coverage and reimbursement may not be available for our current or future products in all territories.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We have a limited commercial operating history.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may fail to supply drug substance to Chiesi or Pfizer.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may be unable to enhance our portfolio of product candidates.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We or our providers may experience manufacturing problems.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Reliance on third parties for final processing of our products and product candidates exposes us to a number of risks.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Developments by competitors may render our products or technologies obsolete or non-competitive.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches and expose our company to liabilities. </span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may face product liability claims.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Our ability to utilize net operating loss carryforwards may be limited.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Clinical Trials and Regulatory Matters</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all.</span></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may experience delays in obtaining regulatory approvals with respect to any drug candidate.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">If the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified, the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may find it difficult to enroll patients in our clinical trials or patients may discontinue their participation in our clinical trials.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Dependence upon third-party service providers in connection with our clinical trials expose us to risks.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to our Financial Condition and Capital Requirements</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We have a significant level of indebtedness and servicing our debt and settling conversion requests may require a significant amount of cash. Furthermore, restrictive covenants governing our indebtedness may restrict our ability to raise additional capital.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Any conversion of our outstanding 2024 Notes into common stock will dilute the ownership interest of our existing stockholders.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may need to raise additional capital to operate our business, which may not be available on favorable terms, or at all.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Intellectual Property Matters</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">The intellectual property and assets owned by our subsidiaries are subject to security agreements that secure our payment and other obligations under our convertible notes.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Relating to our Operations in Israel</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Our results may be adversely affected by political, economic and military conditions in Israel.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">The Israeli government grants we have received for certain research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require us to satisfy specified conditions.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Investing in our Common Stock</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">The market price of our common stock may fluctuate significantly; future sales of our common stock could reduce our stock price.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses or divert management&#8217;s attention.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span><span style="font-weight:normal;">*</span><span style="display:inline-block;width:31pt;"></span><span style="font-weight:normal;">*</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Commercialization and Continued Approval of our Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We currently depend heavily on the generation of revenues from the sales of Elfabrio and Elelyso. Any failure to commercialize Elfabrio, or the experience of significant delays in doing so, will have a material adverse effect on our business, results of operations and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have invested a significant portion of our efforts and financial resources in the development of Elfabrio, and in the past, on the development of Elelyso. Our ability to generate significant product revenues in the future from sales of Elfabrio depends on Chiesi&#8217;s successful commercialization of Elfabrio, which we do not control and may not be able to effectively influence, and on the actions and decisions of foreign regulatory authorities. Chiesi may experience delays in, or be unable to achieve, the commercial introduction of Elfabrio globally. Similarly, we generate revenues from sales of Elelyso which are depend on Pfizer&#8217;s efforts (except in Brazil), which we do not control. Sales of BioManguinhos alfataliglicerase in Brazil are controlled by Fiocruz. The successful worldwide commercialization of Elfabrio and Elelyso depends on several factors, including the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Chiesi&#8217;s efforts under the Chiesi Agreements and the effectiveness of Chiesi&#8217;s commercial strategy and its execution of that strategy, including its pricing strategy and the effectiveness of its efforts to obtain adequate third-party reimbursements and, to a lesser extent, Pfizer&#8217;s and Fiocruz&#8217;s efforts;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>expanding the scope of the countries in which our products are approved for marketing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>maintaining the cGMP compliance of our manufacturing facility or establishing manufacturing arrangements with third parties;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Chiesi&#8217;s development and maintenance of successful sales and marketing organizations for Elfabrio;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the availability of coverage or reimbursement to patients from relevant healthcare payors for Elfabrio and Elelyso;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the willingness of patients with Fabry disease and Gaucher disease to switch from other treatments to Elfabrio or Elelyso, as the case may be;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>competition from other approved treatments of Fabry disease and Gaucher disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the continued acceptable safety and efficacy profile of Elfabrio and Elelyso; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>other risks described in these Risk Factors.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure to commercialize Elfabrio or Elelyso globally or the experience of significant delays in doing so will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any current products or future product candidates may cause serious adverse events, or SAEs, undesirable side effects or have other properties that could halt their clinical development, prevent, delay, or cause the withdrawal of their regulatory approval, limit their commercial potential, or result in material negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As with most infused products, use of our products or any current or future product candidates could be associated with undesirable side effects or adverse events which can vary in severity and frequency. From time to time, we have observed serious adverse events in clinical studies of our products and product candidates. For example, while conducting clinical trials of Elfabrio, we have observed treatable anaphylactic reactions. Specifically with respect to Elfabrio, as indicated in the boxed warning with which it was approved by the FDA, patients treated with Elfabrio have experienced hypersensitivity reactions, including anaphylaxis. There are postmarketing requirements under the FFDCA included with the approval of Elfabrio by the FDA. For example, the FDA requires that a worldwide descriptive study be conducted that collects prospective and retrospective data in women and their offspring exposed to Elfabrio during pregnancy and/or lactation to assess risk of pregnancy and material complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant. Furthermore, the approval of pharmaceutical products generally includes requirements related to the preparation of a Risk Evaluation and Mitigation Strategy, or REMS, or a risk </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">management plan as required by the EMA, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use. For example, Chiesi must follow a risk management plan agreed upon with the EMA with respect to Elfabrio, which includes risk minimization measures in connection with risks associated with hypersensitivity reactions and possible medication errors in the home infusion setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our product candidates, if approved, may also be subject to certain post-authorization reporting requirements. As an example, the EMA has required that Chiesi submit pharmacovigilance documents intended to provide post-authorization evaluation of Elfabrio&#8217;s risk-benefit balance at defined time points after authorization, beginning within six months of authorization, and that an educational program about home administration be agreed upon with the National Competent Authority prior to the use of Elfabrio in the home setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any of the foregoing, including the boxed warning, could prevent us or our commercialization partners from achieving or maintaining market acceptance of a product or a particular product candidate and could materially harm our business, results of operations, and prospects, and could adversely impact our financial condition, results of operations, ability to raise additional financing or the market price of our common stock.</p><a id="page_ci46701_1_33"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">If safety issues regarding our products that were not known at the time of approval are discovered, or if we or the applicable marketing authorization holder fails to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for our products could be adversely affected and the products could lose their approval or their sales could be suspended.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times';">Drug products remain subject to continuing regulatory oversight after they are approved for marketing, including the review of additional safety information. Drugs are more widely used by patients once approved for sale and, therefore, side-effects and other problems may be observed after approval that were not seen or anticipated, or were not as prevalent or severe, during clinical trials or nonclinical studies. The subsequent discovery of previously unknown problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead to the withdrawal of the product from the market. The reporting of adverse safety events involving our products or public speculation about such events could cause our stock price to decline or experience periods of volatility and may have a material adverse effect on our business, results of operations and financial condition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times';">If we or the marketing authorization holder, or MAH, of any of our products fail to comply with applicable continuing regulatory requirements, we or such MAH may be subject to fines and/or criminal prosecutions, and the product may become subject to suspension or withdrawal of regulatory approval, product recalls and seizures and operating restrictions. In addition, the manufacturers we or an MAH engage to produce a product and the manufacturing facilities in which the product is made are subject to periodic review and inspection by the FDA and foreign regulatory authorities. If problems are identified during the review or inspection of these manufacturers or manufacturing facilities, it could result in the facility becoming unable to manufacture the product or a determination that inventories are not safe for commercial sale, which may have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If physicians, patients, third party payors and others in the medical community do not accept and use Elfabrio, Elelyso or any other future products, our ability to generate revenue from product sales will be materially impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Physicians and patients, and other healthcare providers, may not accept and use Elfabrio, Elelyso or any other future of our other product candidates. Future acceptance and use of any of our products will depend upon a number of factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceptions by physicians, patients, third party payors and others in the medical community about the safety and effectiveness of Elfabrio or Elelyso, or any future product, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects, including any limitations or warnings contained in our products&#8217; approved labeling, including the boxed warning associated with Elfabrio in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pharmacological benefits of Elfabrio or Elelyso, or any future product, if any relative to competing products and products under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages relative to competing products and products under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of education, marketing and distribution efforts by Chiesi, Pfizer and any other relevant licensees and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning Elfabrio or Elelyso, or any future product, if any, or concerning competing products and treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price for our products and competing products.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If the market opportunities for Elfabrio, Elelyso or any other future products are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, our development efforts have focused mainly on relatively rare disorders with relatively small patient populations, in particular Gaucher disease and Fabry disease. Estimation of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas and are often inexact and prone to error. As new studies are performed, the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Gaucher disease or Fabry disease in the study populations, particularly in these newer studies, accurately reflect the prevalence of these diseases in the broader world population. If the market opportunities for our products or product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Coverage and reimbursement may not be available for Elfabrio, Elelyso or any other future products in all territories, which could diminish sales of our products or adversely affect the profitably of such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Market acceptance and sales of Elfabrio, Elelyso or any other future products, if any, will depend on coverage and reimbursement policies in the countries in which they are approved for sale. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. Obtaining reimbursement approval for an approved product from individual governments and other third party payors is a time consuming (six to 12 months or longer) and costly process that requires our collaborators or us, as the case may be, to provide supporting scientific, clinical and cost-effectiveness data for the use of our products, if and when approved, to every payor. Data sufficient to gain acceptance with respect to coverage and reimbursement might not be available, or post-marketing studies may be required in order to demonstrate the cost-effectiveness of approved products, if any, to such payors&#8217; satisfaction. Such studies might require our collaborators or us to commit a significant amount of management time and financial and other resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if a payor determines that an approved product is eligible for reimbursement, the payor may impose coverage limitations that preclude payment for some uses that are approved by the FDA or other regulatory authorities. For example, the U.S.&#160;Inflation Reduction Act allows Medicare to negotiate the prices of the prescription drugs. Such initiatives and legislation may cause added pricing pressure on our products. Proposals that could impact coverage and reimbursement of our products, including giving states more flexibility to manage drugs covered under the Medicaid program and permitting the re-importation of prescription medications from other countries, could have a material adverse effect by limiting our products&#8217; use and coverage. To the extent that private insurers or managed care programs in the United States or elsewhere follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on our products, and the adverse effects may be magnified by their adoption of lower payment schedules. In addition, full reimbursement may not be available for high priced products. Moreover, eligibility for coverage does not imply that any approved product will be reimbursed in all cases or at a rate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">that allows us to make a profit or even cover our costs. Limited reimbursement amounts may reduce the demand for, or the price of, Elfabrio, Elelyso or any other future products. If coverage and reimbursement are not available or are available only to limited levels, the sales of Elfabrio, Elelyso or other future products, if any, may be diminished or we may not be able to sell such products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The pricing of our products in different countries may vary widely, thus creating the potential for third-party trade in our products in an attempt to exploit price differences between countries. This third-party trade of our products could undermine our sales in markets with higher prices which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Fiocruz is not complying, and we expect they will continue to not comply, with the terms and conditions of the Brazil Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We do not control and may not be able to effectively influence Fiocruz&#8217;s ability to distribute BioManguinhos alfataliglicerase in Brazil. Fiocruz has not complied with the purchase requirements of the Brazil Agreement in the past, and we expect Fiocruz will continue to not comply and may otherwise materially breach the agreement. Continued non-compliance may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We face the risk of lower than anticipated purchases of BioManguinhos alfataliglicerase by the Brazilian MoH. In addition, we may fail to supply the intended amounts on time, if at all. We also cannot accurately predict the amount of revenues we will generate under the Brazil Agreement in future periods, if any. Any failure by the Brazilian MoH to purchase BioManguinhos alfataliglicerase, by us to supply BioManguinhos alfataliglicerase for purchase or by Fiocruz to distribute BioManguinhos alfataliglicerase in Brazil, or the experience of significant delays in any of the foregoing, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We and our collaborating partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All marketing activities associated with products that are approved for sale in the United States, if any, will be, directly or indirectly through our customers, subject to numerous federal and state laws governing the marketing and promotion of pharmaceutical products in the United States, including, without limitation, the federal Anti-Kickback Law, the federal False Claims Act and HIPAA. These laws may adversely impact, among other things, our proposed sales, marketing and education programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The federal Anti-Kickback Law prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of co-payments and deductibles, ownership interests and providing anything at less than its fair market value. Despite a series of narrow safe harbors, the federal Anti-Kickback Law prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Law include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other state or federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Law, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs, and do not contain identical safe harbors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The federal False Claims Act imposes liability on any person who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payer and not merely a federal healthcare program. Violations of the federal False Claims Act and the analogous state laws may result in substantial financial penalties, some as much as three times the actual damages sustained by the government.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">HIPAA created several new federal crimes, including health care fraud, and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are unable to predict whether we could be subject to actions under any of these or other fraud and abuse laws, or the impact of such actions. Moreover, to the extent that Elfabrio, Elelyso or any other future products, if any, are sold in a foreign country, we and our collaborators may be subject to similar foreign laws and regulations. If we or any of our collaborators are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or restructuring or our operations, any of which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have a limited commercial operating history which may limit the ability of investors to make an informed investment decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elfabrio and Elelyso are our only commercial products both of which are marketed by our commercialization partners. Our operations to date have been limited to acquiring, developing and securing our proprietary technology and undertaking, through third parties, preclinical and clinical trials of our drug candidates and advancing our drug candidates through the regulatory approval processes. These operations provide a limited basis for investors to assess our ability to commercialize our drug candidates and whether to invest in our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any failure by us to supply drug substance to Chiesi or Pfizer may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have agreed to sell drug substance to Pfizer and Chiesi for the production of Elelyso and Elfabrio. With respect to Elelyso, our drug substance supply commitment is for a 15-year period after the execution of the Amended Pfizer Agreement, subject to certain terms and conditions. As part of that obligation, we agreed to substantial financial penalties if we fail to comply with the supply commitments, or are delayed in doing so. The amounts of the penalties depend on when any such failure occurs and for how long it persists, if at all, and other considerations. Any failure to comply with the supply commitments to Pfizer and/or Chiesi may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our strategy, in certain cases, is to enter into collaboration agreements with third parties to leverage our ProCellEx system to develop product candidates. Failure to enter into such agreements, or non-compliance by us or our collaborators with such agreements, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our strategy, in certain cases, is to enter into arrangements with pharmaceutical companies to leverage our ProCellEx system to develop additional product candidates. Our future revenues may depend, in part, on our ability to enter into and maintain arrangements with our existing partners and other companies having sales, marketing and distribution capabilities and the ability of such companies to successfully market and pharmaceutical products on a global scale. Under these arrangements, we may grant to our partners rights to license and commercialize pharmaceutical products developed under the applicable agreements, as we have done with Elfabrio and Elelyso. Commercialization, marketing, distribution and other similar alliances with respect to our products and product candidates will subject us to a number of risks. We may be required to relinquish important rights to our products or product candidates, and the rights of our partners may limit our flexibility in considering alternatives for the commercialization of our products and product candidates. Our partners may control key decisions relating to the development of the products and we may depend on our partners&#8217; expertise and dedication of sufficient time and resources to develop and commercialize our products and product candidates. Our partners may experience financial difficulties which adversely affect their efforts with respect to our product and product candidates. If we or any of our current or future partners breach or terminate the agreements that make up such arrangements, our partners otherwise fail to conduct their obligations under such arrangements in a timely </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">manner, there is a dispute about their obligations or if either party terminates the applicable agreement or elects not to continue the arrangement, we may not enjoy the benefits of the agreements or receive a sufficient amount of royalty or milestone payments from them, if any, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to enhance our portfolio of product candidates, our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our business strategy is to establish a portfolio of product candidates as targets for development and eventual commercialization. We seek to do so through our internal research programs and strategic collaborations. Research programs to identify new product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. A research program may initially show promise in identifying a potential product candidate, yet fail to immediately yield the product candidate for clinical development for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate is not capable of being produced in commercial quantities at an acceptable cost, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the research methodology used may not be successful in identifying potential product candidates; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may, after further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory approval.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure or delay in the establishment of a portfolio of product candidates as targets for development and eventual commercialization may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The manufacture of our products is an exacting and complex process, and any manufacturing problems encountered by us or certain of our providers may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA and foreign regulators require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance with cGMP or similar requirements that the FDA or foreign regulators establish. We or certain of our services and materials providers, including our fill and finish service providers, may face manufacturing or quality control problems causing product production and shipment delays or a situation where we or the provider may not be able to maintain compliance with the FDA&#8217;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing. We or any such third-party manufacturer might be unable to formulate and manufacture our products in the volume and of the quality required to meet our preclinical, clinical and commercial needs. If we engage any contract manufacturers, such manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our preclinical, clinical or commercial needs. In addition, we and contract manufacturers are subject to the rules and regulations of the FDA and comparable foreign regulatory authorities and face the risk that any of those authorities may find that they are not in compliance with applicable regulations. To date, our current facility has passed audits by the FDA and a number of other regulatory authorities but remains subject to audit by other foreign regulatory authorities. There can be no assurance that we or our contract manufacturers will be able to comply, or continue to comply, with FDA or foreign regulatory manufacturing requirements, and the failure to so comply, or continue to comply, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on third parties for final processing of Elfabrio, Elelyso and our other product candidates, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of Elfabrio, Elelyso or our other product candidates or result in higher product costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no experience in the final filling and freeze drying steps of the drug manufacturing process. We rely on third-party service providers in the United States and Europe to perform fill and finish activities for Elelyso and Elfabrio, and have engaged other parties for our other product candidates. The number of potential fill and finish services providers is limited and we face the risk of being unable to identify manufacturers and/or replacement manufacturers on acceptable </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">terms or at all. In addition, the FDA and other regulatory authorities, as applicable, must approve any manufacturer and/or replacement manufacturer, including us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;"> Any failure to identify and maintain fill and finish service providers could delay our preclinical and clinical trials, the approval, if any, of our potential drug candidates by the FDA and other regulatory authorities, or the commercialization of our drug candidates, or could result in higher product costs or otherwise deprive us of potential product revenues.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have limited experience in selling, marketing or distributing products and limited internal capability to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We currently have very limited sales, marketing or distribution capabilities and no experience in building a sales force and distribution capabilities. Under our arrangements with Pfizer and Chiesi, we have out-licensed the marketing rights to Elfabrio and Elelyso, except that we retained the marketing rights to BioManguinhos alfataliglicerase in Brazil. The commercialization of a product requires the commitment of significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution capabilities. If we elect to commercialize our products directly and without strategic partners we may be unable to recruit and retain adequate numbers of effective sales and marketing personnel. In addition, such sales personnel might not access an adequate number of physicians or persuade them to prescribe our products, or may lack complementary products to offer to such physicians. Commercialization by such sales personnel may expose our company to unforeseen costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Developments by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Our products compete, and our products candidates will have to compete, with existing therapies and therapies under development by our competitors. Our commercial opportunities may be reduced or eliminated if our competitors develop and market products that are less expensive, more effective or safer than our products. Other companies have drug candidates in various stages of preclinical or clinical development to treat diseases for which we are also seeking to develop products. Some of these potential competing drugs are further advanced in development than our drug candidates and may be commercialized earlier. See &#8220;<a href="#_Competition"><span style="font-style:normal;font-weight:normal;">Business&#160;&#8211; Competition</span></a>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Most of our competitors, either alone or together with their collaborative partners, operate larger research and development programs, staff and facilities and have substantially greater financial resources than we do, as well as significantly greater experience in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">undertaking preclinical testing and human clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining marketing approvals from the FDA and other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulating and manufacturing drugs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching, marketing and selling drugs.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These organizations also compete with us to attract qualified personnel, acquisitions and joint ventures candidates and for other collaborations. Activities of our competitors may impose unanticipated costs on our business or adversely affect the market for our products which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we in-license drug candidates, we may delay or otherwise adversely affect the development of our existing drug candidates, which may negatively impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition to our own internally developed drug candidates, we proactively seek opportunities to in-license and advance other drug candidates that are strategic and have value-creating potential to take advantage of our development know-how and technology. In-licensing additional drug candidates may significantly increase our capital requirements, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">place a strain on the time of our existing personnel, which may delay or otherwise adversely affect the development of our existing drug candidates or cause us to re-prioritize our drug pipeline if we do not have the necessary capital resources to develop all of our drug candidates, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we acquire companies, products or technologies, we may face integration risks and costs associated with those acquisitions that could potentially negatively impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If we are presented with appropriate opportunities, we may acquire or make investments in complementary companies, products or technologies. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology with our products, diversion of our management&#8217;s attention from other business concerns, the potential loss of key employees or customers of the acquired business and impairment charges if future acquisitions are not as successful as we originally anticipate. In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating to acquired intangible assets. Any failure to successfully integrate other companies, products or technologies that we may acquire may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are highly dependent upon the principal members of our management team, especially our President and Chief Executive Officer, Dror Bashan, as well as the Chairman of our Board of Directors, Eliot Forster, our other directors, consultants and collaborating scientists. Many of these people have been involved with us for many years and have played integral roles in our progress, and we believe that they will continue to provide value to us. A loss of any of these personnel may have a material adverse effect on aspects of our business, clinical development and regulatory programs. We have employment agreements with Mr.&#160;Bashan and our other executive officers that may be terminated by us or the applicable officer at any time with varying notice periods of 30 to 180&#160;days. The loss of any of these persons&#8217; services may adversely affect our ability to develop and market our products and obtain necessary regulatory approvals. Further, we do not maintain key-man life insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also depend in part on the continued service of our key scientific personnel and our ability to identify, hire and retain additional personnel. We experience intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees and their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Under current U.S. and Israeli laws, we may not be able to enforce employees&#8217; covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into non-competition agreements with substantially all of our employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. Under current U.S. and Israeli laws, we may be unable to enforce these agreements against most of our employees and it may be difficult for us to restrict our competitors from gaining the expertise our former employees acquired while working for us. If we cannot enforce our employees&#8217; non-compete agreements, we may be unable to prevent our competitors from benefiting from the expertise of our former employees, which may have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. While our assessment of our internal control over financial reporting resulted in our conclusion that as of December&#160;31, 2023, our internal control over financial reporting was effective, we cannot predict the outcome of our testing or any subsequent testing by our auditor in future periods. Any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information and affect our reputation, which could have an adverse effect on the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management is required to assess the effectiveness of our internal controls and procedures and disclose changes in these controls on an annual basis. However, for as long as we are a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal control could identify deficiencies in internal control over financial reporting that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches, resulting in liability and harm to our reputation, which could negatively affect our business, results of operation and financial condition. We may face liability if we breach our obligations related to the protection, security, nondisclosure of confidential information or disclosure of sensitive data or fail or are perceived to fail to comply with applicable data protection laws and regulations, or consumer protection laws, regulations and standards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Despite the implementation of security measures, our internal computer systems and those of our present and future contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. Although to our knowledge we have not experienced any material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. We have a cybersecurity insurance policy to protect us from such risks. However, to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability despite our insurance policy, and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Further, the global data protection landscape is rapidly evolving, and we are or may become subject to numerous local and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect about individuals worldwide. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with local or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our failure to adhere to or successfully implement processes in response to changing regulatory requirements in this area could result in legal liability or impairment to our reputation in the marketplace, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We could be subject to securities class action litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, results of operation and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If product liability claims are brought against us, it may result in reduced demand for our products and product candidates or damages that exceed our insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The use and marketing of our products and product candidates, including in connection with clinical trials, exposes us to product liability or similar claims if the use or misuse of those products or product candidates cause injury or disease, or results in adverse effects. We presently carry product liability and clinical trial liability insurance with coverages of up to $10.0&#160;million per occurrence and $10.0&#160;million in the aggregate, an amount we consider reasonable and customary. However, this insurance coverage includes various deductibles, limitations and exclusions from coverage, and in any event might not fully cover any potential claims. In the future, we may need to obtain additional product liability and clinical trial liability coverage; however, such insurance is expensive and insurance companies may not issue this type of insurance when we need it. We may not be able to obtain adequate insurance in the future at an acceptable cost. Any product liability claim, even one that was not in excess of our insurance coverage or one that is meritless and/or unsuccessful, may adversely affect the availability of funds for other purposes, such as research and development, which may have a material adverse effect on our business, results of operations and financial condition. Product liability claims, even if without merit, may result in reduced demand for our products, if approved, or result in adverse market reactions, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our ability to utilize net operating loss carryforwards may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our NOL carryforwards as of December&#160;31, 2023, are equal to approximately $234.8&#160;million, of which approximately $24.4&#160;million may be restricted under Section&#160;382 of the Internal Revenue Code, or the IRC. IRC Section&#160;382 applies whenever a corporation with NOLs experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post-change year that may be offset by a pre-change NOL may not exceed the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate. Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, we considered all available evidence, including past operating results, the most recent projections for taxable income and prudent and feasible tax planning strategies. We reassess our valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly. Any ownership change (including as a result of conversion of our outstanding convertible notes into shares of our common stock), or any other limitation on our utilization of NOLs, could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our corporate structure may create U.S. federal income tax inefficiencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd. is our wholly-owned subsidiary and thus a controlled foreign corporation of our company for U.S. federal income tax purposes. This organizational structure may create inefficiencies, as certain types of income and investments of Protalix&#160;Ltd. that otherwise would not be currently taxable under general U.S. federal income tax principles may become taxable. These inefficiencies may require us to use more of our NOLs than we otherwise might and may result in a tax liability without a corresponding distribution from our subsidiary which could have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, on December&#160;22, 2017, the U.S.Tax Cuts and Jobs Act, or the TCJA, that significantly reforms the IRC was enacted. The TCJA, among other things, includes changes to U.S.&#160;federal tax rates, imposes significant additional limitations on the deductibility of certain expenses and adds certain limitations to the use of net operating loss carryforwards arising after December&#160;31, 2017. Effective in 2022, the TCJA requires all U.S. companies to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174&#160;over five years for research activities conducted in the United States and over 15 years for research activities conducted outside of the United States rather than deducting such costs in the year incurred for tax purposes. As a result of the TCJA, we expect to incur an increase in our tax expenses and a decrease in our cash flows provided by operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are a holding company with no operations of our own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We are a holding company with no operations of our own. Accordingly, our ability to conduct our operations, service any current or future debt and pay dividends, if any, is dependent upon the earnings from the business conducted by Protalix&#160;Ltd. The distribution of those earnings or advances or other distributions of funds by our subsidiary to us, as well as our receipt of such funds, are contingent upon the earnings of Protalix&#160;Ltd. and are subject to various business considerations and U.S. and Israeli laws. If Protalix&#160;Ltd. is unable to make sufficient distributions or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may not have the cash resources necessary to conduct our corporate operations or service our debt which would have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Outbreaks of contagious disease or similar public health threats could materially and adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Outbreaks of contagious disease or other adverse public health developments worldwide could have a material adverse effect on our business, financial condition and results of operations. Outbreaks of contagious disease or other adverse public health developments could affect our business in a number of ways, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disruptions or restrictions on our employees&#8217; ability to work effectively due to illness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Temporary closures or disruptions at our facilities or the facilities of our contract manufacturers or suppliers could  adversely affect our ability to timely meet our customer&#8217;s orders and negatively impact our supply chain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Outbreaks of contagious disease could cause delays or disruptions in our supply chain; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The failure of third parties on which we rely to meet their respective obligations to us, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties, could have an adverse impact on our business, financial condition or results of operations; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The impact of contagious disease or other adverse public health developments could also exacerbate other risks discussed elsewhere in these Risk Factors, any of which could have a material adverse effect on us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our operating costs and business operations could be adversely affected by climate-related events and increasing regulatory requirements and security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The effects of climate change (such as drought, flooding, heat waves, wildfires, increased storm severity, and sea level rise, etc.) could affect our ability to continue our operations and cause delays in the development of our existing drug candidates, manufacturing and shipment, all of which could cause reputational harm or otherwise have an adverse effect on our business, results of operation and financial condition. In addition, the impacts of climate change on the global economy and our industry are rapidly evolving. Changing market dynamics, global policy developments and the increasing frequency and impact of extreme weather events on critical infrastructure across different countries could have the potential to disrupt our business, the business of our third-party suppliers and the business of our customers, and may cause us to experience higher attrition, losses and additional costs to maintain or resume operations. We also expect to face increasing regulatory requirements and regulatory scrutiny related to climate matters, resulting in higher associated compliance costs. Failure to uphold, meet or make timely forward progress against our public commitments </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">and goals related to climate action could adversely affect our reputation with suppliers and customers, financial performance or the ability to recruit and retain talent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Clinical Trials and Regulatory Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To commercialize our drug candidates worldwide, we need FDA approval, EMA approval and approvals from other countries&#8217; regulators to commercialize our drug candidates elsewhere, as applicable. In order to obtain FDA approval of any of our drug candidates, we must submit to the FDA a BLA or an NDA demonstrating that the drug candidate is safe and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials. In the European Union, we must submit an MAA to the EMA. Satisfaction of the regulatory requirements of the FDA, EMA and other countries&#8217; regulatory authorities typically takes many years, depends upon the type, complexity and novelty of the drug candidate and requires substantial resources for research, development and testing. The results of clinical trials of our product candidates may fail to demonstrate that the candidates are safe and effective for their intended uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings or other comparable authorities for such clinical trials. Further, even if favorable testing data is generated by the clinical trials of a drug candidate, the applicable regulatory authority may not accept or approve a marketing application we file for the drug candidate or may require us to conduct additional clinical testing or perform post-marketing studies which would cause us to incur additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Failure to obtain approval of the FDA, EMA or comparable foreign authorities of any of our product candidates in a timely manner, if at all, will severely undermine our business, results of operations and financial condition by decreasing our ability to generate product revenues from the sales of such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">We are subject to extensive governmental regulation including the requirements of the FDA and other comparable regulatory authorities before our drug candidates may be marketed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Both before and after marketing approval of our drug candidates, if at all, we, our drug candidates, our suppliers, our contract manufacturers and our contract testing laboratories are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. Failure to comply with applicable requirements of the FDA or comparable foreign regulatory authorities could result in, among other things, any of the following actions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines and other monetary penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the FDA&#8217;s or other foreign regulatory authorities&#8217; approving, or the refusal of any regulatory authority to approve, any drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recall or seizure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of manufacturing or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecutions.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to the approval requirements, other numerous and pervasive regulatory requirements apply, both before and after approval, to us, our drug candidates, our suppliers, contract manufacturers, and contract testing laboratories. These include requirements related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quality control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advertising;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">promotion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">export;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting to the FDA certain adverse experiences associated with use of the drug candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining additional approvals for certain modifications to the drug candidate or its labeling or claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also are subject to inspection by the FDA and comparable foreign regulatory authorities, to determine our compliance with regulatory requirements, as are our suppliers, contract manufacturers, and contract testing laboratories, and there can be no assurance that the FDA, or any other comparable foreign regulatory authority, will not identify compliance issues that may disrupt production or distribution, or require substantial resources to correct. We may be required to make modifications to our manufacturing operations in response to these inspections which may require significant resources and may have a material adverse effect upon our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The approval process for any drug candidate may also be delayed by changes in government regulation, future legislation or administrative action or changes in policy of the FDA and comparable foreign authorities that occur prior to or during their respective regulatory reviews of such drug candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Delays in obtaining regulatory approvals with respect to any drug candidate will materially and adversely affect our prospects, business, results of operations and financial condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Delays in obtaining regulatory approvals with respect to any drug candidate may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay commercialization of, and our ability to derive product revenues from, such drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay any regulatory-related milestone payments payable under outstanding collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to perform costly procedures with respect to such drug candidate; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise diminish any competitive advantages that we may have with respect to such drug candidate.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Delays in the approval process for any drug candidate may have a material adverse effect upon our prospects, business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs, which may have a material adverse effect on our business, results of operations and financial condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Preliminary and initial results from a clinical trial do not necessarily predict final results, and failure can occur at any stage of the trial. We may encounter problems that could cause us to abandon or repeat preclinical studies or clinical trials. The clinical trial process is also time-consuming. Failure or delay in the commencement or completion of our clinical trials may be caused by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected rates of patient recruitment, particularly with respect to trials of rare diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination of dosing issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of effectiveness during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreement by applicable regulatory bodies over our trial protocols, the interpretation of data from preclinical studies or clinical trials or conduct and control of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination that the patient population participating in a clinical trial may not be sufficiently broad or representative to assess efficacy and safety for our target population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to monitor patients adequately during or after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of sufficient funding to finance the clinical trials.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure or delay in commencement or completion of any clinical trials of our product candidates will have a material adverse effect on our business, results of operations and financial condition. In addition, we, the FDA or other regulatory authorities may suspend any clinical trial at any time if it appears that we are exposing participants in the trial to unacceptable safety or health risks or if the FDA or such other regulatory authorities, as applicable, find deficiencies in our IND submissions or the conduct of the trial. Any suspension of a clinical trial may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">If the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified, the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether, which will significantly impair our ability to generate product revenues.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of our clinical trials with respect to any drug candidate might not support our claims of safety or efficacy, the results of our clinical trials may fail to conclusively show superiority over other commercially available treatments for the same or similar indications, the effects of our drug candidates may not be the desired effects or may include undesirable side effects or the drug candidates may have other unexpected characteristics. Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. The clinical trial process may fail to demonstrate that our drug candidates are safe for humans and effective for indicated uses. In addition, our clinical trials, may involve specific and small patient populations. Results of early clinical trials conducted on a small patient population may not be indicative of future results. Adverse or inconclusive results may cause us to abandon a drug candidate and may delay development of other drug candidates. Any delay in, or termination of, our clinical trials will delay the filing of BLAs and NDAs with the FDA, or other filings with other foreign regulatory authorities, and, ultimately, significantly impair our ability to commercialize our drug candidates and generate product revenues which would have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interim, top-line or preliminary data from clinical trials that we announce or publish may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, any interim, top-line or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different than the preliminary data we previously published. As a result, any top-line data should be viewed with caution until final data are available. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more data becomes available. Further, regulatory agencies may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses, or may interpret or ascribe different weight to the data, which may impact the value of the clinical trial and may affect the particular clinical program and the approvability or commercialization of the particular product candidate and our business in general. If regulatory authorities disagree with the conclusions we reach, we may not be able to obtain approval for and commercialize our product candidates, which will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may find it difficult to enroll patients in our clinical trials, or patients may discontinue their participation in our clinical trials, which could cause significant delays in the completion of such trials or may negatively impact the results of these studies and extend the timeline for completion of our development programs or cause us to abandon one or more clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Some of the diseases or disorders that our drug candidates under evaluation are intended to treat are relatively rare and we expect only a subset of the patients with these diseases to be eligible for our clinical trials. Our clinical trials generally mandate that a patient cannot be involved in another clinical trial for the same indication. Therefore, subjects that participate in ongoing clinical trials for products that are competitive with our drug candidates are not available for our clinical trials. An inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, patients who enroll in our clinical trials may discontinue their participation at any time during the study as a result of a number of factors, related to the trials or not, including withdrawing their consent, experiencing adverse clinical events, which may or may not be judged related to our drug candidates, or due to personal reasons, such as planned or actual pregnancies. The discontinuation of patients in any one of our studies may delay the completion of the study or cause the results from the study not to be positive or to not support a filing for regulatory approval of the applicable drug candidate. Any failure to enroll a sufficient number of patients in our clinical trials in a timely manner, if at all, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our clinical trials depend upon third-party service providers and, accordingly, the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain extent, beyond our control, which could impair our clinical development programs and our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We depend upon independent investigators and collaborators, such as universities and medical institutions, to conduct our preclinical and clinical trials. These collaborators are not our employees, and we cannot control the amount or timing of resources that they devote to our clinical development programs. The investigators may not prioritize to our clinical development programs or pursue them as diligently as we would if we were undertaking such programs directly. If outside collaborators fail to devote sufficient time and resources to our clinical development programs, or if their performance is substandard, the approval of anticipated NDAs, BLAs and other marketing applications, and our introduction of new drugs, if any, may be delayed which could impair our clinical development programs and would have a material adverse effect on our business, results of operations and financial condition. Our collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators also assist our competitors, our competitive position could be harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have only limited experience in regulatory affairs, and some of our drug candidates may be based on new technologies. These factors may affect our ability or the time we require to obtain necessary regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have only limited experience in filing and prosecuting the applications necessary to gain regulatory approvals for medical devices and drug candidates. Moreover, some of the drug candidates that are likely to result from our development programs may be based on new technologies that have not been extensively tested in humans. The regulatory requirements governing these types of drug candidates may not be well defined or more rigorous than for conventional products. As a result, we may experience a longer regulatory process in obtaining regulatory approvals of any products that we develop, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We may seek orphan drug or other comparable designations for our product candidates in specific indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States or other applicable jurisdictions may be limited if we seek approval for an indication broader than the orphan designated indication, and may be lost if the FDA, or other applicable regulatory authorities later determine that the request for designation was materially defective, if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, more than one drug can have orphan designation for the same indication. Although we may seek orphan drug designation for other product candidates, we might not receive such designations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to our Financial Condition and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Servicing our debt and settling conversion requests may require a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt. Furthermore, restrictive covenants governing our indebtedness may restrict our ability to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, we have outstanding $20.4&#160;million aggregate principal amount of our 2024 Notes which are secured with a perfected lien on all of our assets. Under the terms of the indenture governing the 2024 Notes, or the 2024 Indenture, we are required to maintain a minimum cash balance of at least $7.5&#160;million. Our ability to make payments with respect to the 2024 Notes and to satisfy any other debt obligations depends on our future operating performance and our ability to generate significant cash flow in the future, which will be affected by prevailing economic conditions and financial, business, competitive, legislative and regulatory factors as well as other factors affecting our company and industry, many of which are beyond our control. If, when required, we are unable to comply with the terms of the 2024 Notes, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. In addition, certain terms of the 2024 Notes regarding the security interest or future indebtedness may restrict us from adopting any of these alternatives. We may be unable to obtain amendments and waivers of such restrictions. If there is a default on such notes, the note holders could, among other things, elect to declare all amounts owed immediately due and payable, which could cause all or a large portion of our available cash flow to be used to pay such amounts and thereby reduce the amount of cash available to pursue our business plans or force us into bankruptcy or liquidation, or, with respect to our indebtedness that is secured, result in the foreclosure on the assets that secure the debt, which would force us to relinquish rights to assets that we may believe are critical to our business. Any default on our debt will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our significant level of indebtedness could adversely affect our business, results of operations and financial condition and prevent us from fulfilling our obligations under our convertible notes and our other indebtedness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our 2024 Notes represent a significant amount of indebtedness with substantial debt service requirements. We may also incur additional indebtedness to meet future financing needs. Our substantial indebtedness could have material adverse effects on our business, results of operations and financial condition. For example, it could:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make it more difficult for us to satisfy our financial obligations, including with respect to the 2024 Notes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">result in an event of default under the 2024 Indenture if we fail to comply with the financial and other restrictive covenants contained in agreements governing any future indebtedness, which event of default could result in all of our debt becoming immediately due and payable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase our vulnerability to general adverse economic, industry and competitive conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the availability of our cash flow to fund working capital, capital expenditures, acquisitions and other general corporate purposes because we will be required to dedicate a substantial portion of our cash flow from operations to the payment of principal and interest on our indebtedness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit our flexibility in planning for, or reacting to, and increasing our vulnerability to changes in our business, the industry in which we operate and the general economy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent us from raising funds necessary to purchase 2024 Notes surrendered to us by holders upon a fundamental change (as described in the 2024 Indenture), which failure would result in an event of default with respect to the 2024 Notes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">place us at a competitive disadvantage compared to our competitors that have less indebtedness or are less highly leveraged and that, therefore, may be able to take advantage of opportunities that our debt levels or leverage prevent us from exploiting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit our ability to obtain additional financing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Each of these factors may have a material and adverse effect on our business, results of operations and financial condition and our ability to meet our payment obligations relating to the 2024 Notes and our other indebtedness. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">We are required to comply with a number of covenants under the 2024 Indenture governing our outstanding 2024 Notes that could hinder our growth.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The 2024 Indenture contains a number of restrictive affirmative and negative covenants, which limit our ability to incur additional debt; exceed certain limits; pay dividends or distributions; or merge, consolidate or dispose of substantially all of our assets, including all of our intellectual property assets and other material assets securing the 2024 Notes. A breach of these covenants could result in default, and if such default is not cured or waived, the holders of the indebtedness could, among other things, elect to declare all amounts owed immediately due and payable, which could cause all or a large portion of our available cash flow to be used to pay such amounts and thereby reduce the amount of cash available to pursue our business plans or force us into bankruptcy or liquidation, or, result in the foreclosure on the assets that secure the debt, including all of our intellectual property assets, which would force us to relinquish rights to such assets that we may believe are critical to our business. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. Any default on our debt will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any conversion of our outstanding 2024 Notes into common stock will dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The conversion of some or all of our 2024 Notes into shares of our common stock will dilute the ownership interests of our existing stockholders. Any sales in the public market of our common stock issuable upon such conversions could adversely affect prevailing market prices of our common stock. In addition, the existence of our outstanding 2024 Notes may encourage short selling by market participants because the conversion of 2024 Notes could depress the market price of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The fundamental change purchase feature of our outstanding 2024 Notes may delay or prevent an otherwise beneficial attempt to take over our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The terms of our outstanding 2024 Notes require us to offer to purchase the notes for cash in the event of a fundamental change. A non-stock takeover of our company may trigger the requirement that we purchase the notes. This feature may have the effect of delaying or preventing a takeover of our company that would otherwise be beneficial to our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may fail to meet the continued market capitalization-based listing requirement or other continued listing requirements of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of the listed companies. The trading price of our common stock has been volatile and has been subject to wide price fluctuations in response to various factors, many of which are beyond our control. The volatility of our stock price has from time to time in recent periods affected our market capitalization. Adverse fluctuations in the price per share of our common stock or our market capitalization may result in our failure to meet the continued listing requirements of the NYSE American, which would require us to take steps to gain compliance with alternate listing standards or take remedial steps to bring us into compliance. A failure to maintain or regain compliance with applicable listing standards could adversely affect the liquidity of our common stock and could result in an event of default under the 2024 Indenture, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may need to raise additional capital to operate our business, which may not be available on favorable terms, or at all, and which will have a dilutive effect on our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the years ended December&#160;31, 2022 and 2021, we had net losses from continuing operations of $14.9&#160;million and $27.6&#160;million, respectively, and, in the year ended December&#160;31, 2023, we had a net income of $8.3&#160;million. The net losses for the years ended December&#160;31, 2022 and 2021 were primarily the result of expenses incurred through a combination of research and development activities and expenses supporting those activities, which includes share-based compensation expense. We may incur losses in future fiscal years as we continue to execute on our strategic goals as drug development and commercialization is very capital intensive. We expect to continue to incur significant operating expenditures, and we anticipate that our expenses will increase in the foreseeable future as we seek to in-license additional technologies, continue to undertake preclinical development and clinical trials for our current and new drug candidates and seek regulatory approvals for our drug candidates. In addition, changes may occur that could consume our existing capital at a faster rate than projected, including, among others, the cost and timing of regulatory approvals, changes in the progress of our research and development efforts and the costs of protecting our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently, our source of potential revenues will be from royalties and commercial milestone payments generated from Pfizer, Fiocruz and Chiesi. We have also generated revenues from research and development services and milestone and other payments we received in connection with our agreements with our commercialization partners, and generated capital from equity and debt offerings and other sources. The revenues we generate from royalties and commercial milestone payments and other sources may not be sufficient to fund our planned operations and capital expenditures. Accordingly, we may need to finance our future cash needs through corporate collaboration, licensing or similar arrangements, public or private equity offerings or debt financings. If we are unable to secure additional financing in the future on acceptable terms, or at all, we may be unable to expand our portfolio of product candidates, commence or complete planned preclinical and clinical trials or obtain approval of our drug candidates from the FDA and other regulatory authorities. In addition, we may be forced to reduce or discontinue product development or product licensing, reduce or forego sales and marketing efforts and other commercialization activities or forego attractive business opportunities in order to improve our liquidity and to enable us to continue operations which would have a material adverse effect on our business and results of operations. Furthermore, any additional source of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Intellectual Property Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The intellectual property and assets owned by our subsidiaries are subject to security agreements that secure our payment and other obligations under our convertible notes, and our subsidiaries have guaranteed all of those obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the issuance of our 2024 Notes, we entered into new security agreements pursuant to which our subsidiaries provided first priority security interests in all of their assets, which consist of all of our intellectual property and other material assets. The security agreements secure certain payment, indemnification and other obligations under the 2024 Notes. If we were to default on certain of our obligations, or in certain other circumstances generally related to a bankruptcy or insolvency, holders of our outstanding 2024 Notes&#160;could seek to foreclose on the collateral under the security agreements to obtain satisfaction of our obligations, and our business could be materially and adversely impacted, which would in turn have a material adverse effect on our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, in connection with the issuance of the 2024 Notes, our subsidiaries guaranteed all of our obligations under the 2024 Indenture. If we were to default on our obligations under the 2024 Indenture, the holders could require our subsidiaries to satisfy all of those obligations under the guarantees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents, the value of our intellectual property rights would diminish and our business, competitive position and results of operations would suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2023, we had approximately 50 pending patent applications. However, the filing of a patent application does not mean that we will be issued a patent, or that any patent eventually issued will be as broad as requested in the patent application or sufficient to protect our technology. Any modification required to a current patent application may delay the approval of such patent application which may have a material adverse effect on our business, results of operations and financial condition. In addition, there are a number of factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent applications to not be granted, including known or unknown prior art, deficiencies in the patent application or the lack of originality of the technology. Our competitive position and future revenues will depend in part on our ability and the ability of our licensors and collaborators to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing the proprietary rights of third parties. We have filed U.S. and international patent applications for process patents, as well as composition of matter patents, for Elfabrio, Elelyso and our product candidates. However, we cannot predict:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and range of protection any patents will afford us against competitors and those who infringe upon our patents, including whether third parties will find ways to invalidate or otherwise circumvent our licensed patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if and when patents will issue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not others will obtain patents claiming aspects similar to those covered by our licensed patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will need to initiate litigation or administrative proceedings, which may be costly, whether we win or lose.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2023, we held, or had license rights to, approximately 90 patents. If patent rights covering our products or technologies are not sufficiently broad, they may not provide us with sufficient proprietary protection or competitive advantages against competitors with similar products and technologies. Furthermore, if the USPTO or foreign patent offices issue patents to us or our licensors, others may challenge the patents or circumvent the patents, or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from or to third parties may not provide any protection against our competitors and those who infringe upon our patents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the life of our patents is limited. The patents we hold, and the patents that may be issued in the future based on patent applications from the patent families, relating to our ProCellEx protein expression system are expected to expire by 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on confidentiality agreements that could be breached and may be difficult to enforce which could have a material adverse effect on our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our policy is to enter agreements relating to the non-disclosure of confidential information with third parties, including our contractors, consultants, advisors and research collaborators, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them. However, these agreements can be difficult and costly to enforce. Moreover, to the extent that our contractors, consultants, advisors and research collaborators apply or independently develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual property. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can be costly and unpredictable. In addition, we rely on trade secrets and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors and others. Despite the protective measures we employ, we still face the risk that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these agreements may be breached;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these agreements may not provide adequate remedies for the applicable type of breach; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our trade secrets or proprietary know-how will otherwise become known.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any breach of our confidentiality agreements or our failure to effectively enforce such agreements may have a material adverse effect on our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we infringe the rights of third parties we could be prevented from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs and may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have not received to date any claims of infringement by any third parties. However, as our drug candidates progress into clinical trials and commercialization, if at all, our public profile and that of our drug candidates may be raised and generate such claims. Defending against such claims, and occurrence of a judgment adverse to us, could result in unanticipated costs and may have a material adverse effect on our business and competitive position. If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we may incur substantial costs and we may have to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain licenses, which may not be available on commercially reasonable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">redesign our products or processes to avoid infringement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stop using the subject matter claimed in the patents held by others, which could cause us to lose the use of one or more of our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of management resources; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pay damages.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any costs incurred in connection with such events or the inability to sell our products may have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we cannot meet requirements under our license agreements, we could lose the rights to our products, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We depend on licensing agreements with third parties to maintain the intellectual property rights to certain of our product candidates. Our license agreements require us to make payments and satisfy performance obligations in order to maintain our rights under these agreements. All of these agreements last either throughout the life of the patents that are the subject of the agreements, or with respect to other licensed technology, for a number of&#160;years after the first commercial sale of the relevant product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our license agreements in a timely manner, we could lose the rights to our proprietary technology which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Relating to our Operations in Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Significant parts of our operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military conditions in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our executive office and operations are located in the State of Israel. Accordingly, economic, geopolitical and military conditions in Israel and the surrounding region could directly affect our business. Any armed conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could adversely affect our operations. Since the establishment of Israel in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors, Hamas and Hezbollah. In October 2023, terrorists from the Hamas&#160;organization infiltrated Israel&#8217;s southern border from the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. The attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, as well as actions that could be taken in the future by NATO, the United States, the United Kingdom the European Union or Israel&#8217;s neighboring states and other countries have created global security concerns that may result in a greater or lasting regional conflict. To date, our operations have not been adversely affected by this situation. Hostilities have not taken place where our facilities are located and we do not anticipate any disruption to the supply of Elfabrio or Elelyso. However, our facilities are in range of certain of the rockets that are being fired from Lebanon and elsewhere. We suffered minimal damages during a rocket attack in 2006. Our insurance policies do not cover damages incurred in connection with these conflicts or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage for the reinstatement value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing such coverage or the coverage might not be enough to cover potential damages. Any damage to our facilities as a result of war or other hostile action may have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Ongoing and revived hostilities or other Israeli political or economic factors, could prevent or delay shipments of our products, harm our operations and product development and cause any future sales to decrease. If hostilities disrupt the ongoing operation of our facilities or the airports and seaports on which we depend to import and export our supplies, materials, drug substance and other products, our business, results of operations and financial condition may be materially and adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">Parties with whom we do business may sometimes decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary to meet our business partners face to face. Further, shifting economic and political conditions in the United States and in other countries may result in changes in how the United States and other countries conduct business and other relations with Israel, which may have an adverse impact on our Israeli operations and a material adverse impact on our business. In addition, several countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of hostilities in the region or otherwise. Moreover, there have been </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">increased efforts by organizations and movements to cause companies and consumers to boycott Israeli goods based on Israeli government policies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our operations may be disrupted by the obligations of our personnel to perform military service which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Many of our male employees in Israel, including members of senior management, are obligated to perform up to one&#160;month (in some cases more) of annual military reserve duty until they reach the age of 45 and, in the event of a military conflict, could be called to active duty. To date, we have not suffered any disruptions to our operations from the absence of employees in connection with the current military action. However, we continue to face the risk that our operations could be disrupted by the absence of a significant number of our employees related to military service or the absence for extended periods of military service of one or more of our key employees. Any such disruption may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">A certain portion of our expenses is incurred in New Israeli Shekels and, accordingly, our results of operations may be seriously harmed by currency fluctuations and inflation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We report our financial statements in U.S.&#160;dollars, our functional currency. Although most of our expenses are incurred in U.S.&#160;dollars, we pay a portion of our expenses in New Israeli Shekels, or NIS, and as a result, we are exposed to risk to the extent that the inflation rate in Israel exceeds the rate of devaluation of the NIS in relation to the U.S.&#160;dollar or if the timing of these devaluations lags behind inflation in Israel. In that event, the U.S.&#160;dollar cost of our operations in Israel will increase and our U.S.&#160;dollar-measured results of operations will be adversely affected. To the extent that the value of the NIS increases against the U.S.&#160;dollar, our expenses on a dollar cost basis increase. Our operations also could be adversely affected if we are unable to guard against currency fluctuations in the future. To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The tax benefits available to us require that we meet several conditions and may be terminated or reduced in the future, which would increase our taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are able to take advantage of tax exemptions and reductions resulting from the &#8220;Approved Enterprise&#8221; status of our facilities in Israel. To remain eligible for these tax benefits, we must continue to meet certain conditions, including making specified investments in property and equipment, and financing at least 30% of such investments with share capital. If we fail to meet these conditions in the future, the tax benefits would be canceled and we may be required to refund any tax benefits we already have enjoyed. These tax benefits are subject to investment policy by the Investment Center and may not be continued in the future at their current levels or at any level. In recent&#160;years the Israeli government has reduced the benefits available and has indicated that it may further reduce or eliminate some of these benefits in the future. The termination or reduction of these tax benefits or our inability to qualify for additional &#8220;Approved Enterprise&#8221; approvals may increase our tax expenses in the future, which would reduce our expected profits and adversely affect our business and results of operations. Additionally, if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Israeli government grants we have received for certain research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received together with interest and penalties which could have a material adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In the past, our research and development efforts have been financed, in part, through grants that we have received from NATI. We, therefore, must comply with the requirements of the Research Law. Under the Research Law we are prohibited from manufacturing products developed using these grants outside of the State of Israel without special approvals, although the Research Law does enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased royalties. We may not receive the required approvals for any proposed transfer of manufacturing activities. Even if we do receive approval to manufacture products developed </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">with government grants outside of Israel, we may be required to pay an increased total amount of royalties (possibly up to 600% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside of Israel, as well as a possibly increased royalty rate. This restriction may impair our ability to outsource manufacturing or engage in similar arrangements for those products or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, under the Research Law, Protalix&#160;Ltd. is prohibited from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix&#160;Ltd. may not receive the required approvals for any proposed transfer and, if received, Protalix&#160;Ltd. may be required to pay NATI a portion of the consideration that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that Protalix&#160;Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to NATI. Approval of the transfer of technology to residents of the State of Israel is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested, will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These restrictions may impair our ability to sell our technology assets or to outsource manufacturing outside of Israel. The restrictions will continue to apply for a certain period of time even after we have repaid the full amount of royalties payable for the grants. If we fail to satisfy the conditions of the Research Law, we may be required to refund certain grants previously received together with interest and penalties, and may become subject to criminal charges, any of which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Investors may have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws against us, our executive officers and most of our directors or asserting U.S. securities laws claims in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A majority of our directors and all of our executive officers are residents of Israel, and accordingly, most of their assets and our assets are located outside the United States. Service of process upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us or our non-U.S. resident directors and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S.&#160;securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S.&#160;federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S.&#160;securities laws against us or our non-U.S. resident officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our non-U.S. resident officers and directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Moreover, among other reasons, including but not limited to, fraud or absence of due process, or the existence of a judgment which is at variance with another judgment that was given in the same matter if a suit in the same matter between the same parties was pending before a court or tribunal in Israel, an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Investing in our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The market price of our common stock may fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The market price of our common stock has experienced significant volatility. The securities of life sciences companies often experience significant volatility in connection with clinical trial and regulatory announcements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We anticipate that the market price of our common stock is likely to continue to fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of Elfabrio by Chiesi;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our sale of shares of our common stock under our ATM program, or market expectations that such sales are to be executed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchases of BioManguinhos alfataliglicerase in Brazil; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and results of the studies of our product candidates under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the announcement of new products or product enhancements by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning intellectual property rights and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our and our competitors&#8217; results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in earnings estimates or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments in the biotechnology industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market conditions and other factors, including factors unrelated to our operating performance, such as the Israel-Hamas war.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility of our common stock may be worse when the trading volume of our common stock is low. We have not paid, and do not expect to pay, any cash dividends on our common stock as any earnings generated from future operations will be used to finance our operations. As a result, investors will not realize any income from an investment in our common stock until and unless their shares are sold at a profit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Future sales of our common stock could reduce our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If our stockholders sell substantial amounts of our common stock, including shares of our common stock underlying our outstanding convertible notes and warrants, or if we sell a substantial amount of our common stock under our ATM program, the market price of our common stock could decrease significantly. The perception in the public market that our existing stockholders might sell shares of common stock may also depress the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A substantial majority of our outstanding shares of our common stock are freely tradable without restriction or further registration under the federal securities laws. In addition, we may sell additional shares of our common stock in the future to raise capital. A substantial number of shares of our common stock are reserved for issuance upon the exercise of stock options, upon conversion of our outstanding convertible notes and upon the exercise of our outstanding warrants. At December&#160;31, 2023, there were outstanding options to purchase common stock issued covering approximately <span style="direction:rtl;">7.0</span>&#160;million shares of our common stock with a weighted average exercise price of $<span style="direction:rtl;">2.13</span> per share. Also at December&#160;31, 2023, there were <span style="direction:rtl;">633,409</span> shares of common stock available for future for issuance in connection with future grants of incentives under our <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended</span></a>, approximately 15.2&#160;million shares of common stock reserved for issuance upon conversion of our outstanding 2024 Notes and approximately 13.4&#160;million shares of common stock reserved for issuance upon the exercise of our outstanding warrants. The issuance and sale of substantial amounts of common stock, or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If securities analysts stop publishing research or reports about us or our business or if they downgrade our common stock, the market price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not control these analysts. If any analyst who covers us downgrades our stock or lowers its future stock price targets or estimates of our operating results, the market price for our common stock could decline rapidly. Furthermore, if any analyst ceases to cover us, we could lose visibility in the market, which in turn could cause the market price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses, divert management&#8217;s attention from operating our business which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The laws, rules, regulations and standards including the rules&#160;promulgated by the national securities exchanges, including the NYSE American, to which we are subject are changed and/or amended from time to time. New or changed laws, rules, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, rules, regulations and standards are likely to continue to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. Members of our Board of Directors and our executive officers, could face an increased risk of personal liability in connection with the performance of their duties. As a result, we may have difficulty attracting and retaining qualified directors and executive officers, which could have a material adverse effect on our business. If our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies, we may incur additional expenses to comply with standards set by regulatory authorities or governing bodies which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The issuance of preferred stock or additional shares of common stock could adversely affect the rights of our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our Board of Directors is authorized to issue up to 100,000,000 shares of preferred stock without any further action on the part of our stockholders. Our Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Currently, we have no shares of preferred stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Our Board of Directors may, at any time, authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, before the redemption of our common stock, which may have a material adverse effect on the rights of the holders of our common stock. In addition, our Board of Directors, without further stockholder approval, may, at any time, issue large blocks of preferred stock. In addition, the ability of our Board of Directors to issue shares of preferred stock without any further action on the part of our stockholders may impede a takeover of our company and may prevent a transaction that is favorable to our stockholders.</span></p><a id="_1840538d_bdc4_45cb_9e40_9e746e71ce34"></a><a id="Item1BUnresolvedStaffComments_626044"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_69c7580c_f6e8_4d30_b7d9_648932e4aec1"></a><a id="Item1CCybersecurity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;1C.&#160;&#160;&#160;Cybersecurity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risk Management and Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our operations include the creation, collection and maintenance of sensitive information, including proprietary and confidential business information, intellectual property, third-party information and employee information. To protect this </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">information, we use managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats on a constant basis. In addition, we use multi-factor authentication (MFA) for external use, perform penetration testing and engage third parties to assess the effectiveness of our cybersecurity practices. We conduct a thorough risk assessment by identifying critical assets, recognizing potential threats and vulnerabilities, and implement strategies to mitigate these risks and their possible impacts. We establish incident response plans and provide cybersecurity training to our employees and monitor their activity to ensure adherence to our security protocols. A material cyber-attack on our systems, or any other third-party partners or vendors and their key operating systems, may interrupt our ability to operate our business, damage our reputation, or result in monetary damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">We have implemented a Data Protection Policy, or the DPP, in order to establish the high-level direction for properly managing the use, privacy, security, retention, and disposal of our information, data and assets, and to manage identified material cybersecurity risks. The DPP was prepared using relevant guidance issued and technology standards that are used across various industries. It applies to all entities who are using our equipment and resources, including but not limited to, employees and temporary workers. Our Senior Director, Information Technology, is primarily responsible for implementing and overseeing the DPP and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks. He is expected to become a certified Information Security Officer in March 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our DPP includes an incident response process that includes reporting thresholds and follows standardized identification and authentication practices. If an incident is identified, it is documented by our Senior Director, Information Technology, who is required to report the incident to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We work with third-party service providers from time to time that assist us to identify, assess and manage cybersecurity risks, including professional SEIM SOC and other services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and penetration testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">No risks from cybersecurity threats have occurred that have affected our business, results of operations or financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including our Senior Director, Information Technology, who reports to our Sr. Vice President, Operations. Management is also responsible for hiring appropriate personnel, integrating cybersecurity considerations into our overall risk management strategy, and for communicating key priorities to employees, as well as for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our incident response process involves management, who participates in our disclosure controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our incident response process is designed to escalate certain cybersecurity incidents and vulnerabilities to members of management depending on the circumstances, including work with our incident response team to help the company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the company&#8217;s incident response processes include reporting to our Board of Directors for certain cybersecurity incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Management is involved with our efforts to prevent, detect, and mitigate cybersecurity incidents by overseeing preparation of cybersecurity policies and procedures, testing incident response plans and engaging vendors to conduct penetration tests. Management participates in cybersecurity incident response efforts by being a member of the incident response team and helping direct our response to cybersecurity incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. Our Chief Financial Officer and IT consultant provide periodic briefings to the Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, if any, cybersecurity systems testing, activities of third parties, and the like.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See &#8220;Risk Factors &#8211; <a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches, resulting in liability and harm to our reputation, which could negatively affect our business, results of operation and financial condition. We may face liability if we breach our obligations related to the protection, </span></a></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">security, nondisclosure of confidential information or disclosure of sensitive data or fail or are perceived to fail to comply with applicable data protection laws and regulations, or consumer protection laws, regulations and standards.<a href="#Item1ARiskFactors_654735"></a>&#8221;</p><a id="_5f731c62_e4f4_42d3_acd1_a31747405d3e"></a><a id="Item2Properties_907582"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;Properties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain a U.S. corporate office in Hackensack, New Jersey. Our headquarters, including a manufacturing facility, executive offices and other facilities, are located in Carmiel, Israel. Our facilities in Israel currently contain approximately 14,700&#160;sq/ft of manufacturing space and 3,400&#160;sq/ft for a pilot plant, 11,700&#160;sq/ft for offsite warehouse space and approximately 43,100&#160;sq/ft of laboratories, front warehouse and office space, and are leased at a rate of approximately $83,000 per&#160;month. In addition, we are entitled to use an additional 14,500&#160;sq/ft in the same facility, which we intend to utilize in connection with an anticipated expansion of our manufacturing facilities. Our facilities are equipped with the requisite laboratory services required to conduct our business, and we believe that the existing facilities are adequate to meet our needs for the foreseeable future. Our original lease for the facility was in effect until 2016 and we have exercised two of three options to extend the term, each for an additional five-year period. The lease is currently in effect until 2026 and we retain an additional option to extend the term for another five-year period thereafter. Upon the exercise of each option to extend the term of the lease includes a 10% increase to the then current base rent.</p><a id="_9643f7c4_a20c_48d6_9596_478af5a47d8e"></a><a id="Item3LegalProceedings_932888"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_f64115fd_9290_4947_8247_cb6518f6823c"></a><a id="Item4MineSafetyDisclosures_147620"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b29db4b8_f692_4aa5_8d2b_e1e37a886d9d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII_453527"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our common stock is traded on the NYSE American under the symbol &#8220;PLX.&#8221; In 2023, we decided to voluntarily delist our common stock from the Tel Aviv Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March&#160;1, 2024, there were approximately 61 holders of record of our common stock. A substantially greater number of holders of our common stock are &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not declared or paid any cash dividends on our common stock. We do not anticipate paying any dividends on our common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table provides information as of December&#160;31, 2023 with respect to the shares of our common stock that may be issued under our existing equity compensation plan.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">C</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Securities&#160;Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Available&#160;for&#160;Future&#160;Issuance</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">to&#160;be&#160;Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Under&#160;Equity&#160;Compensation&#160;Plans</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Upon&#160;Exercise&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Excluding&#160;Securities&#160;Reflected&#160;in</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Column&#160;A)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity Compensation Plans Approved by Stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,965,601</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 633,409</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity Compensation Plans Not Approved by Stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,965,601</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 633,409</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_73db5e54_6a4e_43c6_a9ec_819932e59b8f"></a><a id="Item6Reserved"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">[Reserved]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_072c1887_f0cc_4002_b8cd_8f2981cc790b"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) is intended to help the reader understand our results of operations and financial condition. The MD&amp;A is provided as a supplement to, and should be together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form&#160;10-K. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, include forward-looking statements that involve risks and uncertainties. You should read &#8220;Risk Factors&#8221; in Item&#160;1A of this Annual Report on Form&#160;10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins primarily based on our proprietary ProCellEx protein expression system. To date, we have successfully developed two ERTs; Elfabrio (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which we referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland and Israel. Chiesi is our commercialization partner for Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer, and in Brazil to Fiocruz, an arm of the Brazilian MoH. Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, we have a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;5, 2023, the EC announced that it had approved the MAA for Elfabrio and on May&#160;9, 2023, the FDA announced that it had approved the BLA for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The EMA approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the CHMP. Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. In October 2017 and July 2018, Protalix Ltd., our wholly-owned subsidiary, entered into the Chiesi Agreements pursuant to which Chiesi was granted an exclusive license for all markets, both within and outside of the United States to commercialize Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a CRL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study. The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support the non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, we hold the worldwide commercialization rights to our other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:36pt;white-space:nowrap;">(1)</span>PRX-115, our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:36pt;white-space:nowrap;">(2)</span>PRX-119, our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on our ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. We cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March&#160;21, 2023, the first patient was dosed in our phase&#160;I First-in-Human (FIH) clinical trial of PRX-115. As of December&#160;31, 2023, 56 patients have been dosed in this trial. We expect to publish preliminary results of this study during the second quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July 2, 2021, we entered into an At The Market Offering Agreement, or the 2021 Sales Agreement, with H.C.&#160;Wainwright &amp; Co., LLC, as our sales agent, or the Agent, which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, we were able to sell from time to time through the Agent shares of our common stock having an aggregate offering price of up to $20.0&#160;million, or the ATM Shares. Upon execution of the 2021 Sales Agreement, we terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc., or BofA Securities. During the term of the sales agreement with BofA Securities, we sold a total of 3,296,123 shares of common stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, we sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;27, 2023, we entered into an At The Market Offering Agreement, or the 2023 Sales Agreement, with the Agent. Pursuant to the terms of the 2023 Sales Agreement, we may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of December&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under each of the Chiesi Agreements, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, we received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we and Chiesi amended the Chiesi Agreements in order to provide us with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi Ex-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to us for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and, under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;29, 2022, we entered into a Fill/Finish Agreement, or the F/F&#160;Agreement, and a Letter Agreement, or the Letter Agreement, in each case with Chiesi. We agreed to supply Chiesi with drug substance for Elfabrio and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for Elfabrio, including to support the anticipated global launch of Elfabrio. The F/F&#160;Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into the Amended Pfizer Agreement, pursuant to which we sold to Pfizer our share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, we agreed to transfer our rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where we are responsible for all expenses and retain all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On June&#160;18, 2013, we entered into the Brazil Agreement. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, we have the right to terminate the Brazil Agreement. Notwithstanding the termination right, we are, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Because our operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;<span style="white-space:pre-wrap;">In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on  our business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of our business and operations, among others. As of the issuance of these financial statements, the impact of the war has not had a material adverse effect on our operations.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and short-term bank deposits as of December&#160;31, 2023 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Critical Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in note&#160;1 to our consolidated financial statements appearing at the end of this Annual Report on Form&#160;10-K. We believe that the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Revenues</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our primary sources of revenues include our sales of BioManguinhos alfataliglicerase in Brazil, of drug substance to Pfizer under our Amended Pfizer Agreement and of drug product to Chiesi under the Chiesi Agreements. We recognize revenue from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects sales reserves for variable consideration, potential discounts, rebates and allowances. The sales reserve is calculated based on expected sales and the anticipated net average selling price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The transaction price is the consideration to which we expect to be entitled from the customer. The consideration promised in a contract with our customers may include fixed amounts and variable amounts. We estimate the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent the variable consideration is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, we use significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also generate revenues from the Chiesi Agreements. According to Accounting Standards Codification 606, Revenue from Contracts with Customers, and all the related amendments, or ASC&#160;606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have identified two performance obligations in the Chiesi Agreements as follows: (1)&#160;the license and research and development services and (2)&#160;a contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the&#160;research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The future manufacturing was contingent on regulatory approvals of the drug and we deem these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, we started recognizing revenue from manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The transaction price of the Chiesi Agreements was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which we would be entitled upon the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. We estimate variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, we use significant judgment to determine the probability of a significant reversal of such revenue. Following the approval of Elfabrio by the FDA, we received a milestone payment equal to $20.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We estimate the degree to which deferred tax assets will result in a benefit, after consideration of all positive and negative evidence, and provide a valuation allowance for deferred tax assets that we believe more likely than not will not be realized. In situations in which we are able to determine that our deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, we considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. We reassess our valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, we reverse the related valuation allowance. The tax valuation allowance totaled approximately $56.0&#160;million at December&#160;31, 2023 (see <a href="#_NOTE_13_-"><span style="font-style:normal;font-weight:normal;">Note&#160;13</span></a> to our consolidated financial statements for additional information). Should our actual future taxable income by tax jurisdiction vary from estimates, additional allowances or reversals thereof may be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Significant judgment is required in evaluating our uncertain tax positions. In evaluating the exposure associated with our various tax filing positions, we record reserves for uncertain tax positions in accordance with U.S. GAAP based on the technical support for the positions and our past audit experience with similar positions. For those tax positions where it is more likely than not that a tax benefit will be sustained, we record the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. We believe our tax positions comply with applicable tax laws and we intend to defend our positions, no assurance can be given that the final tax outcome of these matters will not be different from that which is reflected in our historical income tax reserves and accruals. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the provision for income taxes in the period in which such determination is made. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate. <span style="background:#ffffff;">Our liability for these unrecognized tax benefits totaled approximately $0.8&#160;million at December&#160;31, 2023 (see </span><a href="#_NOTE_13_-"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Note&#160;13</span></a><span style="background:#ffffff;"> to our consolidated financial statements for additional information).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Research and Development Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect our research and development expense to remain our primary expense in the near future as we continue to develop our product candidates. Research and development expense consists of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internal costs associated with research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments made to third party contract research organizations, investigative/clinical sites and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing development costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, including salaries, benefits, travel and related costs for the personnel involved in research and development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities relating to the advancement of product candidates through preclinical studies and clinical trials; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, as well as laboratory and other supplies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table identifies our current major research and development projects:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Project</b></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expected Near Term Milestones</b></p></td></tr><tr><td style="vertical-align:top;width:33.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PRX-115&#160;&#8211; PEGylated Uricase</p></td><td style="vertical-align:top;width:2.18%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Phase&#160;I</p></td><td style="vertical-align:top;width:2.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Preliminary results from the phase&#160;I clinical trial expected in the second quarter of 2024.</p></td></tr><tr><td style="vertical-align:top;width:33.21%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PRX-119&#160;&#8211; Long Acting DNase&#160;I</p></td><td style="vertical-align:top;width:2.18%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Preclinical</p></td><td style="vertical-align:top;width:2.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We anticipate incurring increasing costs in connection with the continued development of PRX-115 and PRX-119 and in the expansion of our pipeline. Our internal resources, employees and infrastructure are not tied to any individual research project and are typically deployed across all of our projects. We currently do not record and maintain research and development costs per project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At this time, due to the inherently unpredictable nature of preclinical and clinical development processes and given the early stage of our preclinical product development programs, we are unable to estimate with any certainty the costs we will incur in the continued development of the product candidates in our pipeline for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations. Our future research and development expenses for our product candidates will depend on the preclinical and clinical success of each product candidate, as well as ongoing assessments of each product candidate&#8217;s commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. See &#8220;<a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Risk Factors&#8212;We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.</span></a>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect our research and development expenses to continue to be our primary expense in the future as we continue the advancement of our clinical trials and preclinical product development programs for our product candidates. The lengthy process of completing clinical trials and seeking regulatory approvals for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expense to increase and, in turn, have a material adverse effect on our operations. Due to the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects. See &#8220;Risk Factors&#8212;<a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs, which may have a material adverse effect on our business, results of operations and financial condition</span></a>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We measure share-based compensation cost for all share-based awards at the fair value on the grant date and recognition of share-based compensation over the related service period. The fair value of stock options is determined based on the number of shares granted and the price of our common stock, and calculated based on the Black-Scholes valuation model. For grants made to employees and non-employees, we recognize the fair value of the grant as expense over the service period using the accelerated method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The guidance requires companies to estimate the expected term of the option rather than simply using the contractual term of an option. Because of lack of sufficient data on past option exercises by employees, the expected term of the options could not be based on historic exercise patterns. Accordingly, we adopted the simplified method, according to which companies may calculate the expected term as the average between the vesting date and the expiration date, assuming the option was granted as a &#8220;plain vanilla&#8221; option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In performing the valuation, we assumed an expected 0% dividend yield in the previous&#160;years and in the next&#160;years. We do not have a dividend policy and given the lack of profitability, dividends are not expected in the foreseeable future, if </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">at all. The guidance stipulates a number of factors that should be considered when estimating the expected volatility, including the implied volatility of traded options, historical volatility and the period that the shares of the company are being publicly traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The risk-free interest rate used in the valuation of the options is based on the implied yield of U.S.&#160;federal reserve zero&#8211;coupon government bonds. The remaining term of the bonds used for each valuation was equal to the expected term of the grant. This methodology has been applied to all grants valued by us. The guidance requires the use of a risk&#8211;free interest rate based on the implied yield currently available on zero&#8211;coupon government issues of the country in whose currency the exercise price is expressed, with a remaining term equal to the expected life of the option being valued. This requirement has been applied for all grants valued as part of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Convertible Notes </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board, or the FASB, Accounting Standards Codification, or ASC, 815 requiring that we determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. Our Senior Secured 7.50% Convertible Notes Due 2021, or the 2021 Notes, were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. <span style="background:#ffffff;">The 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at our option, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;25, 2021, we completed the exchanges of a substantial majority of the 2021 Notes with certain institutional note holders, or the Exchanges. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of common stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the common stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of our common stock on the NYSE American on August&#160;13, 2021. The Exchanges are described in greater detail in Note 10 to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges were considered an extinguishment of debt. We allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, we recognized a loss from extinguishment in the statement of operations equal to $0.8&#160;million due to derecognition of the liability component and a reduction of stockholders&#8217; equity of $12.2&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2023, a total of $20.4&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding. In addition, as of December&#160;31, 2023, 2022 and 2021, none of the 2021 Notes&#160;were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Year ended December&#160;31, 2023 Compared to the&#160;Year Ended December&#160;31, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Revenues from Selling Goods</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We recorded revenues from selling goods of $40.4&#160;million for the year ended December&#160;31, 2023, an increase of $15.1&#160;million, or 60%, compared to revenues of $25.3&#160;million for the year ended December&#160;31, 2022. The increase </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">resulted primarily from an increase of $14.1&#160;million in sales of Elfabrio drug product <span style="background:#ffffff;">to Chiesi, </span>following the approvals by the FDA and the EMA of Elfabrio<span style="background:#ffffff;">, </span>an increase of $0.1&#160;million in sales to Pfizer and of $0.9&#160;million in sales to Brazil, resulting from timing differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Revenues from License and R&amp;D services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $25.1&#160;million for the year ended December&#160;31, 2023, an increase of $2.8&#160;million, or 13%, compared to revenues of $22.3&#160;million for the year ended December&#160;31, 2022. The increase resulted from the $20.0&#160;million regulatory milestone payment from Chiesi in connection with the FDA approval of Elfabrio which was partially offset by a decrease of $17.2&#160;million in revenues recognized in connection with the R&amp;D performance obligation under the Chiesi Agreements as we have completed the phase III clinical program thereunder. Revenues from license and R&amp;D services represent mainly the revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cost of Goods Sold</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $23.0&#160;million for the year ended December&#160;31, 2023, an increase of $3.4&#160;million, or 17%, compared to cost of goods sold of $19.6&#160;million for the year ended December&#160;31, 2022. <span style="background:#ffffff;">The increase in cost of goods sold was primarily the result of the increase in sales of goods to Chiesi, Brazil and to Pfizer. Sales to Chiesi included certain drug substance costs which had already been recognized as research and development expenses as it was produced as part of research and development activities. Accordingly, the related cost of goods sold does not include the costs of such drug substance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the year ended December&#160;31, 2023, our total research and development expenses were approximately $17.1&#160;million comprised of approximately $6.3&#160;million in subcontractor-related expenses, approximately $7.8&#160;million of salary and related expenses, approximately $0.6&#160;million of materials-related expenses and approximately $2.4&#160;million of other expenses. For the year ended December&#160;31, 2022, our total research and development expenses were approximately $29.3&#160;million comprised of approximately $17.8&#160;million in subcontractor-related expenses, approximately $7.3&#160;million of salary and related expenses, approximately $1.4&#160;million of materials-related expenses and approximately $2.8&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses was $12.2&#160;million, or 42%, for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022. The decrease in research and development expenses resulted primarily from a $11.5&#160;million decrease in subcontractor-related expenses in connection with our PRX-102 clinical trials, and a $0.8&#160;million decrease in materials-related expenses<span style="direction:rtl;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Selling, General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $15.0&#160;million for the year ended December&#160;31, 2023, an increase of $3.3&#160;million, or 28%, from $11.7&#160;million for the year ended December&#160;31, 2022. The increase resulted primarily from an increase of approximately $2.3&#160;million in one-time cash bonuses, share-based compensation and salary and salary-related expenses, as well as an increase of $0.3&#160;million in travel, conferences and employee training expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Financial Expenses and Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Financial expense, net was $1.9&#160;million for the year ended December&#160;31, 2023, an increase of $0.5&#160;million, or 36%, compared to financial expenses of $1.4&#160;million for the year ended December&#160;31, 2022. </span><span style="font-style:normal;">The increase was primarily due to a decrease of $</span><span style="font-style:normal;">0.9</span><span style="font-style:normal;">&#160;million in income related to exchange rates as well as an increase in our interest expenses of $0.7&#160;million which was partially offset by a gain recognized due to conversions of a portion of the 2024 Notes of $0.4&#160;million and a $0.6&#160;million increase in interest income.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the year ended December&#160;31, 2023, we recorded income taxes of approximately $0.3&#160;million, a decrease of $0.2&#160;million, or 40%, compared to tax expenses of $0.5&#160;million for the year ended December&#160;31,<i style="font-style:italic;"> </i>2022. The income taxes resulted primarily from the provision for current taxes on income mainly derived from GILTI income mainly in respect of Section&#160;174 of the TCJA. Effective in 2022, Section&#160;174 of the TCJA requires all U.S. companies, for tax purposes, to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174 over five years for research activities conducted in the United States and over 15 years for research activities conducted outside of the United States rather than deducting such costs in the current year. The net income taxes gives effect to a valuation allowance release equal to approximately $3.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Year ended December&#160;31, 2022 Compared to the&#160;Year Ended December&#160;31, 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">For a discussion of the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021, see Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and bank deposits. At December 31, 2023, we had $44.6&#160;million in cash and cash equivalents and short term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2023, we raised gross proceeds equal to approximately $24.9&#160;million from the sale of 12,560,150 shares of our common stock under our ATM program. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales were completed during the quarters ended September&#160;30, 2023 and December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2021, we raised gross proceeds equal to approximately $8.8&#160;million from sales of common stock under our ATM program through the sale of 1,867,552 shares of our common stock. In addition, we raised gross proceeds of approximately $40.2&#160;million from a public offering of our common stock before deducting the underwriting discount and estimated expenses of the offering. In connection with the offering, we issued 8,749,999 shares of our common stock at a purchase price per share of $4.60.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;25, 2021, we completed Exchanges with institutional note holders of a substantial majority of the then outstanding 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate of the 2024 Notes is 563.2216 shares of our common stock per $1,000 principal amount of 2024 Notes, which is equivalent to an initial conversion price of approximately $1.7755 per share of common stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the 2024 Indenture which was entered into between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and will be guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operations was $1.3&#160;million for the year ended December&#160;31, 2023. The net income for the year ended December&#160;31, 2023 of $8.3&#160;million was decreased by a $13.2&#160;million decrease in contracts liability, a $3.1&#160;million </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">increase in deferred tax assets, a $2.2&#160;million increase in inventories, a $0.4&#160;million increase in accounts receivable-trade and other assets and a $0.4&#160;million financial income-net. The net income was increased by a $5.3&#160;million increase in accounts payable and accruals, $3.4&#160;million in share-based compensation and $1.2&#160;million in depreciation. Net cash used in investing activities for the year ended December&#160;31, 2023 was $16.7&#160;million and consisted primarily of net investment in bank deposits. Net cash provided by financing activities was $24.7&#160;million resulting primarily from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since our inception, we have incurred significant research and development expenditures which have not been offset by revenues. We have not generated significant revenues from sales of Elelyso, and commercial sales of Elfabrio only commenced in the middle of 2023. W<span style="background:#ffffff;">e have generated operating losses from our continuing operations since our inception although the revenues generated in the year ended December&#160;31, 2023</span><span style="font-family:'28mugxoulnobhnx';"> exceeded our expenditures for the same period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'28mugxoulnobhnx';">Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;background:#ffffff;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of December&#160;31, 2023, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures. We cannot anticipate the costs or the timing of the occurrence of such costs. Although we expect the revenues generated from the sales of Elfabrio and Elelyso will increase, such revenues may not be sufficient to fund the expenditures. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts, (v)&#160;payments of principal and interest on our outstanding 2024 Notes and (vi) tax payments. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect to finance our future cash needs through sales of Elfabrio and Elelyso, corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the milestone payments that may become payable under the Chiesi Agreements. On February&#160;27, 2023, we entered into the 2023 Sales Agreement pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million as we had then completed the ATM program under the 2021 Sales Agreement. As of December&#160;31, 2023, shares of our common </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement. During the quarters ended March&#160;31, 2023 and June&#160;30, 2023, we sold, in the aggregate, 12,560,150 shares of Common Stock under the 2021 Sales Agreement and the 2023 Sales Agreement, generating aggregate gross proceeds equal to approximately $24.9&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Contractual obligations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our contractual obligations include obligations under our convertible notes, operating lease obligations, purchase obligations, certain clinical contracts and the liability for employee rights upon retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our convertible senior notes had an aggregate outstanding principal balance of $20.42&#160;million at December&#160;31, 2023. The notes will mature on September&#160;1, 2024 unless earlier purchased, converted, exchanged or redeemed, and interest is payable on the note semi-annually at a rate of 7.50% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We lease certain assets under operating leases, which expire through 2026, with an option to extend the lease on our main facility to 2031. The leases relate primarily to office, laboratory and manufacturing space and vehicles used by our employees. Our aggregate future minimum commitments under these facility and vehicles leases over the next five fiscal years is approximately $4.1&#160;million as of December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2023, we are subject to open purchase orders issued to certain suppliers and other vendors mainly in connection with our research and development and manufacturing activities that were outstanding as of December&#160;31, 2023 for approximately $8.1&#160;million over the next five fiscal years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have a contractual obligation of approximately $0.4&#160;million as of December&#160;31, 2023 payable over the fiscal year ending December&#160;31, 2024 in connection with contractual arrangements we enter into in the normal course of business with CROs, CMOs and other clinical providers and consultants for clinical trials, preclinical and other research studies and manufacturing services in connection with our primary product development process. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation. In addition, we have a $0.1&#160;million commitment payable to a business development consultant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2023, we have a contractual obligation of approximately $0.7&#160;million for employee rights upon retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are also party to certain research and license agreements. If all of the contingencies with respect to milestone payments under our research and license agreements are met, as of December&#160;31, 2023, the aggregate milestone payments payable would be approximately $8.4&#160;million, and would be payable, if at all, as our projects progress over the course of a number of years. The royalty payments payable by our company in connection with sales of each of our product candidates, if any, shall not exceed low, single-digit percentages of net sales of the relevant product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Effects of Currency Fluctuations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. <span style="background:#ffffff;">Currency fluctuations during the year ended December&#160;31, 2022, resulted in $1.0&#160;million being recognized as financial income.</span> We do not believe currency fluctuations have had a material effect on our results of operations during the years ended December&#160;31, 2022 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain recently issued and recently adopted accounting pronouncements are discussed in Note 1(r) of the financial statements included in Item&#160;8 of this Annual Report on Form&#160;10-K.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_30f86cee_97d6_44e4_a144_21551cbde34d"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Currency Exchange Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and above 50% of our expenses and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Approximately 4<span style="direction:rtl;">4</span>% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Average rate for period</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.230</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.360</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.110</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.519</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.627</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Interest Rate Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><a id="_e85cf5ce_086b_46b6_b3a7_85e9fb56eedb"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">See the <a href="#CONSOLIDATEDFINANCIALSTATEMENTS_TOC"><span style="font-style:normal;font-weight:normal;">Index to Consolidated Financial Statements</span></a> on Page&#160;F-1 attached hereto.</p><a id="_7a2d5ba4_6ee4_4aa0_b495_37b4182db0f9"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_3ed49d26_d066_4b31_865c_1452f477b07e"></a><a id="Item9AControlsandProcedures_730194"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form&#160;10-K. The controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Form&#160;10-K, is recorded, processed, summarized and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The evaluation of our disclosure controls and procedures included a review of the controls&#8217; objectives and design, our implementation of the controls and their effect on the information generated for use in this Annual Report on Form&#160;10-K. This type of evaluation will be performed on a quarterly basis so that the conclusions of management, including the Chief Executive Officer and Chief Financial Officer, concerning the effectiveness of the disclosure controls and procedures can be reported in our periodic reports on Form&#160;10-Q and Form&#160;10-K. The overall goals of these various evaluation activities are to monitor our disclosure controls and procedures, and to modify them as necessary. Our intent is to maintain the disclosure controls and procedures as dynamic systems that change as conditions warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Form&#160;10-K, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information related to our company and our consolidated subsidiaries are made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Management&#8217;s Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S.&#160;generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that: (i)&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of our company are being made only in accordance with authorizations of management and our directors; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Management assessed our internal control over financial reporting as of December&#160;31, 2023, the end of our fiscal&#160;year. Management based its assessment on criteria established in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Management&#8217;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies and our overall control environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on our assessment, management has concluded that our internal control over financial reporting was effective as of the end of the fiscal&#160;year to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles. We reviewed the results of management&#8217;s assessment with the Audit Committee of our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Inherent Limitations on Effectiveness of Controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Attestation Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Changes in internal controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended December&#160;31, 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_44362c0c_efa3_4d18_87d4_01ce4b1afa67"></a><a id="Item9BOtherInformation_882944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Rule 10b5-1&#160;Trading Plansf</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">During the quarter ended December&#160;31, 2023, none of our directors or officers </span><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_TH-BZEUGP0WfNBvwAsmrCw"><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_uvRHJm2sxUiMHiu3LmsYsw"><span style="background:#ffffff;">adopted</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> or </span><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_fyBjZeIOs02gLGSQMTu21A"><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_L6TnwudySkKrbRyMwI6-TA"><span style="background:#ffffff;">terminated</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> a Rule&#160;</span>10b5-1 <span style="background:#ffffff;">trading arrangement or&#160;</span>non-Rule<span style="background:#ffffff;">&#160;</span>10b5-1<span style="background:#ffffff;">&#160;trading arrangement (as such terms are defined in Item 408 of Regulation&#160;</span>S-K).</p><a id="_fc6b7d74_6fee_4cfd_8b69_4b77f1726d50"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="_857abaeb_3dea_48e3_bea8_0240509309d8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIII_463758"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information in our 2024 Proxy Statement regarding directors and executive officers appearing under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management &#8212; Section&#160;16(a)&#160;Beneficial Ownership Reporting Compliance&#8221; and &#8220;Election of Directors&#8221; is incorporated by reference in this section.</p><a id="_c5a6dfa3_5590_4b1d_bb5b_c0834a80431b"></a><a id="Item11ExecutiveCompensation_376320"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our&#160;2024 Proxy Statement under the headings &#8220;Director Compensation,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Report of the Compensation Committee,&#8221; and &#8220;Executive Compensation&#8221; is incorporated by reference in this section.</p><a id="_4db533c9_b802_4b08_914f_4c5e1a1f645e"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our 2024 Proxy Statement under the heading &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; is incorporated by reference in this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_22703b04_4055_4e44_8ff6_29bcb95e8d6a"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our 2024 Proxy Statement under the headings &#8220;Election of Directors&#8212;Corporate Governance&#8221; and &#8220;&#8212;Certain Relationships and Related Transactions&#8221; is incorporated by reference in this section.</p><a id="_39ef67e2_db8b_4306_a9e4_6c71857c9361"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Our independent registered public accounting firm is</span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Kesselman&#160;&amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, </span></a>Tel Aviv, Israel, PCAOB ID. No. 1309.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information appearing in our 2024 Proxy Statement under the heading &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; is incorporated by reference in this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_340625c2_9133_44ad_b56e_ed48c38b06a2"></a><a id="PARTIV_377623"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">The following documents are filed as part of this Annual Report on Form&#160;10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">1.<i style="font-style:italic;"> Financial Statements.</i> The following Consolidated Financial Statements of Protalix BioTherapeutics,&#160;Inc. are included in Item&#160;8 of this Annual Report on Form&#160;10-K:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:27.05pt;"><td style="vertical-align:bottom;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB name: Kesselman &amp; Kesselman C.P.A.s and PCAOB ID: 1309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_216383"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December&#160;31, 2022 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;years ended December&#160;31, 2021, 2022 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Stockholders&#8217; Equity (Capital Deficiency) for the&#160;years ended December&#160;31, 2021, 2022 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2021, 2022 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">2. <i style="font-style:italic;">Financial Statement Schedule.</i> Financial statement schedules have been omitted since they are either not required, are not applicable or the required information is shown in the consolidated financial statements or related notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">3. <i style="font-style:italic;">Exhibits.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:7.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.25%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;width:44.87%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:7.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.25%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.52%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:13.45%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/plx-20230227xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">At the Market Offering Agreement, dated February&#160;27, 2023, between the Company and H.C.&#160;Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;27, 2023</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Def 14A</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Appen. A</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Def 14A</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Appen. A</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;20, 2019</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416086642/v432711_ex3-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"/></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20231231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement between Protalix&#160;Ltd. and Angel Science Park (99)&#160;Ltd., dated as of October&#160;28, 2003 as amended on April&#160;18, 2005</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">January&#160;8, 2007</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Unprotected Lease Agreement</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2008</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Agreement between Protalix&#160;Ltd. and Comercio e Servi&#231;os Ltda. dated June&#160;17, 2013</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Technology Transfer and Supply Agreement made as of June&#160;18, 2013 by and between Protalix&#160;Ltd. and Funda&#231;&#227;o Oswaldo Cruz</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Binding Term Sheet between Protalix Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:42.4pt;"><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Exclusive License and Supply Agreement by and between Pfizer&#160;Inc. and Protalix&#160;Ltd., dated October&#160;12, 2015</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q/A</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;11, 2015</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418013053/tv486893_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License and Supply Agreement dated as of October&#160;17, 2017, made by and between Protalix&#160;Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;6, 2018</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive U.S. License and Supply Agreement dated as of July&#160;23, 2018, made by and between Protalix&#160;Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">November&#160;7, 2018</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420419027423/tv522023_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement made effective as of May&#160;20, 2019, by and between Protalix&#160;Ltd. and Mr.&#160;Dror Bashan</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;21, 2019</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement made effective as of July&#160;28, 2019, by and between Protalix&#160;Ltd. and Mr.&#160;Eyal Rubin</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;29, 2019</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Securities Purchase Agreement</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920070904/tm2022015d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement with Yael Hayon, Ph.D. dated June&#160;7, 2020</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June&#160;8, 2020</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021011566/plx-20210812xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Agreement, dated as of August&#160;12, 2021 among Protalix BioTherapeutics, Inc. and the holders named therein</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;12, 2021</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated U.S. Security Agreement dated of August&#160;24, 2021 among Protalix BioTherapeutics, Inc., the guarantors party thereto, Wilmington Savings Fund Society, FSB, as collateral agent and The Bank of New York Mellon Trust Company, N.A., as Notes Trustee</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Security Agreement/Debenture, made on August&#160;24, 2021 between Protalix Ltd. and Altshuler Shaham Trusts Ltd., as security trustee</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022017554/plx-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fill/Finish Agreement effective on August 29, 2022 made by and between Chiesi Farmaceutici S.p.A and Protalix Ltd.</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">November&#160;14, 2022</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022017554/plx-20220930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement dated August 29, 2022 from Chiesi Farmaceutici S.p.A to Protalix Ltd.</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">November&#160;14, 2022</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000095012310017277/y03091exv21w1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;26, 2010</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Kesselman&#160;&amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#POWER_OF_ATTORNEY"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on the signature page to this Annual Report on Form 10-K)</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule&#160;13a-14(a)&#160;as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule&#160;13a-14(a)&#160;as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20231231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20231231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97.1</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Policy Relating to Recovery of Erroneously Awarded Compensation</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL INSTANCE DOCUMENT - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL SHEMA FILE</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL CALCULATION FILE</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL DEFINITION FILE</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL LABEL FILE</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL PRESENTATION FILE</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">&#8224;&#8224;&#160;&#160;&#160;Portions of this exhibit were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment under Rule&#160;24b-2 of the Exchange Act.</p><a id="_9382b776_852a_4901_9ee3_95da24bd0e0a"></a><a id="Item16Form10KSummary_450405"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;16.&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4aca9ca3_ca7a_4b1f_93e5_574c2466a1fa"></a><a id="SIGNATURES_579077"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, as of March&#160;14, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:middle;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="POWER_OF_ATTORNEY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dror Bashan and Eyal Rubin, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:21.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive Officer</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;14, 2024</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Executive Officer) and Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer, Treasurer and</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;14, 2024</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Secretary (Principal Financial</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">and Accounting Officer)</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Eliot Richard Forster</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;14, 2024</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Eliot Richard Forster, Ph.D.</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Amos Bar Shalev</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;14, 2024</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Amos Bar Shalev</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Shmuel Ben Zvi</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;14, 2024</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Shmuel Ben Zvi, Ph.D.</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Pol F. Boudes</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;14, 2024</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pol F. Boudes, M.D.</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Gwen A. Melincoff</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;14, 2024</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Gwen A. Melincoff</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Aharon Schwartz</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;14, 2024</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aharon Schwartz, Ph.D.</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d7fb1a45_52e9_43e2_a9a7_53f8b61a5275"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><a id="CONSOLIDATEDFINANCIALSTATEMENTS_TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">TABLE OF CONTENTS</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:7.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><b style="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></a><b style="font-weight:bold;"> (PCAOB name: </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:AuditorName" id="Narr_hlyt3h80ZE2Bbrkhf7MJXw"><b style="font-weight:bold;">Kesselman &amp; Kesselman C.P.A.s</b></ix:nonNumeric><b style="font-weight:bold;"> and PCAOB ID: </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:AuditorFirmId" id="Narr_LcnJt_NW0E6KA-YqtkhfEA"><b style="font-weight:bold;">1309</b></ix:nonNumeric><b style="font-weight:bold;">)</b></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</b></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_216383"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December&#160;31, 2022 and 2023</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;years ended December&#160;31, 2021, 2022 and 2023</span></a></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Stockholders&#8217; Equity (Capital Deficiency) for the&#160;years ended December&#160;31, 2021, 2022 and 2023</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2021, 2022 and 2023</span></a></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:61.8pt;"><a id="_d222d9d0_5f50_4df6_a6c0_8ea47dbceee5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;"><img src="plx-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:61.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:86.4pt;"/></span></p><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">To the Board of Directors and Stockholders of Protalix BioTherapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">We have audited the accompanying consolidated balance sheets of Protalix BioTherapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, and the related consolidated statements of operations, changes in stockholders&#8217; equity (capital deficiency) and cash flows for each of the three years in the period ended December&#160;31, 2023, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023 in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Critical Audit Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 8pt 0pt;"><span style="font-family:'Georgia';">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i)&#160;relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial</span> <span style="font-family:'Georgia';">statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:61.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;"><img src="plx-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:61.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:86.4pt;"/></b></p><a id="_Hlk159878737"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Recognition and measurements of sales reserve</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0.2pt 8pt 0pt;"><span style="font-family:'Georgia';">As discussed in Note 2(k) to the consolidated financial statements revenues from selling goods are recorded in the amount of consideration to which the Company expects to be entitled in exchange for its performance obligation upon transfer of control to the customer. The amount of consideration to which the Company expects to be entitled varies as a result of potential discounts, rebates and allowances. A variable consideration is recorded by the Company concurrently with the satisfaction of its performance obligation to the extent that it is probable that a significant reversal in the amount </span><span style="font-family:'Georgia';">of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. As of December 31, 2023, the </span><span style="font-family:'Georgia';">sales reserve for potential discounts, rebates and allowances was $2,861 thousand. The sales reserve is calculated based on expected sales and anticipated net average selling price. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0.2pt 8pt 0pt;"><span style="font-family:'Georgia';">The principal considerations for our determination that performing procedures related to recognition and measurement of the sales reserve is a critical audit matter are </span><span style="font-family:'Georgia';">the significant judgment by management due to the significant measurement uncertainty involved in developing the sales reserve, as the sales reserve is based on assumptions developed related to expected sales and anticipated net average selling price. This in turn led to significant auditor judgment in performing procedures relating to these assumptions. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) testing management&#8217;s process for determining the estimate; and (ii) </span><span style="font-family:'Georgia';">testing the completeness, accuracy, and relevance of underlying data used to estimate the reserves</span><span style="font-family:'Georgia';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Kesselman &amp; Kesselman</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Certified Public Accountants (Isr.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">A member of PricewaterhouseCoopers International Limited</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="dei:AuditorLocation" id="Narr_50e5qw0QxEeYkqbDP_11Pw">Tel Aviv, Israel</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">March&#160;14, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2000.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_17212557_4404_455b_8af3_7d34b7e673c2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDBALANCESHEETS_216383"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><a id="_bce056b9_e47a_4043_bece_09f9fd587143"></a><a id="Tc_yGswH07VIEaN_3DVk9wYBQ_1_2"></a><a id="Tc_dolYMqdx0USnupADshWuFw_2_2"></a><a id="Tc_pWgthRIz2UyOfjz2xHJ1Ow_2_5"></a><a id="Tc_WFj3h2BRNUy4qWxb2RAu6g_3_0"></a><a id="Tc_T2cBoKbDc0KRDucgoCjRXQ_5_0"></a><a id="Tc_oz-fTe8ocUWfZnKxhZflOQ_6_0"></a><a id="Tc_hIYUmKyNbUysGrQ8m17Ofw_6_2"></a><a id="Tc_of9CPyPl8EiWjkCbyLMEnA_6_5"></a><a id="Tc_SaUtguqLv0qrCi67rhkNRA_7_0"></a><a id="Tc_2btxW8zydE-KulI2I-FGJQ_8_0"></a><a id="Tc_auEKlXAQZ0Wg7OJGhtRlqw_9_0"></a><a id="Tc_AKu0rCtM0k-hBArrNM-Jzw_10_0"></a><a id="Tc_ZQDicY08xU6MZ4ZaguyJJw_11_0"></a><a id="Tc_JCcXfi6o20ec2aFm2qWxuQ_11_2"></a><a id="Tc_XM3OMgFy4EmfDb2OLrs2AA_11_5"></a><a id="Tc_FOSFV7ADEEa8ROD7BQxFtA_13_0"></a><a id="Tc_4sS21TYClU-zblV6HPpHvA_14_0"></a><a id="Tc_UhvyATnHMkm1ZWaV3HfDjw_14_2"></a><a id="Tc_6_DzMIboKkW0-LmBuTdBvg_14_5"></a><a id="Tc_2O7zJOUY6UKt9GpQsCXIyw_15_0"></a><a id="Tc_A_rn7N8liEmZKUMny29fYA_16_0"></a><a id="Tc_zGstXRq2uU6bFwXnfm5c1A_17_0"></a><a id="Tc_g5nsZHKeokqy1Bvj0MEhNA_18_0"></a><a id="Tc_h-KR3Fr8bUajPt4he0BiGA_18_2"></a><a id="Tc_MjspVyjBrECewwC4dWc_Tw_18_5"></a><a id="Tc_BUD_qQ0IcUyHxlPtgkqdOw_20_0"></a><a id="Tc_4jjuxnvQp0q4G7wb2g3yUg_22_0"></a><a id="Tc_ElZoQf24W06TKpS0Ty-wpw_23_0"></a><a id="Tc_euaTK_XEE06OUdQyVjiRDw_24_0"></a><a id="Tc__jeqWr1XpE2KZjKNztwksA_24_2"></a><a id="Tc_KbYu7TM9JE-ljLDp693yog_24_5"></a><a id="Tc_kOmkE9MkkU6WxGDFL_QDJw_25_0"></a><a id="Tc_6-cP8v8mo0a2qQlyoWY2OQ_26_0"></a><a id="Tc_-Vo0cD0GH0qxblVd4h2KRA_27_0"></a><a id="Tc_xylzTjt19ka08iCv5Bi6RQ_28_0"></a><a id="Tc_moT7d6HQqUmEoA3QpUdpkQ_29_0"></a><a id="Tc__k0VCTEEU0eBvOsbBIahkw_29_2"></a><a id="Tc_rjkGEa1AHkGyEL1nwd2ajg_29_5"></a><a id="Tc_gUUfC8byCUaIe6qvVFbwYw_31_0"></a><a id="Tc_0LKezfDlKEKATx3WasuJQA_32_0"></a><a id="Tc_2ueOCjTTq0-h82Yov3avWA_32_2"></a><a id="Tc_We72TsrFj0aVmmzfJxcG5g_33_0"></a><a id="Tc_i8cxH09dDU2vwnlh9UgBrg_33_5"></a><a id="Tc__0zB2huWtUGoz3VYtvy6sw_34_0"></a><a id="Tc_EcRUKM0rZ06u0VCjdRPKXg_35_0"></a><a id="Tc_meSpUg1iqky2kFM4TZb67w_35_2"></a><a id="Tc_GxcmZK9cXESv_xP5qFRzbg_35_5"></a><a id="Tc_Nlj-xKv6OUSD5G8hq6Yveg_36_0"></a><a id="Tc_Ld9vB_9_ikacpp4F5XVYBw_36_2"></a><a id="Tc__GxEjsd6pEiDwlqaormEtw_36_5"></a><a id="Tc_Oi8EYR_aOUyzy828MW0Maw_38_0"></a><a id="Tc_UUZiVWgRaUOkXABhFyidHA_40_0"></a><a id="Tc_5cTG5PrrR0-mMLhAvPY5cw_41_0"></a><a id="Tc_cclyAdUdLE6-OkC0upoX5Q_42_0"></a><a id="Tc_vT00n29jkUGDlBVH8iGrOg_43_0"></a><a id="Tc_2ataaNJCekqS0nDzxjqL4Q_44_0"></a><a id="Tc_Xz2HInKRTUOKeponhnvZQw_45_0"></a><a id="Tc_xbnw4AL-n06yIH1qOy73-A_45_2"></a><a id="Tc_D-yXvnkKPUiY-W51L1o0aA_45_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_q49gzeqGK0O5FjktSFC1dA_6_3">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_pFPGFnt4Gk2rKpzviRLUAA_6_6">23,634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_72ugtLFAr0CHHRyebVtBFQ_7_3">5,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_GhRzHjROz0OMul04IbySxA_7_6">20,926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_qaVS3kHj3EeJbDej33qG9g_8_3">4,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_Snt5KqlRaUqYSm9_xZjDWQ_8_6">5,272</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_9KeQegjOz0OZC6MA0bHJ-w_9_3">1,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_kIerSTXolE6K8miZ5fUy3w_9_6">1,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_6mX66HAdxkiFsd4tvkGsOw_10_3">16,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_m5rSpbvHO0KHIglbVwAGCw_10_6">19,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_b5mLGHRws0SprrO9FpaxOQ_11_3">44,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_T2nsUt4kMUSFYb-LflXyug_11_6">69,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_rLa4ANs9k0uItbWCVrhIqg_14_3">1,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_cKPLDllzzEKQRhXHOND9WA_14_6">528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_3YMhKPpgrE-KVG1iSjxdgw_15_3">4,553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_IvPvmSYxwEGy2lcGNQdhAQ_15_6">4,973</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_bkIzO9dHSEiQ18GoCG2z8A_16_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_TWc9SfEI90e4gzahxgjiDQ_16_6">3,092</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_kZgG5Cm6aU-FI762V1dLnA_17_3">5,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_XIOp-RFE50qVVhYx2SgzPg_17_6">5,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_W0bMfqQ0LEidCIcCJUQiWg_18_3">55,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_kWQzZD5ybUakBGs34CKFUg_18_6">84,434</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_OK3CrqJ4NEWHOGq65yWmrA_24_3">5,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_dslWAzPR7UG7IZss7C5bCA_24_6">4,320</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_n56fpBfE1E6qXe-QBye06A_25_3">12,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_9EHJB1_Z0UKUj0CH4vIKlg_25_6">19,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ltVnwc-ifkyl00yLsHPzxw_26_3">1,118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_PBlaaujPvEmoGYdyR_D-_A_26_6">1,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_dtkROJP5qkWqESJVtjRMzA_27_3">13,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_7kMZA7ok4UOtkAxy_vhe8w_27_6">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:zerodash" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_Yzg5jTEWIEKvIsWv5eN6aA_28_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_HHrszWRb7kqTO5bPgKHilQ_28_6">20,251</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_jmQtEEbIZk-EFwxMwgVL2g_29_3">32,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_HF_90uIOOUayGucWU_D3Jg_29_6">45,530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_RB4n09pCW0iWsYkmSpStYg_32_3">28,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_vK817CtsD0WCgg8PH88prQ_33_3">1,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_UFV0fVUqek-Jf9Hj-tA5Hg_33_6">714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_6gQOsNwQs0iOLBjhQ2twgQ_34_3">4,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_WZ7iT8ZaAkWZHrRouDiZfw_34_6">4,621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_If5783zBeE6c8eBIUXOlNQ_35_3">33,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_wakzPLQo9E2t7dcEmcWtpw_35_6">5,335</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_D2nbKE17y0-LWH3jnqaABw_36_3">66,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_PB1YXHJsJ0SAdgdhaS3ZTw_36_6">50,865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_bYYdiibN70uzg36UM7SkXw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_WQHkdTz9AUaHsd57kSzdSA">0.001</ix:nonFraction></ix:nonFraction> par value: Authorized - as of December 31, 2022 and 2023, <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_n09SUmSHSEiktNnj8ZrZyg">144,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_hCr8RApTDkmRbnwlLmqu8A">185,000,000</ix:nonFraction> shares, respectively; issued and <span style="-sec-ix-hidden:Hidden_ZD3tFDQGbkK4hFZHJfpYSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> - as of December 31, 2022 and 2023, <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_fJ9n0gEPhkqNmiHLfLz7jg"><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_2BfQEEee4kWBKr2wR7JIEw">53,790,167</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_SnPXNyymVUaea58yv_zy7w">72,952,124</ix:nonFraction> shares, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc__wPNbYGTGkm5xinTgjwf-w_41_3">54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_lUkGLp-IaU6U5PRigNpHjg_41_6">73</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_N56Q2p2fv0uYb3bupdeaMA_42_3">379,167</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_ogub93uaYUKQOmY3MDdoyA_42_6">415,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc__vg1UsrOjU6GTkUtVWppQg_43_3">389,861</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_XmKPaVQcZEGiPVE0Q4GQYA_43_6">381,549</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total stockholders' equity (capital deficiency)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_wXLi9zP9R02hMRNNj7k2Ag_44_3">10,640</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LW3p33l9OkiLQ2Mo4QZM8Q_44_6">33,569</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders' equity (net of capital deficiency)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_EygM5mDSNEmqLDwE9RJxPA_45_3">55,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_l_1oQIRn3EWQZyWVLUR1xw_45_6">84,434</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4b874c18_9047_4557_96c3_a56c3770605e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands, except share and per share amounts)</p><a id="_9112bd5f_bcf2_4991_a8cc_6ee198dd246e"></a><a id="_d91fdb32_c624_4904_87bf_07693d72df8d"></a><a id="Tc_s_yEsDANXEaF7GTxpIq8BQ_1_2"></a><a id="Tc_xGT0ANJOpkmtkomeqpU76Q_2_2"></a><a id="Tc_RDS1iILarUWcaM3wyzoLdg_2_5"></a><a id="Tc_AaQfAFbALkqi0TQGljo4cQ_2_8"></a><a id="Tc_9MOt58noZ0Soj182BiSLhg_3_0"></a><a id="Tc_mIdayJxECECPGF1dGmWs8g_3_2"></a><a id="Tc_1NjWxmgCKUW7n5MA_whQ_g_3_5"></a><a id="Tc_yfgVMweNw06lp9rU8d39Ng_3_8"></a><a id="Tc__IEp5_WBkkupQKl5hqNAsg_4_0"></a><a id="Tc_ETvN4wdKK0isRWGkZTLxcg_5_0"></a><a id="Tc_LQAHqMV0P0C-cejgSTFDog_6_0"></a><a id="Tc_73iT2rYlMU-eBolDvmkPNQ_7_0"></a><a id="Tc_ReH0Tb9bv0qXVZDus2GAcQ_8_0"></a><a id="Tc_QSL9UTQTcUW7AuHYXWGS_g_9_0"></a><a id="Tc_DuT7C2QRe0yydndvkP5Rtw_10_0"></a><a id="Tc_uFQrfQLVHESgNHEO5uFoHw_11_0"></a><a id="Tc_MaBGxpZnF0ewa4G5G1Y4mQ_12_0"></a><a id="Tc_qPREpPa8n0Ch3tZwwZTmZQ_13_0"></a><a id="Tc_ctMz43hI7U-Coq6uB23odg_14_0"></a><a id="Tc_ORTqBvZ-3EiLyOScGKOIOQ_14_3"></a><a id="Tc_ByVYM2Mvr0-GXQ--4DtADg_15_0"></a><a id="Tc_XOYKoHzScEq5r7BXATXlAQ_15_2"></a><a id="Tc_zd3Jg-Fo6E692FmFI2d6DQ_15_5"></a><a id="Tc_Ox8H4yU8CECd_GdUBacClg_15_8"></a><a id="Tc_ZqmjoQTl-0G0gnIfoCM_HQ_16_0"></a><a id="Tc_GqtAtErDyUmgTu5272FPaQ_17_0"></a><a id="Tc_6jNexiKn60KIzFtSvqSsLw_17_2"></a><a id="Tc_GWAEowGQuk23gyNAa4Daqg_17_5"></a><a id="Tc_-YvS-Ir1EECtLZUIB3OnFA_17_8"></a><a id="Tc_LhGdb81Y4Ui-NS7QAA-nCQ_18_0"></a><a id="Tc_sgDsTq36LkORW_qCNJhaEA_18_2"></a><a id="Tc__5U_F_zpuEqn3i6Go55GqQ_18_5"></a><a id="Tc_j7k82AzI6UCk8Y4R1CiELg_18_8"></a><a id="Tc_Tfq9nI1jw0eKy6tWVYIjmA_19_0"></a><a id="Tc_ZPNmeRxJxEKx_uuJ9GRbKw_20_0"></a><a id="Tc_kFEXGhPTSkO7V7JZTQxnEQ_21_0"></a><a id="Tc_W7oy5_AHp0KbDrdXaBkDqw_22_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_e9UvRO3aE0mfSCcsC-dTvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_UG2R-60XS0SamY2MZRCswg_3_3">16,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pFUzP2PhrEGGo1GT6PZxWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_vOFu_E2lb0GG7u52cOfmOA_3_6">25,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_FCBox10Ye0O87jYJEc-ybw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_VkXFDycEPkm0b3RbDyIBlw_3_9">40,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U-GkrbLvEEer06wV3cdFkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_E6UksxQseUSgfR5H8OuEBg_4_3">21,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kkqXot9cn0WBAMEZIGa-PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_MU2jKI4FXkizv3yraCrloQ_4_6">22,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dFI_S2Cmw0uvW76jwBJ16Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_PZdVXxEcd0KF7Mb4mgMIFQ_4_9">25,076</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Pk1PMu19i0eW0d48qPUH4Q_5_3">38,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_T0RV4XNHjka3_xEYrfnhjw_5_6">47,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_WeY_HuK4U0qN1gj4qbJ_AA_5_9">65,494</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_HY_MbTu-4UiFeSfqE0nPDA_6_3">16,349</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_-KocpYjgRE68DXrOis1P_A_6_6">19,592</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_RtaUL6bSRES0h_pxI_10dg_6_9">22,982</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_YzaofdZO6E2ts3XOMpeN5w_7_3">29,734</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_OSSOcNX1xkKRZdtWCjH-Mw_7_6">29,349</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_6_VZ_Srf-U2sNRfQO_g1oA_7_9">17,093</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_TAs4W1GKD0y3s2qVWOLQHg_8_3">12,729</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_cXlmawtNtkCiznLyXies2Q_8_6">11,711</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_Fed9sG24K0WlR0PlSRDB9w_8_9">14,959</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_oVs835IK6kSznOOis22qjw_9_3">20,462</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_3vmdtpXUy0ejWe5VbNn_EA_9_6">13,014</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_petFMnp9-E-muzgK3rYDqw_9_9">10,460</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_rdfzslNnuUew-rNeJ_qL_g_10_3">7,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_YVDXnQ5iKE-sa7GNVuDW8g_10_6">2,529</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_V25A-aPl7UKs9afWsTZSAQ_10_9">3,180</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_6SoGhbOqrUiNtNGvjsNbfA_11_3">401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_OsZQBWmlpU-4wSfvaQEq6Q_11_6">1,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_aWVpI_kGcUqVa7AreNnZVg_11_9">1,286</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES, NET</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_1lID2xxGCkOFklZAbm57Eg_12_3">7,120</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_cMRHXpw54E60_WucdyMBpQ_12_6">1,383</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_VfZa1bKsmUOtzue-9-hOTQ_12_9">1,894</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INCOME (LOSS) BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_rtHUUDinMUyMB-6DCd_MBw_13_3">27,582</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_g-i6lzK30kyUuac3_GS3iQ_13_6">14,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_foq0wYcW4kC74z60PjbWnA_13_9">8,566</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_zkOWid5cakeiYzSw8YgqIA_14_6">530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_EUsON-Dt7k-4x-kEtPcHDQ_14_9">254</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCOME (LOSS) FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_x44xDYQ9BkWUCRmCdRCFPw_15_3">27,582</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HkY9qvFGrkCt0MvvJgMY_A_15_6">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_QsHPeCe79keI8oh8OMyU7A_15_9">8,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER SHARE OF COMMON STOCK:</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_xYK1TTuEIkWb_UOx4_mLqw_17_3">0.62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_N6EGOMFR6UKD410PpD054g_17_6">0.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_uZ4IZuxI2EuZFGuJ2kHNAw_17_9">0.12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_PAWpkSJTLkGLRoX0Id9mGg_18_3">0.62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_P05jJ_xwOUq0v0_TCkay4w_18_6">0.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_4S31_1WDhU6KTyGiDJmh2w_18_9">0.09</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING EARNINGS (LOSS) PER SHARE:</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EE_G11nO6kGxVoyOEveaxg_21_3">44,140,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_j-3qtDqTbEioD4ED6JDsyw_21_6">48,472,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ghdyGybk30WOaP5nwZCUIg_21_9">67,512,527</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_xbyN3NnMJ0ejWc6oheW_2g_22_3">44,140,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_w0U01BaJPUyyePrwroQt0Q_22_6">48,472,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_LUUzmyflhku3lW0H5gYkMA_22_9">82,424,016</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_67940e0e_f851_4140_8728_3af779894afd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY<br/>(CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands)</p><a id="_8855922c_9f36_478f_8bf1_33e13ceb6cc0"></a><a id="Tc_Rc6BBSI2YUqIkiknPHBbsg_1_7"></a><a id="Tc_x630tSSrcEaWbFu9OyN5NA_2_2"></a><a id="Tc_7udB5hYvY0CAkn-ZiBP-4A_2_4"></a><a id="Tc_q-2XBzq1CkGwoiLcAuzDVg_2_7"></a><a id="Tc_SHqyxIDFukWlOdLO7lU6xA_2_10"></a><a id="Tc_yqqye7cT3ku8TFZnVXsWWQ_3_2"></a><a id="Tc_L9VF8NwYBEeM8lLvofoKjw_3_4"></a><a id="Tc_L6R0v4vUxk6Lz1bTf9RkbA_3_7"></a><a id="Tc_K9MuCKAuxU2hgd5NOzPq-g_3_10"></a><a id="Tc_OvxLKLiNj0-CR0hVV5t8sA_3_13"></a><a id="Tc_kulr24aF2EOXb1iZ4uvtDw_4_2"></a><a id="Tc_k2BphpyINUSHISn0vLGLvw_5_2"></a><a id="Tc_uiMKsaaVH0eeW6p9-SEvoQ_5_4"></a><a id="Tc_QT164fQK4E6D10RuWyiAHQ_6_0"></a><a id="Tc_Qz6-LDlLk0-NxmMpPbzVsg_6_4"></a><a id="Tc_WGXqjb8jwkuk9xIiAnXjXw_6_7"></a><a id="Tc_UFOiiOoCIEi5v1jcnXDZCQ_6_10"></a><a id="Tc_W-9u_T0EDUy_5fDn8kXNag_6_13"></a><a id="Tc_WwL3ysonpkmJAQ7E8Wb7uw_7_0"></a><a id="Tc_zS3-iyDTXEe_tdyghA7CQA_8_0"></a><a id="Tc_ESeXHJ__Mkq5Qvircgp7jA_9_0"></a><a id="Tc_LCI7YZHcc0Oh1BAsAARALQ_10_0"></a><a id="Tc_b7rw9hRgDkydYbIko3xFwQ_11_0"></a><a id="Tc_6RzzfwmUdkSjWKDyL_O-1Q_12_0"></a><a id="Tc_o57F3aAg4kuZjzBpJbV5zA_12_5"></a><a id="Tc_pyqlG6FDU0CCKHR1iXmJhg_12_8"></a><a id="Tc_0feJ1LmhTUqfS8leWLpxmw_12_14"></a><a id="Tc_hsOSaJnlBUWtB9IQYf26FA_13_0"></a><a id="Tc_eaU9qBhVv0yC1QlP9wcHBw_14_0"></a><a id="Tc__xVgOAderEWaoQhg5cTVmw_15_0"></a><a id="Tc_bxkoP3v_1kKEbdy0Il5-kg_16_0"></a><a id="Tc_L6B9FjdT3UCVrcBqwJYzxg_16_4"></a><a id="Tc_X74N39l72kSKQsK-k17Tpw_16_7"></a><a id="Tc_Ac5z04eB1kuhquvvu_A-gA_16_10"></a><a id="Tc_cQcLEJg0U0W3ItWwHDTY1w_16_13"></a><a id="Tc_oN9GgZcPz0uYdv74ZOWyxg_17_0"></a><a id="Tc_NJp9ll1CP0K9Mh4X7uEKlg_18_0"></a><a id="Tc_qCqdxqu_10KefS1Vv1qBXg_19_0"></a><a id="Tc_3OYd7gh-CU-7e8iU6XKGWw_20_0"></a><a id="Tc_IfjaJlOxbEGSgsGzuyMy0A_21_0"></a><a id="Tc_9lpP0u3YkkiAF0H8sKYlbA_21_5"></a><a id="Tc_1tPQK54dk0WgiDunkNB9OQ_22_0"></a><a id="Tc_ZL3YQQT4VkygJp18cgn0LA_23_0"></a><a id="Tc_hEzANAiSZUidfMlDTsy_6w_23_4"></a><a id="Tc_Ut471St3IEiFv2kbU2pzXw_23_7"></a><a id="Tc_EmH0COUqIUmkBt2b14DDpA_23_10"></a><a id="Tc_rae6o1Ei6UuezxgDaEImBQ_23_13"></a><a id="Tc_Nv83p_xTwkG8dTPjnWK3XA_24_0"></a><a id="Tc_LaKo-0S8B0WXJDvf0yXQ2Q_25_0"></a><a id="Tc_BbtMnpj6CUi5lI_xefknHQ_26_0"></a><a id="Tc_vUcYfLh0CUO57aW-i-ZHzA_27_0"></a><a id="Tc_1ZWjDMV2IE2PIcip8WgwIg_28_0"></a><a id="Tc_7m2UuGMsHU2TCzVa6w0ZXQ_29_0"></a><a id="Tc_1MZm8SmBUka0-M2SKBL91g_29_5"></a><a id="Tc_eUafM4XbkUeLAXM2KWfPpA_30_0"></a><a id="Tc_NR1PJfhl30OPHuOjvNtRVQ_31_0"></a><a id="Tc_b-fSJO1IHkuaTEzGXeQXUw_31_4"></a><a id="Tc_qiXAk8EfFEq5UyjN2ld7nQ_31_7"></a><a id="Tc_dZbSws1ZlEixFL13sqQk3g_31_10"></a><a id="Tc_86rAtRVoAkWEkqSt2Yms1A_31_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid&#8211;In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A-V99KoI40mufi3_2xy4zw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Siq3R7Cg2kWg_zHkx0172w_6_2">34,765,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A-V99KoI40mufi3_2xy4zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MvsWgzFONkaUtP7BBN2bvw_6_5">35</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SjXBySsIy0OVSVIytRlcHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_808SkuSHgkyYP1PVHzkWnQ_6_8">320,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HElXUIExK0aOC5Db-v7aeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_eaR79NyFmk6AdvHKqyDC5Q_6_11">347,352</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2020_BND5mOCuk0aUwO4j88CGJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_E92tazfp4EKsdXcagVKJdA_6_14">27,037</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_B9HJLzKAFEqpYEA5azS5YQ_8_2">8,749,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_RKjNCcdEzkqrww5siIdOig_8_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_feqLpnyYYkSsjXNG4wI23w_8_8">37,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_258b9NGb0kWpOaekWwJXEQ_8_14">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_ErAzTp23IkqYtvEBPmAw5w_9_2">1,867,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_G_0LRjNLOEube9ElzdHWPg_9_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_GUPIfgvg5EqbtDH9i5mRXg_9_8">8,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_vhCpFDPBR0C5XdthwHMqrw_9_14">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_6FSgDqLukEuzzXE_HR8U2Q_10_8">1,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kCqOKHB-8UiliO3dMPSMRw_10_14">1,405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock award</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_HYmuYPEeokue3TMpO1FWkg_11_8">970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_lOYA-yc630CWnLPoO8NfUA_11_14">970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_ypYDFuFFcU6a-jOPOxek6w_12_2">173,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reacquisition of equity component of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_wIOx9zu4AUOeoqHUxhAKIQ_13_8">12,019</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_N9gOJDEVzUWvM5Y18tfXug_13_14">12,019</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity component of convertible notes, net of transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_dHaLqy0V_E2oLSek0zYdOA_14_8">12,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_cdEU4VmUeUqc_cSbrTDmwQ_14_14">12,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wHGv4XDWOkqx4oPOB_i_5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_unr5OnCiL0CzvHriqf8i7A_15_11">27,582</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-SYHyIoCv0OzwCFvavC-zA_15_14">27,582</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oMdnHc9qbkOrXZVbmGVf1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_oSLNmfMplEW54il1kYYgjw_16_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oMdnHc9qbkOrXZVbmGVf1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_G9cMsNAjS0-Uo5v0D9KA8A_16_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eyEfL7MvJkeQsA4M6v4ywA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mrk07nva4kyxJLhMRGvEuA_16_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1TbW1rn7nUeqCRQw6xQlRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_b122YKRmR02MrXr8XbxAzQ_16_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_oeP4eajvLkyMfhkfX6PSfg_16_14">6,036</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc__hlQve8LrUWcRBUkOb3OAQ_18_2">7,473,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_HmWJrPylTUmQDhLBx-7LFw_18_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_BqD0u1UjUkWbJyMdJGhWeQ_18_8">8,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_RTPbgbLukUqALvdBU1Ph5w_18_14">8,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_K_Yc9brrGk2br1Cnt_3IWA_19_8">1,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_poFLyFjUc0GCShIlPbrz3g_19_14">1,124</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock award</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_L7Db03TlqU6NrmpC8NOBLw_20_2">759,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_5rTnCdNTF06dAvJX_a1reQ_20_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_PfOgX0Ch6EKrCfbmjU8fyw_20_8">960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_mVC92w6ZvEChHhY4oKUOZA_20_14">961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_7xNc5QlkI0yuS_cK3n3knQ_21_2">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_SSPA3i4YrUi_7GHZ57ujpg_21_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_ibSaugyYx0CzSYUSB_DrPw_21_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lwt4ua-FPk6WAW-XMj40PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1ERbTWtiqEuAQNyMn81ASQ_22_11">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Dlw-IHZQJUGySEWJkktI1Q_22_14">14,927</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2lHvWBXaM0q4Oy29CWa4tg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_SBKG5QlufkGdNav4Fb_TDw_23_2">53,790,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2lHvWBXaM0q4Oy29CWa4tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fOZsFTNZV0-E0KhGtdjbWg_23_5">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sJB3yn3mr0CwfBJ5isgHEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__CPwv3sRGEC12pjTmn2I6Q_23_8">379,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U3XBnkC7qEm6XPK7cp3CoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tGyrPyLYPUiiKpcU_BkBPg_23_11">389,861</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KiZF6nO2nkK_Y5zNmp743g_23_14">10,640</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_wM_5DhZHUkKHZqXHOHKL9g_25_2">12,560,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc__spr-aLYE02gUtAsTSewNA_25_5">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_k5UeE1XEDEmXGp20BQo_vA_25_8">23,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_5BUfner2-0K1dmIr1eGIAA_25_14">23,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_WC3DUsDCGkGoRYE5-yfkiw_26_2">4,691,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_67frxxz9XkSbqSPc9NMEfA_26_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_P9mGnglqWUyJSzDWa8c0hA_26_8">7,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_C_N2FljD40y_1BAQzc6eVw_26_14">7,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_sZISLQ52SUa-6y0MLKQK0Q_27_8">1,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Swei3YATU0eyRwP3uDLVog_27_14">1,928</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock award</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_2vD8jFUumEeI_JiIxot13Q_28_2">1,371,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_rxTCEKUT_kOvksjyrknD-g_28_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_DjoTTyCvI0a6SmioP7jT5Q_28_8">1,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_TPVn2qUUHUG7XeyezbrHeA_28_14">1,520</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_pS_y4QLWTEehvhraowGWqg_29_2">538,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_5KEWruJZAkmbFtHO1dxz7Q_29_8">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_i9EydllffUCt_QXPih6ZLg_29_14">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g52wVaMHREOxVOaAH1rbeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_tChM0AtPA0u747ue2orBlg_30_11">8,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_-LxyhEYMyEWZb3XJSa4AyQ_30_14">8,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EvqBctZ660eMWfEw45p_Nw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_-XaJsyfjOkyeqDQOxI8wjA_31_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EvqBctZ660eMWfEw45p_Nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Hp1V9Oj-FUKRFgvpQLxnhA_31_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whY022XGs0KlMAyNJFGWMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_WSVt1Q9eNkaE1gKKsGLV0w_31_8">415,045</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KoWXKKVDCUWPZuUT1WTDdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Dxdd3tqJnU6Uq2RSonnlRg_31_11">381,549</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_82DfQ5dpa0SFRZSu_T7bCw_31_14">33,569</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a430c62c_46d2_4eb1_8351_16509f57979b"></a><a id="_f039d4ba_6379_4a08_90ba_4461bd382d48"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Represents an amount less than $1.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5388823c_3683_4f55_bba6_8f5e659b62b1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(U.S. dollars in thousands)</p><a id="_15df2cb2_a76a_406b_bdeb_65c569f49b2b"></a><a id="Tc_WPrI1mgyiU-8NZHfTEcSNw_1_2"></a><a id="Tc_LgUxPa0HYkWD6XqbBv7rcw_2_2"></a><a id="Tc_Y15EKubMBEyVOVgUDVzaHw_2_5"></a><a id="Tc_bznHSTbovkK8Bzvl2aUQCg_2_8"></a><a id="Tc_aX-iTjgsrUKcFq_YYrhmZw_3_0"></a><a id="Tc_um3k5RXd30qapIoEEIwBlw_4_0"></a><a id="Tc_OeniYPPb3kSqhGYon5kefg_4_2"></a><a id="Tc_pL8jbXDiLkqQ0MmPtJgSQw_4_5"></a><a id="Tc_8Dn6vqWQCkSuyV4KkL413Q_4_8"></a><a id="Tc_lmhH63DYCk6FldxgG1Fd7Q_5_0"></a><a id="Tc_Id0NLZj0_EOk4Cqiw0HV1g_6_0"></a><a id="Tc__L3cL4gysU2-4jva-XRsZA_7_0"></a><a id="Tc_a81kzFlx9k-yvRKeJyix7A_8_0"></a><a id="Tc_c9SIjWwSmk2wtz4uj5DJ1g_9_0"></a><a id="Tc_C_fQ1olZZEuzVxeiVej0MA_10_0"></a><a id="Tc_tuewzW3bUk6XU3oW8EmsRg_11_0"></a><a id="Tc_pISRKYaZPE-iTM--ahzj0w_12_0"></a><a id="Tc_QI1yo9WGTEGbyXRx9LtYDw_13_0"></a><a id="Tc_ZrxodxPftEGbZy_8KH_X6w_14_0"></a><a id="Tc_nE46enLaC02IQvWssKU4Eg_15_0"></a><a id="Tc_2g34AK1uP060Tdb4Fwl-YQ_16_0"></a><a id="Tc__3T7YD7RAk6ZfIgKowiyRg_17_0"></a><a id="Tc_lCrMi7cmxEGkHlK-Ed2HPw_18_0"></a><a id="Tc_L2M8q6_DfUOraa02eUlUtg_19_0"></a><a id="Tc_8T0DlFwjhk-PyNohHNx_UA_20_0"></a><a id="Tc_-TGs540wsE2I37pinAn-0A_21_0"></a><a id="Tc_O4EYe3YQEkW1QJ5GiskEKQ_22_0"></a><a id="Tc_NB4U5mgDRES75V-sUfGOdw_23_0"></a><a id="Tc_jrDx5XMuAEeDOiebkPDW8g_23_2"></a><a id="Tc_kMY20UcUXEiPMHDxa64dgg_23_5"></a><a id="Tc_tzxRp7nxK0y0nHukWuC6Ow_23_8"></a><a id="Tc_i4-JEFZp502QuziVa_tnIQ_25_0"></a><a id="Tc__Ct6CA7NG06gGRtKHhIXTA_26_0"></a><a id="Tc_mnlw_q6G6Ea65A6XyLiixw_26_2"></a><a id="Tc_Op4DdkAU6kOKSXc9HblX3g_26_5"></a><a id="Tc_Iz5vcA7vqk6jp2MIvJ_9qA_26_8"></a><a id="Tc_G9hfwAz_QEypeLrb5gvdHg_27_0"></a><a id="Tc_YJ_fNWGymEGqfRvwuaRdfQ_28_0"></a><a id="Tc_GpeDbEP34kmFZ4d-eZU23A_29_0"></a><a id="Tc_99fHKGFru0aoDrUlYrJMkg_30_0"></a><a id="Tc_rvn8L3TJgkS-MsrYxyhGlg_31_0"></a><a id="Tc_mdkqLddtEEiLSpAaPyW2DA_32_0"></a><a id="Tc_4c5quxeoBkizHxEmvhijYQ_32_2"></a><a id="Tc_9mmbGvcQeEqP94Ft29jPig_32_5"></a><a id="Tc_YF-sC228IEy3FsA_To5EkQ_32_8"></a><a id="Tc_zpVXrjhwLUiFwya8Nq2XqQ_34_0"></a><a id="Tc_9JNg73OGMk6Gfwnfob1EZg_35_0"></a><a id="Tc_cZ7c6weO0UeJYY3d4hdimA_35_2"></a><a id="Tc_FqOFO60YVkKqbvD410Qplw_35_5"></a><a id="Tc_u42y4jxGAUScQ30nTj2YUA_35_8"></a><a id="Tc_UGgKjjWX1ECwmW5DTtRgrA_36_0"></a><a id="Tc_ezSV-FJciEaH6yIv8gCcDw_37_0"></a><a id="Tc_EhLFGhmHO0q2KzpjdMTsEQ_38_0"></a><a id="Tc_eGP_h3AjQUash2AhcbSxYQ_39_0"></a><a id="Tc_wNVhcULGbE28hOrqnSnbhA_40_0"></a><a id="Tc_8h03aecdCEGbJ0tzK9jOLA_40_2"></a><a id="Tc_2P_ivnlCr0a-G6w17h7xBA_40_5"></a><a id="Tc_2e90qIH_iE67NpeL-imNhA_40_8"></a><a id="Tc_Dh-8aKHfhkW3qusE22lGiQ_41_0"></a><a id="Tc_vTsvkaWZO0mUbHeQ4HkKLg_41_2"></a><a id="Tc_I3sdYAYxG0KwwxltJ30jUA_41_5"></a><a id="Tc_JbBX79MQSU6veoRkPzsMUg_41_8"></a><a id="Tc_2Te8IYJWWECZTMaQCs6v5Q_42_0"></a><a id="Tc_-YMDfMMVQ0ex0wDr1Aq1Yw_43_0"></a><a id="Tc_UjziYvzb-UaqW4yyoxWfOQ_44_0"></a><a id="Tc_NGOVQB49RU-9cDa_HkVFnw_44_2"></a><a id="Tc_-hEVaCARzUSDorsMqS6U_Q_44_5"></a><a id="Tc__ZSYbGqTh0WWZhtQvriPUg_44_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_95wCu9vpa0WZYQK7VcsQwA_4_3">27,582</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_eRxIqCBNME66IJ3OWxiOQw_4_6">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_aQYvlqET0UqUxJjN99ghYQ_4_9">8,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_4F7lTH95VkWy9AWMOTncrg_6_3">2,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_T7cSWygUZUOkwkjz23MmjA_6_6">2,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_gou0Jb1Y_kCQZXe8dJZyNg_6_9">3,448</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_sGUZl2E0MUOHESvkmXcGcA_7_3">1,118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_WwInbjqxfEW7b59FKLaEPQ_7_6">1,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_a5qak1I-FU2IcHktH-lT5Q_7_9">1,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc__5ZtPkMCFkyc0KKgogLApw_8_3">417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc__3x-3o2f30SbSxAW6TpATQ_8_6">989</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_3N2ZJOVsokmupXNWvbavVw_8_9">446</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_C8NCG77X5EmFaQjK4L-4CA_9_3">133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_tzONKoOUBkeHvVtfQVCjDQ_9_6">543</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_8pgfF4x1ZkGnkFFOb4XLnw_9_9">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_KyPymxMtcEGl9JWbvh80ig_10_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc__XZqqXM_jUOZ0uQBjhXdgw_10_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_lrQGkVWZ_0uAnWjs36RdaA_10_9">3,092</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_lmr6__ixbEqjhjAVcA8YVg_11_3">100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_ZXot4GK_Q0mrrU0K3B6-rA_11_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_VDBk__Z4rEC9nlffoxnJAQ_11_9">50</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_1LESkGWb_ky_oYVeWMvrJw_12_3">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_DdoXJmt6hUqfTB_e2jXhnA_12_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_43LNace9kUGdGiR_nwM2HQ_12_9">9</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss on extinguishment of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_ZAmnW2PwMUeQTlFty_IlSA_13_3">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_PMQ445bCxEak-d8uNJk2Nw_13_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_a5GseVbnQkSzdMJsQVjOhA_13_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on conversions of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:zerodash" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_zaKLeqe4t0S0nl4uoITSDg_14_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_f2Aix5xEEE-HJe38DsN5Gw_14_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_Jgmxr2BUf0ymviguvE3IxA_14_9">421</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_MDizW4xrvEWuDQrpBUelTw_15_3">2,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_9M0knonN0kS9I7d5FuGu0g_15_6">300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_iWjBXZ7z_E2b-B15OBToIw_15_9">267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_0HbxYczHREmI-EWOrny1gA_17_3">13,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_GlzLaLICiUmQ78G2G8AxeQ_17_6">7,162</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_DRY-H6sZ2EiwHUZkftdaVg_17_9">13,178</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_hVXuHLYXcUaY2Pou4v_Xcg_18_3">1,032</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_gAPPfaZ9BUS0PLFiPREdWg_18_6">1,194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_s8jibFZ-1kO1Ok0nHUeLMA_18_9">428</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="white-space:pre-wrap;">Changes in operating lease right of use assets,  net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_WVnMyKSSbkK7q-E1YorwHg_19_3">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_KpOmv5km5k-pXejbZpiGkA_19_6">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_nGqwC5bhlkyiYQ73EtN4qw_19_9">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_lOfbexhjE0mIZ9Gfq6MkLg_20_3">4,872</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_b65tmB0t40qBA9KJjhn4NA_20_6">1,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_7ZTlCZgPl0modIZc5ejNgA_20_9">2,241</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_-Noud9nF6EyK0p_RSaPVWQ_21_3">2,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_569VRVgmcESs0bqM5EG0iQ_21_6">4,804</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_5Sjren8fTUuEA4pW-4c1nQ_21_9">5,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_1sQ_jR0TEESzLrESSxYdIQ_22_3">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_HZIcoVgBe0u1q6gCe3AuKg_22_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_cX_-bR2vPkKaoGnCSCOMOw_22_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_rHB4ES-z7kq2ymHgZDeGAA_23_3">10,285</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_qGncWMrCoEa8A_jO5_wvXw_23_6">25,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_mgmE0gdcBEmhZ8uOEP5MEg_23_9">1,318</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_RAYoFVygoE-GhMNlVj_xzg_26_3">37,835</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_76_ocKcQr0qxHmkV5Xl0dw_26_6">16,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_oguq8QL7EkKalxZassWaVg_26_9">20,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_Nv1iuI-LoESbcCrjnII93A_27_3">57,835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_jjuCDjPQwU-9zyF_BxR_nQ_27_6">11,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_m_dPL4H5BEOJBAi0bNyrmQ_27_9">5,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_8j3FHP7VOUqf4qUqfF0tQQ_28_3">1,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_YdkhwqiTJUWG-2Y3CF9Gxg_28_6">628</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ZEhoISNXX0CmBjcQGmEfGQ_28_9">1,149</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_ZmdHegOCJ0eiz-GqvZqsaA_29_3">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_2TWTJ5MwJ0q3m1GxU1s28Q_29_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_qaAkgJkxPkab8IYcW0U4HA_29_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decrease in restricted deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" sign="-" scale="3" id="Tc_cKwYkzdLA0WKgmksp9EaHQ_30_3">436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="plx:IncreaseDecreaseInRestrictedDeposit" scale="3" id="Tc_wHotxHjx9U2wW9Kc2nL9Jg_30_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:zerodash" name="plx:IncreaseDecreaseInRestrictedDeposit" scale="3" id="Tc_oHzGe0SFGUiZUkSH1M2qjA_30_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">Amounts paid (funded) in respect of employee rights upon retirement,  net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_Ffv8B2um7U-vEO0ZOBKsNw_31_3">109</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_uYuyxESsY0eztKLUJhZ32A_31_6">593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_NMrJNEiblUepjn3z-ihzOQ_31_9">142</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_7S7OYZnpRE6Vua0O4FQtgA_32_3">18,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_KN3JVjOiPkS-O2_WjYXuaQ_32_6">5,035</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_pt_s0AW3akG8PT2bCRosBg_32_9">16,711</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Payment for convertible notes redemption and transactions costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_Ggjn1jg0IUqx1HlbXRAYLQ_35_3">30,036</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_uTZ3QDyvvk2qg-pRBSv9ZA_35_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_V7r9vBIZC0W0Mp7DZmnQkg_35_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Payment for promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_AbBUuEYcvk6h2h_4RaUBog_36_3">4,086</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_P8q01hcyykicMuR46m02Ww_36_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_uN903SMK80qqz_Q2F3xgEw_36_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock and warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="3" id="Tc_1C0bYrkoAk68BzGpp0aH-g_37_3">37,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:zerodash" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="3" id="Tc_rFWiuPundU6KufBs8Ia2QQ_37_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:zerodash" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="3" id="Tc_grxtgq6srk6xUrlWSTWlxA_37_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">Proceeds from issuance of common stock under the Sales Agreement,  net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_r3K2zZt_i02oGVN1FMQ4Ng_38_3">8,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_7fzNmfGQh0-0zssrO7eu8A_38_6">8,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_tlbMa6YXokO3r6NP-uFsqA_38_9">23,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_l5MfmWKUUEGpnAmdv5YIzA_39_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_skutvb-o3UaaV0MQZ6I5vQ_39_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_0jOMdPiCFUuKrb8uE_qbQg_39_9">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_csg8KOVg80qTvbk91PtsLQ_40_3">12,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_9BtSGvuxZU2EUpTat2ZQBA_40_6">8,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_VyZIws2L50WR4cP1suD2BA_40_9">24,666</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_a33-HWZYH0qb_fzvj7PzNw_41_3">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_TbsdKAbkmkWdIY0dqfULsA_41_6">77</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_59V0pVsw9kW7GLIyT8rdlw_41_9">114</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_q1MuxuyJ8Uelj3HdlRAUdA_42_3">20,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_fnyKzEmvbUS7pZ0E0MYkTQ_42_6">21,874</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_d3RK2iHyX0msecjLyMyQAA_42_9">6,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2020_BND5mOCuk0aUwO4j88CGJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gbFh_rcVaE6O4Tt0DBC1UQ_43_3">18,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_dZG7pqfQIUuuZzCStKrxrg_43_6">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_QQ2NbeZJF0OHYIM1KxmWxg_43_9">17,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_kvwFcu7tBkyVOSA2HbVv_g_44_3">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_sx0tYXVB0kGvcg578T02wA_44_6">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_EgCLpXP4X0eaGO9Dj1e2Lg_44_9">23,634</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS </b>(CONTINUED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands)</p><a id="_ceb6d648_2733_42c0_a9c0_4f88182ebfa7"></a><a id="Tc_3kOtHxN_EUCGOe5K1YpT4w_1_2"></a><a id="Tc_ZSbNqWmpokmy-i7nlNC_Jw_2_2"></a><a id="Tc_um3kscu7SEuw8j58qWe9ZQ_2_5"></a><a id="Tc_V2wYCpFsn0iaQ2IZ2cmaBw_2_8"></a><a id="Tc_z02VJw59LEeu6ffX5buGcA_3_0"></a><a id="Tc_d4U1LPN1TECcZa7mKjT8nA_4_0"></a><a id="Tc_cxRVuyAHtUK0kXw3jqfw5Q_4_2"></a><a id="Tc_gBOXqA6Z5kKeeFvR_EEMlg_4_5"></a><a id="Tc_fqv4r5ArG0Og6VyIxrljGA_4_8"></a><a id="Tc_cWcXERx-Skix4jc24aPYvw_5_0"></a><a id="Tc_q_89ZP55N0OxNrldjZIwYw_5_2"></a><a id="Tc_tH3zTyUrI0yAjUDjOxk3zw_5_5"></a><a id="Tc_ToIL-n-H8E-zre-slrwcJA_5_8"></a><a id="Tc_YyUQJwkCEEuZkk1Q4i-7wg_6_0"></a><a id="Tc_5QViPPfNakKgDUxNhZ0aOw_6_2"></a><a id="Tc_WQ1XMQVvsEGKNS0hvh5q5A_6_3"></a><a id="Tc_3ZTz6c40m0KTy1fjgF41YA_6_5"></a><a id="Tc_4yIiEVpqo0Khnof7buRZOA_6_6"></a><a id="Tc_DBDO_d2JQ0qgki0D0_5rwQ_6_8"></a><a id="Tc_rc4mbfBrAUuicZtvyLgOcw_7_0"></a><a id="Tc_4uACI4qCiEGWbiEDsBvx8w_7_2"></a><a id="Tc_LrqlVTHJRUm8OnMJWWyA4A_7_3"></a><a id="Tc_8QLuFhPsZEm8yc0ukex01w_7_5"></a><a id="Tc_GfvUB7NGuUCJyTdvXsYPKw_7_6"></a><a id="Tc_aDjaqa5pw0Svkz2InD0qyQ_7_8"></a><a id="Tc_hUNy08tN60uEgFOFcbvmLQ_8_0"></a><a id="Tc_6jH4XyxJgUSRik2lUWPtdw_9_0"></a><a id="Tc_fSoFAwE5mUWroAVQDq1D4A_9_2"></a><a id="Tc_1TSlQmqNK0CdQCpVlMQwXw_9_5"></a><a id="Tc_3Hem7R0JKUOlHlF50K2Hfw_9_8"></a><a id="Tc_xRUusiQiNU-d6xhnIav8Qw_10_0"></a><a id="Tc_dyk8kbbzVkuM27YhoSZwpA_10_2"></a><a id="Tc_6L3p44sq8kapEWgYV25E6Q_10_5"></a><a id="Tc_DS2HHe4IB0qRGYtAgkVOJQ_10_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_JtjDaGKer0ii_31XiKhYQw_4_3">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_QhnV0tRD1USLvDV6mQSMWA_4_6">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc__pwbiPzQckmVw05Ig5rJdQ_4_9">614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_O82578bR7k2YaIwEkXN48Q_5_3">309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_hSrrg0H7bEy3p3t4ZP5nMQ_5_6">794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_ebdWHzTUwkOkGbXIZoqtoA_5_9">1,567</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_JxskienXPkam9so0_9uaBg_6_9">7,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Partial settlement of liability for employee rights upon retirement through transfer of the related funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" scale="3" id="Tc_hPZFCinCm06yWfmhVVDodw_7_9">882</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_kpzwJW-hI0SEiozIqDZfCg_9_3">3,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_wnqalu3YSkiisYmqJ0qvog_9_6">2,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_Mi7hQM5gtUG-lRbIvcIBcA_9_9">2,742</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_UfftQyV3REShBKTVAXm35A_10_3">379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_OVIe-yD42EKrE-v8DCKPMQ_10_6">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_kv2S2Ag58kqnm6ZZGBEX3Q_10_9">355</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">As to extinguishment of convertible notes see <a href="#_NOTE_10_"><span style="font-style:normal;font-weight:normal;">Note 10</span></a>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_30336"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_UxspxtlpnUm_EdnJc2f6Eg" continuedAt="Tb_UxspxtlpnUm_EdnJc2f6Eg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain and Switzerland. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into <ix:nonFraction unitRef="Unit_Standard_agreement_LtAR6Q5w6kqJ8CT_46DuZA" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_LWv_NqMlb0y9IgNZLUeEnw">two</ix:nonFraction> exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont1" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont2"><ix:continuation id="Tb_UxspxtlpnUm_EdnJc2f6Eg_cont1" continuedAt="Tb_UxspxtlpnUm_EdnJc2f6Eg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the BALANCE study (also referred to as Study PB-102-F20). The FDA review team also concluded that the BALANCE study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the BALANCE study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of December&#160;31, 2023, <ix:nonFraction unitRef="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg" contextRef="As_Of_3_21_2023_MSmaAEySeUOElBXVq6cGkQ" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfPatientsDosed" scale="0" id="Narr_SMJPRW_YKE-HSHFfwMgjNw">56</ix:nonFraction> patients have been dosed in this trial. The Company expects to publish preliminary results of this study during the second quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell from time to time through the Agent shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_GvuRJaXm1UWlbfDR82Bxug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_rymLbvaTV0Wx93DdPs7JmQ">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_GvuRJaXm1UWlbfDR82Bxug" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_UDLWWERBEk6gJvsipq7NiQ">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont2" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont3"><ix:continuation id="Tb_UxspxtlpnUm_EdnJc2f6Eg_cont2" continuedAt="Tb_UxspxtlpnUm_EdnJc2f6Eg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_qEwfUVZLKEeMlUabO-wb4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_8dN777WRuE2XArUXg1_RhQ">3,296,123</ix:nonFraction> shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_qEwfUVZLKEeMlUabO-wb4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_-z92SYXwfk-6kfNcP094CA">13.8</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rhLqZfwsikKgSa9TtspiSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_zOLmZ1mQc0KKuytLKpC2Rg">13,980,060</ix:nonFraction> ATM Shares for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rhLqZfwsikKgSa9TtspiSA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_G1pcM1XtCkqCQbM7_lAJFA">20.0</ix:nonFraction>&#160;million, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZMEMUOBNoUyTMPRQ3bJFUQ" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_wbZtLlP3GEOU2N4bW_ZuJg">20.0</ix:nonFraction>&#160;million. As of December&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_46WI__Tnm0OEDK5uErsfzw" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_02dDew4pyUiDSAgtQ9g0Kg">6.4</ix:nonFraction>&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nJOVwAxjsk22aPDfa4pnSw" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_Gsiy4zdLi0y3j73RTXKfrA"><ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I7HBPUkpYkG4hv_N2994ww" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_JyUaidzjI0ygxEU6UkjrtQ">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. was entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_u0hVMes_Fk-O-7E6nCbldQ">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_VderCHs1lU2gRP-HOtMv8Q">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_l3R6AAkJA0ig1zk92aYk2w">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_AdVk8XN5Z0qi__ZVIrU9mg">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it was entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_vaRhyudj7UmLg4_Fy4pUpw">20.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_eJ-H8KcFkESIM5aPrjQhMA" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_HTmkvE06wkKWQIZXNKcsGg">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_U62DmPC_4E27mSZiUh7v1Q" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_XIu3YQJQ3kKVrvuFJK7xUQ">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iyt1XR_TI0OMpk9KrJ5mlA" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_8ZiDMcsaUk-ibWxHugSF6Q">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_T8vMq4SkD0iHfguhY8hxzw" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_V1aPq-pBGkeXoC4Ct4Q2kQ">35</ix:nonFraction>% of the average selling price of the drug product in the applicable territory, and, under the Chiesi US Agreement, such price is based on a range of <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_YYAL7Hdl_U-pTxkWB5nOeA" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_cYpurM9OE0O6wLD58ADy7A">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_ssAFEpgqrkqUmuHATgmJXA" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_tGlgPsV97E6m_Q2p5AzgQw">40</ix:nonFraction>% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont3" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont4"><ix:continuation id="Tb_UxspxtlpnUm_EdnJc2f6Eg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of <ix:nonNumeric contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_IoUaetkJx0G8wYJ_o32Cpg" format="ixt-sec:durwordsen" name="plx:ExtendedTermOfAgreement" id="Narr_6SUYl97O1EGO6ENXqEyxeg">seven years</ix:nonNumeric> upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ymHVK27wsk-xnzEuafVJJA" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_Jl5_8XerL0umGhkLkBscrQ">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. As of the issuance of these financial statements, the impact of the war has not had a material adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. See also <a href="#_NOTE_10_"><span style="font-style:normal;font-weight:normal;">Note 10</span></a> with regards to financial covenants under the terms of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_RZKa5Eb17Ua164v13No0CA">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), including the maintenance of a minimum cash balance of at least $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_s2AbEecD8EKVOXsuUH6r_Q">7.5</ix:nonFraction>&#160;million. As of December&#160;31, 2023, the Company is in compliance with all such covenants. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_5aYgp6xhjEq7eR0hCSo3fQ" continuedAt="Tb_5aYgp6xhjEq7eR0hCSo3fQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont4" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont5"><ix:continuation id="Tb_5aYgp6xhjEq7eR0hCSo3fQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:UseOfEstimates" id="Tb_V-9CykhbfkigkHsZ6q0BLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to the assessment of sales reserves and valuation allowances.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_RUmdbu_nWEegHpDKT0qTAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_M15MCHFrckO4RER3qe_VwA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_kyp0y_y660KB0dey0opLIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2023 and 2022, the allowance was negligible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">No write-off activity and recoveries for the periods presented were recognized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:InventoryPolicyTextBlock" id="Tb_GU7w6v_JDUKI9E9MTdQsog" continuedAt="Tb_GU7w6v_JDUKI9E9MTdQsog_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d187cc1b_a46b_4d94_9d6c_400758cd4370"></a><a id="Tc_PF9d-A5YWECvXxqgKVKCwg_1_2"></a><a id="Tc_-rhNspwCLkWb8t_YpDzKoQ_2_0"></a><a id="Tc_ldzTurvUoEW_H_tv6hRMfw_3_0"></a><a id="Tc_kIRsrftVrUaQPDHgWMhhDw_3_2"></a><a id="Tc_YVHeEk3QlkmI-0e-5_jlzQ_4_0"></a><a id="_k.__"></a><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont5" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont6"><ix:continuation id="Tb_GU7w6v_JDUKI9E9MTdQsog_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_gfsAdOUYBUillW-y4aDX4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="plx:ScheduleOfUsefulLifeTableTextBlock" id="Tb_DAPg96JLB0i_Z01CBrix1A" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_WRnbeAQqwEefX40snBbQkw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_F-xjMv4ilkyaYW66GDU_jQ_2_2"> 5</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_6DVEbvAY4UqBUIIBPTkpNQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ZQuLnitP0Emqo1UOemE4uw">10</ix:nonNumeric>-<ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_8yYtim8BTk2lBe258_oMnQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_UNzbR3hvPUOjiVNm0Uo0sw">15</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_K8BonSjLn02SgJ1mtQ59Tg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_Osrb5_l0-EWMm0neQsRzow_4_2"> 3</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_HIj85kKDe0y315buijb7BA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_x3Wi4D8qCke7YFcbLa9c8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_TUUcQhHUU06ON-Dyq-mjlw" continuedAt="Tb_TUUcQhHUU06ON-Dyq-mjlw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont6" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont7"><ix:continuation id="Tb_TUUcQhHUU06ON-Dyq-mjlw_cont1" continuedAt="Tb_TUUcQhHUU06ON-Dyq-mjlw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances. The sales reserve is calculated based on expected sales and the anticipated net average selling price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent the variable consideration is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YTSB_ILxnkmbVEy0yW3LuQ" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_EffeTNviQkGrPPoDO7Fbig">two</ix:nonFraction> performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also <a href="#_k.__"><span style="font-style:normal;font-weight:normal;">revenue from selling products</span></a> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_LDWdrX5vpECwlOi4Zi3N7g">20.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont7" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont8"><ix:continuation id="Tb_TUUcQhHUU06ON-Dyq-mjlw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_zrwDgTlTQ0ys9HzvpsHaEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_jKwjjNJGlky71p7h8HGtog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2022, the accounts receivables balance was composed of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_rEiciTruOUm2wOSIAx_19Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_M5p6z3OnP0KvYJHWNVMV8A">2.3</ix:nonFraction>&#160;million from Fiocruz, $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_ChiesiMember_JefjA3XnO0-mFmgSL6r5WQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_ZmTE5xJb1EOz7zLueUHM1A">1.2</ix:nonFraction>&#160;million from Chiesi and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_PfizerMember_p6MbltwMMEWI2aMxFJC3uA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_vrPaapDN5UG7Qa-e_-IGEA">1.1</ix:nonFraction>&#160;million from Pfizer, and, as of December&#160;31, 2023, the accounts receivables balance was composed of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_fA3_XWjL2kiVo9BcdeEmJw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_fSFO7t6Hn0aRmyVzVyLrBA">0.7</ix:nonFraction>&#160;million from Chiesi and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_sjRoIJCFyUScH2Tf8mBsdg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_aRSBjri3hkuu1nzxyn6LIg">4.6</ix:nonFraction>&#160;million from Pfizer.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_NyWXV6gN_EO4BQi5UrTk7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for </span>restricted stock <span style="background:#ffffff;">based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees, consultants and other service providers with only service conditions that has a graded vesting schedule using the accelerated method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_Hh2RJWvLpU68mOioDTBzfA" continuedAt="Tb_Hh2RJWvLpU68mOioDTBzfA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net earnings (loss) per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont8" continuedAt="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont9"><ix:continuation id="Tb_Hh2RJWvLpU68mOioDTBzfA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:DebtPolicyTextBlock" id="Tb_0bmI9APyLkeSHTtr1OLAZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_iAqmHavoc0y6aGWMensHBA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_sG7f897B1keHhZ3HYQQCnQ">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="6" id="Narr_gifN6dtR90erhuxuJJ871A">20.42</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_cNQ1D4O7ukaQQMkXZjYndA" continuedAt="Tb_cNQ1D4O7ukaQQMkXZjYndA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ_cont9"><ix:continuation id="Tb_cNQ1D4O7ukaQQMkXZjYndA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_8CxHtb8eO0mCh9YXziO6xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;New accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures<span style="font-family:'Palatino Linotype';">.</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_h5LoHtCFSkC1eRYaLmKkqw" continuedAt="Tb_h5LoHtCFSkC1eRYaLmKkqw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer that amended and restated the Pfizer Agreement of November&#160;30, 2009. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix Ltd. also agreed to provide Pfizer with:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</span>Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">2.</span>Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Promissory note&#160;&#8211; as of the date of the amendment, the Company issued to Pfizer a $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_YBmOU2lAJUOBzWtk50UFrg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="6" id="Narr__p0iPeXevkyVkbBzKMW7dQ">4.3</ix:nonFraction>&#160;million promissory representing the Company&#8217;s share of accumulated losses incurred under the Collaboration </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_h5LoHtCFSkC1eRYaLmKkqw_cont1" continuedAt="Tb_h5LoHtCFSkC1eRYaLmKkqw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operation. The promissory note was subsequently amended. <span style="background:#ffffff;">On March&#160;29, 2021, the Company paid approximately </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_IzrnD5jt5UGo5H0UZZIy6w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="Narr_0fSf7tzEf0GQD8Uo2OhahQ">4.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million to Pfizer satisfying the promissory note in full. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">b.</b>&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#8211; the drug) for the treatment of Fabry disease. Under the terms of the Chiesi Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix&#160;Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nJOVwAxjsk22aPDfa4pnSw" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_VQ1phC_WIEakI8paCjSLfw">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_6gLCL7YyKEq3e3IUzCBs4g">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_-fgb4Rpmf0-M3dDZ02HBLg">10.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_H2NjDL44UEanKbpb_zbiYA">320.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_DxZ7yiKloEeYPqjWugRpiQ" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_r91W30XkqEuL7Tsjl81XyA">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_KSEwWosZJU6bgW9NBu3j-g" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_o4p-yIzf3ECKfAOQPKc3mQ">35</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix Ltd. will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Chiesi does not have sublicensing rights (except for certain territories).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In July 2018, Protalix Ltd. entered into the Chiesi U.S.&#160;Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi U.S.&#160;Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I7HBPUkpYkG4hv_N2994ww" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_6MruQVi1dk6TC3NJ6ac82Q">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_4xcbLVQulECOUyroI9ksvg">20.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_ay03uVfs1ki5KYpsnh6X3w">7.5</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_zXe4J3RzWEy7_PIPWnWm5A">760.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement, which has been reduced to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5MEdadDSM0SF5R2b_ZDHTQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_b0rvJA8TTUOnrIvcX6yPNQ">735.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_MGXDBj87K0SGVdw9QsCN6A" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_0jwQoaDcoUCCmd6qfWV_0Q">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_vo-_yyTgdUqcdD8bTMOyuA" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_P8en1tOv00yNI9FmDY2gXw">40</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_h5LoHtCFSkC1eRYaLmKkqw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Chiesi does not have sublicensing rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, the Company has received, or is entitled to receive, the following payments from Chiesi:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront payments equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YTSB_ILxnkmbVEy0yW3LuQ" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_vwQTuYExtEiBk8L-wDnvPA">50.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million, in the aggregate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q" decimals="-5" format="ixt:numdotdecimal" name="plx:PaymentInConsiderationForDevelopmentServicesPerformed" scale="6" id="Narr_EkeCEqR2tUiLQ4c34GiiXw">45.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in consideration for development services performed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q" decimals="-5" format="ixt:numdotdecimal" name="plx:PaymentsInConnectionWithPerformanceOfAdditionalStudies" scale="6" id="Narr_3Cxw0SwWOEy7Wz6J1BZIDQ">51.3</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in connection with the performance of extension studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">Payments equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YTSB_ILxnkmbVEy0yW3LuQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_DfWUwhmcMUG8EyxxeD4zfw">30.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#160;million in lieu of certain milestone payments.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">c.</b>&#160;&#160;&#160;&#160;On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p></ix:continuation><a id="Tc_slPSyAWZg0qgREBovcjR4Q_1_2"></a><a id="Tc_OOFVTewkv0SOvecodw0_cw_2_0"></a><a id="Tc_kW4j2NoGSUCmNcqocNUNPw_2_2"></a><a id="Tc_BGdHO-URFUycCVovnOnvEQ_2_5"></a><a id="Tc_dcKdQ76tLUKoJT3gt9ay2Q_3_0"></a><a id="Tc_w81MnUimEE2KXkLJeRvFvw_3_2"></a><a id="Tc_aBr034eIB0OrY7OwpkUjfA_3_5"></a><a id="Tc_n_7L-Pgi6ECy9IGYMpIgnQ_4_0"></a><a id="Tc_XE-l3fN_G0GKOjb3FMQQNg_5_0"></a><a id="Tc_PyVREipDdkm7ZRBR7FMVDQ_6_2"></a><a id="Tc_8fw8K8UAnUajArkFY4chIg_6_5"></a><a id="Tc_Mbde7C6FrkSaO7Z1s4VH1A_7_0"></a><a id="Tc_JApJUWp0OUisg_nV51I7sQ_8_2"></a><a id="Tc__lCMzVC6kE-_CqRR-KVCBQ_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_DtF8taYNVkyEfOsql-jezg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3 - PROPERTY AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;</b>Composition of property and equipment grouped by major classifications is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_QDEcIsGDKkmkMOMkwjPHAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_bgO50fNA_kW_vKYNh3YVMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_wO1wIQ41mEyV6im0wexj2A_3_3">18,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_WRnbeAQqwEefX40snBbQkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_5XLceBN0_UqpEx42yfB-vw_3_6">18,933</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_zYIwEllr5UaT82dnyTwL4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_2CfqxnKa6ESGS-9UXC69HQ_4_3">2,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_x3Te36hAu0S8PmYz5LK19g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_OKI5KT2_20ySasODJls_dA_4_6">3,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Upra0nCWlkODQtvrYRKqGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_0QVEPx98y0S9wUVxcx_8tg_5_3">16,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7N3JOpLANkCpswk4FsO4uw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HpX9RFzLr0-MxXw4oske1Q_5_6">17,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_T45OFyidJE6WPNVXdfYciw_6_3">38,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_dWiUsn8mcUWnPlkF4Nx0MA_6_6">39,661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_AOkAdonzhUq2kZUboB-u4g_7_3">33,686</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_VU_xW8FYKUSx8GzQHlCyOg_7_6">34,688</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_V8sBEZ6i2ku4mCVN-W8BHA_8_3">4,553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_nmqaCWq2QkKxXRxsqaySig_8_6">4,973</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>Depreciation in respect of property and equipment totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_HxuLv_aPCUi7bj1pPJSCOg">1.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_K3spC03B0kyiPZIHgNgVHw">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_XleBXTEaGUmIjfl--H6aAg">1.2</ix:nonFraction>&#160;million for the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively.</p></ix:nonNumeric><a id="Tc_-z9b1ZGwxkeny-Nk7tyHvA_1_2"></a><a id="Tc_vcx1KXrtNUWPQKjpoXAcSw_2_0"></a><a id="Tc_0I62W-P2Vkq1Ry2RnIvtxQ_2_2"></a><a id="Tc_gSI13pp3-EmLcCYEt4NafQ_2_5"></a><a id="Tc_c02N0WR83ky41WjA1Z8yAA_3_0"></a><a id="Tc_PJb2562pU0u7edagbx60lg_3_2"></a><a id="Tc_8QGI4ZsvLkyflcTlTc261g_3_5"></a><a id="Tc_pbZR8Jwh5kiOQ-5ogA6tgg_4_0"></a><a id="Tc_eUBFd94SakyOTSRt69LiFw_5_0"></a><a id="Tc_igDCeTVUq0GWyT8Lx4K7Uw_6_0"></a><a id="Tc_lwPa2A2l00uanLOTF5Q0Vw_6_2"></a><a id="Tc_2RXYZtVnUkC177rquph1_Q_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_6hDYIhl2i0SQFiZZfLbgrQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;- INVENTORIES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inventories at December&#160;31, 2022 and 2023 consisted of the following:</span></td></tr></table><div style="margin-top:10pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_Bgiv7iUPc0qFwWAymmoXLQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_WhC_pGOQsEu1SIzstf94WA_3_3">3,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_KPvOuapFs0yqZfftdJnn1Q_3_6">4,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_LEowVWNJY0aiJbh9X-QM0A_4_3">2,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_FqswLKZLeU2amnp9zXtWRw_4_6">9,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_j7H11w3vQkyXEyAV9BMxkA_5_3">10,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_C-653G3xrkK6uKHHzKgVfQ_5_6">5,814</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_z7K43DAcFkqCWuA6LCWT2g_6_3">16,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_8xoat8SLBUWc-6zr_3epeA_6_6">19,045</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>During the&#160;years ended December&#160;31, 2021, 2022 and 2023, the Company recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_YCfOUBpgkkK09gHFaDZMtw">0.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_LlkYvePKwkqTNs0UmF2xhQ">0.04</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_dD2tr5wRnUKVFHrJsWC1aA">0.8</ix:nonFraction>&#160;million, respectively, for write-down of inventory under cost of goods sold.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_9ZHIvVcmv0WB2WjMunCtIg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#8217;s salary for each&#160;year employed) is recorded on the Company&#8217;s balance sheets under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#8217;s balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2021, 2022 and 2023, the Company deposited approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="0" format="ixt:numdotdecimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_wDNemlCHr0C93iBQUUk_mQ">108,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="0" format="ixt:numdotdecimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_sK9ApXKyCEGQQhDilrW-pQ">96,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="0" format="ixt:numdotdecimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_idZIo9DOokS8oUjpuWD9tg">142,000</ix:nonFraction>, respectively, with insurance companies in connection with its severance payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#8217;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plans&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The amounts of severance pay expenses were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_l2-DlpzkmE6qsJET0zkZdg">990,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_O5d1-PbskkOR-HUps4AO5Q">945,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_odZikILpOUSQH6GqOvdK_g">801,000</ix:nonFraction> for each of the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively, of which approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_oaev31gps0Oi4zuiw2alNA">857,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_JgWIhvLVh0KVS3JEfyzVww">800,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_RFT25Tjv6UygiolwQsSTBw">798,000</ix:nonFraction> in the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively, were in respect of the Contribution Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="0" id="Narr_6eHVEsogNEONnh31heXxSA">100,000</ix:nonFraction>, $(<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" sign="-" scale="0" id="Narr_F6rJ-C0uLUiUStXBTASXRw">3,000</ix:nonFraction>) and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="0" id="Narr_6miXzD4l6kKYTp5O19Fj0w">50,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company expects to contribute approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_4iW3B1WCqECY6mC8PZcRJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="Narr_AUJIqN7QOEy2PTo2b2AFHg">922,000</ix:nonFraction> in the&#160;year ending December&#160;31, 2024 to insurance companies in connection with its severance liabilities, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_4ij6hzi0rkmx1gwIssCBgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="Narr_DIduN_r7G06kJlk0mKEzhA">888,000</ix:nonFraction> of which will be contributed to one or more Contribution Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the five-year period following December&#160;31, 2023, the Company expects <ix:nonFraction unitRef="Unit_Standard_employee_EpjUeGM08kCkStcWvhYgyg" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" scale="0" id="Narr_nLdhOeGkdkGWTZZS_VBfzw">no</ix:nonFraction> employee retirement upon normal retirement age. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:CommitmentsDisclosureTextBlock" id="Tb_HLvMCYTwrEyk15yOswtzEw" continuedAt="Tb_HLvMCYTwrEyk15yOswtzEw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;6&#160;- COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Royalty Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is obligated to pay royalties to the National Authority for Technological Innovation (&#8220;NATI&#8221;) on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HLvMCYTwrEyk15yOswtzEw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of the applicable funding arrangements, royalties of <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_4-jgrc8-u0GNmkLJxYHkRA" decimals="2" format="ixt:numdotdecimal" name="plx:RoyaltiesOnSaleOfProducts" scale="-2" id="Narr_jQQuAnpCi06TbtQhX0zmRQ">3</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_QWELD20hJUCp7BaaLVXfkw" decimals="2" format="ixt:numdotdecimal" name="plx:RoyaltiesOnSaleOfProducts" scale="-2" id="Narr_wysrFf37XEW2UdcD0ysRZg">6</ix:nonFraction>% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_T3JAfM2fWECmvcQSRXd74g" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfRoyaltiesToGrantReceived" scale="-2" id="Narr_qS2Yg0fINUqpGwQDqP5YXA">100</ix:nonFraction>% of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on LIBOR (from January 2024 the annual rate is based on SOFR). In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will, subject to certain exceptions, be required to pay an increased total amount of royalties, depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_sDnT6zVWrUuhi2kasN2_WQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_1QFSBQ50y0aD-scpzWvl4g">1.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_04wyWQKORk-L7RWyITxn_Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_dTjMFZ5BwUC52lWlWjNqlA">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_0fEP6-_4Uk2cQqZDJ9ix_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_TF5BfYJWPU6XSiij69kNPg">1.9</ix:nonFraction>&#160;million during the years ended December&#160;31, 2021, 2022 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">At December&#160;31, 2022 and 2023, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_b5QnVZ12wk6qJy-jCttpIA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_N30c8K9My0y1jkaOq4-T2Q">37.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_T3JAfM2fWECmvcQSRXd74g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_ijegiEy7ZEqI4xrLzpLs9w">35.5</ix:nonFraction>&#160;million, respectively (without interest, assuming 100% of the funds are payable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Subcontracting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2023, total commitments under said agreements were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_yi4pzduSA0iPeEkKzhrW3g" decimals="-5" format="ixt:numdotdecimal" name="plx:CommitmentAmount" scale="6" id="Narr_a5mdBlbxtUCjL7zchyh4aA">0.4</ix:nonFraction>&#160;million. In addition, we have a $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_BusinessDevelopmentConsultantMember_yVKHJHqyLk-Kh4whSboFgQ" decimals="-5" format="ixt:numdotdecimal" name="plx:CommitmentAmount" scale="6" id="Narr_kTfQ5SlCLUeAxz7-BKFjDw">0.1</ix:nonFraction>&#160;million commitment payable to a business development consultant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Fill/Finish Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:10pt;">On August&#160;29, 2022, the Company entered into the F/F&#160;Agreement and the Letter Agreement. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F&#160;Agreement did not change the terms and conditions of the Chiesi Agreements. The F/F&#160;Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement and the term may be extended by mutual agreement for an additional period of </span><ix:nonNumeric contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I6KOw7CYo0-cs1kRCGYA5Q" format="ixt-sec:durwordsen" name="plx:ExtendedTermOfAgreement" id="Narr_Ey7Ns5aLAUKS2TsTypb2AQ"><span style="font-size:10pt;">seven years</span></ix:nonNumeric><span style="font-size:10pt;"> upon mutual written agreement prior to expiration of the initial term. Under the F/F&#160;Agreement, the Company is obligated to pay to Chiesi an amount equal to </span>&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_hZumu6sr7UyT0mvTxrhElw" contextRef="As_Of_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CPzVDrt_wUy8VbkR5mm3YA" decimals="-5" format="ixt:numdotdecimal" name="plx:ContractAmountUnderAgreementPayable" scale="6" id="Narr_FsgMTw6VGkuHa4FJfsWkZQ">2.5</ix:nonFraction>&#160;million in connection with the necessary technology transfer, QA tests and capital expenditures. <span style="font-size:10pt;">Such amount is to be paid over the term of the F/F agreement based on the actual vials produced by Chiesi thereunder.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_WsvZhYWkekuIa5kSQX3U6Q" continuedAt="Tb_WsvZhYWkekuIa5kSQX3U6Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 7 - OPERATING LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="Narr_R854Fi7wFk-ocpaT0tq2fQ">option to extend</ix:nonNumeric> certain of such agreements on <ix:nonFraction unitRef="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="INF" format="ixt-sec:numwordsen" name="plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions" scale="0" id="Narr_GrETHQ4OKE-7aoljSjfzMQ">one</ix:nonFraction> additional occasion for an additional <ix:nonNumeric contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_xcGzYNuB40OYtv5EQulX5A">five-year</ix:nonNumeric> period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_vr63tArlm0-q0bAYY5jS7w" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_uS6zxggYQkmvCUoFtnIW3A">7.5</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_MJT48I74nkqfkLgGf8DWVg" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_GhJ_pHPa80WNdQut9WDj2g">10</ix:nonFraction>% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2023, the Company provided bank guarantees of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_ZG9hdjHhokSbaCGlH0B-QA">502,000</ix:nonFraction>, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company entered into several <ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_eAbAHtoxYkGir02r071VSQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_Q3Vo60fFr0GQfmbXRex_Og">three-year</ix:nonNumeric> leases for vehicles which are regularly amended as new vehicles are leased.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8946ca28_4ca3_40ce_8e86_26661032a679"></a><a id="Tc_-U6NQmd8sUK5RrITyPWpkw_1_2"></a><a id="Tc_Fge0yJQJ90iXgDdCQl13Nw_2_0"></a><a id="Tc_5jYMvEMTrU6T3SoY1FHTWQ_2_2"></a><a id="Tc_A_ETtOc2x0K_IzDPSJ-i2w_2_5"></a><a id="Tc_hk2doMFf7EGjAcfIjCXbww_2_8"></a><a id="Tc_zB--Dl3Dz0qzj00WLDg64A_3_0"></a><a id="Tc_3dXx9DJSWkKMCcKn1mqojg_3_2"></a><a id="Tc_UyOJUNFCF0mNLJwO5ucWVg_3_5"></a><a id="Tc_g6Sz_MYNfEKmQuzkQj5x8A_3_8"></a><a id="Tc_fn2QSXvjgkGAPBUEEYvx-Q_4_0"></a><a id="Tc_62QTW40PSUuP5-sCFh1Drg_5_0"></a><a id="Tc_qomtoNz4f0WajCxXY_iJqA_6_0"></a><a id="Tc_BeXAJZ1y9ESdTXpxHYAEFg_6_4"></a><a id="Tc_FByydjUQiUC6IXT3KbElfg_6_7"></a><a id="Tc_Fxj2iqkPlUePNTz6LI1WOg_6_10"></a><a id="_b58a8809_660d_4181_8b1f_66ae75a25a5e"></a><a id="Tc_pxicBS12WUy0v495XCrESg_1_0"></a><a id="Tc_-WOyaCwYMkiqwMuvFp7b6Q_1_2"></a><a id="Tc_LaDBm-8FwEaR1CpQmI033g_2_0"></a><a id="Tc_mRBNbGfhZEm40L_jlk7-CA_2_2"></a><a id="Tc_o6WSZcStxUm9eLd_SEUCOg_3_0"></a><a id="Tc_0z2rNUBymk26nPaVNeXnaA_3_2"></a><a id="Tc_FyhpgJtJP0a1EOHk6Yie7w_4_0"></a><a id="Tc_UQFhOuo3FEqouEx06Du1-g_4_2"></a><a id="Tc_PpcimtV4iU2lcEXYdSGeNA_5_0"></a><a id="Tc_9ywFYl0lT0a56re2IFiJgA_5_2"></a><a id="Tc_KYJKmP-6aUiZmVi2Rfyi-g_6_0"></a><a id="Tc_cL8HXSmopkytNRlBgoAO-Q_6_2"></a><a id="Tc_xu7WPH-3ckmgB48NO9kS0g_7_0"></a><a id="Tc_eG1pTKXZTUeZBsyTGKifLw_7_2"></a><a id="Tc_35y_Y9b9C0WksiTbIhDlLQ_8_0"></a><a id="Tc_723zEPgpj0-miDbFO4U1iA_8_2"></a><a id="Tc_KLrzBvF8LEeWpEOx5WlHRQ_9_0"></a><a id="Tc_1aLZTdwRUkKbTobjubsjAw_9_2"></a><ix:continuation id="Tb_WsvZhYWkekuIa5kSQX3U6Q_cont1"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:LeaseCostTableTextBlock" id="Tb_R0HmIvTxjkSUP9lWXrA80g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2021, 2022 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_2o0YSugy_E-qSKRhl4u4yw_3_3">1,632</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_l4f8VeNhZkCtTkhnWgCMvw_3_6">1,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_eClqWCBpw0-nL4TLQW6K5g_3_9">1,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_z30e6hC3fk6bfEpS4fv9Ug_4_3">1,391</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_KF5f-18fvUWIS2icVo2oUA_4_6">1,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_tbm8Djlk3E2bfQkRaRsZTQ_4_9">1,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_no4NuciM4kyjxzvP1rI9kg_5_3"> 8.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_8T1wIucMOk-HoLnQq7GDCw_5_6"> 8.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_rTnP8onQbUq7ykWu12Pj0Q_5_9"> 6.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_4G390CBPDkmGdAAfA51lOA_6_3">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_muiSQUg5g0KyBcjhKBgbmg_6_6">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Xpu2PuKdTUi0YGYsjL4mXg_6_9">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_dYdmgUoJVUW3iB2E_22oRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_qHz1pMjV40KKK21TCXJTlA_2_3">1,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_HGiF_4SHDESq3REVyPpGJA_3_3">1,397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_9uYu_zc0_EWo_u-7Qu3Ygg_4_3">1,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_7Sff55Xv10mm0OSQ-guMJg_5_3">1,044</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_bz3l-ahmhE6sVnMXpcXa2Q_6_3">4,057</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_T0WI3wHXm0qIDVB8trktnA_7_3">9,032</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_s9Y-3eOkhEujGNNSlzq4Jw_8_3">3,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_iQsJks2XTEuRSRjSlS-_JA_9_3">6,030</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_7ad1ee60_934f_4593_93cf_de1bbaae52b4"></a><a id="Tc_JEMGKozuZEa7pjB-0FYMZA_1_2"></a><a id="Tc_OCsq5E6PM0K0fbcio6bNNA_2_0"></a><a id="Tc_XA-0J-GW8km8W4KmFDvtWw_2_2"></a><a id="Tc_EgeBITP1Akq24mB3Rb4w8g_2_5"></a><a id="Tc_Z-e5QQeYsUm3Bn2SIEPfcg_2_8"></a><a id="Tc_RfTGTTRfl0---i8Tmv7D6g_3_0"></a><a id="Tc_nb8FaFOqb0u2XAiGPg3-9Q_3_2"></a><a id="Tc_loaeabN1QEOZZjnGxhYhDw_3_5"></a><a id="Tc_lgPbOVjW-kmDunVL_U38MA_3_8"></a><a id="Tc_gs4xT4Znv0qcYI5SASUSGw_4_0"></a><a id="Tc_SsYAc_5clEiv1Rcg2YinsQ_4_2"></a><a id="Tc_1g94APU0eUufMpKuhGfBRA_4_5"></a><a id="Tc_bGpO8GnZokS5cgmg1kQNEg_4_8"></a><a id="Tc_2cWo3oFsAEmkMg67HarLlQ_5_0"></a><a id="Tc_ifdxsHXWnEaWve-3wk_Vqw_5_5"></a><a id="Tc_v0M5xZktyUy6kRFbFDoRHg_5_8"></a><a id="Tc_enT2oduy4Ee5q5uecNDuLQ_6_0"></a><a id="Tc_ij2_PBR0dE2dPkkaOE9mYQ_6_2"></a><a id="Tc_qkYhciGABUKeZDInKL3M5w_6_5"></a><a id="Tc_MUtv8vhtD0ODeIxxfT1J3A_6_8"></a><a id="Tc_SZUXkkwIMkiEa1GclBkVeg_7_0"></a><a id="Tc_oaxJdfPq7EOwuQmbuyEapQ_7_2"></a><a id="Tc_qNwt9om8ykSlCYthgpDeCg_7_5"></a><a id="Tc_j7H3m7TJmE67DhwqAbBLvQ_7_8"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="plx:RevenueDisclosureTextBlock" id="Tb_jWvc7bnivEi-nwOWB3Vxcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 8 - REVENUE</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_glPosgLneESIfh65Kq6Nvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_1gt-ZUM87U6djr_4A5S4_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ohYX3iBi8U64kfcmIA2NQw_3_3">10,160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_FK1NoKYDfkC6DWFfd-k4ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_joNqAfbXRUKLdcQyOOiA1Q_3_6">12,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Fqn4nOxM00S03kAdCXfsqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_tlqfpjKjek279z3Wr4e9Lw_3_9">12,522</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_UjTGHkbY20CN6fqj_cqXNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_gaLJPZfAUEO6n3NR3q2mWw_4_3">6,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_aTbJ73vbwU-Xj9MZr0N5Rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_yWs5Tpq1l0SGAtOxscN6qw_4_6">9,452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_W_ciO9dfwEyGfy9D31WFzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_SQpLKLCkI06x2LIUvgFLcw_4_9">10,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_siXWryuQpU285WNgy45APw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3FelXP-ONEurNEEt3AmCNA_5_3">189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_5MUpU_iFQUS9Zerkh9wIMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_DW1P9EXfE0SXT4FXDSY_vg_5_6">3,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_weEzKGUPDUudnECpvmaZ4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_UITC8ppL4kKCJSlx9eo1lQ_5_9">17,495</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_e9UvRO3aE0mfSCcsC-dTvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_D-tPJRYjGk2C71tGb_UGbg_6_3">16,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pFUzP2PhrEGGo1GT6PZxWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3h3HZV2zhk2yfWJVWmvyMw_6_6">25,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_FCBox10Ye0O87jYJEc-ybw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_2VEkCXA2OE-Xgzw310_p_A_6_9">40,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U-GkrbLvEEer06wV3cdFkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_MLRJnp2aiUWIpy1lDmYQyA_7_3">21,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kkqXot9cn0WBAMEZIGa-PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_oTaC0-jY0UW_YIactVl3hA_7_6">22,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dFI_S2Cmw0uvW76jwBJ16Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_H_xgdIxLuU-P4P-k5tTARQ_7_9">25,076</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the year ended December&#160;31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_hjMmAQAWa0GgzSXNhgHGIw" continuedAt="Tb_hjMmAQAWa0GgzSXNhgHGIw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;9&#160;- SHARE CAPITAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Authorized Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_7_24_2023_JDfUxPdHikKEo3CybT518w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ItnIAx6NAk-2UlWAMXy4IQ">144,000,000</ix:nonFraction> </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_aq0luLWnH0GaPo26OXbq4w_1_2"></a><a id="Tc_To9fRrBCi0e-DvHXSmxdxg_2_4"></a><a id="Tc_CHs_-Nvqb0aVij5A_3Y48w_3_2"></a><a id="Tc_YbVJY9VeD0mdB-hJi5LPLw_3_4"></a><a id="Tc_g-kLLjn-1kakaXpH5rXvWQ_4_2"></a><a id="Tc_nB0Q1G_dx0mADPgYMRMnug_4_4"></a><a id="Tc_Myq_D4_r5U2EehEbQ2d3dg_5_2"></a><a id="Tc_I9e-fct22kmufZjzmk6iGw_5_4"></a><a id="Tc_X1gqc-RQu0eyjQSA6wZk1A_6_0"></a><a id="Tc_FXIihwfV5UGG3E7BCkujKw_6_4"></a><a id="Tc_N0Qzej5a3UyPDs0W4JY_Ag_7_0"></a><a id="Tc_FYSl5m7ts0SVJT-A7ej6dA_8_0"></a><ix:continuation id="Tb_hjMmAQAWa0GgzSXNhgHGIw_cont1" continuedAt="Tb_hjMmAQAWa0GgzSXNhgHGIw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">to <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_7_25_2023_tpab9C7-pEeEaYxfCF7NUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_5QoZ5hHebE--bmifv-PXSA">185,000,000</ix:nonFraction>. The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">b.</b></span>Rights of the Company&#8217;s Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s Common Stock is listed on the NYSE American. The Company voluntarily delisted its Common Stock from the Tel Aviv Stock Exchange effective March&#160;22, 2023. Each share of Common Stock is entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_hWE00M5FlEez7fUfIQ-eZg" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="INF" format="ixt-sec:numwordsen" name="plx:CommonStockNumberOfVotingRights" scale="0" id="Narr_qjDc2HlWD0m-wAofITUxPQ">one</ix:nonFraction> vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Stock based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_-Wf9gnqOa0O0OwdXouHwAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_hILnwj56eEWH3eEHiYNEcQ">12,475,171</ix:nonFraction> shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;102 and 102A of the Israeli Income Tax Ordinance (the &#8220;Ordinance&#8221;). Each option grant made to an Israeli citizen is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#8217;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Ordinance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_W0fXcCgf7024CWrW8-hrTA">633,409</ix:nonFraction> shares of Common Stock remain available for grant under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The vesting period of the outstanding options and restricted shares is generally <span style="-sec-ix-hidden:Hidden_8ZPqFDiPQU29lutivXBeTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_NF1mOzE5nku6qIeb4j6l4Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Wr45mzoTbkeKxP0oC-IWvQ">four years</ix:nonNumeric> from the date of grant. The rights of common stock obtained from the exercise of options (once vested) and the restricted stock are identical to those of other common stock of the Company. The contractual term of these options is primarily for <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_rJLQx2leAEWZ1CL6p85CcA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_EqlkgXeXd0iyNtX52Y5PQg">ten years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company&#8217;s management uses the fair value of the Common Stock. <span style="background:#ffffff;">The fair value of options granted for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Options and restricted stock granted to employees and directors:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of share option plans, and related information, under all of the Company&#8217;s equity incentive plans for the&#160;year ended December&#160;31, 2023, and the effect of share-based compensation on the statement of operations for the&#160;year ended December&#160;31, 2023, is as follows:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Options granted to employees and directors:</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_dqYrXP4SpkOoaw0-nNe6mQ" continuedAt="Tb_dqYrXP4SpkOoaw0-nNe6mQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N8BFMU2rM0W5-sfr4UsdRA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_3S-RyXYbeku2y4rYk77K8A_6_2">5,519,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N8BFMU2rM0W5-sfr4UsdRA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_WR1SDXWuSEGO2COBQ2Hvbg_6_5">2.28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_jzlhgOOeC028ojTsnMltSw_8_2">1,700,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Yq0FH0gI9ECjVeT0BDfZVQ_8_5">1.84</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_WArEFFbLfkqQDnD78rlBSw_9_0"></a><a id="Tc_A3EWnsHXMkKZOnbuKKtIqQ_10_0"></a><a id="Tc_F_bT22VtCkWY0_gGkSoIsQ_10_4"></a><a id="Tc_SNzLy6c4JUe1vpW6YujNOg_11_0"></a><a id="Tc_fD6OWhPZR06oqffXjFPB6Q_11_4"></a><a id="Tc_ssfBZMhBtEGi-RyjLS7nMg_1_2"></a><a id="Tc_aHzvO55uoE6G53jTRB91Rg_2_2"></a><a id="Tc_RJ5BUbWZBEy7UuHRdMZ56g_3_0"></a><a id="Tc_CfuPTeWYLkWzqWjBhL0m7A_4_0"></a><a id="Tc_uM7VRW8WrkqjTsMZwKD3dA_5_0"></a><a id="Tc_5EW7DqqBY0qAIja2w1isog_6_0"></a><a id="Tc_KLm96mf6_keYo3z7xeVkcg_7_0"></a><a id="Tc_AbaCVZkRYE-uQtv-dbOkHg_1_2"></a><a id="Tc_L9Sbt4IGakWThBu1ldnyHQ_2_2"></a><a id="Tc_Lejim6y3bE2p0P7fTLX_zQ_2_6"></a><a id="Tc_2OE2dyW5mU-_xSDTq2-5vA_3_2"></a><a id="Tc_p-Zn4o0l0k6Z3KkW2GvCZQ_3_4"></a><a id="Tc_gnYpHBsT1ES2LQZ0AmxVVw_3_8"></a><a id="Tc_2g_4pKf0b0u_Jkzp4Cdrvw_4_2"></a><a id="Tc_M9hjN8QTnEixJ7MA5k4Nkg_4_4"></a><a id="Tc_AsRgsTHowEeVKW_OzYhFNg_4_8"></a><a id="Tc_zdLS6T1010W3EVZv-pBR0g_5_2"></a><a id="Tc_PwGAOJggY0yC1yt9r5lUQA_5_4"></a><a id="Tc_Z4w2z_66r0WcyHzV-oJq1w_5_6"></a><a id="Tc_xbdQfEpUnkmYPIxZaxVOYQ_5_8"></a><a id="Tc_2ffpLXV1skq7GRSxDVaVvw_6_0"></a><a id="Tc_Vf_mMB1et0yZMCKTEZ6Eiw_6_2"></a><a id="Tc_r-jU4tQmg0yHMOyamrfl0w_6_4"></a><a id="Tc_G09S4buoMk69M92XwM8NCg_6_6"></a><a id="Tc_cvHNxysQCEqeR1KOdi1rXw_6_8"></a><a id="Tc_rE-7yIIbz0ajrmWUYR56Kg_7_0"></a><a id="Tc_bppg1CrrlEi0f_HWLCGxpw_7_2"></a><a id="Tc_TfwckcF4pkGxHKD4sLGYbQ_7_4"></a><a id="Tc_qkhvmcb6LkKkcdCAw2lbww_7_6"></a><a id="Tc_pKiKNpZnyUu3rSbFFVh2nA_7_8"></a><a id="Tc_Vvi5cS-Sq0iAEcI6GuDuSQ_8_0"></a><a id="Tc_7LbOt2HLR0Kd4vRrVfLNJA_9_0"></a><a id="Tc_yx3xLpUOzEyPB07y6zumKg_10_0"></a><a id="Tc_MGoJ0cAr0UCd6_KiXLUtZQ_11_0"></a><a id="Tc_7dfIpPqYYkGV_Uu5NttOPA_1_2"></a><a id="Tc_Sqsma833G0KpablLSmawJQ_2_2"></a><a id="Tc_HKdJ-UU8i0apQIjej-gNpw_2_4"></a><a id="Tc_O152hzoxDkylxG0PDIdemw_2_6"></a><a id="Tc_7bJKYe8JVUWjsoDIJPAdjw_3_0"></a><a id="Tc_OM86qpbkL0a6Ja8GTmIiNg_4_0"></a><a id="Tc_p4jBe8XVg0K4Qi2xouJhXg_5_0"></a><a id="Tc_z8F01_8DnkKDEwZS5TGBuQ_5_3"></a><a id="Tc_E0ajiHZrX0CGZgQbGJRQkg_5_5"></a><a id="Tc_-31Be0s960KFwsTSMeeQmg_5_7"></a><a id="Tc_LCXf2-Gcek-1lmfVk8-3zw_6_0"></a><a id="Tc_8vF8eHYmPkiFHLzcjIFlHw_6_3"></a><a id="Tc_ebQqhtauqUWN-yyVBeJCEA_6_5"></a><a id="Tc_RHWJW2I4kE6TnCuPZ4NMIA_6_7"></a><a id="Tc_xxIpAWiigkiDhSusUzRJfQ_7_0"></a><a id="Tc_9BIPu9wgjkuTnkCsgtv_ng_7_3"></a><a id="Tc_Tn4Rh405A0mr1RSHuUJA0w_7_5"></a><a id="Tc_Z4BiT6S_j0izyQvSu1Gp4Q_7_7"></a><a id="Tc_gXqMk54kIUqOqVXVsXF9qA_8_0"></a><ix:continuation id="Tb_hjMmAQAWa0GgzSXNhgHGIw_cont2" continuedAt="Tb_hjMmAQAWa0GgzSXNhgHGIw_cont3"><ix:continuation id="Tb_dqYrXP4SpkOoaw0-nNe6mQ_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited and expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_xN1gGhTo802GpNgG0zlcLw_9_2">254,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_v34OipjZs02wPT-8PGBVhQ_9_5">3.81</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_XBfOrr3z3U6t-y957Z4LtQ_10_2">6,965,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_YpuEVrO7gEOuxxBos9xKHw_10_5">2.13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_lJeGRcWdT06YE3B-CE1OYg_11_2">2,900,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_lPwKwuPfh0aupHXbSfXGWw_11_5">3.10</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Restricted stock granted to employees:</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Tb_XHPRXwS7DEeLl0STjI9Viw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Restricted Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YujFqI1i2U-sAYFqgp2Lmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_3QBTqyAyuk2HiWYMCPJz8w_3_2">291,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_dzHxfLYBE0qT2A92CcAQaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_A0qNh5Tdr0SKLqOGdkVjSw_5_2">1,371,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_dzHxfLYBE0qT2A92CcAQaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_l4T4w-q7NkmlN2j9_b3mNg_6_2">489,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_upSNdbkvUk60NSUBUbvSBA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_ekCNKWdPSkuiHxOw9XWJzg_7_2">1,173,670</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The following table summarizes information concerning outstanding and exercisable options as of December&#160;31, 2023:</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb_yLsa1fXpcUGS4WJUQaAoyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_N7xyLTG4j02Wvr_UjM2Dfg">1.03</ix:nonFraction>-$<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_xoaia1wzFkitLmfnHHa7EA">2.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_4fFw3SaWjU-j0D-jbfOafA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_Ux2Ep-vIkkqZSQ2GnhKH-Q_8_2">5,235,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_dvPBi95db0aaHfp5NYeMbg_8_4"> 8.92</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_4fFw3SaWjU-j0D-jbfOafA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_y6nvbU5s80m_-vNVX8fpZg_8_6">1,312,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_Gms3FnZlgkm1nJ0Uon6Tqw_8_8"> 8.42</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_GEYEgOgat0CH3B09Gchi7w">3.55</ix:nonFraction>-$<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_D6N4cM9I8kaeQiONqL4NMw">3.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_1p-co_pHGEWdS066RgFFvQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_p5QjEVMT8UKNFUEYEUoMGQ_9_2">1,213,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_LS1y6sv2lECS4WbGbWhFxw_9_4"> 5.39</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_1p-co_pHGEWdS066RgFFvQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_F7rGJZyhSkKcKUeXi5Llkg_9_6">1,070,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_H1Fap9n7YU60urhk3sGa0Q_9_8"> 5.24</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_fxY4PiC85EGCK17E0tHWHA">4.69</ix:nonFraction>-$<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_XX4eaby7sUO1x53DokNIdA">5.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_LrNNiJqQIkSf1ulC8PfLpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_3rVL9mi1xEGhhHg4bzFzTg_10_2">441,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_FLgHxTeRTk60dzdftY5I2g_10_4"> 5.71</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_LrNNiJqQIkSf1ulC8PfLpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_wNf-bx5M30mIL45LBHIcGQ_10_6">441,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_sOF8uAtanECCCLIUxFNjCg_10_8"> 4.93</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_Z5ILinr5pki5oFoOTXqaOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_HAAxM4F1dkquxHhciqUqTw">17.20</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_9pTD0HcQLEO_MTuojw_G6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_MGd9GYgwb0yqBDe6tHg8sA_11_2">75,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_Z5ILinr5pki5oFoOTXqaOg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_LDNStT9OgEODuapgoWsEYQ_11_4"> 1.19</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_9pTD0HcQLEO_MTuojw_G6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_OAGZjv-4y063tOIAyEmOzw_11_6">75,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_Z5ILinr5pki5oFoOTXqaOg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_91QvOKcFSEGiLmZqLMbajQ_11_8"> 1.19</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_40dAKtpjUUiBo3plTrNCoA_12_2">6,965,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_CtaB7NjVk0Ws9nzBNepMEg_12_6">2,900,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 90pt;"><span style="color:#231f20;">As of December</span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;</span><span style="color:#231f20;">31, 2023, the aggregate intrinsic value of all the outstanding options and exercisable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">options</span><span style="color:#231f20;letter-spacing:0.05pt;"> was approximately </span><span style="color:#231f20;letter-spacing:0.05pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Narr_St2K0-txmkmzD0Nrij0SpA">2.6</ix:nonFraction></span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;million and </span><span style="color:#231f20;letter-spacing:0.05pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Narr_FMdfLHkdxEmzUGwGnJItmg">0.8</ix:nonFraction></span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;million, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;letter-spacing:0.05pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The fair value of each option granted during 2021, 2022 and 2023 for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the options&#8217; fair value on their grant date:</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_OP0LEr_-vEOTxVevOIuBrA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Jd93bicWJk-u0ptZ1qcGrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_fXIoc7rDEEacOqEbRaZO3A_3_2">1.57</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YMVeyD2j70y4VdJ42iD_fQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_OFsy6m_uZ0mWn4rsdmChKg_3_4">1.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_FhcrPc1xTUGM_S0MOMEiAQ_3_6">1.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Jd93bicWJk-u0ptZ1qcGrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_SHrsY6zyoUWNpyDuf2kG2Q_4_2">1.57</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YMVeyD2j70y4VdJ42iD_fQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_Gl_-ch1-L0qcdS20BmcIXw_4_4">1.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_gXWSAs67gk6Uft97Nololw_4_6">1.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_SIpOgwyOH0KHK9wnlYXtwQ_5_2">0.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_LhZ5QvB2zE-GffO9_gS_HQ_5_4">3.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_LbnoKHX_-Uy3jAUnJ-Abvg_5_6">4.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_SxH3R9DNBkq3JpzUhXEIHA_6_2">84.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_LS2aWO0DHUeBgdUtDWmcyA_6_4">85.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_0AW5KzCbOkGWjEL-CLApEA_6_6">79.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_nptNCX0NdEe8MDMUD-FLbg_7_2">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_A4pRVnQDcUGAHHcQ7_n6uw_7_4">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_WnhXgEPl1UW9cB3VRSCVpQ_7_6">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_1z0ZvXHc7E-oKOSMI3kNQQ_8_2"> 6</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Fz0zTD4AV02xuESWwHemMw_8_4"> 6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_faHsd9AX_0moWKNLXsOgbg_8_6"> 5.75</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The total unrecognized compensation cost of employee stock options at December&#160;31, 2023 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_hkBokTjhcUCOg_nNlkVf7w">2.4</ix:nonFraction>&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_7awvAdTyb0SmsVxBCT9bGA">0.9</ix:nonNumeric>&#160;years.</p></td></tr></table></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_J7pLMokvokugJcZOvhnPHQ_1_2"></a><a id="Tc_XqYIDoZ5YkqX4tiaT2oKlA_2_0"></a><a id="Tc_56YapyNyiEy1LZchyQ0S8w_2_2"></a><a id="Tc_K0apURSeekaiWs6dR6BP4w_2_5"></a><a id="Tc_KfY15OmmRUCZbOPTHsAqUg_2_8"></a><a id="Tc_H1mQKWvUcU61_PeSoxhJXg_3_0"></a><a id="Tc_rJ3JVWD3KEyaljZejsROUg_3_2"></a><a id="Tc_Rg6RCF6lV0-JgxjLfS6kzA_3_5"></a><a id="Tc_Fq-lTIgqxkqw7dBvzjNnJw_3_8"></a><a id="Tc_iIBQiipUake4a3Z1IS032w_4_0"></a><a id="Tc_bjasbR6kBk25d6Nbc1dqUA_5_0"></a><a id="Tc_VKFuGO6YMEyH8nUbMfTcgA_6_2"></a><a id="Tc_pR8-ZfcHDkGu5xcY8d6fBQ_6_5"></a><a id="Tc_2k2pdGqTNE28x7LFpIwQLw_6_8"></a><ix:continuation id="Tb_hjMmAQAWa0GgzSXNhgHGIw_cont3" continuedAt="Tb_hjMmAQAWa0GgzSXNhgHGIw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;">During the three years ended December&#160;31, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_eRwCFAR3GUKalnYKJ4uRZw"><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_wuuOxL0ChUuxREzK6GJQYA"><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_0gcMEfOvgESe4ntgIO8uCQ">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;"><span style="background:#ffffff;">The total vesting-date value of equity classified restricted stock vested during </span>the year ended December&#160;31, 2023<span style="background:#ffffff;"> was </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qMG5qS3iLEyHdybWijdG5Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_mPzGBNGDQkGr3quFuEuvEg">1.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million. As of December&#160;31, 2023, the unrecognized compensation cost related to all unvested equity classified restricted stock of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_C5zBNMbhSkObSb6Xa-cZ3A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_CXj0yrwdG0i7buJgeJ9TJA">1.4</ix:nonFraction></span><span style="background:#ffffff;">&#160;million is expected to be recognized as an expense over a weighted-average period of </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qMG5qS3iLEyHdybWijdG5Q" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_P-DwBLqA-kma-Y2FyMoqWQ"><span style="background:#ffffff;">0.8</span></ix:nonNumeric><span style="background:#ffffff;">&#160;years.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The following table illustrates the effect of share-based compensation on the statement of operations:</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_LTQk3DrrpE6K9Gf_BjH9OQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_G-5RnTikyEe9kMD0HS9VgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hxcmSPdw3UuA42zzKDedow_3_3">269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_nUUou62YI0uMyf3Ceo-SDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_T67WR_b3MkqSgK3QSFdHaQ_3_6">135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_4cbqNYW9bkqJeKPztiOARQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tZ6Gt2pzmU20OULc6kARmQ_3_9">596</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_pPMvRU8ZMk2uuux3HO2TYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_zh2K8BwTLEGE98LvJCT9Xg_4_3">648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7jCMuUnJUkiYu615rQJzSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NC932Tiyq0a42GQsfNIpzA_4_6">518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Pg3HBbrQE0O-vf2piO-deg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_GAyyxiRUiUmAZ3t57GF7Wg_4_9">777</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Wq2H6c6tw0WzLJeQe0xOnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Z9wjv4PPWU2mBIAk21oSBQ_5_3">1,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_VhZ8eBzgxUiYQec9RnyolA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_b9vfafw8fUyy3PqP9Q49QA_5_6">1,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5Lw9SAW0v0e805cbfkLdFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_RlosuyGkGk-oF3FsT3lVUQ_5_9">2,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_gmRj5Hm4V0u12Y5CVSaiCw_6_3">2,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_O8zzJMlljEShUcgKnATMNg_6_6">2,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_8or4CQLVdUW5yhFn1wtpsw_6_9">3,448</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Private and 144A Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On June&#160;7, 2021, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gcdiHe0OrkaRgPsieHDsIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_TwX5zGl91EmPxLLOPaS55g">173,816</ix:nonFraction> shares of Common Stock in connection with the cashless exercise of a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1Yw2nKGMb0-CWAUOtRv76w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_Y2EOqYrBh0ev5-rnzQeOdg">2,816,901</ix:nonFraction> shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2022</span>, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oUGb2yHFvkmftb5K_Hd41w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_nV8uKXm710W6Ubm2rpnoXw">1,000</ix:nonFraction> shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oUGb2yHFvkmftb5K_Hd41w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_qjldWRwa1Ui9A--jgDTYBA">2,360</ix:nonFraction> from such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2023</span>, the Company issued (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_XwwI97cnr0imfvHx08Av8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_KJdbaIFbIUqAZ8sxl2NUbw">301,810</ix:nonFraction> shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_XwwI97cnr0imfvHx08Av8Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_igKpn2ZxikuTmq-57TXhJg">0.7</ix:nonFraction>&#160;million from such exercise and (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_XwwI97cnr0imfvHx08Av8Q" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Narr_kawf0ydrzk-02ZFTPEtK9Q">237,012</ix:nonFraction> shares of Common Stock in connection with the cashless exercise of a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_D3oeVDNTUUiUr-_FfN-zLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_uusLZNgpOk-q9FIWzVhrSg">845,000</ix:nonFraction> shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2023</span>, the Company issued, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7tsfGy4RVUWLVfK_0YWXpA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_gk2YUPPp3kux3MGnpWISIQ">4,691,623</ix:nonFraction> shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during <span style="background:#ffffff;">the year ended December&#160;31, 2023</span>, the Company paid to the converting holders $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7tsfGy4RVUWLVfK_0YWXpA" decimals="-5" format="ixt:numdotdecimal" name="plx:PaymentsToDebtHoldersOnConversion" scale="6" id="Narr_oR0IY14-q0uKoFuVmRPLvw">0.9</ix:nonFraction>&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7tsfGy4RVUWLVfK_0YWXpA" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtConversionDecreaseInPrincipalAmount" scale="6" id="Narr_gbB-ijmLp0qk5NS-59twNw">8.3</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">On July&#160;2, 2021, the Company entered into the 2021 Sales Agreement pursuant to which the Company was able to sell, from time to time through the Agent, shares of Common Stock having an aggregate offering price of up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_GvuRJaXm1UWlbfDR82Bxug" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_x5rmC6kEf0y7s_cf2DOmCQ">20.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million. In addition, on </span>February&#160;27, 2023, the Company entered into the 2023 Sales Agreement pursuant to which the Company may sell, from time to time through the Agent, <span style="background:#ffffff;">shares of Common Stock having an aggregate offering price of up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZMEMUOBNoUyTMPRQ3bJFUQ" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_VWQyjt60e02Sb5n47KDPgw">20.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has no obligation to sell any shares of Common Stock under the 2023 Sales Agreement, and may at any time suspend sales under the 2023 Sales Agreement or terminate the 2023 Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_LrxACSzPi0yrQT4i01lIRg" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfCommissionOnSaleOfShares" scale="-2" id="Narr_ZSH9nCZ68UeQE74RCtSwxA">3.0</ix:nonFraction>% of the aggregate gross proceeds from the shares of Common Stock sold under the 2023 Sales Agreement.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hjMmAQAWa0GgzSXNhgHGIw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2021, but prior to the termination of the BofA Agreement, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_8C7y4du30EGx7NNV_qKuMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ioAivLmzzEWOtIjsxeWm4w">1,867,552</ix:nonFraction> shares of Common Stock under the BofA Agreement. The Company generated gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_8C7y4du30EGx7NNV_qKuMQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_xvX3k1R0vE-uT-GKtqcfng">8.8</ix:nonFraction>&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2022, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ssnGYhUhj0KL7KcjrJIBKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_58H0xp1I20-O3e8qji92Fg">7,473,038</ix:nonFraction> shares of Common Stock under the 2021 Sales Agreement. The Company generated gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ssnGYhUhj0KL7KcjrJIBKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_CFZdLSNybUuWhQsVzAxYPw">8.7</ix:nonFraction>&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2023, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rB-wUzmla0SlVO0p8Yda1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_e5vwVOS7NkuXX3U_Nipd1g">12,560,150</ix:nonFraction> shares of Common Stock under the 2021 Sales Agreement and 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rB-wUzmla0SlVO0p8Yda1A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_myI274H2z06ZooEUmYNWEQ">24.9</ix:nonFraction>&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_7_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_vB9y4DT3xkGRfePGVkNqMg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_vnjwRhak7UaHyG19vLQ7vA">No</ix:nonFraction> sales were completed during the six months ended December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_2_17_2021_To_2_17_2021_SJuIvsv5bUOxBNrdkJQFqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_MAu7kaeByUSTAnWUGIX8YQ">8,749,999</ix:nonFraction> shares of Common Stock in an underwritten public offering at a price to the public of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_2_17_2021_CVbxW9emMEyG2cHIMoZs5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_6uxWQ6gZvUGl4MGgZ2QStQ">4.60</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_2_17_2021_To_2_17_2021_SJuIvsv5bUOxBNrdkJQFqQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_xP1RqoiEEUmz2nlTLLafeg">40.2</ix:nonFraction>&#160;million before deducting the underwriting discount and estimated expenses of the offering. The above included the exercise of the underwriters&#8217; over-allotment option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_2_17_2021_To_2_17_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RTfbrWi6qkSb5DrbSpC38w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_KrfUYfgtwUKgFhVQ6fPS8w">1,141,304</ix:nonFraction> shares of Common Stock. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p></ix:continuation><a id="_NOTE_10_"></a><a id="_21a6b451_5a65_46e8_99fb_c2e160d27adb"></a><a id="Tc_CEJk6gMXT0u0EW8zeRdL4g_1_2"></a><a id="Tc_qcO_lkcFEkGnDPZacBNp7w_2_0"></a><a id="Tc_1e6tGRb4dkmNebYDi4dY4w_2_2"></a><a id="Tc_LqYvXvIk20Stk0l8lmiZ9A_3_0"></a><a id="Tc_d-NNXVJX5UmJPdBbVEhQPA_3_2"></a><a id="Tc_A1v3vzhBsESU9kaiMgRcVw_4_0"></a><a id="Tc_Y5EUsO_n802uGCfC_gdznw_5_0"></a><a id="Tc_iDmYp95IAEWlsMxHkrypfA_6_0"></a><a id="Tc_Gvjf5UqUtEOfcYt-WOCTfw_6_2"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:DebtDisclosureTextBlock" id="Tb_2lpI1-roqkeDIdHxFelluQ" continuedAt="Tb_2lpI1-roqkeDIdHxFelluQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 10&#160;&#160;- CONVERTIBLE NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_iAqmHavoc0y6aGWMensHBA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_an117fJtsE6xQDVaq9qPrw">7.5</ix:nonFraction>% Convertible Notes Due 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2016, the Company issued to certain existing note holders and new purchasers $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u1l6Q7eIvEKTQP9MPBmN9Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_3GyR9fv18ECvUV2MCqPaQQ">62.7</ix:nonFraction>&#160;million aggregate principal amount of its 2021 Notes in a private placement and an exchange pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. In July 2017, the Company issued an additional $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_7_31_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rTPd6I7xUkGiNNPDC-sQZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_JESs2DACjEi9s2VdjXlmKw">10.0</ix:nonFraction>&#160;million in aggregate principal amount of the 2021 Notes in a private placement pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. A portion of the interest payable under the 2021 Notes was allowed to be made in shares of Common Stock at the Company&#8217;s election. On November&#160;15, 2021, all the then outstanding 2021 Notes&#160;matured and were paid in full.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_6gBeWpquBkO5DzLdfEEOMg" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_hj6E_nkDQkig2aZL_HoDCQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2021 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. Dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_7xwVp7WULUasMawEGZ_-Bg_3_3">2,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt discount amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_FaNkzNKinEet_oY-h6jsKw_4_3">2,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_pXnYJ3hy8UGX6EzLmxVx3w_5_3">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_MYQXQ5VHaEK8MQe45ujNDQ_6_3">6,261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_mvKjawkj10SflVhDEOimrA">7.5</ix:nonFraction>% Convertible Notes Due 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On August&#160;25, 2021, the Company completed exchanges (the &#8220;Exchanges&#8221;) of a substantial majority of the Company&#8217;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_RSywV91c8EyVXNBMXvKebA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_IQVqflKVkkuz8wdIYQLxyg">54.65</ix:nonFraction>&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_TLBEs25oVEef93TLzGcLkQ">28.75</ix:nonFraction>&#160;million principal amount of newly issued 2024 Notes, $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_er9Into14EWZTOpKe06IuQ">25.90</ix:nonFraction>&#160;million in cash, and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" scale="6" id="Narr_xJmcX4zQP0SF2us_eftr0Q">1.1</ix:nonFraction>&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg" decimals="INF" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_hwRwnY1DVk-zIIk7JHpciw">563.2216</ix:nonFraction> shares of Common Stock for each $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleBaseValueForConversionRate" scale="0" id="Narr_AE6MOhJGSEK5O_yOyfYujQ">1,000</ix:nonFraction> principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_fnGka0_xq0u105n4eLmHUQ">1.7755</ix:nonFraction> per share of the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2lpI1-roqkeDIdHxFelluQ_cont1" continuedAt="Tb_2lpI1-roqkeDIdHxFelluQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Common Stock), subject to adjustment in certain circumstances, which is based on a <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfPremiumToClosingPriceOfStock" scale="-2" id="Narr_X1h7zO-Gg0awLTWA0qgsrQ">32.5</ix:nonFraction>% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The 2024 Notes were issued pursuant to an indenture (the &#8220;2024 Indenture&#8221;) entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent (the &#8220;Collateral Agent&#8221;). Interest on the 2024 Notes is payable semi-annually at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_vEaVpxPw7EOQKxdiIDy9Nw">7.50</ix:nonFraction>% per annum. The Notes mature <ix:nonNumeric contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_TFv_Wnnr5USS0NNFalHtuQ">three years</ix:nonNumeric> after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges were considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_AEBw7DOixkCFDxd0-sLkkA">0.8</ix:nonFraction>&#160;million due to derecognition of the liability component and a reduction of stockholders&#8217; equity of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A" decimals="-5" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="6" id="Narr_i5crzOXwwUWbbMMwMPb1aw">12.2</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature net of transaction costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="6" id="Narr_-ntmhwo_LUOFBXIj1QjuMQ">12.0</ix:nonFraction>&#160;million was recognized in the Company&#8217;s additional paid in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Transaction costs in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="0" format="ixt:numdotdecimal" name="plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" scale="0" id="Narr_5Wy2lg5VZk-oI4MRPoCW0w">869,000</ix:nonFraction> were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Holders may convert their 2024 Notes&#160;at any time. The initial conversion rate for the 2024 Notes&#160;is <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg" decimals="INF" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_VvxwMZWcykCEMdXBkPFykw">563.2216</ix:nonFraction> shares of Common Stock for each $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleBaseValueForConversionRate" scale="0" id="Narr_BnFnGGlv80Kxv5G7L6XexQ">1,000</ix:nonFraction> principal amount of 2024 Notes&#160;(equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_QeZHFKsbokSlWSNi36_B3A">1.7755</ix:nonFraction> per share of Common Stock). Upon conversion, the Company may settle the 2024 Notes by paying or delivering, as the case may be, cash, shares of Common Stock or a combination thereof, at the Company&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="6" id="Narr_k6N6mhxLOk6tOZLtrmGEtg">20.42</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to the maturity date, the Company may redeem in cash:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</span></span>any or all of the outstanding 2024 Notes if, on or after March&#160;31, 2023, the last reported sale price of the Common Stock for at least <ix:nonFraction unitRef="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="Narr_5CK3QXA13ECpCVSj3lH64g">20</ix:nonFraction> trading&#160;days (whether or not consecutive) during the period of <ix:nonFraction unitRef="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="Narr_VlABrXCxykyi9lNU6wFbPw">30</ix:nonFraction> consecutive trading&#160;days exceeds <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="2" format="ixt:numdotdecimal" name="plx:ThresholdPercentageOfConversionPrice" scale="-2" id="Narr_UzEKI4PCskGXHCTrTl8Pow">130</ix:nonFraction>% of the conversion price on each applicable trading day, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</span></span>all of the 2024 Notes&#160;then outstanding if the aggregate principal amount of the 2024 Notes&#160;then outstanding is less than <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="2" format="ixt:numdotdecimal" name="plx:DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" scale="-2" id="Narr_-17nUi1b6kSUuPojoRXxDA">15</ix:nonFraction>% of the aggregate principal amount of the notes issued on August&#160;25, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">To date, there has been <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="-3" format="ixt-sec:numwordsen" name="plx:DebtInstrumentRedemption" scale="3" id="Narr_OBxSYj-uBU2BseVuQGZ-0Q">no</ix:nonFraction> redemption of 2024&#160;Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The 2024 Notes&#160;are guaranteed by the Restricted Subsidiaries (as defined in the 2024 Indenture) and are secured by a first-priority security interest in all of the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &#8220;Collateral&#8221;), including, but not limited to, (i)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfOutstandingCapitalStock" scale="-2" id="Narr_U0z0KHnLeU-Wih37u1_AMA">100</ix:nonFraction>% of the capital stock of the Guarantors (as defined in the 2024 Indenture) and each Restricted Subsidiary of the </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_unBn6luj-EOtMjfyxXjXdg_1_2"></a><a id="Tc_DFxd8ymM0k6Bzta50s4yUw_1_5"></a><a id="Tc_N4UjUSklHkWax0xWG1qtrw_2_0"></a><a id="Tc_9EIct8bYsEmvrt_Cs1cblw_3_0"></a><a id="Tc_Ok1hXytnkkCFDIYY4hXf8w_4_0"></a><a id="Tc_WO_jiQV860SQbimtS0y-Kw_4_3"></a><a id="Tc_IYnmQrH7iESxKgApn5iQfw_4_6"></a><a id="Tc_A_Lr9hRyKEmfOyxn9rQdWA_5_0"></a><a id="Tc_LZ5tIp4pekSVUPYJTmTttQ_5_3"></a><a id="Tc_DnAVUArovkOZ3mMsx0h7wg_5_6"></a><a id="Tc_Xgr72itsNUuaywKHUl5M-g_6_0"></a><a id="Tc_PTlkiUf55keI1PIwxfGNLA_6_3"></a><a id="Tc_VqHzmsoqnk6yz3eB3qJqtw_6_6"></a><a id="_28195651_5b53_456c_b394_edd9614bd437"></a><a id="Tc_JdO_1dskoUm35CkrS_Yzhw_1_2"></a><a id="Tc_a7vdUvZ_jEys6Qn6lUE1bA_2_0"></a><a id="Tc_tewoGho-rUacllqQ1fSXGw_2_2"></a><a id="Tc_TUzQwaeOjkeMHuJLevTn9g_2_5"></a><a id="Tc_GR7XOEUIfE65-jjJFcoPIw_2_8"></a><a id="Tc_t-jI4BTxyE-aO4Vf34TXKA_3_0"></a><a id="Tc_fLdxjZ42Bk-eijWNZ-19yQ_3_2"></a><a id="Tc_nhR-ZWnCJUaPubuFy10s4Q_3_5"></a><a id="Tc_CZmjI-Dxtk6L6KkxvzMwDA_3_8"></a><a id="Tc_arsz176KfkeklfCW75kZZA_4_0"></a><a id="Tc_FLys95A-006bT1A_LzEqyQ_5_0"></a><a id="Tc_SaCKM0mXg0OowcTwRKBohA_5_2"></a><a id="Tc_xaeVHEGDY0CF5uA4FLqpRQ_5_5"></a><a id="Tc_tGNjN1tbP0e6vyDG2l_okw_5_8"></a><ix:continuation id="Tb_2lpI1-roqkeDIdHxFelluQ_cont2" continuedAt="Tb_2lpI1-roqkeDIdHxFelluQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Company that is held by the Company or any Restricted Subsidiary, (ii)&#160;intellectual property, including all copyrights, copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary information, including, but not limited to, domain names, (iii)&#160;all cash, deposit accounts, securities accounts, commodities accounts and contract rights, (iv)&#160;all real property and leased property, subject to applicable minimum thresholds, as set forth in the 2024 Indenture, and (v)&#160;all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such liens, the Company entered into certain agreements with both the Collateral Agent and Altshuler Shaham Trusts&#160;Ltd., as security trustee in Israel. The 2024 Indenture restricts the ability of the Company, the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&#8217;s assets that constitute collateral securing the 2024 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Upon (i)&#160;the occurrence of a fundamental change (as defined in the 2024 Indenture) or (ii)&#160;if the Company calls the 2024 Notes&#160;for redemption as described below (either event, a &#8220;make-whole fundamental change&#8221;) and a holder elects to convert its 2024 Notes&#160;in connection with such make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the &#8220;Additional Shares&#8221;). In no event will the conversion rate exceed the maximum conversion rate, which is <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="INF" format="ixt:numdotdecimal" name="plx:MaximumDebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_8NvFj4q_80a0nzHvKfgOwg">746.2686</ix:nonFraction> shares per $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" scale="0" id="Narr_djUmPMDDQU6nB96FK7uWLA">1,000</ix:nonFraction> principal amount of 2024 Notes, which amount is inclusive of repayment of the principal of the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">If a fundamental change occurs at any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2024 Notes, or any portion of the principal amount thereof, that is equal to $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" scale="0" id="Narr_U9OsBRbUOEqXnHcdaJiJpA">1,000</ix:nonFraction> or an integral multiple of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" scale="0" id="Narr_oH3NTUpvhE6k9_mMT49dsw">1,000</ix:nonFraction> in excess thereof, on a date of the Company&#8217;s choosing that is not less than <ix:nonFraction unitRef="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q" contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_p6jVivnBs0mBGLiQhyt5oQ" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" scale="0" id="Narr_boNAdmctm02M0nzhorF9KQ">20</ix:nonFraction> calendar&#160;days nor more than <ix:nonFraction unitRef="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q" contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0jdO8xpKLUGP05OvtmHFoA" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" scale="0" id="Narr_Lw5XPnLJc0O85K7gB7EESw">35</ix:nonFraction> calendar&#160;days after the date of the applicable fundamental change company notice. The price the Company is required to pay for a 2024&#160;Note is equal to <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="Narr_ZA3Wz2uBKUq9MbdaThOrPA">100</ix:nonFraction>% of the principal amount of such 2024 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. Under the terms of the 2024 Indenture, the Company is required to <span style="color:#222222;background:#ffffff;">meet certain covenants including the requirement to </span>maintain a minimum cash balance of at least $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_o7pEQZgkL0uumW3Ef77_Pw">7.5</ix:nonFraction>&#160;million. Failure to meet covenants can be considered an event of default and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of December&#160;31, 2023, the Company was in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_VZDiVAJYeUq_J3J-EliWwQ" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Group_V7LOpyPYCUGKJEA63FESSg" continuedAt="Group_V7LOpyPYCUGKJEA63FESSg_2" escape="true">The following parameters were used:</ix:nonNumeric></p><ix:continuation id="Group_V7LOpyPYCUGKJEA63FESSg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_57ZK5w5WGUyALypMdLvZ_w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_h5nh45ocj0Si5yHvK73EoQ_2_2">1.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5BUHKipIbUSYH07fhT7fxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_Qr3vytEXWEeVKT8fimwmuQ_2_5">1.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_5yXfmzhLaEC9tEJVIkFchA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WlO3JuHosU66SIYEqogVsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_6kzqjqNsg0CfP1kVYT8bBw_3_2">0.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_5yXfmzhLaEC9tEJVIkFchA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_sNa-abEf9kq7MgbpeppqKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_dRWkg71cIUOjH7rMAAdl7g_3_5">3.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_a9FL0cjM4UWj0kWAe34-9A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_nMbgAp3eX0W3SaTjKn6ObA_4_2">0.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3ifThMNCrkuKLL1kdLaJ9Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_HMTgDdT7o0Gdq8xsL-OvjA_4_5">0.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_2IMzGamN40K0qlSWNrY3Ig" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_euw-7HnYiUqEWtWdwsPKjg_5_2">78.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_BZLsajDjiEe6-0mciWg6Wg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_0P7IY7njM0KT9fYBvPur5A_5_5">91.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_CON_DW57J06LCucDdq1I-Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_gq5km5oZKEmNx1xBWaV6CA_6_2">7.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_YD_U8HfQWUOjf8ZrXymgNA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_7P6pVcEkIk-xoLB1BRCRwQ_6_5">7.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_ZPLV-meNdk-giSBLLyJNvw" continuedAt="Tb_ZPLV-meNdk-giSBLLyJNvw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_3JYAY1fui0OUhP6pQk-C8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_7FL83cK0WEKlga7HOCirgA_3_3">767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_A6SB-KSPHUOpgmPJyNMoXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_hrw7n7G_dUewvjQ3WMUwnQ_3_6">2,156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_5oma0o22jE2MQy3WI4xqwg_3_9">2,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_3JYAY1fui0OUhP6pQk-C8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_-W6eUnFYPEuEh1mz9JIBtQ_4_3">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_A6SB-KSPHUOpgmPJyNMoXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_KcYOFTnvG0KjKqLd2lSqVA_4_6">300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_N_NSmPP9G0u0-E2SyijYEw_4_9">267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_3JYAY1fui0OUhP6pQk-C8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_rNC-6Ls2MU2kzKjK7vBQmQ_5_3">864</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_A6SB-KSPHUOpgmPJyNMoXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_K5MZNMCkDEaRH5rN1dpqwg_5_6">2,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_dPsSDlKCBEagT89YLUf0-Q_5_9">2,801</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2lpI1-roqkeDIdHxFelluQ_cont3"><ix:continuation id="Tb_ZPLV-meNdk-giSBLLyJNvw_cont1"></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ddd06362_5021_4fde_8812_536599c72313"></a><a id="Tc_Fuc5nW7avUq8dvQUZ-k2lw_1_5"></a><a id="Tc_-WuChhr3hEWuGU7AGm4OqA_2_0"></a><a id="Tc_3QnjtFi1IEu7v8J-Daztzw_3_0"></a><a id="Tc_kFq2NQb_jEitnFFsz1uVOw_4_0"></a><a id="Tc_P-Erhl_L00-b1eOEZjYz4w_4_6"></a><a id="Tc_6yqZnIbxLUaRcoudEMiEEQ_5_0"></a><a id="Tc_0mcq9I-ZzU-QdE-A2xQ7gw_5_6"></a><a id="Tc_hA_39sILQkqdRx1Du30Aqw_6_0"></a><a id="Tc_jpRWTCeAQke-U6UOPwGwyw_6_6"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_12BywQG-2067-bZkjaIgeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;11&#160;- FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dFp5G0LNJUya7KtQK3pNQQ" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_X1MRdXj8ik6M67T9vMrUcA">20.42</ix:nonFraction>&#160;million 2024 Notes as of December&#160;31, 2023 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dFp5G0LNJUya7KtQK3pNQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_nP8QrBZ6EUCKdRVVQlsgAQ">25.6</ix:nonFraction>&#160;million based on a level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The Company prepared the valuation of the fair value of the 2024 Notes&#160;(a Level&#160;3 valuation) as of December&#160;31, 2023. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_iK6dheOsME6WDZ2rvcb61g" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_3I09XpnwBUK1eNxQSTeoEw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_wskF47rnKEWEi245ZoCOOg_2_5">1.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_5yXfmzhLaEC9tEJVIkFchA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_wE9yb5vMiUiXD8b4zFAFDQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_2o08z4x0PkS4NOxsja38Wg_3_5">0.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_XwrlUpDhVkulphV17M8Jmw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_X6zzcAHIdEuvTK5A1Z5hrg_4_5">4.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_251HtAiKnEG6Q7qnPV5dYA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_Xdo0s_oFHESasqvLGbkGww_5_5">69.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_QVm3W7ty10eUY0pOqxsecQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_O4irCzpCNUCH5qQ3FuYJnQ_6_5">11.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2870bcd5_9eed_4bd2_a333_a4e1f5703c4b"></a><a id="Tc_-j3whQtlT022NYkKkVuo0g_1_2"></a><a id="Tc_R23CjHIVDE25p1Bw75I4Dg_2_0"></a><a id="Tc_1xY_wBC_0EGDN6hLIgDG_g_2_2"></a><a id="Tc_AWVNXtUx90m-Wpd7lxOdbg_2_5"></a><a id="Tc_gat6Fac42UyqnwFy0Bb5kA_2_8"></a><a id="Tc_DrNOPtepsEm0MtsplN1-pg_3_0"></a><a id="Tc_C4GDe_e3KUWvDlwD1sCM3Q_4_0"></a><a id="Tc_qKo5Sa6Pp0y6ZoQZ-IQFew_4_2"></a><a id="Tc_BLEouY2kVEmYJU96qf1nDA_4_5"></a><a id="Tc_5j73IBJzw0u437YKX79Kng_4_8"></a><a id="Tc_WSzzY4usLUu3ha7MiPtmXg_5_0"></a><a id="Tc_blGoPDKwREeL0IPGPvUJSw_6_0"></a><a id="Tc_u_EjUCGKQk2cKzA1ugWkJg_7_0"></a><a id="Tc_wGFSQK6tTUCrduVnLXEdtQ_7_2"></a><a id="Tc_xmsVrAR5KUC55Sr4-cTUmQ_7_5"></a><a id="Tc_uzjMmhUhF0W7bjGlIYA52g_7_8"></a><a id="Tc_hCaXWhxwlUukvxqnQ_K32g_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:EarningsPerShareTextBlock" id="Tb_Z4ddAzOdL0qDbLCAWLIrow" continuedAt="Tb_Z4ddAzOdL0qDbLCAWLIrow_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;12&#160;&#8211; NET EARNINGS (LOSS) PER SHARE</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_EFUdxDwvXE2vqXmtRUUymw" continuedAt="Tb_EFUdxDwvXE2vqXmtRUUymw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__XzdTH2QXkOaVHZep8uujA_4_3">27,582</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_EUj32fI3_0uEJeJ6I26ArQ_4_6">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_0W8kxDU0uUOPA80yIHICTA_4_9">8,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_FMcluxMtNkagMemanaCRHA_6_9">1,168</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_6UalptuBUEaB-34fut3eRw_7_3">27,582</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_5pwJk5wTqUWRESz0RPllmg_7_6">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_uT68nmZKDkCrlAY6kEAwbA_7_9">7,144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_i0kcKn_k30qL8s37PEwOqw_9_0"></a><a id="Tc_kWCaF9Zs7Uuag9Esb8UhKg_10_0"></a><a id="Tc_FLxZX8s__k-xje00IPHvkA_11_0"></a><a id="Tc_LSilAGPE2Uy1tKvsSyFQUw_12_0"></a><ix:continuation id="Tb_Z4ddAzOdL0qDbLCAWLIrow_cont1"><ix:continuation id="Tb_EFUdxDwvXE2vqXmtRUUymw_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Q4OMiSVuM0C3irEgvQGgfA_9_3">44,140,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_93zpxM44J0mCwv3IvIHiaQ_9_6">48,472,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_yWhs_eR2o0mQWyegIDDrWg_9_9">67,512,527</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_8-mikr3Gy0uGz70mJ0UqxA_10_9">13,335,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_4bpZG7ndWUGvkHdvoXlu-g_11_9">1,576,059</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_J4L1FiB8BEKTEZbrZP_JWg_12_3">44,140,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Ucc-ojLc8kSBHVcq2gW_Hw_12_6">48,472,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_soVidT04GEO-jwuoKRoLHQ_12_9">82,424,016</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted loss per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_sxPvfKZ4_E6nZxOZsSDnVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_waYeq28qg0Sr-j3vmoXGcQ">28,502,017</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_p8gLt_bw0EKb2iCn7NXpJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_GQWJUpyXd0yTcBkwGk76ww">34,097,716</ix:nonFraction> shares of Common Stock underlying outstanding stock options, warrants and convertible notes of the Company for the years ended December&#160;31, 2021 and December&#160;31, 2022, respectively, because the effect would be anti-dilutive. In the year ended December&#160;31, 2023, the diluted earnings per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_eCN7L55gSkWPyF5sZKKtCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_OOxGPrub-Eajqs9ydrkPFw">18,254,264</ix:nonFraction> shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive.</p></ix:continuation><a id="_NOTE_13_-"></a><a id="Tc_XGaP4kvVRkSDxl0tPRzhCQ_1_2"></a><a id="Tc__FC3eDerOEa0Rdp9vhsyfQ_2_0"></a><a id="Tc_nWHzCDIxfEuF0KIOCK_yEw_2_2"></a><a id="Tc_29sTXkWA7EKFpOhIhITC4A_2_5"></a><a id="Tc_4mEYHdttt0ekXdUDkWNtyA_3_0"></a><a id="Tc_w3jMZ4MJZUOD54JWNS89_A_3_2"></a><a id="Tc_dDkfiEvUG0GGX_2FvFxfHA_3_5"></a><a id="Tc_NEoQuQD_ZkShbYcXrEwcRw_4_0"></a><a id="Tc_c6MFVHTI1kmPJvai22AlAw_5_0"></a><a id="Tc_r8AZjxg9HEuZY10sMgiRFA_5_2"></a><a id="Tc_ymEzLkCheE-ZfkqnamaIdg_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_yQxhUgVseUe5U51Gs1clIg" continuedAt="Tb_yQxhUgVseUe5U51Gs1clIg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;13&#160;- TAXES ON INCOME</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States at a rate of up to <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_MJT48I74nkqfkLgGf8DWVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_9gI6w47G002ztUd8cdOyPw">21</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_BqvfZ5a8YECLflWCc8eLaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_2XIkKs6-MEO_K-ypHBTP3w_3_3">530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_XvEW-q41wUKmWkB-99Hcjw_3_6">3,346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_ZIyAO3FOdESZHLxtIQzGOQ_4_6">3,092</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_UjFwWJqEVkCU33tSpjNRTQ_5_3">530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_MkJ5BAS7vEq1txGo2MNmgA_5_6">254</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company had an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_3TnuhJs0ok2olY0m26zLXA">3</ix:nonFraction>% for the year ended December&#160;31, 2023, compared to an effective tax rate of (<ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Narr_IYhuVC1GzEq-kLZOklFcMw">4</ix:nonFraction>)% for the year ended December&#160;31, 2022. For the year ended December&#160;31, 2023, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_2AP-elCK8Um84ybNCyBt1A">21</ix:nonFraction>% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted into law in December 2017 (the &#8220;TCJA&#8221;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_5_1_2023_To_5_31_2023_wxdHXaWGJUe-pHkKaGr9qA" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_iNKLkm3VJEqqNUe3FRaKTg">20.0</ix:nonFraction>&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released the valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_5_1_2023_To_5_31_2023_wxdHXaWGJUe-pHkKaGr9qA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="6" id="Narr_Sx0LbPIvg0WbvGHfwBBXQA">3.1</ix:nonFraction>&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The TCJA represents fundamental and dramatic modifications to the U.S. tax system. It contains several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yQxhUgVseUe5U51Gs1clIg_cont1" continuedAt="Tb_yQxhUgVseUe5U51Gs1clIg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the TCJA includes, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of NOL deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The TCJA also repealed the corporate alternative minimum tax for tax years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the TCJA included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Modification of interest expense limitation rules under the TCJA provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 30% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Section&#160;174 of the TCJA requires taxpayers to capitalize and amortize research and development expenses for tax years beginning after December&#160;31, 2021. This rule became effective for the Company during the year ended December&#160;31, 2022, and resulted in the capitalization of research and development costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="6" id="Narr_8Z7BkdbSbkyfYMg9y63C6Q">28.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="6" id="Narr_Z2Vl2AnfjEaRXgnpa_gJDg">14.4</ix:nonFraction>&#160;million in 2022 and 2023, respectively. The Company will amortize these costs for tax purposes over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" format="ixt-sec:durwordsen" name="plx:CapitalizedResearchAndDevelopmentCostAmortizationPeriod" id="Narr_y4va3ve5sEWRJkIMEQB6Aw">15 years</ix:nonNumeric> for research and development performed outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that all future profits of its subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company as a &#8220;foreign-investment company&#8221; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tax rates</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The income of the Israeli Subsidiary, other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at the regular corporate tax rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The corporate tax rate was <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2018_To_12_31_2018_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_iZ27SMRREEmvpe0JdqEXIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_srW2NfqaI06yxfYKYpVpjA"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_jJGc7jy940K8Qw9jBJ_iPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_3iETRsetBEWCyNE429-sAA"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_XzqK5SZYk0uC0x8Ph1LJBg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_hTIH5tmLekulhfOeUD1sug"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_Rc3FfJee6ka0ZRjX--HI1A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_6ISbjkGU40yQNgC32Th--A"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_OISz_geoOEqDePVi3rhqJw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_OEJEX2HFOEeTKFUExVdgLA"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_SkKeGJpZk0ix9VIXIl82bA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_tgmGrFPgt0-5A7FJcZ-blw">23</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% for 2018 and thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Encouragement of Capital Investments Law&#8221;)</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; status the Israeli Subsidiary is entitled to various tax benefits as follows:</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yQxhUgVseUe5U51Gs1clIg_cont2" continuedAt="Tb_yQxhUgVseUe5U51Gs1clIg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">a.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Reduced tax rates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary has an &#8220;Approved Enterprise&#8221; plan since 2004 and &#8220;Benefited Enterprise&#8221; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expired in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">b.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Accelerated depreciation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">c.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Conditions for entitlement to the benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary&#8217;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#8220;Approved Enterprise&#8221; from the Investment Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">d.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Amendment of the Law for the Encouragement of Capital Investments, 1959</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise&#8221; (the &#8220;Capital Investments Law Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a2aba8b0_2c4a_494a_b74c_05d76e2dad70"></a><a id="Tc_OMs4j89hEEODEx6ATgLTFA_1_2"></a><a id="Tc_ataaa_Q0TU-HDnp3cHGfOw_2_0"></a><a id="Tc_t4LHNU98w0Kldoud859Vzw_2_2"></a><a id="Tc_awsF35c3B0ilQvhH2pqNJA_2_5"></a><a id="Tc_zT1_r9-vO0-lOtviCOok2g_3_0"></a><a id="Tc_HeHn7_7gC0-fa8ayErng-A_4_0"></a><a id="Tc_ifxHpbwQ2Eyi6F_AJ-KGtQ_4_2"></a><a id="Tc_k1V1bCA4lUWkCetz8_ivqQ_4_5"></a><a id="Tc_dczifysATUu-cq_qDSw_wQ_5_0"></a><a id="Tc_SNYSRRwCak6cQ-7xoALS9Q_6_0"></a><a id="Tc_itRGMyAuYEiBhWdbUnTk0Q_7_0"></a><a id="Tc_icD9oPC9iUik57_kQ77wuA_1_2"></a><a id="Tc_Tse9HX9njkuFDAKCzHXYyA_2_0"></a><a id="Tc_SDJwduJB1kusNnWjTj_nmQ_2_2"></a><a id="Tc_emEAScP_PUamVoU6asgRWQ_2_5"></a><a id="Tc_nO1Sch5P2UOomt9eYtp23w_2_8"></a><a id="Tc_kkD9HaWmLESV_SEvtG_a6w_3_0"></a><a id="Tc_i7mvdXIZX067raNeOcuOzg_3_2"></a><a id="Tc_tceFx7KA-US1x2Rv0H7d7A_3_5"></a><a id="Tc_3uQsamoBcEGN2kBY0QGRKQ_3_8"></a><a id="Tc_n7rZzvNC_023T1A7Sq0xUw_4_0"></a><a id="Tc_egJRsx7Ygk6zi8p5MZXzYg_4_3"></a><a id="Tc_nqKC8UyO80W966mA00dW0Q_5_0"></a><a id="Tc_-YLw7TGP2kKWWHQf-RugLw_5_3"></a><ix:continuation id="Tb_yQxhUgVseUe5U51Gs1clIg_cont3" continuedAt="Tb_yQxhUgVseUe5U51Gs1clIg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023 and 2022, the Company had aggregate NOL carry-forwards equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_q2PnT7sINkCsoYAXSjbSRA">234.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_QDSs9iVyGEe0ReTVU06VvQ">247.4</ix:nonFraction>&#160;million, respectively, that are available to reduce future taxable income as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company&#8217;s carry-forward NOLs, equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_vtfaP8TfsEyMcbIsM1oBkQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_zZBVrsYqr0edtD97q9XD0g">24.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_u3-UCxFuAUOj3iNBJvmi2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_W6jaTs5EBU-ymb5qLFMJeQ">26.7</ix:nonFraction>&#160;million as of December&#160;31, 2023 and 2022, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#8220;IRC&#8221;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Protalix&#160;Ltd.</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">At December&#160;31, 2023 and 2022, the Israeli Subsidiary had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_EyG0dq2VUECJScHNcRo4pQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_q0_wxotGV0yMbhTaGzClyA">210.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_HOk8TyvPSkmZaIMc922oBA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_vc5p7R-ZlUakwNLpwl_O1A">220.7</ix:nonFraction>&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Deferred income taxes:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_ilxCZJyZY0Wvj70HiETfBQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2022 and 2023 were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_3-bE3_NzYEqm9H3O_077LA_4_3">6,568</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_E1hBPOU8AEK_OolmEMKMxA_4_6">4,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="plx:DeferredTaxAssetsOtherTimingDifferences" sign="-" scale="3" id="Tc_wWHzremR50CgLgzLgP9O1g_5_3">2,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="plx:DeferredTaxAssetsOtherTimingDifferences" sign="-" scale="3" id="Tc_1y5NVToygUKnHf8tZrxQhg_5_6">1,387</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_4ibJmK8wNE-a_1WjyICmew_6_3">54,097</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_fN4maw_SAkaIjuAjOtUo7A_6_6">51,472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Qbl-8jvyR0C7Qs57iDWiHg_7_3">58,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_7eMhfhkpXkihLWKCBwRXrw_7_6">51,618</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_Hu20NN9IrkWRaodKW7K7pQ_8_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_HJeB8_4bHEGW1Q7OMpVYbg_8_6">3,092</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A reconciliation of the statutory U.S. federal income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_WdwNmryT9kKce2KEe_08hw"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_-jd-OMpimk2hD4eJGg8QKA"><ix:nonFraction unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_FNW37cJMQUqz1qpxkcYbdQ">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2023, 2022 and 2021 to the effective income tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_IyHhmjSHt0y3KaBK124Pwg" continuedAt="Tb_IyHhmjSHt0y3KaBK124Pwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.49%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax computed at the statutory U.S. income tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_pT_tSNdmpUaj4q8U7iFpFg_3_3">5,792</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_bqImAUIaakuu-tANp7Se7w_3_6">3,023</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="Tc_jiD7_3kDrUuxzvx2mP2LPg_3_9">1,799</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Differences in tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="Tc_1eDBrx04hk-m6iQ52V288w_4_6">1,512</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" sign="-" scale="3" id="Tc_RinmPaeVgkS7jkmCCjV6LA_4_9">899</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutorily non-deductible expenses </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="Tc_g6yEQDHzxku0k_Oba2M6iQ_5_6">2,979</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="Tc_c2lNgfl7DEiGBpH5fexicw_5_9">1,684</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_rROtwdTq1U2VEk0W_ggOTg_6_0"></a><a id="Tc_dCSVcET2CU-rnhNqgh1bJA_7_0"></a><a id="Tc_Jhxqp8t4l0-V66EE5iY56Q_7_3"></a><a id="Tc_xLQDh7nEP0-V_3fSrgG8MA_8_0"></a><a id="Tc_DoeoOKFewUGMgDnICgIZHA_8_3"></a><a id="Tc_jsaKZ_A_XEiWJPqycJUNHg_8_6"></a><a id="Tc_jn0WgxYoc0yI47k-jILU8g_9_2"></a><a id="Tc_Ons8EHYbuESpUTFaKl2wXw_9_3"></a><a id="Tc_WiZ_sLKXv024wHSzjJdiYQ_9_5"></a><a id="Tc_NfHdzU-3F0yrlqtEng17XA_9_8"></a><a id="Tc_-jH-d2swkEyiXtVV3rVkKA_1_0"></a><a id="Tc_kbosicg4Xk-_hOhi96FWUg_2_0"></a><a id="Tc_M5qgKakxt0ihWvwv9oltYA_2_2"></a><a id="Tc_AoLMnPKXdE6MzajLrCmJFg_3_0"></a><a id="Tc_RBqcdUWOlEeumYAG0iIMbw_3_3"></a><a id="Tc_RJxm1tDBHUaw3lVZuOW3hQ_4_0"></a><a id="Tc_MK7agt3YCEibW3jcW_ChLg_5_0"></a><a id="Tc_GrZB1EsFmEquVSi5jMMeyQ_5_2"></a><a id="Tc_5VyOTQLRYESBgw3dQw5l1A_7_0"></a><a id="Tc_Kx-4IdG0J0ytQNXiT76h9Q_7_2"></a><a id="Tc_uKjzOfvE-kWopfz9pIKHvA_8_0"></a><a id="Tc_8iyx_dvfakqn5X5vk3RYpQ_9_0"></a><a id="Tc_7Y5CbelzaEufsYt1zPz43Q_10_0"></a><a id="Tc_5-mChVK7lkawNSjg9HATIg_10_2"></a><a id="Tc_LZw95lbGvUSdgTzbHw4g0g_1_0"></a><a id="Tc_ahrqgFaxvk-pChbv3kIP5Q_2_0"></a><a id="Tc_NNP-Vcw4jkSlhSLvhCR-Aw_2_2"></a><a id="Tc_IlSjVvMjw0mwUvqXt6isEA_2_3"></a><a id="Tc_oeTifx-T00SiUkkFQquc7A_3_0"></a><a id="Tc_MAxD4It5qUWH-8O3gVTQ5g_4_0"></a><a id="Tc_RX0tlVhw-kuM7DJVlDWXyw_4_2"></a><a id="Tc_O--qBeK00UeHTMVOeuDL5Q_6_0"></a><a id="Tc_kWUIK5CQDE65kfZIJ3XbFg_6_2"></a><a id="Tc_KL-gzyZowE-HvKxEzcK7Pw_7_0"></a><a id="Tc_ZceUrlhLwkK1y1Mwmmbr3Q_8_0"></a><a id="Tc_LSa64_3CH0mlpkzxFQxuYg_8_2"></a><ix:continuation id="Tb_yQxhUgVseUe5U51Gs1clIg_cont4" continuedAt="Tb_yQxhUgVseUe5U51Gs1clIg_cont5"><ix:continuation id="Tb_IyHhmjSHt0y3KaBK124Pwg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in Valuation allowances</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_QzmPCgkYtU2mCjs5EDCn6g_6_3">5,792</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="3" id="Tc_ggI9Ll1fOkybh1QJFcIXkg_6_6">2,970</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="3" id="Tc_mx4ji9p2wk-nb20jGu394Q_6_9">6,932</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" scale="3" id="Tc_DNkgdA7Lv0Sf2T3tFqtGPQ_7_6">2,032</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" scale="3" id="Tc_Vn8E9GQoDEeTZFVTUX3CVQ_7_9">3,602</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Withholding tax </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:EffectiveIncomeTaxRateReconciliationWithholdingTax" sign="-" scale="3" id="Tc_GrLJVqod_0abHi08lGvmyw_8_9">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_2WU3rzfbFkG7pY69aMkEGQ_9_6">530</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_Ld5IUckErkqq4Wjz8hIB3w_9_9">254</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Valuation allowance roll-forward</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table presents the change in the Company&#8217;s valuation allowance during the periods presented:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="Tb_NHzEbXY0E0-wsaYxMw89og" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_qF-MVvMDDUS_bdkgf4UO_w_2_3">61,520</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" scale="3" id="Tc_fxWPVhUU2UO5aDySV9WoTg_4_3">2,970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_BE4n6eHMLkq8-XBNEbmH6Q_5_3">58,550</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_K1xhFs2XckOBxw5-Q2gvpw_7_3">58,550</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" scale="3" id="Tc_TvIRSkpe2ki50z4L8CXkag_8_3">728</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" scale="3" id="Tc_orLjeXKpMk2OC2AXPwnWqA_9_3">7,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_RNcV7IL4e02ex_rLTvctlw_10_3">51,618</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Uncertain tax position</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Provisions of ASC 740-10, Income Taxes, clarify whether to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="Tb_KVWCqItcykqYDUws-F_z9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_LHgptcxhnUmd0gzWftCvyA_3_3">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_NRQwQMkvpESzYYCfjjHvqA_4_3">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_ovamEFkJ0kylm_x5mHF7hQ_6_3">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_B_Wi9JeKt0i2WOgqokWQCA_7_3">275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_x42eA-eqP0WSoiLVr-GkJw_8_3">805</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Tax assessments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In accordance with the Income Tax Ordinance, as of December&#160;31, 2023, all of Protalix&#160;Ltd.&#8217;s tax assessments through tax&#160;year 2018 are considered final.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of open tax&#160;years by major jurisdiction is presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="plx:ScheduleOfOpenTaxYearsTableTextBlock" id="Tb_orMxtRJFK0SK_XtEEy--GQ" continuedAt="Tb_orMxtRJFK0SK_XtEEy--GQ_cont1" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_rYb5LIKYEU-DUI4F45twMw" name="us-gaap:OpenTaxYear" id="Narr_mVc_KCfwqUW6mwUadyL1AA">2019</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_o34DNclg302qjFkTJ9TCVw" name="us-gaap:OpenTaxYear" id="Narr_XSOIDRM4rEet2tGr1-eSRQ">2023</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_Uh0a4pl7bU-2Tnjx_lqtJg" name="us-gaap:OpenTaxYear" id="Narr_wT4QaUxwm0upMbWDyElhpw">2020</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_96dVppJwckClqojVBy1Ycw" name="us-gaap:OpenTaxYear" id="Narr_1X01TmQtK0-cx2fCTXMkLQ">2023</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yQxhUgVseUe5U51Gs1clIg_cont5"><ix:continuation id="Tb_orMxtRJFK0SK_XtEEy--GQ_cont1"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_73f960ad_5752_420d_8783_ad8d2e519d13"></a><a id="Tc_GQel1ovpg0KGfh5qV2Z8mw_1_2"></a><a id="Tc_H6nwhavgZE61oD9ySRQHhw_2_0"></a><a id="Tc_FuLacuOTfkWK1zeJ-_cu6g_2_2"></a><a id="Tc_71DCVYsYQkqj-jGmxshSIg_2_5"></a><a id="Tc_IjSXE5t2zUqx85XEsiso1g_3_0"></a><a id="Tc_GTw7OG9BsUGkOKkMclSumQ_4_0"></a><a id="Tc_INQx7gHTWEWcwey5aN6Oew_4_2"></a><a id="Tc_fd3Gj5bMYk2v64h4qkFO3A_4_5"></a><a id="Tc_5vay2Ae_YUy2DIp7ew33dA_5_0"></a><a id="Tc_FupDIz5HskyR6uxCfDA22Q_6_0"></a><a id="Tc_x5ILAKyGX0a5woJS_o2pcQ_7_2"></a><a id="Tc_IM9ROW2LtEScJP2_fc9xVQ_7_5"></a><a id="_6a48e2ae_f89a_48d3_981e_fd922cca3af8"></a><a id="Tc_zMi0bV_nSEqi-VXo9nCubg_1_2"></a><a id="Tc_kjp7hiq9_ECHzXf0-sDeXQ_2_0"></a><a id="Tc_cLUMN0FtpkyP6TD6p0bdGQ_2_2"></a><a id="Tc_V-s6EFJw6EuKVzoGhODTNA_2_5"></a><a id="Tc_A6kMhpghW0K0q-2N230Law_3_0"></a><a id="Tc_EKnExjdk0U2AiRM9UbUx5g_4_0"></a><a id="Tc_jjNXnk4zJ0yvFQ-IiMoOzQ_4_2"></a><a id="Tc_k6A2Ie_XkUGMSM32R3e4KA_4_5"></a><a id="Tc_2YVJH3GDP0qRx9juK1XIBA_5_0"></a><a id="Tc_njiAccUdvUuIpot2fDhUcA_6_0"></a><a id="Tc_MRCmNbjW9EuKQccUkVQJGA_7_0"></a><a id="Tc_JVJG0bpYVEiSv9TT662IBA_8_0"></a><a id="Tc_QCxvW9CsiE6c3onEdsNOzQ_9_0"></a><a id="Tc_5hilj9qJQESqMRF7Jg9sjQ_10_0"></a><a id="Tc_UUEos5FStUW5T18Mdi5ryw_10_3"></a><a id="Tc_OAzhhClX8U2x7iXUSRpWtA_11_0"></a><a id="Tc_99lHBJm8Zk2oWvVLnCqhVw_12_2"></a><a id="Tc_PGTMPQdWNkO16_1f4U416w_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_A0liS0PnhUSLBa13G1BOww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;14&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 54pt;">Balance sheets:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_LOu1lrcjrkm9WyCPL8mhlQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="plx:OtherAssetsInstitutionsCurrent" scale="3" id="Tc_8vEwkWlhIkG61L0rZwiSGA_4_3">364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="plx:OtherAssetsInstitutionsCurrent" scale="3" id="Tc__rrQDhXCGEKHwH_EtsC6RA_4_6">482</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_xIEEvnSL5EGZI8PkhEOzNA_5_3">774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_qheD33-6lk6sEd-QvDcrgw_5_6">444</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="plx:OtherAssetsSundryCurrent" scale="3" id="Tc_i7F01kJL9ESeQP832GgPLA_6_3">172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="plx:OtherAssetsSundryCurrent" scale="3" id="Tc_DY-sGBz0AUCNoTu113A7sQ_6_6">129</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_ripBgmG2BUCsW6CiYMsJ2w_7_3">1,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_PgBSzj1d102Rzhp560E9Ng_7_6">1,055</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_dqJ0OcowpU-vUS1viYiUnw_4_3">1,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_XVdc2vStzUW4gx4zTsNusA_4_6">1,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_bJmMndFm2EOsgldZgT6I8A_5_3">719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_fWlJT9mIUU2Bxzx-lKQYpg_5_6">511</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_McxobQ3ahkOWVzXMJ324vg_6_3">1,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_60ahLgKVPEulqZDIlD6vyg_6_6">1,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_nXLQq3CrzkakzoZrK9cq7w_7_3">7,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_N2Lg_oG_zUyRoHZZof-8Ww_7_6">9,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_z4XA4JSqOkGCW6aA1Worrg_8_3">781</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_es8KDT5EwUG15ljxG3m06A_8_6">637</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_Z_tg1xxSzkyKM0NcwL1Fpw_9_3">530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_2J5kKrMSaEiQ9yKvQVF9kQ_9_6">2,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="plx:ReserveForDeductionsFromRevenueCurrent" scale="3" id="Tc_OWkLjcijjEii2Huv3D7sBg_10_6">2,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_BDYKpXfl2EK17GiUvz9-LQ_11_3">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_YGsuHyG_r0CCWrXP4A0xEA_11_6">614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_5RjcJku31kWv_8Es9OU35A_12_3">12,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_PG7MTXC5jkKR2JXsaV-eYQ_12_6">19,550</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_y1URrFDWGEqyfXWJva-7bQ_1_2"></a><a id="Tc_7OFbQvtv1kmsHP8h5uqWiA_2_0"></a><a id="Tc_ZBoRyMR95EGJQ_-EDyp6PA_2_2"></a><a id="Tc_e_uiEJOHtkaqo2Wf8JwS-w_2_5"></a><a id="Tc_bnmppFQclUqlEISynUsNVw_2_8"></a><a id="Tc_CBUocgcgXkm_d3O9QadmfQ_3_0"></a><a id="Tc_7pk_gnTZIkWiqPvrC98KmQ_3_2"></a><a id="Tc_PX3PpVQ2J0iR8nUeqsVvAA_3_5"></a><a id="Tc_viPQ3j3qGkKq1V8nzEXLow_3_8"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_esWkCau8s0ONAwf83LkAeA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;15&#160;- RELATED PARTY TRANSACTIONS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-Executive Director Compensation</span></td></tr></table><div style="margin-top:12pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_QGABpAgxokaOC5v_8cDRAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bJsWGX3NvUKW3gZlGPknpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_Qqj9fDmZnk6VmvDwESRvGQ_3_3">475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_H8gaQjdU40-YdEqUm0lstA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_ZHujAMHOk0G5g2s_BqAsgg_3_6">368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vv13STm1FEiXvwnu0lUpEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_Mjzkq2ymPkCHXIBDkd5Whg_3_9">429</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In September 2023, with the consent of the Audit Committee of the Board of Directors, the Company engaged one of its non-executive directors to advise the Company regarding business development and licensing efforts on a consultancy basis. For the year ended December&#160;31, 2023, the director earned a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_9_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b6xXIxG3uUumtk0da2OG_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_zzCR2o9bgEy-IZQl-h8IAw">35,475</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in consulting fees.</span></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w" name="us-gaap:SubsequentEventsTextBlock" id="Tb_7ekptLDg206nXWYIKRVDUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE&#160;16&#160;- SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since December&#160;31, 2023, the Company has collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_3_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuM681TIWk-KXTzBvFq0cA" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromExpenseReimbursements" scale="6" id="Narr_X2MU_Fn2S0CyZWSQos2Imw"><ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_w5_kliyzhkCBaXvHO4GYkA" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromExpenseReimbursements" scale="6" id="Narr_4e80kC6BjUa22rIjWWyBbw">0.3</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from expense reimbursements in connection with its collaboration with Chiesi, and approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="Duration_1_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_nqKCRd69hEOEP6D4HvRrJQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_vfUi2810WEiFNERtKV58YQ">4.6</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Pfizer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In January 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw" contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_KnmtJ5iwKEauWLVFJfPcWQ">100,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock, in the aggregate, to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_employee_EpjUeGM08kCkStcWvhYgyg" contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A" decimals="INF" format="ixt-sec:numwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" scale="0" id="Narr_cmFBVxdEHEau5WzQJyxnFw">two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Company&#8217;s employees under the Plan. The restricted stock vests over a </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Ow99Bsimi02ZXYS-PrI0Vg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg" contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_ZpCEy0yQekeE8Duow0KNcA">12</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw" contextRef="As_Of_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y7utRnms1UOqtqZVB3Km0A" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_HQyXpq1-Gk-SG4rMlrO9oQ">161,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>2
<FILENAME>plx-20231231xex4d7.htm
<DESCRIPTION>EX-4.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/13/2024 05:47:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 4.7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The following summarizes the material terms of the capital stock of Protalix BioTherapeutics, Inc. We are a Delaware corporation. The rights of our stockholders are governed by the Delaware General Corporation Law (the &#8220;DGCL&#8221;) and by our Certificate of Incorporation, as amended, and our Bylaws, which are exhibits to our Annual Report on Form 10-K filed with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;) and available at <i style="font-style:italic;">www.sec.gov</i>. The following summary is qualified in its entirety by reference to the applicable provisions of the DGCL and our Certificate of Incorporation, as amended, and Bylaws, which are subject to future amendment in accordance with the provisions thereof. Our common stock is the only class of our securities registered under Section&#160;12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Authorized Capital Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">General</i>. Our charter provides that we may issue up to 185,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per share. The number of shares of our common stock issued and outstanding as of a recent date is set forth on the cover page of our most recent Annual Report on Form&#160;10-K or Quarterly Report on Form&#160;10-Q filed with the Commission. We currently have no outstanding shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Voting Rights.</i>&#160;Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Accordingly, holders of a majority of the shares of common stock entitled to vote in any election of directors may elect all of the directors standing for election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Dividends.</i>&#160;Subject to the preferential rights, if any, of the holders of any outstanding series of our preferred stock, holders of shares of our common stock are entitled to receive dividends when, as and if declared by our Board of Directors (our &#8220;Board&#8221;) out of funds legally available therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Dividend Policy</i>.&#160;We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to finance the growth and development of our business and therefore do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board and will depend upon our financial condition, operating results, capital requirements, covenants in our debt instruments (if any), and such other factors as our Board deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Liquidation.</i>&#160;In the event of our liquidation, dissolution or winding-up, after payment of all of our debts and liabilities, the holders of our common stock are entitled to share ratably in all remaining assets available for distribution after the payment of debts and liabilities and after provision has been made for each class of stock, if any, having preferences over our common stock. Holders of our common stock, as such, have no preemptive or other rights and there are no redemption provisions applicable to our common stock. All of our outstanding shares of common stock are fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Other Rights.</i>&#160;The holders of our common stock have no preemptive rights and no rights to convert their common stock into any other securities, and our common stock is not subject to any redemption or sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our Certificate of Incorporation, as amended, authorizes the issuance of up to 100,000,000 shares of preferred stock with such voting rights, rights of redemption and other relative rights and preferences as may be determined from time to time by our Board. Accordingly, our Board is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of the holders of our common stock. The preferred stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of our company.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Provisions of Delaware Law, Our Certificate of Incorporation, as Amended, and Our By-laws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Delaware statutory law, our Certificate of Incorporation, as amended, and our Bylaws contain provisions that could make acquisition of our Company by means of a tender offer, a proxy contest or otherwise more difficult. These provisions are intended to discourage certain types of coercive takeover practices and takeover bids that our Board may consider inadequate and to encourage persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of increased protection of our ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of their terms. The description of our Certificate of Incorporation, as amended, and our Bylaws set forth below is only a summary and is qualified in its entirety by reference to our amended and restated certificate of incorporation and amended and restated Bylaws, which are exhibits to our most recent Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Blank Check Preferred Stock.</i>&#160;Our amended and restated certificate of incorporation permits us to issue, without any further vote or action by the stockholders, up to 100,000,000 shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares constituting the series and the designation of the series, the voting powers (if any) of the shares of the series, and the preferences and relative, participating, optional and other rights, if any, and any qualifications, limitations or restrictions, of the shares of such series. The ability to issue such preferred stock could discourage potential acquisition proposals and could delay or prevent a change in control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Number of Directors; Filling Vacancies; Removal.</i>&#160;Our Bylaws provide that the number of directors which shall constitute the whole of the Board shall be fixed from time to time by resolution of the Board. Directors shall be elected by a plurality vote of the shares represented in person or by proxy at the annual meeting of stockholders in each year and entitled to vote on the election of directors. Elected directors shall hold office until the next annual meeting and until their successors shall be duly elected and qualified. Directors need not be stockholders. If, for any cause, the Board shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of stockholders called for that purpose in the manner provided in our Bylaws. In addition, our amended and restated certificate of incorporation and amended and restated Bylaws provide that a Board vacancy resulting from the death, removal or resignation of a director, as well as a vacancy resulting from an increase in the number of directors or if the stockholders fail at any meeting of stockholders at which directors are to be elected to elect the number of directors then constituting the whole Board, may be filled solely by the affirmative vote of a majority of the remaining directors then in office even though that may be less than a quorum of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Special Meetings.</i>&#160;Special Meetings of our stockholders may be called, for any purpose or purposes, by the Chairman of the Board or the President or the Board of Directors at any time. Upon written request of any stockholder or stockholders holding in the aggregate not less than 10% of all of the votes entitled to be cast on any issue proposed to be considered at the Special Meeting signed, dated and delivered in person or sent by registered mail to the Chairman of the Board, President or Secretary of our company, the Secretary shall call a special meeting of stockholders to be held at the principal office of the corporation or at such place and at such time as the Secretary may fix, such meeting to be held not less than 10 nor more than 60 days after the receipt of such request, and if the Secretary shall neglect or refuse to call such meeting within seven days after the receipt of such request, the stockholder making such request may do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">No Stockholder Action by Written Consent Unless Approved by the Board.</i>&#160;Our Bylaws requires that all actions to be taken by stockholders must be taken at a duly called annual or special meeting, and stockholders are not permitted to act by written consent. These provisions will make it more difficult for stockholders to take an action opposed by our Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Section&#160;203 of the Delaware General Corporation Law</i>.&#160;Section&#160;203 of the DGCL provides that, subject to certain specified exceptions, a corporation will not engage in any &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for a three-year period following the time that such stockholder becomes an interested stockholder unless (1)&#160;before that time, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder, (2)&#160;upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced (excluding certain shares) or (3)&#160;on or after such time, both the board of directors of the corporation and at least 66<sup style="font-size:7.5pt;vertical-align:top;">2</sup>/<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>% of the outstanding voting stock </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">which is not owned by the interested stockholder approves the business combination. Section&#160;203 of the DGCL generally defines an &#8220;interested stockholder&#8221; to include (x)&#160;any person that owns 15% or more of the outstanding voting stock of the corporation, or is an affiliate or associate of the corporation and owned 15% or more of the outstanding voting stock of the corporation at any time within three years immediately prior to the relevant date and (y)&#160;the affiliates and associates of any such person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Section&#160;203 of the DGCL generally defines a &#8220;business combination&#8221; to include (1)&#160;any merger or consolidation with an interested stockholder or other entity if the merger or consolidation is caused by the interested stockholder and as a result section (a) of Section 203 is no longer applicable to the surviving entity, (2)&#160;sales or other dispositions of 10% or more of the corporation&#8217;s assets with or to an interested stockholder, (3)&#160;certain transactions resulting in the issuance or transfer to the interested stockholder of any stock of the corporation or its subsidiaries, (4)&#160;certain transactions which would increase the proportionate share of the stock of the corporation or its subsidiaries owned by the interested stockholder and (5)&#160;receipt by the interested stockholder of the benefit (except proportionately as a stockholder) of any loans, advances, guarantees, pledges, or other financial benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We have elected not to be subject to Section&#160;203 of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Listing Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our common stock is listed on the NYSE American under the symbol &#8220;PLX.&#8221;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>plx-20231231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/13/2024 05:47:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="plx-20231231xex23d1001.jpg" alt="Graphic" style="display:inline-block;height:93.95pt;width:111.05pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 24pt 0pt;"><font style="font-family:'Georgia';">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><sup style="font-family:'Georgia';font-size:7.5pt;font-weight:bold;vertical-align:top;"> </sup></p><p style="font-family:'Georgia';font-size:10pt;line-height:12pt;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No.&#160;333-237736 and No.&#160;333-264394) and on Form S-8 (No.&#160;333-148983, No.&#160;333-182677, No.&#160;333-203960, No.&#160;333-225526, No.&#160;333-239101, No.&#160;333-266131 and No.&#160;333-273396) of Protalix BioTherapeutics, Inc. of our report dated March&#160;14, 2024 relating to the financial statements, which appears in this Form 10-K.</p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:85.31%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;">X, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:18.25pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';">Tel-Aviv, Israel</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;">March&#160;14, 2024</p></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';">/s/ Kesselman&#160;&amp;&#160;Kesselman</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';">Certified Public Accountants (lsr.)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';">A member firm of PricewaterhouseCoopers</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt;">International Limited</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:18.25pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Georgia';text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>plx-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/13/2024 05:47:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)<b style="font-weight:bold;">) </b>for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;14, 2024</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>plx-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/13/2024 05:47:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)<b style="font-weight:bold;">) </b>for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;14, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President, Chief Financial Officer, Treasurer &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>plx-20231231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/13/2024 05:48:17 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt -0.05pt;">This Certificate is being furnished to the Securities and Exchange Commission as an exhibit to the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;14, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>plx-20231231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/13/2024 05:48:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Sr. Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt -0.05pt;">This Certificate is being furnished to the Securities and Exchange Commission as an exhibit to the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;14, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>plx-20231231xex97d1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/13/2024 05:48:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36.7pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 97.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Approved as of November&#160;14, 20</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">23</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">CLAWBACK POLICY</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purpose</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The purpose of this Protalix BioTherapeutics, Inc. (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) Clawback Policy (this &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to comply with, and shall be interpreted to be consistent with the listing standards (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing Standard</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) as set forth in Section&#160;954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified in Section&#160;10D of the Securities Exchange Act of 1934, as amended (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), Rule&#160;10D-1 promulgated under the Exchange Act (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rule&#160;10D-1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) and</font><font style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Section&#160;811 of the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">C</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ompany Guide of the NYSE American (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NYSE American</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). Unless otherwise defined in this Policy, capitalized terms shall have the meaning ascribed to such terms in Section 2.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2. </font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. As used in this Policy, the following capitalized terms shall have the meanings set forth below.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting Restatement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means an accounting restatement of the Company&#8217;s financial statements due to the Company&#8217;s material noncompliance with any financial reporting requirement under applicable securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (i.e., a &#8220;Big R&#8221; restatement), or to correct an error that is not material to the previously issued financial statements, but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (i.e., a &#8220;little r&#8221; restatement).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">b.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting Restatement Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the earlier to occur of (i)&#160;the date the Board of Directors, a committee of the Board of Directors, or the officer or officers of the Company authorized to take such action if the Board of Directors&#8217; action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement and (ii)&#160;the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">c.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Period</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (that results from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">d.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board of Directors</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the Company&#8217;s Board of Directors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">e.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the U.S.&#160;Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">f.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Executive Officer</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means an individual who is currently or previously served as the Company&#8217;s principal executive officer, principal financial officer, principal accounting officer (or, if there is no such accounting officer, the controller), vice </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36.7pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 97.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), an officer who performs (or performed) a policy-making function, or any other person who performs (or performed) similar policy-making functions for the Company or is otherwise determined to be an executive officer of the Company pursuant to Item 401(b) of Regulation S-K. An executive officer of the Company&#8217;s parent or subsidiary is deemed a &#8220;Covered Executive Officer&#8221; if the executive officer performs (or performed) such policymaking functions for the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">g.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Erroneously Awarded Compensation</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes paid by the relevant Covered Executive Officer; </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i)&#160;the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received and (ii)&#160;the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the NYSE American.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">h.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Reporting Measure</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements and any measure that is derived wholly or in part from such measure. A Financial Reporting Measure is not required to be presented within the Company&#8217;s financial statements or included in a filing with the U.S.&#160;Securities and Exchange Commission to qualify as a &#8220;Financial Reporting Measure.&#8221;</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:top;"><a style="vertical-align:super;" href="#footnote-2">1</a></sup></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">i.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive-Based Compensation</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation is deemed &#8220;received&#8221; for purposes of this Policy in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Policy shall be administered by the Compensation Committee of the Board of Directors (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation Committee</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). For purposes of this Policy, the body charged with administering this Policy shall be referred to herein as the &#8220;Administrator.&#8221; The Administrator is authorized to interpret and construe this Policy and to make all determinations </font></p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="footnote-2"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">1</sup> <font style="font-family:'Times New Roman','Times','serif';">Note that in the final publication of Rule 10D-1, the SEC explained Financial Reporting Measures include, but are not limited to, the following (and any accounting-based measures and measures derived from the following): revenues; net income; operating income; profitability of one or more reportable segments; financial ratios (e.g., accounts receivable turnover and inventory turnover rates); net assets or net asset value per share (e.g., for registered investment companies and business development companies that are subject to the rule); earnings before interest, taxes, depreciation and amortization; funds from operations and adjusted funds from operations; liquidity measures (e.g., working capital, operating cash flow); return measures (e.g., return on invested capital, return on assets); earnings measures (e.g., earnings per share); sales per square foot or same store sales, where sales are subject to an Accounting Restatement; revenue per user, or average revenue per user, where revenue is subject to an Accounting Restatement; cost per employee, where cost is subject to an Accounting Restatement; any of such financial reporting measures relative to a peer group, where the Company&#8217;s financial reporting measure is subject to an Accounting Restatement; and tax basis income.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36.7pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 97.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">necessary, appropriate or advisable for the administration of this Policy, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. All determinations and decisions made by the Administrator pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company, its affiliates, its stockholders and Covered Executive Officers, and need not be uniform with respect to each person covered by this Policy. In the administration of this Policy, the Administrator is authorized and directed to consult with the full Board of Directors or such other committees of the Board of Directors as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to any limitation at applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee). Any action or inaction by the Administrator with respect to a Covered Executive Officer under this Policy in no way limits the Administrator&#8217;s decision to act or not to act with respect to any other Covered Executive Officer under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Covered Executive Officer other than as set forth in this Policy.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Application of this Policy</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Policy applies to all Incentive-Based Compensation received by a person: (a)&#160;after beginning service as a Covered Executive Officer; (b)&#160;who served as a Covered Executive Officer at any time during the performance period for such Incentive-Based Compensation; (c)&#160;while the Company had a listed class of securities on a national securities exchange; and (d)&#160;during the Applicable Period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recovery Erroneously Awarded Compensation</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. In the event of an Accounting Restatement, the Company must recover Erroneously Awarded Compensation reasonably promptly, in amounts determined pursuant to this Policy. The Company&#8217;s obligation to recover Erroneously Awarded Compensation is not dependent on the filing of restated financial statements. Recovery under this Policy with respect to a Covered Executive Officer shall not require the finding of any misconduct by such Covered Executive Officer or such Covered Executive Officer being found responsible for the accounting error leading to an Accounting Restatement. In the event of an Accounting Restatement, the method for recouping Erroneously Awarded Compensation shall be determined by the Administrator in its sole and absolute discretion, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Recovery may include, without limitation, (i)&#160;reimbursement of all or a portion of any incentive compensation award, (ii)&#160;cancellation of incentive compensation awards and (iii)&#160;any other method authorized by applicable law or contract.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The Company is authorized and directed pursuant to this Policy to recover Erroneously Awarded Compensation in compliance with this Policy unless the Administrator has determined that recovery would be impracticable solely for the following limited reasons, and subject to the following procedural and disclosure requirements:</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36.7pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 97.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The direct expenses paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered. Before reaching such conclusion, the Administrator must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the NYSE American;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">b. </font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before reaching such conclusion, the Administrator must obtain an opinion of home country counsel, acceptable to the NYSE American, that recovery would result in such a violation, and must provide such opinion to the NYSE American; or</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">c.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Code.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If a decision must be made under this Section&#160;5 at a time that a Compensation Committee meeting the standards set forth in the Listing Standards is not in place, the decision shall be made by a majority of the independent directors serving on the Board of Directors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prohibition on Indemnification and Insurance Reimbursement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Company is prohibited from indemnifying any Covered Executive Officer against the loss of any Erroneously Awarded Compensation. Further, the Company is prohibited from paying or reimbursing a Covered Executive Officer for the cost of purchasing insurance to cover any such loss. The Company is also prohibited from entering into any agreement or arrangement whereby this Policy would not apply or fail to be enforced against a Covered Executive Officer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Required Policy-Related Disclosure and Filings</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including disclosures required by U.S.&#160;Securities and Exchange Commission filings. A copy of this Policy and any amendments hereto shall be posted on the Company&#8217;s website and filed as an exhibit to the Company&#8217;s Annual Report on Form 10-K.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Covered Executive Officer shall sign and return to the Company within thirty (30) calendar days following the later of (i)&#160;the effective date of this Policy set forth below or (ii)&#160;the date such individual becomes a Covered Executive Officer, the Acknowledgement Form attached hereto as </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, pursuant to which the Covered Executive Officer agrees to be bound by, and to comply with, the terms and conditions of this Policy.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment; Termination</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Board of Directors may amend this Policy from time to time in its sole and absolute discretion and shall amend this Policy as it deems necessary to reflect the Listing Standards or to comply with (or maintain an exemption from the application of) Section&#160;409A of the Code. The Board of Directors may terminate this Policy at any time; </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that the termination of this Policy would not cause the Company to violate any federal securities laws, or rules promulgated by the U.S.&#160;Securities and Exchange Commission or the Listing Standards.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">10.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Recovery Obligations; General Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Board of Directors intends that this Policy shall be applied to the fullest extent of the law. To the extent that the application of this Policy would provide for recovery of Incentive- Based Compensation that the Company already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36.7pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 97.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">obligations, any such amount recovered from a Covered Executive Officer will be credited to any recovery required under this Policy in respect of such Covered Executive Officer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Policy shall be effective as of November&#160;14, 2023 (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). The terms of this Policy shall apply to any Incentive-Based Compensation that is received by Covered Executive Officers on or after the Effective Date, even if such Incentive-Based Compensation was approved, awarded or granted to Covered Executive Officers prior to the Effective Date. This Policy shall not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. This Policy is binding and enforceable against all Covered Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36.7pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 97.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">CLAWBACK POLICY</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">ACKNOWLEDGEMENT FORM</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Protalix BioTherapeutics, Inc. (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) Clawback Policy (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned&#8217;s employment or service with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:31.9%;"><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Signature</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Print Name</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Date</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:75.81%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20231231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20231231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $* V # 2(  A$! Q$!_\0
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M>74;#476&T*+NMP05&9&/SY!R22#GKGA+I?R_/7\!OK;S_+0]6HHHH ****
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M2^!@8 4$#G)I:V*6YT?_  M72[+[5<:E.MG9Q6]E,4-O-Y\9N&95#J4XR1@
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M;MNT[O3'- 5B"0"<=<#I0!]D?\-$^ O^@P__ ("2_P#Q-'_#1/@+_H,/_P"
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M-_#S_H-O_P" <W_Q%?#M% 'W%_PTW\//^@V__@'-_P#$4?\ #3?P\_Z#;_\
M@'-_\17P[10!]Q?\--_#S_H-O_X!S?\ Q%'_  TW\//^@V__ (!S?_$5\.T4
M ?<7_#3?P\_Z#;_^ <W_ ,11_P --_#S_H-O_P" <W_Q%?#M% 'W%_PTW\//
M^@V__@'-_P#$4?\ #3?P\_Z#;_\ @'-_\17P[10!]Q?\--_#S_H-O_X!S?\
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M\//^@V__ (!S?_$4?\--_#S_ *#;_P#@'-_\17P[10!]Q?\ #3?P\_Z#;_\
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MQ".\>\$G'W<$<]!FO#]3^&OB:?P-I&C6_AN**:UTR2'S5,1E6Z#Y+!B^$#
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ME>&-3T.TT;2[JU>UN)_%RWUI%\@VVZQEW(5"50 !@0. 35:7M_6]OR%=VO\
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M'_0N3_\ ?R/_ .*H \ZHKT7_ (9[^('_ $+D_P#W\C_^*H_X9[^('_0N3_\
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M_B/K]:W/L$/]T_\ ?1_QH GX]J./:H/L$/\ =/\ WT?\:/L$/]T_]]'_ !H
MGX]J./:H/L$/]T_]]'_&C[!#_=/_ 'T?\: )^/:CCVJ#[!#_ '3_ -]'_&C[
M!#_=/_?1_P : )^/:CCVJ#[!#_=/_?1_QH^P0_W3_P!]'_&@"?CVHX]J@^P0
M_P!T_P#?1_QH^P0_W3_WT?\ &@"?CVHX]J@^P0_W3_WT?\:/L$/]T_\ ?1_Q
MH GX]J./:H/L$/\ =/\ WT?\:/L$/]T_]]'_ !H GX]JRM5 ^T+_ +O]35[[
M!#_=/_?1_P :R]3M(EG4!?X?[Q_QH @Q1BH_LT7]W_QX_P"-'V:+^[_X\?\
M&@"3%&*C^S1?W?\ QX_XT?9HO[O_ (\?\: ),48J/[-%_=_\>/\ C1]FB_N_
M^/'_ !H DQ1BH_LT7]W_ ,>/^-'V:+^[_P"/'_&@"3%&*C^S1?W?_'C_ (T?
M9HO[O_CQ_P : ),48J/[-%_=_P#'C_C1]FB_N_\ CQ_QH DQ1BH_LT7]W_QX
M_P"-'V:+^[_X\?\ &@"_I8'VK_@)K7X]JP]-M(FN<%?X3_$?\:U?L$/]T_\
M?1_QH GX]J./:H/L$/\ =/\ WT?\:/L$/]T_]]'_ !H GX]J./:H/L$/]T_]
M]'_&C[!#_=/_ 'T?\: )^/:CCVJ#[!#_ '3_ -]'_&C[!#_=/_?1_P : )^/
M:CCVJ#[!#_=/_?1_QH^P0_W3_P!]'_&@"?CVHX]J@^P0_P!T_P#?1_QH^P0_
MW3_WT?\ &@"?CVHX]J@^P0_W3_WT?\:/L$/]T_\ ?1_QH GX]J./:H/L$/\
M=/\ WT?\:/L$/]T_]]'_ !H SM3 ^UG_ '157%2ZC:Q+=$!>P_B/^-5OLT7]
MW_QX_P"- $F*,5']FB_N_P#CQ_QH^S1?W?\ QX_XT 28HQ4?V:+^[_X\?\:/
MLT7]W_QX_P"- $F*,5']FB_N_P#CQ_QH^S1?W?\ QX_XT 28HQ4?V:+^[_X\
M?\:/LT7]W_QX_P"- $F*,5']FB_N_P#CQ_QH^S1?W?\ QX_XT 28HQ4?V:+^
M[_X\?\:/LT7]W_QX_P"- $F*,5']FB_N_P#CQ_QH^S1?W?\ QX_XT 28J:Q_
MX^XOK57[-%_=_P#'C_C4]A!&MY$0N"#ZGTH Z"N#^(7Q.D\$ZWH^E6NAW>MW
MNI132HEM)&FU8MF[)=A_?%=Y7D/QM^$^I?$/7?#U_96>DZC!I\5Q'+:ZM++&
MC&0Q[6!C&<C8?SJX6<US;?\  _S/)S6>)IX24L&KU+QMZ<ROT?V;]'Z&KJ'Q
MIM=!LXYM:TJZTM_[(N=7EBD>-FC6*18_+RI(+,77&#CFM;PY\5-"UG3]%DN[
MZTTV_P!5C62WL);J-I&#$A<;202<=N_%</=?!S6K_0TMO+TK3I%\,7^B+;6L
MDC0QR32*8RI89V@+R3SDU%XF^#OBG6=8L&2^L6TVT;3)HX=YC*M;,ID4@)^\
MW8)5F;Y>F.<UNHTWI?K^K_2QX3Q6;4VYJFY*RLK;OEBW=Z/>ZV6KNU9:=YX0
M^+&A>*WGMQ=165_%<W4'V*>5?-802,C. #T^4GZ5;L_B-HNKWVF0Z5J%GJ4-
M[))'YT%U&0I6+S.!G+<=ES@<GBO.=)^"^OPZE:)<R:7'8VFN7^MI<0%OM#F;
MS0D3?+C&),L<] !CBK]A\&+Z'PSX!TEKFWM_[$LKJUO);<D$M-:M#OCXY(9L
M\XK-J%KWU_X#_4Z:.*S27+&=+KJ[6?Q07ILY._9::ZG7ZI\4M"@TC4+O3+ZV
MUB:S^5X+696(;GJ>PX//M5OP1XQ_X2ZR:5[86TJHDF$?>K(V[!!^JM^7H17%
M>"?A#?66IZ?)K\>F-9Z9HHT2*"Q#8NTWJWFR9 VD;!A1G!+'->FZ3HECH4#P
MV-NL".Q=\$EF8]R3DD_6B2A%66O]?T_P.W!SQ]><:M=*$=G'JWW^3TWUM?9E
MZBBBL3W0HHHH **** "BBB@ HHHH **** "BBB@ KRG]I/Q1IOA#P!;7^JW'
MV:U_M"*/?M+?,4? X^AKU:OFC_@H%_R0JW_[#-M_Z!+5PCS229YV8XF6$P=7
M$05W%-J_D<#I'Q_\"Q%=VM ?]L7_ ,*[C2OVCOA_&HW:X!_VPD_PKX2\%^%[
MOQ7=W$-K+;P"VMVNII;J811I&I )+'CJPK=NO#EQIEX+:*XMM3/EB0R:=*)T
M .>"5S@\=*])86G>US\>J\:YO"G[6-&'+WM+_P"2/N^#]I?X=@<Z\/\ OQ)_
M\35D?M,_#K'_ "'U_P"_$G_Q-?#-QX8U&QT/3M6DA)LKX2F)T.[ C?8VX#[O
M/K5.2SN8HA(\,J1G&&92!S[UHL'3>S9YM3Q S>F[2HP6B>TMFKI_%V/O/_AI
MGX=?]!]?^_$G_P 31_PTS\.O^@^O_?B3_P")KXB\+^$+_P 5ZI/8VS0V\EO;
MR7,SWDHA2.-!EF9FZ8%7=8^'FJ:*T33S6<EI/;RW$%[!=))!,(Q\ZHX."PX&
MWKR/6I>$I)V<C6''6>3I^UCAX..U[2\O[WFOO/M#_AIGX=?]!]?^_$G_ ,31
M_P -,_#K_H/K_P!^)/\ XFO@U[*YC:-6AE5I/N H06^GK2K87;3-"+>8RJ,E
M AW#\*KZE3[LYO\ B(>;?\^8?=+_ .2/O'_AIGX=?]!]?^_$G_Q-'_#3/PZ_
MZ#Z_]^)/_B:^"Q:W!B>412&-#AGVG /N:)+:>&-)'CD2-_NLRD!OH>]'U*GW
M8O\ B(F:_P#/J'W2_P#DC[T_X:9^'7_0?7_OQ)_\31_PTS\.O^@^O_?B3_XF
MO@;)]31D^II_48=V3_Q$;-/^?4/NE_\ )'WS_P -,_#K_H/K_P!^)/\ XFC_
M (:9^'7_ $'U_P"_$G_Q-? V3ZFC)]31]1AW8?\ $1LT_P"?4/NE_P#)'WS_
M ,-,_#K_ *#Z_P#?B3_XFC_AIGX=?]!]?^_$G_Q-? V3ZFC)]31]1AW8?\1&
MS3_GU#[I?_)'WS_PTS\.O^@^O_?B3_XFC_AIGX=?]!]?^_$G_P 37P-D^IHR
M?4T?48=V'_$1LT_Y]0^Z7_R1]]Q?M-_#F.5&.OC 8$_N)/\ XFM3_AJ_X9_]
M!\_^ TG_ ,37YX9/J:,GU-'U*GW8GXBYKTIP^Z7_ ,D?H?\ \-7_  S_ .@^
M?_ :3_XFC_AJ_P"&?_0?/_@-)_\ $U^>&3ZFC)]33^I4^[%_Q$7-?^?</NE_
M\D?H?_PU?\,_^@^?_ :3_P")H_X:O^&?_0?/_@-)_P#$U^>&3ZFC)]31]2I]
MV'_$1<U_Y]P^Z7_R1^A__#5_PS_Z#Y_\!I/_ (FC_AJ_X9_]!\_^ TG_ ,37
MYX9/J:,GU-'U*GW8?\1%S7_GW#[I?_)'Z'_\-7_#/_H/G_P&D_\ B:/^&K_A
MG_T'S_X#2?\ Q-?GAD^IHR?4T?4J?=A_Q$7-?^?</NE_\D?H?_PU?\,_^@^?
M_ :3_P")H_X:O^&?_0?/_@-)_P#$U^>&3ZFC)]31]2I]V'_$1<U_Y]P^Z7_R
M1^A__#5_PS_Z#Y_\!I/_ (FC_AJ_X9_]!\_^ TG_ ,37YX9/J:,GU-'U*GW8
M?\1%S7_GW#[I?_)'Z'_\-7_#/_H/G_P&D_\ B:/^&K_AG_T'S_X#2?\ Q-?G
MAD^IHR?4T?4J?=A_Q$7-?^?</NE_\D?H?_PU?\,_^@^?_ :3_P")JC??M0_#
M>YE#)KXP!CFWD'_LM?G]D^IHR?4TOJ5/NQKQ%S7_ )]P^Z7_ ,D??/\ PTS\
M.O\ H/K_ -^)/_B:/^&F?AU_T'U_[\2?_$U\#9/J:,GU-'U&'=C_ .(C9I_S
MZA]TO_DC[Y_X:9^'7_0?7_OQ)_\ $T?\-,_#K_H/K_WXD_\ B:^!LGU-&3ZF
MCZC#NP_XB-FG_/J'W2_^2/OG_AIGX=?]!]?^_$G_ ,31_P -,_#K_H/K_P!^
M)/\ XFO@;)]31D^IH^HP[L/^(C9I_P ^H?=+_P"2/OG_ (:9^'7_ $'U_P"_
M$G_Q-'_#3/PZ_P"@^O\ WXD_^)KX&R?4T9/J:/J,.[#_ (B-FG_/J'W2_P#D
MC[Y_X:9^'7_0?7_OQ)_\31_PTS\.O^@^O_?B3_XFO@;)]31D^IH^HP[L/^(C
M9I_SZA]TO_DC[Y_X:9^'7_0?7_OQ)_\ $T?\-,_#K_H/K_WXD_\ B:^!LGU-
M&3ZFCZC#NP_XB-FG_/J'W2_^2/OG_AIGX=?]!]?^_$G_ ,31_P -,_#K_H/K
M_P!^)/\ XFO@;)]31D^IH^HP[L/^(C9I_P ^H?=+_P"2/T LOVH/AQ;S[WU\
M8P1Q;R'_ -EJ_P#\-7_#/_H/G_P&D_\ B:_/#)]31D^IH^I4^[$_$7->E.'W
M2_\ DC]#_P#AJ_X9_P#0?/\ X#2?_$T?\-7_  S_ .@^?_ :3_XFOSPR?4T9
M/J:?U*GW8O\ B(N:_P#/N'W2_P#DC]#_ /AJ_P"&?_0?/_@-)_\ $T?\-7_#
M/_H/G_P&D_\ B:_/#)]31D^IH^I4^[#_ (B+FO\ S[A]TO\ Y(_0_P#X:O\
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MM_/SGUV=O7BI^J4OYO,WCQWG<K<N'COR[2^+M\6Y]J?\-,_#K_H/K_WXD_\
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M?$;_ *%2_P#^^1_C1[6'\R#^Q\Q_Z!Y_^ O_ "/-:*]*_P"&<OB-_P!"I?\
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M*E__ -\C_&CVL/YD']CYC_T#S_\  7_D>:T5Z5_PSE\1O^A4O_\ OD?XT?\
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MSY/W7.W!Z&N?_P"&>OB'_P!"O??]\C_&C_AGKXAC_F5[[_OD?XT_W337-O\
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M^1_C5-4G?WNM^GG_ )F,9YPG%O"2?*HK6,_L\MGOI\*VT>I3\4SJ/ACX1@F
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MC[+!_P \8_\ OD4 .WQ_WE_.C?'_ 'E_.F_98/\ GC'_ -\BC[+!_P \8_\
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M7 N+)[M'BE7Y-DEP\J,#GKAP".V*XRO=O^&1?$__ $$]-_[Z;_"C_AD7Q/\
M]!/3?^^F_P *N-2E%63,*F#Q=27-*&IX317NW_#(OB?_ *">F_\ ?3?X4?\
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MO_/Q:?\ ?9_PHYX]Q_5ZO\IY\&I';YA]*]#'P-UW_GXM/^^S_A5>Y^"^M0R
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MJG8YQ7IZO71#X>:C_P ]8/\ OHTH^'VH_P#/6#_OHTN9=RO93[& &IX>M\>
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MTJD$85:L 1=Q9]:EO0N*=S<:14^\P7ZFF^?'_?7\Z5XDD(+(K$>HS2?9XO\
MGDG_ 'R*@W#SX_[Z_G1Y\?\ ?7\Z/L\7_/)/^^11]GB_YY)_WR* #SX_[Z_G
M1Y\?]]?SH^SQ?\\D_P"^11]GB_YY)_WR* #SX_[Z_G1Y\?\ ?7\Z/L\7_/)/
M^^11]GB_YY)_WR* #SX_[Z_G1Y\?]]?SH^SQ?\\D_P"^11]GB_YY)_WR* #S
MX_[Z_G1Y\?\ ?7\Z/L\7_/)/^^11]GB_YY)_WR* #SX_[Z_G1Y\?]]?SH^SQ
M?\\D_P"^11]GB_YY)_WR* #SX_[Z_G1Y\?\ ?7\Z/L\7_/)/^^11]GB_YY)_
MWR* #SX_[Z_G1Y\?]]?SH^SQ?\\D_P"^11]GB_YY)_WR* #SX_[Z_G1Y\?\
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M#\Z/*3^XO_?(H\I/[B_]\B@ \U/[P_.CS4_O#\Z/*3^XO_?(H\I/[B_]\B@
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M^\/SH\I/[B_]\BCRD_N+_P!\B@ \U/[P_.CS4_O#\Z/*3^XO_?(H\I/[B_\
M?(H /-3^\/SH\U/[P_.CRD_N+_WR*/*3^XO_ 'R* #S4_O#\Z/-3^\/SH\I/
M[B_]\BCRD_N+_P!\B@ \U/[P_.CS4_O#\Z/*3^XO_?(H\I/[B_\ ?(H M:9*
M@NN77[I[UK^?'_?7\ZR-,AC-US&A^4_PBM?[/%_SR3_OD4 'GQ_WU_.CSX_[
MZ_G1]GB_YY)_WR*/L\7_ #R3_OD4 'GQ_P!]?SH\^/\ OK^='V>+_GDG_?(H
M^SQ?\\D_[Y% !Y\?]]?SH\^/^^OYT?9XO^>2?]\BC[/%_P \D_[Y% !Y\?\
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MP_\ -^#%_9N)_E_%'@=%>^?\,RV__0<E_P"_(H_X9EM_^@Y+_P!^11]>P_\
M-^##^S<3_+^*/ Z*]\_X9EM_^@Y+_P!^11_PS+;_ /0<E_[\BCZ]A_YOP8?V
M;B?Y?Q1X'6GX<T[^U-:M8",H6W/_ +HY->QO^S(-QV:Y\O;=#S6KX<^ 7_"/
MW,LXU59W=-@S%C:,\_TH>.H6TE^8XY=B;ZQ_(QZ5>M=O_P *PE_Y_D_[X-+_
M ,*QE'_+\G_?!K#ZW1_F.WZI7_E.)H'6NXC^%\LDBK]O0;B!]PU>'P<G'_,2
M3_OV:/K='^8/JE?^4\[HKT7_ (4[/_T$4_[]FC_A3L__ $$4_P"_9H^MT?YA
MK"5OY3SQ:6O0_P#A3TX_YB*?]^S1_P *?G_Z"*?]\&I^M4?YA_5*W\IYZO6G
M5Z"/A!./^8@G_?!I?^%0S_\ 003_ +X-'UJC_,/ZK6_E//QTIXZ5WP^$4P'_
M "$$_P"^#2_\*DG_ .@@G_?!J?K5'^8?U6M_*<'2KUKO?^%33?\ 003_ +X-
M*/A/,/\ F()_WP:/K-'^8?U6M_*<&O6G5W8^%$P_Y?T_[X-+_P *JF_Y_P!/
M^^#4_6:7\P_JU7^4X:GK7<?\*KF_Y_T_[X-*/A=,/^7Y/^^#2^LTNY7U:KV.
M)'6I!TKM!\+Y1_R_)_WP:KW/P_DM7"&\4Y&?NFE]8I=REAJO8Y5>E/'2NC'@
MEQ_R]+_WS3AX+<?\O2_]\U/UBEW&L/4['.CI4BUT \&L/^7E?^^:</"##_EY
M7_OFI]O3[E^PJ=C"7M3QUK<'A-Q_R\K_ -\TH\*N/^7A?^^:3KT^XU0J=C%7
MK3UZ5LCPNP_Y>%_[YIP\,L/^6Z_E4^WI]RE1J=C(3I3UZUK#PXP_Y;C\J</#
MS#_EL/RJ'6AW*]C/L9B]JD6M$:"P/^N'Y4X:&P_Y:C\J7MH=RU2GV,]>E/'2
MKXT4C_EJ/RIPT@_\]1^53[6'<?LI]BDM25H6NAM<2[!*!QG.*N_\(N__ #W7
M\JGVD>X_9R[&,M/6M<>&7'_+<?E3AX;<?\MA^5+VD>Y2IR[&2O2GCI6J/#K#
M_EL/RIW_  C[?\]1^5)SCW*4)=C+IXZUI?V"W_/4?E3O[#;_ )ZC\JGGB4H2
M,]>E/6KXT9A_RT'Y4X:.P_Y:#\JGF0^5E$=*>.E7/[*8?\M!^5._LP_WQ^5)
MR17*RH.E*O6K?]FG^^/RI1IQ'\8_*ES(.5E4=:=5G^SS_?'Y4OV$_P!X4FT5
M9E<=*4=:9<O]FEV8W<9S4?VL?W#^=*Z"S+5.JI]M']P_G2_;A_<-%T%F7:5:
MI?V@/[A_.E&H@?P'\ZFY5B]0.M4O[2'_ #S/YT?VD/\ GF?SHN%B_15'^U!_
MSS/YT?VH/^>9_.BX6+Z]:=6>-4 _Y9G\Z7^U1_SS/YT@L7Z*H?VJ/^>9_.C^
MU1_SS/YTAF@.M.K-_M8#_EF?SI?[7'_/,_G0!HU4NO\ CZM?]X_RJ'^UQ_SS
M/YTT7GVNZM_EV[6/\J!EZ6XCA(#M@FF?;H/[_P"AJ? -&!Z"@"#[?!_?_0T?
M;X/[_P"AJ? ]!1@>@H @^WP?W_T-'V^#^_\ H:GP/048'H* (/M\']_]#1]N
M@_O_ *&I\#T%&!Z"@"#[?!_?_0T?;X/[_P"AJ? ]!1@>@H @^WP?W_T-'V^#
M^_\ H:GP/048'H* (/M\']_]#1]O@_O_ *&I\#T%&!Z"@"#[?!_?_0T?;X/[
M_P"AJ? ]!1@>@H @^WP?W_T-'V^#^_\ H:GP/048'H* (/M\']_]#1]O@_O_
M *&I\#T%&!Z"@"#[?!_?_0T?;X/[_P"AJ? ]!1@>@H @^WP?W_T-5-3O86MP
M _\ $.U:6!Z"J>J@"V' ^\/ZT 8GVF+^^*/M,7]\5+^ H_ 4 1?:8O[XH^TQ
M?WQ4OX"C\!0!%]IB_OBC[3%_?%2_@*/P% $7VF+^^*/M,7]\5+^ H_ 4 1?:
M8O[XH^TQ?WQ4OX"C\!0!%]IB_OBC[3%_?%2_@*/P% $7VF+^^*/M,7]\5+^
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M/M,7]\5+^ H_ 4 1?:8O[XH^TQ?WQ4OX"C\!0!%]IB_OBC[3%_?%2_@*/P%
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MHH **** "BBB@ HHHH **** ,?4_^/L_[HJI5O4_^/L_[HJI0 4444 %%%%
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M%%% !1110 4444 %3V7_ !]Q?6H*GLO^/N+ZT ;E%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 54U-6:W&T$G<.E6Z* .?\
M+E_NO1Y<O]UZZ"B@#G_+E_NO1Y<O]UZZ"B@#G_+E_NO1Y<O]UZZ"B@#G_+E_
MNO1Y<O\ =>N@HH Y_P J7^X]'DR?\\V_*N@HH Y_R9/^>;?E1Y,G_/-ORKH*
M* .?\F3_ )YM^5'DR?\ /-ORKH** .?\F3_GFWY4>3)_SS;\JZ"B@#G_ "9/
M^>;?E1Y,G_/-ORKH** ,*WB<3QDHP&X=O>MVBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *R]4C9IU*J2-O85J44 <_Y,G_/-ORH\F3_GFWY5T%%
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6R9/^>;?E4UG$XNHR48#/4BMJB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20231231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20231231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $G \L# 2(  A$! Q$!_\0
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MR/%/_0?U#_O^U<WBC%'LX=D'M:G\S^\Z3_A9'BG_ *#^H?\ ?]J/^%D>*?\
MH/ZA_P!_VKF\48H]G#L@]K4_F?WG2?\ "R/%/_0?U#_O^U'_  LCQ3_T']0_
M[_M7-XHI>SAV0>UG_,_O.D'Q(\4@_P#(?U#_ +_M7Z3_  >_T_X8>&KBY'G3
MR64;/(_+,<=2:_+4=1]:_4OX)_\ ))_"O_7A'_*O$S6,5"+2ZGT632E*I*[Z
M'8?8X/\ GDG_ 'S1]C@_YY)_WS4]%?-GUI!]C@_YY)_WS1]C@_YY)_WS4]%
M$'V.#_GDG_?-'V.#_GDG_?-3T4 0?8X/^>2?]\T?8X/^>2?]\U/10!!]C@_Y
MY)_WS1]C@_YY)_WS4]% $'V.#_GDG_?-'V.#_GDG_?-3T4 0?8X/^>2?]\T?
M8X/^>2?]\U/10!!]C@_YY)_WS1]C@_YY)_WS4]% $'V.#_GDG_?-'V.#_GDG
M_?-3T4 0?8X/^>2?]\T?8X/^>2?]\U/10!!]C@_YY)_WS1]C@_YY)_WS4]%
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M<'_/)/\ OFC['!_SR3_OFILXHS0!#]C@_P">2?\ ?-'V.#_GDG_?-39'K2T
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M*!/#:6>H6ZS1.N&21<@UC>)_@==:->MK'@N]?3[L'<;4-A6]A7L=A9K:0A0
M,"K)3-?H%"I.BK1?R/I)8>$XI2W[GB_A7XYS:=>KI/C*T?3;Q?E^T%<(Q]37
ML-E>P7]ND]M*D\3C*O&V0:R/%G@;1_&=DUOJ=HDW'RR 8=3Z@UXY<^$/&/P<
MN7N_#]P^KZ*#N>T?DJ/I_45U\M*OK'W7VZ&'-6P_QKFCWZGT$#FEKSSP)\9]
M%\8A;=V_L_4AP]M.<<^QKT$,",UR3A*F[25CMIU(58\T'=#J*;NIU0:A12&C
M- 'GOQK_ .1>T[WU"'^9KD/B;,CZEH"9;>J#&.G:NM^-<R)H>DHV=TFI1!0/
M7FO/_'-W]J\1Z8N<[ %KUL'&^I\IG$DDUWL>C_"8_P"A:F/2YQ^@KOJ\]^$T
MRF#6(P076ZR1_P !%>@YKAQ'\5GMX'_=H>@M%%%<R/0"BBBF 4444 %%%% !
M2'J*6FD\]* .5^)G_(HW'_72/_T,5ROC:53I>D1D9( QS73_ !/F$7A20$$E
MYHD 'KN%<1XONO,;3DS]P#BN_#*[1X&9.R:[H[#X?'_2M2'8%/Y5VU<+\/YE
M_M'4XL_/A&Q[8Q7=5AB/XC/1P3O0C8****YSN"BBB@ HHHH **3F@YH 6BBB
M@ KB_B;_ ,@_3?\ K[7^M=GG@\5QGQ+8?8]+4][M<?D:N'Q(PK_PY&#XZD']
MJZ4 V"J 8KI_AVV[3+O/:Y<?RKBO%UR)_$-F.R@"NR^'!']F7OM=/_2O0K1M
M11X.$:EC),ZZBFDTZO,/I0HHHH **** "BBB@ HHHH **** &R?<;Z&JUA_Q
MZ1_3^M69/N-]#5:P_P"/2/Z?UH _,;X^?\E?\4?]?;?TK@*[_P"/G_)7_%'_
M %]M_2N K[RC_#CZ(_-:_P#%EZLGM+^YL&9K:XD@8C!,;E<CT.*<=4O#="X-
MU-]H'24N=P_K7HOP&?P[?>+;;1=>\/IK U"98XYGE*&$=^!UKU#P+X6\(>.O
MB!XJL;3P?;1IH]HXAM)+ME2:0/@$L?NUG4K1I3=X[(UHT)58KEGNSYMN]7O;
MV/R[B[GG3.=LDA(S^-0RWEQ,(_,FD?RQA-S$[?I7T#\5?A/I,>L>$M+LM)AT
M+7M1GV7&FVUSYZ+&3P^[Z5I>.?@_X:C\4^%)]&TV6'2)-0_LR^BD#+O=2!NY
M[-S6<<53LM-[FDL'5O)7VL?.LNO:E+&8WO[ED(P5:5B#2#7M2\KROM]QY>,;
M?-;&/3%?1OB?X(^'=*U/QG>VEOYVB1V)ELGR?]'F5]KI]14LOPP\(WGP^\_2
M-"_M:/\ L_SFU2SNPUS'-C)#0]=M3]9I6O8OZG53LWW/FF+4[R*W,"7,J0MU
MC60[3^%1&YE,/DF1C$#G83QGUQ7T)X<\">'/#]GX;TR?PG<>+==UF W+^7,8
MS#'GHHXR16MX#^$6D27OC99?"@NKBPGC%KI^JW0MS$K=F8' XJY8F"NTMO0A
M82H[*_E^I\S0WD]NFV*:2-<AMJMCGL?_ *]2#4KP$$74V0V\'>>&]?K7TKX>
M^&/AK7?&7BBPUG0;70X[338Y(TM+S[0D4C' ?<./PIN@?!+1+,^%+/5=.\RZ
MN'O4N7+$>8$7*'^7YT/%4]VA_4JB5D]#YPFUW4;A0LE_<2+D$!I21D=ZA&HW
M0:5A<RAI1ASN/S#W]:]RNM(\"_"_1M&_M_P_+KESJX>9YA,4\B/<0 @[FO+=
M(T*Q\6?$.TTK3#)!I][>+%#YWWU0GO[XK2%2,V[1T,)TITVKRU_S.<^T2^1Y
M(E?RL[MF[Y<^N*;#/);2+)$[1R*<AD."*]G^(%Y\.='?6O#-MX=NK?4+!O(@
MU(2DM+(O!+J> #7I'B7X6Z+HOA2SN;#P5IE]$^E1W,E[/J@BE#E,L1&3DX/Y
MUF\3&*3Y=_0UC@Y2;2EMON?*TNI7<\ZSR7,CS+]UV<EA]#4#R-(Y=V+N>K,>
M2:]&^*?A?3- \+^"+RQMA;S:C9/-<').]MY _2D^)?A73M \(^#+RRM_(N+^
MS,MPW/SMG&:VC4CI;J[&$J,];]%<\X]@.:.U>B_!_P +:;XEB\4?VC;^?]DT
MN2>')(VN.AJ?X,^$],\4)XH.I6PN#::<\\.3C:X/!XJI5%&]^GZDPHN?+;K?
M\#S/H?S[T'V_.OJ^_P#@/X8F\1^&)K"UWV?V-#J=H&/#-&61_H:;X6^%.C/X
M"T_4+;PC8:U=S7$Z2M>ZA]FVJK?+C/6N7Z[3M>QU_P!GU.Y\I#GIS17TA\-O
M WA/6H=:>;0[/4=:2^,1TB2_$8AA]8V/#GM7B_Q,T*W\-^-]5T^UM+FQMHI2
M([>['[R,>A]?K6T*ZG/D1A4PTJ<.>^FQR]%%%=1QBCJ/K7ZF?!/_ ))-X5_Z
M\(_Y5^68ZCZU^IGP3_Y)-X5_Z\(_Y5X6:_PX^I])DG\2?H=M1117S)]>%%%%
M !1110 4444 %<MXC^'FF^)M6AU"Z:=9HU5,1OA6"MN&1CUKJ:Y/X@^(M0T"
MUT]=.$7GW=TL&Z5=P4'OBFKWT)>QCWOP0T&_U-KR:>]9RTCA/-^4%QANU6=0
M^$6C7_GAIKJ,3LK2!''.%"CMQTK@;SX[ZC'#8[!;+<LZPSP[>I9RFX$GVSP#
M3=*^,^IZ/H]RNH7-K=721>9&S_*78S[-F/8<UNHU+;F#=.]K'?-\'-$ ?R9;
MRW:0.KO'+@LC ;E/'3BK%O\ "G1+:..*-9TC28S*N_@$IL(^F*\^U3XUZSI?
MAM-2EDM//=)9TMA$>8T;;@MFMC2/B#J%KX*UK63_ *1,+\)&)#E85?;U_P!D
M9_2DU-)NX)P;22.@O/@SHEV8V\V[B9(8X0R2 ?*@(&1C'>JT7P*\.Q010[[I
MH8T2,H9>'"DD9X_VC7/>)_C+>>'UMDBO-/U&5=AE, ^20,^WAL\'V&:JVOQN
MU V_G7#V;).TR!8E):V*.%7>/?/?%-*IW%>GM8[>U^$6BVU_:7K2W5Q<6K P
MO++G8H! 7ITYJY<_#?3)]%L-.CENK>.QD,L$L4F'5CG/./<UY):_&/6M0UB.
M[%Y:VZVUM<A[=S\MT4<8"C^\0:0_%'6+OQ5'L#0K)(L0@+$A27'./;-/EF[7
M8N>"O9'HJ?!#04MK:V,]ZT-NA15,@YSGDG&3UIU_\&]&?29;6$2LQE\]!-(=
MN\)L&<=L"N1\ _%7799=#T34#%?:AJ/[V.Y5<?N@Q$@;W&*O>-OBCJ]A>ZQ9
MVGD0F"4VD<)4F8@IN\X#^Z*EJHG:Y2=-J]C?\$?#>XTBTUY-8NS=/JBI$RHY
M;9&JE0 Q [&K47P>T%;);64W$\0F$W[R3JP0H,\=,&N2US6=<T3X<^$9X-5V
M3W,BBZN)!DR!HV/4GCFL>S^+_B/0].TZPN$@O+FY2%EO'.Q8E?/WRQP3QQ5-
M3E=IDW@K)KS/7?"?@BR\'Q/%:2S2(0% F8':HZ 8 KHZPO!NL7FN>'K6\OHH
MH;F0'>L+AT^H(]:W:YY7OJ=$;6T"BBBD6%%%% !1110 4444 %%%% #&17&"
M,UG7>@V]YPZ _6M/%+4V3W$U<PK3PI:6C%EC&36M!:I  %7%38HHY4MA));"
MT44510F*:R[L@@$'L:?10!YOX\^"FC^+2;NU']F:H.5N(. 3[@5Y_#X^\8_!
MV;[#XDM3JFF?=BNU.3[<_P!#7T/M%<KX]\!6GC[38[&^GFA@1]^(CC)]Z[:5
M?:%76)Y];#-WG0TE^!A?"#XII\0[*Y6<+#?PN28AW3/!KTBO*?"/P(M/!6OP
M:GINJW",GWHV *N/0UZJ#VK*O[/GO2>AMAO:\EJVX4A-*QP*Y?XB>+8O!WAB
MYO7E5)F'E0 \EI&X Q7.[=3><E!.4MD<)XZ\2IXG\;P:+!$6MM+82S3GH9"/
MNCZ"N-O?*U7Q6=\ZPK$?E+<Y]JV?!GEZ;H%]?7,@NKN8,[3OU9SR:\PNM95;
MF6YR28WSP1FO4HXS"4ERRJ+3S/SK,L6JCYF]V>L^"?$(\/>/)(+B58K2_7:&
M/3>.E>X#D9'2OESQ!>1ZUX>MKR)&W1@-N0?,#V->U_"#QY%X[\)Q3@%;FV/V
M>=3_ 'E[_C6&*=.;4X23N?09/BU)/#R>VJ.Z' I:2O-OBA\5;[P!>VD-KHSZ
MDLZ%BZ[OEQ]!7+"#J/ECN?1U*D:4>:1Z517S]_PTKK/_ $*<W_C_ /A1_P -
M*ZS_ -"G-_X__A75]3K=OQ.3Z]0[_@SZ!I"<5\__ /#2NL_]"G-_X_\ X52U
MG]HS6KS2[F!?#<UHSH5$X+#9QUZ4U@JSTL)X^BE>_P"!]&@YI:^:/A=\=O$<
MUU#IUU82ZXAP-\(_>#ZU])V\K30H[(8V8 E&ZCVK&M0G0=I&]#$0Q"O$DII)
MS2GI6;KNK1Z-IDUS*3\HPH'J>E<]TMSHE)17,]D<9XZU6;4=>M=(BAS;0XGF
MD/=NRC^=<IK#P7>NK'++Y<49X-;>AW:I!<ZA._F%]WSR]2:\\U#58Y;N>3<I
MPV1\W7GM793Q>&HKEE-'Q>.Q"G[S>_Y'<6.KCP[XIM;II"MI,!'(<<8[5Z]'
M*LJ*R$,I&01W%>"2WBZYX<0[.5!R,\^]=[\(_%K:[I$MC,FRYL"(CDYW+V-1
M7G2J)3A*YZF6XE-NE?T/0:*04$XKF/HA:*\F^+GQ1USP-JMI;:9IPO(Y8][,
M8V;!S[5P7_#17B__ * (_P"_+_X5V0PM2I'F5C@J8VG2ERRO?T/I:BOFG_AH
MKQ?_ - $?]^7_P */^&BO&'_ $ 1_P!^7_PJ_J57R^\S_M"CY_<?2A.,]O<T
M Y]Z^8-6_:!\6WNG7,#Z1]G$D94RK$X*>^<4_P"%GQI\52WD.GO8RZ[$2%RH
M^=1]>GYTW@:BBY=A+,:3FH)/7R/IZBH;>5Y88W>,Q.R@E#U!]*D;]*\\]3<.
MN:X;QQ>P7^K6%@IW2POYK@?P_6NLU?4X](TZ>[D("QKD GJ>PKSC2F$\-_JE
MV/\ 2)<ME>0/05M223YY.UCS,;6Y(J">K_(QKQ)-1\0YC8$1'DL>V:ZOP!J@
MM-:OM.DR!,?.3TSWKS)]3,=XT^\@*V"1TK=U741;"SU2S?9)'R7'?VKTIRIU
M8\JDCYG#XCV=5U%W/<NII169X=UJ#7])M[VWD#I(O..Q[UI@Y%>/MH?;QDI)
M2746BBB@H**** "BBB@ HHHH **** &R?<;Z&JUA_P >D?T_K5F3[C?0U6L/
M^/2/Z?UH _,;X^?\E?\ %'_7VW]*X"N_^/G_ "5_Q1_U]M_2N K[RC_#CZ(_
M-:_\65N[-OP7XG?P;XHT_6HXA.]G)Y@C8\-[5T&A_%2YT*^\6W4=LN[7X'@<
MAB/)W-NR#3?AA\+I_B5+J>S4;?3(=/A\Z6:YSM"YQVK6M_@;<:IXI;2M*UNP
MU"WA@^TW.H(Q$,">K$U-25/F:EV*IQKJ*E#N:&A_M"76FPZ-/=Z7%?ZQI,+P
M6NH2-\X5AA<^N*FTS]IWQ$;5H=>5=:"7,=S"TN%,3*<\8]:SM2^ .H6UYI L
M=6L=5T[4;D6JWUJVY(Y#V8=JM>*OV>;OP]I&JWMKKVGZM)I7-U;6Y.^,9P>M
M<]L-VW.I/%ZV>B(K;]H/5+?3_%ED;2-[;7I#-L8_ZAB>=M7[+]HTZ?IKF#PU
M80ZXUJ;0ZC$"A*D8)*C@G%<E\,OA7-\1TU29=3MM*M]/C626:YSC!..WX5U4
M'[-&IOXA;3VUFQ2T^PF_2_R3&T8.#3G'#Q;C+<FG/%32E%W3_P RMX5^/\FC
MZ596FJZ';:S-IY)L[IW9)(LG.,@\C/:I],_:)E:[\0S:[HEOJ\6LR(TD)<HJ
M;?N@8K-U_P" 6K6%QHRZ5?VNN0ZK,;>">U8[0XZ@Y]*E\2? "_T72+V]LM9T
M_6); ?Z9;6DF9(?7/KBAK#/Y@GBEIV]".7XS6EI)K8TCP[!I4.IV0M'C20G8
M<YW9-:D'[2NI^5X:^TV$5Q+HL,D(D+8,H==N3[BC_AFN\>SM-GB+36U2YM%N
MXM-9L2NK+N 'OBN*U+X9W^E:'HFHSRHO]IW3VJQ<[HV4X.:(QP\M%N#GBHKF
MZ'5:!\>4L]+MK36?#=CKKV+L]E-<CYHLG.#Z@'M7GMQXINYO%+:["$M+O[1]
MH18%VJC9R !Z5W-K\ =5E\1:MI\^H6EE9:4J-<ZE.VV)2P! ]SSTJS;?L_O+
MXHBT:3Q-I4?VE%>TG\S<D^XX &.A^M:*5&-VB)1Q$TDP\2_'B'Q#I=\!X5TR
MWUC4$"76I!,LQ[D ]":NZK\?-)U_3;:+5/!UM>7EO:):+<O,P.%7 ./6JFJ_
ML]S6&L7NFVWB&PO[JRMY9[A8<DQ[.JGW-)H_[.NI7VF6$UYK6G:5?7Z>9:6%
MS)B653T^F:RMA[?\.:IXI2_X8?%\;]%NO#6EZ5J_@VTU1M.A:"":60@JI.:?
M_P +QT2[\/V&F:IX+L]1^PQM%!*\A!12<CIZ5CM\!O$$?@W5M?8(%TNZ-K<6
MW_+1<=6'J.:YOQQX%NO!.IVEC<2I/+<V\=PIC'9QD#ZU<8T9.T?S,Y3Q$5>7
MY&K\-_B5#X UO5+LZ3%?V=_"T#VCL0H1CG%;J_&K3--EOFT3PI:Z0MY9O:2+
M%(3G)^]S5FU_9NU6>SA636=.M]:GA\^+2'DQ,RD9 ]CCM5/PS\!9M:\-'6=1
MUZQT*+[2]KY=WD'>O6E)X=MML(K$I62\^A>T[]H_5-+\9+KD-E'L.FII\EJ6
M)5U52H;V-&F?'C3T\-VFD:OX5M]62VEDECDDE9<%R21Q7E&LZ<FE:K=6D=RE
MVD,A03Q_=< ]15.M50I-*R,GBJ\7;F/6?#WQNL-%%Q;3>$["[L/M/VFVB.5>
M ^F\<D5Q'Q \;7?Q"\4W>MWJ)%-/@"./HJ@8 KG:*TC1A%\R6IG.O4G'EDPH
MHHK8YQ1U'UK]3/@G_P DF\*_]>$?\J_+,=1]:_4SX)_\DF\*_P#7A'_*O"S7
M^''U/I,D_B3]#MJ***^9/KPHHHH **** "D-+2&D FZHYH8YPOFQI)M.X;U!
MP?6O!_%^C>,QX@O]0M(I]/M@LXDG68E63 V]_KT'%4/"&@ZMXHUN^GL%U"VT
MJ)F\E;BZ9@)/*&#UY&[\*W5--7N<[J-.UCW2]M=%M9X#<VUG'+*XCA+Q+DMU
M !QUZFIWT+39"I?3[5RIR"T*G!Z\<5X5?> O$5Y/8/-IE_-80&)KFV-S^\DG
M&[?(ISP#D5-J_A?Q[(M@D%O<"ZMVB:.Z2<DJFX[E;)Q]W Z'I3Y/,7-_=/;+
MVPTD+ EU:VF"^R(2Q*1N/89'4U:6PM5@>$6\0B;[T80;6^HKQ&\\!:[J&BV(
MET^\?5K6_CN)KB6Y++*P)^=!G'&1^5,T?X?>*I;:VCO;G4V+7$1O(WD"(^&)
M9E(.2,8I.']X:GK\)[-'I&CWD2,EC:2(F53]POR\\XXXY]*IZ+X8T'1(YM.M
M+6VRV998V569@QSEO49]:\?OO"7C6*TL[:WM+GS()B\4ZW!)5?.)P<G^[ZYK
M;\:>"=8N/';:O:6<\]M/:V\=R8)2C2*A.Y.O!.13Y.G,'-_=/4+C2=&LXTDE
ML;*)%8!2T* *Q/&..N:M_P!FV1DWFU@\P'(?RQD'ZUYCK?@W6=7^%ITZZMY+
MF\2[2>*!I#YBQK)D+NSR0OK7,ZQX(\50>$X+>RLKI]0E65VF^TL7BD+?)_%@
M8%2H\W4;E;H>RQ>$]-AUQ-62W5+I(S$FT85 3DX ]:DU"71[;4K=+M;5;VZR
MD.] 9),#D#C->/V7@3Q8(?M$LNH1W<[S+.\=QEA&4&T 9QUS6=<?#KQ7?PV<
MT=K):WEFMPEO<-,=X# 8)4D@'.:KD_O"<]-(GOTME;3PK#+;Q21(05C= 5&/
M05@WFO>%H[U]-N9['[0I6-H)$''H#QBO/O!O@+78O$.CRZA-J,FF0>;(\-S)
ML"/@;>%/(SGJ:N:[X<U>ZN/%>GQ:1)+_ &K/&T%V2OEH !\Q.<C&*7*D[7#F
ME);'HEGXAT?RBEM>VPCBF%L4C8823LF!T-6;37+&^O[JSM[J*:ZM2!/"C9:/
M/3(KPE/A9XF\/W,%]I\'V@S:J)KZW9\;T4Y64>_'2ND\#>"/$WA_Q?;ZY>QV
MSG4O--^(BV]"S;DW9.#CIQ0X1WN"G*]FCV&EI!TI:Q.@**** "BBB@ HHHH
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M^@J0URSPU*I+F:U/,KY=A\0^:<=3Y6'P'UR53O$D9_VX\_R-+%\!O$$1^24
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M=):6\<+OA%ZECDFO3**TC3C!W2'' 4(NZ1A6GA.TM7B8KN\L?*O;-;03:,
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MQ*<8W-[XK4\,^#]-\(P2PZ=$T:2D,P9LY(&*L>%[Z;4O#]A=7$<D4TL2LZ3
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M_E]_WT*/^&,O"G_/Y??]]"C^TJ'F']D8KLOO/BS!]#2X/H?RK[2_X8R\*?\
M/Y??]]"C_AC+PI_S^7W_ 'T*/[2H>8?V1BNR^\^+<'T-&#Z&OM+_ (8R\*?\
M_E]_WT*/^&,O"G_/Y??]]"C^TJ'F']D8KLOO/BS!]#^5&#Z'\J^T_P#AC+PI
M_P _E]_WT*/^&,O"G_/Y??\ ?0H_M*AYA_9&*[+[SXMP?0_E28/H?RK[3_X8
MR\*?\_E]_P!]"C_AC+PI_P _E]_WT*/[2H>8?V1B>R^\^+1G(X[U^I?P3/\
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MJ4?VQ>_W4H Z#-&:Y_\ MB]_NI1_;%[_ '4H Z#-&:Y_^V+W^ZE']L7O]U*
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M=B_YZO7(=Q0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
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M<-@]\&CEEV#GCW/1/[7'_/,_G1_:P_YYG\ZX"7XF:1;PWEP[O);6Q7=)#$6
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@!1U'UK]3/@G_R2;PK_P!>$?\
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M*Y^M>2P?!_6;CP]#X?O=7M4TF*=Y]UM$RS,Q)*\G@8S7NWV:/^X*/LT?]P4
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M?]P4 8U%;/V>/^X*/L\?]P4 <!K7_(Z^'_\ =F_]!JYK.C223+?Z>WDW\?\
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MBB@ HHHH *;U-.IHZD4 .HHHH **** "BBB@ HHHH **** "BBB@ HHI,^U
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M,\D7]CSR3(B?QEEV\UYW??LO:?>ZW/J3:E(TLDJ2*KKG9M+'C\Z /;%U&U?
M6XB8G@ ."2?2L71_B)X=UZ\N+6QU>UN)X&*R('P5.<=^O(Q7&> ?@+9>"-4@
MO3?37\D ?9YS$_,QSNZ]:JP?LVZ!"L#LSM=)<R3O<#AG#%CLX[ MF@#U@:A:
MGI<1'G'#CKZ5+%-'.@:-UD4]&4@@UXI9?LVP6,*)'K-SN6=I?,9B201C!Y]^
MM>E> /";>"O#EMI)NWO1#G$KC!()SB@#I**** "BBB@ HHHH **** "BBB@
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M1'3KD2VR[IE,1S&/4CL*=8>&M6U6)9+/3KFZC=]BO%$6#-Z#'>N=X>E?FO\
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M!6A']P5#4T?W!2;OJ-:'YB?%7_DI/B;_ *_Y?_0C7*5U?Q5_Y*3XF_Z_Y?\
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M_+_Z$:Y05U?Q5_Y*3XF_Z_Y?_0C7*"OT"G\$?0_,*O\ $EZL****LS"BBB@
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MVJ_M&IX_BCT[5-.BT-[C;Y[E-HCW=2N<]*G^)M_^T3;Z^J^&M5L&LG?:LSE
MHZ<E3R17T++\+?"UWX?.MRV;-?>27#&5NOTJW:_"OPOX@TZVU2^M&FN408/F
M,!T]JIXMMW<(]MA>S7<UOAFFO1^ ]%'B>Z@O=>%NOVR>V7$;R=RH]*[C3/\
M43?Y[5A:3;0V>G006Z[($4!%SG K=TS_ %,W^>U<#=W<VV-"#_5)]!4E16_^
MI3Z5+2 **** "BBB@ HHHH BN?\ CWE^AK-TS_CQB^A_G6E<_P#'O+]#6;IG
M_'C%]#_.@#\OOBK_ ,E)\3?]?\O_ *$:Y05U?Q5_Y*3XF_Z_Y?\ T(UR@K]
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MVCW8AF^9(S@\CUKAO@;X!\7>*?%/@;7M4T4Z+H'A^WN&B-Q*#+<2RXP0HZ
M=Z^IM3M+#6+5K>\C2>%OO(XR#4UL;:TA6*+:D:#"J!@ 5Y\,+RXJ6([JQQQP
M\8UW7ZM6+0Z52O+-I[JWE!QY3$D>N15C[5%_?%'VJ+^^*]$[#&;07,<:AERD
MK.3CJ#6S:Q&"WBC/)50":/M47]\4OVJ+^^* ):*16#C(.12T %%1-<1J<%J3
M[5%_?% $U%0_:HO[XH^U1?WQ0!-14/VJ+^^*/M47]\4 345#]JB_OBC[5%_?
M% $U%0_:HO[XI1<QDX#<T 2TC4M(6"C).!0!X;XKT;QQ?^*9WT^WN[>W9YD9
MXY?D9"@V$9/K4-]X-\6V[3V\BZA>Z.T1'D1SYE,C1$9SZ;J]T^U1#^*L'QIX
ML'A;0)]1CMVO&C*@1H#W.,G'85JJC22L82IIW=SCX/!FK2Z'X'M09K&6PR;B
M2,@O%\A'?BN:7P7XKTJ74(PM[=0RW-P\#Q2A&\QF&R1\=L5V^F?%O37L5FOF
M0222&.);,F8R8&20!R,>]2:_\8-$T9;B(/(]ZD32QQ/&5$F!G /KS57FG9HF
MT&MSAO\ A%_&&G&2_FBO=3NC=REX8YSAH_+4+M'8;L]*(/#/B>"SAV1ZM*&A
MD^1I2K173$88\_< XKO_  _\6O#OB"]AL8+Y?MKKDI_#N !90?;-6]3^)>@:
M1]I^TWA7[-,(),(3AR,@?D*?-*_PARQ>O,>67/P]\8WNE7$-U)=3S74=TDZF
MX.TC:#'@=N<U4U[POXVU)XK:UT^\AM/),,B/+E67RP!G)ZY%>S>&?'NC^+ Y
MT^:0E%5RLL91MIZ'![&M[[5%_?%+VC6Z'[-2V97T2WDM=(LHI1MDC@1&'H0H
M!J]4/VJ+^^*/M47]\5B]3=*RL345&MQ&YP&R:DI#"BF/*L8^8XIGVJ+^^* )
MJ*A^UQ?WZ/M4?][]* )J*A%U&.KBC[5%_>% $U%0_:HO[XH^U1?WJ )J*A^U
MQ?WQ1]JB_OB@":BD5@PR#D49H 6HKB+SX9(^@92OYBE>>.,X9@*;]JB_OT <
MWX#\%+X-TN:U+QSR2SO,TBQ[<Y/&:N>)O#C:W%:+"Z0-#.LN2F<@=JV/M47]
M\4?:XO[XH D PH]:X;5?AI8^(O&YU75;*VU"T6V$<:3C<5?/)QTZ5VHNHC_'
M1]JB_O?I0!P7B_X2:/J&EI%I6CV%O=)/'('\O;@*V3R*[^%/+B53V&.*3[5%
M_?%'VJ+^^*0'%>-/A;IOC[Q#97.M6L5[86L3*D,F?OD]?RJG:_!C0]"\3:/J
MFBZ;;V36CL9"H()4C&!7H'VJ+^^*7[5%_?%%@)!TI:A^U1?WQ2BYC8X#C-,"
M'4+=[A5"8X/>LZ33+C:VW /;FMRHFN(U)!;!]* .&UGP7J&KM&3-&A0@COR#
MFDUSP5J.M+;1F:-%B</D]\5W N81_%BE^U1?WA0!R=WH&IW"0A7C&S!.?I2:
MKX:U#48##YB*I(.:ZW[1%_>H%U%V:D!P_P#PAFI#0#IHF3[A3=[&I[+PIJ5E
MI(LUEC8A=H8_2NQ-S%G[U'VF(?Q?I0!A:?HUU!9Q1RE"ZC!(/%:MI;/;12AL
M<^E6/M47]ZG,X>)B#D8I@):_\>Z?2I:KV1W6R9]*L4 %%%% !1110 4444 1
M7/\ Q[R_0UFZ9_QXQ?0_SK2N?^/>7Z&LW3/^/&+Z'^= 'Y??%7_DI/B;_K_E
M_P#0C7*"NK^*O_)2?$W_ %_R_P#H1KE!7Z!3^"/H?F%7^)+U844459F%%%%
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M\JS0R*&1T.0P/0BO--=\+Z_JOP^TG0(F>YEN) MW/?\ !6($DAPOKP.*Y1/
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MY9AV[M/[P_X8B\=_\]]-_P"_U'_#$7CO_GOIO_?ZBBJ_M&OY"_LO#]G]X?\
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M_E2'6H"?NO\ E110 HUR ?P/^0H.MPG^%_RHHH /[<@Q]Q_R%']MP?W7HHH
M/[<@_N/1_;D/]Q_R%%% !_;</]U_R%']N0_W7_(444 ']N0_W'_(4?VY!_<>
MBB@ _MR'^X_Y"C^W(?[C_D*** #^W(?[K_D*/[;@S]Q_R%%% !_;D/\ <?\
M(4?VY#_<?\A110 '6X#_  O^5!UR$_PO^0HHH 0:U ,_*_Y"E_MR'^Z_Y"BB
M@ _MR'^X_P"0H_MR#/W'_(444 ']N0_W'_(4?VW#_=?\A110 ?VW#_=>C^W(
M?[C_ )"BB@ _MR'^X_Y"C^W(?[C_ )"BB@ _MR'^X_Y"C^W(?[C_ )"BB@ _
EMR'^X].&M0G^!_THHH <=2CF1E4-DC'--MI%BA52"<444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>plx-20231231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20231231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 Q@# 2(  A$! Q$!_\0
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M9;3\S_A1_P -!^ /^AEM/S/^%?G/11]2AW8?\1#QW_/J/X_YGZ,?\-!^ /\
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MA]783VEPT6Y4;'RMCH:Z:D8U)W6Z,ES1/SZ\QA+SQ6M:S'R^M7O%GA6X\/\
MB'4+"4;9;>0C##J,]:HPQR+"<JIKA<>67*="ES*XGV@^9C-8$;?:O&#R$Y%O
M%^IJ_-*RS$>6?SK(TJ=5U#47PS2,P'RC.*N*:3:);VN;US?[2>:BM]6_>?>K
M"OKJ5F)V-^598U(PR9;*@>O%<\HOL:\R._N/%*:5:O.[<*.!ZGL*L^!=6>WN
M)-3OL-=W)R$;G8O8"O+FU0:I?B21O]%A/RJ>C-ZU/>>-#ILT<L;;MC!L9]#0
M_<5D1I)W9]J>!M'UCQ!9R7,=LMHD8!7SF,9;Z5T\UYJNA:/]OO+Z;3[42B ,
M)"27[ "N$_9U\>^)/B]X5DOKUHU%O(T$4@3HB@8'U]Z^E8].TRS\/A;R$7RL
MQD9)!O&\\]Z]&E3]Q,YW))VL8&D!(M"AU+5[PDQ2><=YR#]?4UR7CSXD@Z/%
MJUK$3%#>-#&".22!3_$EPFL78CF;R-,CN,/".-PXXK)\6:_I.FVLP$,<=J+@
MR@/T+' !'Y5\_F&84X594Y2?NK9>G<];#864HQDEN^IS'Q-\4>*D7^T-.L93
MK<MTD%M"PP63 P?IS7/>(_'GQ/\ #NN6-A>V7EW<MH64P'>K,.V>U;OCGQZL
M#:?JKR[8HR/F],\5E6GQ1GUV_BM=/<3WDZX@,G3/^%?#YQB/W]*G3HN4I133
MOM=[,^BP.'DZ<ZCMRQ;OIY=#GF_:$\:V^@E]0TJ[B:1_);]V3@]#DUTO@_XY
M:CK%P+6YMY6@2$6[2%" OS#O3/$GQ G\*:?+IVJ0J+B27<Y5=PRPK2\*_%;1
M=2D&G[;?=(BQ[&0*20PP?K7+A7[+'1C54HM/NVKV6EKF]:ESX9U%!--?TSU+
MX?2QZI)XPD+R;$?&Z-MIZ>U=3I.AV#>'=(D>#SG>Y0;YF+L1D]2:YGX>K#;V
MOC.1.(VD/'X5VNDLG]@Z"JG(,RG^=?M4=CX#J=C#"EO&L<2!(UX"J, 4V9]H
MJ16#+D=*J7C80U>XSXS_ &SY/,\=:0?^G,_^A53\ _$KP0OP>_X0_P 4-?+N
MN6F8VJ>^1S7T/XY^ VA?%G4HM0U::YBFMU\I1 ^!C.:YH_L9>#<_\?5__P!_
M:]*-:E[-0DWH?CN-R#-XYI7QN%C&49W5F]TTKW1Q'@'X[?#KX<Z7+IVF6VIM
M"MQYB22#<S@]?I5#Q[^T+H6L^%?%5GIDMW%>:C.LD#;2ORC&037HH_8R\&DX
M^U7^?^NO_P!:E_X8Q\&_\_5__P!_:7-0O=MEO <3>Q]A&,(QLTDM+)Z:'1>'
M-?TR?P39Z_?7D-M,FD&!L72F/[O]W/7->9>&?VK=!T[PI!:WD%['?V2M&D=L
M (YNNTY[5U__  QUX3,?E_;M3\K^[Y_'Y4S_ (8Q\&Y_X^K_ /[^U"='7F;/
M2K4.(FJ?U>$8N*L[N]WIK^!X;9?M#'6M:MD\1Z=&NDQRM*'TY1%<*?X3N')Q
M^M>@ZU^U/X<T^TTR#2[6]UAH;A97GU#!=%'4*?6NQ_X8Q\&_\_6H?]_12?\
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ME>>&I;N&\G-CIQMI'5<;9/7'<5WO_#&/@WC_ $J_S_UU%!_8R\&@_P#'U?\
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MEEU6XAN84N%R-RXW#V%>B_\ #&7@W/\ Q]7_ /W]_P#K4?\ #&/@W_GZO_\
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MT&\T?4HH&O)+B35TO8592 (P0<9[=*]"_P"&,?!O_/UJ'_?T4?\ #&/@W/\
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MH[Y&>#7G\?A_4PRL;%ECVLAVXX]*]N^+9U./]GKP1]ILVL+NSN/*DW$JV0,
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M[XI >I?V99^8[_98-[YW-Y:Y;/7)QWK!D^'.CS:_#J\D<CW$+B2*,L/+C8#
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MEG^)_A:U@BFEUJW2.0LJY#9)49;C&1@4G_"S_"WV5KD:U;^2LB1;OF^\PRH
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M4#V /2LOQ)\(=)UG0I;"TW64K0BW28,253S/,(^N:] HH Y#_A66C?9XEVW
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MK;V%NL<TD6&+INQ\V!QFN9DOC(UG%!;QVZ.ZC ^9OO>IK4U.X$VU&R7A<_\
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MC;7=Q<00S)++;L$F13RA(R ?PH \CA^">JV6F+I]MJEH8)I+>2Y::)BV8G)
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MY5(KR._F48PDSB;>'SV,3MC=,23Z#KFO>/%%M)J-O9:?.TALKRP6..:(9"D
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M&1LVT9DP3_NUQMU8Q1Z;IPCGP_D1$\>YKT?XD>'KJX\&>#EMXOM:QJ[.8B"
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MT\26.K322V:K9["W[MCOWB3![Y'7M6;X?\/:_IGV*W.GZE#X>ACA2[M4+!F
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MO16TV"QCEAD#"5I5RTF6+<_B: /.M'^+^O:IKBZ6\5K UO)<_:9G7DK%&'&
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M^^11]FA_YXQ_]\BIJ* (?LT/_/&/_OD4?9H?^>,?_?(J:B@"#['!_P \(_\
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MUH T\BC(K,_M >M']H#UH T\BC(K,_M >M']H#UH T\BC(K,_M >M']H#UH
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M4 <Y171_\*Z\3?\ 0%N_^^*/^%=>)O\ H"W?_?% '.45T?\ PKKQ-_T!;O\
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M MW_ -\4 <Y171_\*Z\3?] 6[_[XH_X5UXF_Z MW_P!\4 <Y171_\*Z\3?\
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M=>)O^@+=_P#?% '0V_B[1?MT=R[2!E;)W1EOX,?+S@5SN@ZGI]M)?&Z9E,C
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M_P#?% &W_P )I8_99H6D>0X*HPBVC&S:./K6'HNK06^@W-FUZ]E,\RR!EC+
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M3?\ 0%N_^^*/^%=>)O\ H"W?_?% '.45T?\ PKKQ-_T!;O\ [XH_X5UXF_Z
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M0>:L2?"+Q+;WNJM:Z;&L%T\C6ZK?%?L\C%2)/<@ B@#Z!\Z/./,7/3&14E>
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M,1UP:\!N?A)XJM[S4$@B%QI\BLEE%]N*_97.W][UYZ'BM;P)\,?%7AC["3J
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MA/')K;![Z:(F9;4D9=5([?2BP'MN>U+7S#"OB_6?&$,DU_J\*R74/DR*I4-
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M[U#Q!#H]A8VGVF6**437$Y6)0T0D8$^O.!7H,O@3P].]N\FD6C-;@+&3&/E
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M*01NF[YNY/OT%>K?\(+X?\U9/[)M=ZYP=GKUIUQX)T*[""72[9U4*%RG0*,
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M=2*$:7N5'05;HHH 8RB12K ,I&"".#1'&(U"JH50,!5& *?10 4444 %%%%
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M/4YX[4[ >M45YY\//B+J/C;5+VWETV.UMK-0&N%+$2L>A3(Z5Z'2M8 HHHH
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M>M=5X/\ '>D^-XKJ32I)'6W?RW\V,H>>A /:JLOPM\+S1P*VD0@0 +'M)!4
MYQG-:?A_PAI'A=KIM,LTM6N6#RE226(Z=:/46IMT444#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#"O?^/^7\**+W_C^E_"B@#3TU=MC$/:K59J
MW$MK'M"AP.E1MK$R_P#+ ?G0!K45D?VS-_SP'YT?VS-_SP'YT :]%9']LS?\
M\!^=']LS?\\!^= &O161_;,W_/ ?G1_;,W_/ ?G0!KU5OM/MM5LY;2[@CN;:
M5=LD4JAE8>A%4O[9F_YX#\Z/[9F_YX#\Z -"UM(;&WBM[>)88(U")&@PJ@=
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M[<\X_P!D5:/P'T#[/+;?:+S[).=\\'F_+*XSAS[C<:[7^V9O^> _.C^V9O\
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MSH_MF;_G@/SH UZ*R/[9F_YX#\Z/[9F_YX#\Z ->BLC^V9O^> _.C^V9O^>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4B_>%%% %J.E;[IHH
MH @E^[4+=*** &T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
:!1110 4444 *O6I(_O"BB@"S%T-%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>plx-20231231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20231231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %, Q@# 2(  A$! Q$!_\0
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MW%H\SZPVHV\,P;RF5E"E7QS^59VK?LT7%QI&B?9O[,-[9K*LMO(CBW/F')(
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M%%0I<12J"DJ."< JP.3Z4 34444 %%%% !1110 4444 %%%% !1110 4444
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M1G/W3ZUIZI^U'K%CX9N;I-$TTZSIMS-#?6+71(*1XRT1'WN#WH_K\B.MCZ2
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M5*I'>+%&M3E\,D_F;]%1QRI*H9&#*>A!R*?69L+1110 4444 %%%% !1110
M4444 %(:!TKFOB+J5]I7@[4YM+@:XU)HC';H@S\[< GV&<_A2>B!:NQIQ>(=
M,FMVN$O[=X5E\DR+*"H?.-N?7/:I;[5[/2P#=W45N&Z&5@H/.*^3-1\&^)O
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MU#4;"V.G6LMG*J23M]H.#-GG[V?[W&,U,5S),J6A]0SSQVT+2S.L<2#<SL<
M =S6;<>+-&M(TDFU.UBCD.$9Y  W&>/PKQ_X[VE]>2""^749]*;295B6P#9:
M\/3<%]O7BO&M2^&FJ>(U@74=)OIXX+6X$2MN&T_9U"=#UW9I=P['VAINKV6L
M0^=8W45U'_?C;<*LR2+%&SN0JJ,DGH .]?*>EZ#JGA^;3K&XMM3L_":-$+I+
M,.''^CC;C'.-^?QJWXBU+Q#%!J6EVL>MRFYU*&6V,J,6-KY1!W'Z]15M=@7F
M?2MEK=AJ7F?9;N&X\M0S^6X;:",@FK%G>P:A;I/;2I-"_P!UT.0:^=_V?_!\
MVC?\))'>V-U;W5[I< 42;@&PCAAUP#DBN:T+3-4T?0DLO(U>V\BS*Z7'!OPM
MYYIW;N?3'7C%#5G8#ZT/ZT"O!OC!%XGGN/#$<MS<6FFM9-]JEMXW<K=[1MR$
M.?7';-<!XQG\7:=<WD\UYK4GAZ#3B9KG!0M>B+A]O4+CK[U+T386O8^N*!S7
MR7I]IKFO0:)%HLNLOX>NC8?;&G=PS3$9D().=N.N.*N:7I/BI+G4X[G6-4T^
M]C-RDD<%O)*6A_Y9\DXP!C&.>M#7Z_@)._X?B?5-0R7,43QI(ZJSG" G[Q]J
M^49#KIT%$W:F+>TG8QJ!,8KMBG8YW(P/3MDUW7QE_P"$BO\ X?\ A>;3;>]@
MOS$YF2(EI(R8N,MZY[T/17&M78]YQ17DGP=TS5-"\1:O8W!O#IQL;.9#=.SC
MSFC_ 'N">^>M%-JQ-SMM0^'V@:MK/]J76G))?8"F7)&X#ID X/XUS'B[X#^&
MO$\.EQ1V4=@MG=1S,8EQYB(2=IY[D]>M<9K/COQ'H/Q1\0:9#JD0AO+NSM;<
MW,8\NS#1EB_7GICGBMC4/BMK4'PDU;6XWM!JUC?FP%TR_N),2*OF8]"#].*2
MV37D4]VF>@V/P\\.Z<$^SZ5;IB!K;[N<QL<LISUR?6J:_";PJFG260TI%MV<
M/M#MD$=,'.1] :\FF^,_BY?&!\.QSV5P;1+B>6^A@W"X6.(2!5&< YX.*+CX
MX^)M/.C0O/87<FN6\<\4L<>%T\L^TAP#\P ]<<T[-_,6QZU_PJ?PH)[:7^QH
M0UNH6,#(48Z'&<$^YYJ=/AEX:CL[FV32;=(;DQM(H'#%/N$_2O#_  A\8/$6
MD:UX@L-3U2UU)(3J$R76 $W1 %%7G 'L*U_#GQL\1:UI.I:TTEC#;Z9;QE].
M=,2W3-%OW(<YZ] .,4=+^5Q];?([#P;\$X/"_C>3Q))=K-<+%)%#''%L"ASE
MB>>OTQ5KP_\  _P]I5WK5W>VR:G<:I=S7#M,#A5DZJ!G'3OUK&^&GC[Q3XNT
M_46U**&&)['[3;W,93<C,"=NT'D#U/->7>&/B+XTTJ&?4#KD=_#8Z-%=S0SQ
M B1C<%2O7@X[]:76WD+?5'O4GP8\&RSB8Z%;EEP0.< A=N0,XSCC-7KGX9^&
MKJ*&.328&2*%+=!@_+&IRJCG@ \UXL?C]XQN[+5=6M--MTL8//189BH,>Q<J
MYYR23VZ8J;Q3\:_$OA71[.X.HVE[>106MS=6T=J%7$Q7Y2Q/& >,?C1K^7XC
M_K[CVCQ%\.O#OBR:&35=,CO'AC\I&<G.ST.#R/K31\-?#26J6PTB#R%G:Y"8
MX$A7:6^I'%>&-^T+XGTK0HM:F%EJJ7CW<<=C;1X>W\LX5F(.3UYS6[H?QE\5
M1ZUH5IK$-HEE?7!1KPE 2IBW@8!PN#T/>G:P':>*_@;X=\12:9)#:1V$MC<1
M2AHUX=4Z(1G'3C/6M6V^$'A"S6X6+0[<+<1^5)G)RN=V!D\#//%>#:'\7O$^
MJ:[_ &K<:C&]M/\ 9U6QCCVK@S.N5(.>@%>O_#3QKK7BS39]6O;VP,$R3/%8
M1J%F@*,0 >>>G.:+:7]1=;>AV5EX,T:PT*?1XK%/[.F!$D+DL'SUSDDFLZV^
M%7A:VA2(:1#(B;MHER^-PP?O$]N*\.O?CYXPT_PU;7ZW.FW=QJ,<C1+#%Q:%
M9@@W#/.0>_>M;5?BSXNL]*U.:6_LF>WOCI/V9( )6)0GSASQCTZ<5+6C8^MC
MOO"WP)\.>&]9U34?LR7+W<_FPH^<0+MV[0,^G?K6_=?#'PU=P6$,FDQ>78J4
M@"978I.2O!Y&>QXKP_PS\8O&:6>EZ;:B+4IK6QAGGFF")]I+M@C)/&!Z<YIE
MI\;?%QDUUK>2UAMM)MWO9(Y8M[2?OPFS)/ P>HJFOZ] _K[SW*7X6>%Y+^6[
M;286GE4JQ).,$8.!G X]!3+3X4>%+./;'HT!'S<N"Q.X8;)))/'%<5X$^*>M
MZUXY73=8-O;6UV':U@B0,"H4$8<'KSR"*YKQ#^T1KGAOQG<Z)/:0.MI<2V]P
MX7!&_BV(_P!XYS]*75+N+S/8-,^&?AG29K:6UTJ&.:WD,L4AR65B,$Y)STXJ
MW)X'T-_#YT,Z=#_9>2PM\?*"3DD>AR<U\MZK\1_&EU-K$YUK[%)!;SJ+=$P/
M,$Z#(.<\9KW+P%X[UB:W\56VKE+^[T2-)%E@CV>;F+?MVCOGBFU97?:X^MD;
M5U\&?!MZD:3Z)!($3R_F+?,N<X;GYN?7-2_\*B\)F29SH\1>5=C$LQP/;GCI
MVQ7SA??M5^,=,\/76HN=&NWN[,WEM';@DV&) OES_@?K5;4/C[\0-3UW1M+3
M6-&C2+5[:.XU*S0FWECEC+>7DGJ.AI:WL!],'X2>$_LD-L-'B$<3M(I!;?N/
M4ELY.?<U8N/ACX8NIGEETF%I'=)"W(RR#"GKU KY@?\ :/\ 'MG:2#2_[.E2
MTM;F_N#=(6+JD^S:I!XR*WH_CSXON-1@L-8.GVUPFIVH$]N&$:PS0EP&!Z[?
M6C^OQL)Z'O<7PG\*P6US;QZ3&L-P?G4.WKGY>?EY],5HP^!]#M_#S:&NGQ#2
MVSNM\9!)[GOGWKY/?]JGQWIGAOQ-K!N=%UZSM[M+'3Y+&+#%BQ#2,N<[1T&<
M9JQJO[37C?7O!=C$B:?X9U&?3[NYGO+[Y5F\OA1%R0&/7K1TO_7<JVMCZ0C^
M#?@^&U:!-%A5#*9RRLP<N1@G=G/3WJU/\+?"]S>K=2Z1"\JIY8R3MQC'W<XS
MCOUJO\&=4N]8^%GA>]OIFN;NXL(Y)96.2[$<DUV@]*;5FX]B8NZNCR+5_P!G
MS3-6\46E])+%%IMM)'(EG'%@_(,!2<\C\,UVL_PS\,W%M#!)I%NT4-N;6-2O
M"1%MQ4>G/-=512Z6'UN<7=?"'PE>V$=E-HT4L";L!F8L<]<G.3GW-=586$&E
MV4%I;1B&W@01QHO15 P *M44 %%%% !1110 4444 )1TI"0 23Q7D'Q:_:6\
M+_#&.2W\Y=3U91Q:0-G:?]H]JN%.=67+!79C4JPI1YINR/6Y94@C9Y'$:*,E
MV( 'XFO)OB!^U!X)\!>9$]^-3O$X\BS(;GW/2OC+XF_M(^+OB3+)'->-I^G,
M?EM+8D+CT/K7E+NSG<Q+-[U[U'*^M9_)'SF(SBVE%?-GTOXU_;@\2ZJSQZ%9
M0:5 <@/(-[XKQ;Q'\6O%WBJ9GU+7KR<-_!YI5?R'%<A1FO9IX:E3^&)X-7%U
MJOQ2;))+F:<YDD=SZLV:CHHKHL<EV?H7^QG_ ,D8M/\ KXD_G6-^U?\ \A'0
MO^N3_P ZV?V,O^2,6G_7Q)_.L;]J_P#Y".A?]<G_ )U\M3_WY^I]E5_Y%R]$
M>!4^.:2$Y21D/LV*917T-D?,7.BT;XA>(=!D#6>JW,8'\)<E?R->E^&OVG=6
ML=L>K6L=]'W=/E:O$J*YZF'I5/BB=-/%5J7PR9]G^$OC3X9\6!$CO!9W+<>3
M<?*<^QZ5W:.LB!D(93R"IR#7Y[J[1G<I*M[5W_@?XU^(/!KI']H-]9CK#.2>
M/8]J\JMEO6D_DSVZ&:]*R^:/LP45P7@+XP:)XYC2..86E]CYK:5L'/L>]=Z*
M\6=.5-\LU9GO4ZD*L>:#NA:***@U"BBB@ HHHH 0#%(>G/3WIU<=\5[75;SP
M)J<.C"0WS*N!"<.R[AN /J1FDP6IO:EKFG:48?MMW#!YI81^8WWL#)Q] *FL
M=0M-3LXKJTFCGMI%#))&<J5/>OEW6_!&IZGJ"7EOHNJG1HIF%K;S[C)&QMV5
MFVD\*6Q52;X?^,O#VBZ'9Z)!J-I92:5;MJ:+F0[UE^90I."VWMQQ3L!]4:MI
M=CKEA)9WJ++;2C#)G&[\C5J"*&UACMXU5$1=JQCC 'H*^?OAYX$U<^/-(FU"
M75KS2((9YHFO$,"QN6&U2H)XQTSFKWB?2-<;QMXID^Q:G/J,JK_8MU Q^SQ+
MY9!#<X'/;%#T!:GM.J:UINB0K/?74-I&S>6))&P"WI]>*B?Q!IB:?;:@]Y"+
M2X*K%.6^5RQPH!]Z^5;OX?\ BF]\.18_MB^N"\)N+2>V\M5D ;<X.26//7WK
ML/$'AKQ6WP>\+:=/I1GM+22U>:VMMPO!M;+9&<<>U.W?NA?Y'ONKZ+INN1VR
M7\$5PD$RSQ;SPLB]&'N*T04#;05!].]?*7B+3/%4FFZA:VVBZH;"=[F;3)&W
MM+"3C8I7/&3SDDXIMGH?CFVNHY;.WU2YU:YM KR7BE1;-Y6"5<'#<]B.M+H,
M^K-T>TGY-O>JVG:I9:I T]G/%<1([1F2,Y 93@C\*^8]'\)>)K?3[.:XDUN]
ML/.@.IV'D>26 SN*\Y;GKR,UT7AKPGJ$'P,O[!+;5M)=M4EFBA"%I_+,F5W+
MGD$=1FG878]UAT33H=7N-5BMXA?W$:QRSC[S*OW0?85+J>JV.DV;W-Y/%!;H
M1N=SP"3@?K7S)%;^+;&30;6*VN+%=>9]-N(O,;='&K;Q. Q)7(&,>]4M:\#:
M]-8:[I<>EZGJMJ0)1<W(9) RR@A0 </QGGBE;89]9AXGZ%3Q2!HC@!E/Y5\I
M6?@_QC-'J\DMSK,6J;+K;"EOB.2,KB,>9GL,8&,@BII_AQXCTY+V>R@U9;B*
M/3V@*S.3O*XG(R>OK0!]49CDZ;6Q3RH/4 _6O#_@3INM:/K^J6MW:WLEBT.[
M[?>JT<C2;S\I4D@\=QBO<:&M@&E%/4 _A2A5'0 ?A2T4 -V+G.T9^E*54XR
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ME4DLK'D_AQ5^P_:(\5?V)KVKOJNFW=R(I&CT9(&$UAMDV[I,=0!SS2L_NO\
M@+_@?B?1USX \/7DN^;2;=W+,Q)0=6.2?Q(%:EGHUE8SW,T%M'%)<X\YE'+X
M&!GUXKY/D_:)\70V::8-<TR9)+^* ^*E@_T5%9-Q4CID'Y<UE>"/CKXL\'>
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MR[8)O(7?&!V4XX%.U3PCHFMWB76H:5:7ERB[5EGA5F ] 2*V:* ,=/"NC1A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHJO>7<5A9S7,SB.*)#(['H !DT 4_$.E'
M7-$O;!9WM3<Q-%YT9PR9&,BOS\^+W[+WBGX?3W%];1OK.EDEOM$8RX_WA_6O
MIKPC^U?H.LZY<Z=JD9L8Q,5@N>JLN>,^E>WVUU9ZS8B6&2*[M91P5(96%=]"
MO4P;T6C/(K4J&8QLI:K\#\BW1HV964JRG!##!%)7Z$?%O]D[PYX_66]TQ%T?
M5FYWQ#Y'/N*^,/B/\&O$WPPOGBU:Q?[/G"740+(P^O;\:^EP^,I5]$[/L?*X
MG 5<-NKKNCAJ***[SS0HHHH **5020 .3V%>L_"G]FWQ3\3IXYEMVTW2R06N
MIU(R/8=ZRJ5(4X\TW9&U*C4JRY8*[/*[.SGU"X2WMHGGF<X5(P6)/TKZ-^$7
M['.L^*C#?^)V;2M.;#"$?ZUQ_2OIKX6?L\>%OAA DD%HM[J./FNYU!;\/2O2
M;[4[;38"\\BQJ*^?Q&9RE[M'1=SZG"Y2H^]6U?;H9G@KP9I?@'P_;Z1H\ M[
M.'D+ZGN3[U0\??#;2_B#9I'?J1+$"(ID."F:<FN:AK\^W3(S%;@\W$@P/PJR
MNLW6DRB+4D)3M.@R#]?2O$4Y1ESIZGONE"4>1K0^6_'OP0USP:\DT,1O[ <^
M;$,D#W%>=$%6*D$,."#7Z!Q30:C "I66-AT/->8_$#X!:/XI$ES8*-.OSSNC
M&$8^XKVZ&8W]VK]Y\_B<K?Q47\CY)HKJ/&/PXUOP3<,E_:L8<X6=!E#_ (5R
M]>U&49KFB[H^?G"5-\LU9A1115D!1110 4Y4:1U5 69C@*!DFNP\$?"O7/'$
MR"UMS#;9^:XE!" ?UKZ0\ _ [1/!R)/-&+^_'_+649 ^@KAKXRG1TW9Z.'P-
M7$:[+N>)?#OX%:YXDGAO;K=IEF"&61OOGZ#M7U?8VIL[*" R-(8T"[VZG QD
MU,JK&@P JCL*Y;7/B1HVA74=L\PFF=PK+&<[>>I-?.5\1/$.\CZK#86&&5H[
MG6T5&DBRHKH=RL 01W!J2N4[0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!!THZUC^)/%6F^$M/^V:G<B"(G:O=F/H .2:@\+^-=)\863W6F7(DC1O+=7&
MUD;T(/0T^635TM".:*?*WJ;_ $[4$5$T\:!BTB +P<L!BJ-YXAT^PO[*RGNH
MTN;PD01D\O@9.*23>PVTM6S4HJ(31LQ4.NX<D C(^M--U#U$J$#D_,.!ZT!=
M$V3Z49/I6:_B"RCU9-/:3%PT1F&?N[0<=>E7$NX60LLJ%1U(8$"G9AS(F.:!
MFH);J*"'S&D58P,[L\5G:'XITWQ!HYU.SN ]D"P,K< ;20V?RHL[7#F5[&P.
MO2@DUQFC_%GPUKNJ-I]I?%[@!F4%"%D"\G:3P:WM!\16'B6PBO-/N!-!)G:1
MP>#@\?44W"2W1*G%[.YK45"+B(ACYB$+P3N''U]*!=0D9$J$9Q]X=?2I+NB:
MBLVUUZSO;Z]M8W/FV9 FW# &1D<U=-Q$(_,,BA/[VX8_.BS"Z'X/6C'%9<WB
M6P@URTTAYQ]NNHFFB0?Q(O4YK._X6'H?_"477A\W@75+:$SRPD$80#).?I3Y
M9/9$N45NSI<^M!XKG?"'CK1O&^FRZAI%V+BTBE:%I"-H#*>1S6^T\80.779_
M>)X_.AIIV:",HM73NB2EKE[/XB:)J,ZPV]T78SO;YV\!T&6!/:J_AWXH^'_%
M6H&RTV[:XE#NF0AVDKUP:?)+>Q/M(7M<["BHEFC?.UU.WKA@<?6J&K>(M.T2
MT6YO+N*& R+$'+#!9C@"I2;=D6VDKLU*;C-9FG>(;/4Y+U()<FSD\J4L, -C
M/7O]:OFXC"AS(NT]"6&#^-.S6X*2>Q-14)N80@<RH%/ ;<,'\:E# @8.1ZTB
MA:*** "BBB@ HHHH ;VKQ#]JKQ^WA7P,-,MGV7FIDQ\'D1CK^=>WYXKX0_:=
M\7GQ/\3KN!'WV^GC[.@!XR.OZUT4(<T_0\O,:WL:#MN]#R.N\^'GQH\1?#JY
M3['=--9Y^:UF)93]/2N"HKUW%25F?%4ZDZ;YHNS/O+X9_M%^'O'T<=O/*NEZ
MD>#!,V%8_P"R>]>E:MHNG^(K![:_MH;RUD7!610P(-?F-'(\+JZ.4<="#C%>
MR_#']IK7O!1BM-28ZIIHP-LA^=1[&O/GAVG>!]%ALU4OW==?/_,Z[XO_ +%L
M%Z9M2\'2BWEY8V$GW2?]DU\E^)?">K>$=2DL=7L9;*X4X*RJ0#[CL:_3;P'\
M5_#WQ#M$DTV\3SB/FMW.)%/TJSX[^&?A_P"(NG/::U81S@C"R[<.I]0:ZZ&8
M3I>Y55U^)I7RVCB8\^'=G^!^5-=;X!^%OB+XCZBMKH]A+,I/S3E2(T'UKZRT
M/]AS0['Q1+=7NH2W>DJVZ*UZ$^S'TKZ+\/\ AC2_">G1V>EV<5G;(,!8U _6
MNRMF<4K4U=G%A\HG)WK.R\CPOX1?L?Z'X-\F_P!?*ZQJ0PWEL/W49^G>OH2.
M.WTVW"1JD$*#A5& !65J_BJUTP>6A,\[<+''R:RH]&U/Q(XEOY&LK3M I^9O
MK7S]2M.M+FF[GU%&A3H1Y::L6-0\6M/.;33(6NI^FX?='U-/L?"LEU(+C5YC
M<R=?)'W%_P :W;#3+;2X!%;1+&H]!R:MUB= R*)(4"(H11T I)8DG0I(@=3P
M0PR*DHH YZYT&>P<S:9*4[F!ONGZ>E/L/$JO*;>\C:VN!U#]#]#6]5/4-,M]
M2C*3QAO1NXH 2^TZTUBU:"YACN(7&"K@$5XA\0/V;(+LR7GAZ002\DVK_=/T
M]*]4-IJ/A]BT#->VO]P_>4?UK4TW7K;4@0KA) <%&X(K:E6G1=X,Y:V'IUU:
M:/AC7?#FH^&[QK74;62WF4_QC@^X-9E?>/B3PCI?BRR:WU*TCG4C 8CYA]#7
MD\'[+^FQZZ9GO)'TW.Y;?^(^Q/I7O4LR@X^^K,^=K974C+]V[H^?_#GA+5?%
M5XMOIUI).QZLH^4?4U]"?#[]G*QTCR[O76%[<C!$ ^ZI]_6O6]!\-Z;X:LUM
MM/M8[>)1CY1R?QJQJ.JVFDV[37<Z0QCNQKSZ^.J5=(:(]/#9;"E[T]7^!-:6
M<%C"L-O$L,2C 51@"LKQ%XOTSPS 7NYU$F.(E.6-><>+_C2S[[;1EVCH9VZ_
MA7E5[J%QJ,[37,K2R,<EF.:\L]A*VQV_B[XMZCKI>"S)LK4\84_,1]:X)W:1
M]S,68]Z2B@9]#_"3Q(==\-)%(VZXM#Y39/)'8UW-?/OP:US^S?% MF;$5TNS
M\>U?05 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%)FEH **** "BBB@ HHHH **** "BBB@ HHHH \M^+5M-9^(/"NNR
M6DE]I6G3N;J*-=Y7<N%?;WQ7->+_ !#_ &WX/N=4T+1;S3X(=5MYI)4BV/<1
MALLP4<D5[HZJPPP!'H13?*0)M"J%],<5O&KRI:;'-.ES-ZVO_D?+GBFYU/Q+
M:>(KY1JMKITFK(\8\IN8MF,$==N?2ET_1[N];X>ZKJ.GWX:WGN(5=BS,./W;
M'N 37U%Y";2NQ<'J,4>4F -JX7H,=*V6)LK)?U8YY83F=W+^KW/F/P]%K']M
M6/D1ZHGB(37']K/-N\DQ8;;CMZ8Q53P[X#U"ZC\.FYDU0?;K.\:]!D8?,I)0
M'T]J^J!$@8G8-QZG'6@1( ,(O'3CI1]9ML@^J:WO_6A\Q+<:E9:1IUUJ]C?Z
MA#'X?D22%-V]I/,.T?7&*Y^WT_5%^%F-*N=2\Z;4%EU-)(WS#$1PB \D"OKS
MR8RN#&I'3&*1;:-05$: 'J !S3^M;Z=;_B+ZIM[VRL?*UK8:O#HWAS^WWU6]
M\/$W&!"C+('/^KR.N/3-=_\ #?P]J%U^S[>:7!%-;7LZ7"PI,-KC+$KG\*]L
M,*,H78I4=B.E*J*@PH ]A6=3$>TC:QK3PRA)2N>,^$?$^GW<&C:+%X:N5U*T
MM6BFF>WV+;,$P3N[Y/I7">'_  KK?A_3_#%WI*WL6HW8O8YT+-L PQ0%>@YZ
M5]/B&-7W!%#'J0.M+Y2 #"CCI@=*%7LVTMP>'NDK[;'QWX<TWQ8/#WB9C<Z@
MUPU@5N(C&RXF+_PD]3[BN@U/P+J.GKXA^S/J9^RZ=9W=J/-8YN#C>?<]<BOJ
M001C.(U /7CK2F%#GY%YX/%:/%N]TC%8))6YCYM\20>(GA\3R)'>_9GNK)KG
MR00[0[!YFW^N*J^,)B_@VRLM"M-:_LB:^;$ER7RHV\<#G;GUKZ;,:8(*KSUX
MI/(CVA2B[>PQ4?6+6T_K0T>&O?WCYW^$5MK,^O\ @:?4XKEI;>PO(9)9E(*_
M-\H.?:LCXIZ!K<'Q%\0:WI5E-+<%X;-653@QRKL8CZ9KZ@6)%QA%&.G%!B1C
MDJISZBCZS[_/;^KC6&M#DOV_!'RSH_AC4?"W@L:=);7J:'#KD@OUM@1(\.T8
M(QSC/I5AH-7_ + T\W<>J'P>-7<B-=WVC[/CY<CKC-?3_E)M(*K@]1CK33$A
M4+L4K_=QQ5/%-ZM?U_F1]425DSY8\#Z!>--I<"6E['I\NJ7Q83!E8QE/E+4_
MP%X3U7P[9:$-+M;BWN9+;4&;=G DR0A.>AZ8KZE$,:D811CVH$2+T4 CIQTH
M>*;5K!'")-._]:'S-H-R^G>"]6:RL]=FUS[!B^$A8(9=WS$9[_2N-M/#^IZI
MX5UJ.]M[^?3[>^L[N*/:^0A/SD9YK[*$$:[OD4;NO'6CR(P"-B@'J,=:<<5R
MMM+<'@[I)RVO^*/F2]MM21=4)AU'_A&FUI&N5A#"4VWE@#'?&>M6+31-7UK3
MM#LV_M&/0I==?[,'9A*+4IQO/4#-?2?DQ@$;%P>HQUI1$G'R@8Z<=*GZSY%+
M"J^Y\G^)-*U>U\,PVTLFIK:V>I721*%9@R?P D<_0U]#?"V>]N/ FD/?PRP7
M1A&])SEQZ9_"NJ,*,,,BD9SC%/"A1@# K.I6]I'EL73P_LY\UQ:***YSL"BB
MB@ HHHH R?$NK+H6@:CJ$APMM \F?<#C]:_-/5[]]5U6\O)3NDN)6D8^Y)-?
M>'[26M'1?A+J[*VUYPL _$U\!UZ6%C[K9\GG%2\XP[(****[CYX**** +FE:
MS>Z)>)=6%S+:W"'(>-B.:^H_@)^T?J?B;7++PYK<0N9I_DCNEX/ [U\H5Z5^
MSG_R6'P]_P!=3_(UA5BI1;:/0P=>=.K&,7:[1^@,CB.-F/0#-<:^H:EXIGDB
ML +>S1RCSD]<=@*ZR_\ ^/.;_=-<W\-?^0#-_P!?,G\Z\8^]-/1?"UGH_P Z
MKYUP?O32<L:VJ** "BBB@ HHHH **** "L?5/#=MJ#"5?]'N!R)8^#6Q10!S
M5K?WVDW,=M?J'C=ML<R]_8UT@Z5S_BSB32_^OD?RKH%^Z* //?''Q7MO#D\U
MC9I]HOHSM;=]U#[UXQKOB?4?$=PTM[.TG.=N?E'T%7OB1_R/.L?]=S_(5S=
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MJ/Q;\,:?]@_XFD,XO+I;1#$V?G89&?\ &O)$_9_UG4M=UK4KE;:U_M*VN!'
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M_P#7R/Y5T"_=% 'S)\2/^1YUC_KN?Y"N;KI/B1_R/.L?]=S_ "%<W0 4444
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MSCV.5MOA7X8L])N=-CTN(6ERP:5#SN(Z<U9;X>Z UE>6K:=$T%X5,RMSN*C
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M]-J&FVUQJ<L<2RR0QK_J07"8?T[UK_$'XX^&OAC::3+KD[QR:BH:.*)=S!<
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M:M-H^G7Z746H:@L^JM<L$FC(($07/7)XK[WQBJMCI=KID;QVEO';HS%V6-<
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M*,=:7V6@ZIGR)J'PZ\07/@O21!X2U*+1(+]I;K03>DS3*4PK YX ;G%8,WP
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M444 %%%% !1110 F*,4M% "48I:* $Q1BEHH *3%+10 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[P[!I=B@RHS++CF1NY-=/0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M*'3[BS9%,B/+@B10<?A7I!(K.4)0=I&D)QJ*\1:***DU"BBB@ HHHH ****
M"BBB@ HHHH \9_:._9QT7X\^&7BF1+77+=2;2] ^8'LK>JU^47Q$^&^N?"_Q
M+<Z+KUE)9W,+E0SJ=KCLRGN*_<.O,/CA\ ?#7QR\/O9:O;+'>QJ?LU\@Q)$W
M;GN/:@#\8Z*]5^.'[.GBGX'ZT\&J6KW&FLQ,&H1#,<B^Y[5Y50 4444 %%%%
M !1110!^PO[('_)O'@__ *]OZFO/OVR_^0IX=_ZXR?\ H5>@_L@?\F\>#_\
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M0T4R;@<^GH:^$/C[_P $];NP:YUCX?R?:;89=M+E/SK[(>]?H/BB@#\)]?\
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MWVG6FJ6[0W=M%=0MU29 P_(UY/XO_9-^&/C0N]YX:M[:5A_K+3]V1^5>Q44
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>plx-20231231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20231231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %V PH# 2(  A$! Q$!_\0
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M-K=R6GTF=[9+V8_)*I&T@D_*<9%"U#8_4,ZA:B7RC<PB3^YY@S^53LP5=Q(
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MQ]#]?GNX(Y%1YHU=NBEP"?H*FK\AO'-EXOT_X:>#OB+=^,-0N[G5)&BCB,S
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MQ?X/O=<GU2S\0E&>58Q&T)4<8]>:]Z_X3;P__P!!O3__  )3_&C_ (3;P_\
M]!O3_P#P)3_&CE;Z!]9H_P Z^]'R-I__  32T:VM+ZWG\9:A-%*I\B-8PJHW
M9F'>O?/V<_@8?@%X/N/#ZZN=7A><SI(T6PKGJ*[W_A-O#_\ T&]/_P# E/\
M&C_A-O#_ /T&]/\ _ E/\:=GV#ZQ0_G7WH^<OV_?A+>^.?AU8^(M)A:?4- F
M\YXT&6:$_>Q]#@U4UKX,6W[8WP2^']V^LRZ+)IL)$H$.XE]H4@@].E?2TGC'
MPY-&R2:SISHPPRM<(01[C-1VGBGPM80^5;:II=O%G.R*:-1^0-"B^P?6:/\
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M/E;Q/);?\(_:Q6R@6X/G;&SD\\9KZ:_MS3O^?ZW_ ._H_P :/[<T[_G^M_\
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M6TFI>,]2U'2[=PRV00(&&>A.>/PKZ^_MS3O^?ZW_ ._H_P :/[<T[_G^M_\
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MY(O('@\P#.W<,9KQK]FW]EN+]GO4-:N8]<?5_P"TL95X0FS!_6O9?^$HT?\
MZ"EG_P!_U_QH_P"$HT?_ *"EG_W_ %_QI<LEK8.>+TN?/7QM_8:\.?%;Q7+X
MET[5KGPUJ\YW3O;*&21O[V.QJ_\ !S]D+P_\"+/6-6M9)?$WB.:UDC6:\4 $
M%3E !Z]":]V_X2C1_P#H*6?_ '_7_&C_ (2C1_\ H*6?_?\ 7_&CEEV'SQ[G
MY&>*8_#MOX@\0_VMX$U?2M59G6"TM)F^SK(3U(*YQWP*^A/V0?V>=9\:?!3Q
MOIVK";0;37I(TMYI8OF(7JP4]J^X;BZ\*W<OFSR:3-)_?D\MC^9JY'XCT2%
MD>HV2(.BK,H _6ER.UF@]I'HSRSX,_LUV7PK^%^K^"KG4Y-7LM2,@DEV>6P5
MA@@5XSI__!-70K/4+MG\7ZDVG2AMMK&@3D_=W'N!7UW_ ,)1H_\ T%+/_O\
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M* "BBB@ HHHH **** "O#_VQ?^2,7?\ U]0_^A5[A7A_[8O_ "1B[_Z^H?\
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M4_Z#EI_W[:CZ[0_F#ZAB?Y/R/!Z*]X_X90U3_H.6G_?MJ/\ AE#5/^@Y:?\
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M?Z5E5K#8RGN%%%%60%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %2CH*BJ4=!28T:U%%%8&X4444 %)FEKYY^*GQZUGP7\0CIMO!%_9]OM
M\P.OS2 ]<&JC%RT1P8W'4<!356MM>Q[IJ7B'3M(FBBN[J."23[JL>36@CAU#
M*<J1D$5\X_$#Q-;>*M4T_4K.4/#+;(V <[3W'UKTN^\<2Z;86%O9E7D6%#(Q
MY[#BOE89U&.)KTJRLJ;27=G1"M&HN:.QZ+15'1;UM0TV"X==K2*"17(>'O&%
M_J7Q8\3Z!,R?8-/M;>:$!?FW/G=D_A7TL)*<5);,W.]HHHJP"BN ^.GC+4/
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M:]OKB.UM(5W232MM51ZDT7V8K;HY7XB:%?ZEI]G>Z-&1J<!\M03C]U(-KC\
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M\>T?TK#G_P!<_P!36Y:?\>T?TK#G_P!<_P!32&1T444 %%%% !1110 4444
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M'@WX5:MH?B>QNKE=-AMK R$7=H"+F\W_ //4D=OJ:(]+@^MCUJBBB@ HHHH
M**** "BBB@ HHHH *T='_P!9)]*SJT='_P!9)]* +]W_ ,>[_2LJM6[_ ./=
M_I656L-C*>X44459 4444 %%%% !1110!PVEV(\5^-+_ %&[/FVNF/\ 9[6
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M?A_3H-0E\^^C@19I/[S@#)K1JGHR4[JX4444AA1110 4444 %%%% !6CH_\
MK)/I6=6CH_\ K)/I0!?N_P#CW?Z5E5JW?_'N_P!*RJUAL93W"BBBK("BBB@
MHHHH **** "BLCQ)XEMO#-FDTX:621@D4$?+R,>P%<[%;>-->?SI+VVT*U;)
M6%(_,EQVR3Q6D8-J[=D92J)/E2NSN:*XZRM_&&DZG"L]U::OIS. [;/*E1?7
MT-27GC*>]UY-*T.W6\DB<?:[AS^[A7TSW:G[-WT=Q>U5O>5CK:***R-@HHHH
M **** "BBB@ J4=!452CH*3&C6HHHK W"BBB@ JO>QI/:RQ.VU9%*GGUJ<UR
M/C:"]E\@P!VB&<A/6O-S#%/!X>590<K=$;T*?M:BC>QYIK^CW7A+50RR$+NW
M12J>M/TKQ8NKW[&4JMVK\C^][TGC",Q:2ZWD<I)^X"#G/M7F6B07;ZY ( XE
M#@Y]!WS7X'F6/E&HH4X.,;WMV/T_"8>.*H.=5KF2M?N?0T$<VK70&[+-U8]
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MZ/\ ZR3Z4 7[O_CW?Z5E5JW?_'N_TK*K6&QE/<****L@**** "BBB@ HHHH
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M/EB91\QYP,&O4OAU\%[+7_@'HGAOQ#9O9/@W*)$=DMHY8LNT]B 17IUO\/\
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M_L,'_/,4?88/^>8K(^WS_P#/0T?;Y_\ GH: -?[#!_SS%'V&#_GF*R/M\_\
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MIE/A_P!:GU% '1UCS?ZU_K6Q6/-_K7^M7#<SF,HHHK4S"BBB@ HHHH ****
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MHDMV8-VUK>,[YU'0A:L> ?A[#X0T66TNC:7LTTOFR-#:+#'GH,(*T/&_A/\
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$'*C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>plx-20231231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20231231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G )$# 2(  A$! Q$!_\0
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MX%>__P#!*G]ICP9X \(Q_#/7'O[#Q'J6HR2V;/;L89]W(4-V./7% '->#?\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>plx-20231231xex23d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20231231xex23d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "\ -\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH ^+OVTM8BT_P"*6EQNCL3HT397'_/>?_"O O\
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M.EPR_9([N.]U.[CR!:V<;JTCENQ(^5?5F45Z)_P41_:KU;]HGXY:UIUM?O\
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M-C@:XE:W5L\C$)B '88':OH.BB@ HHHH **** "BBB@ HHHH **** "BBB@
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L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>plx-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2024 5:48:20 PM-->
<!--Modified on: 3/13/2024 5:48:20 PM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2023" targetNamespace="http://www.protalix.com/20231231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:plx="http://www.protalix.com/20231231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" id="DisclosureEarningsLossPerShareDetails1">
        <link:definition>40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)1</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails">
        <link:definition>40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" id="DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails">
        <link:definition>41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" id="DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails">
        <link:definition>41301 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" id="DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails">
        <link:definition>41302 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" id="DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails">
        <link:definition>41303 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" id="DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails">
        <link:definition>41401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>41402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" id="DisclosureConvertibleNotesTables">
        <link:definition>31003 - Disclosure - CONVERTIBLE NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails" id="DisclosureSignificantAccountingPoliciesGeneralDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (General) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" id="DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails">
        <link:definition>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" id="DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails">
        <link:definition>40103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" id="DisclosureCommercializationAgreementsDetails">
        <link:definition>40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" id="DisclosureInventoriesAdditionalInformationDetails">
        <link:definition>40402 - Disclosure - INVENTORIES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" id="DisclosureLiabilityForEmployeeRightsUponRetirementDetails">
        <link:definition>40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" id="DisclosureCommitmentsDetails">
        <link:definition>40601 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails">
        <link:definition>40701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
        <link:definition>40801 - Disclosure - REVENUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" id="DisclosureShareCapitalSummaryOfStockOptionActivityDetails">
        <link:definition>40901 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" id="DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails">
        <link:definition>40902 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" id="DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails">
        <link:definition>40903 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" id="DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails">
        <link:definition>40904 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" id="DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails">
        <link:definition>40905 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" id="DisclosureShareCapitalAdditionalInformationDetails">
        <link:definition>40906 - Disclosure - SHARE CAPITAL (Additional information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" id="DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails">
        <link:definition>41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" id="DisclosureConvertibleNotesAdditionalInformationDetails">
        <link:definition>41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" id="DisclosureEarningsLossPerShareDetails">
        <link:definition>41201 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails" id="DisclosureTaxesOnIncomeValuationAllowanceDetails">
        <link:definition>41304 - Disclosure - TAXES ON INCOME (Valuation Allowance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails" id="DisclosureTaxesOnIncomeUncertainTaxPositionDetails">
        <link:definition>41305 - Disclosure - TAXES ON INCOME (Uncertain Tax Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" id="DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails">
        <link:definition>41306 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" id="DisclosureTaxesOnIncomeAdditionalInformationDetails">
        <link:definition>41307 - Disclosure - TAXES ON INCOME (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41601 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreements" id="DisclosureCommercializationAgreements">
        <link:definition>10201 - Disclosure - COMMERCIALIZATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10301 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10401 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" id="DisclosureLiabilityForEmployeeRightsUponRetirement">
        <link:definition>10501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>10601 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>10701 - Disclosure - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>10801 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapital" id="DisclosureShareCapital">
        <link:definition>10901 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotes" id="DisclosureConvertibleNotes">
        <link:definition>11001 - Disclosure - CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>11101 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" id="DisclosureEarningsLossPerShare">
        <link:definition>11201 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" id="DisclosureTaxesOnIncome">
        <link:definition>11301 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>11401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11501 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30403 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>30703 - Disclosure - OPERATING LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>30803 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalTables" id="DisclosureShareCapitalTables">
        <link:definition>30903 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" id="DisclosureEarningsLossPerShareTables">
        <link:definition>31203 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" id="DisclosureTaxesOnIncomeTables">
        <link:definition>31303 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>31403 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>31503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element name="SevenPointFivePercentageConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <xsd:element name="DisclosureOfLeasesOperatingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DisclosureOfLeasesOperatingLineItems" substitutionGroup="xbrli:item" />
  <xsd:element name="PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_CommercializationAgreementsAbstract" name="CommercializationAgreementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ScheduleOfUsefulLifeTableTextBlock" name="ScheduleOfUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ScheduleOfOpenTaxYearsTableTextBlock" name="ScheduleOfOpenTaxYearsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_PfizerAgreementMember" name="PfizerAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FiocruzMember" name="FiocruzMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FurnitureAndComputerEquipmentMember" name="FurnitureAndComputerEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ContributionPlansMember" name="ContributionPlansMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeSeveranceObligationPayment" name="EmployeeSeveranceObligationPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_RoyaltiesOnSaleOfProducts" name="RoyaltiesOnSaleOfProducts" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_CommitmentAmount" name="CommitmentAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_PercentageOfRoyaltiesToGrantReceived" name="PercentageOfRoyaltiesToGrantReceived" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_DebtInstrumentConvertibleConversionShareNumber" name="DebtInstrumentConvertibleConversionShareNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_DebtInstrumentConvertibleBaseValueForConversionRate" name="DebtInstrumentConvertibleBaseValueForConversionRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" name="MaximumDebtInstrumentConvertibleConversionShareNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UsIsraelMember" name="UsIsraelMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_TaxYearThereafterMember" name="TaxYearThereafterMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_OtherAssetsInstitutionsCurrent" name="OtherAssetsInstitutionsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_OtherAssetsSundryCurrent" name="OtherAssetsSundryCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_PaymentInConsiderationForDevelopmentServicesPerformed" name="PaymentInConsiderationForDevelopmentServicesPerformed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" name="PaymentsInConnectionWithPerformanceOfAdditionalStudies" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_DeferredTaxAssetsOtherTimingDifferences" name="DeferredTaxAssetsOtherTimingDifferences" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AtmEquityOfferingSalesAgreementMember" name="AtmEquityOfferingSalesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncreaseDecreaseInRestrictedDeposit" name="IncreaseDecreaseInRestrictedDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="plx_DebtInstrumentRedemption" name="DebtInstrumentRedemption" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_PercentageOfOutstandingCapitalStock" name="PercentageOfOutstandingCapitalStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" name="DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_PercentageOfCommissionOnSaleOfShares" name="PercentageOfCommissionOnSaleOfShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice17.20Member" name="ExercisePrice17.20Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" name="NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_OfficeOfIsraeliInnovationAuthorityMember" name="OfficeOfIsraeliInnovationAuthorityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" name="LesseeOperatingLeaseNumberOfRenewalTermExtensions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeMember" name="EmployeeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_CommonStockNumberOfVotingRights" name="CommonStockNumberOfVotingRights" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" name="NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PercentageOfPremiumToClosingPriceOfStock" name="PercentageOfPremiumToClosingPriceOfStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" id="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" id="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromExpenseReimbursements" id="plx_ProceedsFromExpenseReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReacquisitionOfEquityComponentOfConvertibleNotes" id="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquityComponentOfConvertibleNotesNetOfTransactionCosts" id="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromSaleOfProducts" id="plx_ProceedsFromSaleOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestonePaymentReceived" id="plx_MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ThresholdPercentageOfConversionPrice" id="plx_ThresholdPercentageOfConversionPrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" id="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ExtendedTermOfAgreement" id="plx_ExtendedTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OptionsAndRestrictedSharesMember" id="plx_OptionsAndRestrictedSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice1.03To2.00Member" id="plx_ExercisePrice1.03To2.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice3.55To3.73Member" id="plx_ExercisePrice3.55To3.73Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice4.69To5.60Member" id="plx_ExercisePrice4.69To5.60Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmployeesAndDirectorsMember" id="plx_EmployeesAndDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GainLossOnDebtConversion" id="plx_GainLossOnDebtConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaymentsToDebtHoldersOnConversion" id="plx_PaymentsToDebtHoldersOnConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtConversionDecreaseInPrincipalAmount" id="plx_DebtConversionDecreaseInPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfPatientsDosed" id="plx_NumberOfPatientsDosed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OutstandingStockOptionsAndWarrantsMember" id="plx_OutstandingStockOptionsAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingStockOptionsWarrantsAnd2024NotesMember" id="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReserveForDeductionsFromRevenueCurrent" id="plx_ReserveForDeductionsFromRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FillFinishAgreementMember" id="plx_FillFinishAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContractAmountUnderAgreementPayable" id="plx_ContractAmountUnderAgreementPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Notes2024Member" id="plx_Notes2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" id="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessDevelopmentConsultantMember" id="plx_BusinessDevelopmentConsultantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" id="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationWithholdingTax" id="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" id="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CapitalizedResearchAndDevelopmentCostAmortizationPeriod" id="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" id="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>plx-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2024 5:48:20 PM-->
<!--Modified on: 3/13/2024 5:48:20 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureEarningsLossPerShareDetails1" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638459488972607009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638459488972607009" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638459488972607009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638459488972607009" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638459488972607009" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638459488972616595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638459488972607009" xlink:to="plx_ShortTermBankDeposits_638459488972616595" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638459488972616595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638459488972607009" xlink:to="us-gaap_AccountsReceivableNetCurrent_638459488972616595" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638459488972616595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638459488972607009" xlink:to="us-gaap_OtherAssetsCurrent_638459488972616595" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638459488972616595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638459488972607009" xlink:to="us-gaap_InventoryNet_638459488972616595" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638459488972616595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638459488972616595" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638459488972616595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638459488972616595" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638459488972616595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638459488972616595" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638459488972626580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638459488972626580" order="5" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638459488972626580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638459488972626580" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638459488972626580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638459488972626580" xlink:to="us-gaap_LiabilitiesNoncurrent_638459488972626580" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638459488972626580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638459488972626580" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638459488972626580" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638459488972636579" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638459488972626580" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638459488972636579" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638459488972636579" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638459488972626580" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638459488972636579" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638459488972636579" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638459488972626580" xlink:to="us-gaap_LiabilitiesCurrent_638459488972636579" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638459488972636579" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638459488972636579" xlink:to="us-gaap_AccountsPayableTradeCurrent_638459488972636579" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638459488972636579" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638459488972636579" xlink:to="us-gaap_AccountsPayableOtherCurrent_638459488972636579" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638459488972636579" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638459488972636579" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638459488972636579" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638459488972646573" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638459488972636579" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638459488972646573" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638459488972646573" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638459488972636579" xlink:to="us-gaap_ConvertibleDebtCurrent_638459488972646573" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638459488972646573" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638459488972646573" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638459488972646573" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638459488972646573" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638459488972656592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638459488972646573" xlink:to="us-gaap_CommonStockValue_638459488972656592" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638459488972656592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638459488972646573" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638459488972656592" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638459488972656592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638459488972646573" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638459488972656592" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638459488972656592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638459488972656592" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638459488972666583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638459488972656592" xlink:to="us-gaap_OperatingIncomeLoss_638459488972666583" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638459488972666583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638459488972666583" xlink:to="us-gaap_Revenues_638459488972666583" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638459488972666583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638459488972666583" xlink:to="us-gaap_CostOfRevenue_638459488972666583" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638459488972666583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638459488972666583" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638459488972666583" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638459488972666583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638459488972666583" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638459488972666583" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638459488972666583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638459488972656592" xlink:to="us-gaap_NonoperatingIncomeExpense_638459488972666583" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638459488972666583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638459488972666583" xlink:to="us-gaap_OtherNonoperatingExpense_638459488972666583" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638459488972676574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638459488972666583" xlink:to="us-gaap_OtherNonoperatingIncome_638459488972676574" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638459488972676574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638459488972676574" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638459488972676574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638459488972676574" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488972676574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488972676574" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638459488972676574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488972676574" xlink:to="us-gaap_ProceedsFromWarrantExercises_638459488972676574" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638459488972676574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488972676574" xlink:to="us-gaap_RepaymentsOfNotesPayable_638459488972676574" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_638459488972686580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488972676574" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_638459488972686580" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638459488972686580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488972676574" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638459488972686580" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638459488972686580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488972676574" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638459488972686580" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488972686580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488972686580" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638459488972686580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488972686580" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638459488972686580" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638459488972686580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488972686580" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638459488972686580" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638459488972686580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488972686580" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638459488972686580" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638459488972686580" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488972686580" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638459488972686580" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_638459488972696578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488972686580" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_638459488972696578" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638459488972696578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488972686580" xlink:to="plx_IncreaseDecreaseInBankDeposits_638459488972696578" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638459488972696578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_ProfitLoss_638459488972696578" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638459488972696578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_ShareBasedCompensation_638459488972696578" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638459488972696578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_Depreciation_638459488972696578" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638459488972696578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638459488972696578" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638459488972706576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638459488972706576" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638459488972706576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638459488972706576" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638459488972706576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638459488972706576" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638459488972706576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638459488972706576" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638459488972706576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="plx_GainLossOnDebtConversion_638459488972706576" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488972716578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488972716578" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638459488972716578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638459488972716578" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638459488972716578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638459488972716578" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638459488972716578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638459488972716578" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638459488972716578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_IncreaseDecreaseInInventories_638459488972716578" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638459488972726576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638459488972726576" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638459488972726576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638459488972726576" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638459488972726576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488972696578" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638459488972726576" order="17" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638459488972726576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638459488972726576" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638459488972736583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638459488972736583" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638459488972736583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638459488972736583" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638459488972736583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638459488972736583" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638459488972736583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638459488972736583" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" xlink:type="extended" xlink:title="40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638459488972736583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_DilutiveSecurities_638459488972736583" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638459488972746582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss_638459488972746582" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638459488972746582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638459488972746582" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638459488972746582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638459488972746582" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638459488972746582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638459488972746582" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638459488972756588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638459488972756588" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638459488972756588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638459488972756588" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638459488972756588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638459488972756588" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638459488972756588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638459488972756588" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638459488972756588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638459488972756588" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638459488972756588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638459488972756588" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638459488972766588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638459488972766588" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488972766588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488972766588" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638459488972766588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638459488972766588" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638459488972766588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638459488972766588" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638459488972766588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638459488972766588" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41302 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638459488972776583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638459488972776583" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_638459488972776583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_638459488972776583" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638459488972776583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638459488972776583" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638459488972776583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638459488972776583" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" xlink:type="extended" xlink:title="41303 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638459488972776583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638459488972776583" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638459488972786584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638459488972786584" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638459488972786584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638459488972786584" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638459488972786584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638459488972786584" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_638459488972786584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_638459488972786584" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_638459488972786584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_638459488972786584" order="6" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent_638459488972786584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="plx_OtherAssetsInstitutionsCurrent_638459488972786584" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638459488972796583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_638459488972796583" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent_638459488972796583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="plx_OtherAssetsSundryCurrent_638459488972796583" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="41402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638459488972796583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638459488972796583" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638459488972796583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_InterestPayableCurrent_638459488972796583" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638459488972796583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedVacationCurrent_638459488972796583" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638459488972796583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638459488972796583" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638459488972796583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638459488972796583" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638459488972806578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638459488972806578" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638459488972806578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_TaxesPayableCurrent_638459488972806578" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638459488972806578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638459488972806578" order="8" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>plx-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2024 5:48:20 PM-->
<!--Modified on: 3/13/2024 5:48:20 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesTables" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPoliciesGeneralDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureCommercializationAgreementsDetails" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirementDetails" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureCommitmentsDetails" roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureRevenueDetails" roleURI="http://www.protalix.com/role/DisclosureRevenueDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalSummaryOfStockOptionActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesTables" xlink:type="extended" xlink:title="31003 - Disclosure - CONVERTIBLE NOTES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (General) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_FillFinishAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfPatientsDosed" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ExtendedTermOfAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" xlink:type="extended" xlink:title="40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" xlink:type="extended" xlink:title="40103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_FiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentInConsiderationForDevelopmentServicesPerformed" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PaymentInConsiderationForDevelopmentServicesPerformed" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_FurnitureAndComputerEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="extended" xlink:title="40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="plx_ContributionPlansMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EmployeeSeveranceObligationPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_RoyaltyAgreementTermsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_BusinessDevelopmentConsultantMember" xlink:label="plx_BusinessDevelopmentConsultantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_BusinessDevelopmentConsultantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_RoyaltiesOnSaleOfProducts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ExtendedTermOfAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ContractAmountUnderAgreementPayable" xlink:label="plx_ContractAmountUnderAgreementPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ContractAmountUnderAgreementPayable" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40801 - Disclosure - REVENUE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeesAndDirectorsMember" xlink:label="plx_EmployeesAndDirectorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesAndDirectorsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeeMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="40903 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice17.20Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice1.03To2.00Member" xlink:label="plx_ExercisePrice1.03To2.00Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice1.03To2.00Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice3.55To3.73Member" xlink:label="plx_ExercisePrice3.55To3.73Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.55To3.73Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice4.69To5.60Member" xlink:label="plx_ExercisePrice4.69To5.60Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice4.69To5.60Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" xlink:type="extended" xlink:title="40906 - Disclosure - SHARE CAPITAL (Additional information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OptionsAndRestrictedSharesMember" xlink:label="plx_OptionsAndRestrictedSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="plx_OptionsAndRestrictedSharesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_OptionsAndRestrictedSharesMember" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_OptionsAndRestrictedSharesMember" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_Notes2024Member" xlink:label="plx_Notes2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_Notes2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_CommonStockNumberOfVotingRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_PercentageOfCommissionOnSaleOfShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_PaymentsToDebtHoldersOnConversion" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestCostsIncurred" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="extended" xlink:title="41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ThresholdPercentageOfConversionPrice" xlink:label="plx_ThresholdPercentageOfConversionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ThresholdPercentageOfConversionPrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentRedemption" xlink:label="plx_DebtInstrumentRedemption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentRedemption" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfOutstandingCapitalStock" xlink:label="plx_PercentageOfOutstandingCapitalStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PercentageOfOutstandingCapitalStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_DilutiveSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" xlink:type="extended" xlink:title="41306 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_UsIsraelMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="41307 - Disclosure - TAXES ON INCOME (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="srt_ConsolidatedEntitiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearThereafterMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_DirectorMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromExpenseReimbursements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>plx-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2024 5:48:20 PM-->
<!--Modified on: 3/13/2024 5:48:20 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net, total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value: Authorized - as of December 31, 2022 and 2023, 144,000,000 and 185,000,000 shares, respectively; issued and outstanding - as of December 31, 2022 and 2023, 53,790,167 and 72,952,124 shares, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity (capital deficiency)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity (net of capital deficiency)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES, NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME (LOSS) BEFORE TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS) FOR THE PERIOD</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for basic calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition Of Equity Component Of Convertible Notes</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition Of Equity Component Of Convertible Notes</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition of equity component of convertible notes</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition of equity component of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity Component Of Convertible Notes Net Of Transaction Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity Component Of Convertible Notes Net Of Transaction Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity component of convertible notes, net of transaction costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred tax asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss (gain) on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnDebtConversion" xlink:to="plx_GainLossOnDebtConversion_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">The amount of gain (loss) on conversion of convertible debt.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain (Loss) On Debt Conversion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain on conversions of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contracts liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable-trade and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInRestrictedDeposit" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase (Decrease) In Restricted Deposit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Decrease in restricted deposit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts paid (funded) in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment for convertible notes redemption and transactions costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Net payment for convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Convertible notes conversions</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" xlink:to="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_lbl" xml:lang="en-US">The amount of partial settlement of liability for employee rights upon retirement through transfer of related funds in non-cash financing and investing activities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_lbl" xml:lang="en-US">Partial Settlement Of Liability For Employee Rights Upon Retirement Through Transfer Of the Related Funds</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_lbl" xml:lang="en-US">Partial settlement of liability for employee rights upon retirement through transfer of the related funds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommercializationAgreementsAbstract" xlink:to="plx_CommercializationAgreementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommercializationAgreementsAbstract_lbl" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUE</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">SHARE CAPITAL</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">CONVERTIBLE NOTES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in the preparation of financial statements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment in value of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risks and trade receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule Of Useful Life Table Text Block</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule Of Useful Life [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Restricted Stock Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Summary of Share Options Outstanding and Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense in Statement of Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest Expense Recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Earnings (Loss) Per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Company's Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of the Beginning and Ending Amount of Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Open Tax Years Table Text Block</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Open Tax Years [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule of Open Tax Years</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental Information, Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FillFinishAgreementMember" xlink:to="plx_FillFinishAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtmEquityOfferingSalesAgreementMember" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to ATM Equity Offering Sales Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">ATM Equity Offering Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">BofA Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfPatientsDosed" xlink:to="plx_NumberOfPatientsDosed_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Represents the number of patients that were dosed in the trial.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Number Of Patients Dosed</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Number of patients dosed</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional amounts payable to cover development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum entitlement of development costs to cover per year</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExtendedTermOfAgreement" xlink:to="plx_ExtendedTermOfAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term  of agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended Term Of Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement amendment payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change in amount receivable for achievement of regulatory and commercial milestones</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional amount payable for achievement of regulatory and commercial milestones</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentReceived" xlink:to="plx_MilestonePaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received upon achievement of certain milestone.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment on net sales percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">The transaction costs in connection with exchange of convertible notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">Debt Conversion, Transaction Costs in Connection with Exchange of Convertible Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">Transactions costs in connection with the exchange of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LaboratoryEquipmentMember" xlink:to="plx_LaboratoryEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FiocruzMember" xlink:to="plx_FiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FiocruzMember_lbl" xml:lang="en-US">Fiocruz</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentInConsiderationForDevelopmentServicesPerformed" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentInConsiderationForDevelopmentServicesPerformed" xlink:to="plx_PaymentInConsiderationForDevelopmentServicesPerformed_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed_lbl" xml:lang="en-US">The cash inflow from consideration received for development services performed.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed_lbl" xml:lang="en-US">Payment in Consideration for Development Services Performed</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed_lbl" xml:lang="en-US">Payments in consideration for development services performed</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" xlink:to="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_lbl" xml:lang="en-US">The cash inflow in connection with performance of additional studies.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_lbl" xml:lang="en-US">Payments in Connection with Performance of Additional Studies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_lbl" xml:lang="en-US">Payments in connection with performance of additional studies</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FurnitureAndComputerEquipmentMember" xlink:to="plx_FurnitureAndComputerEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture And Computer Equipment Member</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture And Computer Equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture and computer equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - accumulated depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory Write-down</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write-down</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_lbl" xml:lang="en-US">Contribution to Insurance Companies [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_lbl" xml:lang="en-US">Contribution to Insurance Companies</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ContributionPlansMember" xlink:to="plx_ContributionPlansMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ContributionPlansMember_lbl" xml:lang="en-US">Contribution to Defined Contribution Plans [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ContributionPlansMember_lbl" xml:lang="en-US">Contribution to Defined Contribution Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="plx_EmployeeSeveranceObligationPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee severance obligation payment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee Severance Obligation Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee severance obligation payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xml:lang="en-US">Postemployment Benefits, Period Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xml:lang="en-US">Severance expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Contributions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" xml:lang="en-US">Gain for the period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" xml:lang="en-US">Contribution in connection with severance liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number Of Employees To Receive Benefits During Next Five Years</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number Of Employees To Receive Benefits During Next Five Years</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number of benefit eligible employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementTermsMember" xlink:to="us-gaap_RoyaltyAgreementTermsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementTermsMember_lbl" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyAgreementTermsMember_lbl" xml:lang="en-US">Royalty Agreement Terms</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Office of the Israeli Innovation Authority [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Office of the Israeli Innovation Authority [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Office of the Israeli Innovation Authority</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" xml:lang="en-US">Arrangement Other than Collaborative [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" xml:lang="en-US">Arrangement Other than Collaborative</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_BusinessDevelopmentConsultantMember" xlink:label="plx_BusinessDevelopmentConsultantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_BusinessDevelopmentConsultantMember" xlink:to="plx_BusinessDevelopmentConsultantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_BusinessDevelopmentConsultantMember_lbl" xml:lang="en-US">Business development consultant member.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_BusinessDevelopmentConsultantMember_lbl" xml:lang="en-US">Business Development Consultant [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_BusinessDevelopmentConsultantMember_lbl" xml:lang="en-US">Business development consultant member</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentsAndContingenciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="plx_RoyaltiesOnSaleOfProducts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Percentage of royalties based on sale of products developed from projects funded.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Royalties On Sale Of Products</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Royalties based on sale of products developed from funded projects, percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfRoyaltiesToGrantReceived" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_lbl" xml:lang="en-US">Required royalty payments represented as a percentage to grants received.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_lbl" xml:lang="en-US">Percentage of Royalties to Grant Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_lbl" xml:lang="en-US">Percentage of Royalties to Grant Received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expense included in cost of revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Royalties</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued royalties</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="plx_CommitmentAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Commitment amount.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Commitment Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Subcontracting commitment amount</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ContractAmountUnderAgreementPayable" xlink:label="plx_ContractAmountUnderAgreementPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ContractAmountUnderAgreementPayable" xlink:to="plx_ContractAmountUnderAgreementPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ContractAmountUnderAgreementPayable_lbl" xml:lang="en-US">Amount agreed to pay under the agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ContractAmountUnderAgreementPayable_lbl" xml:lang="en-US">Contract Amount Under Agreement, Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ContractAmountUnderAgreementPayable_lbl" xml:lang="en-US">Contract amount</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">2028 and thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Option to extend</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Lessee Operating Lease, Number Of Renewal Term Extensions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Lessee Operating Lease, Number Of Renewal Term Extensions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Operating lease, Renewable term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating lease, term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Cash deposited as bank guarantee</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of change in operating lease monthly rental payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeesAndDirectorsMember" xlink:label="plx_EmployeesAndDirectorsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeesAndDirectorsMember" xlink:to="plx_EmployeesAndDirectorsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Represents information pertaining to employees and directors.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and directors</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options to purchase shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Forfeited and Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited and Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeMember" xlink:to="plx_EmployeeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Non vested at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice1.03To2.00Member" xlink:label="plx_ExercisePrice1.03To2.00Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice1.03To2.00Member" xlink:to="plx_ExercisePrice1.03To2.00Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice1.03To2.00Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price ranging from $1.03 to $2.00.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice1.03To2.00Member_lbl" xml:lang="en-US">Exercise Price 1.03 to 2.00 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExercisePrice1.03To2.00Member_lbl" xml:lang="en-US">$1.03 - $2.00</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice3.55To3.73Member" xlink:label="plx_ExercisePrice3.55To3.73Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.55To3.73Member" xlink:to="plx_ExercisePrice3.55To3.73Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.55To3.73Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price ranging from $3.55 to $3.73.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.55To3.73Member_lbl" xml:lang="en-US">Exercise Price 3.55 to 3.73 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExercisePrice3.55To3.73Member_lbl" xml:lang="en-US">$3.55 - $3.73</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice4.69To5.60Member" xlink:label="plx_ExercisePrice4.69To5.60Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice4.69To5.60Member" xlink:to="plx_ExercisePrice4.69To5.60Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice4.69To5.60Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price ranging from $4.69 to $5.60.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice4.69To5.60Member_lbl" xml:lang="en-US">Exercise Price 4.69 to 5.60 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExercisePrice4.69To5.60Member_lbl" xml:lang="en-US">$4.69 - $5.60</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice17.20Member" xlink:to="plx_ExercisePrice17.20Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice17.20Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price $17.20.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice17.20Member_lbl" xml:lang="en-US">Exercise Price 17.20</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExercisePrice17.20Member_lbl" xml:lang="en-US">$17.20</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Exercise price, lower range</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise price, upper range</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of options outstanding at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Weighted average grants date fair value (USD)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (USD)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (Years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OptionsAndRestrictedSharesMember" xlink:label="plx_OptionsAndRestrictedSharesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedSharesMember" xlink:to="plx_OptionsAndRestrictedSharesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OptionsAndRestrictedSharesMember_lbl" xml:lang="en-US">Represents information pertaining to stock options and restricted shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OptionsAndRestrictedSharesMember_lbl" xml:lang="en-US">Options and Restricted Shares [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OptionsAndRestrictedSharesMember_lbl" xml:lang="en-US">Options and restricted shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_Notes2024Member" xlink:label="plx_Notes2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_Notes2024Member" xlink:to="plx_Notes2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_Notes2024Member_lbl" xml:lang="en-US">Represents the information pertaining to 2024 notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_Notes2024Member_lbl" xml:lang="en-US">Notes 2024 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_Notes2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockNumberOfVotingRights" xlink:to="plx_CommonStockNumberOfVotingRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockNumberOfVotingRights_lbl" xml:lang="en-US">Represents the number of votes for each share of common stock is entitled.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockNumberOfVotingRights_lbl" xml:lang="en-US">Common Stock, Number Of Voting Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommonStockNumberOfVotingRights_lbl" xml:lang="en-US">Number of voting rights</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance under share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares of Common Stock remain available for grant under the plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Vesting-date fair value of stock vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized weighted average period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding options intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Exercisable options intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Number of shares per warrant issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfCommissionOnSaleOfShares" xlink:to="plx_PercentageOfCommissionOnSaleOfShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Percentage of commission on sale of shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Percentage of Commission on Sale of Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Commission (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Fair value at grant</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted instrument, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentsToDebtHoldersOnConversion" xlink:to="plx_PaymentsToDebtHoldersOnConversion_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">Payments To Debt Holders On Conversion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">Paid to the converting holders</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionDecreaseInPrincipalAmount" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">The amount of decrease in the total principal amount of debt due to conversion.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">Debt Conversion, Decrease In Principal Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">Decrease in principal amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Measurement input</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Contractual interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Debt discount amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestCostsIncurred_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestCostsIncurred_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestCostsIncurred_lbl" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Face amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt instrument carrying amount</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Amount of accrued and unpaid interest exchanged in cash in debt conversion.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Exchange in Cash, Accrued and Unpaid Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Convertible notes exchange in cash, accrued and unpaid interest</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Base value for conversion rate</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Number of shares for basis conversion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfPremiumToClosingPriceOfStock" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of premium to closing price of stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of Premium to Closing Price of Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Mature term</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:to="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">The maximum price per share of the conversion feature embedded in the debt instrument.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Maximum Debt Instrument Convertible Conversion Share Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Maximum price per share of the conversion feature</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Threshold trading days</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ThresholdPercentageOfConversionPrice" xlink:label="plx_ThresholdPercentageOfConversionPrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThresholdPercentageOfConversionPrice" xlink:to="plx_ThresholdPercentageOfConversionPrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ThresholdPercentageOfConversionPrice_lbl" xml:lang="en-US">Threshold percentage of conversion price on sale price of the company's common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ThresholdPercentageOfConversionPrice_lbl" xml:lang="en-US">Threshold Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" xlink:to="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_lbl" xml:lang="en-US">Aggregate percentage of principle amount of debt outstanding.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_lbl" xml:lang="en-US">Debt Instrument, Aggregate Percentage Of Principle Amount Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_lbl" xml:lang="en-US">Aggregate percentage of principle amount</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentRedemption" xlink:label="plx_DebtInstrumentRedemption" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentRedemption" xlink:to="plx_DebtInstrumentRedemption_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentRedemption_lbl" xml:lang="en-US">The amount of redemption of debt as at the end of the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentRedemption_lbl" xml:lang="en-US">Debt Instrument, Redemption</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_DebtInstrumentRedemption_lbl" xml:lang="en-US">Amount of redemption of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfOutstandingCapitalStock" xlink:label="plx_PercentageOfOutstandingCapitalStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfOutstandingCapitalStock" xlink:to="plx_PercentageOfOutstandingCapitalStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfOutstandingCapitalStock_lbl" xml:lang="en-US">Percentage of outstanding capital stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfOutstandingCapitalStock_lbl" xml:lang="en-US">Percentage of Outstanding Capital Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_PercentageOfOutstandingCapitalStock_lbl" xml:lang="en-US">Percentage of outstanding capital stock</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:to="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xml:lang="en-US">Represents the denomination of the principal amount of debt that is used in conversion calculations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xml:lang="en-US">Debt Instrument Principal Amount Denomination for Conversion Into Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xml:lang="en-US">Denomination of the principal amount of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" xlink:to="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_lbl" xml:lang="en-US">Number of calendar days after the date of applicable fundamental change purchase date.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_lbl" xml:lang="en-US">Number Of Calendar Days After Date Of Applicable Fundamental Change</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_lbl" xml:lang="en-US">Number of calendar days after the date of applicable fundamental change purchase date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt instrument fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsAndWarrantsMember" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding stock options and warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding stock options and warrants and 2024 notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding Stock Options Warrants And 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Financial expenses of 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Weighted average dilutive effect of 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Weighted average dilutive effect of stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net, Classification [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">In respect of:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredTaxAssetsOtherTimingDifferences" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">The amount of deferred tax assets other timing differences.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">Deferred Tax Assets Other Timing Differences</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">Other timing differences</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Ending Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax computed at the statutory U.S. income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Differences in tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Statutorily non-deductible expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance related to deferred tax assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation allowances</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" xlink:to="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_lbl" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to utilization of carry-forward losses and other temporary items without deferred taxes recognition.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Utilization Of Carry-Forward Losses And Other Temporary Items Without Deferred Taxes Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_lbl" xml:lang="en-US">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" xlink:to="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_lbl" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to withholding tax.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Withholding Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_lbl" xml:lang="en-US">Withholding tax</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="plx_IncomeTaxDisclosureTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US">Income Tax Disclosure Table</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">Income Tax Disclosure Line Items</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" xlink:to="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_lbl" xml:lang="en-US">Amount of additions to the valuation allowance for deferred tax asset.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Additions During The Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_lbl" xml:lang="en-US">Additions to valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" xlink:to="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_lbl" xml:lang="en-US">Amount of reductions to the valuation allowance for deferred tax asset.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Reductions During The Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_lbl" xml:lang="en-US">Reductions to valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Ending Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Increase for tax position related to current year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UsIsraelMember" xlink:to="plx_UsIsraelMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UsIsraelMember_lbl" xml:lang="en-US">Israel</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">United States</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open Tax Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open tax year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US">Parent Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SubsidiariesMember_lbl" xml:lang="en-US">Protalix Ltd</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearThereafterMember" xlink:to="plx_TaxYearThereafterMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TaxYearThereafterMember_lbl" xml:lang="en-US">Law for Amending the Israel Income Tax Ordinance, Tax Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Deferred tax liability of research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" xlink:to="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_lbl" xml:lang="en-US">Amortization period of cost capitalized for research and development cost, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_lbl" xml:lang="en-US">Capitalized Research And Development Cost, Amortization Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_lbl" xml:lang="en-US">Amortization period research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Other assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="plx_OtherAssetsInstitutionsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Other Assets, Institutions, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Institutions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="plx_OtherAssetsSundryCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Other Assets, Sundry, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Sundry</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReserveForDeductionsFromRevenueCurrent" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of reserve for deductions from revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Reserve For Deductions From Revenue Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Sales reserves</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Compensation (including share based compensation) to the non-executive directors</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="plx_PfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromExpenseReimbursements" xlink:to="plx_ProceedsFromExpenseReimbursements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">The cash inflow from expense reimbursements in a collaboration agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from Expense Reimbursements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from expense reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of Products</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan_lbl" xml:lang="en-US">Number of employees to whom plan is granting shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Employees Receiving Grant Under the Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan_lbl" xml:lang="en-US">Number of employees granted shares as bonus</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>plx-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/13/2024 5:48:20 PM-->
<!--Modified on: 3/13/2024 5:48:20 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureCommercializationAgreements" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreements" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipment" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirement" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureCommitments" roleURI="http://www.protalix.com/role/DisclosureCommitments" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureOperatingLeases" roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureRevenue" roleURI="http://www.protalix.com/role/DisclosureRevenue" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapital" roleURI="http://www.protalix.com/role/DisclosureShareCapital" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotes" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotes" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureEarningsLossPerShare" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncome" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureOperatingLeasesTables" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureRevenueTables" roleURI="http://www.protalix.com/role/DisclosureRevenueTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalTables" roleURI="http://www.protalix.com/role/DisclosureShareCapitalTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesTables" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureEarningsLossPerShareTables" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPoliciesGeneralDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureCommercializationAgreementsDetails" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureInventoriesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirementDetails" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureCommitmentsDetails" roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureRevenueDetails" roleURI="http://www.protalix.com/role/DisclosureRevenueDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalSummaryOfStockOptionActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureShareCapitalAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureConvertibleNotesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeValuationAllowanceDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeUncertainTaxPositionDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638459488974026604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638459488974026604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638459488974026604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638459488974026604" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638459488974026604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638459488974026604" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638459488974026604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638459488974026604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638459488974026604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638459488974026604" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638459488974026604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638459488974026604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638459488974026604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638459488974026604" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638459488974036595" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638459488974036595" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638459488974036595" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638459488974036595" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638459488974036595" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638459488974036595" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638459488974036595" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638459488974036595" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638459488974036595" order="16" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638459488974036595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638459488974036595" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638459488974046583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638459488974046583" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638459488974046583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638459488974046583" order="19" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638459488974046583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638459488974046583" order="20" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638459488974046583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638459488974046583" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638459488974046583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638459488974046583" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638459488974046583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638459488974046583" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638459488974046583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638459488974046583" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638459488974046583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638459488974046583" order="25" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638459488974056581" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638459488974056581" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638459488974056581" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638459488974056581" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638459488974056581" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638459488974056581" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638459488974056581" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638459488974056581" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638459488974056581" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638459488974056581" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638459488974056581" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638459488974056581" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638459488974066586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638459488974066586" order="32" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638459488974066586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638459488974066586" order="33" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638459488974066586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638459488974066586" order="34" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638459488974066586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638459488974066586" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638459488974066586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638459488974066586" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638459488974077202" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638459488974077202" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638459488974077202" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638459488974077202" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638459488974077202" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638459488974077202" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638459488974077202" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638459488974077202" xlink:to="us-gaap_AssetsCurrentAbstract_638459488974077202" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638459488974077202" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638459488974077202" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638459488974077202" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638459488974077202" xlink:to="plx_ShortTermBankDeposits_638459488974086597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638459488974077202" xlink:to="us-gaap_AccountsReceivableNetCurrent_638459488974086597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638459488974077202" xlink:to="us-gaap_OtherAssetsCurrent_638459488974086597" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638459488974077202" xlink:to="us-gaap_InventoryNet_638459488974086597" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638459488974077202" xlink:to="us-gaap_AssetsCurrent_638459488974086597" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638459488974077202" xlink:to="us-gaap_AssetsNoncurrentAbstract_638459488974086597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638459488974086597" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638459488974086597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638459488974086597" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638459488974086597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638459488974086597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638459488974086597" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638459488974086597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638459488974086597" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638459488974096590" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638459488974077202" xlink:to="us-gaap_Assets_638459488974096590" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638459488974096590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638459488974096590" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488974096590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488974096590" xlink:to="us-gaap_AccountsPayableTradeCurrent_638459488974096590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488974096590" xlink:to="us-gaap_AccountsPayableOtherCurrent_638459488974096590" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488974096590" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638459488974096590" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638459488974096590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638459488974096590" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638459488974096590" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638459488974106586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638459488974096590" xlink:to="us-gaap_ConvertibleDebtCurrent_638459488974106586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638459488974106586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638459488974096590" xlink:to="us-gaap_LiabilitiesCurrent_638459488974106586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638459488974106586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638459488974106586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638459488974106586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638459488974106586" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638459488974106586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638459488974106586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638459488974106586" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638459488974106586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638459488974116598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638459488974106586" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638459488974116598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638459488974116598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" xlink:to="us-gaap_LiabilitiesNoncurrent_638459488974116598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638459488974116598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" xlink:to="us-gaap_Liabilities_638459488974116598" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638459488974116598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" xlink:to="us-gaap_CommitmentsAndContingencies_638459488974116598" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638459488974116598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" xlink:to="us-gaap_StockholdersEquityAbstract_638459488974116598" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638459488974116598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638459488974116598" xlink:to="us-gaap_CommonStockValue_638459488974116598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638459488974126601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638459488974116598" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638459488974126601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638459488974126601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638459488974116598" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638459488974126601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638459488974126601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" xlink:to="us-gaap_StockholdersEquity_638459488974126601" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638459488974126601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638459488974096590" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638459488974126601" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638459488974136584" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638459488974136584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638459488974136584" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638459488974136584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638459488974136584" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638459488974136584" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638459488974136584" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638459488974136584" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974136584" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638459488974136584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638459488974136584" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974136584" xlink:to="srt_ProductOrServiceAxis_638459488974136584" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638459488974136584" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638459488974136584" xlink:to="srt_ProductsAndServicesDomain_638459488974136584" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638459488974136584" xlink:to="us-gaap_ProductMember_638459488974146599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638459488974136584" xlink:to="us-gaap_LicenseAndServiceMember_638459488974146599" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974136584" xlink:to="us-gaap_StatementLineItems_638459488974146599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_Revenues_638459488974146599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_CostOfRevenue_638459488974146599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638459488974146599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638459488974146599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_OperatingIncomeLoss_638459488974146599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_OtherNonoperatingExpense_638459488974146599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_OtherNonoperatingIncome_638459488974146599" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638459488974146599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_NonoperatingIncomeExpense_638459488974146599" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638459488974156582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638459488974156582" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638459488974156582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638459488974156582" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638459488974156582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_NetIncomeLoss_638459488974156582" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638459488974156582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_EarningsPerShareBasic_638459488974156582" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638459488974156582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_EarningsPerShareDiluted_638459488974156582" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638459488974156582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638459488974156582" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638459488974156582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974146599" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638459488974156582" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974166590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638459488974166590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638459488974166590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974166590" xlink:to="us-gaap_StatementEquityComponentsAxis_638459488974166590" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638459488974166590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638459488974166590" xlink:to="us-gaap_CommonStockMember_638459488974166590" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638459488974166590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638459488974166590" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638459488974166590" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638459488974166590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638459488974166590" xlink:to="us-gaap_RetainedEarningsMember_638459488974166590" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638459488974166590" xlink:to="us-gaap_EquityComponentDomain_638459488974176605" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974166590" xlink:to="us-gaap_StatementLineItems_638459488974176605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_StockholdersEquity_638459488974176605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_SharesOutstanding_638459488974176605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638459488974176605" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638459488974176605" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638459488974176605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638459488974176605" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638459488974176605" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638459488974176605" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638459488974176605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638459488974176605" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638459488974186591" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638459488974186591" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638459488974186591" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638459488974186591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638459488974186591" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_638459488974186591" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638459488974186591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_638459488974186591" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_638459488974186591" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_NetIncomeLoss_638459488974186591" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638459488974186591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_StockholdersEquity_638459488974186591" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638459488974196586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974176605" xlink:to="us-gaap_SharesOutstanding_638459488974196586" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_ProfitLoss_638459488974256595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_ShareBasedCompensation_638459488974256595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_Depreciation_638459488974256595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638459488974256595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638459488974256595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638459488974256595" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638459488974256595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638459488974256595" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638459488974266608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638459488974266608" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488974266608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488974266608" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638459488974266608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="plx_GainLossOnDebtConversion_638459488974266608" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638459488974266608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638459488974266608" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638459488974266608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638459488974266608" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638459488974276604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638459488974266608" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638459488974276604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638459488974276604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638459488974266608" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638459488974276604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638459488974276604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638459488974266608" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638459488974276604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638459488974276604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638459488974266608" xlink:to="us-gaap_IncreaseDecreaseInInventories_638459488974276604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638459488974276604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638459488974266608" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638459488974276604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638459488974276604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638459488974266608" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638459488974276604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488974276604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638459488974256595" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638459488974276604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638459488974286592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" xlink:to="plx_IncreaseDecreaseInBankDeposits_638459488974286592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638459488974286592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638459488974286592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638459488974286592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638459488974286592" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638459488974286592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638459488974286592" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_638459488974286592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_638459488974286592" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638459488974286592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638459488974286592" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488974286592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638459488974276604" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638459488974286592" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638459488974296756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638459488974296756" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638459488974296756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638459488974296756" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638459488974296756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638459488974296756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638459488974296756" xlink:to="us-gaap_RepaymentsOfNotesPayable_638459488974296756" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_638459488974296756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638459488974296756" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_638459488974296756" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638459488974296756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638459488974296756" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638459488974296756" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638459488974296756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638459488974296756" xlink:to="us-gaap_ProceedsFromWarrantExercises_638459488974296756" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488974296756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638459488974296756" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638459488974296756" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638459488974306583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638459488974306583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638459488974306583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638459488974306583" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638459488974306583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638459488974306583" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384594889743065831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384594889743065831" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638459488974306583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638459488974306583" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638459488974306583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638459488974306583" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638459488974306583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638459488974316585" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638459488974306583" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638459488974316585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638459488974316585" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638459488974306583" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638459488974316585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_638459488974316585" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638459488974306583" xlink:to="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_638459488974316585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638459488974316585" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638459488974316585" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638459488974316585" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638459488974316585" xlink:to="us-gaap_InterestPaidNet_638459488974316585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638459488974316585" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638459488974316585" xlink:to="plx_InterestReceivedNet_638459488974316585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638459488974326585" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638459488974326585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreements" xlink:type="extended" xlink:title="10201 - Disclosure - COMMERCIALIZATION AGREEMENTS">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638459488974336611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommercializationAgreementsAbstract_637041422967633303" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638459488974336611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10301 - Disclosure - PROPERTY AND EQUIPMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638459488974336611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967633303" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638459488974336611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10401 - Disclosure - INVENTORIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638459488974336611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638459488974336611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" xlink:type="extended" xlink:title="10501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638459488974336611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638459488974336611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="10601 - Disclosure - COMMITMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_638459488974346598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422967633303" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_638459488974346598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeases" xlink:type="extended" xlink:title="10701 - Disclosure - OPERATING LEASES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638459488974346598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638459488974346598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="10801 - Disclosure - REVENUE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_638459488974346598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_638459488974346598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapital" xlink:type="extended" xlink:title="10901 - Disclosure - SHARE CAPITAL">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638459488974356594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638459488974356594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotes" xlink:type="extended" xlink:title="11001 - Disclosure - CONVERTIBLE NOTES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638459488974356594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422967633303" xlink:to="us-gaap_DebtDisclosureTextBlock_638459488974356594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="11101 - Disclosure - FAIR VALUE MEASUREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638459488974356594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638459488974356594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShare" xlink:type="extended" xlink:title="11201 - Disclosure - EARNINGS (LOSS) PER SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638459488974366596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638459488974366596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncome" xlink:type="extended" xlink:title="11301 - Disclosure - TAXES ON INCOME">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638459488974366596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638459488974366596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="11401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638459488974366596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638459488974366596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11501 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638459488974376605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422967789587" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638459488974376605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11601 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638459488974376605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638459488974376605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638459488974386603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638459488974386603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638459488974386603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638459488974386603" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638459488974386603" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638459488974386603" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638459488974386603" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638459488974386603" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638459488974386603" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638459488974386603" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638459488974386603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638459488974386603" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638459488974396588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638459488974396588" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638459488974396588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638459488974396588" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638459488974396588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638459488974396588" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638459488974396588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638459488974396588" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638459488974396588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638459488974396588" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638459488974396588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638459488974396588" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638459488974396588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638459488974396588" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967804651" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_638459488974406594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967804651" xlink:to="plx_ScheduleOfUsefulLifeTableTextBlock_638459488974406594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967809657" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638459488974406594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967809657" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638459488974406594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30403 - Disclosure - INVENTORIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638459488974406594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638459488974406594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - OPERATING LEASES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638459488974416592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638459488974416592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638459488974416592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638459488974416592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenueTables" xlink:type="extended" xlink:title="30803 - Disclosure - REVENUE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638459488974416592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638459488974416592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalTables" xlink:type="extended" xlink:title="30903 - Disclosure - SHARE CAPITAL (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638459488974416592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638459488974416592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638459488974416592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638459488974416592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638459488974416592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638459488974416592" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638459488974426591" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638459488974426591" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesTables" xlink:type="extended" xlink:title="31003 - Disclosure - CONVERTIBLE NOTES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422967819664" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422967819664" xlink:to="us-gaap_StatementTable_638459488974426591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974426591" xlink:to="us-gaap_DebtInstrumentAxis_638459488974426591" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488974426591" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488974426591" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974426591" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638459488974426591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638459488974426591" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974426591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638459488974426591" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974426591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974426591" xlink:to="us-gaap_StatementLineItems_638459488974426591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638459488974426591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974426591" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638459488974426591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_638459488974436594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974426591" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_638459488974436594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974436594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_638459488974436594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488974436594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974436594" xlink:to="us-gaap_DebtInstrumentAxis_638459488974436594" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488974436594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488974436594" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488974436594" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974436594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974436594" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974436594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974436594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974436594" xlink:to="us-gaap_StatementLineItems_638459488974436594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638459488974436594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974436594" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638459488974436594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" xlink:type="extended" xlink:title="31203 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638459488974446594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638459488974446594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" xlink:type="extended" xlink:title="31303 - Disclosure - TAXES ON INCOME (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638459488974446594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638459488974446594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638459488974446594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638459488974446594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638459488974446594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638459488974446594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_638459488974446594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_638459488974446594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_638459488974456599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_638459488974456599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_638459488974456599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="plx_ScheduleOfOpenTaxYearsTableTextBlock_638459488974456599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="31403 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638459488974456599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638459488974456599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="31503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638459488974456599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638459488974456599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (General) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638459488974466598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974466598" xlink:to="us-gaap_TypeOfArrangementAxis_638459488974466598" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638459488974466598" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974466598" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974466598" xlink:to="plx_AmendedPfizerAgreementMember_638459488974466598" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974466598" xlink:to="plx_ChiesiAgreementsMember_638459488974466598" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638459488974466598" xlink:to="plx_ChiesiUSAgreementMember_638459488974466598" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638459488974466598" xlink:to="plx_ChiesiExUSAgreementMember_638459488974466598" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974466598" xlink:to="plx_FillFinishAgreementMember_638459488974466598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974466598" xlink:to="dei_LegalEntityAxis_638459488974466598" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638459488974466598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638459488974466598" xlink:to="dei_EntityDomain_638459488974466598" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638459488974466598" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638459488974476642" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974466598" xlink:to="srt_StatementGeographicalAxis_638459488974476642" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638459488974476642" xlink:to="srt_SegmentGeographicalDomain_638459488974476642" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638459488974476642" xlink:to="country_BR_638459488974476642" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974466598" xlink:to="srt_RangeAxis_638459488974476642" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488974476642" xlink:to="srt_RangeMember_638459488974476642" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974476642" xlink:to="srt_MinimumMember_638459488974476642" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974476642" xlink:to="srt_MaximumMember_638459488974476642" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488974476642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974466598" xlink:to="us-gaap_DebtInstrumentAxis_638459488974476642" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488974486600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488974476642" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488974486600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638459488974486600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974486600" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638459488974486600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974486600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638459488974486600" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974486600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974486600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638459488974486600" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974486600" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638459488974486600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974466598" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638459488974486600" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974486600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638459488974486600" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974486600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638459488974496604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974486600" xlink:to="plx_AtMarketEquityOfferingMember_638459488974496604" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_638459488974496604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974486600" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_638459488974496604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638459488974496604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974466598" xlink:to="plx_SignificantAccountingPoliciesLineItems_638459488974496604" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638459488974496604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638459488974496604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed_638459488974496604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_NumberOfPatientsDosed_638459488974496604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638459488974496604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638459488974496604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638459488974496604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638459488974496604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638459488974496604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638459488974496604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638459488974506590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638459488974506590" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638459488974506590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638459488974506590" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638459488974506590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638459488974506590" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638459488974506590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638459488974506590" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_638459488974506590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_638459488974506590" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement_638459488974506590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_ExtendedTermOfAgreement_638459488974506590" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_638459488974506590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_AgreementAmendmentPaymentReceivable_638459488974506590" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638459488974516588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638459488974516588" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638459488974516588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638459488974516588" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638459488974516588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_MilestonePaymentReceived_638459488974516588" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638459488974516588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_PaymentOnNetSalesPercentage_638459488974516588" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638459488974516588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638459488974516588" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638459488974516588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="us-gaap_ConvertibleDebtCurrent_638459488974516588" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_638459488974526725" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_RevenuePerformanceObligationNumber_638459488974526725" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638459488974526725" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638459488974526725" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638459488974526725" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638459488974526725" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_638459488974526725" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_MaintainOfMinimumCashBalance_638459488974526725" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638459488974536602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="us-gaap_OperatingLeaseLiability_638459488974536602" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_638459488974536602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_638459488974536602" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_638459488974536602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974496604" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_638459488974536602" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" xlink:type="extended" xlink:title="40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974546601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974546601" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974546601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974546601" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974546601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974546601" xlink:to="plx_LaboratoryEquipmentMember_638459488974546601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974546601" xlink:to="us-gaap_FurnitureAndFixturesMember_638459488974546601" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974546601" xlink:to="us-gaap_ComputerEquipmentMember_638459488974546601" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974546601" xlink:to="srt_RangeAxis_638459488974546601" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488974546601" xlink:to="srt_RangeMember_638459488974546601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974546601" xlink:to="srt_MinimumMember_638459488974546601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488974546601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974546601" xlink:to="srt_MaximumMember_638459488974546601" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638459488974556603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974546601" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638459488974556603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638459488974556603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638459488974556603" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638459488974556603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" xlink:type="extended" xlink:title="40103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638459488974556603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="plx_SignificantAccountingPoliciesTable_638459488974556603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638459488974556603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974556603" xlink:to="srt_MajorCustomersAxis_638459488974556603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638459488974556603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638459488974556603" xlink:to="srt_NameOfMajorCustomerDomain_638459488974556603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember_638459488974556603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638459488974556603" xlink:to="plx_FiocruzMember_638459488974556603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638459488974556603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638459488974556603" xlink:to="plx_ChiesiMember_638459488974556603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638459488974556603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638459488974556603" xlink:to="plx_PfizerMember_638459488974556603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638459488974556603" xlink:to="plx_SignificantAccountingPoliciesLineItems_638459488974566595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638459488974566595" xlink:to="us-gaap_AccountsReceivableNetCurrent_638459488974566595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommercializationAgreementsAbstract" xlink:to="us-gaap_StatementTable_638459488974566595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974566595" xlink:to="us-gaap_TypeOfArrangementAxis_638459488974566595" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638459488974566595" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974566595" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974566595" xlink:to="plx_PfizerMember_638459488974566595" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974566595" xlink:to="plx_ChiesiAgreementsMember_638459488974566595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638459488974566595" xlink:to="plx_ChiesiUSAgreementMember_638459488974566595" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638459488974566595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638459488974566595" xlink:to="plx_ChiesiExUSAgreementMember_638459488974566595" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974566595" xlink:to="srt_RangeAxis_638459488974576613" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488974576613" xlink:to="srt_RangeMember_638459488974576613" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974576613" xlink:to="srt_MaximumMember_638459488974576613" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974576613" xlink:to="srt_MinimumMember_638459488974576613" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974566595" xlink:to="us-gaap_StatementLineItems_638459488974576613" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="us-gaap_NotesPayableCurrent_638459488974576613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="us-gaap_RepaymentsOfNotesPayable_638459488974576613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638459488974576613" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638459488974576613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638459488974576613" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_638459488974586593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_638459488974586593" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638459488974586593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638459488974586593" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638459488974586593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="plx_PaymentOnNetSalesPercentage_638459488974586593" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentInConsiderationForDevelopmentServicesPerformed" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed_638459488974586593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="plx_PaymentInConsiderationForDevelopmentServicesPerformed_638459488974586593" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_638459488974586593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_638459488974586593" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_638459488974586593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974576613" xlink:to="plx_AgreementAmendmentPaymentReceivable_638459488974586593" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968011145" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974586593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968011145" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974586593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974586593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974586593" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974586593" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974596605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974586593" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974596605" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember_638459488974596605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974596605" xlink:to="plx_LaboratoryEquipmentMember_638459488974596605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember_638459488974596605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974596605" xlink:to="plx_FurnitureAndComputerEquipmentMember_638459488974596605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638459488974596605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974596605" xlink:to="us-gaap_LeaseholdImprovementsMember_638459488974596605" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638459488974596605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638459488974586593" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638459488974596605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638459488974596605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638459488974596605" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638459488974596605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638459488974596605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638459488974596605" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638459488974596605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638459488974596605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638459488974596605" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638459488974596605" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968167243" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638459488974606599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968167243" xlink:to="us-gaap_Depreciation_638459488974606599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638459488974606599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638459488974606599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638459488974606599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638459488974606599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638459488974606599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638459488974606599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638459488974606599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638459488974606599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - INVENTORIES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_353300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638459488974606599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_353300" xlink:to="us-gaap_InventoryWriteDown_638459488974606599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="extended" xlink:title="40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_StatementTable_638459488974616595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974616595" xlink:to="us-gaap_RetirementPlanTypeAxis_638459488974616595" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_638459488974616595" xlink:to="us-gaap_RetirementPlanTypeDomain_638459488974616595" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_638459488974616595" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_638459488974616595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_638459488974616595" xlink:to="plx_ContributionPlansMember_638459488974616595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974616595" xlink:to="us-gaap_StatementLineItems_638459488974616595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974616595" xlink:to="plx_EmployeeSeveranceObligationPayment_638459488974616595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974616595" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_638459488974616595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974616595" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638459488974616595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_638459488974616595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974616595" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_638459488974616595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974616595" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_638459488974626599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974616595" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_638459488974626599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422968167243" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422968167243" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638459488974626599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638459488974626599" xlink:to="srt_RangeAxis_638459488974626599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488974626599" xlink:to="srt_RangeMember_638459488974626599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974626599" xlink:to="srt_MinimumMember_638459488974626599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974626599" xlink:to="srt_MaximumMember_638459488974626599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638459488974626599" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638459488974626599" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638459488974626599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638459488974626599" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638459488974626599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638459488974626599" xlink:to="us-gaap_RoyaltyAgreementTermsMember_638459488974636596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638459488974626599" xlink:to="srt_CounterpartyNameAxis_638459488974636596" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638459488974636596" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638459488974636596" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638459488974636596" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember_638459488974636596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638459488974626599" xlink:to="us-gaap_TypeOfArrangementAxis_638459488974636596" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638459488974636596" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974636596" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974636596" xlink:to="plx_ChiesiAgreementsMember_638459488974636596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974636596" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember_638459488974636596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_BusinessDevelopmentConsultantMember" xlink:label="plx_BusinessDevelopmentConsultantMember_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488974636596" xlink:to="plx_BusinessDevelopmentConsultantMember_638459488974636596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638459488974626599" xlink:to="plx_CommitmentsAndContingenciesLineItems_638459488974636596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts_638459488974636596" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638459488974636596" xlink:to="plx_RoyaltiesOnSaleOfProducts_638459488974636596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_638459488974646594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638459488974636596" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived_638459488974646594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_638459488974646594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638459488974636596" xlink:to="us-gaap_RoyaltyExpense_638459488974646594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_638459488974646594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638459488974636596" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_638459488974646594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount_638459488974646594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638459488974636596" xlink:to="plx_CommitmentAmount_638459488974646594" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement_638459488974656618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638459488974636596" xlink:to="plx_ExtendedTermOfAgreement_638459488974656618" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ContractAmountUnderAgreementPayable" xlink:label="plx_ContractAmountUnderAgreementPayable_638459488974656618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638459488974636596" xlink:to="plx_ContractAmountUnderAgreementPayable_638459488974656618" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638459488974656618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_638459488974656618" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638459488974656618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments_638459488974656618" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638459488974656618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638459488974656618" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638459488974666615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638459488974666615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638459488974666615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638459488974666615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638459488974666615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638459488974666615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638459488974666615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638459488974666615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638459488974666615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638459488974666615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638459488974666615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638459488974666615" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638459488974666615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638459488974666615" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638459488974676605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638459488974676605" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638459488974676605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638459488974676605" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638459488974676605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638459488974676605" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488974676605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638459488974676605" xlink:to="srt_RangeAxis_638459488974676605" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488974676605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488974676605" xlink:to="srt_RangeMember_638459488974676605" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638459488974676605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974676605" xlink:to="srt_MinimumMember_638459488974676605" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488974686604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974676605" xlink:to="srt_MaximumMember_638459488974686604" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974686604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638459488974676605" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974686604" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974686604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638459488974686604" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974686604" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_638459488974686604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638459488974686604" xlink:to="us-gaap_VehiclesMember_638459488974686604" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_638459488974686604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638459488974676605" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_638459488974686604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_638459488974686604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638459488974686604" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_638459488974686604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_638459488974686604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638459488974686604" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_638459488974686604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638459488974686604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638459488974686604" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638459488974686604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638459488974696600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638459488974686604" xlink:to="us-gaap_SecurityDeposit_638459488974696600" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_638459488974696600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638459488974686604" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_638459488974696600" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40801 - Disclosure - REVENUE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974696600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_638459488974696600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638459488974696600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974696600" xlink:to="srt_ProductOrServiceAxis_638459488974696600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638459488974696600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638459488974696600" xlink:to="srt_ProductsAndServicesDomain_638459488974696600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638459488974696600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638459488974696600" xlink:to="us-gaap_ProductMember_638459488974696600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638459488974706600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638459488974696600" xlink:to="us-gaap_LicenseAndServiceMember_638459488974706600" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638459488974706600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974696600" xlink:to="srt_StatementGeographicalAxis_638459488974706600" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638459488974706600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638459488974706600" xlink:to="srt_SegmentGeographicalDomain_638459488974706600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638459488974706600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638459488974706600" xlink:to="plx_PfizerMember_638459488974706600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR_638459488974706600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638459488974706600" xlink:to="country_BR_638459488974706600" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638459488974706600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638459488974706600" xlink:to="plx_ChiesiMember_638459488974706600" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974706600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974696600" xlink:to="us-gaap_StatementLineItems_638459488974706600" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638459488974706600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974706600" xlink:to="us-gaap_Revenues_638459488974706600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974716600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974716600" xlink:to="us-gaap_AwardTypeAxis_638459488974716600" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974716600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974716600" xlink:to="us-gaap_EmployeeStockOptionMember_638459488974716600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974716600" xlink:to="srt_TitleOfIndividualAxis_638459488974716600" order="2" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638459488974716600" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488974716600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeesAndDirectorsMember" xlink:label="plx_EmployeesAndDirectorsMember_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488974716600" xlink:to="plx_EmployeesAndDirectorsMember_638459488974716600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974716600" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638459488974716600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638459488974716600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638459488974716600" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638459488974716600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638459488974716600" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638459488974726590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638459488974726590" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638459488974726590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638459488974726590" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638459488974726590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974716600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638459488974726590" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638459488974726590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638459488974726590" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638459488974726590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638459488974726590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638459488974726590" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638459488974726590" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638459488974726590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638459488974726590" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638459488974726590" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384594889747265901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638459488974726590" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384594889747265901" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638459488974726590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638459488974726590" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638459488974726590" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974736586" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974736586" xlink:to="srt_TitleOfIndividualAxis_638459488974736586" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638459488974736586" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488974736586" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488974736586" xlink:to="plx_EmployeeMember_638459488974736586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974736586" xlink:to="us-gaap_AwardTypeAxis_638459488974736586" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638459488974736586" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974736586" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974736586" xlink:to="us-gaap_RestrictedStockMember_638459488974736586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974736586" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974736586" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638459488974736586" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974736586" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638459488974736586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638459488974746593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974736586" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638459488974746593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638459488974746593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974736586" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638459488974746593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638459488974746593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974736586" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638459488974746593" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="40903 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638459488974746593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638459488974746593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638459488974746593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638459488974746593" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638459488974746593" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638459488974746593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638459488974746593" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638459488974746593" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice1.03To2.00Member" xlink:label="plx_ExercisePrice1.03To2.00Member_638459488974756602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638459488974746593" xlink:to="plx_ExercisePrice1.03To2.00Member_638459488974756602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice3.55To3.73Member" xlink:label="plx_ExercisePrice3.55To3.73Member_638459488974756602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638459488974746593" xlink:to="plx_ExercisePrice3.55To3.73Member_638459488974756602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice4.69To5.60Member" xlink:label="plx_ExercisePrice4.69To5.60Member_638459488974756602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638459488974746593" xlink:to="plx_ExercisePrice4.69To5.60Member_638459488974756602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member_638459488974756602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638459488974746593" xlink:to="plx_ExercisePrice17.20Member_638459488974756602" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638459488974756602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638459488974746593" xlink:to="us-gaap_AwardTypeAxis_638459488974756602" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974756602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638459488974756602" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974756602" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638459488974756602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974756602" xlink:to="us-gaap_EmployeeStockOptionMember_638459488974756602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638459488974766618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638459488974746593" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638459488974766618" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638459488974766618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638459488974766618" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638459488974766618" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638459488974766618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638459488974766618" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638459488974766618" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638459488974766618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638459488974766618" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638459488974766618" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638459488974766618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638459488974766618" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638459488974766618" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638459488974766618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638459488974766618" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638459488974766618" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_638459488974766618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638459488974766618" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_638459488974766618" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974776686" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974776686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638459488974776686" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974776686" xlink:to="us-gaap_AwardTypeAxis_638459488974776686" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974776686" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638459488974776686" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974776686" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638459488974776686" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974776686" xlink:to="us-gaap_EmployeeStockOptionMember_638459488974776686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974776686" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974776686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974776686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638459488974776686" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974776686" xlink:to="us-gaap_SharePrice_638459488974776686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638459488974786613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974776686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638459488974786613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638459488974786613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974776686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638459488974786613" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638459488974786613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974776686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638459488974786613" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638459488974786613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974776686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638459488974786613" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638459488974786613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974776686" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638459488974786613" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638459488974786613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638459488974786613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638459488974786613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638459488974786613" xlink:to="us-gaap_IncomeStatementLocationAxis_638459488974786613" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638459488974786613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638459488974786613" xlink:to="us-gaap_IncomeStatementLocationDomain_638459488974786613" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638459488974796599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638459488974786613" xlink:to="us-gaap_CostOfSalesMember_638459488974796599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638459488974796599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638459488974786613" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638459488974796599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638459488974796599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638459488974786613" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638459488974796599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638459488974796599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638459488974786613" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638459488974796599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638459488974796599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638459488974796599" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638459488974796599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" xlink:type="extended" xlink:title="40906 - Disclosure - SHARE CAPITAL (Additional information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974796599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974796599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638459488974806601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974796599" xlink:to="us-gaap_AwardTypeAxis_638459488974806601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974806601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638459488974806601" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974806601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OptionsAndRestrictedSharesMember" xlink:label="plx_OptionsAndRestrictedSharesMember_638459488974806601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488974806601" xlink:to="plx_OptionsAndRestrictedSharesMember_638459488974806601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638459488974806601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_OptionsAndRestrictedSharesMember_638459488974806601" xlink:to="us-gaap_EmployeeStockOptionMember_638459488974806601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638459488974806601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_OptionsAndRestrictedSharesMember_638459488974806601" xlink:to="us-gaap_RestrictedStockMember_638459488974806601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638459488974806601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974796599" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638459488974806601" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974806601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638459488974806601" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974806601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974806601" xlink:to="us-gaap_PrivatePlacementMember_638459488974816611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974806601" xlink:to="plx_AtMarketEquityOfferingMember_638459488974816611" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974806601" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_638459488974816611" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638459488974806601" xlink:to="us-gaap_OverAllotmentOptionMember_638459488974816611" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974796599" xlink:to="us-gaap_PlanNameAxis_638459488974816611" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638459488974816611" xlink:to="us-gaap_PlanNameDomain_638459488974816611" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638459488974816611" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638459488974816611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974796599" xlink:to="us-gaap_DebtInstrumentAxis_638459488974816611" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488974816611" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488974816611" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_Notes2024Member" xlink:label="plx_Notes2024Member_638459488974816611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974816611" xlink:to="plx_Notes2024Member_638459488974816611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488974826759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974796599" xlink:to="srt_RangeAxis_638459488974826759" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488974826759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488974826759" xlink:to="srt_RangeMember_638459488974826759" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638459488974826759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974826759" xlink:to="srt_MinimumMember_638459488974826759" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488974826759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974826759" xlink:to="srt_MaximumMember_638459488974826759" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638459488974796599" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638459488974826759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_CommonStockSharesAuthorized_638459488974826759" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights_638459488974826759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="plx_CommonStockNumberOfVotingRights_638459488974826759" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638459488974836593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638459488974836593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638459488974836593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638459488974836593" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638459488974836593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638459488974836593" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638459488974836593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638459488974836593" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638459488974896601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638459488974896601" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638459488974906614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638459488974906614" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638459488974906614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638459488974906614" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638459488974906614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638459488974906614" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638459488974906614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638459488974906614" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638459488974906614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638459488974906614" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638459488974906614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638459488974906614" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638459488974916602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638459488974916602" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638459488974916602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_638459488974916602" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638459488974916602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638459488974916602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638459488974916602" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638459488974916602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ProceedsFromWarrantExercises_638459488974916602" order="16" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638459488974916602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638459488974916602" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638459488974926594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638459488974926594" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_638459488974926594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="plx_PercentageOfCommissionOnSaleOfShares_638459488974926594" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638459488974926594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638459488974926594" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638459488974926594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_SharePrice_638459488974926594" order="21" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638459488974926594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638459488974926594" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638459488974926594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638459488974926594" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638459488974936592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638459488974936592" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638459488974936592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638459488974936592" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion_638459488974936592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="plx_PaymentsToDebtHoldersOnConversion_638459488974936592" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_638459488974936592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638459488974826759" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount_638459488974936592" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422968636206" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974946599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422968636206" xlink:to="us-gaap_StatementTable_638459488974946599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488974946599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974946599" xlink:to="us-gaap_DebtInstrumentAxis_638459488974946599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488974946599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488974946599" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488974946599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974946599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974946599" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974946599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974946599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974946599" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974946599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638459488974946599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974946599" xlink:to="us-gaap_MeasurementInputTypeAxis_638459488974946599" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638459488974946599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638459488974946599" xlink:to="us-gaap_MeasurementInputTypeDomain_638459488974946599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488974946599" xlink:to="us-gaap_MeasurementInputSharePriceMember_638459488974956601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488974946599" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638459488974956601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488974946599" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638459488974956601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488974946599" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638459488974956601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488974946599" xlink:to="plx_MeasurementInputYieldMember_638459488974956601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974946599" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488974956601" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488974956601" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488974956601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488974956601" xlink:to="us-gaap_FairValueInputsLevel3Member_638459488974956601" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974946599" xlink:to="us-gaap_StatementLineItems_638459488974956601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_638459488974956601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974956601" xlink:to="us-gaap_DebtInstrumentMeasurementInput_638459488974956601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637520135041292011" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974966594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637520135041292011" xlink:to="us-gaap_StatementTable_638459488974966594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488974966594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974966594" xlink:to="us-gaap_DebtInstrumentAxis_638459488974966594" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488974966594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488974966594" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488974966594" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974966594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974966594" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974966594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974966594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974966594" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974966594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974966594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974966594" xlink:to="us-gaap_StatementLineItems_638459488974966594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638459488974966594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974966594" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638459488974966594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638459488974976604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974966594" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638459488974976604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488974976604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974966594" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488974976604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638459488974976604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974966594" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638459488974976604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred_638459488974976604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974966594" xlink:to="us-gaap_InterestCostsIncurred_638459488974976604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="extended" xlink:title="41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422968636206" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638459488974976604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422968636206" xlink:to="us-gaap_StatementTable_638459488974976604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488974976604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974976604" xlink:to="us-gaap_DebtInstrumentAxis_638459488974976604" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488974976604" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488974986610" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974986610" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_638459488974986610" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488974986610" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488974986610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974976604" xlink:to="srt_RangeAxis_638459488974986610" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488974986610" xlink:to="srt_RangeMember_638459488974986610" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974986610" xlink:to="srt_MinimumMember_638459488974986610" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488974986610" xlink:to="srt_MaximumMember_638459488974986610" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638459488974976604" xlink:to="us-gaap_StatementLineItems_638459488974986610" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtInstrumentFaceAmount_638459488974986610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638459488974986610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638459488974986610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638459488974986610" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_638459488974996766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_638459488974996766" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_638459488974996766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_638459488974996766" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_638459488974996766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_638459488974996766" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_638459488974996766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_638459488974996766" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_638459488974996766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_638459488974996766" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638459488974996766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638459488974996766" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638459488974996766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtInstrumentTerm_638459488974996766" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488974996766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638459488974996766" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_638459488975006758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_638459488975006758" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_638459488975006758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_638459488975006758" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_638459488975006758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_638459488975006758" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_638459488975006758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_MaintainOfMinimumCashBalance_638459488975006758" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_638459488975006758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_638459488975006758" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt_638459488975006758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_ConvertibleDebt_638459488975006758" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_638459488975006758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_638459488975006758" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_638459488975006758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_638459488975006758" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ThresholdPercentageOfConversionPrice" xlink:label="plx_ThresholdPercentageOfConversionPrice_638459488975016593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_ThresholdPercentageOfConversionPrice_638459488975016593" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_638459488975016593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_638459488975016593" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentRedemption" xlink:label="plx_DebtInstrumentRedemption_638459488975016593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_DebtInstrumentRedemption_638459488975016593" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PercentageOfOutstandingCapitalStock" xlink:label="plx_PercentageOfOutstandingCapitalStock_638459488975016593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_PercentageOfOutstandingCapitalStock_638459488975016593" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_638459488975016593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_638459488975016593" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_638459488975026591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_638459488975026591" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_638459488975026591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_638459488975026591" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638459488975026591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488974986610" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638459488975026591" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975026591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975026591" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488975026591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975026591" xlink:to="us-gaap_DebtInstrumentAxis_638459488975026591" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488975026591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488975026591" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488975026591" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638459488975026591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488975026591" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638459488975026591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488975036600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638459488975026591" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488975036600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488975036600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975026591" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488975036600" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488975036600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488975036600" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488975036600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638459488975036600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488975036600" xlink:to="us-gaap_FairValueInputsLevel3Member_638459488975036600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638459488975036600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975026591" xlink:to="us-gaap_MeasurementInputTypeAxis_638459488975036600" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638459488975036600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638459488975036600" xlink:to="us-gaap_MeasurementInputTypeDomain_638459488975036600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638459488975036600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488975036600" xlink:to="us-gaap_MeasurementInputSharePriceMember_638459488975036600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638459488975046613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488975036600" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638459488975046613" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638459488975046613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488975036600" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638459488975046613" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638459488975046613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488975036600" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638459488975046613" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_638459488975046613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638459488975036600" xlink:to="plx_MeasurementInputYieldMember_638459488975046613" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488975046613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975026591" xlink:to="us-gaap_StatementLineItems_638459488975046613" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_638459488975046613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488975046613" xlink:to="us-gaap_DebtInstrumentMeasurementInput_638459488975046613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975056599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975056599" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488975056599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638459488975056599" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488975056599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638459488975056599" xlink:to="us-gaap_FairValueInputsLevel3Member_638459488975056599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975056599" xlink:to="us-gaap_DebtInstrumentAxis_638459488975056599" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638459488975056599" xlink:to="us-gaap_DebtInstrumentNameDomain_638459488975056599" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638459488975056599" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638459488975056599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638459488975056599" xlink:to="us-gaap_StatementLineItems_638459488975056599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638459488975056599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488975056599" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638459488975056599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638459488975066604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638459488975056599" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638459488975066604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638459488975066604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638459488975066604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638459488975066604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638459488975066604" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638459488975066604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638459488975066604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638459488975066604" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638459488975066604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_638459488975066604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638459488975066604" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_638459488975066604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638459488975076661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638459488975066604" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638459488975076661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638459488975076661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638459488975066604" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638459488975076661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638459488975076661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638459488975076661" xlink:to="us-gaap_NetIncomeLossAbstract_638459488975076661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638459488975076661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638459488975076661" xlink:to="us-gaap_NetIncomeLoss_638459488975076661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638459488975076661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638459488975076661" xlink:to="us-gaap_DilutiveSecurities_638459488975076661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638459488975076661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638459488975076661" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638459488975076661" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638459488975076661" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638459488975076661" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638459488975076661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638459488975086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638459488975076661" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638459488975086664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638459488975086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638459488975076661" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638459488975086664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638459488975086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638459488975076661" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638459488975086664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638459488975086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638459488975076661" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638459488975086664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638459488975086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638459488975076661" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638459488975086664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638459488975086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638459488975086664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638459488975086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638459488975086664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638459488975096602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638459488975096602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41302 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638459488975096602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638459488975096602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638459488975096602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638459488975096602" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638459488975096602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_638459488975096602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638459488975096602" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_638459488975096602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638459488975096602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638459488975096602" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638459488975096602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638459488975096602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638459488975096602" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638459488975096602" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638459488975096602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638459488975096602" xlink:to="us-gaap_DeferredTaxAssetsNet_638459488975096602" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" xlink:type="extended" xlink:title="41303 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638459488975106602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638459488975106602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638459488975106602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638459488975106602" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_638459488975106602" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_638459488975106602" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638459488975106602" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails" xlink:type="extended" xlink:title="41304 - Disclosure - TAXES ON INCOME (Valuation Allowance) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638459488975106602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_638459488975106602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_638459488975106602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_638459488975116599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_638459488975116599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638459488975116599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638459488975116599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails" xlink:type="extended" xlink:title="41305 - Disclosure - TAXES ON INCOME (Uncertain Tax Position) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638459488975116599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefits_638459488975116599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638459488975116599" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638459488975116599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6384594889751165991" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefits_6384594889751165991" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" xlink:type="extended" xlink:title="41306 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_IncomeTaxContingencyTable_638459488975126614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_638459488975126614" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638459488975126614" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638459488975126614" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638459488975126614" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638459488975126614" xlink:to="plx_UsIsraelMember_638459488975126614" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638459488975126614" xlink:to="country_US_638459488975126614" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_638459488975126614" xlink:to="srt_RangeAxis_638459488975126614" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488975126614" xlink:to="srt_RangeMember_638459488975126614" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488975126614" xlink:to="srt_MinimumMember_638459488975126614" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488975126614" xlink:to="srt_MaximumMember_638459488975126614" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems_638459488975126614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_638459488975126614" xlink:to="us-gaap_IncomeTaxContingencyLineItems_638459488975126614" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems_638459488975126614" xlink:to="us-gaap_OpenTaxYear_638459488975136600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="41307 - Disclosure - TAXES ON INCOME (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="plx_IncomeTaxDisclosureTable_638459488975136600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638459488975136600" xlink:to="srt_RangeAxis_638459488975136600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638459488975136600" xlink:to="srt_RangeMember_638459488975136600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638459488975136600" xlink:to="srt_MaximumMember_638459488975136600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638459488975136600" xlink:to="srt_ConsolidatedEntitiesAxis_638459488975136600" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis_638459488975136600" xlink:to="srt_ConsolidatedEntitiesDomain_638459488975136600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_638459488975136600" xlink:to="srt_ParentCompanyMember_638459488975136600" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember_638459488975136600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_638459488975136600" xlink:to="srt_SubsidiariesMember_638459488975136600" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638459488975136600" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638459488975146610" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638459488975146610" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638459488975146610" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638459488975146610" xlink:to="plx_TaxYearThereafterMember_638459488975146610" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638459488975136600" xlink:to="plx_IncomeTaxDisclosureLineItems_638459488975146610" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638459488975146610" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638459488975146610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638459488975146610" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638459488975146610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638459488975146610" xlink:to="plx_MilestonePaymentReceived_638459488975146610" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638459488975146610" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638459488975146610" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_638459488975146610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638459488975146610" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_638459488975146610" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_638459488975156601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638459488975146610" xlink:to="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_638459488975156601" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638459488975156601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638459488975146610" xlink:to="us-gaap_OperatingLossCarryforwards_638459488975156601" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638459488975156601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422968852328" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638459488975156601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent_638459488975156601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638459488975156601" xlink:to="plx_OtherAssetsInstitutionsCurrent_638459488975156601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638459488975156601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638459488975156601" xlink:to="us-gaap_PrepaidExpenseCurrent_638459488975156601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent_638459488975156601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638459488975156601" xlink:to="plx_OtherAssetsSundryCurrent_638459488975156601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638459488975166605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638459488975156601" xlink:to="us-gaap_OtherAssetsCurrent_638459488975166605" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="41402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638459488975166605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638459488975166605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638459488975166605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="us-gaap_InterestPayableCurrent_638459488975166605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638459488975166605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="us-gaap_AccruedVacationCurrent_638459488975166605" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638459488975166605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638459488975166605" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638459488975166605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638459488975166605" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638459488975176604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="us-gaap_TaxesPayableCurrent_638459488975176604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638459488975176604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638459488975176604" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638459488975176604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638459488975176604" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638459488975176604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638459488975166605" xlink:to="us-gaap_AccountsPayableCurrent_638459488975176604" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638459488975176604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422969008821" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638459488975176604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638459488975176604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638459488975176604" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638459488975176604" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638459488975186611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638459488975176604" xlink:to="us-gaap_RelatedPartyDomain_638459488975186611" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638459488975186611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638459488975186611" xlink:to="us-gaap_RelatedPartyMember_638459488975186611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638459488975186611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638459488975176604" xlink:to="srt_CounterpartyNameAxis_638459488975186611" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638459488975186611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638459488975186611" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638459488975186611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638459488975186611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638459488975186611" xlink:to="srt_DirectorMember_638459488975186611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638459488975186611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638459488975176604" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638459488975186611" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638459488975186611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638459488975186611" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638459488975186611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638459488975196604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638459488975196604" xlink:to="us-gaap_SubsequentEventTypeAxis_638459488975196604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638459488975196604" xlink:to="us-gaap_SubsequentEventTypeDomain_638459488975196604" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638459488975196604" xlink:to="us-gaap_SubsequentEventMember_638459488975196604" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638459488975196604" xlink:to="us-gaap_AwardTypeAxis_638459488975196604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638459488975196604" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488975196604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488975196604" xlink:to="us-gaap_EmployeeStockOptionMember_638459488975196604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638459488975196604" xlink:to="us-gaap_RestrictedStockMember_638459488975196604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638459488975196604" xlink:to="srt_TitleOfIndividualAxis_638459488975196604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638459488975196604" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488975196604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember_638459488975196604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638459488975196604" xlink:to="plx_EmployeeMember_638459488975196604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638459488975196604" xlink:to="us-gaap_TypeOfArrangementAxis_638459488975206598" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638459488975206598" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488975206598" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488975206598" xlink:to="plx_PfizerAgreementMember_638459488975206598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638459488975206598" xlink:to="plx_ChiesiAgreementsMember_638459488975206598" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638459488975196604" xlink:to="us-gaap_SubsequentEventLineItems_638459488975206598" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="plx_ProceedsFromExpenseReimbursements_638459488975206598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638459488975206598" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638459488975206598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638459488975206598" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638459488975206598" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638459488975206598" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_638459488975216595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="plx_ProceedsFromSaleOfProducts_638459488975216595" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638459488975216595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638459488975216595" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan_638459488975216595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan_638459488975216595" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638459488975216595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638459488975216595" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20231231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638459488975216595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638459488975206598" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638459488975216595" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470741312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,052,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Kesselman & Kesselman C.P.A.s<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470468240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 23,634<span></span>
</td>
<td class="nump">$ 17,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">20,926<span></span>
</td>
<td class="nump">5,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">4,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">19,045<span></span>
</td>
<td class="nump">16,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">69,932<span></span>
</td>
<td class="nump">44,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,973<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">3,092<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,909<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">84,434<span></span>
</td>
<td class="nump">55,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">4,320<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">19,550<span></span>
</td>
<td class="nump">12,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">20,251<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,530<span></span>
</td>
<td class="nump">32,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">4,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">5,335<span></span>
</td>
<td class="nump">33,998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">50,865<span></span>
</td>
<td class="nump">66,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value: Authorized - as of December 31, 2022 and 2023, 144,000,000 and 185,000,000 shares, respectively; issued and outstanding - as of December 31, 2022 and 2023, 53,790,167 and 72,952,124 shares, respectively</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">415,045<span></span>
</td>
<td class="nump">379,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(381,549)<span></span>
</td>
<td class="num">(389,861)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (capital deficiency)</a></td>
<td class="nump">33,569<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (net of capital deficiency)</a></td>
<td class="nump">$ 84,434<span></span>
</td>
<td class="nump">$ 55,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354471091536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, issued</a></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="nump">53,790,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding</a></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="nump">53,790,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470884976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 65,494<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="nump">$ 38,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(22,982)<span></span>
</td>
<td class="num">(19,592)<span></span>
</td>
<td class="num">(16,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(17,093)<span></span>
</td>
<td class="num">(29,349)<span></span>
</td>
<td class="num">(29,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(14,959)<span></span>
</td>
<td class="num">(11,711)<span></span>
</td>
<td class="num">(12,729)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="nump">10,460<span></span>
</td>
<td class="num">(13,014)<span></span>
</td>
<td class="num">(20,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(3,180)<span></span>
</td>
<td class="num">(2,529)<span></span>
</td>
<td class="num">(7,521)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="num">(1,894)<span></span>
</td>
<td class="num">(1,383)<span></span>
</td>
<td class="num">(7,120)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">8,566<span></span>
</td>
<td class="num">(14,397)<span></span>
</td>
<td class="num">(27,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS) FOR THE PERIOD</a></td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
<td class="num">$ (27,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC</a></td>
<td class="nump">67,512,527<span></span>
</td>
<td class="nump">48,472,159<span></span>
</td>
<td class="nump">44,140,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED</a></td>
<td class="nump">82,424,016<span></span>
</td>
<td class="nump">48,472,159<span></span>
</td>
<td class="nump">44,140,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 40,418<span></span>
</td>
<td class="nump">$ 25,292<span></span>
</td>
<td class="nump">$ 16,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 25,076<span></span>
</td>
<td class="nump">$ 22,346<span></span>
</td>
<td class="nump">$ 21,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470589664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 320,280<span></span>
</td>
<td class="num">$ (347,352)<span></span>
</td>
<td class="num">$ (27,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">34,765,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,582)<span></span>
</td>
<td class="num">(27,582)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">368,852<span></span>
</td>
<td class="num">(374,934)<span></span>
</td>
<td class="num">(6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">8,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">7,473,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="nump">759,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,927)<span></span>
</td>
<td class="num">(14,927)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">379,167<span></span>
</td>
<td class="num">(389,861)<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">53,790,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">23,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="nump">1,371,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">538,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,312<span></span>
</td>
<td class="nump">8,312<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 415,045<span></span>
</td>
<td class="num">$ (381,549)<span></span>
</td>
<td class="nump">$ 33,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Notes Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reacquisition Of Equity Component Of Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReacquisitionOfEquityComponentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354467637456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
<td class="num">$ (27,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,448<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net</a></td>
<td class="num">(446)<span></span>
</td>
<td class="num">(989)<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(543)<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred tax asset</a></td>
<td class="num">(3,092)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on sale of fixed assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnDebtConversion', window );">Gain on conversions of convertible notes</a></td>
<td class="num">(421)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability</a></td>
<td class="num">(13,178)<span></span>
</td>
<td class="num">(7,162)<span></span>
</td>
<td class="nump">13,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable-trade and other assets</a></td>
<td class="num">(428)<span></span>
</td>
<td class="num">(1,194)<span></span>
</td>
<td class="num">(1,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(2,241)<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="num">(4,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">5,295<span></span>
</td>
<td class="num">(4,804)<span></span>
</td>
<td class="nump">2,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(10,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="num">(20,420)<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(37,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">57,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,149)<span></span>
</td>
<td class="num">(628)<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInRestrictedDeposit', window );">Decrease in restricted deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts paid (funded) in respect of employee rights upon retirement, net</a></td>
<td class="num">(142)<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(16,711)<span></span>
</td>
<td class="num">(5,035)<span></span>
</td>
<td class="nump">18,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment for convertible notes redemption and transactions costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">23,954<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">24,666<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
<td class="nump">12,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">6,523<span></span>
</td>
<td class="num">(21,874)<span></span>
</td>
<td class="nump">20,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</a></td>
<td class="nump">17,111<span></span>
</td>
<td class="nump">38,985<span></span>
</td>
<td class="nump">18,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</a></td>
<td class="nump">23,634<span></span>
</td>
<td class="nump">17,111<span></span>
</td>
<td class="nump">38,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">794<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes conversions</a></td>
<td class="nump">7,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds', window );">Partial settlement of liability for employee rights upon retirement through transfer of the related funds</a></td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">2,742<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
<td class="nump">3,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of partial settlement of liability for employee rights upon retirement through transfer of related funds in non-cash financing and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476052304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain and Switzerland. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the BALANCE study (also referred to as Study PB-102-F20). The FDA review team also concluded that the BALANCE study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the BALANCE study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of December&#160;31, 2023, 56 patients have been dosed in this trial. The Company expects to publish preliminary results of this study during the second quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of December&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it was entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and, under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. As of the issuance of these financial statements, the impact of the war has not had a material adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. See also <a href="#_NOTE_10_"><span style="font-style:normal;font-weight:normal;">Note 10</span></a> with regards to financial covenants under the terms of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of December&#160;31, 2023, the Company is in compliance with all such covenants. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to the assessment of sales reserves and valuation allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2023 and 2022, the allowance was negligible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">No write-off activity and recoveries for the periods presented were recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances. The sales reserve is calculated based on expected sales and the anticipated net average selling price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent the variable consideration is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also <a href="#_k.__"><span style="font-style:normal;font-weight:normal;">revenue from selling products</span></a> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2022, the accounts receivables balance was composed of $2.3&#160;million from Fiocruz, $1.2&#160;million from Chiesi and $1.1&#160;million from Pfizer, and, as of December&#160;31, 2023, the accounts receivables balance was composed of $0.7&#160;million from Chiesi and $4.6&#160;million from Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for </span>restricted stock <span style="background:#ffffff;">based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees, consultants and other service providers with only service conditions that has a graded vesting schedule using the accelerated method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net earnings (loss) per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, a total of $20.42&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;New accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures<span style="font-family:'Palatino Linotype';">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470693184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIALIZATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommercializationAgreementsAbstract', window );"><strong>COMMERCIALIZATION AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COMMERCIALIZATION AGREEMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer that amended and restated the Pfizer Agreement of November&#160;30, 2009. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix Ltd. also agreed to provide Pfizer with:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</span>Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">2.</span>Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Promissory note&#160;&#8211; as of the date of the amendment, the Company issued to Pfizer a $4.3&#160;million promissory representing the Company&#8217;s share of accumulated losses incurred under the Collaboration </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operation. The promissory note was subsequently amended. <span style="background:#ffffff;">On March&#160;29, 2021, the Company paid approximately </span><span style="background:#ffffff;">$4.0</span><span style="background:#ffffff;">&#160;million to Pfizer satisfying the promissory note in full. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">b.</b>&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#8211; the drug) for the treatment of Fabry disease. Under the terms of the Chiesi Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix&#160;Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$10.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$320.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix Ltd. will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Chiesi does not have sublicensing rights (except for certain territories).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In July 2018, Protalix Ltd. entered into the Chiesi U.S.&#160;Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi U.S.&#160;Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$20.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$760.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement, which has been reduced to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$735.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">40%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Chiesi does not have sublicensing rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, the Company has received, or is entitled to receive, the following payments from Chiesi:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront payments equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$50.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million, in the aggregate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$45.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in consideration for development services performed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$51.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in connection with the performance of extension studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">Payments equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$30.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#160;million in lieu of certain milestone payments.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">c.</b>&#160;&#160;&#160;&#160;On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommercializationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommercializationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476307936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3 - PROPERTY AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;</b>Composition of property and equipment grouped by major classifications is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,933</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,084</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,644</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,661</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,686)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,688)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,973</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>Depreciation in respect of property and equipment totaled approximately $1.1&#160;million, $1.1&#160;million and $1.2&#160;million for the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476096848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;- INVENTORIES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inventories at December&#160;31, 2022 and 2023 consisted of the following:</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,176</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,055</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,814</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,045</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>During the&#160;years ended December&#160;31, 2021, 2022 and 2023, the Company recorded approximately $0.4&#160;million, $0.04&#160;million and $0.8&#160;million, respectively, for write-down of inventory under cost of goods sold.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476133008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#8217;s salary for each&#160;year employed) is recorded on the Company&#8217;s balance sheets under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#8217;s balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2021, 2022 and 2023, the Company deposited approximately $108,000, $96,000 and $142,000, respectively, with insurance companies in connection with its severance payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#8217;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plans&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The amounts of severance pay expenses were approximately $990,000, $945,000 and $801,000 for each of the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively, of which approximately $857,000, $800,000 and $798,000 in the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively, were in respect of the Contribution Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately $100,000, $(3,000) and $50,000 for the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company expects to contribute approximately $922,000 in the&#160;year ending December&#160;31, 2024 to insurance companies in connection with its severance liabilities, approximately $888,000 of which will be contributed to one or more Contribution Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the five-year period following December&#160;31, 2023, the Company expects no employee retirement upon normal retirement age. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476115216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;6&#160;- COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Royalty Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is obligated to pay royalties to the National Authority for Technological Innovation (&#8220;NATI&#8221;) on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of the applicable funding arrangements, royalties of 3% to 6% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on LIBOR (from January 2024 the annual rate is based on SOFR). In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will, subject to certain exceptions, be required to pay an increased total amount of royalties, depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $1.2&#160;million, $1.2&#160;million and $1.9&#160;million during the years ended December&#160;31, 2021, 2022 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">At December&#160;31, 2022 and 2023, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $37.4&#160;million and $35.5&#160;million, respectively (without interest, assuming 100% of the funds are payable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Subcontracting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2023, total commitments under said agreements were approximately $0.4&#160;million. In addition, we have a $0.1&#160;million commitment payable to a business development consultant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Fill/Finish Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:10pt;">On August&#160;29, 2022, the Company entered into the F/F&#160;Agreement and the Letter Agreement. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F&#160;Agreement did not change the terms and conditions of the Chiesi Agreements. The F/F&#160;Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement and the term may be extended by mutual agreement for an additional period of </span><span style="font-size:10pt;">seven years</span><span style="font-size:10pt;"> upon mutual written agreement prior to expiration of the initial term. Under the F/F&#160;Agreement, the Company is obligated to pay to Chiesi an amount equal to </span>&#8364;2.5&#160;million in connection with the necessary technology transfer, QA tests and capital expenditures. <span style="font-size:10pt;">Such amount is to be paid over the term of the F/F agreement based on the actual vials produced by Chiesi thereunder.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476069712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 7 - OPERATING LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the option to extend certain of such agreements on one additional occasion for an additional five-year period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by 7.5%-10% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2023, the Company provided bank guarantees of approximately $502,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2021, 2022 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,632</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,391</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,409</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,397</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,125</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,044</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,057</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,032</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,002</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,030</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476144928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 8 - REVENUE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,522</p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,401</p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,495</p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,418</p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,076</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the year ended December&#160;31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476125808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;9&#160;- SHARE CAPITAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Authorized Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 144,000,000 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">to 185,000,000. The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">b.</b></span>Rights of the Company&#8217;s Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s Common Stock is listed on the NYSE American. The Company voluntarily delisted its Common Stock from the Tel Aviv Stock Exchange effective March&#160;22, 2023. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Stock based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to 12,475,171 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;102 and 102A of the Israeli Income Tax Ordinance (the &#8220;Ordinance&#8221;). Each option grant made to an Israeli citizen is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#8217;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Ordinance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, 633,409 shares of Common Stock remain available for grant under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The vesting period of the outstanding options and restricted shares is generally <span style="-sec-ix-hidden:Hidden_8ZPqFDiPQU29lutivXBeTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or four years from the date of grant. The rights of common stock obtained from the exercise of options (once vested) and the restricted stock are identical to those of other common stock of the Company. The contractual term of these options is primarily for ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company&#8217;s management uses the fair value of the Common Stock. <span style="background:#ffffff;">The fair value of options granted for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Options and restricted stock granted to employees and directors:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of share option plans, and related information, under all of the Company&#8217;s equity incentive plans for the&#160;year ended December&#160;31, 2023, and the effect of share-based compensation on the statement of operations for the&#160;year ended December&#160;31, 2023, is as follows:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Options granted to employees and directors:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,519,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.28</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,700,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.84</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited and expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.81</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,965,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.13</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,900,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.10</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Restricted stock granted to employees:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Restricted Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">291,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1,371,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">489,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1,173,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The following table summarizes information concerning outstanding and exercisable options as of December&#160;31, 2023:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.03-$2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,235,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,312,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.42</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.55-$3.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,213,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,070,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.24</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$4.69-$5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 441,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 441,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.93</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$17.20 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.19</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,965,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,900,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 90pt;"><span style="color:#231f20;">As of December</span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;</span><span style="color:#231f20;">31, 2023, the aggregate intrinsic value of all the outstanding options and exercisable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">options</span><span style="color:#231f20;letter-spacing:0.05pt;"> was approximately </span><span style="color:#231f20;letter-spacing:0.05pt;">$2.6</span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;million and </span><span style="color:#231f20;letter-spacing:0.05pt;">$0.8</span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;million, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;letter-spacing:0.05pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The fair value of each option granted during 2021, 2022 and 2023 for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the options&#8217; fair value on their grant date:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.57</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.57</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The total unrecognized compensation cost of employee stock options at December&#160;31, 2023 is approximately $2.4&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 0.9&#160;years.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;">During the three years ended December&#160;31, 2023, there were no exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;"><span style="background:#ffffff;">The total vesting-date value of equity classified restricted stock vested during </span>the year ended December&#160;31, 2023<span style="background:#ffffff;"> was </span><span style="background:#ffffff;">$1.0</span><span style="background:#ffffff;">&#160;million. As of December&#160;31, 2023, the unrecognized compensation cost related to all unvested equity classified restricted stock of </span><span style="background:#ffffff;">$1.4</span><span style="background:#ffffff;">&#160;million is expected to be recognized as an expense over a weighted-average period of </span><span style="background:#ffffff;">0.8</span><span style="background:#ffffff;">&#160;years.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The following table illustrates the effect of share-based compensation on the statement of operations:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 596</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 777</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,075</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,448</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Private and 144A Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On June&#160;7, 2021, the Company issued 173,816 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 2,816,901 shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2022</span>, the Company issued 1,000 shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $2,360 from such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2023</span>, the Company issued (i)&#160;301,810 shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $0.7&#160;million from such exercise and (ii)&#160;237,012 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 845,000 shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2023</span>, the Company issued, in the aggregate, 4,691,623 shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during <span style="background:#ffffff;">the year ended December&#160;31, 2023</span>, the Company paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $8.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">On July&#160;2, 2021, the Company entered into the 2021 Sales Agreement pursuant to which the Company was able to sell, from time to time through the Agent, shares of Common Stock having an aggregate offering price of up to </span><span style="background:#ffffff;">$20.0</span><span style="background:#ffffff;">&#160;million. In addition, on </span>February&#160;27, 2023, the Company entered into the 2023 Sales Agreement pursuant to which the Company may sell, from time to time through the Agent, <span style="background:#ffffff;">shares of Common Stock having an aggregate offering price of up to </span><span style="background:#ffffff;">$20.0</span><span style="background:#ffffff;">&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has no obligation to sell any shares of Common Stock under the 2023 Sales Agreement, and may at any time suspend sales under the 2023 Sales Agreement or terminate the 2023 Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to 3.0% of the aggregate gross proceeds from the shares of Common Stock sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2021, but prior to the termination of the BofA Agreement, the Company sold 1,867,552 shares of Common Stock under the BofA Agreement. The Company generated gross proceeds equal to approximately $8.8&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2022, the Company sold, in the aggregate, 7,473,038 shares of Common Stock under the 2021 Sales Agreement. The Company generated gross proceeds equal to approximately $8.7&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2023, the Company sold, in the aggregate, 12,560,150 shares of Common Stock under the 2021 Sales Agreement and 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $24.9&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales were completed during the six months ended December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of Common Stock in an underwritten public offering at a price to the public of $4.60 per share for gross proceeds of approximately $40.2&#160;million before deducting the underwriting discount and estimated expenses of the offering. The above included the exercise of the underwriters&#8217; over-allotment option to purchase 1,141,304 shares of Common Stock. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476060304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 10&#160;&#160;- CONVERTIBLE NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;7.5% Convertible Notes Due 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2016, the Company issued to certain existing note holders and new purchasers $62.7&#160;million aggregate principal amount of its 2021 Notes in a private placement and an exchange pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. In July 2017, the Company issued an additional $10.0&#160;million in aggregate principal amount of the 2021 Notes in a private placement pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. A portion of the interest payable under the 2021 Notes was allowed to be made in shares of Common Stock at the Company&#8217;s election. On November&#160;15, 2021, all the then outstanding 2021 Notes&#160;matured and were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2021 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. Dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt discount amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;7.5% Convertible Notes Due 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On August&#160;25, 2021, the Company completed exchanges (the &#8220;Exchanges&#8221;) of a substantial majority of the Company&#8217;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Common Stock), subject to adjustment in certain circumstances, which is based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The 2024 Notes were issued pursuant to an indenture (the &#8220;2024 Indenture&#8221;) entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent (the &#8220;Collateral Agent&#8221;). Interest on the 2024 Notes is payable semi-annually at a rate of 7.50% per annum. The Notes mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges were considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $0.8&#160;million due to derecognition of the liability component and a reduction of stockholders&#8217; equity of $12.2&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature net of transaction costs of approximately $12.0&#160;million was recognized in the Company&#8217;s additional paid in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Transaction costs in the amount of approximately $869,000 were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Holders may convert their 2024 Notes&#160;at any time. The initial conversion rate for the 2024 Notes&#160;is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes&#160;(equivalent to an initial conversion price of approximately $1.7755 per share of Common Stock). Upon conversion, the Company may settle the 2024 Notes by paying or delivering, as the case may be, cash, shares of Common Stock or a combination thereof, at the Company&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, a total of $20.42&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to the maturity date, the Company may redeem in cash:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</span></span>any or all of the outstanding 2024 Notes if, on or after March&#160;31, 2023, the last reported sale price of the Common Stock for at least 20 trading&#160;days (whether or not consecutive) during the period of 30 consecutive trading&#160;days exceeds 130% of the conversion price on each applicable trading day, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</span></span>all of the 2024 Notes&#160;then outstanding if the aggregate principal amount of the 2024 Notes&#160;then outstanding is less than 15% of the aggregate principal amount of the notes issued on August&#160;25, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">To date, there has been no redemption of 2024&#160;Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The 2024 Notes&#160;are guaranteed by the Restricted Subsidiaries (as defined in the 2024 Indenture) and are secured by a first-priority security interest in all of the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &#8220;Collateral&#8221;), including, but not limited to, (i)&#160;100% of the capital stock of the Guarantors (as defined in the 2024 Indenture) and each Restricted Subsidiary of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Company that is held by the Company or any Restricted Subsidiary, (ii)&#160;intellectual property, including all copyrights, copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary information, including, but not limited to, domain names, (iii)&#160;all cash, deposit accounts, securities accounts, commodities accounts and contract rights, (iv)&#160;all real property and leased property, subject to applicable minimum thresholds, as set forth in the 2024 Indenture, and (v)&#160;all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such liens, the Company entered into certain agreements with both the Collateral Agent and Altshuler Shaham Trusts&#160;Ltd., as security trustee in Israel. The 2024 Indenture restricts the ability of the Company, the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&#8217;s assets that constitute collateral securing the 2024 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Upon (i)&#160;the occurrence of a fundamental change (as defined in the 2024 Indenture) or (ii)&#160;if the Company calls the 2024 Notes&#160;for redemption as described below (either event, a &#8220;make-whole fundamental change&#8221;) and a holder elects to convert its 2024 Notes&#160;in connection with such make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the &#8220;Additional Shares&#8221;). In no event will the conversion rate exceed the maximum conversion rate, which is 746.2686 shares per $1,000 principal amount of 2024 Notes, which amount is inclusive of repayment of the principal of the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">If a fundamental change occurs at any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2024 Notes, or any portion of the principal amount thereof, that is equal to $1,000 or an integral multiple of $1,000 in excess thereof, on a date of the Company&#8217;s choosing that is not less than 20 calendar&#160;days nor more than 35 calendar&#160;days after the date of the applicable fundamental change company notice. The price the Company is required to pay for a 2024&#160;Note is equal to 100% of the principal amount of such 2024 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. Under the terms of the 2024 Indenture, the Company is required to <span style="color:#222222;background:#ffffff;">meet certain covenants including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to meet covenants can be considered an event of default and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of December&#160;31, 2023, the Company was in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476133008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;11&#160;- FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the outstanding $20.42&#160;million 2024 Notes as of December&#160;31, 2023 is approximately $25.6&#160;million based on a level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The Company prepared the valuation of the fair value of the 2024 Notes&#160;(a Level&#160;3 valuation) as of December&#160;31, 2023. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476020224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;12&#160;&#8211; NET EARNINGS (LOSS) PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,582)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,312</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,168)</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,582)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,144</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,140,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,472,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,512,527</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,335,430</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,576,059</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,140,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,472,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,424,016</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted loss per share do not include 28,502,017 and 34,097,716 shares of Common Stock underlying outstanding stock options, warrants and convertible notes of the Company for the years ended December&#160;31, 2021 and December&#160;31, 2022, respectively, because the effect would be anti-dilutive. In the year ended December&#160;31, 2023, the diluted earnings per share do not include 18,254,264 shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354471088512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;13&#160;- TAXES ON INCOME</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States at a rate of up to 21%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,346</p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,092)</p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company had an effective tax rate of 3% for the year ended December&#160;31, 2023, compared to an effective tax rate of (4)% for the year ended December&#160;31, 2022. For the year ended December&#160;31, 2023, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted into law in December 2017 (the &#8220;TCJA&#8221;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $20.0&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released the valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $3.1&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The TCJA represents fundamental and dramatic modifications to the U.S. tax system. It contains several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the TCJA includes, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of NOL deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The TCJA also repealed the corporate alternative minimum tax for tax years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the TCJA included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Modification of interest expense limitation rules under the TCJA provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 30% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Section&#160;174 of the TCJA requires taxpayers to capitalize and amortize research and development expenses for tax years beginning after December&#160;31, 2021. This rule became effective for the Company during the year ended December&#160;31, 2022, and resulted in the capitalization of research and development costs of approximately $28.5&#160;million and $14.4&#160;million in 2022 and 2023, respectively. The Company will amortize these costs for tax purposes over 15 years for research and development performed outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that all future profits of its subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company as a &#8220;foreign-investment company&#8221; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tax rates</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The income of the Israeli Subsidiary, other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at the regular corporate tax rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The corporate tax rate was 23% for 2018 and thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Encouragement of Capital Investments Law&#8221;)</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; status the Israeli Subsidiary is entitled to various tax benefits as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">a.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Reduced tax rates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary has an &#8220;Approved Enterprise&#8221; plan since 2004 and &#8220;Benefited Enterprise&#8221; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expired in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">b.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Accelerated depreciation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">c.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Conditions for entitlement to the benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary&#8217;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#8220;Approved Enterprise&#8221; from the Investment Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">d.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Amendment of the Law for the Encouragement of Capital Investments, 1959</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise&#8221; (the &#8220;Capital Investments Law Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023 and 2022, the Company had aggregate NOL carry-forwards equal to approximately $234.8&#160;million and $247.4&#160;million, respectively, that are available to reduce future taxable income as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company&#8217;s carry-forward NOLs, equal to approximately $24.4&#160;million and $26.7&#160;million as of December&#160;31, 2023 and 2022, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#8220;IRC&#8221;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Protalix&#160;Ltd.</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">At December&#160;31, 2023 and 2022, the Israeli Subsidiary had approximately $210.4&#160;million and $220.7&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Deferred income taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2022 and 2023 were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,625</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,115)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,387)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,472</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,092</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A reconciliation of the statutory U.S. federal income tax rate of 21% in 2023, 2022 and 2021 to the effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.49%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax computed at the statutory U.S. income tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,792)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,023)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,799</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Differences in tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,512</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (899)</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutorily non-deductible expenses </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,979</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,684</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in Valuation allowances</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,792</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,970)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,932)</p></td></tr><tr><td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,032</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,602</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Withholding tax </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td></tr><tr><td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Valuation allowance roll-forward</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table presents the change in the Company&#8217;s valuation allowance during the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61,520)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,970</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,550)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,550)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (728)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,660</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Uncertain tax position</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Provisions of ASC 740-10, Income Taxes, clarify whether to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 275</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 805</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Tax assessments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In accordance with the Income Tax Ordinance, as of December&#160;31, 2023, all of Protalix&#160;Ltd.&#8217;s tax assessments through tax&#160;year 2018 are considered final.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of open tax&#160;years by major jurisdiction is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2019-2023</p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020-2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476069712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;14&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 54pt;">Balance sheets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 482</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 444</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,055</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,009</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 637</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td></tr><tr><td style="vertical-align:top;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,550</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470609968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;15&#160;- RELATED PARTY TRANSACTIONS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-Executive Director Compensation</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In September 2023, with the consent of the Audit Committee of the Board of Directors, the Company engaged one of its non-executive directors to advise the Company regarding business development and licensing efforts on a consultancy basis. For the year ended December&#160;31, 2023, the director earned a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$35,475</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in consulting fees.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476069712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE&#160;16&#160;- SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since December&#160;31, 2023, the Company has collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from expense reimbursements in connection with its collaboration with Chiesi, and approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.6</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Pfizer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In January 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">100,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock, in the aggregate, to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Company&#8217;s employees under the Plan. The restricted stock vests over a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$161,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:10pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470977200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain and Switzerland. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the BALANCE study (also referred to as Study PB-102-F20). The FDA review team also concluded that the BALANCE study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the BALANCE study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of December&#160;31, 2023, 56 patients have been dosed in this trial. The Company expects to publish preliminary results of this study during the second quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of December&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it was entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and, under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. As of the issuance of these financial statements, the impact of the war has not had a material adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. See also <a href="#_NOTE_10_"><span style="font-style:normal;font-weight:normal;">Note 10</span></a> with regards to financial covenants under the terms of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of December&#160;31, 2023, the Company is in compliance with all such covenants. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to the assessment of sales reserves and valuation allowances.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2023 and 2022, the allowance was negligible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">No write-off activity and recoveries for the periods presented were recognized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment in value of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances. The sales reserve is calculated based on expected sales and the anticipated net average selling price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent the variable consideration is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also <a href="#_k.__"><span style="font-style:normal;font-weight:normal;">revenue from selling products</span></a> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks and trade receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2022, the accounts receivables balance was composed of $2.3&#160;million from Fiocruz, $1.2&#160;million from Chiesi and $1.1&#160;million from Pfizer, and, as of December&#160;31, 2023, the accounts receivables balance was composed of $0.7&#160;million from Chiesi and $4.6&#160;million from Pfizer.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for </span>restricted stock <span style="background:#ffffff;">based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees, consultants and other service providers with only service conditions that has a graded vesting schedule using the accelerated method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net earnings (loss) per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net earnings (loss) per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, a total of $20.42&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;New accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures<span style="font-family:'Palatino Linotype';">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476140208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ScheduleOfUsefulLifeTableTextBlock', window );">Schedule of Useful Life</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Useful Life Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476069712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,933</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,084</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,644</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,661</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,686)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,688)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,973</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476119696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,176</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,055</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,814</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,045</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476015728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2021, 2022 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,632</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,391</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Analysis of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,409</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,397</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,125</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,044</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,057</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,032</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,002</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,030</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476020224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,522</p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,401</p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,495</p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,418</p></td></tr><tr><td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,076</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470399456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,519,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.28</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,700,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.84</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited and expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.81</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,965,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.13</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,900,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.10</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Restricted Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">291,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1,371,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">489,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1,173,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Share Options Outstanding and Exercisable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.03-$2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,235,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,312,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.42</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.55-$3.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,213,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,070,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.24</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$4.69-$5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 441,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 441,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.93</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$17.20 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.19</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,965,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,900,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.57</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.57</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense in Statement of Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 596</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 777</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,075</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,448</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470560992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member', window );">Notes 2021 and 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text">The following parameters were used:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2021 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. Dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt discount amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470879952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354467627952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Earnings (Loss) Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,582)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,312</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,168)</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,582)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,144</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,140,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,472,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,512,527</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,335,430</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,576,059</p></td></tr><tr><td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,140,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,472,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,424,016</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470589152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,346</p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,092)</p></td></tr><tr><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2022 and 2023 were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,625</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,115)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,387)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,472</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,092</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Tax Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.49%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax computed at the statutory U.S. income tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,792)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,023)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,799</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Differences in tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,512</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (899)</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutorily non-deductible expenses </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,979</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,684</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in Valuation allowances</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,792</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,970)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,932)</p></td></tr><tr><td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,032</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,602</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Withholding tax </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td></tr><tr><td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Company's Valuation Allowance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61,520)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,970</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,550)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,550)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (728)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,660</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Reconciliation of the Beginning and Ending Amount of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 275</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 805</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ScheduleOfOpenTaxYearsTableTextBlock', window );">Schedule of Open Tax Years</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2019-2023</p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020-2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOpenTaxYearsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Open Tax Years Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfOpenTaxYearsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470657184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Supplemental Information, Balance Sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 482</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 444</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,055</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,009</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 637</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td></tr><tr><td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td></tr><tr><td style="vertical-align:top;width:75.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,550</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476219136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354461768304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (General) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 29, 2022</div></th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 21, 2023 </div>
<div>item</div>
</th>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfPatientsDosed', window );">Number of patients dosed | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,954,000<span></span>
</td>
<td class="nump">$ 8,236,000<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,251,000<span></span>
</td>
<td class="nump">20,251,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,549,000)<span></span>
</td>
<td class="num">(381,549,000)<span></span>
</td>
<td class="num">$ (389,861,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,030,000<span></span>
</td>
<td class="nump">$ 6,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,980,060<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,560,150<span></span>
</td>
<td class="nump">7,473,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Minimum cash balance required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt', window );">Transactions costs in connection with the exchange of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement amendment payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Revenue, Performance Obligation, Number | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735,000,000.0<span></span>
</td>
<td class="nump">$ 735,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement amendment payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change in amount receivable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember', window );">Fill/Finish Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The transaction costs in connection with exchange of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Notes Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExtendedTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term  of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ExtendedTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfPatientsDosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of patients that were dosed in the trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfPatientsDosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354469793232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354471557696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">$ 5,272<span></span>
</td>
<td class="nump">$ 4,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_FiocruzMember', window );">Fiocruz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_ChiesiMember', window );">Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354468907168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIALIZATION AGREEMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Jul. 23, 2018</div></th>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 13, 2021</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentInConsiderationForDevelopmentServicesPerformed', window );">Payments in consideration for development services performed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies', window );">Payments in connection with performance of additional studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement amendment payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement amendment payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentInConsiderationForDevelopmentServicesPerformed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from consideration received for development services performed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentInConsiderationForDevelopmentServicesPerformed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow in connection with performance of additional studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470959312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 39,661<span></span>
</td>
<td class="nump">$ 38,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation and amortization</a></td>
<td class="num">(34,688)<span></span>
</td>
<td class="num">(33,686)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net, total</a></td>
<td class="nump">4,973<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">18,933<span></span>
</td>
<td class="nump">18,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember', window );">Furniture and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">3,084<span></span>
</td>
<td class="nump">2,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 17,644<span></span>
</td>
<td class="nump">$ 16,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470468288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,191<span></span>
</td>
<td class="nump">$ 1,086<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354469851616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,176<span></span>
</td>
<td class="nump">$ 3,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">9,055<span></span>
</td>
<td class="nump">2,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,814<span></span>
</td>
<td class="nump">10,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 19,045<span></span>
</td>
<td class="nump">$ 16,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354467691280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470713440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EmployeeSeveranceObligationPayment', window );">Employee severance obligation payments</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsPeriodExpense', window );">Severance expense</a></td>
<td class="nump">801,000<span></span>
</td>
<td class="nump">945,000<span></span>
</td>
<td class="nump">990,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions</a></td>
<td class="nump">798,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">857,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Gain for the period</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="num">$ (3,000)<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears', window );">Number of benefit eligible employees | employee</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember', window );">Contribution to Insurance Companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Contribution in connection with severance liabilities</a></td>
<td class="nump">$ 922,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember', window );">Contribution to Defined Contribution Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Contribution in connection with severance liabilities</a></td>
<td class="nump">$ 888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EmployeeSeveranceObligationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee severance obligation payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EmployeeSeveranceObligationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees To Receive Benefits During Next Five Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period expense related to postemployment benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354469723552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 29, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ContractAmountUnderAgreementPayable', window );">Contract amount | &#8364;</a></td>
<td class="nump">&#8364; 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Arrangement Other than Collaborative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentAmount', window );">Subcontracting commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_BusinessDevelopmentConsultantMember', window );">Business development consultant member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentAmount', window );">Subcontracting commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty Agreement Terms | Office of the Israeli Innovation Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Royalty Agreement Terms | Office of the Israeli Innovation Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Royalty Agreement Terms | Office of the Israeli Innovation Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfRoyaltiesToGrantReceived', window );">Percentage of Royalties to Grant Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.5<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ContractAmountUnderAgreementPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount agreed to pay under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ContractAmountUnderAgreementPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExtendedTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term  of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ExtendedTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfRoyaltiesToGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required royalty payments represented as a percentage to grants received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfRoyaltiesToGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RoyaltiesOnSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties based on sale of products developed from projects funded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RoyaltiesOnSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_BusinessDevelopmentConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_BusinessDevelopmentConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=plx_OfficeOfIsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=plx_OfficeOfIsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354466497232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,471<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
<td class="nump">$ 1,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 1,484<span></span>
</td>
<td class="nump">$ 1,404<span></span>
</td>
<td class="nump">$ 1,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">12.80%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354469783664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2028 and thereafter</a></td>
<td class="nump">4,057<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">9,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">3,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 6,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470941600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions', window );">Operating lease, Renewable term | item</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, term of agreement</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Cash deposited as bank guarantee | $</a></td>
<td class="nump">$ 502,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, term of agreement</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of change in operating lease monthly rental payments</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of change in operating lease monthly rental payments</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisclosureOfLeasesOperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases Operating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisclosureOfLeasesOperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Number Of Renewal Term Extensions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Change in Operating Lease Monthly Rental Payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354468149872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 65,494<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
<td class="nump">$ 38,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">40,418<span></span>
</td>
<td class="nump">25,292<span></span>
</td>
<td class="nump">16,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">12,522<span></span>
</td>
<td class="nump">12,403<span></span>
</td>
<td class="nump">10,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">10,401<span></span>
</td>
<td class="nump">9,452<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">17,495<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 25,076<span></span>
</td>
<td class="nump">$ 22,346<span></span>
</td>
<td class="nump">$ 21,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354460268144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Stock Option Activity) (Details) - Employee Stock Option - Employees and directors<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year | shares</a></td>
<td class="nump">5,519,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,700,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and Expired | shares</a></td>
<td class="nump">254,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year | shares</a></td>
<td class="nump">6,965,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year | shares</a></td>
<td class="nump">2,900,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year | $ / shares</a></td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">1.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and Expired | $ / shares</a></td>
<td class="nump">3.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year | $ / shares</a></td>
<td class="nump">2.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year | $ / shares</a></td>
<td class="nump">$ 3.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354472483808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Restricted Stock Activity) (Details) - Employee - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">291,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">1,371,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="nump">489,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non vested at end of year</a></td>
<td class="nump">1,173,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354468921024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">6,965,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">2,900,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.03To2.00Member', window );">$1.03 - $2.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range | $ / shares</a></td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">5,235,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">1,312,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55To3.73Member', window );">$3.55 - $3.73</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range | $ / shares</a></td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range | $ / shares</a></td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">1,213,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 4 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">1,070,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69To5.60Member', window );">$4.69 - $5.60</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range | $ / shares</a></td>
<td class="nump">$ 4.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range | $ / shares</a></td>
<td class="nump">$ 5.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">441,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">441,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member', window );">$17.20</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range | $ / shares</a></td>
<td class="nump">$ 17.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">75,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">75,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.03To2.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.03To2.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55To3.73Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55To3.73Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69To5.60Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69To5.60Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354468089216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 17, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average grants date fair value (USD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average grants date fair value (USD)</a></td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD)</a></td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">4.44%<span></span>
</td>
<td class="nump">3.32%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">79.41%<span></span>
</td>
<td class="nump">85.94%<span></span>
</td>
<td class="nump">84.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (Years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470941344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,448<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
<td class="nump">$ 2,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">$ 1,432<span></span>
</td>
<td class="nump">$ 1,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354461942304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Additional information) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 25, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 24, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommonStockNumberOfVotingRights', window );">Number of voting rights | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of Common Stock remain available for grant under the plan | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,409<span></span>
</td>
<td class="nump">633,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,954,000<span></span>
</td>
<td class="nump">$ 8,236,000<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under share-based payment arrangement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,475,171<span></span>
</td>
<td class="nump">12,475,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,810<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per warrant issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,816,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 2,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted instrument, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentsToDebtHoldersOnConversion', window );">Paid to the converting holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtConversionDecreaseInPrincipalAmount', window );">Decrease in principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,980,060<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,560,150<span></span>
</td>
<td class="nump">7,473,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfCommissionOnSaleOfShares', window );">Commission (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">BofA Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,141,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember', window );">Options and restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember', window );">Options and restricted shares | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember', window );">Options and restricted shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding options intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable options intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Vesting-date fair value of stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockNumberOfVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes for each share of common stock is entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockNumberOfVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionDecreaseInPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in the total principal amount of debt due to conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionDecreaseInPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentsToDebtHoldersOnConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentsToDebtHoldersOnConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfCommissionOnSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfCommissionOnSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354461632224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details) - Level 3<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 25, 2021 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="nump">1.78<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input | Y</a></td>
<td class="nump">0.67<span></span>
</td>
<td class="nump">3.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0487<span></span>
</td>
<td class="nump">0.0044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.6990<span></span>
</td>
<td class="nump">0.9135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.1157<span></span>
</td>
<td class="nump">0.0766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470960944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsIncurred', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">2,534<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsIncurred', window );">Total</a></td>
<td class="nump">$ 2,801<span></span>
</td>
<td class="nump">$ 2,456<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total interest costs incurred during the period and either capitalized or charged against earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354466399184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>D </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,036,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(831,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,019,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 62,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying amount</a></td>
<td class="nump">$ 54,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(831,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="nump">25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest', window );">Convertible notes exchange in cash, accrued and unpaid interest</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate', window );">Base value for conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleConversionShareNumber', window );">Number of shares for basis conversion | shares</a></td>
<td class="nump">563.2216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="nump">$ 1.7755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfPremiumToClosingPriceOfStock', window );">Percentage of Premium to Closing Price of Stock</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Mature term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt', window );">Transactions costs in connection with the exchange of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Minimum cash balance required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumDebtInstrumentConvertibleConversionShareNumber', window );">Maximum price per share of the conversion feature | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746.2686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ThresholdPercentageOfConversionPrice', window );">Threshold Percentage Of Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding', window );">Aggregate percentage of principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtInstrumentRedemption', window );">Amount of redemption of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfOutstandingCapitalStock', window );">Percentage of outstanding capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock', window );">Denomination of the principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange', window );">Number of calendar days after the date of applicable fundamental change purchase date | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange', window );">Number of calendar days after the date of applicable fundamental change purchase date | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued and unpaid interest exchanged in cash in debt conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The transaction costs in connection with exchange of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate percentage of principle amount of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Base Value For Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleBaseValueForConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Conversion Share Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the denomination of the principal amount of debt that is used in conversion calculations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of redemption of debt as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Notes Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumDebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumDebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of calendar days after the date of applicable fundamental change purchase date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfOutstandingCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfOutstandingCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfPremiumToClosingPriceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium to closing price of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfPremiumToClosingPriceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reacquisition Of Equity Component Of Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReacquisitionOfEquityComponentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ThresholdPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage of conversion price on sale price of the company's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ThresholdPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354468788144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 25, 2021 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="nump">1.78<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input | Y</a></td>
<td class="nump">0.67<span></span>
</td>
<td class="nump">3.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0487<span></span>
</td>
<td class="nump">0.0044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.6990<span></span>
</td>
<td class="nump">0.9135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.1157<span></span>
</td>
<td class="nump">0.0766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354472238048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - Level 3 - 2024 Notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying amount</a></td>
<td class="nump">$ 20,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt instrument fair value</a></td>
<td class="nump">$ 25,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354460267536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
<td class="num">$ (27,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Financial expenses of 2024 Notes</a></td>
<td class="num">(1,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) for diluted calculation</a></td>
<td class="nump">$ 7,144<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
<td class="num">$ (27,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Common Stock outstanding for basic calculation</a></td>
<td class="nump">67,512,527<span></span>
</td>
<td class="nump">48,472,159<span></span>
</td>
<td class="nump">44,140,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Weighted average dilutive effect of 2024 Notes</a></td>
<td class="nump">13,335,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average dilutive effect of stock options</a></td>
<td class="nump">1,576,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Common Stock outstanding for diluted calculation</a></td>
<td class="nump">82,424,016<span></span>
</td>
<td class="nump">48,472,159<span></span>
</td>
<td class="nump">44,140,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember', window );">Outstanding Stock Options And Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">18,254,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember', window );">Outstanding Stock Options Warrants And 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,097,716<span></span>
</td>
<td class="nump">28,502,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354472169888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Summary of Taxes on Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current taxes on income</a></td>
<td class="nump">$ 3,346<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="num">(3,092)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354471097744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>In respect of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="nump">$ 4,625<span></span>
</td>
<td class="nump">$ 6,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DeferredTaxAssetsOtherTimingDifferences', window );">Other timing differences</a></td>
<td class="num">(1,387)<span></span>
</td>
<td class="num">(2,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">51,472<span></span>
</td>
<td class="nump">54,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(51,618)<span></span>
</td>
<td class="num">(58,550)<span></span>
</td>
<td class="num">$ (61,520)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 3,092<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DeferredTaxAssetsOtherTimingDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets other timing differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DeferredTaxAssetsOtherTimingDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470452608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Reconciliation of Tax Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax computed at the statutory U.S. income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,799<span></span>
</td>
<td class="num">$ (3,023)<span></span>
</td>
<td class="num">$ (5,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Differences in tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Statutorily non-deductible expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,684<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation allowances</a></td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="num">(6,932)<span></span>
</td>
<td class="num">(2,970)<span></span>
</td>
<td class="nump">$ 5,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition', window );">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,602<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EffectiveIncomeTaxRateReconciliationWithholdingTax', window );">Withholding tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to utilization of carry-forward losses and other temporary items without deferred taxes recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveIncomeTaxRateReconciliationWithholdingTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to withholding tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EffectiveIncomeTaxRateReconciliationWithholdingTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470644784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning Balance</a></td>
<td class="num">$ (58,550)<span></span>
</td>
<td class="num">$ (61,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod', window );">Additions to valuation allowance</a></td>
<td class="num">(728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod', window );">Reductions to valuation allowance</a></td>
<td class="nump">7,660<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending Balance</a></td>
<td class="num">$ (51,618)<span></span>
</td>
<td class="num">$ (58,550)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additions to the valuation allowance for deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reductions to the valuation allowance for deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354477351232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Uncertain Tax Position) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase for tax position related to current year</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 805<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354477306192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Schedule of Open Tax Years) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember', window );">Israel | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember', window );">Israel | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354468775024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance related to deferred tax assets</a></td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="num">$ (6,932)<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">$ 5,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Deferred tax liability of research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod', window );">Amortization period research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,800<span></span>
</td>
<td class="nump">247,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,400<span></span>
</td>
<td class="nump">26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Protalix Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,400<span></span>
</td>
<td class="nump">$ 220,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Protalix Ltd | Law for Amending the Israel Income Tax Ordinance, Tax Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized for research and development cost, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476955904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_OtherAssetsInstitutionsCurrent', window );">Institutions</a></td>
<td class="nump">$ 482<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_OtherAssetsSundryCurrent', window );">Sundry</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">$ 1,055<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsInstitutionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsInstitutionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsSundryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsSundryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354461754496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,437<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,009<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">2,876<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReserveForDeductionsFromRevenueCurrent', window );">Sales reserves</a></td>
<td class="nump">2,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 19,550<span></span>
</td>
<td class="nump">$ 12,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReserveForDeductionsFromRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of reserve for deductions from revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReserveForDeductionsFromRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470922864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Compensation (including share based compensation) to the non-executive directors</a></td>
<td class="nump">$ 35,475<span></span>
</td>
<td class="nump">$ 429,000<span></span>
</td>
<td class="nump">$ 368,000<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354470353648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 14, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>employee </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 14, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,371,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pfizer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds From Sale Of Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromExpenseReimbursements', window );">Proceeds from expense reimbursements</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Restricted Stock | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan', window );">Number of employees granted shares as bonus | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from expense reimbursements in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees to whom plan is granting shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354471512784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
<td class="num">$ (27,582)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140354476077376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$I^*= /X_I%S>5A(=W!\O>;Z_U!+ P04    " !B.&Y8+<\2V;(&   .'
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MX'X8TN-%U:5<M]]OF;RPAAA:\];U]/KD&;DK?,G<]4+&#OS%3L-.CG51/I;
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MW/1P[_7&,GK<YL6-_FAX"!^I3_/589'"5;_)LHGV-,ZB)$8I?;CIF?C:(F5
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MWS.,8N<ZGI (%H>;-L6ROX6S0* ]M3F'C>%M^H#W@O39L&2<6CJ=!M! Z_E
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M^#C'D;Q63S+"KH1[2K;FAX_UMB43D9PKSW0)=[M(I=2YNCIZ*9706QID=5+
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M).LC/1RQ8N7%.R9HGE4DE(CJ=<[9\4<!4=FC6DKC9(]BFTIXJ[<3ST".JVC
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M5']-4)@"?7_.N5H'9H/V^S3\ U!+ P04    " !B.&Y8"ME#UZ4"  !+!@
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M+I M@"FF%:X%7;4QE!WKR& K$N4"Q@:&OB+K -::,N3O6KLA-8%0@HG#\UJ
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MH'\":%B!]G.MW6K!#MK_%I-_ %!+ P04    " !B.&Y8-C->D)(#  !5"
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M NK D=,:XYTQ $69-*;B12K82JLM"Y/$"X( _Y!R.!LW39]]03Z!)HC#%JT
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MR$'@N6@BMED#$6@+T<'OV$>=R8(@HZ_']FVG3 H,QV_-_Y9G ED!WAK"J;2
M14=YU1QTE6Z4@>[:46O?\YB0I/^:=V)=#9JM!"UC'@E75AH!;T\C2$RHU=#!
MI?-O""1UZV(/'%UNG2L53-RA/PM"40MZ <HE\&H<$? 2@!W#P"\R:=WTSE!(
M 3RK$"MIR7OR*L.]K9F%6Y=&AT,WY#EB:3T:P_'HEL'3E.8B.9AO2E1ESV'(
M OM\#!W&ZS!<W-4QWZ@1T]F1=%Y0LT(A#9A6H @K1G;)!"I4%ATT.\MG'&$/
M4M?6\(4J1BTC3F<UB+IURT,/;LP;/Y,7!^:%_=JXK:7&E29M\]@DCKTDF)\*
M1RWPO-"+2K2H8WNH'Q>*.V$H#REAMU%9PP<<,8P%!Z,,I5:Y2T*,A5T)-5\O
M#S*M08&: -INM!"DE\9]D&"C122&Q%=<:K;C>=7NI*>6((&.FAI''M'YOAMM
M>0''']K:*^3F^/)]_3FM#,?L.QUJ= F0N<=/UF(\[I2@UBV!$G>)5U8G"[4I
M3*.-JQR 870#R)"CNFBI40D:P %;!9N\ST*???PF%;4L/6>+YG#80GG?-XU7
M4W9 *@MW)J5MTKD-&+BGKX&6Q9^5M/>TL[H]BB@Z*('A]X)KYG:<(^Z,RU*,
M4DK2,C<ZLL_6,6@P[R*;DFV$2R2?NIXDO%HIQ$%0"[]H5?L4+:+,0?SB+S__
M>(#'@\&_T_D7ANYW?'![<]/DD#:!NQ\, S4U/\6=T*DT1\;42FC:Z(& 1ST<
M #]>BK4LBOK80FH>>^-P[L7AN)UXSB(_FF%N#8FF85FE&T_'"9T&_U%K._2F
MD),G8=#VA/XL01!9"=IJT *P.TE,RJ)QXH51T@Z-_5FXSR1HM65OXLTG8V\2
MA /VPA@R8=(# >3>G,B; T/C(.[-B?T>?\L+]ODI$?CMWD+><?U$[]AS!A"C
MQYW;$YHACYJS&1C-0TC<.CT_:LW]9V/=UJ9>/(6_2=2^^4V8_H!D-O?"R:23
M!H)]YX;LV:<C&4YC;S(-#A9/+QR(4XP3OV1GAW^0GYD^O@'$ &YIIX:^?LCM
M.B]I]ZCC^_+W@X93S\<]H0&ROAC[?7V1#CWG &E.0L\^7IS"GD>QZ0BO+H7I
MO^DX/!QSO0]IG;^T#J$*S+\M5CY."= ?0^#7=0W<+I>K;JECVJ0!YZ$?Q*/S
MR \Z]QQ[43P>(-W,GW<! >$!QZ5I/.EU)Q$[C_WQ> 3_IW%O:!3&7IQTL#;V
MXWFO.Y@&WCR<]KH!-,\3?S(?G8_]2<"2) 2("Z #CF9-(_'G,7 ^]:. P:DM
M'@> Q>%\\+NA>(BL+78<X.?^\V1J2T>-]5K#>1^2)0D&D861:9>)81+R4'YZ
M+&"IE(;EJCM*R"!-!;-,V%;F.=6N8=IYX,^:%UYSW(!$)K_W6Z:SBR.9H=@_
M%$*DU!@)$CFYW#&4 O;_GC@.8?"V">8F&+D!3&S4)+ ^4Y:YI/SO(&NOU5DG
M?0,]4%HF=>]P]/>AX:FM\=1X-$._$?4;G8O^OJ\:DL4XY?=D??;KS=N+7J8R
MGO8:/9>G'*9IM CEDJK': SF?I8&ZWEPK-+(2O,:'';&?H2\)([@D?A) H_?
M%&3O,L=<O(60Q(\#Z)J-_3D.F<Y]0(T?V=NZLL7N)5:G6[+0U?Q=WV$4@$H(
MT)ZAXDW']J3W"T!D?*!XX>+%8H4+CA!8 U@75*@=Y/2I,I3'-Q%1YU-M4-LC
M^YX\$M!)$[_.Z;]Y08S 1G!(YI:"]0@IK$ORPSCJ#L^!/Z?MPOCL;9<KN7,Q
MO3]],*&JC0O#0K6)NJNH]EGLCDQ-:2>3&=5VM. Y\$FE2ZSA-)4-24E.4=<;
MJ"J"0]HE_)ZEZGK B!R_PSEWPDMS0 RY0H0X.(/6R5J-?@BZN =V5GD0]!\Q
M5W,LQ6);CMY4+_8$MF!-X*/UCH?M.RR%[5E[=,S:L\;:J^,Y)ZQ: 4? O?D^
MI]R_/\\<(.T1;WWVJW_CLPP$17>F^IVJ#/@DH .A+:$L!>J;.M;62F6&&=5#
M&CB'3>:]5ACWCY#C^01/,8(N)VB+%+ ;JY+T4=O''' \268'[\;AX;OI=,IN
M!/@#7H#5U2M:A6>XX9&]L(QQL! <BL:S?BON;2>0=!VB((@))Y_!Z=@+9OUV
M["4]MC.??=)RA\%'Q>LD6;"/X#,85*:]9YQZ=7HQ+/":"L_3<"B:A9-3Y<$C
M6(!$4FXVD$:8KD" V1:$L=9U>;FLP!9X*1 A><CQPI-+.$9@)6 R&-Y?-5#E
MM&X=5@&4IT* A[3W5@?L#.#T@0)/],1Q\9/'/3H :[5V!,-&[[G^*BQ[MOCR
M_J*UFC,:7@H>,QKXL]"DK+J"3Q%TPS&E6T B[!"@7^9W]\-]&I3@(MA KP&W
M]FH]RBV]<L^-5M7:S5NLJ<A]PGH;OG/'WUXFKAI97 (#4ZH229^#>7L0_P[F
M9)ET54,@^/U7Z+N2N[%C:IG+M4/.6G[RJ1-K=R5PLMV>HMW6NN7WF'?0+HJZ
M,Q6<!^"]H<$/4\![&Y<WHU0G1V&!/L5+$;IYHBC$RQ"ZOG%2DI'VKUPY[A1;
MB*_Z*L/I*/:#'YO2;*?1M580/X>A=4(Q!,X/R_;4&(3_R\JB)5$9W<44ZJ1W
M!W.E5HN^ZOLN3=R$WFPR]<;CZ'%C#FD-_:2!FFQ?)9 ] .ZC6H?)Y*P[#!Z#
M2U/A#3FJYLF@="B<UUQ\M0;S -43P.X@GCW)>0]0XB]+/?V^4L=/DSJ,O/$D
M\,)Q\&UB=Z?K[ZN/*(%4_HD*60#H=&V7PV-.EXM>2HP"P%KXQ4ES"G ?7[0[
M"4I"^WL<-)]C?%"/TC3R#H[[]*'8"4- =@II105 F0ZVI9_%4E=X(Q0^E% @
M5Q2/,V^:S+WY_.35(Z):X<QUJZ6UHH"=BU9MX1UQM<;X&AG:$52?"C"[KJ^G
MW,7EP%B8E S-E 1^U)II*6".@&0QJU+;Z*?E!U]DTM#%LJL6M:66-M-K+B1K
M?IT/\24<!>I[[?K+C7Z:-%@$C-N42/#\,,+[=NMVAK+9I-I4*O3")/3B(#FA
M4=\!VXU(*^0?RT5T<(&=#S_&'.G*E>_=-:=N;\!:=9.G?BQ!N(V K4RSG_BV
M? %K^/3-)AK$@%>-:@+^L>_N+GM?0 *)-7WGB;- C>YCR/9M^RGIPGU!V0UW
MWZ&"OZ\E'+)SL8*I@3\=GS'MONUT#:M*^IYRJ:Q56_JY$1Q4BP.@?Z64;1JX
M0/N![>O_ E!+ P04    " !B.&Y8\\3;(:H-  #))P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6S=6MMRW#82_164UDE)56-J[B-?JV1;WGC+<5R6
MG90?(1(S@YB7"0!*5KY^3S= $N2,9&^2IWVP18) H[O1E].->7I3F2]VJY03
M7XN\M,^.ML[M'I^>VG2K"FF3:J=*?%E7II .KV9S:G=&R8P7%?GI=#Q>GA92
MET?/G_+8>_/\:56[7)?JO1&V+@II;E^HO+IY=C0Y:@8^Z,W6T<#I\Z<[N5&7
MRGW:O3=X.VVI9+I0I=55*8Q:/SLZGSQ^,:?Y/.%7K6YL]"Q(DJNJ^D(O;[)G
M1V-B2.4J=41!XL^U>JGRG B!C3\"S:-V2UH8/S?47[/LD.5*6O6RRG_3F=L^
M.SH[$IE:RSIW'ZJ;GU209T'TTBJW_+^X\7,GF)S6UE5%6 P."EWZO_)KT$.T
MX&Q\QX)I6#!EOOU&S.4KZ>3SIZ:Z$89F@QH]L*B\&LSID@[ETAE\U5CGGK_\
MY=VO%Q\^OGGQ]D*\^^7CQ>734P>R]/$T#21>>!+3.TA,IN+GJG1;*R[*3&5]
M J?@IV5JVC#U8GHOQ5<J3<1L,A+3\71V#[U9*^2,Z<W^CI">Q/PP"?*-QW8G
M4_7L",9OE;E61\]__-=D.7YR#X/SEL'Y?=2_C\'[2= R,1F+AV*/F)")6"6+
M'\3+JKQ6QNFK7(EWE5-6O*H5*7DBWI0"6E?%E3(8F"Q'PFT5%A0[6=X*;6VM
M,N$JD6(]7%VHK]HZ76Y$"3IB6^69,E;(,A,E/'%7FW0+7\'0@^4T6<%R\YR=
M<+,Q:B.Q9&=TF>J=S(4LJKITHEH+[:SGQC.';23-N^;Y.92/:.!X$TD<8(MR
MHV@S6TM\ 'N7P=GGQ_+D>'HB:EBD85'PI3;::= ]3UU" O^GSF])V-5!8;&%
MS#)-Y,#D@\DX&;=BZ&])0O2^+<E?X_Q<["K#<\-&NG0*-@EZ\E;2V79K(QYN
M),XG1Q#V!WFE$$8R6BSL5F(Y48,*"M"]=%7Z14@7J^7'?YU-)ZLG5C0!-1&_
ME"!][6UFLF!OA<]B#UZ'?^"P=M;AP,A2(EX036O#.L[$#7@'YSHC5M9UGB?B
M(Y:O*^*5UCF6R2H8!Y*0VX)[!V6W4JNOR%!6(46DU:;4?X*N43DTS7+VM?!8
MD!SCV9/_^>]G)8T/<)VC4(@Z_I1<)N(5N)6&#]IMJ]I",'OB]X73.8/D4Q_B
MN:'^0$Q'9XM%^_Y*73F1:9NR0<&N<.!_2C[T9LITM%AU"]Y6%NHQ50'2Y)>U
MMENVL6;"V6S2/G]D!79[+T?3Y61/XJMO18TY6<!YO4&6$M/V_&-72O$W5W02
MC;=:<4P3:(_I^,E%,\KODR<G9(02".&*K,9I<%G(WRM8_VUC[$-SO,/";C0,
MI0E6ND2L<G5PY3AB>5MKV<#,ZRJ_)LO!<!MAB*G8X_'^8#%/EHLV(-P5 [Z3
M6]CU_@[3LV1U_PX(M7D;K_A F-P(:Q?)HUZX2J7=CGSHW.U,]57#!146/Y@D
MD^$\N _GN)(#O$Q34P=?K<O@J,&,W=94]6;KHQ"Q(3*0]4K5I>8#3-E\/(@C
MT4C6X)3S)CQ:L5C.$EC \JY@1*N43+=@>#0>CP^J(Z)XK/ZH$6USY8.K+ ^Q
M QJI/]RA2E8K^.(.'L[<1(?9,G0R(BO]':&0Z6>_PPG8WTB'P>Q2;=*ZH/-.
MZ5!NMAK\0U9"D9F@;"AF4_(P:+O0==&$JS2O+&F^Y6^X.:VEL7>?+R_$>:$P
MCZS'M:O]*B/9SJK622>SV$E;\^[.+-(@A^5@6G&>8E5FD!0!O.?+O/9-\ZEU
M:,6VPC9#2<?=*%7&KN%YV=328(,*(70G#;P=@T:Y:L1LO9#E%Y+H':#%9X!\
M\3-0/,3Z:$BJEM"[Y#R!C5M(CG&EV&1_TSE@\\:1[N0UGJQXC?PH+JM4*X=5
MKR]?\**40CAX)9/:T$G&PKWL/I[3QT8\PA'!%\*9],VZR<@6!_Q0EB62 "P,
M)R6],T HQ-CQ#VQL]+WP!Q&G2?(R"'.K*,'(M0NIG<Z&+,NKJEJ/X)VY0A;
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MF[;>3RQ!:$PT"EBO*45]KF^H[8$FR'6'4;+=]N#UJ*WU6?ZMO/8:YWC=X#^
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M:>Q)>C-^=,6W*AV(R2@1X^%X\LAZD\#BA->;_#R+=H'C_@7(+IZ;E4S5JST
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M [G"1S(.5N%,K$JCV9# 2<9V5]X!-H6:R^YK+TE9(!#IE21ZY53GNEZ3FV@
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MS8VG3*-]? ,$GLMG#$^=FD2%Q27>9CS^ XJ@TZ&7S5/7(KM=-=-<FX4%PB5
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M2M- M6FY9<DSE$<X$H5'RB0Z@S/JTQ;MDE/'3:O3:5A?NKW\DSZ4H]RX;JO
M[9RZ)37>IJ&/ZCYV#*__!IZ8W&3F)')<F]2@W>UX(.L.6QM:E*ZKK80V/=(-
MM^:G!*4-,-_70NAWPQ9H?G.&?P%02P,$%     @ 8CAN6'5KL.<C P  :@<
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M0CO29C_,Z#%$PPZTOM3:;0U.T#ROPU]02P,$%     @ 8CAN6"THK( L P
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MUQ&8O@WW$Z?;T/JVVE$C#<.&7BXTWH#V*ZW=:>(##&_AXE]02P,$%     @
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MR?,J^6CVJLBJY*)N?[B%+O,JA;_#E> NMH@^!)X7S.'#]WF9FP9P =^\U:H
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M0$XLVX8 +81#%/%' :XIV*A$A2#N 8FPL#.A/[_S%C0B#3RS?B#!9D<@G:?
M@"Z E%:-0&IU^%/Z"N2(9A**O%M=9" @JK6F"PL4S,1ZQ@"M(C;4(%Z04"^J
MD^ 3(1F$!X26JLEL=ASX1?"Y:Y>@8PNTY0NM; 0G1S6(WH58>UF5MCW&R=%.
MKT$&K($<P:1$Y0C?G.3[[W\<PQ)_2 0;+_?)X_G\\9RVA9_YY:Q-NL.-P" $
M0-I2W:B\(+/,BDJ%!A['\CFL;L]#%IY";]$2;4@&1"GDJ5D:R'2:(WN1(&:V
M; M5>_,V RJH0598FQ:MI4:Q"M (*OD<JT0#JU.LK\202H05H"AF#,\L:!<:
MM%=SL['"$"QZ.)_^LT5]A]>'GL4)BD^4I6BHD0X[NJ9_/KW$>SNYG,U/9XOC
MR"95306;.> $I<ZEBY1D<@1W575U:;S%8G;LZ2,T]^G1CLU_N .&E7*ZVAP3
M)H@IT"#@9H,7O*N LIQ2-P9P)Q2GRK(E8PU\,40(H#C=J')-D3']YO)S<@08
MA!61U:Q3I.IDE1<VLH'/'2<4$YC/'EJ%^Q:<=_C(WS"=HGO-%/XBD6"\7([/
ME>49.1]HL .+8>P)?$@@2XJ#H2($-S;?!J8<V3) &38RE;%6Q&_!$29O)%.-
MPL^&%P4<KO,R]C-$QS*_:*#KENQ>;ZQ(Q QL,J^@D-I+3>HU<F0Q;*V6E2!1
M; \1\,L<EDPW)<9^;JUIT!^N)DV9 D%O85?,(9!RSTNXM*:5Z!Y8TWK7'%B^
M451+XJ>=6%]59&SR^=CQH:WLX\Y(?ZSIP@AI&.SS4<+^@*N]LUV^PZ"$#L*8
M8I:!7E?;"A#+&_D%GR5'\V.6M/-'_0[9KD O*$6&U]_1A3<ZBZ*GGUZ_N2V(
MUL&22%&T'K7,%]])TAZ3AS&?/T?5OT&<4U1V6X$-DL-3FD,N2&VHQ,$F !X
M#Q3\IN>$YJ.%!?'7GP#1@Q4"NZ&HTZL/9#0>QF'!#$3Z"T/1< WE&K_:@,8X
MP7"'"Q[D-4ID%Q+[\/J+.0'=1)N*I8$AVF6C<@I,!?$T*^2[](44= @5*G[B
MI;;$('^.P7(PQ#*R=_K-9B51%:0P-!B(DO"'I<;(,4?AUP@^2F2P-G=H$?W9
MYB)J*X*:HT0NC,E&)O -L BQK83&5UKB54Z @KQ@P=H-='>D X9S&['Q0.?@
MX3%<R* "!:3>HD2=G5)LC&Q-BGPCWR[F8509M(QQMA]I,_"&[O0NDDM\#(39
M"8<E7>3YRJ5+.OX% B5\8WV$5X!9,AO/'$2/'GO-NE$W2%]@/P<088X$EXO1
M E3,3E+%1H_9(%XPYE3RQ;'T)[Q0TH&$?NL<!@,4#[<!^KIN.., X#P,0@IL
MS<6"JQM/.&_8>B2B33ZBOT"9 !=)"*,'9!Q>JX(BU;WA@[?3BVGR#Z"I/<F^
MY.]JNWL.FT\GR;MW%Q/K)Q]DDVA-M>YNB/'P8 ?2TA0EQ@BV=AF'A;7@/P7Q
M''(80*>Z'$L?]#%R:&F)X1G41JNN X9A@:I=L[5+T"4&%! G<I 74 F0LU2E
MW\C/2E ;ZN27V70VFR<[N"AZ(([*\$/7^) /3@$I<4P.$+-&"Y.L$+D@T"%L
M][4[A.V7!:R?;/.BH.Q'B,(O[Y-K M'["U_!I0#RTVEK0SKWPP^;*$I"H@DN
M_1J$"8@%1SC7[P/:D;Q-1'-5$#(4EXDHYV6U.D^N :2:6'\2)UL[W_JCO/+\
M@-#9LUB"BN)A!UN$9S.@T3'8A,$W7.5LLOCU\60.MKJ_X/">V+ZG7Z_KRAC.
MUF'R$GU3E*7?R3@$1OQE?C9]:B]G$.0^] O),[$'K&]YGK]@"7D62<BA8\W/
M)K\^G4UFCV>)IXR?.4M(:+15K9>W9'85WFG$I6W0B!UBH\!:=?=!0LKGKI[T
M0?[/2JJS<4GE&/ANJ7&P4@PH)@%06DSN(RXF(=K_,H>/**-_GEH?3Q\Z25)K
MK$A+O /,032B*A_IZ,,12!GZGO*L@LO^<+R+BO8$IT>*6.37[J=!)8M\M07C
M'Y';[N!B,)^N;ME JCI!=@#OE\6C0(#"D4&WEA(O</02B4PZ6$#142#5XZ;_
MS-TP_YX3-7E3N-((&V<0J$U("AU8^Z(>L7-1F4;LN@:=[51C!F%\D[.8T\6T
M<H1*GP3&95P"A,^!>XPA!;NT)8B!F^YB)(\1<@B@PO*]?-MN^?I"_4?Y%G2[
M#W! ?-"'KI]#3KSWD\?_TYCZ4J$CKKLXV5! D^#+G$]/84)P_%H.BQX>V>6V
M\B:FLP,B];S4(6>N.;#2W?DU82[(Y^MCZ>C@58<G33#85/1(-REXF9_UF;#B
MM:EDB3E6A FU*-?>AGFOP^1>N K%)_F'UIKLQ01>'J6.B HE.A@9C;AEJ55]
M0G"D:I<W:.K;Q7&EC%/RWP!W8 V$I!K(I'#1I09"Y7TT5M:LABW^.06DODMP
MBO*2'0D!6K1E24:Q971U\3@(;4"6A[?C G?6K1)1]I^1* -=!):R#>/?G\JM
M;FE+!CV+O:.(SBU$.;HV)=M*\<\IB.9Q7>IUU5 -0:IK\G'!X6M7X%JR$64=
M>-!Y@(=(-CGMO\3BGEAS>;+H$5>A8^UWTY0FMK%ORRV4W910;JJIZBUB2!5L
M9-.G*-7D,)KB5IS+"0AY#Q>.9)^2OQMO9IUTLE$L[+V+,P(D=<820!QZJJ/)
M=.VC(0=(B.HYHXVIKB /4V).\2NLZ<!J%;"B(M/G8!%;&*@+?4.LK6LPYHE\
MP5G.>0,413G9CH[6%%4>4EU*=K"(ZMHL8WJ;R)'@@\6M212R+J*E_^ A>C!5
MC?R*)OFC?\,USN ?.?)/XT-QZ1M!8S%"E-%CB<3'H= /KS\.WL/97P>O4R
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M8OB_M<8X"\-$[BL;+Z1/J.@.J+ZN4HQV!\LQF#G@96?3TMQ#D(%!33G+E&2
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M/S@=.B";<=(86E1U"Z^$-@.AWA9F J.T <:_%D+O#'M!-].3/U!+ P04
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MG5H!:)&/VZ6V1=,R'%#78T<'ONNU=39T?!:N5-[$3=O4P42BOA.SJ#,=^.2
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M>4<M);*T,LJS3N!Y42=GO'#&PVKL5HZ'HM09+_!6@BKSG,EOYYB)U<CQG<W
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M+&--G-NCZR.2"L:H5"3C1"]%H2A/U4&]'*,)^1W(342#G?^$Y*R0$HTGFCX
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MCME]LMJ.E:!%X3;24FBSW]QQ8_Y0H+0&YOU*"/TJV #U7Y3!7U!+ P04
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MI+.[;Z/%W2U,1[/%,RQFH\?Y:+*X__XXAY,%67+4IX/0V$3./<RVH.,:-/X
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MT/.J.>][T83HM!&JQ936C;RVB%)]*8N\YE930=W6ZTTYZ>"C4X[4-%334<U
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M<U'4"U1_?Y/GY=,W]03?\N*/YN%<_A]02P,$%     @ 8CAN6)%D#X#+ @
M(PL  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULM99=;]HP%(;_BI5)
M4RM539P _1A$:NG'(E&*2KM=3+LPX02LVG%J.P6D_?C9":1,@G1"R@VQ$Y_7
MSS%O<DYW(>2KF@-HM.0L53UGKG5VZ;HJG@,GZE1DD)HGB9"<:#.5,U=E$LBT
M".+,]3VOXW)"4R?L%O=&,NR*7#.:PD@BE7-.Y.H:F%CT'.QL;CS1V5S;&V[8
MS<@,QJ!?LI$T,[=2F5(.J:(B11*2GG.%+Z]Q8 .*%3\H+-36&-E4)D*\VDDT
M[3F>)0(&L;82Q%S>H0^,627#\;86=:H];>#V>*-^5R1ODID0!7W!?M*IGO><
M<P=-(2$YTT]B\1W6";6M7BR8*G[1HES;,8OC7&G!U\&&@-.TO)+E^B"V G!K
M3X"_#O +[G*C@O*&:!)VI5@@:5<;-3LH4BVB#1Q-[;\RUM(\I29.A^/H?AC=
M1?VKX3.ZZO<?7X;/T? >C1X'43^Z':.CL?'!-&> 1()>%"0Y0P.:P#$ZN@%-
M*%/'75<;$"OGQNM-K\M-_3V;WD!\B@)\@GS/#_X-=PU_E81?)>$7>JT]>@,R
M$9)H(5?H]BVGF7&-1K\>@$] _MZ%5RMG7X1+E9$8>HYQN@+Y#D[X]0ON>-]J
M8(,*-BC4@SVP(VE>*:E7)VC$B.$DZ72;>F"6HT@#5SO)@P;(6Q5YJ_:8-^0%
M,FR03U!>VH(96^Q"KA=MHQ40J6KPVA5>NU;I+I<IU;F$ZJ]'?] #32G/^2ZN
M6K4#C[)3L78:-$&G ?*SBORL"1/4BV+O4Q><5WSG![B +/>YH%;MP+.\J%@O
M&G3!10/DV/NH&UX3/OA$%7_^.<!;I0W7BO4%SW(-\C^+0KW:H0?Z4<.PWZ 9
M<!,E#7_4-%Q;> YV0[UJL-\,[E;+8]O'!R)G-%6(06*DO-,S\W6794=63K3(
MBBYH(K3IJ8KAW'2Q(.T"\SP10F\FMK&J^N+P+U!+ P04    " !B.&Y8A UJ
M02(#  !&#0  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RU5UUOVC 4
M_2M65DVMM#5??+6#2"Q=.Z2.(J#;P[0'$RY@-;&9;:#KKY^=A#01(2I2^@)Q
M<L_AG.,;<M/=,?XD5@ 2/4<A%3UC)>7ZVC1%L(((BTNV!JJN+!B/L%1+OC3%
MF@.>QZ H-!W+:ID1)M3PNO&Y$?>Z;"-#0F'$D=A$$>;_OD+(=CW#-O8GQF2Y
MDOJ$Z777> D3D(_K$5<K,V.9DPBH((PB#HN>T;>O?=O1@+CB)X&=R!TC;67&
MV)->#.8]P]**((1 :@JLOK;@0QAJ)J7C;TIJ9+^I@?GC/?MM;%Z9F6$!/@M_
MD;E<]8R.@>:PP)M0CMGN.Z2&FIHO8*&(/]$NK;4,%&R$9%$*5@HB0I-O_)P&
MD0/8C2, )P4X;P6X*<"-C2;*8ELW6&*OR]D.<5VMV/1!G$V,5FX(U=LXD5Q=
M)0HGO<G@;CBX'?C]X13U??_A<3@=#._0Z.%^X ^^3="YSV@ 5'(<I\X6R.<P
M)Q*-B7@2"-,YFG(\!S2& ,@6ST*X0.<W(#$)Q07ZC!XG-^C\[ *=(4+1=,4V
M0F%$UY1*O)9@!JG0KXE0YXC0&P@ND6M_0H[EN"5P_^UPIP@W5619;DZ6FQ/S
MN<=R(TM*%B3 5*)^$+ -E80NT8B%)" @T.][!4 #"9'X4V8V86^4L^M[]UJL
M<0 ]0]V< O@6#._C![ME?2FS7A-9(0@W"\*M8O=2\T+=T_L&4+L>]T29[X2L
M'9/IOYBMUW3::D.V>3^'18UFIY45%70V,IV-2IVWA 5\\U*FJ1)XZE[41%;P
MV,P\-M^U*9MU!E$362&(5A9$J\ZFK"0[U7="ULPUK^-:5GGSMC,_[4H__DIM
M'RF37HD[57I-9 6+G<QBYUU[MU-G$#61%8*XRH*XJK-WKP[:K9WKML3.88WM
M'&M)VWJ='*Q*H:,%>0%>^B2O!)ZZ&76Q%6WF!B3[71LSI:\KC)K8BF&\3CUV
MY2QQ:G.F;(4G>>N@/4NJ;/N@/\W<D*O?,'Y@OB14H! 6"F9=ME5_\V1H3Q:2
MK>.Y=\:DFJ+CPY5ZT0&N"]3U!6-RO]"C=/;JY/T'4$L#!!0    ( &(X;EBD
MX_>NBP<  -Y,   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+6<:V^C
M1A2&_\K(756[4C<VX%O2Q%)B;E,UNU&RVTK]-@OC&"T7%["35/WQ'3 !8_ $
M5F^_Q ;/><Z WYP9YC5</D7Q]V3->4J> S],K@;K--U<#(>)L^8!2\ZB#0_%
M)ZLH#E@J-N/'8;*).7/SH, ?JJ/1=!@P+QPL+O-]=_'B,MJFOA?RNY@DVR!@
M\<L-]Z.GJX$R>-UQ[SVNTVS'<'&Y88_\@:=?-W>QV!J6%-<+>)AX44ABOKH:
M7"L75)UG 7F+/SS^E!R\)]FA?(NB[]D&=:\&HZQ'W.=.FB&8>-GQ)??]C"3Z
M\7<!'90YL\##]Z]T,S]X<3#?6,*7D?^GYZ;KJ\%\0%R^8EL_O8^>;%X<T"3C
M.9&?Y'_)4]%V-"#.-DFCH @6/0B\</_*GHL3<1"@C$\$J$6 >APP.1&@%0%:
MUPSC(F!\'# ]$3 I B9=,TR+@&G7@%D1,#L.T$X$S(N >=<,YT7 >2Z'_?>7
M?_DZ2]GB,HZ>2)RU%K3L3:Z@/%I\YUZ8B?TAC<6GGHA+%\O/M[?&_9)>_T[_
MNOY"/W\BU]:]8=P:G[X\D/<Z3YGG)Q_(1_+U02?OWWT@[X@7DB_K:)NPT$TN
MAZGH1(8:.D7"Y3ZA>B*A0FZC,%TGQ A=[K;$&V_$JQ+ 4!Q]>0K4UU-PHTJ)
MMRP^(^KY+T0=J4K; <G#?]OZ(ES+PI5Y2[@N#__LI&=$R;,KL[;3(0_7N7-&
M-"7OO-82;G8/5UO"K>[A;:?.?NO,OQ!%.QE-.YRY?7)E(M&!5OXK:#EO?()W
MQUY$%4^)&$'()HX"+TFB^(6$4<I;.G<CA65CU$6R80Z_&HA!*.'QC@\6/_^D
M3$>_MDD,"=.1,&,/F^6P;.3<+4:7P]VAPMYL835;C$?S:;V1C>PU!<%J.AJ7
M.AK+=;3R_N%QFV2D<7TE@X3I2)B!A)E(F(6$V4@8!<%J@IV4@IW(!?MVL9,"
M^BH7"=.1, ,),Y$P"PFSD3 Z:19W;52- #5%3DM%3I%#\;1E?!D=#4)+:<:^
MJD/"#"3,1,(L),Q&PB@(5E/GK%3G3*K.Y=KCB4>N'V/.,YFV707=2!%]*R82
MIB-A!A)F(F$6$F8C810$JVEW7FIW+M7NIRC\&//5-G39-Y^335%H8^YP;Y?M
M:M.R%-E7R_-&L58GC6JM=VIE[%M-#EIEC8XO4)#=MY P&PFC(%A-5N>EK,Z[
M#-A)MCCD1&'BN3QF^6IF-H2[?,?]:),K+<OL.3PA&QYG:[6M:T WTFQ]%8>$
MZ4B8<=[0[[BI<A.9TD+";"2,@F U_2JC:AUTU$?!8;$8_^2EZU>ILM#A)%H1
MYKI>]B'S29)N73$9:).P/%]?#4-I.I1F%+1:&5:TAHRA22THS8;2*(I6E_+!
MDKXBE7(Y,25,_'7S=]T&>CFXMV:1-!U*,PK:H6:UEJD#-*D%I=E0&D71ZII5
M*\VJ7:ZIOCY4EU6M I52>@L42=.A- -*,Z$T"TJSH32*HM5U7'E(BMQ$NJ[F
M!BR(MMF$0I3>_%HKC<3$8L?KTV$G2MK7#^1Y>BM=:Y0[M5GN=&A2 THSH30+
M2K.A-(JBU25<V5>*W+^Z9<]>L V(D*>7^ON)A)CU-E1;"5K,C\D+9ZV>ESQ9
M;QV/&SJ>39HRAMI94)H)I5E0F@VE412M+N/*U%+DKE:C$I>%.%N28(Z8<.Q*
M<<?\<>NS-#,96.@*60<!CQU/Q :>SY,T"D]<Y$&-,:7II<RF;64::GJU9=5:
MEB&@62THS8;2*(I65VYE?BER]ZME+DS^)459;E4ATEI90FDZE&9 :2:49D%I
M-I1&4;2ZHBO#3)$[9J]^;A22D*<D8?Y^ =@1.]EC^U($U$ K:(IR^"NEL_%Q
M785:8YURFM"<%I1F0VD41:MKL#*^%+GS=:*J>N')J@JUO: T'4HSH#032K.@
M-!M*HRA:7=&5YZ9T,MUZ556HL5;0CBI<]F/<>EF%>F;=DIK0I!:49D-I%$6K
M_WB^,LY4N7%6U%7C^>-;B[=R4%_Q06DZE&9 :2:49D%I-I1&4;2ZE"OC3'W#
M.$,MWLKS]%8ZU$=3F\Y7VT]KH$E-*,V"TFPHC:)H=0E7/IHJ]]&PB[?R9+UU
M#+7;"MJACI7F6ID!36I":1:49D-I%$6KZ[CRT=2>/MK_L7HK[T-O>4-OXE*;
M-TUI+9:= <UJ0FD6E&9#:11%J^N[,ME4N<GVX[_1D8-[BQ9)TZ$T THSH30+
M2K,+VDP^EE%4TKIF*T=-E3MJ[5=Z<FM"CNRM5NBM8U": :694)H%I=E0&D71
MZJ*NS#:UVZUF/1;1Y,3>FH;:;07M:'5,FQS/&CHU,Z%]LZ T&TJC*%I=A95!
MIG:ZI:REM)[V)^3(WC*$WF,&I1E0F@FE65":#:51%*TNZLIQ4^6.VX^45JCG
M!J7I!>T-X\'HULR$]LV"TFPHC:)H>Q4.#YYU)*[R'_,'927BFG\;IOMGO91[
MRX=Q7>>/H#K:OU0N=*5EOZ%<6/M';57X_9._;EG\Z(4)\?E*I!J=S<3,)=X_
M3&N_D4:;_$E+WZ(TC8+\[9HSE\=9 _'Y*HK2UXTL0?E(L\5_4$L#!!0    (
M &(X;E@[2-WCA0,  -X.   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;+57:V_;-A3]*X16# F01D_+<F8;:.,4#=!V7AX;AF$?&.G:)DJ)*DG9S7[]
M2$F1)8<1FDW^(HG2O4?G'%U2E],=XU_%!D"B[RG-Q,S:2)E?V+:(-Y!B<<YR
MR-23%>,IEFK(U[;(.>"D3$JI[3E.:*>89-9\6MY;\OF4%9*2#)8<B2)-,7]\
M#Y3M9I9K/=VX(>N-U#?L^33':[@%>9\ON1K9#4I"4L@$81GBL)I9[]R+2S?0
M"67$[P1VHG6-M)0'QK[JP74RLQS-""C$4D-@==K")5"JD12/;S6HU;Q3)[:O
MG] _E.*5F <LX)+1/T@B-S,KLE "*UQ0><-V'Z$6--)X,:.B/*)='>M8*"Z$
M9&F=K!BD)*O.^'MM1"M!"34G>'6"]Z,)?IW@ET(K9J6L!99X/N5LA[B.5FCZ
MHO2FS%9J2*8_XZWDZBE1>7*^O/EU>75S]R=Z]V6!KGZ[OUY^OOIRATYN5;TD
M!07$5FC)5=5P^8APEJ"K;P7)U7>4I^AD 1(3*D[16W1_NT G;T[1&T0R=+=A
MA5#!8FI+Q5&_R8YK/N\K/MX+?!80GR/?/4.>X_F&],L?3_>ZZ;9RIK'':^SQ
M2CS_)7MJZ6=H27$FNPZ@OSZI<'0M(15_FZ16V($96T_0"Y'C&&:6FH$"^!:L
M^<\_N:'SBTGX0& =&_S&!K\/O65#WM@ 3S:<H35GPOBM*]1QB:H7E.W<GX2A
M.[6W;66&J,CS)TU4AW+04 YZ*7\"(51=XC@NTH)B"8F:W<J:F.!J_5 2<,JX
M)/^4-TSTJS>,6L3>^D$810?\36%^&(5F :-&P.C_>)Z!.D@F,34Q'SVC%$S&
M_@%O0]!HY)M9APWKL-]V_, XEHP_[LF:"/:BO'9J# 36$3QN!(^/N$*,A[1A
M(+".#5%C0W24%2)Z5H-N-/$/*]44%4Q&YE*=-)0GO90_%#PCLN!0DHU9FA<2
M>'_9]B*^]GL-!-81[SK['[]SQ,*MP0=R8BBTKA6M'L@]2O'6L.VZ])TH."A>
M0Y07>2^LL^Z^,W%[__CJ!Z>ZUPVC"2)ISMD6-%DSS4'[D*'0NK+WG8CK'[-L
M>_N<5ULQ$%K7BGV'X_:W./^Y;(-G#9<[#H-G=6L("R>>>U"X=FOSH7=^GS%?
MDTP@"BN5YYR/5>'S:C-5#23+R_W( Y-J=U->;M0&%+@.4,]7C,FG@=[B-%O:
M^;]02P,$%     @ 8CAN6.TTA9]Q @  D@8  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#$N>&ULK57O;]HP$/U73EDUM=+6_**4=1 )&J;U0SL&[:9]=).#
M6'7LS#;0_?>SG9#1*D6=U"_$9]][N7MG7H9;(1]4@:CAL61<C;Q"Z^K"]U56
M8$G4J:B0FY.ED"71)I0K7U422>Y )?.C(.C[):'<2X9N;R:3H5AK1CG.)*AU
M61+Y9X),;$=>Z.TVYG15:+OA)\.*K'"!^JZ:21/Y+4M.2^2*"@X2ER-O'%ZD
M/9OO$GY0W*J]-=A.[H5XL,%5/O("6Q RS+1E(.:QP4MDS!*9,GXWG%[[2@O<
M7^_8O[C>32_W1.&E8#]IKHN1-_ @QR59,ST7VZ_8]'-F^3+!E/N%;9,;>)"M
ME19E S85E)373_+8Z+ '"/LO *(&$#T']%X Q T@?BV@UP"<U'[=BM,A)9HD
M0RFV(&VV8;,+)Z9#F_8IMV-?:&E.J<'I9#;_-IO.;W_!^":%Z?>[J]GU].86
MCL=Y3NU@"(,K7M\N$YW <8J:4*9.X"/<+5(X/CJ!(Z <;@NQ5H3G:NAK4Y=E
M][.FADE=0_1"#6$$UX+K0L&4YY@_)?!-0VU7T:ZK2720,<7L%.+P T1!%'<4
M=/EZ>-0!3U\/#P]T$[<SBAU?_%\SZM*YYNEU\U@'N5 5R7#D&8M0*#?H)>_?
MA?W@<Y=&;TF6OA'9$_UZK7Z]0^QF'H8TH^X&=ZE6H\\=VMKD)@G#3V9PFWTU
M.I*"0?]I4MK%% [:I+IZ?^_?6J)<.==3D(DUU_45;W=;8QT[/WFV/S&&6_OC
M/YK:K:^)7%&N@.'24 :GYV<>R-H!ZT"+RGG"O=#&8=RR,!\-E#;!G"^%T+O
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M(^_,0P4LR*I2,][^A$[/L>'+>27M+VI=[FGHH7PE%:\[L.Z@ILP]R5,WARU
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M.!3]*U9V5;52=_* \)@"TD!HBS0/!#.[ZD<GN8#5Q,[:!F:D_OBUDY"&28A
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MFHJP'6;45Z$T!O1]*83>3LP/NDXM^@]02P,$%     @ 8CAN6/O_OVO, @
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M\!7*@'J2+R0I4[_H4-I:!@IWC).L! L/LB0O_O%CF8@:P/9? #@EP#D%>"\
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MBHGI>C[FD<L1G7[)+K74=WV":C:J.::D&R/];>"B\_5D\[6DAS\E(R>RFD^
M+F"(:A&JQ90F!JDK\)CJ D]W#*7>*/N\7?%(4X36=E#-1C4'U5Q4\U#-1[4
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MGA;-@/K?;_.\>OZAF<%37OR^6>S+_P=02P,$%     @ 8CAN6/GNN8;* P
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MYV 77,,+;HE>L)$X>M'KB S#@HYW $QP32;X*)J$#=#$KM8XHW/ ":[I!+>
M)]B,%&'_EX0.L$=X:!O5\(&/TD=X(GW8E1KG<P[^P#6 X!8(!!NIH3<8O(['
M.&Z @P-TX==TX1^EB_ X7=A%&O^/?0ZZ\&NZ\%N@"]_( QAW7^\<\T OZO5>
M1>/NG!GI [LOA"]I*E ,"U6H6%$I\.T9V+8C658<(STQ*5E2-%= YL#U '5_
MP51L94>?3%4GD>/_ 5!+ P04    " !B.&Y8C.!R2+4#  "K#P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U-RYX;6R]5]MNVS@0_15"+8H$V(VNEIW4-A!;
M+C9 FP9QVGVFI;%-5")=DK*S_?HE)461K4MC0+LOMDC-',XY)$<SXP/C/\06
M0*+G)*9B8FREW-V8I@BWD&!QQ79 U9LUXPF6:L@WIMAQP%'FE,2F8UF^F6!"
MC>DXFWO@TS%+94PH/' DTB3!_)\9Q.PP,6SC9>*1;+923YC3\0YO8 GRV^Z!
MJY%9HD0D 2H(HXC#>F+<VC>![6J'S.([@8.H/"--9<78#SVXBR:&I2."&$*I
M(;#ZV\,<XE@CJ3A^%J!&N:9VK#Z_H'_*R"LR*RQ@SN*_222W$V-DH C6.(WE
M(SO\!06A@<8+62RR7W0H;"T#A:F0+"F<500)H?D_?BZ$J#C8?HN#4S@XIPY>
MBX-;.+AO=? *!R]3)J>2Z1!@B:=CS@Z(:VN%IA\R,3-O19]0O>]+R=5;HOSD
M=/[U_OOB\>EN]GF![K\^+9;H8JG.5I3&@-@:W5$)'(1$BV=UT@2@1PC9AI)?
M$%VBBP D)K&X1'^B;\L 7;R_1.\1H>AIRU*!:23&IE0QZI7,L(AGEL?CM,1C
M.^@+HW(KT()&$!T#F(I<R=!Y83AS.A$#"*^0:_^!',MQ&P*:O]W=:7 /WNYN
M=[!QR_UR,SRO!>\S$P*I^P+/DM!-2L1674*IMRID= ]<DI7:.<HD-(J?@P\S
M<)T2]E-K;.ZK:OS6(JA;C%R[M#EBY96LO$Y6MPE3D?_"62I07")8242$2#$-
M03$34B!UGO+YB(B0I50V\<N7&51B<_SA"<.ZC6N=<FS$<9M)#DJ2@TZ2^@2@
M^[:=Z?35V?]&[' ($T.E=P%\#\;TPSO;MSXV'>D^P8*>P(XT\TO-_$[-YBH7
M</5M2'&L$DN1BR#/14TJ=J*=JV*?8(%?/U&CP:#Y1 U+=8:=Z@35ZX!PY1(U
M:=.)=:XV?8(%P[HV@V&+-J-2F]%_F2@[P<\5JT^P8%03JS7]7I=:77=J]<0D
MCIM4Z'0[5X4^P8+KF@J^X[?(8%NOQ9#UNQ3MM:?H;N=SY>@5+>@+[5BX2A5I
M]YJG"[CC*^]Z)U_J)BM[X)]\JQNLAI6/_C$CYY61\_^4),4ZW35)@U&]*&DP
MNF[C^5I/VMT%9>O=M^MUGC.R[-/ &ZR\^A8UU(R^=Q*Z6>EB$N";K!L4*!,V
M+_?+V;+CO,WZK)/YF>Y$L^[H%29O8[]@OB%4H!C6"M*Z&BHM>=X9Y@/)=EFO
MM&)2=5[9XU9UT\"U@7J_9BHY% .]0-F?3_\%4$L#!!0    ( &(X;EC-/1XX
M- D  !U3   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;+V<:V_;.!:&
M_PKA'2Q:H!M;E"])-PF06!*GBTD:-)W9SXQ,VT)U\4ATT@#[XY>ZQ#0MF;$6
M[\Z7VK)Y'M(Y;X_(5Y0N7[+\1[$60I*?29P65X.UE)O/PV$1KD7"B[-L(U+U
MS3++$R[58;X:%IM<\$45E,1#.AI-APF/TL'U9?790WY]F6UE'*7B(2?%-DEX
M_GHKXNSE:N ,WC[X%JW6LOQ@>'VYX2OQ*.3OFX=<'0UWE$64B+2(LI3D8GDU
MN'$^,_>B#*A:_!&)EV+O/2E_RE.6_2@/OBRN!J-R1"(6H2P17+T\B[F(XY*D
MQO%G QWL^BP#]]^_T8/JQZL?\\0+,<_B?T<+N;X:G _(0BSY-I;?LI=?1?.#
M)B4OS.*B^I>\-&U' Q)N"YDE3; :01*E]2O_V?PA]@+&QP)H$T / ESG2(#;
M!+@' 90>"1@W >-3 R9-P.34@&D3,#TU8-8$S*IDU7_=*C4>E_SZ,L]>2%ZV
M5K3R397?*EIE)$I+*3[*7'T;J3AY/?]Z_X?_[?N7V]]\<O_UN_](/MPL%E$I
M$QZ3+VDM=G7TD7SPA.117'R\'$K5<QD_#)M>YG4O]$@O#B5W62K7!?'3A5B8
M@*$:\F[<]&W<M]1*O-FNS@B=?")T1!WR^Z-'/OSRD?Q"AJ18\UP4S4O74.U@
M3X1GQ'4JL+L#>\=YWND\^L;KP/BG8QP+)K!C_K6-WS#.S()A)X_&F79CC*RZ
M.S6Z%7=\A'NO:N^&OZI2)XE2'@FS]%GD,GJ*!4DSV?GWO[4BRU+^N=CP4%P-
M5*TN1/XL!M=__YLS'?VS2QPU;%;!RC+^?#VZ'#[OI_O=%GZ[A3L:N=/1Z*!A
M@!PY \&,O(UW>1M;\_9;5A1$G5C$3QFEJVU4K*L49LO3,FB%]\W@^-T,OMO"
MKUM,]EK\X]QUV@E$#IR!8$8")[L$3JP)_"9X^*?*6U7XR[P)=21?5?J239;V
MR:6UG[ZY1,(\),R?M!3BJ%IXT98(LE<&@AD2F>XD,K5*Q#]%$9](*JIO9,[3
M@M?3S3 K9*=6K!WVU0H2YB%A_K1+*W36U@JR5P:"&5J9[;0RLVJEFJ3<'RL1
MUMB^:4?"/"3,1\(")(R!8(8TSG?2.+=*(U!@PI-LF\HN;5B#^VH#"?.0,!\)
M"\Y;\YERJC)JU1?6;CBMRM!>0R.G%[N<7EASZHDG2:*TD/FVFO>%/,]?U430
MDN>+UE FX^FD/>:YM>>^.43"?"0L0,(8"&9HP1EI1V%D5<.75 K%E23G4G3E
MWA[?]S]Y0RM?]'S^;#2;',SZH;WZ4%H I3$4S<S_GJ/D_#\7@W9Z;W4@:1Z4
MYC>T]Y>9T&X9BF;*@VIYT+]HJ6GOJ+=2D#0/2O,;FG&*I[3C%!] ^V4HFBD5
M[08Z=CM0+2/&QY<1]N#>Z4?2/"C-A]("*(VA:*9$M/'HV)W'=Y833MO)H^>S
MKGFFO9_>^4?2?"@M@-(8BF;F7_N6CMVX_)^N&#AM]XY.+CK*Z=S>>V]50"U(
M*"V TAB*9JI"6Y6.W:N<'ZI 34;#-4]70BU3U?*T6'\B/ SSK5@0GB[(-MWP
M:*&^JU<NG9KI</&<3LE C4@HS8?2 BB-H6BF9+1CZ=@MRUM>"/+,XZW8JR/U
MAHMCR]A9I^]R* >H00FE^5!: *4Q%,V4@W8I';M->;]-GD1>+D6:_02E*)YX
M$17[TOC/\6T!MTT'SG[%F$S=,TJ=Z:%&H$8EE.9#:0&4QE T4R/:]73LMN=<
M"V&31VH>NE&*J02AA*&WHG2*HR:7-4\7C[/9;#(YE ;4_X32?"@M@-(8BF9N
M3M(>*+5[H \B#]64E*L)ARHA#[E(HFU"9$;F<5:4SOA#)1CUW:/,PA]=$J&=
MOJ9+#Q5B'TE?A4!I/I060&D,13,5HEU2:G=)WW7)F_CW?.WYB>T\^WAZ9Q9)
M"Z TAJ*9F=4&)[4;G'=<;M4I0*4WZ<RK/=HEKX+GW1L7H0XEE.9#:0&4QE T
M4P_:Q:1V%Q-G>-L[ZNMXTO8^18=V73?VH/WZ4%H I3$4S92*=C.IW<W\KG=-
M%?6VJ<JOR-*TV;G_$LDUD6NA_8R3M8-T_>:T[:N>3]N[WSQHKSZ4%D!I#$4S
ME:-]4&KW0>^B-$K4%+/TMM0Z->:IFE[F9:7)#_?;-WJ ;M1L:/NUI';96X*
M6J!06@"E,13-%(2V0*G= KWC/RM!'*Y,R[V9JG[LF1A+44]8;&:&O;/>:IFV
MK9'9>'I&I^?30[U _4\H+8#2&(IFZD7[G]3N?]ZL5KE8J;5(J9@TC#8\MEQ7
ML\-ZZZ'MI-+1F':5#ZC_":4%4!I#T4PY:/^3VOW/[VM%76?QHMS)O2@=BP5_
M+52-\#KE -VVV=",RW,M(4!-3B@M@-(8BF8*09N<U&YR:B&H4T8APFUYZ^AI
MHD :>O.&MB\*MR4*J+T)I050&D/1S+OTM+WIVNU-+8H]H_/KDNPYXI7!V24+
M.[JO+!J:XQA&NGMXSQ[4U832 BB-H6BF,+2KZ=I=S;U9A.& -W.*V+97QX[N
M+0RG+8S1F7/HBD([]:&T $IC*)JI#.V*NG9?\Z;*>ZD%M2 5R>;-#%N(IVXU
M0#=WNNT-E*W[>J%^*)060&D,13.5L'>/M]T/-:^-95M92)Y6LXF0;R*IUAW%
ML6MB=G)O4;@=YXY#54"M3R@M@-(8BF:J0EN?KMWZ]$2:)5'*W^I":5(<KD2M
M]0+J;S8T^]X>#]JG#Z4%4!I#T4QQ:'?3?>_V]-TIH_*S/NU-+SK% #4W&YJ]
M3D!]32@M@-(8BF9*0?N:KMW7U/<$J'5GXWIW2@#J6$)I'I3F0VD!E,90-%,L
MVM1T[::FWL47\EBD"Y[7C@5?2O5Q>8I9E&L5]3W?;.(HY.4EM.56-2PWE*OS
M3G.1;;/-U;NB:7[$[["/I;?B9N^;8- >?2@M@-(8BF;J2+NAKMT--8M.?66E
M4P)0'Q1*\Z T'TH+H#2&HIEBT8ZI:W=,_]JB S59W0Z3M>680$U6*"V TAB*
M5NMHN/>0OD3DJ^KYB^4N#[6PJ9][M_MT]XS'F^K)A@>?SYW/?OVD1HVI'QQY
MQ_-5E!8D%DN%')W-5"+S^EF,]8',-M6C )\R*;.D>KL6?"'RLH'Z?IFI&M<<
ME!WLGHAY_5]02P,$%     @ 8CAN6.,).>L0 P  ;PL  !D   !X;"]W;W)K
M<VAE971S+W-H965T-3DN>&ULK59=;]HP%/TK5C9-G;3E$P)T@$0IU2J5"L'*
MU$<WN8!5)\YL!UII/WYV2#-@)AHJ+V G]QS.N0<GM[MA_%FL "1Z26@J>M9*
MRNS2<42T@@0+FV60JCL+QA,LU98O'9%QP'$!2JCCNV[H))BD5K];7)OP?I?E
MDI(4)AR)/$DP?[T"RC8]R[/>+DS)<B7U!:??S? 29B ?L@E7.Z=BB4D"J2 L
M11P6/6O@70Z] E!4S ELQ,X::2M/C#WKS6W<LURM""A$4E-@];6&(5"JF92.
M7R6I5?VF!NZNW]AO"O/*S!,6,&3T)XGEJF>U+13# N=43MGF.Y2&FIHO8E04
MGVA3UKH6BG(A65*"E8*$I-MO_%(V8@?@MXX _!+@_R\@* %!872KK+!UC27N
M=SG;(*ZK%9M>%+TIT,H-276,,\G57:)PLG\SN)VB^>#N883&H\'L83H:C^Y_
MH(N9^K_$.07$%N@&$X[FF.: !D+EG>D Q&=T<0T2$ZI67Y'O^@UTSR0(M;F#
M-5 4=!VI%.K?<:)2S=56C7]$S35$-@J\+YHN0(_H(W*06&$.PL UK.<:Y$L;
M^<V"RZOA<E3'JK;Y5=O\@KQQA'RFB="$DPALD\U:M#Z:ER+#$?0L=?8$\#58
M_4\?O-#]9O)Y)K(]HT%E-*@U.@8L<@[JX$I$TBR7Z'=]*E=;/F]+J)\BZ[YG
MM]I=9[WKR5@5-*JJ/;&-2FRC5NSH)5-/!XB1!)Z8M-7"3XWE3&1[3IN5T^;)
ML3R:'#?_[;-KAZV#- Q5@>T&YC3"2F-8JW%*Q#-:< #$L023N%K\J7&<B6S/
M:JNRVCHM#I/;+85ZH>Q&X3;:AV&8Z]S&D</1KC2V:S7.&<624")?3>)JL:=&
M<2:R/9N=RF;G_5%T3"T..YV#)(QE'2]HFI/PW+\O7;=6Y",!&AM?C[6X4W,X
M%]N^RYW1PGM_%"7'09,]KWEX+,R%;BL,#])P=J8A/8J.,5^25" *"P5T[99B
MX-OI;KN1+"L&I"<FU;A5+%=J(@:N"]3]!5-S3;G1,U<U8_?_ %!+ P04
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M!&%X11"V@M!Q-P<YRCG1)(FE.(&TU<;-!JY5IS9PE-M+V6II=JG1Z>1QNMS
MZ_1IMX#58KK=;1:KQ?,+]*991NUK(PR6O+E[D_6A-T=-*%-]^ Y/>$0&D8G"
M(!S!L]"HX 8HAY="U(KP3,6^-I#V*#]M@68-4'@%:([I *+A-^L9P6X[A]Y-
M_T\;W_38-1IVC8;.=W35=Z\-FM*R-C.E(252?E!^ %**FNM+H(WAG3.TPWU,
MPF 4!K%_O, 1=1S1?W'DA$HX$E;C)83H7X3Q;? W@G]V__936A%Y,$< P]SH
M@L'=V /9C&>3:%&YD=@+;0;,A87YHE': K.?"W.7;6*GK/N/2#X!4$L#!!0
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MT 'X?<ZY>IGH1MU>Y,*_4$L#!!0    ( &(X;ECRGL*O @0  *(/   9
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;*U7VV[C-A#]%4)=% G06#=?4]M
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M!FD,\/M:"/TV,!-4;?G\/U!+ P04    " !B.&Y8G@G]*K@"  #*!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6RM56U/VS 0_BM6AB:0!FF2)F&L
MC=07IO&A@"BP?37)M;%P[,YV6O;O9SMM:$N:L6E?$K_</7Z>\_FNM^+B6>8
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M_7>J?05F_^V)9F%>LS"_65C0+"S\85C]3<EM =XQ%^!O\'.<KE)=#LS*MCD
MI;F@- ^4YH/2 E!:"$6KNVU;LG?L-YB,'- R/BC-!:5YH#0?E!: TD(H6MV(
MVS*^8ZS.MIN,S*S6_G.T(_G^NYV@C7J@-!^4%H#20BA:8:SNSJ:,E+#'?(,.
M1Y%ZE:_8D%"=K38!7>9;7_;.3^VSL-C*L\44.XMN,'N,,XX2,I=(ZV0TZ"!6
M;-8I#@1=YEL_'J@0-,T_+@B>$:8"Y/=S2L7+@6J@VC(U^1]02P,$%     @
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MTI$\,/9+3ZZ3H>5HAR"#6&H&K#XK&$.6:2+EQN^:TVJ.U,#M\8;]DXE=Q?*
M!8Q9]HTD,AU:%Q9*8('+3$[9^C/4\1@'8Y8)\XO6M:UCH;@4DN4U6'F0$UI]
M\6.=ARV XFD'N#7 ?0GH[0!X-<!["?!W /P:X!\*Z-8 $[I=Q6X2%V*)@P%G
M:\2UM6+3 Y-]@U;Y(E3_3V:2JUVB<#*81C>C>12BR6@Z_X[FT]'=;#2>7W^Y
MFZ&3$"0FF3A%9^A^%J*3MZ<#6ZHS-=*.:_ZKBM_=P=]!MXS*5*"()I"TX,?_
MP;M["&P5;!.QNXGXRMW+.(/B''G.>^0ZKM?FT'YX"+&"=W;"P\/A;@L\.AS>
MV9,,KY'?,WS^+ODAPQ(2-,%</J$_*"1<W6#&VX3>RZ3?LTM1X!B&EGJP!/ 5
M6,&[-YV>\[$MR<<D"X])%AV)[)D<?B.';]B]@^28<TP%KA[4'S?*%%U+R,7/
M-G'\8XIS3++PF&31D<B>B=-MQ.GNO2MCEJOJ++#1XX30."L30I=(I)B#J58)
MBK=L3I%D2*: **-G\ AQJ6LB2NHK)MIDK#SH&P]TB5\%7M?O=P?V:EN?UU:^
M^\%QG.=F80M9[^*56=3"UN]NFU79LK>*3 Y\::J[4!&75%:O;[/:-! C4S=?
MK(]58U'U ?]HJJ[D%O,EH0)EL%"4SGE?N<:K2E]-)"M,*7M@4A5&,TQ5<P1<
M&ZC]!6-R,]$'-.U6\!=02P,$%     @ 8CAN6..&Z1K8!   .B,  !D   !X
M;"]W;W)K<VAE971S+W-H965T-S(N>&ULM9IM;ZLV%(#_BL6FZ4Z:2H"\M%T2
MJ2EP=Z?UKFO6[L.T#PXY2= %G-JF::?^^-E (;3$;:2S?B! .(^-G_@D/7B\
M8_R;V !(\I@FF9A8&RFWY[8MH@VD5)RP+63JG17C*97JD*]ML>5 ET50FMAN
MKS>T4QIGUG1<G+OFTS'+91)G<,V)R-.4\J<9)&PWL1SKY<1-O-Y(?<*>CK=T
M#7.0M]MKKH[LFK*,4\A$S#+"836Q+ISST#G5 <45=S'LQ-X^T;>R8.R;/OBR
MG%@]W2-(()(:0=7+ UQ"DFB2ZL=]!;7J-G7@_OX+/2QN7MW,@@JX9,E?\5)N
M)M:I19:PHGDB;]CN%ZAN:*!Y$4M$L26[\MK!P")1+B1+JV#5@S3.RE?Z6 W$
M7H#K'@APJP#W54#?.Q#@50'>1UOH5P']CP8,JH#!ZP#G0,"P"A@68U\.5C'2
M/I5T.N9L1[B^6M'T3J&KB%8#'&?ZDS677+T;JS@YG=_.YL$?M\'7/TEPI[9S
M\LD'2>-$_#BVI6I 7V9'%>RRA+D'8 ZY8IG<"!)D2UAVQ/OF>/>]^/"=]DT
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MQ3<5)\=#SL&H52=4FH]*"U!I(1:M[;DI/3G&PL?T3LWF.%N3+?"8=16=9V;
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
M8CAN6!Y,TBO&!0  Q#    \   !X;"]W;W)K8F]O:RYX;6S%FTMSFT@0@/_*
ME$[)967Q4I*R7#66L#U5"%A KLU>4AA&]E00N #9<7Y]!A1E&TOJVDO;)T6
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M3T<"  #5*P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+;J-
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M_)-Z#^/7H0S7GN\U7O\GJ1[/YY;KY2_+[YV3N_>"<WU;,3S]!5!+ P04
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M_U/6W\YMOSE^>I:];8?7?#;]H?7F&5!+ 0(4 Q0    ( &(X;E@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 8CAN6,I.EFGN    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 8CAN6)E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !B
M.&Y8K8I?B,\'  !J,P  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ 8CAN6"W/$MFR!@  #AP  !@
M         ("!$A   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( &(X;EBZ*  HE@(  #L'   8              " @?H6  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !B.&Y8X'A>)E4%  #,%0
M&               @('&&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ 8CAN6* I2S28!P  ]30  !@              ("!41\  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &(X;E@6O5"TB0H
M .0R   8              " @1\G  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !B.&Y8E5^6QV0K  "TAP  &               @('>
M,0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 8CAN6*GZ
M@$J/!@  &!,  !@              ("!>%T  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( &(X;EBB93==SP(  *L&   8
M  " @3UD  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !B
M.&Y8"ME#UZ4"  !+!@  &0              @(%"9P  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &(X;EC'_H3E208  .40   9
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M970Q-2YX;6Q02P$"% ,4    " !B.&Y8\\3;(:H-  #))P  &0
M    @(%*CP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M &(X;E@4<H+E404  /<,   9              " @2N=  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ 8CAN6*(;.W!L!   XPP  !D
M             ("!LZ(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !B.&Y8L>;@6$X3  "G.P  &0              @(%6IP  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &(X;EB@6BJ180,
M /((   9              " @=NZ  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ 8CAN6'5KL.<C P  :@<  !D              ("!
M<[X  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !B.&Y8
M+2BL@"P#   7!P  &0              @('-P0  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( &(X;E@L<RYVL2X  +>9   9
M      " @3#%  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ 8CAN6.>/R0Y' @  #@4  !D              ("!&/0  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !B.&Y8X*V/8]D"  !\!@
M&0              @(&6]@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( &(X;E@$->!UAP(  -\%   9              " @:;Y  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 8CAN6)M[I->P
M P  +0H  !D              ("!9/P  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !B.&Y8);J+:?0"   !!P  &0
M@(%+  $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &(X
M;EAM?*4%A 4  (D1   9              " @78# 0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ 8CAN6*ZCJ_$C!   ^ T  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( &(X;ECC<H&'B@(  -<%   9
M  " @<H= 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M8CAN6-J<B]X\%0  <5X! !D              ("!BR ! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !B.&Y8D60/@,L"   C"P  &0
M            @('^-0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( &(X;EB$#6I!(@,  $8-   9              " @0 Y 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 8CAN6*3C]ZZ+!P
MWDP  !D              ("!63P! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !B.&Y8.TC=XX4#  #>#@  &0              @($;
M1 $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( &(X;ECM
M-(6?<0(  )(&   9              " @==' 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ 8CAN6+COM5Z& @  S 8  !D
M     ("!?TH! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M" !B.&Y8M U9H&D"  " !@  &0              @($\30$ >&PO=V]R:W-H
M965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( &(X;EA39D2\IP,  !H.   9
M              " @=Q/ 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!
M A0#%     @ 8CAN6"V.''-^!0   R8  !D              ("!NE,! 'AL
M+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !B.&Y8I7-2HS$#
M  "U"0  &0              @(%O60$ >&PO=V]R:W-H965T<R]S:&5E=#0V
M+GAM;%!+ 0(4 Q0    ( &(X;EC[_[]KS (  (@'   9              "
M@==< 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 8CAN
M6#.2O#!R P  B0P  !D              ("!VE\! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !B.&Y80-^/;F\#   '#P  &0
M        @(&#8P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( &(X;EB(83?X50,  *(*   9              " @2EG 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 8CAN6.PQB.ZZ @  >P8
M !D              ("!M6H! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !B.&Y8JJ]M$0L%  ".&@  &0              @(&F;0$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( &(X;EA8'U+1
M"00  (L2   9              " @>AR 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ 8CAN6)SPAB7) P  '!(  !D
M ("!*'<! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !B
M.&Y8SY9ZAPT0  !WY0  &0              @($H>P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( &(X;ECY[KF&R@,  )44   9
M          " @6R+ 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#
M%     @ 8CAN6(S@<DBU P  JP\  !D              ("!;8\! 'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !B.&Y8S3T>.#0)   =
M4P  &0              @(%9DP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;%!+ 0(4 Q0    ( &(X;ECC"3GK$ ,  &\+   9              " @<2<
M 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 8CAN6$DD
MDY44 @  +P0  !D              ("!"Z ! 'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6Q02P$"% ,4    " !B.&Y8^?3(II$$  #Q%0  &0
M    @(%6H@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M &(X;EBA;=+%L@(  &P(   9              " @1ZG 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ 8CAN6!WG9MP3 P  U D  !D
M             ("!!ZH! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " !B.&Y8\I["KP($  "B#P  &0              @(%1K0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( &(X;EB>"?TJN (
M ,H'   9              " @8JQ 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ 8CAN6*^3B;2E @  (P<  !D              ("!
M>;0! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " !B.&Y8
M/;Z6N,H"   ""P  &0              @(%5MP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( &(X;EALSO086P8  #XU   9
M      " @5:Z 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ 8CAN6&+JV&R, @  T@8  !D              ("!Z, ! 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !B.&Y8=<?J<%@#  "1"@
M&0              @(&KPP$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( &(X;EA87CFWX (  'H)   9              " @3K' 0!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ 8CAN6..&Z1K8
M!   .B,  !D              ("!4<H! 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    " !B.&Y81/>[8F0"  "&!@  &0
M@(%@SP$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( &(X
M;EAD.J)K0P(  (H&   9              " @?O1 0!X;"]W;W)K<VAE971S
M+W-H965T-S0N>&UL4$L! A0#%     @ 8CAN6'JJERET P  M1<   T
M         ( !==0! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !B.&Y8EXJ[
M',     3 @  "P              @ $4V $ 7W)E;',O+G)E;'-02P$"% ,4
M    " !B.&Y8'DS2*\8%  #$,   #P              @ ']V $ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ 8CAN6,?7<T]' @  U2L  !H
M     ( !\-X! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ 8CAN6!^=A6\) @  V"H  !,              ( !;^$! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     %( 4@!U%@  J>,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>365</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - COMMERCIALIZATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommercializationAgreements</Role>
      <ShortName>COMMERCIALIZATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenue</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapital</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotes</Role>
      <ShortName>CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShare</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30703 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30803 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenueTables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenue</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30903 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapital</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31003 - Disclosure - CONVERTIBLE NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesTables</Role>
      <ShortName>CONVERTIBLE NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31203 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31303 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncome</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31403 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (General) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (General) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails</Role>
      <ShortName>COMMERCIALIZATION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureCommercializationAgreements</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40402 - Disclosure - INVENTORIES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails</Role>
      <ShortName>INVENTORIES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40601 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommitmentsDetails</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureCommitments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASES (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>OPERATING LEASES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40801 - Disclosure - REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenueDetails</Role>
      <ShortName>REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenueTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40902 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40903 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40904 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40905 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40906 - Disclosure - SHARE CAPITAL (Additional information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails</Role>
      <ShortName>SHARE CAPITAL (Additional information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41201 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41301 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails</Role>
      <ShortName>TAXES ON INCOME (Summary of Taxes on Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41302 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41303 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails</Role>
      <ShortName>TAXES ON INCOME (Reconciliation of Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41304 - Disclosure - TAXES ON INCOME (Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails</Role>
      <ShortName>TAXES ON INCOME (Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41305 - Disclosure - TAXES ON INCOME (Uncertain Tax Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails</Role>
      <ShortName>TAXES ON INCOME (Uncertain Tax Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41306 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails</Role>
      <ShortName>TAXES ON INCOME (Schedule of Open Tax Years) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41307 - Disclosure - TAXES ON INCOME (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails</Role>
      <ShortName>TAXES ON INCOME (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41601 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="plx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20231231.xsd</File>
    <File>plx-20231231_cal.xml</File>
    <File>plx-20231231_def.xml</File>
    <File>plx-20231231_lab.xml</File>
    <File>plx-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="plx-20231231x10k.htm">plx-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20231231x10k001.jpg</File>
    <File>plx-20231231x10k002.jpg</File>
    <File>plx-20231231x10k003.jpg</File>
    <File>plx-20231231x10k004.jpg</File>
    <File>plx-20231231x10k005.jpg</File>
    <File>plx-20231231x10k007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="651">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20231231x10k.htm": {
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "plx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "plx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 286,
   "keyCustom": 79,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 33,
   "memberCustom": 34,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 4
   },
   "contextCount": 212,
   "entityCount": 1,
   "segmentCount": 70,
   "elementCount": 636,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 651,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.protalix.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A-V99KoI40mufi3_2xy4zw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A-V99KoI40mufi3_2xy4zw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.protalix.com/role/DisclosureCommercializationAgreements",
     "longName": "10201 - Disclosure - COMMERCIALIZATION AGREEMENTS",
     "shortName": "COMMERCIALIZATION AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipment",
     "longName": "10301 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "longName": "10401 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement",
     "longName": "10501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT",
     "shortName": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.protalix.com/role/DisclosureCommitments",
     "longName": "10601 - Disclosure - COMMITMENTS",
     "shortName": "COMMITMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeases",
     "longName": "10701 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.protalix.com/role/DisclosureRevenue",
     "longName": "10801 - Disclosure - REVENUE",
     "shortName": "REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.protalix.com/role/DisclosureShareCapital",
     "longName": "10901 - Disclosure - SHARE CAPITAL",
     "shortName": "SHARE CAPITAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotes",
     "longName": "11001 - Disclosure - CONVERTIBLE NOTES",
     "shortName": "CONVERTIBLE NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "longName": "11101 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShare",
     "longName": "11201 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncome",
     "longName": "11301 - Disclosure - TAXES ON INCOME",
     "shortName": "TAXES ON INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "longName": "11401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactions",
     "longName": "11501 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "longName": "11601 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables",
     "longName": "30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:ScheduleOfUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:ScheduleOfUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables",
     "longName": "30303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "longName": "30403 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesTables",
     "longName": "30703 - Disclosure - OPERATING LEASES (Tables)",
     "shortName": "OPERATING LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.protalix.com/role/DisclosureRevenueTables",
     "longName": "30803 - Disclosure - REVENUE (Tables)",
     "shortName": "REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalTables",
     "longName": "30903 - Disclosure - SHARE CAPITAL (Tables)",
     "shortName": "SHARE CAPITAL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
     "longName": "31003 - Disclosure - CONVERTIBLE NOTES (Tables)",
     "shortName": "CONVERTIBLE NOTES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_VZDiVAJYeUq_J3J-EliWwQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_VZDiVAJYeUq_J3J-EliWwQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "longName": "31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables",
     "longName": "31203 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables",
     "longName": "31303 - Disclosure - TAXES ON INCOME (Tables)",
     "shortName": "TAXES ON INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "longName": "31403 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables",
     "longName": "31503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (General) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (General) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_LtAR6Q5w6kqJ8CT_46DuZA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_21_2023_MSmaAEySeUOElBXVq6cGkQ",
      "name": "plx:NumberOfPatientsDosed",
      "unitRef": "Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
     "longName": "40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_WRnbeAQqwEefX40snBbQkw",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_WRnbeAQqwEefX40snBbQkw",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails",
     "longName": "40103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_rEiciTruOUm2wOSIAx_19Q",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
     "longName": "40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)",
     "shortName": "COMMERCIALIZATION AGREEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:RepaymentsOfNotesPayable",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_YBmOU2lAJUOBzWtk50UFrg",
      "name": "us-gaap:NotesPayableCurrent",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "longName": "40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "longName": "40302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "longName": "40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails",
     "longName": "40402 - Disclosure - INVENTORIES (Additional Information) (Details)",
     "shortName": "INVENTORIES (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
     "longName": "40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)",
     "shortName": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:EmployeeSeveranceObligationPayment",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:EmployeeSeveranceObligationPayment",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.protalix.com/role/DisclosureCommitmentsDetails",
     "longName": "40601 - Disclosure - COMMITMENTS (Details)",
     "shortName": "COMMITMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I6KOw7CYo0-cs1kRCGYA5Q",
      "name": "plx:ExtendedTermOfAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CPzVDrt_wUy8VbkR5mm3YA",
      "name": "plx:ContractAmountUnderAgreementPayable",
      "unitRef": "Unit_Standard_EUR_hZumu6sr7UyT0mvTxrhElw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails",
     "longName": "40701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)",
     "shortName": "OPERATING LEASES (Schedule of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails",
     "longName": "40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)",
     "shortName": "OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "longName": "40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)",
     "shortName": "OPERATING LEASES (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.protalix.com/role/DisclosureRevenueDetails",
     "longName": "40801 - Disclosure - REVENUE (Details)",
     "shortName": "REVENUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Fqn4nOxM00S03kAdCXfsqg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
     "longName": "40901 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)",
     "shortName": "SHARE CAPITAL (Summary of Stock Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N8BFMU2rM0W5-sfr4UsdRA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N8BFMU2rM0W5-sfr4UsdRA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
     "longName": "40902 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)",
     "shortName": "SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YujFqI1i2U-sAYFqgp2Lmw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YujFqI1i2U-sAYFqgp2Lmw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
     "longName": "40903 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)",
     "shortName": "SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
     "longName": "40904 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)",
     "shortName": "SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_2_17_2021_CVbxW9emMEyG2cHIMoZs5A",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails",
     "longName": "40905 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)",
     "shortName": "SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
     "longName": "40906 - Disclosure - SHARE CAPITAL (Additional information) (Details)",
     "shortName": "SHARE CAPITAL (Additional information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_7_25_2023_tpab9C7-pEeEaYxfCF7NUg",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
     "longName": "41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)",
     "shortName": "CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_57ZK5w5WGUyALypMdLvZ_w",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_57ZK5w5WGUyALypMdLvZ_w",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
     "longName": "41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)",
     "shortName": "CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
     "longName": "41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)",
     "shortName": "CONVERTIBLE NOTES (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_7_31_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rTPd6I7xUkGiNNPDC-sQZA",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "longName": "41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_3I09XpnwBUK1eNxQSTeoEw",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "longName": "41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dFp5G0LNJUya7KtQK3pNQQ",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dFp5G0LNJUya7KtQK3pNQQ",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
     "longName": "41201 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:DilutiveSecurities",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
     "longName": "41301 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)",
     "shortName": "TAXES ON INCOME (Summary of Taxes on Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails",
     "longName": "41302 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)",
     "shortName": "TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails",
     "longName": "41303 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)",
     "shortName": "TAXES ON INCOME (Reconciliation of Tax Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails",
     "longName": "41304 - Disclosure - TAXES ON INCOME (Valuation Allowance) (Details)",
     "shortName": "TAXES ON INCOME (Valuation Allowance) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "plx:DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails",
     "longName": "41305 - Disclosure - TAXES ON INCOME (Uncertain Tax Position) (Details)",
     "shortName": "TAXES ON INCOME (Uncertain Tax Position) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails",
     "longName": "41306 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)",
     "shortName": "TAXES ON INCOME (Schedule of Open Tax Years) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_rYb5LIKYEU-DUI4F45twMw",
      "name": "us-gaap:OpenTaxYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfOpenTaxYearsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_rYb5LIKYEU-DUI4F45twMw",
      "name": "us-gaap:OpenTaxYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfOpenTaxYearsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
     "longName": "41307 - Disclosure - TAXES ON INCOME (Additional Information) (Details)",
     "shortName": "TAXES ON INCOME (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails",
     "longName": "41401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "plx:OtherAssetsInstitutionsCurrent",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "plx:OtherAssetsInstitutionsCurrent",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "longName": "41402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_9_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b6xXIxG3uUumtk0da2OG_g",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b6xXIxG3uUumtk0da2OG_g",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "longName": "41601 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_dzHxfLYBE0qT2A92CcAQaA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_nqKCRd69hEOEP6D4HvRrJQ",
      "name": "plx:ProceedsFromSaleOfProducts",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts payable and accruals - other",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r719"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r18"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r680"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties",
        "terseLabel": "Accrued royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r45"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less - accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r157",
      "r555"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Additional amount payable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs",
        "terseLabel": "Additional amounts payable to cover development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r583",
      "r824",
      "r825",
      "r826",
      "r872",
      "r901"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r391"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r754",
      "r764",
      "r790"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r757",
      "r767",
      "r793"
     ]
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "AgreementAmendmentPaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement amendment payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r758",
      "r768",
      "r785",
      "r794",
      "r798",
      "r806"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r432"
     ]
    },
    "plx_AmendedPfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "AmendedPfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "verboseLabel": "Debt discount amortization",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r61",
      "r94",
      "r292"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r498",
      "r696",
      "r697",
      "r820"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r158",
      "r182",
      "r225",
      "r231",
      "r235",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r468",
      "r472",
      "r488",
      "r549",
      "r611",
      "r719",
      "r732",
      "r834",
      "r835",
      "r885"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r163",
      "r182",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r468",
      "r472",
      "r488",
      "r719",
      "r834",
      "r835",
      "r885"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AtMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "AtMarketEquityOfferingMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares",
        "terseLabel": "ATM Shares"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AtmEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "AtmEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ATM Equity Offering Sales Agreement.",
        "label": "ATM Equity Offering Sales Agreement",
        "terseLabel": "BofA Securities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737",
      "r750"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737",
      "r750"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737",
      "r750"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "country_BR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "BR",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "plx_BusinessDevelopmentConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "BusinessDevelopmentConsultantMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business development consultant member.",
        "label": "Business Development Consultant [Member]",
        "terseLabel": "Business development consultant member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "CapitalizedResearchAndDevelopmentCostAmortizationPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized for research and development cost, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Research And Development Cost, Amortization Period",
        "terseLabel": "Amortization period research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r155",
      "r677"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r99",
      "r179"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r99"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Change in amount receivable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "plx_ChiesiAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ChiesiAgreementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements",
        "terseLabel": "Chiesi Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiExUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ChiesiExUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ChiesiMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ChiesiUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "verboseLabel": "Number of shares per warrant issued",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants issued (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COMMERCIALIZATION AGREEMENTS",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r139",
      "r149"
     ]
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "plx_CommercializationAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "CommercializationAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMERCIALIZATION AGREEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_CommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "CommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment amount.",
        "label": "Commitment Amount",
        "terseLabel": "Subcontracting commitment amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r67",
      "r550",
      "r597"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r729",
      "r824",
      "r825",
      "r872",
      "r898",
      "r901"
     ]
    },
    "plx_CommonStockNumberOfVotingRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "CommonStockNumberOfVotingRights",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes for each share of common stock is entitled.",
        "label": "Common Stock, Number Of Voting Rights",
        "terseLabel": "Number of voting rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r598"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r598",
      "r617",
      "r901",
      "r902"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, $0.001 par value: Authorized - as of December 31, 2022 and 2023, 144,000,000 and 185,000,000 shares, respectively; issued and outstanding - as of December 31, 2022 and 2023, 53,790,167 and 72,952,124 shares, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r551",
      "r719"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net, Classification [Abstract]",
        "verboseLabel": "In respect of:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risks and trade receivable",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r141"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r468",
      "r469",
      "r472",
      "r473",
      "r522",
      "r671",
      "r833",
      "r836",
      "r837"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r468",
      "r469",
      "r472",
      "r473",
      "r522",
      "r671",
      "r833",
      "r836",
      "r837"
     ]
    },
    "plx_ContractAmountUnderAgreementPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ContractAmountUnderAgreementPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount agreed to pay under the agreement.",
        "label": "Contract Amount Under Agreement, Payable",
        "terseLabel": "Contract amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314"
     ]
    },
    "plx_ContributionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ContributionPlansMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution to Defined Contribution Plans [Member]",
        "terseLabel": "Contribution to Defined Contribution Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt",
        "terseLabel": "Aggregate principal amount",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r128",
      "r895"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Current",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Convertible notes",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt instrument fair value",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ConvertibleNotesDue2021And2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r182",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r488",
      "r834"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "terseLabel": "Cost of goods sold",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r274",
      "r299",
      "r520",
      "r684",
      "r686"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current taxes on income",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r455",
      "r461",
      "r823"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Convertible notes conversions",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued and unpaid interest exchanged in cash in debt conversion.",
        "label": "Debt Conversion, Converted Instrument, Exchange in Cash, Accrued and Unpaid Interest",
        "terseLabel": "Convertible notes exchange in cash, accrued and unpaid interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Converted instrument, shares issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "plx_DebtConversionDecreaseInPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DebtConversionDecreaseInPrincipalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of decrease in the total principal amount of debt due to conversion.",
        "label": "Debt Conversion, Decrease In Principal Amount",
        "terseLabel": "Decrease in principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The transaction costs in connection with exchange of convertible notes.",
        "label": "Debt Conversion, Transaction Costs in Connection with Exchange of Convertible Debt",
        "terseLabel": "Transactions costs in connection with the exchange of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE NOTES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "CONVERTIBLE NOTES",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r180",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r286",
      "r293",
      "r294",
      "r295"
     ]
    },
    "plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate percentage of principle amount of debt outstanding.",
        "label": "Debt Instrument, Aggregate Percentage Of Principle Amount Outstanding",
        "terseLabel": "Aggregate percentage of principle amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r73",
      "r74",
      "r127",
      "r128",
      "r188",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r499",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r821"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt instrument carrying amount",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r128",
      "r296"
     ]
    },
    "plx_DebtInstrumentConvertibleBaseValueForConversionRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DebtInstrumentConvertibleBaseValueForConversionRate",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Base Value For Conversion Rate",
        "label": "Debt Instrument Convertible Base Value For Conversion Rate",
        "terseLabel": "Base value for conversion rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r273"
     ]
    },
    "plx_DebtInstrumentConvertibleConversionShareNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DebtInstrumentConvertibleConversionShareNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Conversion Share Number",
        "label": "Debt Instrument Convertible Conversion Share Number",
        "terseLabel": "Number of shares for basis conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r271",
      "r499",
      "r694",
      "r695"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r272"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Measurement input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r188",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r499",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r821"
     ]
    },
    "plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the denomination of the principal amount of debt that is used in conversion calculations.",
        "label": "Debt Instrument Principal Amount Denomination for Conversion Into Common Stock",
        "verboseLabel": "Denomination of the principal amount of debt"
       }
      }
     },
     "auth_ref": []
    },
    "plx_DebtInstrumentRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DebtInstrumentRedemption",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of redemption of debt as at the end of the reporting period.",
        "label": "Debt Instrument, Redemption",
        "verboseLabel": "Amount of redemption of debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "verboseLabel": "Redemption price, percentage",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "terseLabel": "Mature term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred tax asset",
        "verboseLabel": "Deferred taxes on income",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r124",
      "r147",
      "r460",
      "r461",
      "r823"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r871"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r871"
     ]
    },
    "plx_DeferredTaxAssetsOtherTimingDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DeferredTaxAssetsOtherTimingDifferences",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax assets other timing differences.",
        "label": "Deferred Tax Assets Other Timing Differences",
        "terseLabel": "Other timing differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "negatedPeriodEndLabel": "Ending Balance",
        "negatedPeriodStartLabel": "Beginning Balance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additions to the valuation allowance for deferred tax asset.",
        "label": "Deferred Tax Assets, Valuation Allowance, Additions During The Period",
        "negatedLabel": "Additions to valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reductions to the valuation allowance for deferred tax asset.",
        "label": "Deferred Tax Assets, Valuation Allowance, Reductions During The Period",
        "terseLabel": "Reductions to valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "Deferred tax liability of research and development costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r871"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "terseLabel": "Gain for the period",
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r87",
      "r114"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r316",
      "r317",
      "r338",
      "r610",
      "r704",
      "r894"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "verboseLabel": "Contribution in connection with severance liabilities",
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r705"
     ]
    },
    "us-gaap_DefinedBenefitPostretirementLifeInsuranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPostretirementLifeInsuranceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution to Insurance Companies [Member]",
        "terseLabel": "Contribution to Insurance Companies",
        "documentation": "Plan designed to provide postretirement life insurance benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contributions",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Financial expenses of 2024 Notes",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director",
        "verboseLabel": "Director"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r899"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE CAPITAL"
       }
      }
     },
     "auth_ref": []
    },
    "plx_DisclosureOfLeasesOperatingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "DisclosureOfLeasesOperatingLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Leases Operating",
        "label": "Disclosure of Leases Operating [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737",
      "r750"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737",
      "r750",
      "r786"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r203",
      "r205",
      "r217",
      "r218",
      "r219",
      "r223",
      "r482",
      "r483",
      "r546",
      "r560",
      "r689"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r205",
      "r217",
      "r218",
      "r219",
      "r223",
      "r482",
      "r483",
      "r546",
      "r560",
      "r689"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net earnings (loss) per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r220",
      "r221",
      "r222"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r444",
      "r462"
     ]
    },
    "plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to utilization of carry-forward losses and other temporary items without deferred taxes recognition.",
        "label": "Effective Income Tax Rate Reconciliation, Utilization Of Carry-Forward Losses And Other Temporary Items Without Deferred Taxes Recognition",
        "terseLabel": "Utilization of carry-forward losses and other temporary items without deferred taxes recognition"
       }
      }
     },
     "auth_ref": []
    },
    "plx_EffectiveIncomeTaxRateReconciliationWithholdingTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTax",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to withholding tax.",
        "label": "Effective Income Tax Rate Reconciliation, Withholding Tax",
        "negatedLabel": "Withholding tax"
       }
      }
     },
     "auth_ref": []
    },
    "plx_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "EmployeeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee",
        "terseLabel": "Employee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "plx_EmployeeSeveranceObligationPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "EmployeeSeveranceObligationPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee severance obligation payment.",
        "label": "Employee Severance Obligation Payment",
        "terseLabel": "Employee severance obligation payments"
       }
      }
     },
     "auth_ref": []
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "EmployeeStockIncentivePlan2006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan",
        "terseLabel": "2006 Employee Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "plx_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employees and directors.",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and directors"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r150",
      "r167",
      "r168",
      "r169",
      "r189",
      "r190",
      "r191",
      "r193",
      "r199",
      "r201",
      "r224",
      "r247",
      "r248",
      "r311",
      "r425",
      "r426",
      "r427",
      "r456",
      "r457",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r513",
      "r569",
      "r570",
      "r571",
      "r583",
      "r642"
     ]
    },
    "plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "EquityComponentOfConvertibleNotesNetOfTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component Of Convertible Notes Net Of Transaction Costs",
        "label": "Equity Component Of Convertible Notes Net Of Transaction Costs",
        "terseLabel": "Equity component of convertible notes, net of transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r754",
      "r764",
      "r790"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r751",
      "r761",
      "r787"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "plx_ExercisePrice1.03To2.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ExercisePrice1.03To2.00Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price ranging from $1.03 to $2.00.",
        "label": "Exercise Price 1.03 to 2.00 [Member]",
        "terseLabel": "$1.03 - $2.00"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ExercisePrice17.20Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ExercisePrice17.20Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price $17.20.",
        "label": "Exercise Price 17.20",
        "terseLabel": "$17.20"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ExercisePrice3.55To3.73Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ExercisePrice3.55To3.73Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price ranging from $3.55 to $3.73.",
        "label": "Exercise Price 3.55 to 3.73 [Member]",
        "terseLabel": "$3.55 - $3.73"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ExercisePrice4.69To5.60Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ExercisePrice4.69To5.60Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price ranging from $4.69 to $5.60.",
        "label": "Exercise Price 4.69 to 5.60 [Member]",
        "terseLabel": "$4.69 - $5.60"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ExtendedTermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ExtendedTermOfAgreement",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended term  of agreement.",
        "label": "Extended Term Of Agreement",
        "terseLabel": "Extended term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r485",
      "r526",
      "r527",
      "r528",
      "r694",
      "r695",
      "r702",
      "r703",
      "r704"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r485",
      "r528",
      "r694",
      "r695",
      "r702",
      "r703",
      "r704"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r526",
      "r527",
      "r528",
      "r694",
      "r695",
      "r702",
      "r703",
      "r704"
     ]
    },
    "plx_FillFinishAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "FillFinishAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fill/Finish Agreement [Member]",
        "label": "Fill/Finish Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_FiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "FiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiocruz"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r619",
      "r730",
      "r875",
      "r876",
      "r900"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758",
      "r768",
      "r794"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758",
      "r768",
      "r794"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758",
      "r768",
      "r794"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758",
      "r768",
      "r794"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758",
      "r768",
      "r794"
     ]
    },
    "plx_FurnitureAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "FurnitureAndComputerEquipmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture And Computer Equipment Member",
        "label": "Furniture And Computer Equipment [Member]",
        "terseLabel": "Furniture and computer equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_GainLossOnDebtConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "GainLossOnDebtConversion",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) on conversion of convertible debt.",
        "label": "Gain (Loss) On Debt Conversion",
        "negatedLabel": "Gain on conversions of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss (gain) on sale of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of convertible notes",
        "terseLabel": "Loss on extinguishment of convertible notes",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42",
      "r43"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737",
      "r750"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment in value of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r107"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE TAXES ON INCOME",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r88",
      "r130",
      "r225",
      "r230",
      "r234",
      "r236",
      "r547",
      "r557",
      "r691"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r627"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r627"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r121",
      "r123"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "plx_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure Line Items",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "plx_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure Table",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r436",
      "r445",
      "r449",
      "r453",
      "r458",
      "r463",
      "r464",
      "r465",
      "r578"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAXES ON INCOME",
        "totalLabel": "Total taxes on income",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r148",
      "r200",
      "r201",
      "r228",
      "r443",
      "r459",
      "r561"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r439",
      "r440",
      "r449",
      "r450",
      "r452",
      "r454",
      "r575"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance related to deferred tax assets",
        "verboseLabel": "Change in Valuation allowances",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Differences in tax rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r444"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax computed at the statutory U.S. income tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Statutorily non-deductible expenses",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable-trade and other assets",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "IncreaseDecreaseInBankDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase (decrease) in contracts liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r819"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Decrease in other long term liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "plx_IncreaseDecreaseInRestrictedDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "IncreaseDecreaseInRestrictedDeposit",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit",
        "label": "Increase (Decrease) In Restricted Deposit",
        "negatedLabel": "Decrease in restricted deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Weighted average dilutive effect of 2024 Notes",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r219"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Weighted average dilutive effect of stock options",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r219",
      "r393"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r758",
      "r768",
      "r785",
      "r794",
      "r798",
      "r806"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r810"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r810"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r810"
     ]
    },
    "us-gaap_InterestCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestCostsIncurred",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net",
        "totalLabel": "Total",
        "documentation": "Total interest costs incurred during the period and either capitalized or charged against earnings."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r291",
      "r696",
      "r697"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Interest Expense Recognized",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r177",
      "r178"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "verboseLabel": "Interest Payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "plx_InterestReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "InterestReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r681"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r678",
      "r719"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r154",
      "r159",
      "r249",
      "r250",
      "r252",
      "r532",
      "r687"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r683"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r682"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "plx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Schedule of Operating Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Maturity Analysis of Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted cash flows",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "2028 and thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfRenewalTermExtensions",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Number Of Renewal Term Extensions",
        "label": "Lessee Operating Lease, Number Of Renewal Term Extensions",
        "terseLabel": "Operating lease, Renewable term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, term of agreement",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_LessorDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r182",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r469",
      "r472",
      "r473",
      "r488",
      "r596",
      "r690",
      "r732",
      "r834",
      "r885",
      "r886"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (net of capital deficiency)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r129",
      "r553",
      "r719",
      "r822",
      "r829",
      "r874"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r153",
      "r182",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r469",
      "r472",
      "r473",
      "r488",
      "r719",
      "r834",
      "r885",
      "r886"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r70",
      "r71",
      "r72",
      "r75",
      "r182",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r469",
      "r472",
      "r473",
      "r488",
      "r834",
      "r885",
      "r886"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and R&amp;D Services",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "plx_MaintainOfMinimumCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "MaintainOfMinimumCashBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance",
        "terseLabel": "Minimum cash balance required"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r701",
      "r839",
      "r896",
      "r897"
     ]
    },
    "plx_MaximumDebtInstrumentConvertibleConversionShareNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "MaximumDebtInstrumentConvertibleConversionShareNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum price per share of the conversion feature embedded in the debt instrument.",
        "label": "Maximum Debt Instrument Convertible Conversion Share Number",
        "verboseLabel": "Maximum price per share of the conversion feature"
       }
      }
     },
     "auth_ref": []
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year",
        "terseLabel": "Maximum entitlement of development costs to cover per year"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r387",
      "r530",
      "r568",
      "r588",
      "r589",
      "r650",
      "r652",
      "r654",
      "r655",
      "r657",
      "r672",
      "r673",
      "r692",
      "r698",
      "r712",
      "r721",
      "r838",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price.",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "plx_MeasurementInputYieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "MeasurementInputYieldMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "auth_ref": []
    },
    "plx_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "MilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received upon achievement of certain milestone.",
        "label": "Milestone Payment Received",
        "terseLabel": "Amount of milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r387",
      "r530",
      "r568",
      "r588",
      "r589",
      "r650",
      "r652",
      "r654",
      "r655",
      "r657",
      "r672",
      "r673",
      "r692",
      "r698",
      "r712",
      "r721",
      "r838",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r701",
      "r839",
      "r896",
      "r897"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "NatureOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME (LOSS) FOR THE PERIOD",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r101",
      "r131",
      "r151",
      "r164",
      "r165",
      "r169",
      "r182",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r215",
      "r225",
      "r230",
      "r234",
      "r236",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r483",
      "r488",
      "r559",
      "r620",
      "r640",
      "r641",
      "r691",
      "r730",
      "r834"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income (loss) for diluted calculation",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r204",
      "r209",
      "r210",
      "r211",
      "r212",
      "r216",
      "r219"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758",
      "r768",
      "r785",
      "r794"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_NoncollaborativeArrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncollaborativeArrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Other than Collaborative [Member]",
        "terseLabel": "Arrangement Other than Collaborative",
        "documentation": "Arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL EXPENSES, NET",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "plx_Notes2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "Notes2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2024 notes.",
        "label": "Notes 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current",
        "terseLabel": "Promissory note",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of calendar days after the date of applicable fundamental change purchase date.",
        "label": "Number Of Calendar Days After Date Of Applicable Fundamental Change",
        "terseLabel": "Number of calendar days after the date of applicable fundamental change purchase date"
       }
      }
     },
     "auth_ref": []
    },
    "plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employees To Receive Benefits During Next Five Years",
        "label": "Number Of Employees To Receive Benefits During Next Five Years",
        "terseLabel": "Number of benefit eligible employees"
       }
      }
     },
     "auth_ref": []
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "auth_ref": []
    },
    "plx_NumberOfPatientsDosed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "NumberOfPatientsDosed",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of patients that were dosed in the trial.",
        "label": "Number Of Patients Dosed",
        "terseLabel": "Number of patients dosed"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OfficeOfIsraeliInnovationAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "OfficeOfIsraeliInnovationAuthorityMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office of the Israeli Innovation Authority [Member]",
        "label": "Office of the Israeli Innovation Authority [Member]",
        "terseLabel": "Office of the Israeli Innovation Authority"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Tax Year",
        "terseLabel": "Open tax year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r230",
      "r234",
      "r236",
      "r691"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r718"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r508"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r718"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r718"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "plx_OptionsAndRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "OptionsAndRestrictedSharesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock options and restricted shares.",
        "label": "Options and Restricted Shares [Member]",
        "terseLabel": "Options and restricted shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r719"
     ]
    },
    "plx_OtherAssetsInstitutionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "OtherAssetsInstitutionsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).",
        "label": "Other Assets, Institutions, Current",
        "terseLabel": "Institutions"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OtherAssetsSundryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "OtherAssetsSundryCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).",
        "label": "Other Assets, Sundry, Current",
        "terseLabel": "Sundry"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r756",
      "r766",
      "r792"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r759",
      "r769",
      "r795"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r759",
      "r769",
      "r795"
     ]
    },
    "plx_OutstandingStockOptionsAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "OutstandingStockOptionsAndWarrantsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants.",
        "label": "Outstanding Stock Options And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OutstandingStockOptionsWarrantsAnd2024NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "OutstandingStockOptionsWarrantsAnd2024NotesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants and 2024 notes.",
        "label": "Outstanding Stock Options Warrants And 2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option",
        "terseLabel": "Over-Allotment Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of partial settlement of liability for employee rights upon retirement through transfer of related funds in non-cash financing and investing activities.",
        "label": "Partial Settlement Of Liability For Employee Rights Upon Retirement Through Transfer Of the Related Funds",
        "terseLabel": "Partial settlement of liability for employee rights upon retirement through transfer of the related funds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "plx_PaymentInConsiderationForDevelopmentServicesPerformed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PaymentInConsiderationForDevelopmentServicesPerformed",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from consideration received for development services performed.",
        "label": "Payment in Consideration for Development Services Performed",
        "terseLabel": "Payments in consideration for development services performed"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PaymentOnNetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PaymentOnNetSalesPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage",
        "terseLabel": "Payment on net sales percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts paid (funded) in respect of employee rights upon retirement, net",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r817"
     ]
    },
    "plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PaymentsInConnectionWithPerformanceOfAdditionalStudies",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow in connection with performance of additional studies.",
        "label": "Payments in Connection with Performance of Additional Studies",
        "terseLabel": "Payments in connection with performance of additional studies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "plx_PaymentsToDebtHoldersOnConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PaymentsToDebtHoldersOnConversion",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.",
        "label": "Payments To Debt Holders On Conversion",
        "terseLabel": "Paid to the converting holders"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement",
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r76",
      "r113"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r339",
      "r341",
      "r347",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r382",
      "r383",
      "r384",
      "r704"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PercentageOfChangeInOperatingLeaseMonthlyRentalPayments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Change in Operating Lease Monthly Rental Payments.",
        "label": "Percentage of Change in Operating Lease Monthly Rental Payments",
        "terseLabel": "Percentage of change in operating lease monthly rental payments"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PercentageOfCommissionOnSaleOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PercentageOfCommissionOnSaleOfShares",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on sale of shares.",
        "label": "Percentage of Commission on Sale of Shares",
        "terseLabel": "Commission (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PercentageOfOutstandingCapitalStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PercentageOfOutstandingCapitalStock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding capital stock.",
        "label": "Percentage of Outstanding Capital Stock",
        "verboseLabel": "Percentage of outstanding capital stock"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PercentageOfPremiumToClosingPriceOfStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PercentageOfPremiumToClosingPriceOfStock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of premium to closing price of stock.",
        "label": "Percentage of Premium to Closing Price of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PercentageOfRoyaltiesToGrantReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PercentageOfRoyaltiesToGrantReceived",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required royalty payments represented as a percentage to grants received.",
        "label": "Percentage of Royalties to Grant Received",
        "terseLabel": "Percentage of Royalties to Grant Received"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Agreement",
        "label": "Pfizer Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867"
     ]
    },
    "us-gaap_PostemploymentBenefitsPeriodExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PostemploymentBenefitsPeriodExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits, Period Expense",
        "terseLabel": "Severance expense",
        "documentation": "Period expense related to postemployment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Other assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r253",
      "r254",
      "r679"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ProceedsFromExpenseReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ProceedsFromExpenseReimbursements",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from expense reimbursements in a collaboration agreement.",
        "label": "Proceeds from Expense Reimbursements",
        "terseLabel": "Proceeds from expense reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants, Net",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ProceedsFromSaleOfProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ProceedsFromSaleOfProducts",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from sale of products.",
        "label": "Proceeds From Sale Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r533",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r675",
      "r699",
      "r720",
      "r814",
      "r831",
      "r832",
      "r839",
      "r896"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r533",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r675",
      "r699",
      "r720",
      "r814",
      "r831",
      "r832",
      "r839",
      "r896"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r164",
      "r165",
      "r175",
      "r182",
      "r192",
      "r200",
      "r201",
      "r225",
      "r230",
      "r234",
      "r236",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r467",
      "r470",
      "r471",
      "r483",
      "r488",
      "r547",
      "r558",
      "r582",
      "r620",
      "r640",
      "r641",
      "r691",
      "r716",
      "r717",
      "r731",
      "r816",
      "r834"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r142",
      "r145",
      "r146"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r156",
      "r556"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, plant and equipment, net, total",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r548",
      "r556",
      "r719"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r142",
      "r145",
      "r554"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r339",
      "r387",
      "r419",
      "r420",
      "r421",
      "r529",
      "r530",
      "r568",
      "r588",
      "r589",
      "r650",
      "r652",
      "r654",
      "r655",
      "r657",
      "r672",
      "r673",
      "r692",
      "r698",
      "r712",
      "r721",
      "r724",
      "r830",
      "r838",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r339",
      "r387",
      "r419",
      "r420",
      "r421",
      "r529",
      "r530",
      "r568",
      "r588",
      "r589",
      "r650",
      "r652",
      "r654",
      "r655",
      "r657",
      "r672",
      "r673",
      "r692",
      "r698",
      "r712",
      "r721",
      "r724",
      "r830",
      "r838",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "plx_ReacquisitionOfEquityComponentOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ReacquisitionOfEquityComponentOfConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reacquisition Of Equity Component Of Convertible Notes",
        "label": "Reacquisition Of Equity Component Of Convertible Notes",
        "negatedLabel": "Reacquisition of equity component of convertible notes",
        "terseLabel": "Reacquisition of equity component of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r751",
      "r761",
      "r787"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r517",
      "r518",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r616",
      "r618",
      "r649"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r517",
      "r518",
      "r519",
      "r520",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r616",
      "r618",
      "r649"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "verboseLabel": "Compensation (including share based compensation) to the non-executive directors",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r517"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r627"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r517",
      "r518",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r616",
      "r618",
      "r649",
      "r884"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r516",
      "r518",
      "r521",
      "r579",
      "r580",
      "r581",
      "r625",
      "r626",
      "r627",
      "r646",
      "r648"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Payment for convertible notes redemption and transactions costs",
        "terseLabel": "Net payment for convertible notes",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment for promissory note",
        "verboseLabel": "Payment for promissory note",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r274",
      "r299",
      "r520",
      "r685",
      "r686"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r868"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r868"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r434",
      "r893"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "terseLabel": "Research and development expenses",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "plx_ReserveForDeductionsFromRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ReserveForDeductionsFromRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of reserve for deductions from revenue.",
        "label": "Reserve For Deductions From Revenue Current",
        "verboseLabel": "Sales reserves"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r752",
      "r762",
      "r788"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r753",
      "r763",
      "r789"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r760",
      "r770",
      "r796"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock",
        "verboseLabel": "Restricted Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r112",
      "r552",
      "r572",
      "r573",
      "r577",
      "r599",
      "r719"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r189",
      "r190",
      "r191",
      "r193",
      "r199",
      "r201",
      "r247",
      "r248",
      "r425",
      "r426",
      "r427",
      "r456",
      "r457",
      "r474",
      "r476",
      "r477",
      "r479",
      "r481",
      "r569",
      "r571",
      "r583",
      "r901"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r388",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r388",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "plx_RevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "RevenueDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUE"
       }
      }
     },
     "auth_ref": []
    },
    "plx_RevenuePerformanceObligationNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "RevenuePerformanceObligationNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r674",
      "r688"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r182",
      "r226",
      "r227",
      "r229",
      "r232",
      "r233",
      "r237",
      "r238",
      "r240",
      "r246",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r488",
      "r547",
      "r834"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r718"
     ]
    },
    "plx_RoyaltiesOnSaleOfProducts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "RoyaltiesOnSaleOfProducts",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties based on sale of products developed from projects funded.",
        "label": "Royalties On Sale Of Products",
        "terseLabel": "Royalties based on sale of products developed from funded projects, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyAgreementTermsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Agreement Terms",
        "documentation": "Terms of the royalty agreement under research and development arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense included in cost of revenue",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "SaleOfStockMaximumOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Earnings (Loss) Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Tax Expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense in Statement of Operations",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r84",
      "r85",
      "r86"
     ]
    },
    "plx_ScheduleOfOpenTaxYearsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ScheduleOfOpenTaxYearsTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Open Tax Years Table Text Block",
        "label": "Schedule Of Open Tax Years [Table Text Block]",
        "terseLabel": "Schedule of Open Tax Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r623",
      "r624",
      "r627"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Party Transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r868"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r392",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Share Options Outstanding and Exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r49"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ScheduleOfUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ScheduleOfUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Useful Life Table Text Block",
        "label": "Schedule Of Useful Life [Table Text Block]",
        "terseLabel": "Schedule of Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Cash deposited as bank guarantee",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r585",
      "r586",
      "r587",
      "r651",
      "r653",
      "r656",
      "r658",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r676",
      "r700",
      "r724",
      "r839",
      "r896"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expenses",
        "terseLabel": "Selling, general and administrative expenses",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "verboseLabel": "Number of shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non vested at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Vesting-date fair value of stock vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price (USD)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Grant Date Fair Value",
        "verboseLabel": "Fair value at grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r392",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employees to whom plan is granting shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Employees Receiving Grant Under the Plan",
        "terseLabel": "Number of employees granted shares as bonus"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under share-based payment arrangement",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of Common Stock remain available for grant under the plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of year",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "terseLabel": "Forfeited and Expired",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited and Expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options to purchase shares",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding options intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "verboseLabel": "Exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Share-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r397",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r428",
      "r429",
      "r430",
      "r431"
     ]
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price, lower range",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "terseLabel": "Number of options exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "terseLabel": "Number of options outstanding at end of year",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price, upper range",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Weighted average grants date fair value (USD)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Term of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life (Years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable options intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ShortTermBankDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r27",
      "r150",
      "r167",
      "r168",
      "r169",
      "r189",
      "r190",
      "r191",
      "r193",
      "r199",
      "r201",
      "r224",
      "r247",
      "r248",
      "r311",
      "r425",
      "r426",
      "r427",
      "r456",
      "r457",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r513",
      "r569",
      "r570",
      "r571",
      "r583",
      "r642"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r585",
      "r586",
      "r587",
      "r651",
      "r653",
      "r656",
      "r658",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r676",
      "r700",
      "r724",
      "r839",
      "r896"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r224",
      "r533",
      "r574",
      "r584",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r621",
      "r622",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r725"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r224",
      "r533",
      "r574",
      "r584",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r621",
      "r622",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r725"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r755",
      "r765",
      "r791"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r26",
      "r44",
      "r112",
      "r287"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r77",
      "r78",
      "r112",
      "r576",
      "r642",
      "r659"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r77",
      "r78",
      "r112",
      "r403"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r27",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r77",
      "r78",
      "r112",
      "r583",
      "r642",
      "r659",
      "r731"
     ]
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "auth_ref": []
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity (capital deficiency)",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r81",
      "r82",
      "r103",
      "r600",
      "r617",
      "r643",
      "r644",
      "r719",
      "r732",
      "r822",
      "r829",
      "r874",
      "r901"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHARE CAPITAL",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r181",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r480",
      "r645",
      "r647",
      "r660"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r525"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Protalix Ltd"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r881",
      "r882",
      "r884"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Beginning and Ending Amount of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r122",
      "r123"
     ]
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of Company's Valuation Allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "SupplementalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Supplemental Information, Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "plx_TaxYearThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "TaxYearThereafterMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Law for Amending the Israel Income Tax Ordinance, Tax Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "plx_ThresholdPercentageOfConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "ThresholdPercentageOfConversionPrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage of conversion price on sale price of the company's common stock.",
        "label": "Threshold Percentage Of Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r883"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivables",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r243",
      "r244",
      "r245"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r447"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase for tax position related to current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "plx_UsIsraelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20231231",
     "localname": "UsIsraelMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates in the preparation of financial statements",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r138",
      "r140",
      "r143",
      "r144"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED",
        "totalLabel": "Weighted average shares of Common Stock outstanding for diluted calculation",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r219"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC",
        "verboseLabel": "Weighted average shares of Common Stock outstanding for basic calculation",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r219"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0001558370-24-003161-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-003161-xbrl.zip
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M0YX(--B?-]?%0W<:L:G#Q=%C<9F$B#,<1 ")J8*19U>8(Q?)Z&.V/A#->OJ
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MH3;3.:+UW$_FNE]\_/7_ %!+ P04    " !B.&Y86 %CV D3  !;_P  %
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M.28+3Q#G&9*2%):K;1^H.Z:)73;-&($58#T&&X79%^("BPH)=Z )60E\[9C
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MU/8ZKOX/UFR7PQ7B<(4X7"$.5XC#0]GAH:P--WZUJ<]>2O;*^@/+"\M^=^-
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M%>EK)P8W#D0DT0<K.W>GH^L7BA8.V,ZQ;QKRGWU-_D-\1?_\_U!+ P04
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MCL9K'L&@=O^J,WO4[JL$P.KO=<Q!31L^1-$&_4W%FH8)+?77J !::,Q;%Z,
MU<L6)2C2'8N!%\75"H?F;F/Y/[S=_G]>Y^X#67^6](6&!^W;AO+/F&DV51:K
MR33B;T@I,_+@BL08\>>OT5-?C&RN%I LO9S]-+O[-$,/(5K.*79X)$D7VXP7
M[1FW H,9 %$P6XUX2 !((8X:!XH 0,*O:3.H@13UKX+9D)=^,^;26/&\>. M
M73XL%M</A!U!K[&=?4*9YCRS5>N:,1Y$O+'E['4/BY/6((TXF,N"A3#5M<*
M@+2 -'*D\( "A^\E)"R2H:$;1B>A9@^SZ?+J1]X=Z9HM1;>+>PC1D-E_WL_N
M'F;83^!HP,@]?: AC;T 6D)L=G[H0\P)WBR8#<@6&3$ULY5XE71-*TR<%,X6
MK-73.@7RA&3HHE%+A8 S]G::H+/;V_G=!R;H[&ZV9/M ,,#I]<?YW?QA!8'1
MGV:.V&!1S$.$?F^C1'=F44(Z4&6FSKBRKDP)AEM)YI@/0WF5K*7Q.P >.M&_
M*6&P!?\B]'_W@<SOKA8?9XS_Q<,#<K(1KS=U%X51+H9Y<=&#(RI\@P@5K=?
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MBA,%L-H+E.T'^3:V5D*&;=<V;!N7YI7%I<:R24-GV7'"7>WEA;5O;Y+9'<_
MNP1GB>(6\E?!W? )*A%T#D&&1?<&=68:7('H0YUA..4'+$21G0#;$^[\)(GB
M-VX/Z&\H1A"EETR0O, 1.*+=+@H?TFC]VS3<_.S%S&NFT.Z[X9K;B@)^AD@+
M0579(A;H3F2.6//9<(-25(+B-=J $DF %%]0/V?$>##$@3R2'H0&,F6UKP5L
MDKC0G!1AM,C/A=!W0_<,L$XQ&?]KNW/)K93=XGY1@^?&A;91*-TUMA()_?+:
MP%6#-LXE;93-T*%+ZN[":4T-HM'BZA!NP!,R?8JI1<AYK U-5^F% RVDWF=D
MW/$CF:^<O=)X[2?Z&S$CBAO>0R>*SG$<PZ/[##5##1:5(9$"RR$_82E0_G=P
M"OER>RZQZY,#H^<1JSXM1NUX;+K;)5-!R/E+IG8BURZ9MH6@KEPMS;9;T3KG
M=<TK$RV]E"Y"$!W^!\ER+VP3P0NDY>DI\ =V-*C^0H*<A^O@L&%"BI8D7O A
MC@[[O))PF/KA@6ZR1ZI1J#-[%QC#<R<N2%]W4_A<H;@_5\2NK_:<,5CK<]8(
M\ ;5\;FWA4,W_T$:&7E/X^Y<WMS,KE9D<4-F_WGUX_3NPXPLIZL9$3\_D,4=
MX3>KT[MK\</L/S[-?YK>SNY6#[@N_*3)N^?)IO4,QFQ*Y<\D/IWFNX[-!)YK
MQIENV0V/RP&*R\40L9Y)P<A.:@YT(J<?%V[V^'<5!,$0460S3TC!UI$/%YPA
M[X*=^ QWLQ69WUTM9].'&9NZF?CI*_:[+](C#_$ISM9?]N[^SL^;#>N<AG4P
MXBG++#1>U@\Q.Y?3V^G=U0RV<UH?0:8K,F._9S"_S*;+,6;B(?7BU-6YN)Q]
MF-_=0:)@TXR,YD1O@N@S5)MC/Y;IO>%&$86!O7X0)8>8-J3 GDX6UY7V,27'
MWO04FF@.]72FE3Z5 -T)R2A+^>_@2%6!2E*2=Z>8U$ 3]/#I_OYV]I%YC.GR
M%[8!NUDL/TY7<W8V9O\GU9EB'D:5=DSN%K"5^VEQ^Q/\H<Q41LY'SKHGS5[W
M--SX*9L'""I B<O-Y2&]B])?:'KO^1OM9-NB8[J.=B)6780=+I(K:,.<PN1%
MDR\9G^0$R.,AA<Q&\D93 D30+\]/E-;UVA-'3106CZGGAW#ODA\6;Z*XVG:A
MJ0782101DXA/GXA*GG%W<CBIR*?R6\]6!HH7T?;B4]Y$A.14X=UF$7N!O-GC
M!B0C]0]KSO;O?59*2;4M2$@D31.5IRFDGVL]3)PIZ5QM)9R]C8"Y8OL;G@,K
MGO"^UTRU/3J>CV@KHNP0;'%1K+\=<XJB"I7>UA-24" EB0D11-!7]!.%O:J]
M69+Z8@^0\>^QL;S@@:9IP',*%]O"QS#O,\O>O'-/E7S:1^&R>/"^>HZCP]/S
M"MY0;6F\V"YI .\X;@[A1EDP<K"AD-X0##QUQ6.#@<;!>Y4PJ$#*0CU>40AS
M+P8G23$Z_+9HL,D7PH9*#R057(CG@XP-H! +1@C4CN#=P,(HO. 1!RE'*-PH
M'Z-C/908]SMDPY%R/'A-48Q(V) D'U/TB$L(C$K*84DV+LD'!@J0&)T-3_CX
MF$\P<*:T;V6&*:TH-.[>[^&PWPOQO" /A,U#)MR.NYB& +$U-M[.KZ6 \L;/
M$A5EW]>*MWIL4L(F12272 1&"\]:;/M.E+42A[V>/US=+AX^+6=%EA*/JF)W
MOV*NCZU=$(ZJ/_[40F'VL%(R7&U350%!ZD2EX$%1.4] \;#E!.(;699)%D'T
M?^?'(0$TP>ANT]Q\JI6<>U-X]H1ZG(*\: ]-%8JLA<*JMZEEN*RO60-!K*>I
MX:6I-GV<(? ]BY]106M$82M$H:TY*/8;X ZLYS./N[IDC229Q[J/ G_=7/K*
MA("WYC2+(2\_>FB4E:B)G?JV9?[A;GXSOYK>K<CTZFKQZ8Y?%]\O;N=7\QGR
M?N722_P$ZD73)'=8TW#SX#^%_M9?0_'HFK@K^II>!OK7XJ>1Q-/*/J9"UMM3
MZ*%H]ND,U[.P@*2HGUX2Y2$>B2PIZ9*<,/D52!-.&__<,L#,#.D5E)LZ>&L.
MSV1A%RPDR%_(ZQ81:RR<35\+@?)-H 7*J);7BJ?Z+<CBX\?9\FH^O9W_'Y&/
M-/VPG/$#,G8J>!2PD2,X7+W0*3S(?N(2E2E738M(*PJ("4;M!:WD&-FCXZ09
MM>5/<5,G42 2B4H"X6B^OCF%\'2)G;5*;5.0AD.$!1YJ 0\[H8ZJ>)B1L$IY
MV'!5O^!8+NYGR]4O/ ,5TMOO0=D<U37[): ="0<UT'(1:(/OEE[:.\6C]DG5
M[DF.+@5]B.V@94)6?,C(OED_'C%B8-Y<- I2O<70@B/=:#3P4P]&WOW$M&>Q
M1 \:*5AO<N9F%*>4R.BL3?"NJ%&35RI0<!RO1;REBU"N& <[S^]IF.1!HC)W
MQ?ZQ7AL*F&??UH)6S[[6Z$AGWY;\U53R=CZ]G-_.V?)_LUB2V<?[V\4OLQE9
MSC_\N'H@G^[9T7 Y6\V7,_Q-P3V35,C)>T+=1TRP0N!+&M*MGR8MMNZ=R2%N
MXT^<@LJ6OB,MG.W]2<S6][R"'-_BBY9H58HD)^GJMK_?Z3@C)P"1:#\5D>=P
M<\6+2#W1<-WJH7D[&JBK5WMAC]8O>P)8*UA;#I71S/G*@>"E)$R;6P0SDA/J
M9WU78,+ 5K V-P(%DJ,K0#>Q7#&46PK-3ZP=MAX<SSB:1)#-0@>+8A!F9NH/
M4>]GRRF_]K^%XEX.* ZEU:>TC<D^34BX2M0LSK$JZ3'0%*J)I?J6DR--CE]T
M.Y93TTDTMRQF25]H>*!+NHZ>0C\+%%S3+87*%-D?&]QO.Q*8_=W:BUKM^6:/
MC]0'KBV#]6H+LY]F=Y]F_:=N9<,W[WN;@'$2M9K9S_.S])!HN?I-+"E?TC)Z
M/MO3;LKM+=PD>GX(SCB-2"R((F7NMQ8I0W!LN]Y-E!YL]/0R'06[O 50$6;.
M'K->08_5AV<OIH]L3=QDS0V;4OU/)8I8TJ.7Z:@4^CB)(D[YCQY8KB<9_SA=
MSLC5]'Z^FMXB/T^&1E;/4;!AY@R9%.D;]/6T#^6TP$=\HMQ6R,HC95MDG&?*
M[;A3-S++\/^9" J\?ZYCJTIO\KIC>E!LQSH>I /&K?AD%PM20Z)5<VH19+_[
M:;9<S2]O9U L%/M86^6]R3%KH5W1&*/3U8 ZH#--#H87_'(U@:>=*([I_XWG
MQS]Y@7RL:-I\FU'P+,%&%-D<3/ H-M',4$V;;J;S)?EI>OMI1C[.IE @!/]J
M725&DV-MP'%+J8Q.UHC@C%HU>2G (1Q)<KN.!=4[R>6@O<R\&&)ET$V''WH;
MW*\>'+&988,(E1:#&EB<QG]&9NHMY*9+:)_Q0-[=+AX>OB+WLR7AAQ^W-*C)
MVQK@W=$AHY?5 CNA14U>*(>'MF&$8[@4#6@MC9M&,0_7T8ZNO-<6;W\,&)C/
M-AH%J;[:T((C/=IHX*=^JS3]3]&.<WYWM?CHGAHUO_\QH3BE2 WO?_3PKJA2
M\_L?0"$,Q]'8:P>9^K0/Y1V\7+JRN:RJ%0;.;;RE(/F5? /XZ.52K/AI*!V:
M=6F:WI*'U73%?RVW=4*N\;;9\/03+\AZ5E7DM/>X'>@@5H3K*G2E4%Q;(CCU
MX[IQ62\-6= A!:%*W5\W?7M?XI^116=7^%"'_(U7+H>B]E'8%%-N1L-,![03
MJ9H":,9!2ONS84J11G3+U.R:W$^ANL-J.;U[@(9_BSOTC%2U./;+1BL*[BF@
MY5+1 MTIM6R3LR<Z$W 21*;AZ,+0@\B.&N7#X3&A?S^P+>OLQ2*13P^.V7O!
M+$*UV8(:%JF[@HD9Q:[B\F'V'Y]@^P")HMAON8ZY;TR2T\.[HSOF)#@=L!/:
MT[@I+>")0'#)P;86IE=;4 95[KR4)[QFKX"8M^?E<]],[QLL<' "*];"Y*&5
M1@2T1P^6G-541N!!OZD24Y1T'KB+J"Y:U*L@OPI<XL*%_RG"?: A0PB<*#Q_
M5#C[S6S_;9'1B\E;BJ<H&]^ B5D@WHHU?2GX$GV2^0:G+*M?8?=2R7A<@_N4
M,%<Q2U)_QXY9QZU'=4!X!J1F5S:4*@2*0:A8J.G")]%YO@##T_K&+6(;>6@.
M!GT\H1<B4_6])Q8B^/NV"$HG3/U%07OD),PHIOY3>'6(8QJNJ^&^<,/_&=CL
M0GN@AYB\>>HD5!([NQ+#2?H\C=MZXJ2@1W*"U2@;U#^3:;IK];W/RR%<9S=3
MZXPF<NTH+WF&"ECL/_"4Z\4+P!G9&;DE+F(EJ3;"50I*V2#BU)6RYZS^E@3Z
MY('M\1\D=(>7W9/EI246KJ4Q9[&A>>G$;.N<B#9[WF- A4B:6;#$Q;.T5L+)
MEF:%B&)I+3BK)R!DX*2$=]"V>I80V;Z*PMAVBY<>W(&*ZQ9+E X6M]*ZG6,N
MP!U>>#J*9&J3C-M=QLXL[-$=["IC83:VN&YUD['306,G&8=-K2>QN;PTQT5>
MC'9[SX^!CP74O-Q'B1<LMK=1^'0+K9*G24)M3UG=2"$N8B>(7EG@.M#!6?PZ
M,UI?10I2)(I)3@Q"AD#N@M,C@J##]CS,A/@A>>$OC-EL!# ; 9\-CU/#WGIF
MCS)LMYXZ< <>^UAM/=6PN(]\;/=I^0,?EPVHDTRI]XJ]^:Q7"K6S" L\E^J[
M6MA((Y(CE5SM-"RO<BDA.GU!?:J<<8F(;5 )9:KZS ONOM @XGO;V2O40#2'
M#*TP,8W*6K"J636B(1F6)5\*E1.8_/0BX9(,V>%EJB>A-Y+0:ZCEB=U-A2EO
MF(K;^J6?_'85TXV?PD^Z.PH3!F8?E49!JDU4M.!('50:^%&T3Y$P" !.B$#*
M_N&L)9TJ*SL2K86@,4,1%^PI1/=A)<O"\\CI^E :Y!+J\\H5?!?[K)K\G$O#
M#G00 TJ,"ULG2H@I_MT%KR3_MR>#\RR@*Y_U''N@=,%+.A.9%C3O2/,N>@4]
M'O)T.)%DF'E92[3<JBEE=^YKQ'*GOI3%F:\!Q8E:4W;GH'K%*8<7SVXBWM&4
MT%S,=T&4)%]!)PJ2  G\(L-V]J.$Q"TN;&$G"C"THL)VR@*0#EN O2!LV_A"
MX]2'A)0P2K'CA:+1E>AO9:?Q1@SLCFI&0>KMU)3@B+W4#/QH&ZGE[=.<LXDN
M(@$LKD'<T<_2JYHX"MF/:_% H,TCL/9D\$RGJ\BR/;6E@6)DW9A4;%P^2^_$
M2)60TU'Y'B? *R=@7R$T0'6[]3/=' *ZV'Y*Z/80W/I;NH* BNDEM@T24HT[
M:W&*,G>-&&B/L6U9JQ^B,T1XQBQ0"> 2CBP9#<[3[-[%^O58+LS&=*=+%U6D
M<S3?LG.FI1.KLKU85MF5CN95GI11Z8Y5G2RG;%F5=,J9&^F4I<LHTK+%D[S4
MN!*W1T>\)V@I8N5RP!(7YT:@%7-&U93>#60D1K=!BVWN$ )CAVG8R1C:;%I9
MFQ8:,SQC%* :FE&"(H5E#+RHXQ?,,AB\BV;13AC9"K(B/NRLYT*(1@26"IXX
M2[>^]^@'?OKV$>H.L?]:&DH'2M@QSDZ"UV.?K<@@QD0[\*F-E1[I\804Y"8D
M)^BFY?8U$[)5%Q)/0R]XRVH"N67JUW[B/3W%]$E<UF^S]% KX[;$16TM;B_<
M40?Q9D2L1N&VG-6O^"JXH(MY,K"#%GF*H+(-0BZ*%[[],R]\K!8?V03+S;0Z
M@X;WHA9I-,ETG?HOMHMO'X1=."V>.BWJ<V17JL@GS-/8;I&"QDEFB6C)A.14
MW0L)#3<WA]W.B]_ 4\B344R%4V[C\5CL)4W2V%^G=,.9GX:;H]]\"OWT)(?2
M\Y#.N)I!IM+@A'H=SP7W-(! QC5>[\3*83(3AHAO[9=\]//Q<*-,;^G[:M/E
MI/^KNWWX;3(]I,]1[/].-Y_"#8VEM8"G(5^^S5YIO/83>L]$I$LV!:=OJWH8
MV!E?.."TMMJ6G3RJ"WYQ,+$Z>D<Q/"G')P=@H+K;X3Q,R.,;R=D@G _"&7'>
M68XXY])VD7<PSO:<9'%(DY0M/!#SX3>.@K0#+Y844W7OO<%EZ/2S%V_DG3/T
ME1>]%I/DL!._ZWP*/640MUSCZ=/5Y :[C^",RSM5!&OWE@U$^$BU(VPQ')'&
M.P\'-NP,RNY>.4FNN*G9;A]$;Y0^T/B%N66U@Y\&G(TL:LBK'# W?T]C/]K
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M"];_C/.952SFWUC^V^@?N#YX[>OFWW6PR,=]'*5>X+]>^M'JF<;>GAY2?YU
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MZDET(8)CU]W%S8V^/04TC]"5566E*J\HJW@09"<D9*?7DC)?3^!7)7VFO7P
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M6DZR,>!ABA@$MSY!+Q.2O_87&832-(#T<I'MG" I*.)7->AS!O),P:,I,"O
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M@[#5AA<M"""UPFC-8;UB5HDCSJA,ASVH_"S1Q3;1L>7M?Z6_/"1^2)-$"AM
MY?U#D'J& LY66#CK>PN!\J7= @5M5;?FK:9/.6:ET<&ZP"4[CHST *8'L>1
M5XF+[1'&^&9#//?<[7R>0ICPFM-AZC-7%*Y]FMQJ>EK;HV$]!+47J7P5VHR#
MUY3/FCE5)_4<-2M[+B';];0>U!O@BM;9:D1LD(VS"!\\N)R^CZ/-89VJ3,4
MBV,?C<SG1J$%1+.$!H[JK[HH8X"1>^(GH3C')H]>0C>$G8(23]S\[S,ZN?N%
M5E'01HK]_K\H_'Y["#=HS:':BEW DT5(  -2I7(<Q.6QNQS6'TQ\I^*[32 K
M/%.! 1H[%;07VX+75?2!;>?3+*]+V9S."@VI:5,+D8H6318X> V9K)E3W*[^
M_>#'3)OB["HH?XQ,8BA&G+ ?V1^]A'B2EL$EZQ,03XJN<U@MF+I+7O6;I1DR
MV3AZGFJ)VB\.4[PQ+\/-#\R/@="OO W/QJL0F!?;YL?2^=6O&X^^6[&<O>XF
M?K@.#K 2\I<-"2\#&K.E,CP@O_R>KM?Q@6X*H\L:SK(=/(32C$V*[5!1.RQ8
MBW;4/:$1#ZLS@B5CJJX'@%HZ5V0CZD&4N%&4'J(PR@(':A#LZ$J]^(#J[PY$
M31K>P>=@T%'B@%88J#V[J+4)6K#\<'A<9QF(\!IG?3SA ]6P8\,)MCZQ$V%<
M9%YD?<Z5XEA@(=:VLQ.H4N?.C()HFI:\U7TQQR >0&]@O\Z.9 2._.()N)=3
M03/BKH(5.;J9A!RWS#V<D P=NZK?:<(-9?!0 B6(DD/,SH*\PU^RV/..W^'3
MK>$6PPX-Q^3;B)3;O T.FM';,U=_TUZ@PC%&(),"&\?4!Q.GOZN+D\]JI43
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M$YJF9DH3>N5P^JT*BG)!NUKH.PF5KUJIEPK1'073BV52L3J6$TJF8TOQX$4
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MX]'US5<+C!P_#Y39%N3V\-$PW6^&M0//D"J[O",8WXK<G@X,UX:4]IX<SYL
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MB^,/KE@]@6-*$ %X@0'0=-"%6O"W\D806GN"+183G-.B]02(2XH(I$M-0)H
M^%FXFBP?X)Z!@E"J7#WA88L087-5DQDP7*T?30N,=IM7X&+@.RU2+^2X>A^!
M=EWQ@ K[.@5O)I+%]D?&!C>><,7J" J'!!$PW5J-)F0;<.'D':@Z."3VT9G0
MW?>=)1E/:JTZPBLN4(3VC1;#<&Y\#)=0 X$_,.H(8X(DE$\+>MF]OKO6'CD1
M42+,;K7 K+=<0F5ZT7_@ 1ETB'AARM81*UXQ(ISN-,7I0@"GBV;@A!<C/D&W
M=0*J#W\<NW/GA\V"Z5BRQB QA(@APEDY*H,H6&#'[L1UWLTP !X5IY/B-0:+
M1Y(8L:K-&JF.3QS/-ZS_,;?4;2&N<(W18LL18U6U=0-- CT7& 1TDG^N%Q[,
MGL<(X&P892* HG%:D[5CDVT3IT7JA017[V,TJC9.S, B>%'1N7B=HYL@#!JG
M1>J%!E?O8S1P%HDRT8@N"F?[S:MC8:!(_;U>.+"['H. ,Q3H:!:*F37X6 3A
M/ EV/5RQM/Q7W>O;2XVAXY8@1E /LT%_YR*1PQL71#VHS9U'W)+AB]<+*6%)
M8L3T," $+NS()^4=/!B^$<E!L:WBBM<1,0%)XJM</2P)Z ;&[<.CVIOC[JFW
M3(=2=<2'+4 ,2UU\)$*Y9AO#LNYWGFG#0QP1OE2I.L+'%B"&#V=*T!>^P0:X
M;W""_^HZ/_PU>L5FV.11B"U=1SCY!8EAQ5D==(0U=DAX-.V9O_$'KNNX?0=V
M,_#3?+2,-XHC!KE2O4#.*4^,M20?C>-JVBEO.EX#RV(-XV2A>@'+V?\8R*I-
M(]%FVMELG#!/0_#**_ERG'R6H%1*RWP-93XEF'Z8"<L38U@O%X\^0(' K*&]
M!!__!<A#\*1<+1'E$"$&L2X&F>C8]&AZ"\-"#Y'(SHNDHO6"4DB*&$V<<49'
M-(_;@%BZ1_@;W"F%4+)>6(H($4.)L]KH#V7H;<L'9J)LG>%DB1&[?N.,.CH"
MVH.B+0/Q\$>2U-_K!1R[ZS%8]3+U?'.L7?30T0(NV=AS4BZM@2[40%=C\/A%
MB$'4PW?D=W@D^B_;^6'/@.$Y-E@./6]'\4HEE*\C6"*BQ*!5[402]GRR>[7,
MQ:/E&.0KBD29.H+#ZGX,2-4^);W=TH1M$&Y@$W^M%PBLCL?JQUE*M#=Y1<(]
MFNYFN"2C%OZ]EKA1NAXC)\D^4@ER<5IE,G9QB;0*;FY@:_JC1^U\C)\DTTBY
M^ T7*S<2LN?[P O53MC*DPO7"U5!.6* )5E+L@#_QZ\9%3W!7\@("L&3ZSH)
M!3$D1*>-0D(<FH,_]\>CV?AI^-";#QY:][VGWJ@_:,U^&PSFLX+Q(%:&]QKH
M;N?]\F88VR@>A^5[\6^.)(Y^\3T1HO,0OB6.K$0('"%2%1+CIGW5N;JXN.O>
M7%ZT;^[:A4=G'C'#,#P,@=*%M!J;A75^',D"TDH*6N'#$R1XDG)4SX]]9.CE
MHL!)62V9P $?"7,>\9H!/<J?WK.7Z#\H]<>[84&YO9[?-UQW;]IO03!- A6X
MZFI,#1Z4LPS)+[46C,F$TH*_^#Y;.ZX_!^[FWK#_? !;-%^>6N^(Y=*RWG:O
M[V[JB;"8A)1P-WG1/&[@3CTL2EH'H@ATQV14(^#C'61YJC2&&+F%I43;J=$:
MD0C32"=#MF#C*, IHJ10/A4#?\B5!6E.@#Q9I'%@,X6C!/^I$<P\0[O9HYI[
M0!<UI?K(C%(UTB/'7@B<];+%-<8_%_"<$BK8\57 @0>P,FVPO <V_,&?6(8=
M*N'1<=$_HM\G=$(@AW [&K.&DP!9_LA1@A8'P\+$BK.((L']9"I1\NZ!5J6)
M=!&6MS%33M#7.-=ZE!6#S MRA2:R0E!:!8=*F5>#N4Z8J>R40?;7(&EXH C2
M89-6)ZVX.ZBXTUN5^M%$7&!)I]!WX+XZVG EU")UQZHQ^KGVIS1P"T\#U9Y(
MXNS/**NU'28*73L6E,Q#:Z._9YQ0>*MKR0B)5Y6%]"!IDY&>)JKE$M]=)KF"
MEGPI!#*5,SS22SJDD!:3XAZ<16X\3G+N0%E$N92C)=U)QM-=\B5)444TXU!\
MH@T4H KPW:AA:FA)&%EX,YG$U$0C&1-<. DQ)EGCO!G#U$0SS"OI@V&LQ#V=
M-/1*9\:;',J0=/PB;8>J<0#I.W:@MM]-?]W?>;ZS 2XGGWBJ:LFJPN3)+7DS
M9I]$$O4'\,IP%\(73FFGTZ[VX8U,7O#*JG@RJ<90EU4@]S&\F83@E%.6[Y V
MACUN?P-J'=TY(=DDPZF 1JXA3-\#8GG=2<*)*G,Q84C<C)/P!-@>0LE>!@<Y
ME/_!!;[I@B@),?H%V&PM9X]^D?#!\+ :)_D@R/U*8QE8AIZ:,9L13I-,)C+K
MI776@:O(;3.XE4]RI8X0IVD.*MPUB>R6=*>(LEV24H9HLY5F4^',"$"#O>8G
M*!0/U?318HJ4AJQ,<(($]H), TJ-<Z"%J/C->+TA[#/#J>>&DD10>EGO/C1R
MMDS$6::^[CXIIB4Y!-'$SQE,*14<IZLF06^Y-$,I)H:Y'-I]8VO"U2ZA#M)E
M,[-B6H4H/W>%H3BE$26GW$I?B5=#G2GP#?3H96"X-EQ@O=YBL=OL+!3_!SV'
M69BDA8==L9G4R2EW _W\LZKDWJ-H20WE>Q,:,8J&A4L>;ZHF!DN1.=V_SX$T
MN7004:AHX#D\A6+?E4JCSTT"'-; -Q?&(<LI,Q3=-7\HNM;/J4_\HWFAZ:H^
MG4#]CMV@H\M@;SX!;I 8AGU@(=5,CX7+[O7M5?7S@0B*A*.+D+Q*'/FK94J8
M+ZBW\]=P"OK[.++)##FMT51F<,G9C&NWC-1!D'=N+H2EF\T#BHS-"%4ED$B-
MITJSV< 25%40J[+WA8=?>N-5=-,,_\JY)[R@AR>>S>%_G@<CN!\</[;&D\&T
M-Q_" A7L!L/P 8>>,C: A-*I]Z97-S<75]6$(SYT;(Y<_5F;V*"0EH-51,TX
M@P!30$F[.4ONE.VY?@)E^*\CPO ?* [*<K?PX9X5N._F O0^S-,[35(Q+5'F
MP.D(KI!D%'@5O)SE@RVP,X3]]AZ<C6&>9F>@EM4*0"$LL!!R"DC$L9I 3:CG
MSV#SFDG_A"V3ENBJ>WUWIP5DG+K/SJMLZ73"ZPG*9WO@*"P5.4+IQF$H(B?Q
M@%OES@;N;,$0_DCRYLD6U K#7&N?H&R2#!.2-S="=Z7OP-X1';;B/^L-+!TC
MW'TG1:IF/$WH.QX\?D>"$@T+B3+-0I@M6M&1>Q?";(,W=(*O#N@I! 4J%&5\
M>(#B6DX0KG'PL45K#W%44^HTBPCBHA:U,^I"C!FP8'-O7X$-7,-"L0B6&],V
MT?'>-]\!G2%\E9M%E0(R%S5$ZL*9PS.7T"KTY'BDC0&F9+/8P"N@+!_M:EWY
M@Q=S(\=V8JGITP.I>,,H(")E43]L;:: 4Z%#_O,2(2S=<!Y0A)3E^E;MZ2$K
M+'T^()9O%A'$Q%3@PE9)BIUX^7N$2@S?+.V@_,=[RGNP<EQPB T.O,$'W#)!
MZ4W;</>!?M$K2!2$R EV6$,;TAMX](L_)5],XW3=O;[5(-=?;CJ6K:B(T'<-
M<NL]J"8:R%%4 "HS,Z6;R"H^(6-;65OJKJ=J4HR SSS_I,HTBP!LT6+8"]M(
MJUW:XN<NL3/JO>&9"P+>V++-PIU?Q!C_)CT:.Y7^P;1V/M$YDU"ZV82@"1E3
MHDF/P7X'*(4)6/;>X7[J#8QVZ/IVO,KX)M+F#:$VFD6?XJ+'I)+IX*DIJ:*Q
MQ>L3+-C*61!+2/B86C)C:V2I5:4C<7]MV&_ &]K9%W?1T_#P;2^P%X?7BPQ7
MXTL15^/^;[W1U\&L-1S!/XS[__7;^.EA,)W]?ZW!OU^&\S]:/_=[D^&\]]1Z
M&#P.^\/!J/]'Q4_4N .5P)Y\%ZK_O7MS&F2O)E[*W6IC8.?4-,6?ARRCGH[*
M><".1KFSV3IV$&PHZ[W,54<K*@@@28&?6TR=_"L3#V.HGI69<GH#R(T%SK^'
M1U*=,"2$9Z'B2:W36&S%I=;)>_8TE@H58'SAQB(K("[1"ZL*TU!:8NR+$FK9
MM(0WW6[[-'AK30'EEY;H(55G!W?=D,RU(Z++5GL'=VD1G70#FXX;#G N^22=
M@K; -1UDCW#]"EU@.:UI#)-1[9'G$D_22,\"?S2+564#@<0/ TL\[%PH_B3H
M8A"'9@1^!'\AKP <=1O&EMPB-S))%$$=X9C*29^3RIKR)R\-N"G%HP;](MMN
MK8^ )1WX_P*FP%]0M34S+.#UWEP0#,<3IHA5UI0I@C.-!)D51'XID18A\?/R
M E>[\<3@%EI!S'Q-EZ!@K(1IMU#>H_$JD8)K!A:P)"4A1Z$VF\$V=:J0%)._
M\@"&U+$HF7F<C9X%]8KH0M(#E,JYUUO^WYT7YDJ9.X0K@4!/KX8'EL@$"6PO
M 'T*_MJ9GNF#*.Q&J-,I6#AO=M *+:F$ZL^F,;OM7M]I$/ Y-W\KT9:L=S78
M%3Y76G/\WB_RH3V5V_-=<Q'XZL"QW_MAN$MX!$*A$AUW!4Q_YV9FSH*M-8-R
M*I0@ZT%+H<=ZLLD3+AYR*12VJ1615/!!&MLH^E)JT) X>U$VQ;\;KFO *7_P
M =R%Z>'))E)?*V(I,VOPB5WX294.IHT"#"$TH!5%Y" M8/<0HX[FS)D"8Q%N
M_H*CS8D/0>JL,W)\+'=$F]"*/84F&"F2%WZ_QWBVF2O@*Y8K3/F"E7<.!X=G
M+) 0*/ 7CC'Y&FH.;R3*W\37?P6?_-:5&?RBR7K?1[K<K= U0(9S4-T)P"F?
MK =YH9/(P*XR/)X<WZ"[[O7M*7=K!3R7>+)>RYWBGAW_E;Z8,[SUH^7\X,V\
M<27T'*XW^ZWU^#3^O8K,&XFG4P<AQ=ZV9:I]O[FJ9LZ&:Q7JS,1UWDV(ROW^
MQ0/+H7V(U]>#VY?W,-L@/<&(>$.IL7%Q#>?$"B^?Q(#"KODRQ&]&N&2HA97I
M4S9_QP):D4 RF%F6,.36S^0@]^(174C9"Q.>D9([Y+DC9P92\:GSHF=I&FQ&
M!D+\E09MYYLIK"6_2J,!80/-IZ5F+)4/ '9W8=*8DRSRR9<T7YBZD3335.[
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MWH<AK  &64*I!B,K(G$I;SL5)@(]+L S\\TV5^8"O0$+@\3 E7KB6.8BX9U
MS0+::</_V_JE=6P3I00=?AT-'X?]WFC>ZO7[XY?1?#CZVIJ,GX;]X:"*!*!9
MZ3C2?Y(K?;]M5W,4NC<\TT.O]Q+#S%Y289Q#Y.XMLA]<D2;3P^-"GP6?!5UV
M2I>N!G5Q)$N9&I#G'W+<0AF20FV\N2#,%,PY,5QD)X;^^/EY,.T/>T_#_^G-
MA^-1J_=U.@B3!(O/"OC@AN1^$X8\9RT(\DW[JG-U@?R)NI>7E^UJ_%W[C@4[
M[B"#T#OH(1>[MZ"C1T6S1KQ "VEF7W:[G0HOP8H A;$)%]2"JOU=*:,[?OZ-
M>U3/&-:7V6$]F8XG@^G\CU9O]- :_/ME.$$CNH)EGOBJG7&^9=;39? 3.\H_
M^D6:T&KX%P,K.P$45D2M9P!,N%;&P+_*#OSAZ!L<Z.-I-9OZ6(0]\TH^N36D
MU/I^&IZ_,CE8@YA61:M!*Z!YG)E%4,J:[[EY+=J< _8Z.V"?AKW[X=,0+M6/
MXVEK\#QY&O\Q&+2FPZ^_S6>MEPG<D4\'\^%T4-$"GLPA';@DQ2+S>]V(M*!I
M.E9/8#7/V9Q6DT0!]$63K7+KHM:+.SHEF;[(8;V+/ZP/YSG/YC)F@E@$"&@_
M>)'P!NR%D >>2!NZ;/$3G18YTM,JI0E^U;V^TR /47%P<&=Z8374>IRG'8-X
MQ_I-=JRC\WLO,-(_#7JS2G;S3\#S')=[;).+5S!F46? *1JL,4NOI.6896&4
M'(LYQ*OY]GT*X'%E!SA'X6UV%$X'\#C],JA@\$5=1^G@WFPSVG_%&<6C/S(&
MI%@3DJZRHW;9"R6]L):#+0\F\56VH*@*%L&J;K374*^1NS?G0+S#7&#_UIL.
M6OW>9#CO/54P'!,K_"IY*(H\UX)\G8&DKW!27<8Q%!D#M%BCWROR6T.A1]:.
M!?GI(0.MOT>QDO@WQMSUT^,"9:70(+E&<<BRZW(QC31GIDA$:PO";_'-%ITV
M[J \^C:8SH?W3X/6:#RO9/>,'+BY]\[XPKH<@-.]8PUP0FD]AS._WK/C5D10
MQ4^6+LH<IX^&Z7XSK!UXAB>(G8@!O(-Q37OL#:>M;[VGET'K&9YT7RJS=!_$
M.G:/QR>-5NW[134#%M<GUK"EUM%J\ II/SMLQ06M^2EX8+@V/.][*)'X!+C!
M]H1SO&(\Q@:]Z6@X^CIK_?PTGLW^T9H,IN'NO((A&TL62\589<G%JX@4==(9
MUO@DED]3M@LIJT'(,18RJ5A*0I(U9[\[-SZ -[:'-OP;[X#$^'K->_\]F+7&
MH]9PU!\_5S$,0PF@.-S[74H-73:]F"ZR?4#(5;0<I:(PX!Q"!$6N]>U.XF6+
MNX\>4AK6X2U;XI$+YW#&>'#-7B:3IV /W)O^T7H<CGHCY)[=FLU[\^#7<)P_
MCJ?/@;>V)!?MY(L=]AM$CAHI]MS<WEW?WE0RB'O+I1D2[(!6HK?\(UNX':V&
M>U[ LL-=CAYJ/0=$EC[T_'D?O&"&VDO&W62,>(P+V'3P!(?V0VO20Q[;\VEO
M-.OUT>BNPFQ%$H]YUT2OILN$0.HG_U0@T$*:_"@9C@:O,W,AE9T)BJJAUG/
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M/J>^RW:G?2GLU!=^H.8N?2EO[MOV5?<ZEY<N_M708@V6.PL$N3)7.^O)7(%
M:30W/W:E%)6OVGH$BA#4\'% %Y"YUB[RN'P&0D/V,CMD\5D-JARIY:0WN&W#
M";V:]S+$CN:^]]1[G.<#1N NM,%#/I' 0&BD7V5'>B*-097#6WX^@TZ[HE<R
MAR7HT+O0;]"GKMBBU;4:TT*88,Q]162N><B8TR"Q(L/Y)CN<3X,95SFFZQW5
M&**!8@QR#5I"Z31?.Y"OI_9![>,8\\O5E/<SN-C-A^0DS^AI$?PO)RN$6VH
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M()I>ZT(XO5;\U9:S:H7?;:$/UR3=%D=.*.TR]$U<!Z[>_GYB(1K82S13![Y
MN%Q=HM73(^@*CJ#3^;6*</IBZ&2W.X6DKSJZC@Q?=+S,]WN4"HD2#(6CII:$
M*81WECYYU:!3^B^R(N!'J>%1.&IJ28*\J G@S]" ZJ ;3^&EEN/N#STB!MH@
MEJT7=@R-IW>58C+K-%H?=ZYM^BC;O+U\-#_03_2\?.0*#<4WI^ ZQ:@-'Y
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MK6I_,>P8C@]5,_ .@IEH_&J9;Z$#2?A2#S.<V97T!I>.4WI,YY15BUF[N',
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M[KN?0Z-\]4KRD&CP"!E\; &*1?S-0:'W+2A666,$_^7/45*%@B4Y+)S!.'E
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MJN\CRZ_KF2CT?_BS;\(#_'%@Y3FL,AL];VXIT%W,OJ)7MNJ]TQ.1:J+'1G%
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M-K(5S6*KDWML25[Y=6=(/G%CPJB-ZU%\^S$%QN(O*(\9.HT/X,_^'F5&<NQ
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M06_V,AT\#T;S=.H=].%6\.56XM/5!L [*.,HC4<(@P<[\)VGVO?KC'-;R;)
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MQJHM5KC.8N]&Z(6UPD\8!#9^%"FK'GV30 \HVHYA[XDS(J94+3"C*#Z-&J^
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M,7Y*04MX+WQW=WUU=7WZ8#AJM!6UVDHW"T6*!$+_@\S<__G_ U!+ P04
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MDOO/WY*R("S;5<%_?\P$<ZQH,5LW?C.D8?^!'_T%;V\](RF6H0KN;TW7 'I
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M$V;8CU[9?^0%?'10?8J ?QQ6EJRJF@E.Z*5I27-[RWH\<L'="Q+P9^NN>>R
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M7<?)5^(ICI])R[VOG0J$9SZ*\&[;?<"N<IG.="ZUBS4MQY/S U\\$9O/?-"
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M8^U>T1TSN**;P44TDG^LW?IY?-8,.BL&W1SYS2X17;5-'4UW1>04O0=G)1C
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M /_;PEL6%!49X<@S@D!W VF)X0BUL6?C>%ZP"L+2'!KK:SEBV5#<^<)I6[A
MLO8\'M\WP:X"EO,6]%],^)CL1\DV4O,W84'[&/M-</T>\N$[*-2".<JWM)#^
M-1T%FV%_H!T.M3!T6H&&_6&H,!34[Q+*+@F@: OT(H/92SKR[M;W54&<HLL
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M-0\;U7$3"1P?GNS5Y\058N6J:;FIKI%[N$):$B[:<*,?&^KZP-^\9SMO4SO
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MW ']_ZO!]J?M[;W^O^;GW^& _^.[5W1PM.#O;L0?LX;CL_[^(9)B&"WO+^V
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M"4TW@N,3<N,70VY<'T#CA^R*,S.95N/( \1K*<$;ARY#=%\#EYLMCM^^W.K
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M<P\1"R1 :X8/].2J"P)9 (\%>;Q2]'$T#&UR(8B$J*WHW;*"6?))YLS=T&8
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M"X_(=TIT^R ^WOBD6:E>K-0>F>\^J:0D"BAL9TM7[#WG,@M'!G!4=JS3%AE
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M6- PME[,$32U63=>:W6^,9P]XXSALJJ[:@7)G ACI>+E#9WISL/K^:J%)Z!
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MR(^QWEX/[M;A=7QUU+2F_<*6-UR5VO8_8X?\C)[JSIOG+]_>=:IWSFA9@,'
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M9L]1@8)Q)(0RR(FXCC+7-&DLY0 0*3H;3([&N="RY[0FDS4E"T39C1%]@+>
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MT,-,9A%!#_*Q2/5VQ: K34[.,(7AHN=EV!JG&O<Y%9S6LIT]4QAP4<\YK-T
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MR<+Q0ST='*-0%%#4?!!1[2??=$)C>%KHAP26E]LS0_(VU@3')3S'C.)2Q,/
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MK*N<-6BCJ[K<U*K"O-21/*'N)J+@8>T;J!?G=#\A1B0Y:ASC='4.E)3/T*Z
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M_L]\1G=:W\VL9!D.%-(HN=[3E)'F@I=>Y/B@)GA(K?T#N!D1YD%@2$G/>C#
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M2WH#U?+SXW56-:?$ 7<R>UN&-9BW1-9]6<0I2;>G&W!,I8P54Z>I#!8W0=O
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M(*O'57E<E='F6F\"@S@$;DQIJSQ8SK.B.RZVXV+['(O-EA%85NO2CGFT%*%
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M/9^4ZZHIM?M:GX*\N=.BORRP%N5Y*&=6=A,W&;Z.G-GD%JW0Y[?1]EQPI%%
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M"L9\Q\4IEC(>Y\>:45H,Z4UQ;/4:5^2S',-6>F7L0SJ-Q,L*#V;!@J/FH@'
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ME(1_TEIO!*M"6#9Q8]N/".[&<VRM(EPVXKGMXM3[< )I>"H9R"2":9-_[W_
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M7Y-+-]9:ZC<#:&*3%#(S/@3#.=W--OWW8@P1RI:IPX,&<$)FU>1J>T^8QNK
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M FWIQ0_0]*W;& ^R([\7KZ+AP(8P^1:9(^>*&R!W)4(@39:50B(4DN]_:!K
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M_HTC-E>9K?1=DJS<8Z2XR;+7M#%;[ 3OH_"I2$0 6R-R6W/R<#\P.EG2J6H
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MR]=*; S@H8AA=572DR[R;1#UDT=F;\#!C7)[?%&51RBQID] 2 .&Q8")3Q%
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M]-=1P+L3E*]F:]8<J=+ <\Z%G%OR]CB3WY5Z;,7TKZ][7MQB0AO<T=ZZ-W@
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MC+6GP^)G;] K33HXRY>JK=(J\&?DN%B?W-L=IM&'][]J)X[[M'R3+9D@4Q#
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ME^.=+10V?=LMR&@JX-L766(A3F0+ZY)3,NS]I=6R&W$H1F/F#_*K-[]_3H^
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MF3G50.9M7^G<J''R6.$,AYJ0)J5;HMN(HNP/6Q!/"'X/= S?/F/JZ#KE<],
M'IU]D(5SA1SQW7#!R5 >9.J"YV1'98A==I)2'<[;8<[(<@_7=W E^&NK=WGX
M B&>F$5<0GBA!]3.I?)"1YD,YS=#TJ?88UC<.9Z;S%SO*VO4# 5 I2388'(W
M%UG6AGG.$3S?E22Q]._FSHZC ;E@*Q70BF4 .XWVEZ0J'O!;E\D66197'\(W
M>RKHV]= T__S:"#]@571H8J%1%X"31F0@JO]\8DC3C"]T623U+&-7.AD '=B
M@G!>&Y%%3 /##01\N.,N5:=G8]P&(:N2O'0#Y]S^O)AMV)4R_I3#.-%!L8'D
M")"4&F;"O/FCG SSZUMFZZIEB+ 6$ (BW*%\3WPJ"Y&2K4I3OZ/(FM>ESC5@
M*.A^RS/6'7D<I/0SRAA?:BEY.\^,M]3L[S+CDI-(923!BPS5"=VK"Y9QEDF
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M$>7W>15VWK=A96_EO.2]&N=G$$QX4+Q_#]=]LLV!.$M"@EB<$\3T56_&X&!
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M\I]L2/#)$F4^H*T) [FYPG?WLF%AU)R'R_D0L_YG^>2RG1?F."]-D6&[B)\
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MVFQ -\J 2'% 1>T-0=;GA,F-915B=T&%P *%Y=EY9D]V?3!I25$O&WSFW1[
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M54,RUOB[LJ?)9E#81ROK ("MM/*2]\I<KV5Q68#),,2 \D4NNDDIXI<##"]
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M_&[<7<)%:OW$O?3"\LAJ+B].59T,+\D0!HLM&#!!B:U65W;)E36@^/!K6,0
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MX[D=X3GU:);C4#H>ORKFZ:L9NI!,R9-PGP;>2C:W N-WB.#>/!FDAMP]'7Y
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MV>;5*'^0]PG^J([=BMBMU6S:9I/1KV<W&JV/M\U&JVNWA_2^<;"SL*THKNE
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MU;A=1%]#:@VIR\ X#;=+/9\]4]^E0(":7Q5#E9IAU0*IFE\5P[,Z=JR!;AF
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MQ?*.5>'\*2?7MRJ;X$,2LR'Q0T7B?MKO2$*[46F4E"?3"YA<&:4LM*6,7,P
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M"T[I+0989VIE=,/PYV""6[ U&<^/P$S AF7 :FWPZ$F@NYF%'D09?YR)P'#
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M%<=VO&8Y/PHG0'=A7X[<,"06*4I@2'IO5(QY>=N@&T!3T(B7(]G8S-/3P6J
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M$;:N,7F^.#,[I"IV R._7#\,=IMDZ,&R^BS5('F7)1REV@JK.0=G.XLU''K
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M#S%\JTE9^FQ5<[;U\=09]YFF,IXDB$%]^LID,?+0+GJ!%]>7 /?JAHM3W9N
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M1C*?^3-MU0N9(+]O##A@I@'4!/[1D<5CO)E\#P ?'/CNOY]SZ^-' #B2 P=
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M.&O8RY'QG'3H=M\DL:6^J/B25%GGW;5&'8Z4+<\>-)LCTE&6T]+ ]VC'&D_
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M@$Z/R5-L]-?J2FBSG55G^S"KIE*3:1]J55/OWG#\VGRPCCK/RS/;M$C_#L9
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M%IKFL'=1[D6"_>(>7T?YKQLZWH5L,F-#7S F!A%,"3"GNF&%2)WH>YL"5P.
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M%9FL';UCDY<T.+X7HG]#VOY\#_J-6AFO4'4]N6+#4VFWFRM2Q6Y&XPN6ZVV
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MBM7,_?OPB]1O;.Z(/[YPRA__9FK55JU<S/)M(<NTVO@_%1)6<&,.N7*MUV*
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M9/=,6V= V;WS[YZ9BG#/DH2?,K;QY;F0PN>T-MCZT9YV"RBMQ:JOY);? F0
MQG\)S;;Y]W\801V+(T/1+W38OY9H@FWT";:5L;8.74KQ^_XFI<)P$@NK?I9K
MFXFRK4*&GJ6 [D%1602F,5:,!3X3QJ.)AH69"8MS>-?XP(I)^I@"6@@JQC[S
M8@<!?)^HMH0!^.O'R(NVA$'O[O?> _L=ICM%FAY<*];B$'3#!0L6WW"]^1@*
MLQPCVP881T"K?HK -L\$XP7@P@@AC1&7&,'68!;AS6&V,D>DWZM"$1_<)/AO
M+3"4'+X@V# K RN+^&^Z=L?DX3!,VE"@4Q.!; N?X0D9*OX98^(1 H)9AKDA
M?B@Y:6:*L4O!U^.1ML*T[I?W_+V'WG2)QX!<(+Z)S%VX7<:L/N&]QX?%\@YI
MP$=(S3HM<<>WY-\J<A&1V>B&*F-%##%_Z4!X^$L8RFE#?%+4O^%K]3%>;CAL
MW*5]\IF/5VJDDR_]%GP)RIW$__M?7"2,A1'')?ZC,S5S(ZJRSF0,^\E[4$[1
M)?R[_TF8\2Y<"YH^4,$?5A1-,2U,3/@O!22J^!+_\K%PWT*]L&=([B$Q-5(D
MPT#! ,(RJB*"RT6;ZB:A$DHWBD,WWE$^_@(]9H\/B[%_LH.]8X Z>'<@ _S2
MQ),@,L;:B>;0I2P#\V:F& ?N&%M;((O1$))-E] ,$'(N>R+>5[A^B\@^GWP2
M@6UC!H//!60 +BM\&4"P9[= VF1K%OZ.!W27?$RLJ.&7R_B91#F[!RL.,TLP
MY"AI6E-E?_A322(RF@V3HIWQ.;(M60Q6NF7B92'G6F/0P-8(RS$]7PSFJD2
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M5QDT_J;Q7\Q0G&@<%8XO!D_=B-POA%"YY]_Q<M3O%V*$W*4(Q*^Y.^+9,6#
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M=W_X'5)JN6<?&IKH%NFK)R&#I.QC1FN/,8QH8-&MEL!7BX'Q47GS>Z/"BQU
M8LN1NV_/3H\U$>6P&&%_)$1:@[FUWJYR0'I,.57%$B(M;@_T#]'W(K>3%>C,
M#L00J6ZDG1E\ F"#40O$A029^T<O<PL;2(3#W?O9AU, .-TPJ,+C%$&0!I:R
M,Z: L)43(!RT@S]X,6DHI_@;7'C>4A&:*4*;2*2J!X&3DX>X78"1BM9$)"+#
M4"BAV*JET!> YJ60R).'U2)I,TP:0LHG#_%YDTYLRQ,'$D%\LK\E5;"/V32
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MK[GFW1%RX0U83B\DTM;<42Y]%C\^UAO XMX!Z3#JMEUZJ>W[M8W>3,-X-/.
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M0>ER'8-@"I,D%8\7'$:/8?8S!JXS*(LT[ 0D(,(*?H"DPS4^$,ER P_<%#-
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M(I+VE.ZR?'V2BC^4TZPR'+#A3-I0MN%3NJ/^$E?C(NI1B!2%+TWTT_W!?W]
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M_;_H4B_B9L1%\[?WB\^=<FSMHE. ^@^Q*Q%U_A\O\Z.F8]Y'VO'$CF.2]EQ
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M2NW7&G&I'O<JMWBJ]H(Z2F,1=&.N.P6[G"U%!53<5=G3#HHJZ"2ZB4PZ80&
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MMR[)QTCTOBZWMRYW'+O-=;GCV&VNRQW'SKHNV/VY?P7R2^KQU28A\8%)."N
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M1K)EOD:8DWQYRB^?A[,ETTFQG6G9UM)6?GQ+A#E1AS"GE.=2^5*^U0MDJXT
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MF54$L\+V._6?3A.GKSH,*_.FB(?JV6:J'F4VC) )FL/YMK-4(Q!?_LC>&M'
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M- =Z=OQQ2^3=\ZZT1O5H4TV7VNC$V,:#J6)VFL$L=J$W#MW=UG"5. 0*0F!
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M9LK"G:5?!!7-Q X0U-T_4#QISM(:[&U3HGF*&"T(3H,9:I-P)+QOWO;$>MY
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M9\3..K!HYCJNWCX.:DT-4=S'/M'_("Y_(/,)BRI:D &1O0!_JW(;>6[/7</
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M0=R1N1= 7"4[Y#JZ3-24N5HC9JG1.#ZO39R^1F0R]8#3]/4@_%O*[M<TQVM
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MWZ-]T. %X%=GA7"]?YZQ*]^?@HA3*[I@;EB<[97'JW8W,1NIY/H$[/BI*-C
M;9*"=9L/;4T(8@X6'G:A Y?9 6O*J.!"U]<:C^H-K,(8H^B*J7<V77%5+]D9
M(_T+T(KG%N#QE@'4XL4X$?#<U&E["A#D1?@Y?!.[--#X%D6#>[L+FG.;***:
MMA</592L/YQMZ=X'*$#@?.)*JG.-SQURKX&?.#"3Q/[C()JW+O=YCI5Y9NJ"
M3L;PQ$M)-T%>!=Q?!_>4@(1XF^;]'H4P^&=LB)P278-M^G>AFS+DDC^&J')0
MV3RYIXL=Z,'>I=S8U%7;$CTXQ9P7O;9>\EUX/F/\%[S+_K]GN<9N. !_L=XQ
MW/4+[_ISNCH12[Q88QT2XI,($4K$G1 BE(@[(40H$7="B,0K=4DA(4*)^)*$
M>&.9TZN^PL7SIC,;./;2]H6-N&C6ZBPFN_^7!/XH_/#__:)^O5?0$C$R===S
M=_]]9=#N0.2,"*,)HK!/-3GQSSC^X&6.+C2U^3/8Y3*\$<K[MY3WC]CY7UC$
M8;#X!PKQCR8X$1+\K7[+UR9X_ <2_'UJ^K:=3P*56N]I[@PENTPG.^=+AOUF
MV[G K.7K>OL.W_IFR'Z'K6_.K6]]7]^0)^4C^+O+1QZ%5'PL\[U')6J#]0[Q
M)5\PFA_JUX$J5 -*4*5^2><31HYA.+Z^9,8M;EB/IT=Q-.<E1GVH@WPH%Z%<
M!,@%\6ZY&%2[XC9'S!+8ENP*CR0AYT;2=>2BGC>W]'QD#[%Y3R,-4YAGI^4)
MD L2RL6UBK)O)"JWEXL[;97VJ7)QS7+#B\E%?LH;#1[?=-A"==3&JO4J(Z>;
M0"[@V)%8D@SEXIN$N;RC+1%8CO8AF_C6;W(K1?^ST.NNK-WWU,SG@0.(BJ)]
MM81'Y[L"T+!=-,P!O=OJ;*^VV.9LB5 *1'-$7MAZ#B7H)TC07=G%GR5!!744
MY:=XM((M>:%-8)DY7^JO@01=W<[^5./A8@>,7RO^^(Z"<5>&\6<)QJ3?:Z=-
M.C%1:%:R4HF:KNHJ%(RK&]K?V:J^PSA42S:5B&2(8L3@+#$,K_W@\-K^P.+"
M-L31I--Y;"P2P[8B+Y1Q=,>JU*"1?KE5-7YTY.;]-ODDVJ;&%$GVV7K<*(O)
M32??.^X83=X*.*&\Y(&XE&#V3C2M%I":/7Y&#PVWVJ5%?;+>UHM8N5A.K35U
MT+?6S1$%;7,LE@PZROAU(Q6OI#7_$XK71<2+.!*O]QOLQMA2R8(U! :['9VE
M^&BUNXZNOY1X5:9#JKG*$#LF6I"D>FHT:8^*4+R X1Z/Q8E0O'Y:$/SCXG6I
MGI6IE*TM!\LNK12R#)]>F%2KTO]BXC76]'*Q/XJRV_@LS6J/T?1X-0'B!8?R
MQ,CO%6<_7[R^9BR]J\,"?FC^AO&_;QG_"PWWLR(>L,&'*!RDX5G3?5.,MU*Y
M6D99QA\7.W;:9TK%](B&IGN2C,6OU+KZDT7MNH;Z#Y*='V"5GR\[E3;!]>I8
MKLB*F8G 6KG>G-]"V0%V>9**I;YPX/#3K/ ?)#L_P.0^7W:P=(\J[[+CNE+H
MS9A*-%M)+Q@H.W!F0BI&7JD_\GW)SK<)K#NY)TV(;&51%<+ ^G>._(7F^<5@
MTA.;YT!26UBU;!^K"8R8K.:J;"Z:KXPGHP2*JU]I&N/M1?$'1]5#\_W39"M-
M+EI=K9GCV4*Z6.2;B9%&VVL@6V0H6]\RI!Z:]Y\F6SUMVI\P#15G>RD^$^^V
MVMGNH@EDB_[!LO4UX^D>R2.J+(F1W["YAAD6IW_1\. ;&LI>VPK_T&BY,]IQ
MOP1?<%H<O@<K?(<-5_TBGV"B>KG>KI;B2JW9'"6AD1VA/S"--63]K\GZUS:2
M[X?U\SMLU\F1Z2Y&;&RFW5L7Q7EU#5B?_"#KWU'5Z[<M![_!@-+G3-/[X6B)
M*YI"*MT?87.]5ZY5^F9],IX C@:69X2*):@OR]2O=5/Y4''WK089A<,>WCU=
M0;R_80^6;G$J\*L-D=<G&ISD!E#I(.C@%]-"8R!<@ &+ PASF+)DG3;L<P9!
MR$_G&?V4:33[!XG&2N;%8&>^IFLKT80#DN%BS0ZD@O_O6;#M-=T:B.!=/<($
M#J.9*AE=Z<RF/)NM3T9:356Z4F(-IQ*=9K*/1LHXDS/>37@XQL-S,RT],A8C
MOAO!GJT1[G08QP*PJB[ NWX]17@ULC;0IN1UP_T(7H?[*)S@UJLT>-$QUIZ;
MW4TFVTF-"VE8I'\R$MLA,%R]&7M!6\#=EC5G,HC78=;7.)=7P0V@!IT^09$X
MA(UK=,Y]5D\2I&]<G0-:^2A!/>V/^W^.^O[N TI1=W:1VSK-]UYNOV%'N4S$
MJ--6F)/ H_]PZIK;FIX!F8KMF[+]V7=?@QL1P3$X)#+B^QENR,ENPGDBOCT[
MFA?B?NUX9(CWX2OMC7UH3N Q.,#$-U6%Q('9="5B^8Q;9.#ZK%LN,C6@"/]/
MIYX-;($,?P8,"P1._=??0<[]"*@D9#4 @("#X@$K[$?J_9?[>\%Q5R?=ZUZQ
MU!JM>B==*?4CF5*]4V1:Z0;#=DK9MMN<ME3+QFZU.D0$.$[2)4*MWF':SK(Z
M]4BV7FO7*Z5<NL/D(OE2+5W+EM*52+L#/J@RM4[;)TK/0< Q_P:Q)>>9\H^)
M1:6J*RM=L2>/_+"^FFJ-8A/B^"^'A/LK^\M!*:</J8&R[).6S'4(O:RF1\0(
M>WHE10^XQ;:VE9DM7AGRTVT3:R?7(^+TGF6,6["MMB@JG-PS::%%9QHDO)(Z
MN5(:X%1]/F^QV>&XWN@4S?22G8 KDT^O+.+S9KFW8GF6QD<-L:UOIH]]V.CH
M9)W&8_RQV\O%R\R64V=#<6:VZNS$:15V?&5K0K>R>5KM8M''R696D=JTLH--
MQ4[6F5]&U4YILMPHRW5"R*QVLYKVN 97GJQ3+F6:LKQ@.44DN?@0+[6Q. '/
MPYZL<SSCS'&+5C(*00ET;<SCPI)-CZC3*[OEO%VHTX,JLRTF-79<E3K\Q*TS
M/;YRT4I&AQ)?S"D%F]KP@Z1 2YDFN/+DC0B%6 B%9:?&$,E-HI)?E-;-RAI<
MZ;W1$_WDS:>:SJKS=#/=X[#"9-?NUZ:38J&T'L%+XXY="+X!]*[UVM7DM8 0
M?A9)IF))9WY?SIF1!N>*65-X?!6IY8@8W.3Z,/'4$)TY99>?,'V[HHVG Z>1
MG06,:-C'WQ2UDY@#?$3)- $]G5UT3"1GY+1_OIEW2%QX>D <&4YB:YW-IUOQ
M EOF5&U0?B3MUG!]=E+Q SO[>2G[V^SLVK;KFPJ6G;+VIL7LRG3AL3E(?\;.
M?E["]C8[BTWX*B/55Q.F+9*:-2G5DW:V^>NOI@?45K[V@3?_6$0SG(_\MP<T
ME1&"$W1/.&T;$60AHND6<.. H;$3(_ SB]L STX3)=F"\Q(!8331H>Q:MJ;H
MDOTC+FD O8RL1W:E/WTLH7^. AO0&X.F->IA>YAIN;1E:QOA5<XT90E.@X1G
MS8 '!9U59Y\<-\Z;=.E:H7"_((R_B.*O+P\->PZ:#!MX]:7C)A\3J=9^HQ!3
MN^*TK!:H93LN5X"E(&S'/7DF%*@;#'9F$&%+&EBC#3\TZU"C=J:<YDW$1&0M
M:8YT(O]\'Z@.C*_,&[M"IE;(-96"$5_:>9NQ5\P$-=\Y:]AO($F?!&*.9ZP'
MV 2OA6F0+>X$8N!(=-L-0IS#YS 6<RM.?&,$+YCULM0N4ZN.IVVE/FZ/Z3X7
MY8?Q]!>)WF7[,VQKK(4")B?&]N-$?$QU'M.0NX+.H;R'NUX.U,&A\QKZNV:*
M3\-VT8"PG;N&:T7OWH8N]QZY:T1SZTQEF8XJ<RXZ(/+;JK[L-<]18&B4N!OX
M>)+>.9/\7A P3,B\E &1[B\A<YAE[1 ,B+$-A +@NXE4@2A)0)B100<9.8H2
MK\<ZP9E6#58-O@2U(+Q8!T*,_FK>?G#U60*9!MO HY_JTE.1@\)HGLZPKG2:
M2CQG& N&+J<*TB@S*Z;JS7"&]>2^9EC3,?R'#FATTA@QC#J$S.]J7B.6#.ER
M?W3!8Z&XW"%9DC'BAXXWO6^ZA#!VGW0)8>PNR9*($3]T@/Q]TR6$L?ND2PAC
M=TD68(T1(5VN1I>W'H1\S<>_V28DO?HJIQ9-ML#J^;.WY:J(?OL]\=><O7>*
M??*]4^SC>"R1O.L!N $;^NI0^V<RQ4%#[=\G8S?>KQ=W1PZH_G0E[M??WVRL
M'8L(,))IF+"\P)KJMLEI CRK+'\)@7MU UYB#X<%3O][,D)Y+UK$>T4K%:/H
MFW/*!27KHK/D0QYQ#2CJON?-OYU'+C=^/N01#T>(;\8C\8OHX%O.WCQ]YZQ[
M=&NBZX()B?.6[GXO"\&=O>D5#=H/1 ?N;)/^[P7>RTEVW&.O*/^;GELT_]Y2
MR><JYDL:K\_%ME=O47$+%XY*FZ!0UJ4VIXJF6]94B%(MK2,K6T9,*=4<5FRG
MNI/CRK7X&RK7W(()40BNIV"<(J]]&5I\?_Y^NN'G[8:PCK-VFB1VNW).%'1X
MR"0.$)).7:>I:P@F/Q=,G)3#3P>3YPZ)O ],-);5;9H8E#"[NI7B65&/MG.3
MSP>3#IWHM4;C>%59MB?E>+.=%XJ<-P ]3H5@$H+)Q2T3(@23Y\JLWP<F)#]>
MU@:]U%A9/HKEQLZ2Z^E6\_/!Q!K2!8M8[.8L@=79"D\KZ=8<@DGJUU\J1;\
M)E\O7]$239$S^"DZF"6(*U'5%ZAXUZW.-[]"(.-ML/AYN/>S7OFURK1OB'\?
M\<P\R4MK0NX@=RXJN8BX:%17+38YK"J$;=N;>+%.= 8W,*]V4Z*<S*P[%:;
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M)D;$N<%^*-1IRV$69WBNQRM>D[J5W7KD^G.<[:EC*==*$IF-/7F7@/J>7>4
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M+1$)LDCL,'JHZPP[']1Z#(S)DZ]F;U\&DDA:57V_1]:B =.J\X4J0JH*!P0
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MGKX+.E;65+^A51YYK)ZDRHE))L$P;5CH%W" (8".AS8C?C'VQ5,"C />U>5
MEF7>/6GFU*'Y-;UL>@8 .@$(3!^GOO=)U<.1I@XSZF^I$3W4I: "PX R*$]-
MM-SV+\$I]V$ZWML1=J;,+E/5L<!UIG6C\5K*/<@21A[VWG2++(#I^U('X@=8
M0^?$C'0G#BEN]F%)U%_DE/?VQJ/3JYA%34.">K8<!?=>X,NC#*N;[";0/T>#
ML"3T#["8YZ)H'2(".F 03K-,?ZP*]3-!#YB[![W<!"R,J3JQO'V4$IF_8T[U
MSJ_NJ]]_A ET]HGZJKMS=<G5X+"O=L;9ML#C,'IBP32'$Z6"V?:\%V>D1&+4
M6 ?/W3AN01')<[(*@W\P-(EHO:<Q;$(W/FGAL]IW[I$X8,-"1G] H6YT0ED%
MW.T<1X&]:O8GW'E>5+V6/9Y '?N&3@DA $S(+X?XT+Y6RFL3CWKAO'"RZBBB
MQ:$S]FB$AXQ8#@7&G$2%^Y8WZ,&Q@(XQVD[43.AH5TY;#/F/=VN"OVW1;RY2
M >10(_'#?5 7#O#-P I,I+F<F\.M =N*3ENBE) ,QYS '?9D>BQ#4QMZ*KK@
M!<B#NL_ .Z%["L?-DDH:N$:,I.&I3HZ?QL[JB/8^O14LEWA:$WSBV1WFY&[Z
M<2"RR]%C_#'*J')OW7RJ<8 T&.C0;!I%V,$M*NX[R[ !#6="'*AK+0@(,+P.
M+JCIFN']FN%,V>QZQ.B(_%23E[9HHAJ5#GC=C(J\$RBX!0"UBU$W4:DOMHU!
MEBV4'YDT'<\S[?;D22KQI4M'0+6) !(6X"W QH@.KTFZJNIKU.V+,\ ;6BB2
M 2MB;4"C/Z=MF1?!*<]7GGPQR3G4(6&QEV=/';Z)G3]VRG)Z*;K57LXT.90L
M69CB'^\'_Z)@<92[(%C-PCNE15YQ&ZK$XFQ+]SYPRK#0)T?56KZ98NXUAWJX
MI%-A91G>NMSGX<X[OWNH62(>(UZ<:N8KVO$]$C:(D #/>/OH_1Z%M_[C5+O!
MTN%7J\S<RC_T8.]2;FSJJFV)GU%=]OQ\-=_WSF<=7\W@E<=4AG2Y#5U2,2JD
MRQW2A8CA(8[=(5WP&!$/Z7)_= EQ[#[I G LI,OUZ'+^W/-W6\PWVY?D&_;E
MOD>H)U_9@&>']'[\W1Q</)XACB\V$2 "LO 9(\23+YU7"F:'\=$S_0<[8,J*
MP'W'*/_WO^/+<,#+UM9-9>!D%SY%*%XS=*Y\DNUK;-(WE"[R*M)U77S]+ US
MOK;UJU9_:HGG15&2/E.LX#PE6=J^N#U.1R8GK?N;;>?^N9A2O<&[OZYH+R?X
M-Z4LBJGZ7S?^]'5?R;'?M(_D,PWNO;OM<Q&9[?['HBP:L/?8%F5^T!-.+B]I
M"]LRT07Q)[=T,QC.=!QP56>[$(]N\O0"5/.+TNWNG:C$L$RMJ5Z!W:8KVT55
MJ*R&H_5E$OQ/'_ZT *3#CZ:4-B4IG9]A;9G:%E?E1)S1F\XI/#P6)T^RG1>S
MC.Y,C(_@_!.MH1^_#2'L?6+[W/N&P@Q;+,N+TIAM#XI80IIV$M+F\Z"P:<17
M6XOI]QBQ6^XD)7F^GMM-YYCQ%:'P_BR:=V/ ^VS9.S-<F<W"&44&*\*^0B3H
MLRW4KX3+^SJWP8C:]J7Y;EKAF&S*8AZ[)27/3Z\SL?$+V*$>E\-)@^Z]>FH]
M_F@7=9.EZ79IP"SU2=?\//BEE=URMJR9$RPK-7"E.^@DQYFUTV<! Z;2]2S1
M+XFU=QZ$NZ]W#H'K6UN2 6!FUK@H-V:DE+),5"?CA;A8+,N?!V9"JZ=,$CA?
M8NNS8L*HIM."FI@XK6#B,>Q:8'9/(=$P"/KK;TLVE8@$A_3"0_1A!/0GA )N
M-B?\"UB=4![R0!S\D\3=>W*I? 7C9U62[<TPI9<6XV0TE;[,8)]G =L[Q@2;
M=U7'D_0B+O:Q7KS-=69EC:Z/8:,M9'YBI\<^OG(@]&WIO?^$P<XPV'D/"/=%
MS=,74"\N2YUIM98U%+M<J>"*4.$>4\W/0[UBM3/)"9V$CA6$97)C5J+UU0RB
M'@51C_Q>,<]WH]ZWB&MV=5C-"/$M#&I^D]A :&&>7(#R20=6=V]'E*J[ C>O
MD5@96ZKM7LT8Q$L7FAIY#LR*]CJ:*&H#F5TR/:LGK,U&>39Q.JXFDK'4%:W+
MNP75,( 9@E1H)+X"7)EAQ>1FN9G,B'04F_-R;_+_L_>E3:HB3=O?GU]!G/N9
MB#-OM-XLXG)FGA-!*^Z[XM)?" 14!$%9W'[]6U6 >Z_'A>YF(F:FVRZA*K?*
MS,J\*MZ]H>'"ZXE"/Z%/*GBIG1KV'Q=UQZ09%P Z143/@,1\FD3FC;W!X"<K
M^XJL26&.,HS@OX<'":=Y_$>D MX#TK4JG^G2B2(>+Z<=,2/-B4+DAJ'Y:$ZK
M4]IX*K'3ZHI8/7:%3CP-;WZ /F,TF0@3DF%",C1GH:_Y!R:NG^&Y9'[8Z'*U
MR3#Y9/;6TU'UAF<NB7I\UA%9M:!&5D;YD7ALIIO+!C!Q-#1Q\5. Z^^;??PO
M0MSY?>;NN&O?]WA@DPXOHX-77AU ^, GO=%L70V\ZHJ@BX?R[J?S76 N1I?\
M#V YBF[)&<42-0,JP3FTJO: ?ZJ7.Y&I7)74R$AI/9;+ZV)UL3R]]>;\.'3K
M#7&,574;Y+4=&I8'! 4OSW"O1[$->Q]F3G9I@9FR:(QT\'P)0VWU+GCB(1[;
MKR\++84>0L>B!/$]<0L"!R!!)T)&!( 11#3^39%O@L8(/$J2(2<"P(G0-@6$
M$:%M"@HC0ML4$$Z$MBD@C AM4U 8$=JF@' BM$V79<0[3[E?36[<;M4WQ/A[
M6>1NN^0_12L3#0U^^'\_DC\^2(\8'DU0@88N^^<5K+*^+)@8JTNR='H?AE]!
M<"'XLJ"(#O$>(_%QPW!GH3B@Q,]_E4,ZP)]_*3:8O0C^S$5;44R"B6;3<B]<
M,1Q+T"7KW_\JOR\#8Q84YE_4;I ?M1L$$4T&&_+P-;L!SY"_G&4(A>-BPD%^
M%N$XL94OKNQYC.%!* 9GQ(#Z+&(0.._AGF5:X)EI\#=8@^*<.=J^&#_OO<A[
M0-'$[UV#!Y[YOY=8B9L'"F(=W;N+Z-YZ)>1QG0YQ4*=SBYHZJMAG^L304? :
M-Z['9PTUDDX>E.A&J'<4L!W7[X!YL_Z%HLP47A^_00O>EK)1NTJV;#E)B26\
MRY:TD9#(U]**.6)XBJ=^_$[$KU2K&QJ-T&A\=J-!'A@-\A;7RL9;CY%2JY[G
M:K/1M%Y<5RM&[RY&8VPN$WHBQTN<O%Q,&E2WPBWU!C :<> M/A#TE>I?0[,1
MFHW/;C:"4Q-\>[-! U[A!DE.6++26%/=0FPU7T)LN10T&_2U@(H#9S9N'H7>
M=*G[0N!>#SZP,<6R''3OMFA8MGM_-?I<4BP1<,7^ KF%6VX&]TLFG1+A8@VJ
M_O9PY\4%9Z_X]''IOBFH#;.*#DP X%<:V@!&ES*>\EMG]HI(-RYS>K9?9QUV
M3$PWJ6+AT6[P,1B7IJX8EH;V([0?7\5^?/H0]0_L1TGLU[)M?9'#2Y/2O"R1
M6FO>@?AP($2E<#PT(*$!"0W(EP]6_\" 5/EJ:UJOIW*X@T=8LK56)GUV"0P(
M#%:OF1B_HWC]B47YG.>C;=CT^S6S#/=-3AX:40H84<EP8'_T7;:(ZV8O[[[6
MX.P8GSYD]=.;:(LHZ& "8 9GM@>SFH[$RQ99X4AU US,Q.*Q,6WP-(Q/D_'O
MDLD,;4QH8\*P]EHVID17GJJ5M)IAA6:>-JN$-(/G);1[S!H+CUE#*Q-:F3#V
M_4,K(]6M5D8KI1]98=1.IOIE;HA'H">#3F63./&EK,PUHU\?ZBR8?9('N&6_
MS^"QN3V4>ZVAHB8+)F3EV(>@\@T#G-0U>D.?+5,G8WOX;BY)LA$R==P!^C\'
MG:U;Z8(P7(;YRS=B>^OR.FI))&XC.>(VS@I#\.I?@K84UI8/AIR*;O.>O[9V
M$!(" ^:4HO_"]GZ&!#FA)H3XVJ/9 827][5#%"__PU<:>#W6V,;L%PDV,2@Y
MX%=O83$BFJ"OQ*PCJ#5JQYI_!6QL0J/ZGW8M?59X4>.:#DV9=M"JXWWTXS="
MGH/E [""'8B"M95EP97GRZSAI-WAE4:)>K/69LJ%'O98J+7S;).ILUR[D&YY
M39:%:CIZK]FY>'?DE@G56IMMN=-JU[!TK=JJE0L9ILUFL&RARE33!::,M=K@
M@PI;;;?V5.DY$W HO^?$\LBF^'B!I#8K$!'3F*MRIB#E5UE9TYP&P@&DGO_6
MB^B!9PW8U2$F/[A%"&A)O"1)>)R*DSP-4R.QH23SR21P,6@J3J=28H*D"$@.
M*.&"OSMG'9'6NPEAP<V3TJ+!/4544EL"%X4^'AGI.NGQV*3&;-?)<0DF-XW5
MY@Q/\OCQ2*JA3X";0A18)[%(%B,986-OX(7%)R/5[)RL-@;\A%5L/9NU-H33
MJ<$D^,G(>H0UQQI?QO'(@)!K[-.DOXDMW?.VPY'Q]?Q)+PQ694YHBH8CL16%
M9:&_<?),?"K.4X7(TX:+-"0VPI"K1F*T=..?PY%CAJ=25J'<  Y><T5D' IG
MYDL^?OK,R:S9;:=EIJ'*$2[.U>K+W'(-1_K/_#B\)T4OXCEKQ1%<MS18M#J)
M":_%EL=NV187=X>R:9TB;!+DXWK9R$5(/)Z(#)[4B5 8R:,K86:>F)ES()H[
MH^+:%()P_Q_!LDRAB768,L=B%99I<4UD4"YH!L]-AZ*CU,Q']4P;4Z!K:U1-
M!D@*'CX$5,86D,S8=(?GBZ ^L:%[#"1HF& A_$]8C:8I E)D1;:B6';W;<7"
M!H(E2YBA(]#/&;SM OPDV-C2<#0)&R"(4!D80 D;FL84C;($=_,"E@*]XP$#
M[YT)BHL=:@JZ-91-3-B^=?T ^[7!:.1?:&MWC!?8#&1[*<LZ!LB@RC9X#/2T
M%;!@.'4;O6]OC9@DV/(E-Z%7J2^(Z! -@JI:7M0%Y!3ZPHHU!J\2]KDQ]A&C
M71H"<AHFH/H&C#,&8 (+M.]#CCCZW@<* I'&',N%7_76N_]@$'E!6%9X9>W
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MIC,-40C=CP"^-E!T8PKWBZDAR9K[J&W( B1_.C-TN,O!)Z%72(?!DGO!!,9
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MO':_APN-MH?X)FJR8$*:C;WY;;U[.,]K0+X]2Q@RMO/@/2\^&Z'P8V"W_SD
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M_OX UI#$_T+;A!<3N\M]\*!,@6.DP T9^ *FN49;NNNZV1$4HT*OW/5]T K
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M%DR^)**IL#HU,$60K[K'=R-"\AU$N*H!ORL%3H+G=Y($A&[PP__[0?_X*'F
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M%Z]#8J<SS5C+<M/5J[(B(-E3Y!>*$*1Y$:^)QG+&119<BU@H?873EVX;.?%
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M^GEQ?^#-^AG'A7%Y5.K464>;/V4*6B:^6(^\3N^'./YJ)]-G3T]XE+K\24;
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M98ODDR8Z*\1W0LKBNW/".]>X8[7&,_$\I$1OHB9:L/FMRY!+9U2*-T(TWS
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M$C#Z%#:I&GM^NQ]J1NO;C95L[K8(X#\D A*<:U>D0*:0AEM(8K0_.0;PC<(
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M+L+9[?FU3(TDHVZ)CZ&]&KZ?C0O_PMEHZ@*EIB6B"=>)QM%,>-E_KX.ZX2@
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M-2ZER'NS.> RE4SDG88[$*3<@]ZPJN(6#M?K&?4"H5(/HCXS^#6:SCE?\V)
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MI=]\B'5P<J#Q+K?Q-P?O?T2;@H8/8T]PN[ I 9EW[Z!=;MAW0P8HX-8/C6
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M*\D_N4NV$Z 0$>A#&@ #?)/ ^DT?BS^Y1_RI% #^)D+^FT)O_X8KR;\9.T2
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ME_3WI0PV*(-:X(5CA(#M_+3S?$WX-JQ1FD:1G0[>G.CUN8):TE>RHW,K@_
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M,D VL3;_J4 AM-+8_;I[<V52>0R$I9U=C-Y4(\R ?$H$*9+?99(^=C+"%\Z
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ME-09]\-6^J*"X96W+MQ2,Q,[)9*Z(L6 $ ^&W;EAN[;"@.Q=D%"$;X\?MZV
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M ">JD?6#7N?#B1DS]Y?Z$ZO%_*(5N%:L1WZ8_V%R9$=_/8/=VX4J2C;0<,U
M(V*U^8*WBU9MPQS ,CCO]SF201$/YG9Q]4<%SFQX^2=9+Q0Q3X%B@%S-TS&+
M7NO.&*PO,.LV;5/PL_(4',N.^R:?8]%0:CX*;RDP2,V<1CW<:"W_HJCF#+R$
MB3FNL3?3.:DY0C9+^LW\C2ZMY=FRE"C0-1C_4@=814QTM2@^3>KVMJBV:1M\
MI9P!J8B>S(/3^G);/)?T6RHY4RGQ-PS?;R,<^])A=9C$:M$ES1AW\;A8!@0C
MI/0NVE9O5U*/CVGBKK*5"6]H38B&[ $.R^R4-+&MM,<*A3]JHKIL_(?H =GA
MQ8M:9T9#+AP,&ALY91%L/:C?VQN8)K*D#VK!"C)R]&L:H3EWBQ<E I:#EF5V
M,2)?0G=L"S0P0EP,2!%^R]9\F52-R.V\VO5 G &Q:J3-IE#DI FRB.20WUM2
M[KQ.JNHE+#>!&FB$VVDQP$IUL9?YI\\A^(:J2EJ##T9Z^ZY9'KFOH#_A&B>V
M,'D+V9YB=Q-343JD/H*3WS4(NUO!@*!RS'=0ZY\L*QK[?;6X(W(6XCVB>^#>
MYZ)F8,Y7>EQDJ!HH$I>]X8DI+;')*I_/MD>^=:L()8R^"-UW\^FDZ7T*WPO_
M>ZE''3J*J*&+E[G<1OUM0<H6]-GWJ99^DUT8K]WMU:>SE26 //3[D<_.^UG%
MOQ(,JF36;,W_,/\QI)G<:K7[LFC$J"#AE#J&Q?X*3'JO6P;)?%(5%>1[ZFEW
M=Y];\Z6=XG=;*N2XZ "O>7DN>#V6;8YXC_XA\TE=FS4O<E Z.9H/+:)2<E/I
MUGV71?%"<T/?%O$>,,%[YK6VVZWC[(\-BD53CUG7F1^=6GN5_4ZNPG=-\Y#$
M#MV!=5"0O?BFW_VW<+Y7(.;751[6DS0/M6Y>>>&J7NO;SU36&_(J#^$64Q^5
M=QSRO=#KJP0(KF3Y?7:S\]I7J"+6)M]\M,''PLG\$U>!WX3D.W]^3&&9US&M
MWI0J+X>19H'DH*;1D1E2[G3F1HX2#+W4V7\A?Z$R#YC$9LS><%JST"RM6=NK
M?+=M7XC-=ES&P?JWW],,!WYW2HQ+5UF[)12,7ZGP+8D:,ATV'KUE<OZ-,$MK
ME$#F-,M"&Z+/ETN67IW+)!@^*V>>'A75=P[B$#A:7T;&+9E8#M0;CXK7\R:4
MWXO5&9!:MF\Q?N?Z4L"RE=O!>Y_R"%OFK=#<I-@Y]*2SF.81[J%A\U9XP_95
MT=\E'1/?_F<;CAF^I??"UK4>,2!?7L":EP9R0DD%$ZEKA)<]=WQ2GOS>HC4K
MMDKY7(;#FQ[W$KD7FE9H+7?N:-8MG? 5Z%G29:T>PCZ,4V:MT'<Y;G;7 E7A
M=T8O(C)/;)+;[+0F*$J:<"TUS5O!8[,#W^_GI\\>^+WENC]RRORCLQ\\S;LC
MJ(8%=5C+E6C;[%AZ_J37HW+,X="7,06ANYDY452^BD2C#Q0G@; )3;?GDIQJ
MI^Q.1XOE U6?DLSL1M[)Q<KV8B_."<3VZ11_1C>MI1!3=*_FOK-Q0YY5/9!H
MU"ES=T^=Q?'F9H'C2ZK8.GN#J24=S,9*_V)?R_Y">-SKAF<!5R!9Q]M\DJCB
MIC=-U,[:.>'8&CH_/,8T/,VM#?=_NJ7CO18<V3$YF_/82C3_6YL@^KRDW<Y!
MD>NL2N=93?H!LYXI<Q=9(W?LP=)L!N3BUX<DZ\R1VM1+/-P]FIGOZV[F,C=8
M$-R<8$G2*/0_9BN>>="]"G,?,;YR0.'QOCW;?_#DJ]#DT;8EI'N A;4UTBX_
M+;/$<T31X-G%Z+U2JTZ='_$GVI1JN$UK4DO#<JXU/EI_=ZZX162T4F"V29X0
MGQ%NV&W^7%PJ!A.(S58VK\+8B9>OC.0H:G=%9@2HX+C8_0YDTMM#LA=Y+I=>
MW40Y.0EH"NR'M!Z+:@0GSE>6X SY:1J[,VUX':=34DAM5[<L"ZE4@]_UY.,B
M)!&_ES @FZ=BZ=1@V&2</0,R+R]-(W.9F]4S()<G&FD?WM#-&_E_/NFZ*(FE
ML0HQ(-BS*)*5,;![&)R;_56AOS3K*9>/4;'!BH>#=SK^5OHW]I6K@^C(VJ!M
M!V$RP.G)9T-RT:;W]N<]$! Q=@%OV_*RRTC*!7:<5?GZ]BB';,YDQS-S(FJD
M]4J?@8?KCXO<<J$;(/M8Y.XV?X^/?83,!03X8[P'P"F?K<Z<3(=3)ICOHA1$
M ZU@<K;OR^XH=%;!/\N<K'WN>7_E:SI/JV P%JE2]GR'W0S**@S=. JG;#]A
M:G%D&]+UV^>97\Q^J0"C[=6GT^)AD]H=#(@*)_.U%E1>%_UAKA!R1G'-QJZ3
M 9F$:\-FSR;M+'>!KOV!W?T9-**M/T:-'+2E,=[BM;B58?@)]>(8BOSZUQLJ
M.DQ+>YGOJ$ 1*=3ZW3S0$M4U(SQFG..%_AX&Y,Q/F3153!T,_NFDG=JLW3[H
M++3/#A"M[48C","DOM9?%D1(\/,,R/L L(6H7! 6S:!T_2,OZ-%=F?,.;(8&
M(P2"86?+1I(9$# BO32KV V.Q3X@>C)KR11'%2O'SC%U-)1Y0&TR4WOI4F7,
MEFUUN""37ZRPUI'5J%@0MVUU1SU9TN1,E7Y$4H6-WZ-8YW>\:(L8YNQ=(3,1
M"UW?Q.ZT7?&4Q%&KI6D;^EO!IM^^;"F<FE_0DW1EJ<V%S<P A'A'8B 'V<N<
M,ILQW+-J_B7K1YU9[UI_*>N+$:"U!>2,EU+J\F$SDZ"F=K4R_JZ8NXQAGI*W
M01.QDH/L"5;[J'BAGFZ,GM%?6=@1U<WZT:0=O;6$J*\/A<V4@=2F_CMLY@LU
MF^^)A_B/CH+WU=FJ>4<^?8$M!<UH\Y[D(-O"Q,R&^%KO9OSH8,)&AW&BF&6.
MW1S4+6@,'!/D1!'=%I541W!7G#31_*+!>J)=C$ ]2V! E ;6L[8C5F'64M\N
M]/1C<*],@%8GD ^] G$_).N!(KT,J6\:FV ?9BM>!2%RM"0P(/LI0(<N6<\%
MY1PM]*,U(QR31@L8W^CUOTM8E@/Y:\IZ%IC9'+TXD*9D2^IZ#[2JD/5?A=?3
M$1PM&7$<,=%J(-LTA!7^$F"+.'9P,^K-7"TM@2 1R0$&,RCX]31>)^@WF)A)
MD[S17;>,>TG+&[0ULA[M!0/BJ6?/967()ZJ&L&REQ9N^'_WFHDO+!1SIKOD!
MWS':V4GVT!%8@O1PT X[CXJ5:1HBC?8)5@9<U<U\3F7=R"HWD-:YVB>]<@9D
MW1US:MMO0;S6&\F3CVA<:A0=H.,BN8N6"9N+H\Z7W:^IMNE+E+T&FXFC+@ 8
M->H&+.%T@7_P9UKV3P5Z'W3C.]WUU9/#Q8MM]'X6NE%2>RS%A&FC<]_?<)1,
M (-CUKUDYI>_.#XSC&'2E@4'@1?/5@)LDAP"*0S(YRPB^W'^@&>G*;[0<1H[
M%/EGH=+O_^]2A_\/W7^"TKN]A(=VCBP,R!\KB/O\ 5F+GPX^_$JIW^W<)SST
MB$Y*69$!?.]BGZ40.??P_',40-[MZ![ *^#&H.VERN.L8,9[PXB; 5E;XV$A
M<,P9__CGBN__O=1R,=;ITN(-5.6"L2=_0"%&E_ZVBJ.2I@6QHJ5+$X*5>WAV
M&C5);+ ]UX[X_4\4'+,I=9)LUPRU5\HQ7"$"P*9L4CK'9GY2G9TY2Z?.WC\;
MD?)+I,SZ*>6?I'0?=YK;,=.CIRQ8,/<H=\S'N3YG,2"XP0F_KGO_8['[3PH*
M'BK:>_W!'@G?3/?_+:,0O/N4U13O*5?EF@9XE2_8 H<552=7!+2*NF>C[@9,
M62CG>6T_B6J1"7784MCUT==8;=#6..+\#I>O:Z8UB1XZ>;.<*!>3;X>GG)O=
MUGS=6'SM^_%K,X]C]I]J.'^8<%T\%7;<5V),"-,YV>O?X^/XI>*#Y]#MWCN5
MR2-?'SB<0N4I&_K<CS%@-YNS4W7R]OC&P;88OS(;A<P6'S66^.Y_HP0N3'.O
MIZHJ/#?*6=NI'1^,C44#ET1M7)!VE_2&*UK0L-VDMZ&31$<;(]20BAL]8K[7
MD(/U&_S@B%T)XNJ8AG1^5=K^![YJ@F^J!=[BV6:\ANR@DVHX4_&I2]S<1:@O
M=K&:SDLVF)*K]1=O#9\*E8&("I0L^J*_5.=*VR5^5G6,'_^&/D#R:?! "-$_
M=9H-J>\U%*S[=N5.O0R/[X-]32>4V@3'3U8)V;ODU4M2<+0P<>,Q^9<E@K4Q
MOI^<-N2ERG2;V\3E+NL=U$R8X:HK_89FDWK.G^VV;WV,:#,UWHPL]DLYL1[J
MV;Z"O=P3C[99&Z[C6;>1&1K7=#F7);B&2#58;COS2I>SRIWM^P4M98--$!>/
M?F<F6JF,M#9!N=S/C=>)'%EP)WC /K"DSQNHG+P=![WPZO1C[^[[OEY$]\_9
M*AEJF4VQSF.2X<WVHW(:$\?[WD"EJ&'E2VKB?GOZ L9N;UX5CR#.-<(/D] -
M/ CE./>=RP8K9R_N_]!J%5;2Q+46<)<(4O-'O=$E#U4Y]428WP[Z^?T@'-86
M^68770=_I9X_OU8K.=A[IF38N3+6CK6#OXIMFY>,W28Q()$\/+17DD!TC*-A
MY)VY!O5OT6E\RYZE@5@[Z3=F<N78X'9I#H30RZRJLD2*C.HIE;X#DO2-3*HM
M_ @X:7)67?:P8+G_)#YR_)J#O76/@-WKV5 9 S'#_!.W%9W,V(E8G*XGN^\]
M>;8!CZ&+@PB)MV\L+L1- @GPXT-A S7BG<4<H8G0\K[E+7L#GP3ES2<WX$\D
M)D7M.9<<[\?<K3UX]N%K/JC\5*7IE?1<;!XPP;]7YEBT6R;(=M@9D+W#T!)L
M@[N:4^I]SEL_EB6A;(,L>[?E!5#>E@,KY6M'OUEPM<=F&+?LN^-B?.$\E4/6
M@ '!SP7E55FRS[RXV)H,"Q;NR\^EO@VXSSNTOS-B)/<UH;279:P,%LZOU%WE
MDOD$.V@_EQ>6TRC4<[VK."U58L^(NH*:RZ*-B##28_?+C)F3=A\2B=/O!"8K
M%+T8$&4$G$:^!-2[>F[0?8N3*.MV<V+BYM:'<=+]2V#ZI1P&IC7S:W-4L@UL
M9YKY]= N? =YO1L@-*,_9J8,UG_Q<\!N7%Q$[?4?KA'N57R8/+3TKN*IMVKC
MB..H^B%+(P&KH?O0IX$DPV'KP*5--*X#QS^%U?&'>"[1N87K8(<7UV\+5G%/
M]1-ZM7B:!G<G+E/9RNU4;K7QU[ <$<O7^5"IQ!8LDJ\_^+?[)PN":1;J-98Y
M'R[]-DY7/@NR,N#J^#_>Q[W0#4DBF>\ 67FVS7U8_"0P2D]_)OH/-@S?@P3Y
M/:J OI 7C /S'?PR4&'WZ#_?TQD\9+9@) IL-3C+X*^3:__AYU5_?\ M&1"H
MDY\M6V(K77D*9" S7@14#<<"]HCOP^1%[SH5K_0?/\R,6BT4?5Z\ J0/<3RJ
MY)@S>ZEZ4B%*)$L<MCB4^+L?Y9*9Z9,:OI(H1$E->6=*Q1>,SY+I_+9S8;2A
MSBW3WYXG!E7;+HX7X<<\2Z_W+F/$_>3&M;@M_-)*8QP-1O;,O-(/"-UW_NO$
MT=]]5+DR%-^5GM^M5D#@@I[ BI!4@=WP+]OQ'[G7M/B(!97AP[0+@ZN:1WWK
MG-:1IQ\XRR3&J-VDQ:&?\GHY8)JLWOG0^'?UWI:>:QY\/1WI$2"_[&+&@*@*
MR8L;MQ+[V"<7:D#BSG=BUI$JV5>,YK>]6A*3KV:7:EL1BDC8^OBN3OU0%N^W
M>Z<V#?:7K\KC$"D3Z.?K).VEKSURZ5%@MGFEXOV#L[BD[=(1Y0\ 8BM;U$76
MDF:/;$);'AP;[R.0DV"DP(F=UXK(M6-32E4#L$$SGOYQC:.5U_GR4UXIEH5A
M7[S224U"+*#]]YULXVAP#[R[GD^@:BAJ6CL6/%81*[;G+4RJNLC/48!&),='
M&93"2=#I-]M_].^.;V')17/C7-1S_54*2)LI!<.R_BK$V%G31UY/'^CS6HT,
MQQPY>B%9\7!Y<YL)29P(W.^:)A)>R\:Q)ZQ\ZK\\6!$V;68JD8T[);I'GH4R
MUK?:JY/>7;J%P9[QV>_B AA6$W:2KK11Q&T](FRG"(T'/92V8]S23L8]/'?+
MR$$@[K%+XOVGP\^?AQI:YOD>BKVWM@^=)949$;+BH=[_FQ?@:)0M>H<!P92B
MGP[DZZHI%J\S( KTAUO>W@M8LO&Z8E0=L-=!47Y-V1Q,L&WJN<HO'[)_^OE\
M2)1HN]6)(8UU%<CC=;O^^>2TDN7*D[>.O%P9T$D.%N7FU%6%, ^N#6!EC0$1
ME)*F'$(P(*+B"VQ$Z6'S>M[2$&5V-8L4FQW>A+GMM*I$U4('^T_*VDK[5&W@
M>#4YH<NWU-V5?R,!$TLP[IIRJ90LY5B+5)NVS+9+.E[M+8+A2I^=Y;\'KN<I
M&4X:JSZ5=O5I=FN3FVUV6,X(&,F1IV@,%SN+P@18'UQI5S='+-"AODIKL2^A
MID'Z)+^\10/>FO@AUX*OBADZEN%:M34%STD#-VA)^ ^:7JXTA<D2M'4*SI(O
M(:W,ZH):R(_5U(C4=DT%M=#PCQ9I'N4^+1UP$D!B;;L5.;V3@DX! Q;@I8@]
MX&MT^$N%\?RZ)/YZS\J%]#Y5^URC#8SC#U9!9Z<[I:1[4Y5IO7>\):87UA4-
M]W__W!?C\85-V_A@1VOB8;OYO6L<X2M;AI'05XC.XK*BR.Y%=<<=O=482_VJ
M4-\TIZ9IF;;[751C?"N[FDZO,,DT%^[CXB*1_,#?ZM;SAW>=O5<.UAY?:H,K
MYMI^V23DN&,=WFTJNP"OS$0T)2_,SV^\Q\B%2<K%2)YY>PS:^C'LZ]$#QT\;
M &]\A7(\KZ^*VR/:\H3>P>1@<::FSK?N1;_UVNOH';S+<[.W"IA<4:C/LB,.
MW$^D:$2.5E'J'N^Q"$NQ1%6\,E1R"9<Q03?"#_FJD,(\TLC^^_I7)"_-\Q]/
MB6,I,=J1P4-<PG\W5,!&1*7P:^:,=Q);Q,L9D)<GUUCH+VC&#,@>!F1W$Z@+
M^[GSF7\> _*, :%YUUB.S&W?@\70<.Q;$X8+EY>S)C*(\%JEH_*]:6-IE?IQ
M<&*<TQ?__4=KI(AJRRMX+9]O5Z62,DEVNE]Z5J7PFA_B)H<B&C^6"\-&63?0
MW66?P\<$@P6/-/*^N,G'=>TK]%FC\T"DC:#/"3?N-+%(@WEE<':X./:_8W;X
M1]I_?]SM[8L?L=^;4)]FG/Q,G@&1,E^MYC?!CGK/BWPZ#+3&4M!JL=([9A5L
M(BQ)ZS/TI:Z95MI ?D P9(Y:#E1L>CDS(&Y+GWY6%3-?5>*_D[31AA7[6;DY
MBNY5.J,6)4S=0+;\,O"8 4FT)^M.-S,@BL/KO\S$P>8^^-_UN@!TR%%S?EDZ
M!R?/CL?\NZU#XIX?X2=$OCKP52^Y_R?[9OQUY%;KR=GT9D?*;7-EJ4)<Z+^,
M*/[T<J]3]]HI!N07(M0O+ZZ<.JRP/P&E_()L^COGG@[R3T"9?T(V5/DOV(I*
M_[;D%IG*GA$ICOC'Z%F$]<*&YM^FAJ6\%4/_-P3NO[,3_K*E;]0PM7A!]UF'
MGKAM,(0Q^'\ 4$L#!!0    ( &(X;EB4ISEHH)T  -RQ   7    <&QX+3(P
M,C,Q,C,Q>#$P:S P,BYJ<&?LNW=45-VV+U@(BF2)(E$%)(/D#"J2!206&<FA
M+)"<04!!LF3).8<BQP*4'$1R 44L<A&KB$5NOGO.=_N<OF]T]^O[>O0_O?:>
M8^PYU]ZKUIPKS=]:LVYG;I<!CY3EE>0!6/<  *R["W [!Y %8-^[]]=]EW#N
M[OL/[]_'P;F/CXO[X"$A/B$A 3X! 1$QV2,B8E)B H)'5(](R2DH*2D)21Y3
M4U%0DU%04OQ5"!;VW3<X]_'NW\>C("(@HOB?3K<_ :0/L5BQA["QG@/ND6)A
MDV+==@,8[^IY'^L_$N"?">O>71T?X#[$PR>X>Z'^$> >%C;V/1SLOVI]E^MW
MEP_ (;U/]HSO]0-R#3/<YTX4_(&Q.0^9WE3_HM0<0S$+F#L'X>%3/:9^0L/R
M@I6-G4-02%A$5$Q<]JV<O(*BDK*6MHXN4$_?P,+2RMK&UL[>Q=7-W</3RSOX
MR]>0T&]AX7'Q"8E)R3]24G/S\@L*BXI+2FMJZ^H;&IN:6SJ[NGMZ^_H'!L<G
M)J=@TS.S<,3*ZMKZQN86<AM]>'1\<GJ&.;_X2R\L #;6W^E_J!?IG5[W<'"P
M<7#_T@OKGL=?+Y#BW'_&]X#LM0:NF1/Y<_[ AQ1O8G.J?^$Q"6BB*,V=Q_"I
MF 41+.B_5/L/S?[O*1;T_TBS_U3L?]<+#B#$QKIK/&Q2@ Q@MUW"\Q;0G<1(
MY:L"!E4LSLWUN;Z1H^OFB'2]U\2+T9?FD#EZ:<]X=EWFN(H>Z26A")B>O7D#
MO6G?B!+U84..,:8#2UATE41:Q=4Q^@SLMX#LFYQ;0  \YM^X9JA&^-)L5XW8
M=87Z1H#7>$!G/UK]&O>$Y/)F\E^>IX97(C5V$;.X]257(P?_ER5*I4L\/:V7
M2;G>5+H%$##UR!PS3LH<7&K\*P,4">=3J VU9( 5'<E D3((2\^BF^"+T.M;
M@/V_,1MH>;;33[O!\,D;F[,,UBNN&(I;P&C ^UM QY["OW%&BVP]#'_HO_L8
M9/V^.<J_!7R-7<FZ(-F^,U+QOS)E:3W4>7=*DX"TSK,67;-0-9):MX#7U[(W
MMX!ZQG_C7#SS*'Q$W5_OV0<(7/Z)OZ%2" _8DBD.6#K-^Y?G2D<*\Q@;XGZI
M_P^,R/X?U;/YJ\37:*:>I[> _G]8P_3. +@=$S?4GO8K:UX3 U:TDC%#?'V:
MH,-)-T:#:Q4,ZRV .:NSXP3!> @A%XK4?CZ^[4>ERJZ<7WE!'SJS? O(O/MA
MW[%349G-N( E(2G*(QO8=[]HDO.UK+-A1HO@&R_6ZR.ML5>/_G_9_X0L[I\R
MRW_(U)+<OI"I*_>VH>7:TN@/V?K:9..B5\#<PP'5OVX!DO$WYWF[WP-&F&\!
M[:"LX-Z&^(8QCJS>ACTWZGUMR@\N;ZT+:EE4I<+\^W"O#M4O-V+^_JIDJXPK
M>/?3/[ZTO:1C/!J0.4C-# ?\+Q>FB>8)8I'\U_XBK%#!#7C]3T[P;UNHR_V_
M+U/-9!L&R/X7::K!_WKE_[O"^/^AZ:0HL'#_7Y>.7\<QGJ]U)*K* =Z 5^1$
MHQ00&C_#1TO@8@R)9C>K?AQML</E-O#/,GS^T@$#IFB%:[_&X\I[K;> F*Q#
MX-7=/&0*ON;\#('F7(EZ,QT9W )ZDLOPV7(;Q8+"V?(E[E-HO'LM1Z$)R UG
MCV3+#0?<T9N[[!]W&:_^E?#%8RK\"WW);P%QJ@C3"U3,.7#]Q[9T_44*2OU&
M2>1KP$ZGS+H)%>A*]")+*2Z S#\4+$<!_)UE0J$A!_@'*:H]L,6R+0>B0Q(9
MP[1>@;X+ ;_\J?+@-" JF:V\6G@C_&GVNV^'B6>1-6?N%&5R"299=9RKL+6Y
M-<KLR[UU/;[WWF2XRC4M%6F&?3)P\T<#4=%&9NVA;51FKH:YM?7JCY MW'73
MCQNKYF3Q#V+S/PE#2B@EO0ORAYIYS,WJ9(A%M9:0<C^,J8I+W>'U%1.*SQ/U
MGO4NRY,\61YO*+.."FGYS-#$SXL9^]#"/::ST='8*.=E$\WB$+D/D%&VF]S#
MD==R>1A)]_CHP:B?@")/A+:N;L6*G\C;EP2MB0H9W4[98M:LA???P?<BW6]<
M&_DZ<V4$RR.Q[Y_T2+QLX1W3_N@V1*1,S=+0$FZ9(=D_V'0^/8D?/MWM[;=?
MYE3TVCEN82[;BY38/>B36.YOGBAQCL;3Q**D<;_"9S09!6>1V,C4(75:.S)0
MJ*)A^A+N[/IJ^\*"?_J8]6/Y/8J4@OR7N>%L@+^I>/V[_)?X<"_1\AA252YA
M36H4L<2XP^"*0Q\)FJ1/8ZOAT/_2CO)P*<I?V#@M!<?%X;VZ]SQF%C)/&Z:I
MI,X<R4MY5%GRJ#DV+#%0^@3]8_YCA@)!%FM4CWKFF$TN,HON1/' 7+%J+HV:
M>7I<AN"&W6@;C\:H)N3X03O=V+$2]PF?JZ5?Q"@?Y /&J73(JH0)3ZU'C#F3
M,RY:^%-QG(TT+;GHX%Y6@)UX^-*K\H<;=: !*.MJFBIKEY9]<J5<'6<<L.0"
MZ(&X4Y>!O]HP@W^/%<<YY3QYF_. W>339O5)W7:OTHL3D>+\D?HG*^5;5.'O
MQD>QY"C>_T6XO*M+3Y26*\1IZR9,-?29#V<UWZ?YG>\8W9_>(SZUPKEYTO2M
M8X'(.4^FP#6+5N 6\' _4X(6\_H:E(1)M,-)]J<G_DQ*O4JO3CGW)H'#,.TW
M"HUI:7*P(4ZZ4NOXR4C.C)[J+A:TVS6+<MF$EFZK%]'OM-+O!&/4'1I@XJEL
MM/Z33N= ;W&781=8^)=YC2V$O7(%]1_#*GIVV]P:\<YPMNQ[?]/WR/%Q&D 7
MVKW9";'W;'^O(@F9\%EGR;8/UN33$6'0%ND$O<"7C^FL3EB^29R\>B>#5C(*
MF%:\!1P_,UJ*C!/(M?W5]TG.3>.+%2A3EP>ZM="S"_(4Z?.."><U$!.,=70(
MWDQ0BBM"&D\YF9*LZNV[T:>S<SAA@"!]G?!(N(()37[IN%;R^]QP3J;B?P[\
M_R2.BM,B4-%34$K24S4LB_!:(V#W":[ZQ*'X?.F4G(M@Y+9*'+'BHC3G^/LC
M/Y+K$]URH31NI5EPI45**/.S/YR_H: <>("MG9FY8M=3+@H+-]=; .'Q%EAP
MIT$O0>DTU'C9)9HSUS6/QA>9Z49G5 IT39509LMM5M?^/U;D+_J8Y=0>4J87
MT)<?H+ZC:WD9=2QDT'4CQ7018 "XZL6<WP)8 GH83TZ7QIOP#V[^=1)L/PQ%
M(;9BAD&W "J3\B54S.>3$7JCX0>AYF>'G:UK>%?/(4:^'&@=R+>*8W97KPGM
M)MK<S]%&/@PG2_XC5,"+PJC5,F[VP6T7Y.#W^_%#YG.ALK$FD.6"EM&3CE!Q
MA6\.2:O=CX2&E"M$[<B>?^%('C'M;2XU9\%KRJL,H1%Z6O!BWQ<=@)+I;;&$
MH8VVXGI8NLZ=V)DV')5_34B25X!>7!GH*?'.J/&(]B6Y1#+VMBVMI(XL#\NJ
M3(,EI4J1!*!B/)J5,YW'?$T+HR\\AS]>:6:IH+XFMMJ1]_;U7"2([!<'3/7\
M@@?032I0"N<5;L3]FM",4W?<J4; LWX>T&Q=N#:>>3./PN5;X?),@3M&E8V(
M/=FN^)X'>1]AXT,T@^$+DY'!IL K\*C_ E69!Q@QK*O+EW<+L.,IEQ[^^41:
M-T 9(2UPQ8<F"7,\SG!1OQN,/$0\V,Q#')%@HT:<,15*=D,XN$2H*C;<@6:6
M:="UXXL)+\S5= \D1;P-HF_M#N_P] Y<3.XR?0C57[G$A8Z[>E56Q/[^N--+
M[49Y++08O^+GTGM#B<8-K??<NV(!XS"8&7Z/?57ZX,1UA#58/@]-TKG(B(K.
M*56R<@LPOWF:JJ)7SG/S1^&3FGA)/EJ(ID[3.O;7^*)J&:,(I$N&7*JR[)-@
M1"!5TIPCGI&7PF+6X\X#\F&K N/">+[&*4:KM-4P]6Q(@3^UKUQHGP$PPM$Q
MCI/-;4&94S[4W3WOQ=(A*!M6+T&VB#?!;1VVYUKA53X!(FF)C0X0T$3K6' J
MRTQU_';ZI9'NE<<M<[<\QQ[VUJ. O28,C=&@:RJ0YUJLF:;B^LPRR9]:%HS3
M"IN0RIZX*K\EM#KB3].W: TI_\1CT^ZHAUV0&9,NQ(*6NASLN4U;Z]27T2I^
M]QA)F^/*K&Z#]I05E8-OTS>^&O9P_RSN-, K@;>?=-KZ<\RWG4L,FQ;QT^+#
M$V-2<7\ZTF7(["W-"%PGVZ1L6%HX"&2V)PYLF3R9DE0MY<DHU%?Q\E1BT%:)
MQTR7\7ZK)\'8"$2I+8]<E]1>^SC,-A:9)(S,;GLTU:+]TXH6^FQ6:'>>)FFV
M[G*Y''%4;ZFZ<M1J)*0:T#E$L8J^$9EV"9KR?^R9]Q;&53>T\-S'9VBB <>L
M.W24)K['%.]*:[D,RZ<<J:DW]QAO0XQ>U0\/\<.-!&_+GVS<U]0[?@=2F0\;
M&Q"-4S0#[ ]9+M,<9L68"(P*+9@?#BE63U;PF$$#I W+C@3Y76(2);3?M"FI
MRG%6;DQT37RA@]C,'(JSY;:1#]QY))_OZ/M?[LI]>@58AY8TWBU@X 4*<NVI
M<%5V^/LOK/3N/[!2VC^Q$H'0#9V?>OZ 3)B,;,/=++>A#OEG*9_Q0:Y%FN:?
M)4/U,::5BSMG#,\CM/3JL;S:V=[<RWU4X-1:^<DEQF"U3@:P[?]\*J^12EJN
MK=RIH*>[('F/D(5+";?D>7OTW#F09,4Q[#23$LUDY^$.?,#G4.N7^RP]R2_G
MU05L-!UBZ3*8NE ;!&LG @$;5$'W# (IXII3TC>0^H':9C.$FMM9>%<J;@5#
M8(<D)P61U"$'VANI 0!1$6K8 QA +2@EO)[=8AAA)]GPB3DF"8[U0:I7[J6O
M]:@3#;A9?U&==\"V:JC7V:_*OKEH)AG?NS4]^(H9YB (UNP\)5!![J]@\5HG
M)+VA(/IQO'SCID82U#)G:(\GV9QJY407M/RUR^*AO#BA><LP[ZH0]"PUWR-)
MLXN^KK*Z7%'_MZVT'6TFKI"[8Q0-A3,I'="#8,,+Q/Q^7;]A?Q6U$6UW2FSP
M<8/7GVJGQ3U/ZD_B:0!S4.Q/2PX*ZB";HXU2NPX<H?MUWQ;/R8W#AFH/6-<.
M@P*S($)S\*L/8PZ[^4U1/%7?XG9M4;\C^:EM&BD3&?M4.58U/,=%(M3U$ DF
MRL331P2^[=U@07;M7:JBMMX=&4)(?89 %ZR1A*[C0VWF$]GF7[%Y\%"4T/"2
M+SE,KOO!HM4E#<Z2;3PE\:()S+'2JW+#--*;CIO06@)2]VZPZN?S\S5"/$+<
MH@<-.>@_B5))B:XU?!&:SM_7O>:QF!G50A(W&;XZ_]KR<KL%_!JV!C:^?31_
M/TY$I2PL0@F_E')&RFNC=!CEV'VF-<,,L5O[>0\:ONE2E*0=<K(VG=V#CGD#
MY>>N'?Q=+5@ %ZBSD K@B":)$L<"UT"+2]_4W>B3'LQVV$HW"4Z6NK,F9;F$
MCMW@[[@G4Z>^#Z?T+7F:#HFO%UZE7B/_PYF+,NV*TI)OA2U:!@U4'I_41=O2
MU0I\EC]"3@N-RZ&%>P\48 ?@"@<358YG7$F'+Z8_:->L;M\W\_18=8LN<.+?
M%HY#QCYX']<T&-G7@7.Q*BBFG3@5*)_^CG/DR\7P8DRA(8$G-WP,+1KB3+0T
M%/7;:;K-UE,6H5N0[9D+NUZ3;PCK,LOGP1P&G4AY5<YU2LN,0VTG*M/W1QX1
MRE;R%^4P&B!_]JBD)T76J_%JB*=KE;"#R#_]B]^)]7#8>F?4"Z8FCC9P'6 B
M8\?-*;'?[K3?PH2N]D85R_EPO@9OW//VGOZ:0;8BD9"TWOEAK2N:\UBAMQTK
M5#]<_G"R>404DBEI@3(Q$XR.M;2IVC&EC_ZEGM'$M%[M*28F'+MLEM?4/%/T
MU!V[P%5<(;1>U?ITD5Y:6.5#EP\O(6A<,"OX2'!KK!/W750;Y]P-HR^WJF ^
MY)$NP]10T"]U>(G2$[,J%V?5-%."*S;R+CN;8L/R,7%$G%R_4-1*0."T@= .
MB(&@S4]ZE[YW4IBR[:L/_==4^!L*P$N.@7?36Q0<:N%UIOT72F8(T0+NRTQ>
MA&FTB]UT63YF<.QXKN?<?Q3XL&]RNFK6Y%> 0_R<<GSW*@>ZX75Y#)4GK0(Z
M(]YPVSU,A)'KL]GD1;")F N"A/J*KMFG@V1>&I(;W+S'&)>'O)9S.QR'E/M-
MS^6$"GV4Z6W.6RHY?B16 )%$L?;Z/>Y]!E[HJ#UYUC6GYC12#7E-^'#868VL
M<(_%HB%#42=&D'YTF[VU9.I!CMRS.ZR_V4%S"U@SF6@[>1B04BF[\K'_(NES
M"G@[F!H);UF*<GENZZTL[*%4\I:"Q 0T<N7B<0HA14:D[V*!8+]Z+[+8TY68
MIWT88E _;@$Y]A;CFXS9E1?0,X3@X <8$\YCP_+86P 6Y998)9T"6G]O.6 A
M9XN;0L.H__C.N2W\VQW'4O0.-["3/,XF!J[87(6+,)Z,RUP3 CE7[;21WF\M
M+3_S#=^YAN0;I)Z:KUZS;(0!&%J_.C'PMAS1JKV[_BE:><7?JA"8(O&B-:\*
MXQLP7O]LAN)&9PY(@+JQNAF;7!D9^?+1QX)R09<Z9D5@[)?$:-0=IJUT:?I/
M[S%_(S@58/#7C+]R\^(6T"^C>@N U-_4SVX&]SAED<WXQ:AH+>XYG=,T^2IV
M=J#6/F"V7U^7%0!F.#Z;MP2$@EO?M8Z DAD'FR"/C<*N9*TEV.ZU\H;B!%B;
M7!K+'$/>U('E&(A)2RR8_[2$VPEN'Y$4_.<2\R]$RSKOF%,*8T0C&2<NIE*D
M5_V(=*ON\+GB31;L#K>W_Y_C]KP[1/TW;F>MZVBNL@:!PIZ:OWSG &0:74EW
M4^ERY2&:7+*E9^'Q(-DQB4 ]N9+P6YD#/S9!78"PWZ=81-LDY'SQ6':#O$?Q
M?H4^6X5\8^"HKD/YU=GEP45#QE4:M%-?87"J+^LSE,<*1#QWHVQ'$_4J]?='
MTAQ.?.9FKEHCFC??;7Z,(Q/ 3/(O&KUC.GH1>U7]9;Y[[P(X*D/I3X[DVV$@
M&]^M^^'*[:.19=6;!G;9S.U5)VE%&IB(8600Q5=:"*5CL+">:Y@0R>[05CYA
MZX(B;?/N/,RI1ZMFPB=5!5?W$ CO^U.S T^H_K%XL_X]DM).+UA1:$]E\+!]
MR6E]E=87UBO%9RJ/R5J."76M4._U:$BZ<0^C#TL:. P8VP#"D2>47!V$DDQ>
MJ,N1<4'>/=M;0.W5QA37?I=1GS"_K.PT6!UF9W#*N^VF5>LWDFH^>?"\\27+
M[Q("MRA+"76$!FW*.VFEV,A7FV:2-M.4QZRADGB($9)9C..[K$X/!NYIMQ]$
M0^<NU+_Y-G.C^>5 GB0(JEB6@Z@D4WR"L@B\5:H6_S)7[M_*"RF!/U<J]7YP
MUC4</S/CD. \]R_Z/;JH[I!FGJHX_:RAS"*S[ZX+:A(IHQ[)3<X20>DW0TXN
MIL?;&3 6B J/7A.V*I@KK3&QA*JP&).*RD@=LR;?3[^NF,ZT;%^R,:Z1KUPG
MQA*_6YI\)IN=N[T"'[,%)&_*]F@MY%PKY^JJRV[BU2_((]X,!#@]7WM$HRFO
MX/W%7N1U@9D+FYT\W;[,R[,3B'/+N"0!JD-^K*/Q2H:GV:4L-&6#G.*0:?[5
M0XG4PP6F-]5HFVX)5<YW_*^+%A>YWI\O^;W/O,%4/-,4<!@;[70M4BT;,CT2
M&ZE36?-Z#CRL;;4^2)9N*NR23!KGBI50>)X>(AO$.7OSU,17;&S) #7<&.I0
M<4+PX/#IY)?\NAI>G)9,@!"2@05CF+O53E';7(723?$C1VK,#_A(%S]/$'M7
M31H?'WP.<R2GSC_W.!:*)M8$LX/;-P?'MX$N?VH'7)A^=[C-#I@="V'WCXMY
MF.][US(H0>0Q10@_@5>HCB!>+O!7*#PJ?OB3L]KIXJMK=FD6#%!M5))I>6B(
M,^#YRLWOH4_S5WOIU@U1BDB'REZR/"G',:.CF ]B>?7>O+]N 01V[2P1/8QP
MX9N 6<%FUE#FJ$IQFJSED2_'(Q2LX<0%'WF("M./NN*C*DEPPTNT-=HN_/,[
M([*X6Y90DB,Y5Y>C?AWB%^VW@&69D!=HQI 75?5+-J>"XAG9%EV"5K$W(6D(
MQZ_B A@"]4EN*)-9A?&PD[CR=$OH;$-IXU#D2:5IY43][ITC8C.Y[YLOAARF
M/ [M<L3V5#<(-?"JDY!2,%!9)1UG[B#]9G82%4/L XRX>C=:<26RZ@=4KZ]K
MKFX(UV1J;&6$1GHSFE: \;==UN0I7XX7$?L@JX?&Y"@GG<+_^]MX<@#*(<\8
MQ$;:"MB _@VR2#]/YYT\1A=_+D1>"E12J;Y"\JV>Z-ZTNK&HW.;" A=M@?&O
MUP?A]F>CR=4Q/BC9UQV3\$.[ _TA183D4L)C:H<IF_<8N3S3<T1A2Z3:X#B.
MTQ\*MKT^Y65':8EMOBZ+*D/N(?$N20GO).>T0-8Y26S5\7:!;6_I&.>6K\,5
M4^-R&_(CA\D6TL,_3NE@VT+<S<&N!R#Z(U^Z,4# "\,A]^_BK7T\!$Q8S>KT
MHF54MP!\5Q7;U7"A#":ER,%6#$YAI_0/B/24M-".N&G(A&:2BKK4N/[XS%NO
M*%H' NL&P9AOXE\A0?45EK> _'>\G?+,8GHZIR>W $N;X_S)<8?E=%HEIFPH
M1B#7^,?<<&M8'#6", [K,/NII07]=IWI/:@$!:EL.S(GBHP_Q(2.G=DFYC3*
M99$5,^2%.&E0A A>R^O,6+TDB7LUTA@R@CMC70J_<I@DZLCX=/HQOJZ?BH6E
M(EQ49U'J:(EBO&0>6%0?O3B-H(H !]AYCR\8&1E4O836;)I_?F62(5:6+$-T
M/'!L2"0NYE"Q6OU]"*=:*517;$3T3&@MJ8/ZI$)6+WK7Q&"NHKZ^W\=#AGM,
M@1I?!OHZ7X;"+:*#4J%*D),YXM'GZF=*3G^D:M63'*;--X/:8K=*[EI,!02R
MD-J1=?A*^2XX?3/.*1Z6$8!RE/=[8:CWMKS75 IGG+ZU\^.3OH_X:[[8:*!Q
MDC')VTE"(#PD[W)F7\?I,KM;D7;>'.(YMQ(-,?,IUX=[/?K!(AS;J9WRC;WU
M#_9E;D%I&'R=5;5L9@FET.43]7S"1-5\=T&ZN(2<0PP<6YH(X,.N+M/P91C5
M'0!;B9!WOR#W/U0K?Y0]0O\2%#<ME.'R%N.">+(\Y:[N\CRB+.S!N\ \B\E,
ML7(?F8@;IM'C/?%.Q%-H<[.BOB/=KE[BT=D0'7D?I:H:T"[>D_,%=,08E17$
M!64D[['C&G^&]2HE$)Z737VO1;P3Y5#M5>GI#3N\8,MI_DZ_0Q"J7LP$:P1E
M MN+WH+!=ZY.OIZ&' 7@7ZE7SBE(0'_:FZAMD_CS-4B=HEY8W4G(!7^B,RDI
M4M_BB5#%_=)7 )T>U7"V=14SYJ3.NW$IAQ<.XMD-PL*M+AI[Q>"X.A*4*A.A
MU%K/.)N:O>[P=)E\_[[7E;0T.N;7;'O7BHI6J5V6.V>]F/3\+4#65':/<A!S
M]E,W4WK"HKH]T_:#PM*W:'Z_G89$OQR@7J;?1P&/#"(6#+7I0VGVHFX)SL1T
M+A%4\XMG"P*_((H0=E3,SPCU^R"4O;=#V:?(+&]A0%F,K$DIB?U@1^UF&VM.
M RW\T* !H:C*28>_?O/<LX$7U]-\XV1=.R4T$2"9%-N$3?EG;W+1^;V:YBP=
M:S14.9,5#:7A(J5J&)]1$=S,^1[3(AW4-+?$J8/67Q+OK&9,:!0[K<AZX.7M
M$.CGY_*TI?6'0-W!5/HAZ#=/?:)ABH.S4M31KR<0S6@!/"7GP=R)WU<[_#VE
M,2EMLSO2>.B'J+,8YJ 5G?#Q:_<0*9'HQ'WLV-CQ=B/T_37OZ= *R'/Y!6JB
M9MS?)!8FTZC@OEC/@TXG-2S#-(M3K\E;@)?/C5 (^T2:UI?XYN,GTMQ*DI*9
M\+P6.GP#Y2/'<$9*1RB6CQU19>1%W)^O$94'R8ROC:J"B\\MFH_=..03O/*]
M=2B/SJX$*VMO 6_2ES"W ,R=HT;$67X+&"T2N9&YH9PZ$5_H((_?F92X(;QX
M\#T=.'(+0(VWC%SCNP2LW@(0VO59< $#Z/C^!U.B8=L_7]\N5\WVF23 \&O'
M.STOV$UN 8''MG<>?ZKT8U]W--WT>^2T+MG.MT\BG3*>TO7'&= *0;;=$.$/
M>/+;4F4TDZROX?+'?(^Z.;OC4I6&V9'Z+?L5#%&%JB[L,FR=@=O>0*GQ^:V$
M!*# +)U-=+U^/;WWM&(XW9QLV,;W,X=!F0SGU*Y?'I7ESD/K/4^688NA[B7W
M_^1(G'\]\ST\>0$]>C]ED;3O)<+>9>F[X+5GG(#VM.=,TE+H6:W&]S_RN5%P
MLBB+(<84PI#YG'8O2?N=>B6 $ 6.P?!^6?8G.!Z4RW&+/,V(;@FQ]\X"(VT>
M'0^O#.#[L=R1 S4;/[]%JWGP6FB8N):RB"IOEB2M:#DD7I.\SOW^7HWSQ\4S
M6\@+3#-:P0@E7&8'+K3K/!2S6/QM8?UKI/Z3*6K,A/<6D/WP%M#!>T,Y2\BM
M'+NA*\IA83>>S 4)D$7:<VYD86PAC^\:!2=@*?ENRI=!Y$+-;@&O2&\!_J97
M'#<%P*$#@9O1O,TS1F7RR-,S0>PL[_-@W>ML7T.?(J.?%PJSW;&)_.5J^#Z;
M%+> KUDTOCK<:^(^,T.5W8I&Q>>3?M[^KHL/<B.2S;AZXU.#U$V9D-L<M%XF
M>A8>D=V[V0E2KX]+:(\ADB<BQ,V5M'V/JTRW853X'BH$YY6XJ&M0^=2)Z'&4
MN$_S0P*:M7O>F9W0564S29&+@IE;@&(R=^(:R6M#325I+PF]([[ZYN?9F9!#
M/@B9JD*W6%0@*8,*PVPEY"=-=AT,4H?DQ^G[H_[N#,+O]Z[/<^+@*>>'V/%&
M-^.WA@12FL.G2HPL?0'VQT4<;A:#^3$I72M2&4 -#ZFAD@+*%,2"/5& 4F-;
MXW=Q1>AJ]8'!AS5@3$/H7*^RDI(;53A;=O:_GBG]A>]K_'HO:"KN[,@0>RU3
MH1^_+S(Z!2+!',<@KVVQCVA7-Z\2;P$4 =-S <K+G!W_OC%_.2C3%9,K(P2Y
MTC=L%;YZO.*!<@P7O+87_7)@P_J#R:++!_@ZYTJ[>10"-72CK]F?7O:D"V$:
MF)^K(1)!A'8B;UA42G8GP<?]KAA?I'7SG]'F/GM8(X;6J=2SH*Z"T[!JDAL1
MO"<B'L3WZ&=FN:JJDM:&O7%X$<TVQ_M]6]N .A98&G&4U&(RY4UU?B?*8)M,
MY ]ER&/III*Z$;A'M_Q4SG2B6W8RWWSG..+=NR))"UAM/>]G\:_U&]^YW$#T
M0+5)![G2)8.&M6C9V5#[^A7([,9!%UR^S <$L;NH2P6*Z,+6#B)M<"M<YHCF
M7$HD31J\GW,ZPDFT&R>N]"W!3#Y@;UGA7IEMZDSWJ4M>N"#R O1#4LB,N E6
M.+K-=^]+"35S\7(ZD 4UA#!:(IW03G&3 ',LJ4=9)H'25W%6&Q'&VHRU\H4W
MS\!2]6D4=9=X'2I7\;3RQ$1B?214J]P#19+:XPG&$[< _L:O_C(#>4A=W=3*
M4'#Y<%'<Q_V,6>8(5M%^R<C3DN,1^ O=5C0A?#_,L:RGO#^*F660 WR9;5Y[
MYW-^-JC_VAO9HG-=V4Q<QM<8Y*,K(1N=O3E>@&;]27#]6+&MK0;F>FUNB'63
M K9[81DZ+=V44RYP'N194.3X1LQ?P,! J2**J:O*[OVV^YNQ526\&9>,6:$2
MW#W.DG,3FDO5+T"RK:J!A]\;"'.F'=2;\FZ>5*)W]X0](U3!FAMC#BL3^M6<
M93S+N.V<X9/M3Y:0!@QAQ2,<O*<9$_!RH_VHA.6-;WTDW%3+F^'A&UMN!KA]
M";7C>Q5"640S.Q#SW5,MHYA4KO3EB\\^P,QYS\)]1XJ&UH<J*AUU?CE4]^'%
ML_T ;Z +"(6KD]QMT) EG6-G957 (?2G0 (<I@)X=29Y7":\5'LYM/*MSDY2
MM4#A- %8E_5[/GY?%&"1<P$+U[9P_Y;@1*[T$LW;]\U7MF )"V',OZ0W^8@%
MED_.U=<,.'Y1N=W!*)@1H-H0H8URJU]?;\LUX![Z_1,!!*S"2NT[:N=A-#W[
M:> 56H++,DXOFR8]YW<^XB5G@JDRNSLEIG9)Y"8@ _=$/_],JX*OOW\DZ4A)
MIY17A#9>B=UU<EZ,&=K7<<P!*E2 -.@(!@O)3^38/DW5?\B1OY%U!UOZWK:B
MKD-22CUY1C0N"<$49- O%)K.XMZZ$KX/T#C^1%/UIP\?J[0(-U(M'8XY3846
M;S1WT'E2[?P2SRB(ZBZ1;!1&S[-'NCM]EZYWBGHBH7 DD( F!2:OV5^)8!))
M/@NU:>XB^4QGESI'I?*J\4FCG0S+T&7O)JS:P>2=22UO%O7;\B,HOFRR'KCH
M@@.L]W1]1'55;=0:846A(Q&*7GP"[$^P9U;KM5 C/_7K(43T-AK3Y:YL[>.G
M[<:+KQ?;[)00<^"J\.X"2^C%X[H#N(SV^)5ERYJPQJZXO=VA01*+L8YRR*F@
M71:#X#%JH3"V#*.[I*MB9YDDQIR8?'^ V<E$HQPY4&#?J!L[7P"7??9:,L#M
MIY2<5H4.OBHG$VLXY+&#!<Q7"MW2)?>8:L)3K7._:T_&KN';N@DV$NHLY\3X
M2!+L@2;H$?%>V&;64O_,%)-;3'VO&<ZI./;%E-\@Y4^;4E_2.[;<\)E-BO]Z
MU##$-^D'.A%8SKJ*<\2_!4Q_"1B$<DUCG$ZDXYEOF*^)X>%LD!1IZ-_;4NQ$
MW,_R[SD4;X2(=9Y7YZ>I(=I>_SJ!X*+]HU;Y5@BNWXRS'U]^J UCU0_3?4?4
M=M.&2RG;24-<L1+E<.%S?Y*[KC@%FMC48GU/G>W#R9K#%:>;JI!/^GZ>&DQJ
M_'1:KCX3VP5L0U?3%$V&YE%Q ]"Y;=M[C-;-XB=/[!F5]'/CIS- G4PH_99Y
M24W4/QS9)1_IO3('I5FX7 ZPTC;V%TEBQVK9WSQ&[T9\^&XX3U#F'I;7HC3
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M48Z?ZV>@LGE#Q:K% X6O-_I1\P-53,M@A#J3V+;]1BMBV&1[M<?;U^!MW"W
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M1TBD*VG>6C6]',NWHI"S;2EB2>OGU/8FXWDUXJ#0KR=9N%Y.N5E[$;Y[C ?
M2:'S,U31*O=2C*\Q@D#L>+T66[/Q^TO?S23(Z$M^NQ94M_]A9H\9IRRIDG;A
M_H]MMGS!Z)]Y;0J"93B\S%\XV)CC9X 1GAVK.AOUQ<+!RV7 MC:+ZLJ@C))]
MF6Y8'5*YK$[-NSY/SD3!;Q42!A<)Y%995&-I9EJK_[8^<PM0/BP6#'A\Y01]
M3!/?'H88=:X*#%I%+NT8BP3ZX[*TC<(D-?BFW'0E&A0]GC/NF#13@ CMO^60
MRM\+_'S?]6@BIX#;:NDJ6D>MD-6@1:'Q_(<T.4HW<;GU?OT$M^Y3W.%G3SRD
M\Z=?L=M6LHNPNGOT<A D<?3+*JH_R-!V2V&-4(;Z6"U\>F9!?0L X5)$2+::
MMIA2>C9LH).OL16X000R\NG7&Q?$"3M[Q&/@6-*I-6R>0>_43:B.^PTM2CZ#
M*/E@-OHR"9=9<;[:T3?>Q.&&>8I%_TMRA_6K9KG7 U>@=32EG7:/N([ZB-/4
ME)%VR:"(WW ,S;L&[_ 0OZK@X."!TU)QM_5JF]@-::7+TM>BE3R'-X?;FJS-
ML;].I.Q_ZM/TGY,U?2=.*_L30A93YP"T&5+!R5"8.;[F[&YPFN_"L:&]T>6J
M+RK9YD#LC<L-1E;*>?9F^)7,SI=G6I"5D_SVA&@9;C1'/TXHVW^OU%?A(RHI
MQ/([[9SAJS@'GU-S(BJ^QP5CVC="$8=3W>I7$SAZ07-AV$VCL@.WB;\_9]"^
M'LOR^KO33/3R!7!8-:_73=:1#L>H-C1J>G\5(IUXO!0Z-2U70T;7%";KYV0R
M1>,_**P M_1%YV\-655O3LO@F+7>N=0^Q1,:9&&XB<3]"CB,"0Q%4G8UO@_K
MV+$)5C=?UW__<6.\'*<F10R:*JZ$V#%M7:>K"T^TDPE'20+%W0O!E:E,1$/G
M3T,U+]LU9DY+DQEQ+%J:@/':SM6",23[O3HIP987AYQ3;'F9KY ]F6Y6J*Q!
M-#]HVB L$U->QJ875.:H&HS=<-^MG6HTN4O\?F%J30KL_MP&:9 7:\%'+>8_
M$]%-*P4#;=239!X*G"N<6=+6W%]#2!*5;M '&%VAJ8+X5]^B(P?%' U*5G=F
M*W9QW+\H,7]\-]@&E$*;@%[DN3QU$IH/;QK\AMEH]VY35'F$'&9DB:P8,7D?
M)PXV4;1H-=<#]U-C%Q<*-L0Q_9%]'MA9O&.$,_%N)%X@]N;$4"D5I$6=V.B]
M+]19-=E6L#!"K.=YI+>[)X3)C6..HB.;X6ZL=QU3(JRN>33C(*_@C>ZG.L1=
MV'BYSS^U1453O@'#PRD(>Z\HA$1L::GFNTX446]I5T&3N_Q?JO1;SA$H-;P7
M)S4Y _,;=<;E#(H'/800=D0=\."8/UK\--@2T^*W,P/E(W^=:\ 4IUPH8%+
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M0JMJ*N_=%W+#@:F97F9H=DV=&IS77^QR)-A,D)T"95PG0V:N-)JA34VQM+M
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M'.ND( FS14#.KWY_9YMA%V;$NI,1(==@+B_+$Q5@+3N7!FAG(59@^'W,(-/
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M:$3+_A?MK%"IXG?IY2%\S7-/.N^\8=TD5TY^6%[A%%NT_\(M?X:[_*%)$X#
MS)TD=XY<G%(,"X/1)-U')#V0414]PTO<N4##DG1STN-IS3!M N_!8\<W?,UG
M/V)T>:+76E/MF)S1]>HGVSUPQGV'P8^YF;'?J\.,FD6W?C20REPZT4L:)'-%
MH;8X 7)P)7NVAZ8PP\Q)HCEQ!2)2D6#R7'JTQZYC[^-S:=18<,U&?$T.^PY2
MB)QLW'D4WG'.T%]SOQ&Y$M/[X<4]U*?0= -0@4%H==YT+S4\UZ+@YK4Z#6'X
MPJYYU5[I=3[V32YM]ONK%U%3!P6YU4>:^9A8/\+H+WFH&$W<SH'^W'S5=XE
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M)=IF6H:_LH:C[ WO"R?,-3T!?)?)K0W!X[QN6@;XTZR:X1:K),%2]N3EG/3
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M:]4@_-)<0L^4SW@)!Q^>I[TUR[@G!&%3/^Y$T,3&2YL9';)_6B1)X<<5JIO
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MTRB"EZBNMG/W]7:G_Z+DJ+^SNLX2[0/]1\&E?#; NW)(?0(<R.#<V?4QPPW
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M' ""EUY]O*WS);!K^#=TRA_0.[,2M_[S;T(H.\,142/=;Q2Y/U"N>'0"(1M
M_7/*7V+R_:,:5VT9+G\P9OI/&-\ ?@MG_CC#!1*I0_2KFCG)7+>L)Z=!!+9+
M"^@;L/96\O7Z2JDDQ50ZAR)UI'JL7>+$NC:02H88YC,U,O_=4AIZ \#:T3D:
MW[@!?'%@.]\ZZ7(DYLVB&BF^ ;2\(KLZ<0'!'P6A7!H '_X=]?$=41?YAML"
M7M&60 95,E"$4]#U_*%[>+?2R+\!'(2VWP"$M,.0$GHW@.1BD?]!_A_D_T'^
M?QU92$LH;_V*=IC@W.08GMH&6LT80O]0BU!V2C65;_'U*6D:Y-)(%V2:%AS"
M7.ULUSEG%'Y^ R@^AQS3:F;90T@@*YG(!!1T]08P%&+C#17)/F 3/<*!4C>H
MRHN1&.G^Y=SD'?%_LWCSUT3\'_'=_[XI]_K_XJ9<KO9L-QK#.QN&N[LD,==I
MO#FWELQ0S)B'TIU<,<,;@(G,%H@)5/[L!!@%,)-7@\"(+L)ZPG:QW25612B_
M*^N<?FG,.,RX?*,C?_X!(^L7 MO_/83O]A0E8QX?(U#\I:'['RK!O@]5WSZO
MUG1OXU\_3L4O"EP_O@$\%,M3;[<UYY BSF_ VA/^'HE,IG*&^\G$CDC%%GP*
M/R*<^H I*J:/!PZ.H^VP'E-(TBT5/^ZBH V]!_@LK]I=0$%EUA7L?@>C8$9;
MZD5/=EHJWK]*-[,?P$(<E_4?T7;_(3$2B(K<%S,8S.W&<M#C>2[W?KS'] 9
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M6\>%*9'&JI4\9RXLB=^2:N0?4,!L4A?MB.^L<Z+&A<D#]^;'6?:R:I,^=.(
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M\*!$6AJ3+ 38N[H_G5>9IH[!*^=TP;DZL@RY 5!\X:Q&?NGL\6.T/J5;=^X
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M:+K4GG:B,0#9N<0@2'(IYB:3HN2]Q\ M1S#3;/I">?!IU[*#R&/7P(13L^M
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M(E>)H0ZJWK&^<:=PX:A(Y^P9,RRB-:SU#S;HGM24<V-J3[':T6@2QX$5[3<
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M[?KP<IT@XZZ6=-\P7X!W4B=X)0HN.3EM$GVMX#K9AH"F,XL/[#=/]<F%"[N
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M_PX&OL?0!<3?%O^"^%?,OR&8H5R /VS_Q/"/H.HBFW,#T[^]___C0?U/5U7
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M$E\C=]W,QMX1.Y,7D6_C'+[QU'R3:5-4,TC+X+Y:?7 QJADV'1@FI&5@*XM
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M45WE<-L'K)S6+,+U^:#89N*(LP JT#-98WV<@,KU98G"&,&^[TH8\)8X%MX
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MLGQ%5$9C2C]OS-!<U,..>]_N]W+N:;S:X\ =-AWA_L Q//TK/!'12^[//_I
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M;^3KX&NGDL/%M^-@T/55D9K1(/<\V(A[ (!FTG06!I;96NME9\T^22_,T#T
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M\_P6FT.(1QAQ+ A<2]Q=WNZMB$OXEB^L&7UG.TJR&!<WC]C6X8D9:/$-NEA
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M[E^^ IVRGZP(?+F>&2^A-_<BA6UYK1H\956C2M.B=#*,XD_^L_B$FVM'0U3
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MZ#8G?8\>(YQ=W>7FM<$#;IA"V-ET77W4KV]5&!BRB+Y;.QC&FSV%OQ[BK@^
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MFN0B/\QS>V^E7I.$BP9<-<H@5\+/(),';*R']JO!O'I&B?W!']YR4]>M^_M
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MT]AK_64,K+&0_9"O]Q3D@(8I*$13Q%NTIO2.R9#L;,\U:@"L\:'?J,$?FYW
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M^!,CG3[;2N!P-BE29<=5?;8@7E].\%I&N;ZE'GY50:39AG2'@QMZ%0OR]S]
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MI>LOJ7\_)_T4?PSP&7:0+D35S-"MA=@G<$S:.'X5ZX!<@\4QS@K'?F]-@(:
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MZ@KTI!0!T8.6I O1=\DC*\OGVWDP< O&47^O,=D-AD@(*'-6D1K>&2SYZ]N
M4M9C8>O=;F?J=S=2;&NY&75@'CD XU_LL(R7/B]G>J.)9(ER,1Q03/KAW)ET
M?VP^TC*.C1BGQ [->X$M2B\5<&;Z=%57;>WPB0_$ !RFTQ:YQV.X,(AB-Z-*
M.C?W=O9[Y_Y)W%>/!MK7OF.K6?LQZR4EG.=LP!>Q59P,G]Z[4I X.%F,XOD=
M*5=_O&?-GG0 V1@(C:FP!3=:?[/F^<&<=[:OE;HV\]FSU,D!YG- -\ZYEC(O
M_,)2]3=&LIO?)S&\RE<2$:E:H/ ]+._&6.O,!"K+<" R,]%^J]QTU]0!)R=#
M..IFH14 \ZH)+XQ&,$<_^VHU>NR7 QV;%UXBG&3:DOS\WM-N?W4FFG'\@#YQ
M^'#<!T71VK4$\$.Y4?&K1<ESFI=(9WK97!PFOXPJ!)&S"RH%*&>99#V2R<G>
M4\VD!,@=,;57#.</%_9N&1HL/ 7^:L#"S.91.H<V5,DH(^A@;QG;GRBV#$;1
MG[?M1GZD#FX-DW<1OSC5!$_ ;)VLX\@F0_1G 3PNK*,)>E0\F9Z=NR:L<[><
MQZE1#N>4"O#Y^>L9#3;^L\OW49.L 7EJIM+"U6^.O#_P/^9<NQ(,.5J),.4T
M=BMI^D5T_8PMNM XZ3Z679>]A-_9'CX/ +VV+%EI@6);9[YG@ZX4JL)L!"GD
M;F@*Q*>0B'M"GU1C1U+U9P*IINS?*'VYR+_],N_Z*>>W#;'+T40(PIIW.0XX
M*L>[]"Q.QH(66J+$6BM?B4-HEL_@I@8%.Q:!3K455N^7NUW(X9H8ZE\><?D+
M[W2;=_PJ)&J[>4(E]'V=OH7@*^7 !- K#HBSQ2Z0A@QA"ZLD[14Q6DRX^B+-
MC3MAY/PFPMV4=5NXDPBHX=%X\%5#ENX3D884ZA\0F6[[\0. :TV6]*\MP&;W
MOZ1XA,3RNI,%X[\+LV5B"^+==W7CE38#7)&:ZJ/<.X0KRA2[<!4:.&T9H80(
M\-I"-8V1K2Z!'2G)DRZXT^#'U:'X58FI;5X30_NFWKL/WK%Z/"3&N?B3@6P[
M67KS,N:5$J-E+4GS+=7=DKB59SG$=@8K"R2PY5T(NY*(;M3+YCV_25@F\+?-
M_4@;90-"MP!HRW3OJ(/J[>[IXDZGXQ 2E'Q6Z,2HWIT9?5))7I%G%-FL=6%L
M/^ZACYW"O9'4_\XXA43U>UJG$=L2Z9[P>SV-K#D-HO=U5$B:.DZM^08^J?+-
MXX?K/'-+<N;)Q-&)Q8L>5>M?V^)J62SIOL:$HS^?$:ST.>B7G;2LO>'?W!C-
M'Y2<H^-YJG7& 330R7 NL)V>)BG3G%_FC^9G3"3"QE5U]ZL.\R2L,K$3D2CA
MNVB/96C$HSD1."(7QWWI.2IBQPM\5%$6YK(B<SN!F$/9:%=A _/"0GN1+2VU
MS6#^K!V$]+.];0!2R*^G5E 'W73C^^&+2_--U%L?WWF/AD3ZB<VV(X[,H-=-
M^]7A=56I:PT58)2X0UF=-XDV884?4FU_7D^A:QY CDVZ*7 S<#;F$U6)ANNY
M 9S#(QC(HQ1&@K#B3^?B).*JG@IF8',D7DNE1 Q C(L+1A7!^H5?^@%L9F2&
M:,&@F4_A!R#(>M$=D6X)_7WJ[FGGB-M0;C?.6)5/^ZVVG&5[ BU5:G_#CX^6
MX);+,XRFSD%:C=>5$:<!JBDNJAUQO!Q&$\WO-;EF)-008TBU[KK#';/5P(50
MKZ_9(R7$X+!63,"X44']V=1'^"'3='W?H,FYRY8C@-^YR-".28.D@/IDS2V2
MZ)AB.S/0=H?C;>2MXM'/J*AIQY"/3ZZ8VXNI[HEF[U\@K(Q$@#O@#%O'@KYM
MG0/W#^="DLDN"4'0H[F5S\WV)22P^=UJ]JU$^A&J&O/JI-"6[- ?(+6Y&YV6
MH]N4R^M,+TTCE1=-4>;H[#$W2M=/*%*ELXO0>R4Q%QE$[ 4> &RHEMNL/=;H
M\3+0(CN[9:ZQ,R&.K;;VZ&6V&++,C7+DE><>VY6^A<%UB\]V+Q*P!@Z8(-GZ
MP>,,$D#V2*)0)*H8G9FX-@(H;$G@9]?*.R"E$(=LW6N&*]RG="'H"T4"Z)8E
M/LWRX]7/P<V39J$PSQ4*[HWJZA_7TX8/ .* %\YDMOP+6II*,4G9:&IDNW%W
M;%P&"#/.HA*^([N7V-XB?K:7RHQT@[)4/-9Y5;[W2!EP1>=#_O>)'K7V*/@=
MQ %U-+V,?K OU*6(XC4QV0< X9#),K?6QD;"#.2MWX3'8700Q20/X;LXIE.:
M5[4;!%HG0=G9X&U(#C)82,R$JEZP!D=B;[CRP#+QN1+.AU<%DQ^F<W*#ANN7
MJ289&R MX?N_3+?A":0LN@?)Y/W;:E([?J$^^U*.(@=7GD"K.I"V[9;.SSX\
ME?1B^V.9KIFN=V@0.Q@_YVU"""Z>QLQ\8Q;#:NW.,M;TK5!Z?)ISJ0HG=BS9
M8BT)]@- 76'5JV+8^<(/,IUWLJ(Q5[]GG_O$E"2P$#FNV_&YR)T][+$(]E#6
M8T[5BM/@+:-_C26@V,\ 6=>57+-$6/)U!G/6.*/6/P#80;$Q@I=JK2Z$]U#X
MA?^W2D\L>Z'#PC@@*&[E>2U5:!ICS&49Y %0%P-)058S<N&(GR?9_=J=PHF&
M)_$5:=? N2<'>^\4I./70DK PICO!*7VZ6\UF+QUS-N!!+]OF\RK;SBY7>$8
M'#"T9HZ3I-A@OR=2R[7#M_-S7'0SEG87_RE/[ZASJJV+$B_U4N+Y+4-JOTCJ
M?*JZD5 +_4MCL@> SRR*(W.>L?_H[0??+.K4G@< EMT[7X'Y)= XG -$F(F4
MM#"1#FU 0-=L/,4ENMBFF[,O3)AXL=]_<EC'R31O7%CYP"3+85_!GPE[DV 9
M1Y=03T<C2:5CG'PCU%H<Y0A..Z_FL:F:AB=8"#%Z#9;IM#5C 6GB8291-#1'
MB<O!-G:8M09R+U+(.JVU&7'#]L<_(3+6PNM#UV_,%V5Y'>1$(X8GT!_7M=TB
M?Y0=:+=NK.?)LEHS3?XB6_@Y[MY^?%-_+NS'XT8Y=[&NVS#YQF\W;OPB6#C7
MIB'FX%V?Y%(_/]LOAT-S1,&:(EV*]@R'@5 <66B@:S_5"9Y2<M +'W/9V!D@
M^"5CD%W;.JBZRC6^N](WKO5(Z?)UQ)M)OBB#1S\87[7W69]M!KK7D3PF3[_?
M!;#=B/)_3\5O3QQ13BO0S>*DX_%U"PG:&>$>1IH\]Q7SS.\OZ"^[:Z15LT4Q
M]D$!+%^5\@63[Z2?%_5.A1>C#K<V++%'SS[ESLR\Z/>#03OGK([8VVASM)RS
M]^&8>XUZ?4^?YI[&^4_!!=?$= 1$*O-:+*COLW ^S#8L;%8MK<12=]?4!S$B
M+ ;#3>#E9E2%9=R,UK01R(O'VNN(ZC7R[_C?6VW&"4-X EUGJ'GP^(=6;BDG
M^85>0\L7(OPE?^\&-*NC)SY]'G_1L*]_25NWZ(KP$GW*3V",A6\78T%N7IN&
M!&USE:*&!6@<%4[#1>Q3*@GJQZ6%H3_ZU"8UO(]YNW5L18/MN@430^7UHAR0
M#R?:E4YS< -PI@*R*+5;']UQ^NS&JCZ:#L#-[O!6!G<[&VQZ#Y5RC*;6 RZ@
M4MXV_)B@"CN]$+LD0IJSE22[Y2C7KQS?4W8FQ*[.+%+<B/L&M9N>$/->N[/6
M<A08TH$TM1J&83LHKKZ/.1/#-_:V/2+QQWDM>A-H*3%%16!0G(;[;LA%>N#^
M@@)\2WUD@(>^1T+Z; 4T9._-/X =0G+ZC!/CHE<GY#9>+3^:5:KW[^NL<HJ(
MVX_ NS'MP_;)>R*D.K,' (W+ Z")M=.TU:[UWRNOBG:*%8&,-:.WNX9]HQTC
M9/[JZ*3'WNL224<W<BY,O';O+,U")?2N<\P.34A\UF'HD;>V_FR#[NS/%'IC
MN!M1(V[D("UOFB*BP"_!;%T3)&).8BR_44VA3G2#K,-QS;+&;,C N5TV/\*(
MGG%M#I:521@VTU*D>>[9P+Y!-G%[X\2MM/E%911*&3+!TXWUG!%0[A'\,/*<
MY3=?!DES4U)(0P?-^3XM7K!5H/N-WTB@[.\L4\\O"PR'EU>1U:'W(]7GGUB5
MIR UE^7<W66X_.D+[R$2<4<1(7D3?'J4,LV.G/N'*J-9Q[]ZWJ>\F[QCL[@G
M'IUF(DT_AUZ$YY'U$,AEZT$NU8+]=D"J HX2B^Q0<J$.A53,@E',2?3YMO.W
MRL"<'%;7WZ[E:VQ35TSIXM):L?$>OQ1H5EV!7M<HE%J+6UO28QDAXB&_V<RC
MWZJFLQ3*H%9X=>/'X*E,3NJ@Y0A&4O9<1QL#Y[Z'UE3/;L8.IF4@(+@A6E^=
MQPR+>ZH?,;&+V?TN\P7/H=HKX .@X@2"<Q-X;&P&JWY6_ZEH$>]I?Z4L=D]R
M0S=90&\\G90I,*GSG ^WOU7#A+<3!HTB0#B-(Z !7%Q6B>0,-Y+/RCYV(\7A
M<1CP^A3TNZSL31.H!1E,.S.KF*$%S9T"%D9$GP2S>NTP[!B>]?/1G*^14MP7
MK^5$+.-_. ?>"!]PO0_=,P]7;*K!&H :Z@1EP;BH!\(/]9K;:\"":.1BWR2G
M2F*^FG)/99!?CZT,B-*^&3/AW&][<7SW*]UR\K!D85_@$GO%+!1YD]*E@$!
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MRZ%_, SP/\ZNKM"'%H/#<XH.8IDAK\@9+1K#'"5N?*YG' MOG:;Y72V>CEJ
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M"A+K@?=,R:,1.W'!J Y8""5_]K:[C.V2SP^]=$@R1DPF\.CGA)$&1R'D4N%
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M/.^[2FPHP7>X]X"P5LEVY)-3[HCZ/PF7FT;ZJ[1O9O '<L*MH)[RE)BBU7L
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M+C=80F'*"B&JP:\H'H]LC+ A)G=22LXA=346%;.SY/1TM2^(P?T?)A-=M0R
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M!/_^ID]VQ7[1L.W'O,]_L&MRM!4J_)?GJ/4F4L9-(A),9OX-RA64OWZ[_ZY
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M+B4H]J<\JYO @Z%(W@WFXI)D[J)(QN/$7]4FQ"[SJ<H&(,6&)KN@^I+,W.7
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ME%1E#.*^)8&\_K>76OH.EGK!"A#E_<C84/_8_<B ;._"67O9U+KV6[-.3#P
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M]NA"S-)V?Q]SIZ/V.AEDR,;>LM%,9(RRMT!M*VD]WH\_>\]+E *P=?@L[ 5
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M=WV<X[;VB0[_MYIR0SD@*<V;H$@;;4.$!8P:TW+?RE'__3C<IW<V _O+A'1
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M<BN8S;^V9&AWB*47J_QUXE)[U=8?*:W1?O'3[4+E=(K!(;F?3^"3_Y7U_C7
M]QJ ^CC?)**W(R/CN]CZW%_]FU<_ 95EY=U]0;\4_C@>_'-_=T3\;RJJ,,$M
MV+C6X4[O)?_TF\AQE"B)?Z-[&NX:H!RI-E+U5/ @"[#)0QSY15(K+C-C;E<I
MF.-.60=EAJ^@WSUBMLJJ_L@#5:J7"G8V/:C4YJJRG+V7]0F$#=35FBVCMSS
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M$;XZD.&2J6B6D*0H[1':U] ?VD"[GR'/;@V&(F0LV2GEX-W:.3:$K;XFSJ&
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M50C<[A2E'6G.-N_"(*,%?$HSJADL.6:"VHL>'+O/XZZ\H19=B"%%GZG)N#T
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M#44CP?&TP#3I1&R@9";6:8A([7L.=JBM)Q@3_TFO8:USZ/)O!X<#Q75B%F'
M$[@&G:P!T9[]/SI6:7=?M*"WG+FDY3S5XZ^=#/1T/N_1>'$^B,507+9QR[Q8
MC FW1)3['^M>_*&OIR@Y:6^BLK.^.U4OX.\^)5NR6#Z@"5Q2<W<I,UN//5'C
M'.7\JS(7,)/(>6G;DKEV(04*X0/].0#341#3#^3^8IVX8MT>):G29LAON.5
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M.+8YO,B8]R/%VF\T_2G#.EC]$.?X])(+YT^M&R/67J:?>UO4QTP@7_=Z_J.
M7W/.1VX?5T*?M)V53?#I"$8>_GFOBZ1YGT2 6EJN4Q9X$8>7'GF7CLL813+E
MIK_G=)HL*]),29&%^NL)$A- !GP?>\SY[?MN+P-@.3YB&\&1</$ >(&?D/ ;
MK&BYBQ_+2J9"Y_*)<LRE\]7'=I2%OFR&-;,IRS*P=L)3\.N7..)R]\EMS12E
MV?R$40W\#RGVV0V6.J(/ %\JY/$;'S)9QS9,.32%@B_I ?#,2P>D*S.9\<M?
MXSX3]GI$Z#L=@_CAAXO..+ T"COA$[QF-GSNJ/X!P 2,>#SRN2[8;SP8JS1(
M8LJ;WNW=7-'LYD8)=\7SV.P1VI:\I@$G]R,>9K:<]36UCW\Y"](VSG[*5'%4
M3I^C,U$)@SG@(G8PGPM"E&<H6TR/E=O+P*PM0M!O&W]<"(@Z33R5%F)ME.Q-
M*YLL-19^KI3RTBK%HY:A/53R.O2&1:W9)K3:>,1::K[MBY3:/DNRD %1AM7(
MB^658P(C+-)-LFX92?"%5QTC$*Q8@2G7F6E[M4GK(/+3'E0JGW]H](G6E1G;
M<XK4;Z]Y,C(GJQSQ (B_,H%!@X4'"%\&Q9X9"$KW2'<)):9%FC\ V-.L97[!
M1VW=V'Y=1"'T(N^Q$O6MH@=P?**EO!QFK6NY(E[XR$;"(:*5"4=%OX,N^2",
M";?6WDZ;4-)QPO[&G.S%Z#]7V8)"Q&D*$Z+A<WB';2*;C#1PO_*W3?,-')W5
MM=CU*9[?+P<,&84\)-!0'=AT/?#9PL'Z0,^ZO1P/JB=^3+O@$=A)64V/C>>(
M/#!+_$76Z)#+^F'SGY(^N7@P\W2;4JE(5756ALE!#5RAX&LO;6Q\1A-#I\#I
M3//O>YY;^;:IXZI%G89&I^6?:CJJZ>/.)BZ%V+J9VXDB@;"BLSJEQ;8/%*W>
MPHUZO5PCU:1X/ E=,D*#1=Z@'\C8B>$2$Q8I'*MJ3IY LD'VV-^9/6;.0<NE
MMQ]0[;!FSQ\JOM0:4J.ERD52A8^U>1[_ZJ^5JS2OQV0@WL,63R_S7"H_4_HL
MO.ZUQZNWS!,T$AAX)-?G1WXA,Q!3O!;!,7ML]Z0QC95KV<U<Q2+ 6#A8UH$U
M7H/6/OH-?L';(J/D;U1[R>%SF(N@MR@&:) W[;CQ6%:-J4D_R< R;.RG&N#<
M)V.F1=-MFS+!N4W@K@#TJ^ @&P?QRNN4@WU8)PR:W DQN3;A)59)Y[QMEQPN
MT%-W"7^**[T='_@;;NHB?&KMD+A-.F*IT!9:_\\\M(MB%O:S_.3ZX;>O_29&
M=>9"-OAR+0G7VF?[7D2<9;-@13S:-/P&26#@R]6:^CE[J]H2/B\[XLK/'*6]
M;**&]P5KU7.2N0/<.E/1P,V]XDYGR9?_>@0%>/;$/3%%WA$2$T19Z&>A#)MU
MKOAHQ#O_GB+)5U120'SG9CK8=1AIX\=7@P+VYQ 8^CYWM(!+5M D+L@M53Y=
MM_PP]'4;$G0A$E=R^W9!."46M4[\@E!K88^6&-;*2;)2GM&N.D$Y!9Z_E)]Q
M[EAP[1AT0V=1"?EKM*7X##B^.%M(HU%/*%KFTKBO46H!/ #,)0J_KI=,=C!B
MH%5^N19 )^CS_@+0M^9T[E-.P0F#C^54'% ZU$*U<"<=)J$')BB)B:OB);W?
M/6$9H<V\VUR)<FL36/*TT,XC4_-23?I'H427BG@DU(>I H.5\O#0F'U/;CBR
M5EQJM-X]G;C*?7$]JBAJM0?5&+\;N55<]@LIQL5OV;">$C8@QN1MH0O.W-7S
MVQY PZ^1Y:'X5"]AF3:M:<R4#!^?)*]7)G^B:)_5GKU(,(*&3/".^0I^*Z%^
M8ISB(?FA>+9^!9WLZ>3T:?JV9LC:@/N(V%%R-9@GJ!*W/\E)\2QD149KTP(^
M8K:=^;X@^GNBS?=&ACQNQ7>HC7CAL)9@<$&;Z?K:*-OXW#!54O83ZU'[\U,+
ME550#I.7T/*2&S6>39R@Q/! \-]R7.69JOR]G@F'U9B]%Q\':Y +X1 )IQ!1
M%%$C;_Q!S@SHZI,3A0Y?GK-XD^+PIS55&4F#JQ1II7*,$\*NAJVJ]$S1G;Z0
M57*7=]M.:@=P_=%FL5DC'SFK35=K!)2N.4L7YC*61T8F<[94US0%7XDNG$LE
MY18EDJH4:UL421W?^7 T#]WRH C1K;:_BN:GYE[6M3GPGF;ZQ,TN3OU9-?37
M63%1L,7K=2/X]+:=)>YQZ>T3357+_U>+(OYW>8R5,[%XP2U'BA2C\;ZU AI'
MTP?X#K&@*I\+&,MR+ S&"$OEGB=PI#<_/7_:2_H)9[NKL)M.\ZIK30SH :\J
M\B^ME4>?4>-%D@H>2R>7,-0OAP#\/%2^]9IRJ[$*DK6>?%UTP)IB*&[;[M^H
M7R_]%XY]/L'-@&O:+I^J@N9=:J+U2E!517(.<=;33/- A9Q@694;05,5KMW]
M#P0;_#H2TCE5V<0LLT%2FY5"O3G8DF\I4,,N-%3#7M3>'*R,)MUSLL^1OC1]
MBPN^9$C=U;YJ,_AR:MRGR##B$O)^_F.E$C.5TEQ"AI-S(.BY"IT-F;"MF!"T
M&GE9E=6+:)AH/ULQ13W)_"*P;BQ_KN*V'X/]>54H&:*>[5N.+.6=,5,-W9)W
MJ*,-K=\P7V/[H52G1A=:,%#9Q+5=J;!M$;8@.1GC+<[#_L5B5*1_56H%?U^]
M52LXRM)/?WOB%Y@F_M1@)N<,R(JKTQHW_]:-\\F;$M0C<'Z+F=BV2/]&3[OU
MP)4D[8HQ7(6G6IZ=X,\OTF</ 'OQ4RT-31\%VC5?6WI^M/\LV^S%X *TZK0!
MZ)>OG/<]Z*?U<K5U(^O>-_<;H=]D7[2/\7<;U=+=B=[?'K0J3)I:-WP\[*R_
MNXJ^E?MQ2),=N=?8.$?.EB4'4[:)X&#B/CY=**B]*W]R\@NEMI50[D(/+9JU
MF@_:L17Z=6*1745(=#6G8>,K%OJX7NHKSS;9ZL!"5IP]633U!\/UDL.<691;
M3S#W@.&4N<6H'(3@U5,NE9>F<G_($3D/@&/C<FB$WK;"5/$<_TR_Z\DI&V>9
M<^5+'?4K)+PU-"&4\E9A4V#SF7"EL..,$U_/WK2LP:>7&^<9/7\4VR]/A!L:
MLW>\6E*ZQO'UYMWX=[,V-;W^J&Z2A-EH)EU_('1#!TR+U/ZZ6JSNW5' &DB4
MM:00I0/G21FR/0 ([0F/,_,FOFTEC%YJ:,,.PM1_.1>LU5_>##)=E#8PPB/V
M;FZ\+RH?;X)RS,;;F^=N^U[^BP6/B&M*2NG;)[MDF._W#A"G.FW-.49CNJTN
MA#3IM*4W?=;M1J$1-*JUT9Q0U\W6>+3&1:N>6!S]FTZ&SWB;!7>_^'E%H*3+
M!^9$S8T-TU8$5ZFFK+'G-8]8M@M$0_%<3H_-O$O:BW/Y(TZUX^S:*&+4R<JX
MF_$+7)$1K[RP6J9"L$%@&B?/HH. J+2GS,T"33B[BA2T35>#Y 9_T/[3)RXF
M:]Y2&-VM=/B;Q$=^QE='<BD!6[<2-[H']YRHY&].3ENA+&K96DTMS?Y5Y.:O
MK#PJVFYFZT/A(0^ ?I/UM.+>PE ;LR0/7LES:M-W-!QONC-CZ*.D)(0CG3HV
MSO9_P&]QIGF$">6TZIJ:&@/QO_&Y5#79*[M'TYTI5$X^#Q*:#=+=%-HR4P;M
MU]H"QK186>GVF9M#XRSH:;=.DRY"B>F)@$VG$74'Q)SQ5+5+ ]K8-W;E2 M&
MMH4@C3(3H)\K\H);PK;Q?NE/JK*=TK">9/CD.E+]=HBWK(RXBY%@!3\<;YP*
M[)V';GS#LAQ^'*\A%];"6Y4=:G5EJ#_H!_M]U&?#P\'YQ+\W9%ZLI;('KE(8
M:KT&/UA -W(+Q65N9K!*UJ*F#$IZ'P KM#T=0BBB.DN/I"+CI?*A[%K8KI<!
MO"],5C^'_ $ 90I@@"!2HJXM$KSQ<UN;V8WY>(C W;0I/+"C.P]NAL--NS3V
M*GA[Y>Y:\J\/Y'P_+9O?L_>\#C9HSK-'_YSAL5HHJ:L)5E[4;JEO5-M.??)=
M>SHZF$L.<#_+,6#.,2M\""%8 _G0Y/6ALP(B1ZK2-4A>9F.E#0:0=G2M92ZW
MNM](_;:P!0(U5E9H#<_A>^+?K7;3&G&L@J\1/UKN<KUH9UBR[F^.TKX14'1'
M+S56VPTBN(@QIB;S*4DBE:2:K_C9)2.6D36L/\7N3P,I.8J<-V[M@&Z/@8=G
M2+U)=[8#Y+%MVRMCC2,6]VWJDJJ4ZSF&:(.R&V&_4$.(UW74:3J;OP%3[Z/O
M'__,+7HC^ %+F(1>@QSA6@T"GVB.QCSB2=K!*Z/ 10B2L?[%E6\^]P:Q2'S]
M(L4HBVD9@Q<+S[/[4[F 6F@H*#/Z /%,># 9,?+ACW7$AS0;Y3>]A,F2WD53
MHI(RAO]<E'=S8=:-\5R5#614J*VJ<$CG1/][4(%,E W&'NVC5E^^$DJRL6JJ
M?.5+!@3V<PP_]0S;3,8<?^"_ESWT=2E<,?FM8>WOZ>YP4KO*C>7&'R)U\_Z>
M^:Y@(*-TLK@#LJMNY?\1O.Z=+67Z"C<1#R2ULD//!^J]$44:7(?-,2^X(>:P
MTU0Y- L(:8[-<1N,L]&>9W,9)F.VS7^8NGD[3V%J/"&M20S/,)OWG L7-U))
MI!KX+F^,MQJ:!*/7IX./2I'F-=U[":V/=K5OI# ^H.SQG#U@<"D-CF4T5Y3"
M;9)YY.8<Q;4B"%FYX?_QUX!Z,;DA1GT;.S#G(D@W7)5 [JF?R6QW &%5FHU9
MY2;NDTD.#M8'P&5IY1BQ.B?6^#WG4.=9JA_(6TX@2')&E6\D_7G'1JH$W;9(
MKR,#,VSVDL7ZYX%)=-)6W?XH>CH=^JF F\YYHQ>\=KCNFE0?Y7(B7?)'#9^N
M2:H53&Q"!'&<JF"'DY&>EUK3JDSI_9:""!EAR@=IEC3*\\SO!_1+C>&Y?@7P
M_%<O3L59)#;IT+]HW/H@I,/E3@O9LJQM\3<:L:'V\!>,2%=VN%C CKN%CIIG
M\: 7+UCC?8OSZZCX&(X:K$K=F.Z6MPRL38L4\T0%TAKX$H!$K+3PI9O9CD:*
MD<&8QN1;??;EB4K>JF;>N6KM$C4&*]AG]K>Y[FF1MV:'$$@_#;H!'RGD2'G%
M4ZUETYK4^&I,XA&=Y^)WDC2+]\')&Q.@MMBV!2I!9]K8ZSE&FYJ:J)0T-VR-
M=*W^#]0'#B?"0>-;*2\.SAPUBK4KUD%PRE3HW0^A]B(CA?>K*I[?[S\XO4%!
MDZ#63?.G(OA#NPW-=7'.?7YQT\,$1MX[ "?D(TMKMFI=%]<IL3% D@_X;[]Z
M]8IZ:Y9X'A#WDX["H'KYH8=+40HU)ANQ9M?;E]/G?N!+ ZJ#16@*PE^,K$N]
M)FY=G*4OI^R!*\V%XMPSK:X.!UQG[ER]'*L:.YP"=.1IJU_C <4YTL72J7:\
M))1ML,O0,F4]3]M@VKRBHKY\TY'@YM+?B^X;[V\8F;7YZN[2MO!?K=^%;E&V
M-Q(S9XTA%+YPW*P&S'4PHY+K$,"$<I%Y[Y?%JR9%*W;OI-^Q8U7_#3'/[ZB_
M8<7>'TZ19FR2\BI=5*_57''>I*UK)>&7;4;\NEZ+F'8(JBMV"F&:^@+RD6P?
MH]"W,!MFNUO=H=]\' ^D(_ \-<\[B]1%$37_PB2? N>+6T3MQ#]&OZS%&?/G
M>40M(7)(6+3<DNFD2JV&BR/"PO(3J7<'9C/\H"1_*SJ=.#W3%53NB:+M)]XJ
MXZN'DIAM;&CQ&2#?8*'E:Y\H6[P15&GW:H'$!BD539::Y'GJN*C#@0[.+G3V
MQ[JJG5)@"1G_XWCT*9&?E/I91QZ:%O^MJIB0Z";UUPRP=HB3<<4F*,LN0HCK
M;AF/L/<WR*N:D=-/OP_,55U7/\M[Z2^,J42 K+/0>F)C=A(&VWM472MFN+$B
ME?I]#.0H\7EII4!0>;DD7[9ST?N^(E5;\2%LF[V.1$G;7,&:^K!,MB]?![$O
M69+K]ZIA( 9%-Y*T 6HT0?4%1[M8*2_]9,Z1M'%Y[Z]U8XV*->2UH#^4\)PX
MQ]A A.L;2]KMM?ZMW+8V]>K0=?O)3Y]:I5_&)OAD#,P"JB7^+%#+2<=K:20L
MB2H1WF6-35\LD)@<0U5&6,$A$2VK:GV>7/"S)-B5+TN:<5NNC]!0$457C31<
M3#4UD>D\J<76HN\2-[7%G,*;5_CI_#8TIYV].2_QQ]\<ZMTXM@D6Z[$E=1A\
M.'A*#2W:K8$UIZKQU@L.X6"U/'9'YEC4RO^4CWY-*?Y(A?KP[UPE>;PT]]9N
M[ZHC(PF8U^[4)'%)7@_AH;5XKK5)K-6167X6V65G\6A9NWQY:2P#;O."])G:
M_BF%3$CFT7.C%9/RIRZ(6+'UI^&>E_WJ:84.Y.^YD@%8CY.S2/ZX1=6K"D_B
M8=XX+;%'*H/1N]X2CSR !.LZ(5N>UX8_@^2^*"#X7\#B63-ZRU[8+9$.R(F_
M6GT.7N.>I9G!^=PS-3#-0&"K/(O1ZW8A;PLQU67538Z-!S"&_3S '8?1&/Q$
MK'EVZY4K>O+.-^SV3[4+4C7^_?PH2D:EW03%4(YHQPE]D8N_O-4X6^7"2TJE
M]ER1+N$;*S7UX49#X$32UB$]G@3I! E-6Q(?L90&'4P&Q_$&^&:K5Y'V&0XC
MEZP;M))Q$8$[3FDNA,J?!'WT7@JMF_Q^=O#JU6ZT:$''QM?DCCMNJ0%93A3;
MA:ZF?[D6?!=< FB8==&)K6)9A@C1?]*6D#:<B]&L<S @<WH4IV4@1 4GKN[G
M7@*J<0TMH(03>IKE5:]I '\A.JC)>#R0#BCG\G@N&XGO2+B[LZP^LYF/ZF)A
MH2_W[ &SH,QS$4 2T8+@\K?PO+4X& 0@[%[Z:O*J;J,]$ %"UYRLN."=2.62
MA&<<@ Z=\%(-J+IQF:+H:'S)XZ\_K(T?)WJLP6FI)]>CO@M8]'V JYLH_I]L
M@WY.M\"1<,MAO:V)%\RM:^AD7 T<=:EX*NT)_&C5;!$'YH=TK3]OG3^N-$#[
M?2-G\H53U3TYQ$S]<ZRL=[FW+.YTY7(K)S3&)O;^?![]WWPR9HNY]28W8Z(K
MJM*-%I"5VU9(NS]D>,UF13W;5=S)<QVR3I*N93B)U^2-Z-(FKZ8[E "/$V5N
ML^J!.SPNU$%343M!E;*%3D.TDRI#3;5XB!4FP%$"?6'<'G;@)1<60GKV^S-R
MX4ITIM>)K="C8C^@H&-OG]YS8Z;!2SNJA2^F\ !-<I?O/1].F:')CF0;.;Y9
MNH!*G<4,M =[WVFK+1Y5CO?Y&L9#[$/3A:-?=RN<0DQR5K9].A'CC/I-9^@D
M9]E>*_:FP#CTU^6T6"Z!/]8OO#I3O?_F>=X2G<T*R^,W;7Y(LH$9#R6'\ECB
M0SVXC8*$I\FZ/#'R*OQHZ>FV=V#[R88XZ\FYQ2R,_79,+ =$;8:]OK%]T9N*
M2< 6IMB<VDH:<%'$6 \N<)<MVOE-@N_"+!RL4 C9PQ[=306WG;^JOR?AF*=7
MB>^TZ\3U:SD80%Q+[:;/S$BQ/E\3Q$UZRD5%5)+<,'8K<Y=9GX1O-.>MZ6%\
M6@71 9_ J4YHAY7<&XQ*-#=]JP81' .JLHSF%88^N3-[H\<4+F#;C$\,%HNX
M<E'NUXV#:Y;2?"TYR$]+O:7]XK.[&^TSJBVG%HH3 OI[,D=)P89H_3/12B=;
M9]2!*&I%GK=S^I1&3@++];'VZ<>+JGU3C%.!7_1I[^S:H$ P04W="KO ER7/
MPW[_M+L"5YXV2J(RT:R,"7YP=U@0SJOG'IBK8OYCXBJ3['\Y8"^Z&JY 7]0W
M3C]@I"+[&G#2*V)PWZX44KP[>-2XZ;]=HQ1]30Y[8J3H-8S^S-]6V'0SF@'4
M#WIZ5@$W;RQYRL?<,']BW=IDM,="%/9D91 K.3/S['#[\[K,XG9C@DJF\&@D
M<Z]7Z09[C\J$ZN!XLH!Y8SA2_:1[#A6,C]8],X^ U_:+0MW=RDZ=<IUR]_R6
M<S%=E_0IC@M3G?9R3W\+(F=[LNO6C,V"&_BJ7$W4S#5;E?=DY.G+YZJ)'07D
M)YF:[K*#R#[5O(S_2TZZ)TB*C+[,:Q27[11C+CH;/)K<W, S YH95]YFK*SV
M^Z2X>]FPJ\[]RAA\QY!Y^-XJ#[[$4 *Y5<)P;ST XJZCDB;JK\9@1:J-T9N%
M>A_W]TP]C<48ZRPB3KP#[Q1^M']H5S;F24=F;7@24#XE$@M<++=*Q)/WQXFZ
MX?-CZ>TG;+$8,W H&;MZ]]=A@/*LN]+M2=#CLYBPRSQMW9DC"^^_LK;MO<]>
MF@UR.*8-;IMGA".5<8L _HP)G786.)C>/B$GL>?KP#5U*Y_HA<U^+.E0]_A'
MR=S\FU='\\6WTNTQQG-%65? " 1"504\[O8\+6[D)9VH^'A@]!.JBWY\S?";
ME>\,-6>!B@O>3I6Z.VV-'6#;)C+@A,X@DUEK1O(S.IK6!P!>ZYL'P&>/2<7S
MHAORAI$UZ(1O_<]&5^L-]E:\=SJX8$>+Q[?\Y4"1]CXQ0EIMF0GLP=.1U_M%
M]AQ'VUO\HFKL8E>D0[\JSE=)53]P20707+[3#4?*TSVYZN8GLJC70GK2I:E@
MJZ+&%![S-Z]46J<L-_;(.FOMW2TP'=+09C1@P?:P4DPN_S$X4N4KG5W268'"
MU/[,'DPM$CFK*4U;-$&CW0XQ.?Y?>QTLME<#DJHJM]I5--./73>!X4\;A_5N
M9$W#9-M!L@Q^*>:215.S(1L(3:FCU&^T.E_>6#7)'9(;AR'7 @WKR7%+<<\*
MGY9/RU_C481-@ME5<:,N;V2T1C8Q!\!F&G:2.E7CW"M;5CILK.M%F7\Z0(FI
M?=LL:0<M/0"S1*/WGAW9/:F<$4[!HK../+70=];KAB5U>0^*Y!7X!0SVEGW*
M>OY4:6S<G3]X(B#'8H=Q+VBMQ-%<<(YY>@J3=># =^*2?LZMND?:HR;5;<?(
MB:8S"(UON/,UG',5'G6J!#GO1YS3QK*EP;774E*_\U&6,#1<_D@*.*:>"/ M
M&-4^21GYRDN<$\3_RZ_JL \-ZURQZUF@;-0  F.+/=U==5R'!E;3M7D4H"88
M->E)ZRH@)<CYV%LM'^8C<;=!A_5;4,E7&T\0\B7D<3E(4J8XQ@8&TXG]J*<U
MO0I6D]W+^Y=H-QGP3?\O^V#8>/_/2I+_+3$-[6?$[NS3?K+NH+O*6];L,)FC
M\/=-$T=)"'=UX0\B%@V,W-:XH(9:QSA;_UIK?4?0.:4_=88U!0=T=%#$6!87
MHVN523,!^I!M8^[<=_?-U_4Q_XDGTCP\7)D3:X)LDS]*;_P'B;D;:">O*F1F
MW5,H41;8Q-)@E+*9$N62^(;6>"O.\GD;R:I@X0@.SIGL%?D&(A[P9^M,L6>Z
M[U?J:N'T$<EJQ8X&Q704?&D[F<LI-)+A!:RAO3&^J\*WNI ,H?B-'/B)]7J_
MK.HD40=7 &$18T*<<")L? E\Z<V>]KJIWLJ]IFL0(5/.UH'O9Z)617^TX[!+
M^B2\B)W3]^X\,G^?O?7@GYWEKMT^.@L^[D[74+N%>?*G<U@^]VC5<+D<#)B#
M;'%$N[[,$JNU4[.*H&2PW'UY$WE6M9#QXM&(G^]61])6L);&N(RK%8]1(:$4
ME?6JQXK^CW'O+U^+_O?W[_^%$#\L_P]02P,$%     @ 8CAN6,-5!#*(@
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MP$Q-$DQ&2T8B "!E)B%C)B'T X#$>5*0_.T _/T@(27.D9**FH:6CGA!\R4
M*0D9&2DYV9]9$T<CB>, <F8*EJLWM2@OFSV@$O!GE7F:5D0MJ-W0PV8^CA*2
M?1@034/+SL')Q2U\343TNIB<O(*BDK**SBU=/7T#0R,+2RMK&UL[>V<75S=W
M#T^OP,=!P2&A8>$QSY['QL4G)*9GO,K,RG[])J>XI+2LO**RJOI=8U-S2VM;
M>T=O7__ X-#'X4\3DU/3,[-S\PMKZQO??_S<W-K>01\>'9^<GF%^G__1BP1
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MPR1#DH9SLWW@ 90/U][LEP1GJ<6"W%=7I.ZTY0WZ]I>],![^[)\R?5C1 Z>
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M2H@HR7P,3P @_@:5]8AI1LL8=(%';IAFF3K0%8@;PV5"P:?LI@Q0.;1IC,5
M@(EGO2%KMW\+2;$+R"E ['BE0:(+2>K3S0OK-;F2PJ>%P'_[3I]']/_2[#CR
MKZ$(^ZN\SY(]1&.-=HOBXNJPQJCL7CRUAD@ZZ[APNEFP1(_,@?K- O$MT[AN
M9GXRE%-:H41/!W=DQX=KXLD8/G^;_]81,07JHT8/=NU6_CH'-,*S5D:>[B'3
ME=\U?Q;'V]\E2^/%B6)&M*+%3_XM(@+)10Z\P< *+E*' "BR:;.)P\\A#_4D
M"8#='2".MK4(:WL.5^Z''8H,P*+!:2@&5C.P >PJ!:N9YG_2>\]]'S')GPD?
M3L0\^'(%BQ-%+YG=F5L,\5$-=^>U\ #\Q^,Z_T!DQ[.KV=AT4SH"8/89[%.7
M"%$$< JVVTE$Y6=^T>!#0S4I L")F0 00\&)GQ]A9@1 _2_L[H]-M.P%2((
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MYSO9=&3_R=EC6)/C)Y4ZY"OX;DO* 8]U/ONZJP2O;K<;615IK3G9)F2,#%+
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M^6I#G&7B?'-<FG#ZLLCMO#:><'3!] SV.IH/]TKCJHG&\NY VCT(R^!"?J?
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M.$B(S_+#D>UNZU')\^/)>E8/2];V)PM7])[M5[A:%O3@WXV92O"%>:BV"H*
M/&.-)F+.F 6M7MY2"_&4;,6C/N]\JUC'YJ H83N?_G;PA.3/<L>#.;C!T<]N
MAB=OJ=7V[C*3IZUT1/-XE]H;FS?KN.,Y&;!;UCVKU.86%"2 X?C,D*[PW?-J
MZ)5YF.IOKN!LZ6A-GE@[K>DT%,7TNI%E(SZ/K<#]])K83DJ_U"MV^D2LXIA7
ME+[XW73O$PC)=@4U3N;RS,<&5&MLTE-D3[97N$7#A*/NA6T3'\+;IIZ#['O
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MS]9(EY*]2_\#'\^0HUI\!5M"R&+I"NV 8O'+;[CQ *N6-F=3/SH-VA@/7T)
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M$/4F6*I*.S>(^22\@.%Y"7LV7FO"KDJB-!HSW9%E]]79)%9/! -L4]E/>F3
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MQSJ*8)/LGH4:<OE1\7M<.]H47ES/X%\23>SQV17]]Q G'W\R%I?Z$(?7'A,
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M.LK8L9X$ F^FX^U@O%ZN3V,=ML/:G?NVO$EK[QU]'6:PU!TF\^ZJ+HAL1WM
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M==V_]5SONQ[.%(<,B%I;6%D (!X  '$?@#,#F %@'I[#P16$.Z!\4"@$ A6
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MMV8^SS/S$4<?'-&TG#='@(:AI*G]O@8]O?_>]_VK89SI?P-02P,$%     @
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M4J?]R\3KB*GFS7J.)YC;K5+LJC*(3[W%U56-#V3<FD=K:#&Y,Y62!4+K$:T
M 1QL!0LPQA/B@I2E":NOBZH.T_;"G#< PKK"J;\TS%D8T@VC_C)$Q [8V&7
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MVSAHQ(+#E394D9AS;"UF7B4XI\>$3K.(5!Z:FI+8T92>=7)LLIVD@$5(G%O
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MU=Y3.WO3JE);ES]5/]HL(X7XJTZH=&KPZ)U94XHSL#V/EKZ%VSFW3D&[KHP
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MA#MN,=6^EM\6]K]@_\^#6;+@QY[,D+O?/L7O[KO^'.(A(^E33?UETK-HWL/
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M1^'2050B2E<0&O>@I 2K;%ZND69%,C9'1<@CRODRV=9;KH"5_B6WHEX;\Y-
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M/M(X>=#;((DV2*(-DNC9D40I')G&< UJ+\?"HYF6%#("^1;?2T-GJ8>%U.%
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ME@9E10'-#9WFN$3+TP\],124:8+.N])4JKH6RL6W1=(2P:T5O,23^-G;:"+
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MK)LRD">53[3-5;EK,RRMJ[21[>&C"?01AT5Z--K9!:7.5CX5X9!-GZ5!JP7
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M:ZX^%##9Q6]CP8]Q/DE._A]02P$"% ,4    " !B.&Y8&S_#/S(9  #8!@$
M$               @ $     <&QX+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    (
M &(X;EA8 6/8"1,  %O_   4              "  6 9  !P;'@M,C R,S$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( &(X;EA*J2X'H#\  )$X!  4
M      "  9LL  !P;'@M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( &(X
M;EB4]MJ5$H4  ,5@!P 4              "  6UL  !P;'@M,C R,S$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( &(X;EB=)49V<&8  "L<!P 4
M  "  ;'Q  !P;'@M,C R,S$R,S%?<')E+GAM;%!+ 0(4 Q0    ( &(X;E@Z
M0U=RXN\# $*2)  4              "  5-8 0!P;'@M,C R,S$R,S%X,3!K
M+FAT;5!+ 0(4 Q0    ( &(X;EC,8Z#F1'$  %Z9   7              "
M 6=(!0!P;'@M,C R,S$R,S%X,3!K,# Q+FIP9U!+ 0(4 Q0    ( &(X;EB4
MISEHH)T  -RQ   7              "  >"Y!0!P;'@M,C R,S$R,S%X,3!K
M,# R+FIP9U!+ 0(4 Q0    ( &(X;E@1 >5X4[D  "G2   7
M  "  ;57!@!P;'@M,C R,S$R,S%X,3!K,# S+FIP9U!+ 0(4 Q0    ( &(X
M;EB.YXU4#[D  (>_   7              "  3T1!P!P;'@M,C R,S$R,S%X
M,3!K,# T+FIP9U!+ 0(4 Q0    ( &(X;EC#500RB(   #"7   7
M      "  8'*!P!P;'@M,C R,S$R,S%X,3!K,# U+FIP9U!+ 0(4 Q0    (
M &(X;ECCY1?2R P  )@-   7              "  3Y+" !P;'@M,C R,S$R
M,S%X,3!K,# W+FIP9U!+ 0(4 Q0    ( &(X;E@,X/?!AP4  )@=   7
M          "  3M8" !P;'@M,C R,S$R,S%X97@R,V0Q+FAT;5!+ 0(4 Q0
M   ( &(X;EB3)<M8?@@  "HL   7              "  ?==" !P;'@M,C R
M,S$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( &(X;EAE:2>O=@@  -@J   7
M              "  :IF" !P;'@M,C R,S$R,S%X97@S,60R+FAT;5!+ 0(4
M Q0    ( &(X;EC3XNVR=P4  * 5   7              "  55O" !P;'@M
M,C R,S$R,S%X97@S,F0Q+FAT;5!+ 0(4 Q0    ( &(X;EA.=L/3B@4  $,5
M   7              "  0%U" !P;'@M,C R,S$R,S%X97@S,F0R+FAT;5!+
M 0(4 Q0    ( &(X;ECZX&2*FQ(  +U%   6              "  <!Z" !P
M;'@M,C R,S$R,S%X97@T9#<N:'1M4$L! A0#%     @ 8CAN6"<XY;^;&P
MWK@  !<              ( !CXT( '!L>"TR,#(S,3(S,7AE>#DW9#$N:'1M
64$L%!@     3 !, " 4  %^I"     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>plx-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_vB9y4DT3xkGRfePGVkNqMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gcdiHe0OrkaRgPsieHDsIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-07</startDate>
            <endDate>2021-06-07</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2021_To_2_17_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RTfbrWi6qkSb5DrbSpC38w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KoWXKKVDCUWPZuUT1WTDdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whY022XGs0KlMAyNJFGWMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U3XBnkC7qEm6XPK7cp3CoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sJB3yn3mr0CwfBJ5isgHEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1TbW1rn7nUeqCRQw6xQlRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eyEfL7MvJkeQsA4M6v4ywA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HElXUIExK0aOC5Db-v7aeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SjXBySsIy0OVSVIytRlcHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EvqBctZ660eMWfEw45p_Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2lHvWBXaM0q4Oy29CWa4tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oMdnHc9qbkOrXZVbmGVf1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A-V99KoI40mufi3_2xy4zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2021_CVbxW9emMEyG2cHIMoZs5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_LrNNiJqQIkSf1ulC8PfLpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69To5.60Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_1p-co_pHGEWdS066RgFFvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55To3.73Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_9pTD0HcQLEO_MTuojw_G6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_4fFw3SaWjU-j0D-jbfOafA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.03To2.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69To5.60Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55To3.73Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_Z5ILinr5pki5oFoOTXqaOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.03To2.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N8BFMU2rM0W5-sfr4UsdRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_-Wf9gnqOa0O0OwdXouHwAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YMVeyD2j70y4VdJ42iD_fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Jd93bicWJk-u0ptZ1qcGrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_rJLQx2leAEWZ1CL6p85CcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_upSNdbkvUk60NSUBUbvSBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YujFqI1i2U-sAYFqgp2Lmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_dzHxfLYBE0qT2A92CcAQaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_KfS7JDB3k06YGo1S5puwCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_NF1mOzE5nku6qIeb4j6l4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_0fEP6-_4Uk2cQqZDJ9ix_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_04wyWQKORk-L7RWyITxn_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_sDnT6zVWrUuhi2kasN2_WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Fqn4nOxM00S03kAdCXfsqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_weEzKGUPDUudnECpvmaZ4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_W_ciO9dfwEyGfy9D31WFzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_FCBox10Ye0O87jYJEc-ybw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dFI_S2Cmw0uvW76jwBJ16Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_FK1NoKYDfkC6DWFfd-k4ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_5MUpU_iFQUS9Zerkh9wIMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_aTbJ73vbwU-Xj9MZr0N5Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pFUzP2PhrEGGo1GT6PZxWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kkqXot9cn0WBAMEZIGa-PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_1gt-ZUM87U6djr_4A5S4_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_siXWryuQpU285WNgy45APw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_UjTGHkbY20CN6fqj_cqXNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_e9UvRO3aE0mfSCcsC-dTvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U-GkrbLvEEer06wV3cdFkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_IzrnD5jt5UGo5H0UZZIy6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b6xXIxG3uUumtk0da2OG_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vv13STm1FEiXvwnu0lUpEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_H8gaQjdU40-YdEqUm0lstA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bJsWGX3NvUKW3gZlGPknpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_6DVEbvAY4UqBUIIBPTkpNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_8yYtim8BTk2lBe258_oMnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_K8BonSjLn02SgJ1mtQ59Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7N3JOpLANkCpswk4FsO4uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_WRnbeAQqwEefX40snBbQkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_x3Te36hAu0S8PmYz5LK19g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Upra0nCWlkODQtvrYRKqGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_bgO50fNA_kW_vKYNh3YVMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_zYIwEllr5UaT82dnyTwL4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oUGb2yHFvkmftb5K_Hd41w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rB-wUzmla0SlVO0p8Yda1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rhLqZfwsikKgSa9TtspiSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ssnGYhUhj0KL7KcjrJIBKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_qEwfUVZLKEeMlUabO-wb4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2021_To_2_17_2021_SJuIvsv5bUOxBNrdkJQFqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_8C7y4du30EGx7NNV_qKuMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_EyG0dq2VUECJScHNcRo4pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_vtfaP8TfsEyMcbIsM1oBkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_HOk8TyvPSkmZaIMc922oBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_u3-UCxFuAUOj3iNBJvmi2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_rYb5LIKYEU-DUI4F45twMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_Uh0a4pl7bU-2Tnjx_lqtJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_o34DNclg302qjFkTJ9TCVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_96dVppJwckClqojVBy1Ycw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_YBmOU2lAJUOBzWtk50UFrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g52wVaMHREOxVOaAH1rbeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lwt4ua-FPk6WAW-XMj40PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wHGv4XDWOkqx4oPOB_i_5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_eAbAHtoxYkGir02r071VSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_6gBeWpquBkO5DzLdfEEOMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_VZDiVAJYeUq_J3J-EliWwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qMG5qS3iLEyHdybWijdG5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_C5zBNMbhSkObSb6Xa-cZ3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_SkKeGJpZk0ix9VIXIl82bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_OISz_geoOEqDePVi3rhqJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_Rc3FfJee6ka0ZRjX--HI1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_XzqK5SZYk0uC0x8Ph1LJBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_jJGc7jy940K8Qw9jBJ_iPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_iZ27SMRREEmvpe0JdqEXIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_4iW3B1WCqECY6mC8PZcRJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementLifeInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_4ij6hzi0rkmx1gwIssCBgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">plx:ContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_3I09XpnwBUK1eNxQSTeoEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_XwrlUpDhVkulphV17M8Jmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_251HtAiKnEG6Q7qnPV5dYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_wE9yb5vMiUiXD8b4zFAFDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_QVm3W7ty10eUY0pOqxsecQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5BUHKipIbUSYH07fhT7fxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3ifThMNCrkuKLL1kdLaJ9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_BZLsajDjiEe6-0mciWg6Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_sNa-abEf9kq7MgbpeppqKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_YD_U8HfQWUOjf8ZrXymgNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_57ZK5w5WGUyALypMdLvZ_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_a9FL0cjM4UWj0kWAe34-9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_2IMzGamN40K0qlSWNrY3Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WlO3JuHosU66SIYEqogVsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_CON_DW57J06LCucDdq1I-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_iAqmHavoc0y6aGWMensHBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rTPd6I7xUkGiNNPDC-sQZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u1l6Q7eIvEKTQP9MPBmN9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_RSywV91c8EyVXNBMXvKebA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dFp5G0LNJUya7KtQK3pNQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2023_tpab9C7-pEeEaYxfCF7NUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_24_2023_JDfUxPdHikKEo3CybT518w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_D3oeVDNTUUiUr-_FfN-zLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1Yw2nKGMb0-CWAUOtRv76w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-07</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_BND5mOCuk0aUwO4j88CGJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_eCN7L55gSkWPyF5sZKKtCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_p8gLt_bw0EKb2iCn7NXpJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_sxPvfKZ4_E6nZxOZsSDnVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_A6SB-KSPHUOpgmPJyNMoXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_3JYAY1fui0OUhP6pQk-C8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5Lw9SAW0v0e805cbfkLdFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Pg3HBbrQE0O-vf2piO-deg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_4cbqNYW9bkqJeKPztiOARQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_VhZ8eBzgxUiYQec9RnyolA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7jCMuUnJUkiYu615rQJzSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_nUUou62YI0uMyf3Ceo-SDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Wq2H6c6tw0WzLJeQe0xOnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_pPMvRU8ZMk2uuux3HO2TYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_G-5RnTikyEe9kMD0HS9VgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_b5QnVZ12wk6qJy-jCttpIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_sjRoIJCFyUScH2Tf8mBsdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_fA3_XWjL2kiVo9BcdeEmJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_PfizerMember_p6MbltwMMEWI2aMxFJC3uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_rEiciTruOUm2wOSIAx_19Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_ChiesiMember_JefjA3XnO0-mFmgSL6r5WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I7HBPUkpYkG4hv_N2994ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nJOVwAxjsk22aPDfa4pnSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_XwwI97cnr0imfvHx08Av8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y7utRnms1UOqtqZVB3Km0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_46WI__Tnm0OEDK5uErsfzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZMEMUOBNoUyTMPRQ3bJFUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_GvuRJaXm1UWlbfDR82Bxug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_4-jgrc8-u0GNmkLJxYHkRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_QWELD20hJUCp7BaaLVXfkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_nqKCRd69hEOEP6D4HvRrJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuM681TIWk-KXTzBvFq0cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_w5_kliyzhkCBaXvHO4GYkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_T3JAfM2fWECmvcQSRXd74g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_LrxACSzPi0yrQT4i01lIRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_vr63tArlm0-q0bAYY5jS7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_MJT48I74nkqfkLgGf8DWVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_YYAL7Hdl_U-pTxkWB5nOeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iyt1XR_TI0OMpk9KrJ5mlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_ssAFEpgqrkqUmuHATgmJXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_T8vMq4SkD0iHfguhY8hxzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_MGXDBj87K0SGVdw9QsCN6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_vo-_yyTgdUqcdD8bTMOyuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_DxZ7yiKloEeYPqjWugRpiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_KSEwWosZJU6bgW9NBu3j-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="As_Of_3_21_2023_MSmaAEySeUOElBXVq6cGkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-03-21</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_p6jVivnBs0mBGLiQhyt5oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0jdO8xpKLUGP05OvtmHFoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_wxdHXaWGJUe-pHkKaGr9qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_IoUaetkJx0G8wYJ_o32Cpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I6KOw7CYo0-cs1kRCGYA5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7tsfGy4RVUWLVfK_0YWXpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-25</startDate>
            <endDate>2021-08-25</endDate>
        </period>
    </context>
    <context id="As_Of_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CPzVDrt_wUy8VbkR5mm3YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-29</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_yi4pzduSA0iPeEkKzhrW3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_BusinessDevelopmentConsultantMember_yVKHJHqyLk-Kh4whSboFgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:BusinessDevelopmentConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ymHVK27wsk-xnzEuafVJJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_U62DmPC_4E27mSZiUh7v1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YTSB_ILxnkmbVEy0yW3LuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_eJ-H8KcFkESIM5aPrjQhMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5MEdadDSM0SF5R2b_ZDHTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_pZvuo2NuB0adTw1Fuq0XEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2024_JH8KKO0890u2Q8I5mpLHzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_5yXfmzhLaEC9tEJVIkFchA">
        <measure>plx:Y</measure>
    </unit>
    <unit id="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Vote_hWE00M5FlEez7fUfIQ-eZg">
        <measure>plx:Vote</measure>
    </unit>
    <unit id="Unit_Standard_EUR_hZumu6sr7UyT0mvTxrhElw">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q">
        <measure>plx:D</measure>
    </unit>
    <unit id="Unit_Standard_employee_EpjUeGM08kCkStcWvhYgyg">
        <measure>plx:employee</measure>
    </unit>
    <unit id="Unit_Standard_agreement_LtAR6Q5w6kqJ8CT_46DuZA">
        <measure>plx:agreement</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      id="Hidden_OpKEeYznFEKbgT9Kjt0XEg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      id="Hidden_V_gQmWVwdkeibqOYS8aNww"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_7GU4zUGp-kq0GCi9ny_hRQ_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_z-cwl7ehlk6oy6m3dNTBiw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_InmwRDTt_UK6YEzUdHKfjw_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_qMskS9TJVE-lOo17bm2ryg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_lMaB9GvyH0OSPDZ8tyRe7Q_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="INF"
      id="Hidden_ZD3tFDQGbkK4hFZHJfpYSQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">72952124</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_KfS7JDB3k06YGo1S5puwCg"
      id="Hidden_8ZPqFDiPQU29lutivXBeTw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_RW89Mir6n0mz11Dd4IZuvA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_wZFXYU2HdkGUrSURuz6zgg_1_1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_cZc0ntATQE2obdGSt6QRPQ">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc__M7dixhhn0eSTFYiAfCH1Q_1_1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_yeB201uaQEeY7WQyY7VrpA">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_kObjhsCvhEeycWMReGnKbg">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_tEJRTPcEN0OFV2q3F6zq2A_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_nBbbX1AK_UC7SVzWzSb_iQ_1_1">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_Fm8BwX3TG0ieljEHFl9zKA">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_qiYduSWNeUyBg7BZwwvSog">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_uLBjY25G70m_7S08M1nARA">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_zvfoPaEzOkuUclz6JeLFqQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_vrnSGa0HXEO8KCHNA0BbgQ_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_L-ZiQLDr00Cm7s5neiVLIg">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_AWJoKHRmOUeAkE4bvB-Qmw">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_xdX5xLUVOEqyWDw7wDLKAg_1_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_mkEn8JqG_0y5r4he0xf8wQ_1_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_yQurpyev0ECM0g9bh0CNQg_1_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_GlCR980F1USaljEfYxRD9Q">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_Ciaiug8xNU-O6it0Aae_Hg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_i4OrfMutNkuNB0x61mjcgQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_kpxX3q234kK2nS64laq8_A">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_2dCLZK4vs0yN6DtXDuzR2g_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_GzpjK7eMREm-_MnhhV3TiQ_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tc_r1nWpqRsU0Ki94ClOluOww_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_ILk5fn1Ssky9axt5s7NObw">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_WcPMnVeDHk6kPRHBQB80Ow">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_2BIxCQhv8E27zx0aYh_fKg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_pZvuo2NuB0adTw1Fuq0XEQ"
      decimals="-5"
      id="Narr_wynfjtxW1kSShqmB4kd1tQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">139300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_1_2024_JH8KKO0890u2Q8I5mpLHzw"
      decimals="INF"
      id="Narr_oJcZgTII9UuHSmssmyTVwQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">73052124</dei:EntityCommonStockSharesOutstanding>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw"
      id="Narr_TH-BZEUGP0WfNBvwAsmrCw">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw"
      id="Narr_uvRHJm2sxUiMHiu3LmsYsw">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw"
      id="Narr_fyBjZeIOs02gLGSQMTu21A">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_tshp1KKPXU-F1I4HpKqkmw"
      id="Narr_L6TnwudySkKrbRyMwI6-TA">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_hlyt3h80ZE2Bbrkhf7MJXw">Kesselman &amp; Kesselman C.P.A.s</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_LcnJt_NW0E6KA-YqtkhfEA">1309</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_50e5qw0QxEeYkqbDP_11Pw">Tel Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_q49gzeqGK0O5FjktSFC1dA_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">17111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_pFPGFnt4Gk2rKpzviRLUAA_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">23634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_72ugtLFAr0CHHRyebVtBFQ_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5069000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_GhRzHjROz0OMul04IbySxA_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20926000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_qaVS3kHj3EeJbDej33qG9g_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4586000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_Snt5KqlRaUqYSm9_xZjDWQ_8_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5272000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_9KeQegjOz0OZC6MA0bHJ-w_9_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1310000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_kIerSTXolE6K8miZ5fUy3w_9_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1055000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_6mX66HAdxkiFsd4tvkGsOw_10_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">16804000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_m5rSpbvHO0KHIglbVwAGCw_10_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">19045000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_b5mLGHRws0SprrO9FpaxOQ_11_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">44880000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_T2nsUt4kMUSFYb-LflXyug_11_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">69932000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_rLa4ANs9k0uItbWCVrhIqg_14_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1267000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_cKPLDllzzEKQRhXHOND9WA_14_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">528000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_3YMhKPpgrE-KVG1iSjxdgw_15_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4553000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_IvPvmSYxwEGy2lcGNQdhAQ_15_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4973000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_bkIzO9dHSEiQ18GoCG2z8A_16_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_TWc9SfEI90e4gzahxgjiDQ_16_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3092000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_kZgG5Cm6aU-FI762V1dLnA_17_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5087000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_XIOp-RFE50qVVhYx2SgzPg_17_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5909000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_W0bMfqQ0LEidCIcCJUQiWg_18_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">55787000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_kWQzZD5ybUakBGs34CKFUg_18_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">84434000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_OK3CrqJ4NEWHOGq65yWmrA_24_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5862000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_dslWAzPR7UG7IZss7C5bCA_24_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4320000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_n56fpBfE1E6qXe-QBye06A_25_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12271000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_9EHJB1_Z0UKUj0CH4vIKlg_25_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">19550000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_ltVnwc-ifkyl00yLsHPzxw_26_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1118000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_PBlaaujPvEmoGYdyR_D-_A_26_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_dtkROJP5qkWqESJVtjRMzA_27_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">13178000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_7kMZA7ok4UOtkAxy_vhe8w_27_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_Yzg5jTEWIEKvIsWv5eN6aA_28_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_HHrszWRb7kqTO5bPgKHilQ_28_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20251000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_jmQtEEbIZk-EFwxMwgVL2g_29_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">32429000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_HF_90uIOOUayGucWU_D3Jg_29_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">45530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_RB4n09pCW0iWsYkmSpStYg_32_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">28187000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_vK817CtsD0WCgg8PH88prQ_33_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1642000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_UFV0fVUqek-Jf9Hj-tA5Hg_33_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">714000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_6gQOsNwQs0iOLBjhQ2twgQ_34_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4169000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_WZ7iT8ZaAkWZHrRouDiZfw_34_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4621000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_If5783zBeE6c8eBIUXOlNQ_35_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">33998000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_wakzPLQo9E2t7dcEmcWtpw_35_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5335000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_D2nbKE17y0-LWH3jnqaABw_36_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">66427000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_PB1YXHJsJ0SAdgdhaS3ZTw_36_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">50865000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="INF"
      id="Narr_bYYdiibN70uzg36UM7SkXw"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="INF"
      id="Narr_WQHkdTz9AUaHsd57kSzdSA"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="INF"
      id="Narr_n09SUmSHSEiktNnj8ZrZyg"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="INF"
      id="Narr_hCr8RApTDkmRbnwlLmqu8A"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="INF"
      id="Narr_fJ9n0gEPhkqNmiHLfLz7jg"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">53790167</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="INF"
      id="Narr_2BfQEEee4kWBKr2wR7JIEw"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">53790167</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="INF"
      id="Narr_SnPXNyymVUaea58yv_zy7w"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">72952124</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc__wPNbYGTGkm5xinTgjwf-w_41_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">54000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_lUkGLp-IaU6U5PRigNpHjg_41_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">73000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_N56Q2p2fv0uYb3bupdeaMA_42_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">379167000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_ogub93uaYUKQOmY3MDdoyA_42_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">415045000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc__vg1UsrOjU6GTkUtVWppQg_43_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-389861000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_XmKPaVQcZEGiPVE0Q4GQYA_43_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-381549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_wXLi9zP9R02hMRNNj7k2Ag_44_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-10640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_LW3p33l9OkiLQ2Mo4QZM8Q_44_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">33569000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_EygM5mDSNEmqLDwE9RJxPA_45_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">55787000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_l_1oQIRn3EWQZyWVLUR1xw_45_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">84434000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_e9UvRO3aE0mfSCcsC-dTvw"
      decimals="-3"
      id="Tc_UG2R-60XS0SamY2MZRCswg_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">16749000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pFUzP2PhrEGGo1GT6PZxWA"
      decimals="-3"
      id="Tc_vOFu_E2lb0GG7u52cOfmOA_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25292000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_FCBox10Ye0O87jYJEc-ybw"
      decimals="-3"
      id="Tc_VkXFDycEPkm0b3RbDyIBlw_3_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">40418000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U-GkrbLvEEer06wV3cdFkg"
      decimals="-3"
      id="Tc_E6UksxQseUSgfR5H8OuEBg_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">21601000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kkqXot9cn0WBAMEZIGa-PA"
      decimals="-3"
      id="Tc_MU2jKI4FXkizv3yraCrloQ_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">22346000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dFI_S2Cmw0uvW76jwBJ16Q"
      decimals="-3"
      id="Tc_PZdVXxEcd0KF7Mb4mgMIFQ_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25076000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_Pk1PMu19i0eW0d48qPUH4Q_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">38350000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_T0RV4XNHjka3_xEYrfnhjw_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">47638000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_WeY_HuK4U0qN1gj4qbJ_AA_5_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">65494000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_HY_MbTu-4UiFeSfqE0nPDA_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">16349000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_-KocpYjgRE68DXrOis1P_A_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">19592000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_RtaUL6bSRES0h_pxI_10dg_6_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">22982000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_YzaofdZO6E2ts3XOMpeN5w_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">29734000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_OSSOcNX1xkKRZdtWCjH-Mw_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">29349000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_6_VZ_Srf-U2sNRfQO_g1oA_7_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">17093000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_TAs4W1GKD0y3s2qVWOLQHg_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12729000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_cXlmawtNtkCiznLyXies2Q_8_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">11711000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_Fed9sG24K0WlR0PlSRDB9w_8_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">14959000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_oVs835IK6kSznOOis22qjw_9_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-20462000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_3vmdtpXUy0ejWe5VbNn_EA_9_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-13014000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_petFMnp9-E-muzgK3rYDqw_9_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">10460000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_rdfzslNnuUew-rNeJ_qL_g_10_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7521000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_YVDXnQ5iKE-sa7GNVuDW8g_10_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2529000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_V25A-aPl7UKs9afWsTZSAQ_10_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3180000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_6SoGhbOqrUiNtNGvjsNbfA_11_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">401000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_OsZQBWmlpU-4wSfvaQEq6Q_11_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1146000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_aWVpI_kGcUqVa7AreNnZVg_11_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1286000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_1lID2xxGCkOFklZAbm57Eg_12_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-7120000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_cMRHXpw54E60_WucdyMBpQ_12_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-1383000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_VfZa1bKsmUOtzue-9-hOTQ_12_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-1894000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_rtHUUDinMUyMB-6DCd_MBw_13_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-27582000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_g-i6lzK30kyUuac3_GS3iQ_13_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-14397000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_foq0wYcW4kC74z60PjbWnA_13_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8566000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_zkOWid5cakeiYzSw8YgqIA_14_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">530000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_EUsON-Dt7k-4x-kEtPcHDQ_14_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_x44xDYQ9BkWUCRmCdRCFPw_15_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-27582000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_HkY9qvFGrkCt0MvvJgMY_A_15_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_QsHPeCe79keI8oh8OMyU7A_15_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="2"
      id="Tc_xYK1TTuEIkWb_UOx4_mLqw_17_3"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="2"
      id="Tc_N6EGOMFR6UKD410PpD054g_17_6"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="2"
      id="Tc_uZ4IZuxI2EuZFGuJ2kHNAw_17_9"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="2"
      id="Tc_PAWpkSJTLkGLRoX0Id9mGg_18_3"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="2"
      id="Tc_P05jJ_xwOUq0v0_TCkay4w_18_6"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="2"
      id="Tc_4S31_1WDhU6KTyGiDJmh2w_18_9"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="0"
      id="Tc_EE_G11nO6kGxVoyOEveaxg_21_3"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">44140233</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="0"
      id="Tc_j-3qtDqTbEioD4ED6JDsyw_21_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">48472159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="0"
      id="Tc_ghdyGybk30WOaP5nwZCUIg_21_9"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">67512527</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="0"
      id="Tc_xbyN3NnMJ0ejWc6oheW_2g_22_3"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">44140233</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="0"
      id="Tc_w0U01BaJPUyyePrwroQt0Q_22_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">48472159</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="0"
      id="Tc_LUUzmyflhku3lW0H5gYkMA_22_9"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">82424016</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A-V99KoI40mufi3_2xy4zw"
      decimals="INF"
      id="Tc_Siq3R7Cg2kWg_zHkx0172w_6_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">34765280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A-V99KoI40mufi3_2xy4zw"
      decimals="-3"
      id="Tc_MvsWgzFONkaUtP7BBN2bvw_6_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SjXBySsIy0OVSVIytRlcHw"
      decimals="-3"
      id="Tc_808SkuSHgkyYP1PVHzkWnQ_6_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">320280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HElXUIExK0aOC5Db-v7aeQ"
      decimals="-3"
      id="Tc_eaR79NyFmk6AdvHKqyDC5Q_6_11"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-347352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_BND5mOCuk0aUwO4j88CGJQ"
      decimals="-3"
      id="Tc_E92tazfp4EKsdXcagVKJdA_6_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA"
      decimals="INF"
      id="Tc_B9HJLzKAFEqpYEA5azS5YQ_8_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA"
      decimals="-3"
      id="Tc_RKjNCcdEzkqrww5siIdOig_8_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw"
      decimals="-3"
      id="Tc_feqLpnyYYkSsjXNG4wI23w_8_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">37616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_258b9NGb0kWpOaekWwJXEQ_8_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">37625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA"
      decimals="INF"
      id="Tc_ErAzTp23IkqYtvEBPmAw5w_9_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA"
      decimals="-3"
      id="Tc_G_0LRjNLOEube9ElzdHWPg_9_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw"
      decimals="-3"
      id="Tc_GUPIfgvg5EqbtDH9i5mRXg_9_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8573000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_vhCpFDPBR0C5XdthwHMqrw_9_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8575000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw"
      decimals="-3"
      id="Tc_6FSgDqLukEuzzXE_HR8U2Q_10_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_kCqOKHB-8UiliO3dMPSMRw_10_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw"
      decimals="-3"
      id="Tc_HYmuYPEeokue3TMpO1FWkg_11_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">970000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_lOYA-yc630CWnLPoO8NfUA_11_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">970000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gkYoLAKpdkmmcOoBumAiMA"
      decimals="INF"
      id="Tc_ypYDFuFFcU6a-jOPOxek6w_12_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">173816</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw"
      decimals="-3"
      id="Tc_wIOx9zu4AUOeoqHUxhAKIQ_13_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_N9gOJDEVzUWvM5Y18tfXug_13_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PYwLveBFtUWoWCrVvs7ruw"
      decimals="-3"
      id="Tc_dHaLqy0V_E2oLSek0zYdOA_14_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_cdEU4VmUeUqc_cSbrTDmwQ_14_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wHGv4XDWOkqx4oPOB_i_5Q"
      decimals="-3"
      id="Tc_unr5OnCiL0CzvHriqf8i7A_15_11"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-27582000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_-SYHyIoCv0OzwCFvavC-zA_15_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-27582000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oMdnHc9qbkOrXZVbmGVf1g"
      decimals="INF"
      id="Tc_oSLNmfMplEW54il1kYYgjw_16_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oMdnHc9qbkOrXZVbmGVf1g"
      decimals="-3"
      id="Tc_G9cMsNAjS0-Uo5v0D9KA8A_16_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eyEfL7MvJkeQsA4M6v4ywA"
      decimals="-3"
      id="Tc_mrk07nva4kyxJLhMRGvEuA_16_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1TbW1rn7nUeqCRQw6xQlRg"
      decimals="-3"
      id="Tc_b122YKRmR02MrXr8XbxAzQ_16_11"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew"
      decimals="-3"
      id="Tc_oeP4eajvLkyMfhkfX6PSfg_16_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-6036000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw"
      decimals="INF"
      id="Tc__hlQve8LrUWcRBUkOb3OAQ_18_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">7473038</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw"
      decimals="-3"
      id="Tc_HmWJrPylTUmQDhLBx-7LFw_18_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw"
      decimals="-3"
      id="Tc_BqD0u1UjUkWbJyMdJGhWeQ_18_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8229000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_RTPbgbLukUqALvdBU1Ph5w_18_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8236000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw"
      decimals="-3"
      id="Tc_K_Yc9brrGk2br1Cnt_3IWA_19_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1124000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_poFLyFjUc0GCShIlPbrz3g_19_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1124000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw"
      decimals="INF"
      id="Tc_L7Db03TlqU6NrmpC8NOBLw_20_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">759482</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw"
      decimals="-3"
      id="Tc_5rTnCdNTF06dAvJX_a1reQ_20_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw"
      decimals="-3"
      id="Tc_PfOgX0Ch6EKrCfbmjU8fyw_20_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">960000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_mVC92w6ZvEChHhY4oKUOZA_20_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">961000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xcyEudOCH0yUrueqYcS8sw"
      decimals="INF"
      id="Tc_7xNc5QlkI0yuS_cK3n3knQ_21_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pKbk14Eyp0CnmmX2dWNNiw"
      decimals="-3"
      id="Tc_SSPA3i4YrUi_7GHZ57ujpg_21_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_ibSaugyYx0CzSYUSB_DrPw_21_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lwt4ua-FPk6WAW-XMj40PQ"
      decimals="-3"
      id="Tc_1ERbTWtiqEuAQNyMn81ASQ_22_11"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_Dlw-IHZQJUGySEWJkktI1Q_22_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2lHvWBXaM0q4Oy29CWa4tg"
      decimals="INF"
      id="Tc_SBKG5QlufkGdNav4Fb_TDw_23_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">53790167</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2lHvWBXaM0q4Oy29CWa4tg"
      decimals="-3"
      id="Tc_fOZsFTNZV0-E0KhGtdjbWg_23_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sJB3yn3mr0CwfBJ5isgHEg"
      decimals="-3"
      id="Tc__CPwv3sRGEC12pjTmn2I6Q_23_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">379167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U3XBnkC7qEm6XPK7cp3CoA"
      decimals="-3"
      id="Tc_tGyrPyLYPUiiKpcU_BkBPg_23_11"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-389861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_KiZF6nO2nkK_Y5zNmp743g_23_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-10640000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg"
      decimals="INF"
      id="Tc_wM_5DhZHUkKHZqXHOHKL9g_25_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">12560150</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg"
      decimals="-3"
      id="Tc__spr-aLYE02gUtAsTSewNA_25_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">13000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A"
      decimals="-3"
      id="Tc_k5UeE1XEDEmXGp20BQo_vA_25_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">23941000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_5BUfner2-0K1dmIr1eGIAA_25_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">23954000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg"
      decimals="INF"
      id="Tc_WC3DUsDCGkGoRYE5-yfkiw_26_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">4691623</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg"
      decimals="-3"
      id="Tc_67frxxz9XkSbqSPc9NMEfA_26_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A"
      decimals="-3"
      id="Tc_P9mGnglqWUyJSzDWa8c0hA_26_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7778000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_C_N2FljD40y_1BAQzc6eVw_26_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7783000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A"
      decimals="-3"
      id="Tc_sZISLQ52SUa-6y0MLKQK0Q_27_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1928000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_Swei3YATU0eyRwP3uDLVog_27_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1928000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg"
      decimals="INF"
      id="Tc_2vD8jFUumEeI_JiIxot13Q_28_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1371362</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg"
      decimals="-3"
      id="Tc_rxTCEKUT_kOvksjyrknD-g_28_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A"
      decimals="-3"
      id="Tc_DjoTTyCvI0a6SmioP7jT5Q_28_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1519000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_TPVn2qUUHUG7XeyezbrHeA_28_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1520000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lPXBeNf7WkWSAAadbPCumg"
      decimals="INF"
      id="Tc_pS_y4QLWTEehvhraowGWqg_29_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">538822</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GTPFq98qfUKV8Cb-hSto9A"
      decimals="-3"
      id="Tc_5KEWruJZAkmbFtHO1dxz7Q_29_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_i9EydllffUCt_QXPih6ZLg_29_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g52wVaMHREOxVOaAH1rbeg"
      decimals="-3"
      id="Tc_tChM0AtPA0u747ue2orBlg_30_11"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_-LxyhEYMyEWZb3XJSa4AyQ_30_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EvqBctZ660eMWfEw45p_Nw"
      decimals="INF"
      id="Tc_-XaJsyfjOkyeqDQOxI8wjA_31_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">72952124</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EvqBctZ660eMWfEw45p_Nw"
      decimals="-3"
      id="Tc_Hp1V9Oj-FUKRFgvpQLxnhA_31_5"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whY022XGs0KlMAyNJFGWMw"
      decimals="-3"
      id="Tc_WSVt1Q9eNkaE1gKKsGLV0w_31_8"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">415045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KoWXKKVDCUWPZuUT1WTDdw"
      decimals="-3"
      id="Tc_Dxdd3tqJnU6Uq2RSonnlRg_31_11"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-381549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_82DfQ5dpa0SFRZSu_T7bCw_31_14"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">33569000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_95wCu9vpa0WZYQK7VcsQwA_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-27582000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_eRxIqCBNME66IJ3OWxiOQw_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-14927000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_aQYvlqET0UqUxJjN99ghYQ_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8312000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_4F7lTH95VkWy9AWMOTncrg_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2375000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_T7cSWygUZUOkwkjz23MmjA_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2085000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_gou0Jb1Y_kCQZXe8dJZyNg_6_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3448000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_sGUZl2E0MUOHESvkmXcGcA_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1118000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_WwInbjqxfEW7b59FKLaEPQ_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1086000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_a5qak1I-FU2IcHktH-lT5Q_7_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1191000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc__5ZtPkMCFkyc0KKgogLApw_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-417000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc__3x-3o2f30SbSxAW6TpATQ_8_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">989000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_3N2ZJOVsokmupXNWvbavVw_8_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">446000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_C8NCG77X5EmFaQjK4L-4CA_9_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">133000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_tzONKoOUBkeHvVtfQVCjDQ_9_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-543000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_8pgfF4x1ZkGnkFFOb4XLnw_9_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_KyPymxMtcEGl9JWbvh80ig_10_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc__XZqqXM_jUOZ0uQBjhXdgw_10_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_lrQGkVWZ_0uAnWjs36RdaA_10_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-3092000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_lmr6__ixbEqjhjAVcA8YVg_11_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">100000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_ZXot4GK_Q0mrrU0K3B6-rA_11_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-3000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_VDBk__Z4rEC9nlffoxnJAQ_11_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">50000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_1LESkGWb_ky_oYVeWMvrJw_12_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_DdoXJmt6hUqfTB_e2jXhnA_12_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_43LNace9kUGdGiR_nwM2HQ_12_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-9000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_ZAmnW2PwMUeQTlFty_IlSA_13_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-831000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_PMQ445bCxEak-d8uNJk2Nw_13_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_a5GseVbnQkSzdMJsQVjOhA_13_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_zaKLeqe4t0S0nl4uoITSDg_14_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</plx:GainLossOnDebtConversion>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_f2Aix5xEEE-HJe38DsN5Gw_14_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</plx:GainLossOnDebtConversion>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_Jgmxr2BUf0ymviguvE3IxA_14_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">421000</plx:GainLossOnDebtConversion>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_MDizW4xrvEWuDQrpBUelTw_15_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2673000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_9M0knonN0kS9I7d5FuGu0g_15_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">300000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_iWjBXZ7z_E2b-B15OBToIw_15_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">267000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_0HbxYczHREmI-EWOrny1gA_17_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">13230000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_GlzLaLICiUmQ78G2G8AxeQ_17_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-7162000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_DRY-H6sZ2EiwHUZkftdaVg_17_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-13178000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_hVXuHLYXcUaY2Pou4v_Xcg_18_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1032000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_gAPPfaZ9BUS0PLFiPREdWg_18_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1194000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_s8jibFZ-1kO1Ok0nHUeLMA_18_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">428000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_WVnMyKSSbkK7q-E1YorwHg_19_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-241000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_KpOmv5km5k-pXejbZpiGkA_19_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_nGqwC5bhlkyiYQ73EtN4qw_19_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-13000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_lOfbexhjE0mIZ9Gfq6MkLg_20_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4872000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_b65tmB0t40qBA9KJjhn4NA_20_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-1150000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_7ZTlCZgPl0modIZc5ejNgA_20_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2241000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_-Noud9nF6EyK0p_RSaPVWQ_21_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2385000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_569VRVgmcESs0bqM5EG0iQ_21_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-4804000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_5Sjren8fTUuEA4pW-4c1nQ_21_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5295000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_1sQ_jR0TEESzLrESSxYdIQ_22_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-51000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_HZIcoVgBe0u1q6gCe3AuKg_22_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_cX_-bR2vPkKaoGnCSCOMOw_22_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_rHB4ES-z7kq2ymHgZDeGAA_23_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-10285000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_qGncWMrCoEa8A_jO5_wvXw_23_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-25000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_mgmE0gdcBEmhZ8uOEP5MEg_23_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-1318000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_RAYoFVygoE-GhMNlVj_xzg_26_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">37835000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_76_ocKcQr0qxHmkV5Xl0dw_26_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">16000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_oguq8QL7EkKalxZassWaVg_26_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20420000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_Nv1iuI-LoESbcCrjnII93A_27_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">57835000</plx:ProceedsFromSaleOfShortTermDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_jjuCDjPQwU-9zyF_BxR_nQ_27_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">11000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_m_dPL4H5BEOJBAi0bNyrmQ_27_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_8j3FHP7VOUqf4qUqfF0tQQ_28_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1459000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_YdkhwqiTJUWG-2Y3CF9Gxg_28_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">628000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_ZEhoISNXX0CmBjcQGmEfGQ_28_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1149000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_ZmdHegOCJ0eiz-GqvZqsaA_29_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">53000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_2TWTJ5MwJ0q3m1GxU1s28Q_29_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_qaAkgJkxPkab8IYcW0U4HA_29_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_cKwYkzdLA0WKgmksp9EaHQ_30_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-436000</plx:IncreaseDecreaseInRestrictedDeposit>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_wHotxHjx9U2wW9Kc2nL9Jg_30_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</plx:IncreaseDecreaseInRestrictedDeposit>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_oHzGe0SFGUiZUkSH1M2qjA_30_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</plx:IncreaseDecreaseInRestrictedDeposit>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_Ffv8B2um7U-vEO0ZOBKsNw_31_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">109000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_uYuyxESsY0eztKLUJhZ32A_31_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-593000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_NMrJNEiblUepjn3z-ihzOQ_31_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">142000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_7S7OYZnpRE6Vua0O4FQtgA_32_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">18921000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_KN3JVjOiPkS-O2_WjYXuaQ_32_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-5035000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_pt_s0AW3akG8PT2bCRosBg_32_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-16711000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_Ggjn1jg0IUqx1HlbXRAYLQ_35_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">30036000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_uTZ3QDyvvk2qg-pRBSv9ZA_35_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_V7r9vBIZC0W0Mp7DZmnQkg_35_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_AbBUuEYcvk6h2h_4RaUBog_36_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4086000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_P8q01hcyykicMuR46m02Ww_36_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_uN903SMK80qqz_Q2F3xgEw_36_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:RepaymentsOfNotesPayable>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_1C0bYrkoAk68BzGpp0aH-g_37_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">37625000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_rFWiuPundU6KufBs8Ia2QQ_37_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_grxtgq6srk6xUrlWSTWlxA_37_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_r3K2zZt_i02oGVN1FMQ4Ng_38_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_7fzNmfGQh0-0zssrO7eu8A_38_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8236000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_tlbMa6YXokO3r6NP-uFsqA_38_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">23954000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_l5MfmWKUUEGpnAmdv5YIzA_39_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_skutvb-o3UaaV0MQZ6I5vQ_39_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_0jOMdPiCFUuKrb8uE_qbQg_39_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">712000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_csg8KOVg80qTvbk91PtsLQ_40_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12078000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_9BtSGvuxZU2EUpTat2ZQBA_40_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8238000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_VyZIws2L50WR4cP1suD2BA_40_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">24666000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_a33-HWZYH0qb_fzvj7PzNw_41_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">6000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_TbsdKAbkmkWdIY0dqfULsA_41_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-77000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_59V0pVsw9kW7GLIyT8rdlw_41_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-114000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_q1MuxuyJ8Uelj3HdlRAUdA_42_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_fnyKzEmvbUS7pZ0E0MYkTQ_42_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-21874000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_d3RK2iHyX0msecjLyMyQAA_42_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">6523000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_BND5mOCuk0aUwO4j88CGJQ"
      decimals="-3"
      id="Tc_gbFh_rcVaE6O4Tt0DBC1UQ_43_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">18265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew"
      decimals="-3"
      id="Tc_dZG7pqfQIUuuZzCStKrxrg_43_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_QQ2NbeZJF0OHYIM1KxmWxg_43_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew"
      decimals="-3"
      id="Tc_kvwFcu7tBkyVOSA2HbVv_g_44_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_sx0tYXVB0kGvcg578T02wA_44_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_EgCLpXP4X0eaGO9Dj1e2Lg_44_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">23634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_JtjDaGKer0ii_31XiKhYQw_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">94000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_QhnV0tRD1USLvDV6mQSMWA_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">143000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc__pwbiPzQckmVw05Ig5rJdQ_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">614000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_O82578bR7k2YaIwEkXN48Q_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">309000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_hSrrg0H7bEy3p3t4ZP5nMQ_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">794000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_ebdWHzTUwkOkGbXIZoqtoA_5_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1567000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_JxskienXPkam9so0_9uaBg_6_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7783000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_hPZFCinCm06yWfmhVVDodw_7_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">882000</plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_kpzwJW-hI0SEiozIqDZfCg_9_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3410000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_wnqalu3YSkiisYmqJ0qvog_9_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2198000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_Mi7hQM5gtUG-lRbIvcIBcA_9_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2742000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_UfftQyV3REShBKTVAXm35A_10_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">379000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_OVIe-yD42EKrE-v8DCKPMQ_10_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">93000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_kv2S2Ag58kqnm6ZZGBEX3Q_10_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">355000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_Z-Mhe0Wf2EuGM3tMUQ-onQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;General&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain and Switzerland. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the BALANCE study (also referred to as Study PB-102-F20). The FDA review team also concluded that the BALANCE study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the BALANCE study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;21, 2023, the first patient was dosed in the Company&#x2019;s phase&#160;I First-in-Human (&#x201c;FIH&#x201d;) clinical trial of PRX-115. As of December&#160;31, 2023, 56 patients have been dosed in this trial. The Company expects to publish preliminary results of this study during the second quarter of 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of December&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it was entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and, under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#x2019;s business and operations, among others. As of the issuance of these financial statements, the impact of the war has not had a material adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. See also &lt;a href="#_NOTE_10_"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Note 10&lt;/span&gt;&lt;/a&gt; with regards to financial covenants under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;), including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of December&#160;31, 2023, the Company is in compliance with all such covenants. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2023, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to the assessment of sales reserves and valuation allowances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Functional currency&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#x2019;s revenues are derived in dollars. Most of the Company&#x2019;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#x2019;s financing has been provided in dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#x2013; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#x2013; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Accounts Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2023 and 2022, the allowance was negligible.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;No write-off activity and recoveries for the periods presented were recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;g.&#160;&#160;&#160;&#160;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#x201c;moving average&#x201d; basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#x201c;moving average&#x201d; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;h.&#160;&#160;&#160;&#160;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;The Company&#x2019;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;j.&#160;&#160;&#160;&#160;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Deferred income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Uncertainty in income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Tax benefits recognized in the financial statements are those that the Company&#x2019;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#x2019;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;k.&#160;&#160;&#160;&#160;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances. The sales reserve is calculated based on expected sales and the anticipated net average selling price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#x2019;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent the variable consideration is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also &lt;a href="#_k.__"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;revenue from selling products&lt;/span&gt;&lt;/a&gt; above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;3.    Revenue from R&amp;amp;D services&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;l.&#160;&#160;&#160;&#160;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#x2019;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#x2019;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2022, the accounts receivables balance was composed of $2.3&#160;million from Fiocruz, $1.2&#160;million from Chiesi and $1.1&#160;million from Pfizer, and, as of December&#160;31, 2023, the accounts receivables balance was composed of $0.7&#160;million from Chiesi and $4.6&#160;million from Pfizer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;n.&#160;&#160;&#160;&#160;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. &lt;span style="background:#ffffff;"&gt;This option pricing model requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company measures compensation expense for &lt;/span&gt;restricted stock &lt;span style="background:#ffffff;"&gt;based on the market value of the underlying stock at the date of grant&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected to recognize compensation cost for awards to employees, consultants and other service providers with only service conditions that has a graded vesting schedule using the accelerated method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elects to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;o.&#160;&#160;&#160;&#160;Net earnings (loss) per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;p.&#160;&#160;&#160;&#160;Convertible notes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate. The Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. &lt;span style="background:#ffffff;"&gt;The Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2023, a total of $20.42&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;q.&#160;&#160;&#160;&#160;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;r.&#160;&#160;&#160;&#160;New accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures&lt;span style="font-family:'Palatino Linotype';"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_UxspxtlpnUm_EdnJc2f6Eg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;General&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain and Switzerland. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the BALANCE study (also referred to as Study PB-102-F20). The FDA review team also concluded that the BALANCE study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the BALANCE study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;21, 2023, the first patient was dosed in the Company&#x2019;s phase&#160;I First-in-Human (&#x201c;FIH&#x201d;) clinical trial of PRX-115. As of December&#160;31, 2023, 56 patients have been dosed in this trial. The Company expects to publish preliminary results of this study during the second quarter of 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of December&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it was entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and, under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#x2019;s business and operations, among others. As of the issuance of these financial statements, the impact of the war has not had a material adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. See also &lt;a href="#_NOTE_10_"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Note 10&lt;/span&gt;&lt;/a&gt; with regards to financial covenants under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;), including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of December&#160;31, 2023, the Company is in compliance with all such covenants. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2023, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="INF"
      id="Narr_LWv_NqMlb0y9IgNZLUeEnw"
      unitRef="Unit_Standard_agreement_LtAR6Q5w6kqJ8CT_46DuZA">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <plx:NumberOfPatientsDosed
      contextRef="As_Of_3_21_2023_MSmaAEySeUOElBXVq6cGkQ"
      decimals="INF"
      id="Narr_SMJPRW_YKE-HSHFfwMgjNw"
      unitRef="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg">56</plx:NumberOfPatientsDosed>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_GvuRJaXm1UWlbfDR82Bxug"
      decimals="INF"
      id="Narr_rymLbvaTV0Wx93DdPs7JmQ"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_GvuRJaXm1UWlbfDR82Bxug"
      decimals="-5"
      id="Narr_UDLWWERBEk6gJvsipq7NiQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_qEwfUVZLKEeMlUabO-wb4g"
      decimals="INF"
      id="Narr_8dN777WRuE2XArUXg1_RhQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_qEwfUVZLKEeMlUabO-wb4g"
      decimals="-5"
      id="Narr_-z92SYXwfk-6kfNcP094CA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rhLqZfwsikKgSa9TtspiSA"
      decimals="INF"
      id="Narr_zOLmZ1mQc0KKuytLKpC2Rg"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">13980060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rhLqZfwsikKgSa9TtspiSA"
      decimals="-5"
      id="Narr_G1pcM1XtCkqCQbM7_lAJFA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZMEMUOBNoUyTMPRQ3bJFUQ"
      decimals="-5"
      id="Narr_wbZtLlP3GEOU2N4bW_ZuJg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_46WI__Tnm0OEDK5uErsfzw"
      decimals="-5"
      id="Narr_02dDew4pyUiDSAgtQ9g0Kg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">6400000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nJOVwAxjsk22aPDfa4pnSw"
      decimals="-5"
      id="Narr_Gsiy4zdLi0y3j73RTXKfrA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I7HBPUkpYkG4hv_N2994ww"
      decimals="-5"
      id="Narr_JyUaidzjI0ygxEU6UkjrtQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg"
      decimals="-5"
      id="Narr_u0hVMes_Fk-O-7E6nCbldQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg"
      decimals="-5"
      id="Narr_VderCHs1lU2gRP-HOtMv8Q"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug"
      decimals="-5"
      id="Narr_l3R6AAkJA0ig1zk92aYk2w"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug"
      decimals="-5"
      id="Narr_AdVk8XN5Z0qi__ZVIrU9mg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q"
      decimals="-5"
      id="Narr_vaRhyudj7UmLg4_Fy4pUpw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:MilestonePaymentReceived>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_eJ-H8KcFkESIM5aPrjQhMA"
      decimals="-5"
      id="Narr_HTmkvE06wkKWQIZXNKcsGg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_U62DmPC_4E27mSZiUh7v1Q"
      decimals="-5"
      id="Narr_XIu3YQJQ3kKVrvuFJK7xUQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iyt1XR_TI0OMpk9KrJ5mlA"
      decimals="2"
      id="Narr_8ZiDMcsaUk-ibWxHugSF6Q"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_T8vMq4SkD0iHfguhY8hxzw"
      decimals="2"
      id="Narr_V1aPq-pBGkeXoC4Ct4Q2kQ"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_YYAL7Hdl_U-pTxkWB5nOeA"
      decimals="2"
      id="Narr_cYpurM9OE0O6wLD58ADy7A"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_ssAFEpgqrkqUmuHATgmJXA"
      decimals="2"
      id="Narr_tGlgPsV97E6m_Q2p5AzgQw"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:ExtendedTermOfAgreement
      contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_IoUaetkJx0G8wYJ_o32Cpg"
      id="Narr_6SUYl97O1EGO6ENXqEyxeg">P7Y</plx:ExtendedTermOfAgreement>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_ymHVK27wsk-xnzEuafVJJA"
      decimals="2"
      id="Narr_Jl5_8XerL0umGhkLkBscrQ"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="INF"
      id="Narr_RZKa5Eb17Ua164v13No0CA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="-5"
      id="Narr_s2AbEecD8EKVOXsuUH6r_Q"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_5aYgp6xhjEq7eR0hCSo3fQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_V-9CykhbfkigkHsZ6q0BLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to the assessment of sales reserves and valuation allowances.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_RUmdbu_nWEegHpDKT0qTAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Functional currency&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#x2019;s revenues are derived in dollars. Most of the Company&#x2019;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#x2019;s financing has been provided in dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#x2013; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#x2013; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_M15MCHFrckO4RER3qe_VwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_kyp0y_y660KB0dey0opLIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Accounts Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2023 and 2022, the allowance was negligible.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;No write-off activity and recoveries for the periods presented were recognized.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_GU7w6v_JDUKI9E9MTdQsog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;g.&#160;&#160;&#160;&#160;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#x201c;moving average&#x201d; basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#x201c;moving average&#x201d; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_gfsAdOUYBUillW-y4aDX4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;h.&#160;&#160;&#160;&#160;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;The Company&#x2019;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <plx:ScheduleOfUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_DAPg96JLB0i_Z01CBrix1A">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_WRnbeAQqwEefX40snBbQkw"
      id="Tc_F-xjMv4ilkyaYW66GDU_jQ_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_6DVEbvAY4UqBUIIBPTkpNQ"
      id="Narr_ZQuLnitP0Emqo1UOemE4uw">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_8yYtim8BTk2lBe258_oMnQ"
      id="Narr_UNzbR3hvPUOjiVNm0Uo0sw">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_K8BonSjLn02SgJ1mtQ59Tg"
      id="Tc_Osrb5_l0-EWMm0neQsRzow_4_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_HIj85kKDe0y315buijb7BA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_x3Wi4D8qCke7YFcbLa9c8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;j.&#160;&#160;&#160;&#160;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Deferred income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Uncertainty in income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Tax benefits recognized in the financial statements are those that the Company&#x2019;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#x2019;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_TUUcQhHUU06ON-Dyq-mjlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;k.&#160;&#160;&#160;&#160;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances. The sales reserve is calculated based on expected sales and the anticipated net average selling price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#x2019;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent the variable consideration is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also &lt;a href="#_k.__"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;revenue from selling products&lt;/span&gt;&lt;/a&gt; above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;3.    Revenue from R&amp;amp;D services&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YTSB_ILxnkmbVEy0yW3LuQ"
      decimals="INF"
      id="Narr_EffeTNviQkGrPPoDO7Fbig"
      unitRef="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg">2</plx:RevenuePerformanceObligationNumber>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q"
      decimals="-5"
      id="Narr_LDWdrX5vpECwlOi4Zi3N7g"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:MilestonePaymentReceived>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_zrwDgTlTQ0ys9HzvpsHaEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;l.&#160;&#160;&#160;&#160;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_jKwjjNJGlky71p7h8HGtog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#x2019;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#x2019;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2022, the accounts receivables balance was composed of $2.3&#160;million from Fiocruz, $1.2&#160;million from Chiesi and $1.1&#160;million from Pfizer, and, as of December&#160;31, 2023, the accounts receivables balance was composed of $0.7&#160;million from Chiesi and $4.6&#160;million from Pfizer.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_rEiciTruOUm2wOSIAx_19Q"
      decimals="-5"
      id="Narr_M5p6z3OnP0KvYJHWNVMV8A"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_ChiesiMember_JefjA3XnO0-mFmgSL6r5WQ"
      decimals="-5"
      id="Narr_ZmTE5xJb1EOz7zLueUHM1A"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_srt_MajorCustomersAxis_plx_PfizerMember_p6MbltwMMEWI2aMxFJC3uA"
      decimals="-5"
      id="Narr_vrPaapDN5UG7Qa-e_-IGEA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_fA3_XWjL2kiVo9BcdeEmJw"
      decimals="-5"
      id="Narr_fSFO7t6Hn0aRmyVzVyLrBA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_sjRoIJCFyUScH2Tf8mBsdg"
      decimals="-5"
      id="Narr_aRSBjri3hkuu1nzxyn6LIg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_NyWXV6gN_EO4BQi5UrTk7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;n.&#160;&#160;&#160;&#160;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. &lt;span style="background:#ffffff;"&gt;This option pricing model requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company measures compensation expense for &lt;/span&gt;restricted stock &lt;span style="background:#ffffff;"&gt;based on the market value of the underlying stock at the date of grant&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected to recognize compensation cost for awards to employees, consultants and other service providers with only service conditions that has a graded vesting schedule using the accelerated method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elects to account for forfeitures as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_Hh2RJWvLpU68mOioDTBzfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;o.&#160;&#160;&#160;&#160;Net earnings (loss) per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_0bmI9APyLkeSHTtr1OLAZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;p.&#160;&#160;&#160;&#160;Convertible notes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate. The Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. &lt;span style="background:#ffffff;"&gt;The Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2023, a total of $20.42&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_iAqmHavoc0y6aGWMensHBA"
      decimals="INF"
      id="Narr_sG7f897B1keHhZ3HYQQCnQ"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="-4"
      id="Narr_gifN6dtR90erhuxuJJ871A"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20420000</us-gaap:ConvertibleDebt>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_cNQ1D4O7ukaQQMkXZjYndA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;q.&#160;&#160;&#160;&#160;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_8CxHtb8eO0mCh9YXziO6xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;r.&#160;&#160;&#160;&#160;New accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures&lt;span style="font-family:'Palatino Linotype';"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_h5LoHtCFSkC1eRYaLmKkqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer that amended and restated the Pfizer Agreement of November&#160;30, 2009. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix Ltd. also agreed to provide Pfizer with:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;1.&lt;/span&gt;Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;2.&lt;/span&gt;Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Promissory note&#160;&#x2013; as of the date of the amendment, the Company issued to Pfizer a $4.3&#160;million promissory representing the Company&#x2019;s share of accumulated losses incurred under the Collaboration &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Operation. The promissory note was subsequently amended. &lt;span style="background:#ffffff;"&gt;On March&#160;29, 2021, the Company paid approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$4.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million to Pfizer satisfying the promissory note in full. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&lt;/b&gt;&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#x2013; the drug) for the treatment of Fabry disease. Under the terms of the Chiesi Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix&#160;Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#x2019;s requests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The consideration consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Upfront, non-refundable payment of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in development costs, capped at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million per&#160;year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments for additional studies, as may be approved from time to time by Chiesi.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Milestone payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$320.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments as consideration for the supply of the drug. The payment will vary from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;35%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of Chiesi&#x2019;s average selling price of the drug, depending on the amount of annual sales.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;6.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Protalix Ltd. will be the sole manufacturer of the drug.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Chiesi does not have sublicensing rights (except for certain territories).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In July 2018, Protalix Ltd. entered into the Chiesi U.S.&#160;Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi U.S.&#160;Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#x2019;s requests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The consideration consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Upfront, non-refundable payment of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$20.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in development costs, capped at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$7.5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million per&#160;year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments for additional studies, as may be approved from time to time by Chiesi.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Milestone payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$760.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement, which has been reduced to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$735.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments as consideration for the supply of the drug. The payment will vary from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;40%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of Chiesi&#x2019;s average selling price of the drug, depending on the amount of annual sales.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;6.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Protalix will be the sole manufacturer of the drug.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Chiesi does not have sublicensing rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2023, the Company has received, or is entitled to receive, the following payments from Chiesi:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Upfront payments equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$50.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million, in the aggregate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$45.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in consideration for development services performed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$51.3&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million in connection with the performance of extension studies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;Payments equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$30.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;&#160;million in lieu of certain milestone payments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;c.&lt;/b&gt;&#160;&#160;&#160;&#160;On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_YBmOU2lAJUOBzWtk50UFrg"
      decimals="-5"
      id="Narr__p0iPeXevkyVkbBzKMW7dQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4300000</us-gaap:NotesPayableCurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_IzrnD5jt5UGo5H0UZZIy6w"
      decimals="-5"
      id="Narr_0fSf7tzEf0GQD8Uo2OhahQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4000000.0</us-gaap:RepaymentsOfNotesPayable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nJOVwAxjsk22aPDfa4pnSw"
      decimals="-5"
      id="Narr_VQ1phC_WIEakI8paCjSLfw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg"
      decimals="-5"
      id="Narr_6gLCL7YyKEq3e3IUzCBs4g"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg"
      decimals="-5"
      id="Narr_-fgb4Rpmf0-M3dDZ02HBLg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fuOpdHDVA0upJl1sdlKHJg"
      decimals="-5"
      id="Narr_H2NjDL44UEanKbpb_zbiYA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_DxZ7yiKloEeYPqjWugRpiQ"
      decimals="2"
      id="Narr_r91W30XkqEuL7Tsjl81XyA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_KSEwWosZJU6bgW9NBu3j-g"
      decimals="2"
      id="Narr_o4p-yIzf3ECKfAOQPKc3mQ"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I7HBPUkpYkG4hv_N2994ww"
      decimals="-5"
      id="Narr_6MruQVi1dk6TC3NJ6ac82Q"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug"
      decimals="-5"
      id="Narr_4xcbLVQulECOUyroI9ksvg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug"
      decimals="-5"
      id="Narr_ay03uVfs1ki5KYpsnh6X3w"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RE3m0OBQ60654lxYr7aPug"
      decimals="-5"
      id="Narr_zXe4J3RzWEy7_PIPWnWm5A"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5MEdadDSM0SF5R2b_ZDHTQ"
      decimals="-5"
      id="Narr_b0rvJA8TTUOnrIvcX6yPNQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">735000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_MGXDBj87K0SGVdw9QsCN6A"
      decimals="2"
      id="Narr_0jwQoaDcoUCCmd6qfWV_0Q"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_vo-_yyTgdUqcdD8bTMOyuA"
      decimals="2"
      id="Narr_P8en1tOv00yNI9FmDY2gXw"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YTSB_ILxnkmbVEy0yW3LuQ"
      decimals="-5"
      id="Narr_vwQTuYExtEiBk8L-wDnvPA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">50000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:PaymentInConsiderationForDevelopmentServicesPerformed
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q"
      decimals="-5"
      id="Narr_EkeCEqR2tUiLQ4c34GiiXw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">45000000.0</plx:PaymentInConsiderationForDevelopmentServicesPerformed>
    <plx:PaymentsInConnectionWithPerformanceOfAdditionalStudies
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_W5LsnZ6K5kyACOvAvT2l6Q"
      decimals="-5"
      id="Narr_3Cxw0SwWOEy7Wz6J1BZIDQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">51300000</plx:PaymentsInConnectionWithPerformanceOfAdditionalStudies>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YTSB_ILxnkmbVEy0yW3LuQ"
      decimals="-5"
      id="Narr_DfWUwhmcMUG8EyxxeD4zfw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">30000000.0</plx:AgreementAmendmentPaymentReceivable>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_DtF8taYNVkyEfOsql-jezg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&#160;&#160;&#160;&#160;&lt;/b&gt;Composition of property and equipment grouped by major classifications is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less &#x2013; accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,686)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,688)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,973&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&lt;/b&gt;Depreciation in respect of property and equipment totaled approximately $1.1&#160;million, $1.1&#160;million and $1.2&#160;million for the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_QDEcIsGDKkmkMOMkwjPHAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less &#x2013; accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,686)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,688)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,973&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_bgO50fNA_kW_vKYNh3YVMQ"
      decimals="-3"
      id="Tc_wO1wIQ41mEyV6im0wexj2A_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">18495000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_WRnbeAQqwEefX40snBbQkw"
      decimals="-3"
      id="Tc_5XLceBN0_UqpEx42yfB-vw_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">18933000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_zYIwEllr5UaT82dnyTwL4A"
      decimals="-3"
      id="Tc_2CfqxnKa6ESGS-9UXC69HQ_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2823000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_x3Te36hAu0S8PmYz5LK19g"
      decimals="-3"
      id="Tc_OKI5KT2_20ySasODJls_dA_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3084000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Upra0nCWlkODQtvrYRKqGQ"
      decimals="-3"
      id="Tc_0QVEPx98y0S9wUVxcx_8tg_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">16921000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7N3JOpLANkCpswk4FsO4uw"
      decimals="-3"
      id="Tc_HpX9RFzLr0-MxXw4oske1Q_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">17644000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_T45OFyidJE6WPNVXdfYciw_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">38239000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_dWiUsn8mcUWnPlkF4Nx0MA_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">39661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_AOkAdonzhUq2kZUboB-u4g_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">33686000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_VU_xW8FYKUSx8GzQHlCyOg_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">34688000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_V8sBEZ6i2ku4mCVN-W8BHA_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4553000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_nmqaCWq2QkKxXRxsqaySig_8_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4973000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-5"
      id="Narr_HxuLv_aPCUi7bj1pPJSCOg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-5"
      id="Narr_K3spC03B0kyiPZIHgNgVHw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-5"
      id="Narr_XleBXTEaGUmIjfl--H6aAg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1200000</us-gaap:Depreciation>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_6hDYIhl2i0SQFiZZfLbgrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;4&#160;- INVENTORIES&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Inventories at December&#160;31, 2022 and 2023 consisted of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,045&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&lt;/b&gt;During the&#160;years ended December&#160;31, 2021, 2022 and 2023, the Company recorded approximately $0.4&#160;million, $0.04&#160;million and $0.8&#160;million, respectively, for write-down of inventory under cost of goods sold.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_Bgiv7iUPc0qFwWAymmoXLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,045&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_WhC_pGOQsEu1SIzstf94WA_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3508000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_KPvOuapFs0yqZfftdJnn1Q_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4176000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_LEowVWNJY0aiJbh9X-QM0A_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2678000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_FqswLKZLeU2amnp9zXtWRw_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">9055000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_j7H11w3vQkyXEyAV9BMxkA_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">10618000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_C-653G3xrkK6uKHHzKgVfQ_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5814000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_z7K43DAcFkqCWuA6LCWT2g_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">16804000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_8xoat8SLBUWc-6zr_3epeA_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">19045000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-5"
      id="Narr_YCfOUBpgkkK09gHFaDZMtw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">400000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-4"
      id="Narr_LlkYvePKwkqTNs0UmF2xhQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">40000.00</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-5"
      id="Narr_dD2tr5wRnUKVFHrJsWC1aA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">800000</us-gaap:InventoryWriteDown>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_9ZHIvVcmv0WB2WjMunCtIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#x2019;s salary for each&#160;year employed) is recorded on the Company&#x2019;s balance sheets under &#x201c;Liability for employee rights upon retirement.&#x201d; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#x2019;s balance sheets under &#x201c;Funds in respect of employee rights upon retirement.&#x201d; These policies are the Company&#x2019;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2021, 2022 and 2023, the Company deposited approximately $108,000, $96,000 and $142,000, respectively, with insurance companies in connection with its severance payment obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#x2019;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#x2019;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#x201c;Contribution Plans&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The amounts of severance pay expenses were approximately $990,000, $945,000 and $801,000 for each of the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively, of which approximately $857,000, $800,000 and $798,000 in the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively, were in respect of the Contribution Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately $100,000, $(3,000) and $50,000 for the&#160;years ended December&#160;31, 2021, 2022 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company expects to contribute approximately $922,000 in the&#160;year ending December&#160;31, 2024 to insurance companies in connection with its severance liabilities, approximately $888,000 of which will be contributed to one or more Contribution Plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;During the five-year period following December&#160;31, 2023, the Company expects no employee retirement upon normal retirement age. &lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="0"
      id="Narr_wDNemlCHr0C93iBQUUk_mQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">108000</plx:EmployeeSeveranceObligationPayment>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="0"
      id="Narr_sK9ApXKyCEGQQhDilrW-pQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">96000</plx:EmployeeSeveranceObligationPayment>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="0"
      id="Narr_idZIo9DOokS8oUjpuWD9tg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">142000</plx:EmployeeSeveranceObligationPayment>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="0"
      id="Narr_l2-DlpzkmE6qsJET0zkZdg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">990000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="0"
      id="Narr_O5d1-PbskkOR-HUps4AO5Q"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">945000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="0"
      id="Narr_odZikILpOUSQH6GqOvdK_g"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">801000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="0"
      id="Narr_oaev31gps0Oi4zuiw2alNA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">857000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="0"
      id="Narr_JgWIhvLVh0KVS3JEfyzVww"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="0"
      id="Narr_RFT25Tjv6UygiolwQsSTBw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">798000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="0"
      id="Narr_6eHVEsogNEONnh31heXxSA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">100000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="0"
      id="Narr_F6rJ-C0uLUiUStXBTASXRw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-3000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="0"
      id="Narr_6miXzD4l6kKYTp5O19Fj0w"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">50000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="As_Of_12_31_2023_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_4iW3B1WCqECY6mC8PZcRJA"
      decimals="0"
      id="Narr_AUJIqN7QOEy2PTo2b2AFHg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">922000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="As_Of_12_31_2023_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_4ij6hzi0rkmx1gwIssCBgw"
      decimals="0"
      id="Narr_DIduN_r7G06kJlk0mKEzhA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">888000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="INF"
      id="Narr_nLdhOeGkdkGWTZZS_VBfzw"
      unitRef="Unit_Standard_employee_EpjUeGM08kCkStcWvhYgyg">0</plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_HLvMCYTwrEyk15yOswtzEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;6&#160;- COMMITMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;Royalty Commitments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is obligated to pay royalties to the National Authority for Technological Innovation (&#x201c;NATI&#x201d;) on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under the terms of the applicable funding arrangements, royalties of 3% to 6% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on LIBOR (from January 2024 the annual rate is based on SOFR). In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will, subject to certain exceptions, be required to pay an increased total amount of royalties, depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $1.2&#160;million, $1.2&#160;million and $1.9&#160;million during the years ended December&#160;31, 2021, 2022 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;At December&#160;31, 2022 and 2023, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $37.4&#160;million and $35.5&#160;million, respectively (without interest, assuming 100% of the funds are payable).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Subcontracting Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2023, total commitments under said agreements were approximately $0.4&#160;million. In addition, we have a $0.1&#160;million commitment payable to a business development consultant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Fill/Finish Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:10pt;"&gt;On August&#160;29, 2022, the Company entered into the F/F&#160;Agreement and the Letter Agreement. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F&#160;Agreement did not change the terms and conditions of the Chiesi Agreements. The F/F&#160;Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement and the term may be extended by mutual agreement for an additional period of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;seven years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; upon mutual written agreement prior to expiration of the initial term. Under the F/F&#160;Agreement, the Company is obligated to pay to Chiesi an amount equal to &lt;/span&gt;&#x20ac;2.5&#160;million in connection with the necessary technology transfer, QA tests and capital expenditures. &lt;span style="font-size:10pt;"&gt;Such amount is to be paid over the term of the F/F agreement based on the actual vials produced by Chiesi thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <plx:RoyaltiesOnSaleOfProducts
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_4-jgrc8-u0GNmkLJxYHkRA"
      decimals="2"
      id="Narr_jQQuAnpCi06TbtQhX0zmRQ"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.03</plx:RoyaltiesOnSaleOfProducts>
    <plx:RoyaltiesOnSaleOfProducts
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_QWELD20hJUCp7BaaLVXfkw"
      decimals="2"
      id="Narr_wysrFf37XEW2UdcD0ysRZg"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.06</plx:RoyaltiesOnSaleOfProducts>
    <plx:PercentageOfRoyaltiesToGrantReceived
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_T3JAfM2fWECmvcQSRXd74g"
      decimals="2"
      id="Narr_qS2Yg0fINUqpGwQDqP5YXA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">1</plx:PercentageOfRoyaltiesToGrantReceived>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_sDnT6zVWrUuhi2kasN2_WQ"
      decimals="-5"
      id="Narr_1QFSBQ50y0aD-scpzWvl4g"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_04wyWQKORk-L7RWyITxn_Q"
      decimals="-5"
      id="Narr_dTjMFZ5BwUC52lWlWjNqlA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_0fEP6-_4Uk2cQqZDJ9ix_A"
      decimals="-5"
      id="Narr_TF5BfYJWPU6XSiij69kNPg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1900000</us-gaap:RoyaltyExpense>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_b5QnVZ12wk6qJy-jCttpIA"
      decimals="-5"
      id="Narr_N30c8K9My0y1jkaOq4-T2Q"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">37400000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_T3JAfM2fWECmvcQSRXd74g"
      decimals="-5"
      id="Narr_ijegiEy7ZEqI4xrLzpLs9w"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">35500000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <plx:CommitmentAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_yi4pzduSA0iPeEkKzhrW3g"
      decimals="-5"
      id="Narr_a5mdBlbxtUCjL7zchyh4aA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">400000</plx:CommitmentAmount>
    <plx:CommitmentAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_BusinessDevelopmentConsultantMember_yVKHJHqyLk-Kh4whSboFgQ"
      decimals="-5"
      id="Narr_kTfQ5SlCLUeAxz7-BKFjDw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">100000</plx:CommitmentAmount>
    <plx:ExtendedTermOfAgreement
      contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_I6KOw7CYo0-cs1kRCGYA5Q"
      id="Narr_Ey7Ns5aLAUKS2TsTypb2AQ">P7Y</plx:ExtendedTermOfAgreement>
    <plx:ContractAmountUnderAgreementPayable
      contextRef="As_Of_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CPzVDrt_wUy8VbkR5mm3YA"
      decimals="-5"
      id="Narr_FsgMTw6VGkuHa4FJfsWkZQ"
      unitRef="Unit_Standard_EUR_hZumu6sr7UyT0mvTxrhElw">2500000</plx:ContractAmountUnderAgreementPayable>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_WsvZhYWkekuIa5kSQX3U6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE 7 - OPERATING LEASES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the option to extend certain of such agreements on one additional occasion for an additional five-year period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by 7.5%-10% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2023, the Company provided bank guarantees of approximately $502,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth data regarding the Company&#x2019;s operating leases for the years ended December&#160;31, 2021, 2022 and 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,057&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_R854Fi7wFk-ocpaT0tq2fQ">true</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="INF"
      id="Narr_GrETHQ4OKE-7aoljSjfzMQ"
      unitRef="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg">1</plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      id="Narr_xcGzYNuB40OYtv5EQulX5A">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_vr63tArlm0-q0bAYY5jS7w"
      decimals="3"
      id="Narr_uS6zxggYQkmvCUoFtnIW3A"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.075</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_MJT48I74nkqfkLgGf8DWVg"
      decimals="2"
      id="Narr_GhJ_pHPa80WNdQut9WDj2g"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.10</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="0"
      id="Narr_ZG9hdjHhokSbaCGlH0B-QA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">502000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_eAbAHtoxYkGir02r071VSQ"
      id="Narr_Q3Vo60fFr0GQfmbXRex_Og">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_R0HmIvTxjkSUP9lWXrA80g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth data regarding the Company&#x2019;s operating leases for the years ended December&#160;31, 2021, 2022 and 2023:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_2o0YSugy_E-qSKRhl4u4yw_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1632000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_l4f8VeNhZkCtTkhnWgCMvw_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1398000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_eClqWCBpw0-nL4TLQW6K5g_3_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1471000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_z30e6hC3fk6bfEpS4fv9Ug_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1391000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_KF5f-18fvUWIS2icVo2oUA_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1404000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_tbm8Djlk3E2bfQkRaRsZTQ_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1484000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew"
      id="Tc_no4NuciM4kyjxzvP1rI9kg_5_3">P8Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      id="Tc_8T1wIucMOk-HoLnQq7GDCw_5_6">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      id="Tc_rTnP8onQbUq7ykWu12Pj0Q_5_9">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew"
      decimals="3"
      id="Tc_4G390CBPDkmGdAAfA51lOA_6_3"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="3"
      id="Tc_muiSQUg5g0KyBcjhKBgbmg_6_6"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="3"
      id="Tc_Xpu2PuKdTUi0YGYsjL4mXg_6_9"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_dYdmgUoJVUW3iB2E_22oRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,057&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_qHz1pMjV40KKK21TCXJTlA_2_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1409000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_HGiF_4SHDESq3REVyPpGJA_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1397000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_9uYu_zc0_EWo_u-7Qu3Ygg_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1125000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_7Sff55Xv10mm0OSQ-guMJg_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1044000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_bz3l-ahmhE6sVnMXpcXa2Q_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4057000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_T0WI3wHXm0qIDVB8trktnA_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">9032000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_s9Y-3eOkhEujGNNSlzq4Jw_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3002000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_iQsJks2XTEuRSRjSlS-_JA_9_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">6030000</us-gaap:OperatingLeaseLiability>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_jWvc7bnivEi-nwOWB3Vxcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE 8 - REVENUE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,076&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;During the year ended December&#160;31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_glPosgLneESIfh65Kq6Nvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,076&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_1gt-ZUM87U6djr_4A5S4_A"
      decimals="-3"
      id="Tc_ohYX3iBi8U64kfcmIA2NQw_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">10160000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_FK1NoKYDfkC6DWFfd-k4ng"
      decimals="-3"
      id="Tc_joNqAfbXRUKLdcQyOOiA1Q_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12403000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Fqn4nOxM00S03kAdCXfsqg"
      decimals="-3"
      id="Tc_tlqfpjKjek279z3Wr4e9Lw_3_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12522000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_UjTGHkbY20CN6fqj_cqXNA"
      decimals="-3"
      id="Tc_gaLJPZfAUEO6n3NR3q2mWw_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">6400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_aTbJ73vbwU-Xj9MZr0N5Rw"
      decimals="-3"
      id="Tc_yWs5Tpq1l0SGAtOxscN6qw_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">9452000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_W_ciO9dfwEyGfy9D31WFzg"
      decimals="-3"
      id="Tc_SQpLKLCkI06x2LIUvgFLcw_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">10401000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_siXWryuQpU285WNgy45APw"
      decimals="-3"
      id="Tc_3FelXP-ONEurNEEt3AmCNA_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">189000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_5MUpU_iFQUS9Zerkh9wIMQ"
      decimals="-3"
      id="Tc_DW1P9EXfE0SXT4FXDSY_vg_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3437000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_weEzKGUPDUudnECpvmaZ4w"
      decimals="-3"
      id="Tc_UITC8ppL4kKCJSlx9eo1lQ_5_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">17495000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_e9UvRO3aE0mfSCcsC-dTvw"
      decimals="-3"
      id="Tc_D-tPJRYjGk2C71tGb_UGbg_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">16749000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_pFUzP2PhrEGGo1GT6PZxWA"
      decimals="-3"
      id="Tc_3h3HZV2zhk2yfWJVWmvyMw_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25292000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_FCBox10Ye0O87jYJEc-ybw"
      decimals="-3"
      id="Tc_2VEkCXA2OE-Xgzw310_p_A_6_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">40418000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U-GkrbLvEEer06wV3cdFkg"
      decimals="-3"
      id="Tc_MLRJnp2aiUWIpy1lDmYQyA_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">21601000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kkqXot9cn0WBAMEZIGa-PA"
      decimals="-3"
      id="Tc_oTaC0-jY0UW_YIactVl3hA_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">22346000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dFI_S2Cmw0uvW76jwBJ16Q"
      decimals="-3"
      id="Tc_H_xgdIxLuU-P4P-k5tTARQ_7_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25076000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_hjMmAQAWa0GgzSXNhgHGIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;9&#160;- SHARE CAPITAL&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;Authorized Capital&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#x201c;Annual Meeting&#x201d;). At the Annual Meeting, the Company&#x2019;s stockholders, among other matters, approved an amendment to the Company&#x2019;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 144,000,000 &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;to 185,000,000. The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;b.&lt;/b&gt;&lt;/span&gt;Rights of the Company&#x2019;s Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s Common Stock is listed on the NYSE American. The Company voluntarily delisted its Common Stock from the Tel Aviv Stock Exchange effective March&#160;22, 2023. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Stock based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to 12,475,171 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;102 and 102A of the Israeli Income Tax Ordinance (the &#x201c;Ordinance&#x201d;). Each option grant made to an Israeli citizen is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#x2019;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Ordinance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2023, 633,409 shares of Common Stock remain available for grant under the Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The vesting period of the outstanding options and restricted shares is generally &lt;span style="-sec-ix-hidden:Hidden_8ZPqFDiPQU29lutivXBeTw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; or four years from the date of grant. The rights of common stock obtained from the exercise of options (once vested) and the restricted stock are identical to those of other common stock of the Company. The contractual term of these options is primarily for ten years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company&#x2019;s management uses the fair value of the Common Stock. &lt;span style="background:#ffffff;"&gt;The fair value of options granted for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Options and restricted stock granted to employees and directors:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A summary of share option plans, and related information, under all of the Company&#x2019;s equity incentive plans for the&#160;year ended December&#160;31, 2023, and the effect of share-based compensation on the statement of operations for the&#160;year ended December&#160;31, 2023, is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;a)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Options granted to employees and directors:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,519,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,700,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited and expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,965,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,900,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;b)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Restricted stock granted to employees:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Restricted Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;291,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1,371,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;489,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non vested at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1,173,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;c)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;The following table summarizes information concerning outstanding and exercisable options as of December&#160;31, 2023:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;end&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.03-$2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,235,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,312,736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.55-$3.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,213,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,070,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$4.69-$5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 441,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 441,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$17.20 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,965,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,900,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 90pt;"&gt;&lt;span style="color:#231f20;"&gt;As of December&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#231f20;"&gt;31, 2023, the aggregate intrinsic value of all the outstanding options and exercisable&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231f20;"&gt;options&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt; was approximately &lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;$2.6&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;&#160;million and &lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;$0.8&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;&#160;million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;d)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The fair value of each option granted during 2021, 2022 and 2023 for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the options&#x2019; fair value on their grant date:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Weighted average grants date fair value (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Exercise price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;e)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The total unrecognized compensation cost of employee stock options at December&#160;31, 2023 is approximately $2.4&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 0.9&#160;years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;"&gt;During the three years ended December&#160;31, 2023, there were no exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;"&gt;&lt;span style="background:#ffffff;"&gt;The total vesting-date value of equity classified restricted stock vested during &lt;/span&gt;the year ended December&#160;31, 2023&lt;span style="background:#ffffff;"&gt; was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million. As of December&#160;31, 2023, the unrecognized compensation cost related to all unvested equity classified restricted stock of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.4&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million is expected to be recognized as an expense over a weighted-average period of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0.8&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;years.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;f)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The following table illustrates the effect of share-based compensation on the statement of operations:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 777&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Private and 144A Offerings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On June&#160;7, 2021, the Company issued 173,816 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 2,816,901 shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;During the year ended December&#160;31, 2022&lt;/span&gt;, the Company issued 1,000 shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $2,360 from such exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;During the year ended December&#160;31, 2023&lt;/span&gt;, the Company issued (i)&#160;301,810 shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $0.7&#160;million from such exercise and (ii)&#160;237,012 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 845,000 shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;During the year ended December&#160;31, 2023&lt;/span&gt;, the Company issued, in the aggregate, 4,691,623 shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during &lt;span style="background:#ffffff;"&gt;the year ended December&#160;31, 2023&lt;/span&gt;, the Company paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $8.3&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;On July&#160;2, 2021, the Company entered into the 2021 Sales Agreement pursuant to which the Company was able to sell, from time to time through the Agent, shares of Common Stock having an aggregate offering price of up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$20.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million. In addition, on &lt;/span&gt;February&#160;27, 2023, the Company entered into the 2023 Sales Agreement pursuant to which the Company may sell, from time to time through the Agent, &lt;span style="background:#ffffff;"&gt;shares of Common Stock having an aggregate offering price of up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$20.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has no obligation to sell any shares of Common Stock under the 2023 Sales Agreement, and may at any time suspend sales under the 2023 Sales Agreement or terminate the 2023 Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to 3.0% of the aggregate gross proceeds from the shares of Common Stock sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the year ended December&#160;31, 2021, but prior to the termination of the BofA Agreement, the Company sold 1,867,552 shares of Common Stock under the BofA Agreement. The Company generated gross proceeds equal to approximately $8.8&#160;million in connection with such sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the year ended December&#160;31, 2022, the Company sold, in the aggregate, 7,473,038 shares of Common Stock under the 2021 Sales Agreement. The Company generated gross proceeds equal to approximately $8.7&#160;million in connection with such sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the year ended December&#160;31, 2023, the Company sold, in the aggregate, 12,560,150 shares of Common Stock under the 2021 Sales Agreement and 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $24.9&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales were completed during the six months ended December&#160;31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Public Offering&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of Common Stock in an underwritten public offering at a price to the public of $4.60 per share for gross proceeds of approximately $40.2&#160;million before deducting the underwriting discount and estimated expenses of the offering. The above included the exercise of the underwriters&#x2019; over-allotment option to purchase 1,141,304 shares of Common Stock. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_7_24_2023_JDfUxPdHikKEo3CybT518w"
      decimals="INF"
      id="Narr_ItnIAx6NAk-2UlWAMXy4IQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_7_25_2023_tpab9C7-pEeEaYxfCF7NUg"
      decimals="INF"
      id="Narr_5QoZ5hHebE--bmifv-PXSA"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">185000000</us-gaap:CommonStockSharesAuthorized>
    <plx:CommonStockNumberOfVotingRights
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="INF"
      id="Narr_qjDc2HlWD0m-wAofITUxPQ"
      unitRef="Unit_Standard_Vote_hWE00M5FlEez7fUfIQ-eZg">1</plx:CommonStockNumberOfVotingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_-Wf9gnqOa0O0OwdXouHwAQ"
      decimals="INF"
      id="Narr_hILnwj56eEWH3eEHiYNEcQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">12475171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="INF"
      id="Narr_W0fXcCgf7024CWrW8-hrTA"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">633409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_NF1mOzE5nku6qIeb4j6l4Q"
      id="Narr_Wr45mzoTbkeKxP0oC-IWvQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_rJLQx2leAEWZ1CL6p85CcA"
      id="Narr_EqlkgXeXd0iyNtX52Y5PQg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_dqYrXP4SpkOoaw0-nNe6mQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,519,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,700,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited and expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,965,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,900,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N8BFMU2rM0W5-sfr4UsdRA"
      decimals="INF"
      id="Tc_3S-RyXYbeku2y4rYk77K8A_6_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">5519315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N8BFMU2rM0W5-sfr4UsdRA"
      decimals="2"
      id="Tc_WR1SDXWuSEGO2COBQ2Hvbg_6_5"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ"
      decimals="INF"
      id="Tc_jzlhgOOeC028ojTsnMltSw_8_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1700410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ"
      decimals="2"
      id="Tc_Yq0FH0gI9ECjVeT0BDfZVQ_8_5"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ"
      decimals="INF"
      id="Tc_xN1gGhTo802GpNgG0zlcLw_9_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">254124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BDToVaFG4EiobI2a0FWCWQ"
      decimals="2"
      id="Tc_v34OipjZs02wPT-8PGBVhQ_9_5"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw"
      decimals="INF"
      id="Tc_XBfOrr3z3U6t-y957Z4LtQ_10_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">6965601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw"
      decimals="2"
      id="Tc_YpuEVrO7gEOuxxBos9xKHw_10_5"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw"
      decimals="INF"
      id="Tc_lJeGRcWdT06YE3B-CE1OYg_11_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">2900503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_b76DQYnj3U2JXZhEkd_Xqw"
      decimals="2"
      id="Tc_lPwKwuPfh0aupHXbSfXGWw_11_5"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">3.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_XHPRXwS7DEeLl0STjI9Viw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Restricted Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;291,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1,371,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;489,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non vested at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1,173,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_YujFqI1i2U-sAYFqgp2Lmw"
      decimals="INF"
      id="Tc_3QBTqyAyuk2HiWYMCPJz8w_3_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">291474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_dzHxfLYBE0qT2A92CcAQaA"
      decimals="INF"
      id="Tc_A0qNh5Tdr0SKLqOGdkVjSw_5_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1371362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_dzHxfLYBE0qT2A92CcAQaA"
      decimals="INF"
      id="Tc_l4T4w-q7NkmlN2j9_b3mNg_6_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">489166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_upSNdbkvUk60NSUBUbvSBA"
      decimals="INF"
      id="Tc_ekCNKWdPSkuiHxOw9XWJzg_7_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1173670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_yLsa1fXpcUGS4WJUQaAoyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;end&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.03-$2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,235,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,312,736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.55-$3.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,213,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,070,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$4.69-$5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 441,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 441,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$17.20 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,965,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,900,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA"
      decimals="2"
      id="Narr_N7xyLTG4j02Wvr_UjM2Dfg"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA"
      decimals="2"
      id="Narr_xoaia1wzFkitLmfnHHa7EA"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">2.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_4fFw3SaWjU-j0D-jbfOafA"
      decimals="INF"
      id="Tc_Ux2Ep-vIkkqZSQ2GnhKH-Q_8_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">5235410</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA"
      id="Tc_dvPBi95db0aaHfp5NYeMbg_8_4">P8Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_4fFw3SaWjU-j0D-jbfOafA"
      decimals="INF"
      id="Tc_y6nvbU5s80m_-vNVX8fpZg_8_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1312736</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.03To2.00Member_L4RnIRjIOEWVtM4HLydZvA"
      id="Tc_Gms3FnZlgkm1nJ0Uon6Tqw_8_8">P8Y5M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g"
      decimals="2"
      id="Narr_GEYEgOgat0CH3B09Gchi7w"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">3.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g"
      decimals="2"
      id="Narr_D6N4cM9I8kaeQiONqL4NMw"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">3.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_1p-co_pHGEWdS066RgFFvQ"
      decimals="INF"
      id="Tc_p5QjEVMT8UKNFUEYEUoMGQ_9_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1213341</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g"
      id="Tc_LS1y6sv2lECS4WbGbWhFxw_9_4">P5Y4M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_1p-co_pHGEWdS066RgFFvQ"
      decimals="INF"
      id="Tc_F7rGJZyhSkKcKUeXi5Llkg_9_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1070917</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55To3.73Member_qY4XmWmICUSWQecoku4U3g"
      id="Tc_H1Fap9n7YU60urhk3sGa0Q_9_8">P5Y2M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw"
      decimals="2"
      id="Narr_fxY4PiC85EGCK17E0tHWHA"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">4.69</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw"
      decimals="2"
      id="Narr_XX4eaby7sUO1x53DokNIdA"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">5.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_LrNNiJqQIkSf1ulC8PfLpw"
      decimals="INF"
      id="Tc_3rVL9mi1xEGhhHg4bzFzTg_10_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">441500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw"
      id="Tc_FLgHxTeRTk60dzdftY5I2g_10_4">P5Y8M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_LrNNiJqQIkSf1ulC8PfLpw"
      decimals="INF"
      id="Tc_wNf-bx5M30mIL45LBHIcGQ_10_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">441500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69To5.60Member_q-UM8c2fQkS_6XfClBd1Uw"
      id="Tc_sOF8uAtanECCCLIUxFNjCg_10_8">P4Y11M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_Z5ILinr5pki5oFoOTXqaOg"
      decimals="2"
      id="Narr_HAAxM4F1dkquxHhciqUqTw"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">17.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_9pTD0HcQLEO_MTuojw_G6A"
      decimals="INF"
      id="Tc_MGd9GYgwb0yqBDe6tHg8sA_11_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">75350</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_Z5ILinr5pki5oFoOTXqaOg"
      id="Tc_LDNStT9OgEODuapgoWsEYQ_11_4">P1Y2M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_9pTD0HcQLEO_MTuojw_G6A"
      decimals="INF"
      id="Tc_OAGZjv-4y063tOIAyEmOzw_11_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">75350</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_Z5ILinr5pki5oFoOTXqaOg"
      id="Tc_91QvOKcFSEGiLmZqLMbajQ_11_8">P1Y2M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ"
      decimals="INF"
      id="Tc_40dAKtpjUUiBo3plTrNCoA_12_2"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">6965601</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ"
      decimals="INF"
      id="Tc_CtaB7NjVk0Ws9nzBNepMEg_12_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">2900503</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ"
      decimals="-5"
      id="Narr_St2K0-txmkmzD0Nrij0SpA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ"
      decimals="-5"
      id="Narr_FMdfLHkdxEmzUGwGnJItmg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_OP0LEr_-vEOTxVevOIuBrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Weighted average grants date fair value (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Exercise price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Jd93bicWJk-u0ptZ1qcGrQ"
      decimals="2"
      id="Tc_fXIoc7rDEEacOqEbRaZO3A_3_2"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.57</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YMVeyD2j70y4VdJ42iD_fQ"
      decimals="2"
      id="Tc_OFsy6m_uZ0mWn4rsdmChKg_3_4"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.03</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ"
      decimals="2"
      id="Tc_FhcrPc1xTUGM_S0MOMEiAQ_3_6"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.84</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Jd93bicWJk-u0ptZ1qcGrQ"
      decimals="2"
      id="Tc_SHrsY6zyoUWNpyDuf2kG2Q_4_2"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YMVeyD2j70y4VdJ42iD_fQ"
      decimals="2"
      id="Tc_Gl_-ch1-L0qcdS20BmcIXw_4_4"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ"
      decimals="2"
      id="Tc_gXWSAs67gk6Uft97Nololw_4_6"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg"
      decimals="4"
      id="Tc_SIpOgwyOH0KHK9wnlYXtwQ_5_2"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w"
      decimals="4"
      id="Tc_LhZ5QvB2zE-GffO9_gS_HQ_5_4"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw"
      decimals="4"
      id="Tc_LbnoKHX_-Uy3jAUnJ-Abvg_5_6"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg"
      decimals="4"
      id="Tc_SxH3R9DNBkq3JpzUhXEIHA_6_2"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.8430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w"
      decimals="4"
      id="Tc_LS2aWO0DHUeBgdUtDWmcyA_6_4"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.8594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw"
      decimals="4"
      id="Tc_0AW5KzCbOkGWjEL-CLApEA_6_6"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.7941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg"
      decimals="4"
      id="Tc_nptNCX0NdEe8MDMUD-FLbg_7_2"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w"
      decimals="4"
      id="Tc_A4pRVnQDcUGAHHcQ7_n6uw_7_4"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw"
      decimals="4"
      id="Tc_WnhXgEPl1UW9cB3VRSCVpQ_7_6"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg"
      id="Tc_1z0ZvXHc7E-oKOSMI3kNQQ_8_2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w"
      id="Tc_Fz0zTD4AV02xuESWwHemMw_8_4">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw"
      id="Tc_faHsd9AX_0moWKNLXsOgbg_8_6">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_szgUbdRp8Uut-DVakbtTEQ"
      decimals="-5"
      id="Narr_hkBokTjhcUCOg_nNlkVf7w"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw"
      id="Narr_7awvAdTyb0SmsVxBCT9bGA">P0Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_g-S5b544XUO3rKe8xTFWOg"
      decimals="INF"
      id="Narr_eRwCFAR3GUKalnYKJ4uRZw"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rbtl4GtZ70yu-j9c-MVw-w"
      decimals="INF"
      id="Narr_wuuOxL0ChUuxREzK6GJQYA"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_99unqYqV6kGCEcAps5RLXw"
      decimals="INF"
      id="Narr_0gcMEfOvgESe4ntgIO8uCQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qMG5qS3iLEyHdybWijdG5Q"
      decimals="-5"
      id="Narr_mPzGBNGDQkGr3quFuEuvEg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_C5zBNMbhSkObSb6Xa-cZ3A"
      decimals="-5"
      id="Narr_CXj0yrwdG0i7buJgeJ9TJA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qMG5qS3iLEyHdybWijdG5Q"
      id="Narr_P-DwBLqA-kma-Y2FyMoqWQ">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_LTQk3DrrpE6K9Gf_BjH9OQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 777&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_G-5RnTikyEe9kMD0HS9VgA"
      decimals="-3"
      id="Tc_hxcmSPdw3UuA42zzKDedow_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_nUUou62YI0uMyf3Ceo-SDg"
      decimals="-3"
      id="Tc_T67WR_b3MkqSgK3QSFdHaQ_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_4cbqNYW9bkqJeKPztiOARQ"
      decimals="-3"
      id="Tc_tZ6Gt2pzmU20OULc6kARmQ_3_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_pPMvRU8ZMk2uuux3HO2TYg"
      decimals="-3"
      id="Tc_zh2K8BwTLEGE98LvJCT9Xg_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">648000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7jCMuUnJUkiYu615rQJzSQ"
      decimals="-3"
      id="Tc_NC932Tiyq0a42GQsfNIpzA_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">518000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Pg3HBbrQE0O-vf2piO-deg"
      decimals="-3"
      id="Tc_GAyyxiRUiUmAZ3t57GF7Wg_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">777000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Wq2H6c6tw0WzLJeQe0xOnQ"
      decimals="-3"
      id="Tc_Z9wjv4PPWU2mBIAk21oSBQ_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_VhZ8eBzgxUiYQec9RnyolA"
      decimals="-3"
      id="Tc_b9vfafw8fUyy3PqP9Q49QA_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5Lw9SAW0v0e805cbfkLdFQ"
      decimals="-3"
      id="Tc_RlosuyGkGk-oF3FsT3lVUQ_5_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2075000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_gmRj5Hm4V0u12Y5CVSaiCw_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_O8zzJMlljEShUcgKnATMNg_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_8or4CQLVdUW5yhFn1wtpsw_6_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gcdiHe0OrkaRgPsieHDsIA"
      decimals="INF"
      id="Narr_TwX5zGl91EmPxLLOPaS55g"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">173816</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1Yw2nKGMb0-CWAUOtRv76w"
      decimals="INF"
      id="Narr_Y2EOqYrBh0ev5-rnzQeOdg"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">2816901</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oUGb2yHFvkmftb5K_Hd41w"
      decimals="INF"
      id="Narr_nV8uKXm710W6Ubm2rpnoXw"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oUGb2yHFvkmftb5K_Hd41w"
      decimals="0"
      id="Narr_qjldWRwa1Ui9A--jgDTYBA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2360</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_XwwI97cnr0imfvHx08Av8Q"
      decimals="INF"
      id="Narr_KJdbaIFbIUqAZ8sxl2NUbw"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">301810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_XwwI97cnr0imfvHx08Av8Q"
      decimals="-5"
      id="Narr_igKpn2ZxikuTmq-57TXhJg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">700000</us-gaap:ProceedsFromWarrantExercises>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_XwwI97cnr0imfvHx08Av8Q"
      decimals="INF"
      id="Narr_kawf0ydrzk-02ZFTPEtK9Q"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">237012</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_D3oeVDNTUUiUr-_FfN-zLA"
      decimals="INF"
      id="Narr_uusLZNgpOk-q9FIWzVhrSg"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">845000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7tsfGy4RVUWLVfK_0YWXpA"
      decimals="INF"
      id="Narr_gk2YUPPp3kux3MGnpWISIQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">4691623</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <plx:PaymentsToDebtHoldersOnConversion
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7tsfGy4RVUWLVfK_0YWXpA"
      decimals="-5"
      id="Narr_oR0IY14-q0uKoFuVmRPLvw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">900000</plx:PaymentsToDebtHoldersOnConversion>
    <plx:DebtConversionDecreaseInPrincipalAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7tsfGy4RVUWLVfK_0YWXpA"
      decimals="-5"
      id="Narr_gbB-ijmLp0qk5NS-59twNw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8300000</plx:DebtConversionDecreaseInPrincipalAmount>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_GvuRJaXm1UWlbfDR82Bxug"
      decimals="-5"
      id="Narr_x5rmC6kEf0y7s_cf2DOmCQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZMEMUOBNoUyTMPRQ3bJFUQ"
      decimals="-5"
      id="Narr_VWQyjt60e02Sb5n47KDPgw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:PercentageOfCommissionOnSaleOfShares
      contextRef="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_LrxACSzPi0yrQT4i01lIRg"
      decimals="3"
      id="Narr_ZSH9nCZ68UeQE74RCtSwxA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.030</plx:PercentageOfCommissionOnSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_8C7y4du30EGx7NNV_qKuMQ"
      decimals="INF"
      id="Narr_ioAivLmzzEWOtIjsxeWm4w"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1867552</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_8C7y4du30EGx7NNV_qKuMQ"
      decimals="-5"
      id="Narr_xvX3k1R0vE-uT-GKtqcfng"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ssnGYhUhj0KL7KcjrJIBKg"
      decimals="INF"
      id="Narr_58H0xp1I20-O3e8qji92Fg"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">7473038</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ssnGYhUhj0KL7KcjrJIBKg"
      decimals="-5"
      id="Narr_CFZdLSNybUuWhQsVzAxYPw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rB-wUzmla0SlVO0p8Yda1A"
      decimals="INF"
      id="Narr_e5vwVOS7NkuXX3U_Nipd1g"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">12560150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rB-wUzmla0SlVO0p8Yda1A"
      decimals="-5"
      id="Narr_myI274H2z06ZooEUmYNWEQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">24900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_vB9y4DT3xkGRfePGVkNqMg"
      decimals="INF"
      id="Narr_vnjwRhak7UaHyG19vLQ7vA"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_17_2021_To_2_17_2021_SJuIvsv5bUOxBNrdkJQFqQ"
      decimals="INF"
      id="Narr_MAu7kaeByUSTAnWUGIX8YQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_2_17_2021_CVbxW9emMEyG2cHIMoZs5A"
      decimals="2"
      id="Narr_6uxWQ6gZvUGl4MGgZ2QStQ"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">4.60</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_17_2021_To_2_17_2021_SJuIvsv5bUOxBNrdkJQFqQ"
      decimals="-5"
      id="Narr_xP1RqoiEEUmz2nlTLLafeg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">40200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_17_2021_To_2_17_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RTfbrWi6qkSb5DrbSpC38w"
      decimals="INF"
      id="Narr_KrfUYfgtwUKgFhVQ6fPS8w"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1141304</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_2lpI1-roqkeDIdHxFelluQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE 10&#160;&#160;- CONVERTIBLE NOTES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;7.5% Convertible Notes Due 2021&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2016, the Company issued to certain existing note holders and new purchasers $62.7&#160;million aggregate principal amount of its 2021 Notes in a private placement and an exchange pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. In July 2017, the Company issued an additional $10.0&#160;million in aggregate principal amount of the 2021 Notes in a private placement pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. A portion of the interest payable under the 2021 Notes was allowed to be made in shares of Common Stock at the Company&#x2019;s election. On November&#160;15, 2021, all the then outstanding 2021 Notes&#160;matured and were paid in full.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2021 Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. Dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Debt discount amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;7.5% Convertible Notes Due 2024&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On August&#160;25, 2021, the Company completed exchanges (the &#x201c;Exchanges&#x201d;) of a substantial majority of the Company&#x2019;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#x2019;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Common Stock), subject to adjustment in certain circumstances, which is based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The 2024 Notes were issued pursuant to an indenture (the &#x201c;2024 Indenture&#x201d;) entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent (the &#x201c;Collateral Agent&#x201d;). Interest on the 2024 Notes is payable semi-annually at a rate of 7.50% per annum. The Notes mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#x2019;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges were considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $0.8&#160;million due to derecognition of the liability component and a reduction of stockholders&#x2019; equity of $12.2&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature net of transaction costs of approximately $12.0&#160;million was recognized in the Company&#x2019;s additional paid in capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Transaction costs in the amount of approximately $869,000 were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Holders may convert their 2024 Notes&#160;at any time. The initial conversion rate for the 2024 Notes&#160;is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes&#160;(equivalent to an initial conversion price of approximately $1.7755 per share of Common Stock). Upon conversion, the Company may settle the 2024 Notes by paying or delivering, as the case may be, cash, shares of Common Stock or a combination thereof, at the Company&#x2019;s election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2023, a total of $20.42&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to the maturity date, the Company may redeem in cash:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a)&lt;/span&gt;&lt;/span&gt;any or all of the outstanding 2024 Notes if, on or after March&#160;31, 2023, the last reported sale price of the Common Stock for at least 20 trading&#160;days (whether or not consecutive) during the period of 30 consecutive trading&#160;days exceeds 130% of the conversion price on each applicable trading day, or&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;b)&lt;/span&gt;&lt;/span&gt;all of the 2024 Notes&#160;then outstanding if the aggregate principal amount of the 2024 Notes&#160;then outstanding is less than 15% of the aggregate principal amount of the notes issued on August&#160;25, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;To date, there has been no redemption of 2024&#160;Notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The 2024 Notes&#160;are guaranteed by the Restricted Subsidiaries (as defined in the 2024 Indenture) and are secured by a first-priority security interest in all of the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &#x201c;Collateral&#x201d;), including, but not limited to, (i)&#160;100% of the capital stock of the Guarantors (as defined in the 2024 Indenture) and each Restricted Subsidiary of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Company that is held by the Company or any Restricted Subsidiary, (ii)&#160;intellectual property, including all copyrights, copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary information, including, but not limited to, domain names, (iii)&#160;all cash, deposit accounts, securities accounts, commodities accounts and contract rights, (iv)&#160;all real property and leased property, subject to applicable minimum thresholds, as set forth in the 2024 Indenture, and (v)&#160;all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such liens, the Company entered into certain agreements with both the Collateral Agent and Altshuler Shaham Trusts&#160;Ltd., as security trustee in Israel. The 2024 Indenture restricts the ability of the Company, the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&#x2019;s assets that constitute collateral securing the 2024 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Upon (i)&#160;the occurrence of a fundamental change (as defined in the 2024 Indenture) or (ii)&#160;if the Company calls the 2024 Notes&#160;for redemption as described below (either event, a &#x201c;make-whole fundamental change&#x201d;) and a holder elects to convert its 2024 Notes&#160;in connection with such make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the &#x201c;Additional Shares&#x201d;). In no event will the conversion rate exceed the maximum conversion rate, which is 746.2686 shares per $1,000 principal amount of 2024 Notes, which amount is inclusive of repayment of the principal of the 2024 Notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;If a fundamental change occurs at any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2024 Notes, or any portion of the principal amount thereof, that is equal to $1,000 or an integral multiple of $1,000 in excess thereof, on a date of the Company&#x2019;s choosing that is not less than 20 calendar&#160;days nor more than 35 calendar&#160;days after the date of the applicable fundamental change company notice. The price the Company is required to pay for a 2024&#160;Note is equal to 100% of the principal amount of such 2024 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. Under the terms of the 2024 Indenture, the Company is required to &lt;span style="color:#222222;background:#ffffff;"&gt;meet certain covenants including the requirement to &lt;/span&gt;maintain a minimum cash balance of at least $7.5&#160;million. Failure to meet covenants can be considered an event of default and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of December&#160;31, 2023, the Company was in compliance with all covenants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2024 Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt issuance costs and debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_iAqmHavoc0y6aGWMensHBA"
      decimals="INF"
      id="Narr_an117fJtsE6xQDVaq9qPrw"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u1l6Q7eIvEKTQP9MPBmN9Q"
      decimals="-5"
      id="Narr_3GyR9fv18ECvUV2MCqPaQQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">62700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_31_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rTPd6I7xUkGiNNPDC-sQZA"
      decimals="-5"
      id="Narr_JESs2DACjEi9s2VdjXlmKw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_6gBeWpquBkO5DzLdfEEOMg"
      id="Tb_hj6E_nkDQkig2aZL_HoDCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2021 Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. Dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Debt discount amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A"
      decimals="-3"
      id="Tc_7xwVp7WULUasMawEGZ_-Bg_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2855000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A"
      decimals="-3"
      id="Tc_FaNkzNKinEet_oY-h6jsKw_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2575000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A"
      decimals="-3"
      id="Tc_pXnYJ3hy8UGX6EzLmxVx3w_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-831000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A"
      decimals="-3"
      id="Tc_MYQXQ5VHaEK8MQe45ujNDQ_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">6261000</us-gaap:InterestCostsIncurred>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="INF"
      id="Narr_mvKjawkj10SflVhDEOimrA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_RSywV91c8EyVXNBMXvKebA"
      decimals="-4"
      id="Narr_IQVqflKVkkuz8wdIYQLxyg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">54650000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg"
      decimals="-4"
      id="Narr_TLBEs25oVEef93TLzGcLkQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">28750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q"
      decimals="-4"
      id="Narr_er9Into14EWZTOpKe06IuQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25900000</us-gaap:RepaymentsOfConvertibleDebt>
    <plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q"
      decimals="-5"
      id="Narr_xJmcX4zQP0SF2us_eftr0Q"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1100000</plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest>
    <plx:DebtInstrumentConvertibleConversionShareNumber
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg"
      decimals="INF"
      id="Narr_hwRwnY1DVk-zIIk7JHpciw"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">563.2216</plx:DebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentConvertibleBaseValueForConversionRate
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q"
      decimals="0"
      id="Narr_AE6MOhJGSEK5O_yOyfYujQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg"
      decimals="4"
      id="Narr_fnGka0_xq0u105n4eLmHUQ"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.7755</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <plx:PercentageOfPremiumToClosingPriceOfStock
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q"
      decimals="3"
      id="Narr_X1h7zO-Gg0awLTWA0qgsrQ"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.325</plx:PercentageOfPremiumToClosingPriceOfStock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg"
      decimals="INF"
      id="Narr_vEaVpxPw7EOQKxdiIDy9Nw"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q"
      id="Narr_TFv_Wnnr5USS0NNFalHtuQ">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A"
      decimals="-5"
      id="Narr_AEBw7DOixkCFDxd0-sLkkA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Gd5OXTsDZ0W54su8-mw16A"
      decimals="-5"
      id="Narr_i5crzOXwwUWbbMMwMPb1aw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12200000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="-5"
      id="Narr_-ntmhwo_LUOFBXIj1QjuMQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12000000.0</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="0"
      id="Narr_5Wy2lg5VZk-oI4MRPoCW0w"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">869000</plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt>
    <plx:DebtInstrumentConvertibleConversionShareNumber
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg"
      decimals="INF"
      id="Narr_VvxwMZWcykCEMdXBkPFykw"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">563.2216</plx:DebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentConvertibleBaseValueForConversionRate
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ISkNdjmZW06ZFfaldJ_P1Q"
      decimals="0"
      id="Narr_BnFnGGlv80Kxv5G7L6XexQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_bQyumyrpR0aDbt4qulT7Kg"
      decimals="4"
      id="Narr_QeZHFKsbokSlWSNi36_B3A"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.7755</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="-4"
      id="Narr_k6N6mhxLOk6tOZLtrmGEtg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20420000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="INF"
      id="Narr_5CK3QXA13ECpCVSj3lH64g"
      unitRef="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="INF"
      id="Narr_VlABrXCxykyi9lNU6wFbPw"
      unitRef="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <plx:ThresholdPercentageOfConversionPrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="2"
      id="Narr_UzEKI4PCskGXHCTrTl8Pow"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">1.30</plx:ThresholdPercentageOfConversionPrice>
    <plx:DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="2"
      id="Narr_-17nUi1b6kSUuPojoRXxDA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.15</plx:DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding>
    <plx:DebtInstrumentRedemption
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="-3"
      id="Narr_OBxSYj-uBU2BseVuQGZ-0Q"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</plx:DebtInstrumentRedemption>
    <plx:PercentageOfOutstandingCapitalStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="2"
      id="Narr_U0z0KHnLeU-Wih37u1_AMA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">1</plx:PercentageOfOutstandingCapitalStock>
    <plx:MaximumDebtInstrumentConvertibleConversionShareNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="INF"
      id="Narr_8NvFj4q_80a0nzHvKfgOwg"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">746.2686</plx:MaximumDebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="0"
      id="Narr_djUmPMDDQU6nB96FK7uWLA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1000</plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
    <plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="0"
      id="Narr_U9OsBRbUOEqXnHcdaJiJpA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1000</plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
    <plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="0"
      id="Narr_oH3NTUpvhE6k9_mMT49dsw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1000</plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
    <plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_p6jVivnBs0mBGLiQhyt5oQ"
      decimals="INF"
      id="Narr_boNAdmctm02M0nzhorF9KQ"
      unitRef="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q">20</plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange>
    <plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_0jdO8xpKLUGP05OvtmHFoA"
      decimals="INF"
      id="Narr_Lw5XPnLJc0O85K7gB7EESw"
      unitRef="Unit_Standard_D_QTXo3_8FT0y-eRCFptUN4Q">35</plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="2"
      id="Narr_ZA3Wz2uBKUq9MbdaThOrPA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_AHH6FM6r4Eeuc4gy7POzsg"
      decimals="-5"
      id="Narr_o7pEQZgkL0uumW3Ef77_Pw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_VZDiVAJYeUq_J3J-EliWwQ"
      id="Group_V7LOpyPYCUGKJEA63FESSg">The following parameters were used:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_57ZK5w5WGUyALypMdLvZ_w"
      decimals="2"
      id="Tc_h5nh45ocj0Si5yHvK73EoQ_2_2"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5BUHKipIbUSYH07fhT7fxw"
      decimals="2"
      id="Tc_Qr3vytEXWEeVKT8fimwmuQ_2_5"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WlO3JuHosU66SIYEqogVsw"
      decimals="2"
      id="Tc_6kzqjqNsg0CfP1kVYT8bBw_3_2"
      unitRef="Unit_Standard_Y_5yXfmzhLaEC9tEJVIkFchA">0.23</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_sNa-abEf9kq7MgbpeppqKw"
      decimals="2"
      id="Tc_dRWkg71cIUOjH7rMAAdl7g_3_5"
      unitRef="Unit_Standard_Y_5yXfmzhLaEC9tEJVIkFchA">3.03</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_a9FL0cjM4UWj0kWAe34-9A"
      decimals="4"
      id="Tc_nMbgAp3eX0W3SaTjKn6ObA_4_2"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0005</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3ifThMNCrkuKLL1kdLaJ9Q"
      decimals="4"
      id="Tc_HMTgDdT7o0Gdq8xsL-OvjA_4_5"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0044</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_2IMzGamN40K0qlSWNrY3Ig"
      decimals="4"
      id="Tc_euw-7HnYiUqEWtWdwsPKjg_5_2"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.7895</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_BZLsajDjiEe6-0mciWg6Wg"
      decimals="4"
      id="Tc_0P7IY7njM0KT9fYBvPur5A_5_5"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.9135</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_CON_DW57J06LCucDdq1I-Q"
      decimals="4"
      id="Tc_gq5km5oZKEmNx1xBWaV6CA_6_2"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0787</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_YD_U8HfQWUOjf8ZrXymgNA"
      decimals="4"
      id="Tc_7P6pVcEkIk-xoLB1BRCRwQ_6_5"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0766</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      id="Tb_ZPLV-meNdk-giSBLLyJNvw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2024 Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt issuance costs and debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_3JYAY1fui0OUhP6pQk-C8Q"
      decimals="-3"
      id="Tc_7FL83cK0WEKlga7HOCirgA_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">767000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_A6SB-KSPHUOpgmPJyNMoXQ"
      decimals="-3"
      id="Tc_hrw7n7G_dUewvjQ3WMUwnQ_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2156000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="-3"
      id="Tc_5oma0o22jE2MQy3WI4xqwg_3_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2534000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_3JYAY1fui0OUhP6pQk-C8Q"
      decimals="-3"
      id="Tc_-W6eUnFYPEuEh1mz9JIBtQ_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">97000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_A6SB-KSPHUOpgmPJyNMoXQ"
      decimals="-3"
      id="Tc_KcYOFTnvG0KjKqLd2lSqVA_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">300000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="-3"
      id="Tc_N_NSmPP9G0u0-E2SyijYEw_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">267000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_3JYAY1fui0OUhP6pQk-C8Q"
      decimals="-3"
      id="Tc_rNC-6Ls2MU2kzKjK7vBQmQ_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">864000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_A6SB-KSPHUOpgmPJyNMoXQ"
      decimals="-3"
      id="Tc_K5MZNMCkDEaRH5rN1dpqwg_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2456000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      decimals="-3"
      id="Tc_dPsSDlKCBEagT89YLUf0-Q_5_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2801000</us-gaap:InterestCostsIncurred>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_12BywQG-2067-bZkjaIgeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;11&#160;- FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;The fair value of the outstanding $20.42&#160;million 2024 Notes as of December&#160;31, 2023 is approximately $25.6&#160;million based on a level 3 measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;The Company prepared the valuation of the fair value of the 2024 Notes&#160;(a Level&#160;3 valuation) as of December&#160;31, 2023. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dFp5G0LNJUya7KtQK3pNQQ"
      decimals="-4"
      id="Narr_X1MRdXj8ik6M67T9vMrUcA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20420000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_dFp5G0LNJUya7KtQK3pNQQ"
      decimals="-5"
      id="Narr_nP8QrBZ6EUCKdRVVQlsgAQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">25600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_uVUMh5VKAE-zjFwLaa-jjQ"
      id="Tb_iK6dheOsME6WDZ2rvcb61g">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_3I09XpnwBUK1eNxQSTeoEw"
      decimals="2"
      id="Tc_wskF47rnKEWEi245ZoCOOg_2_5"
      unitRef="Unit_Divide_USD_shares_QeqnEFx5oUe4FFJRVO5yWQ">1.78</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_wE9yb5vMiUiXD8b4zFAFDQ"
      decimals="2"
      id="Tc_2o08z4x0PkS4NOxsja38Wg_3_5"
      unitRef="Unit_Standard_Y_5yXfmzhLaEC9tEJVIkFchA">0.67</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_XwrlUpDhVkulphV17M8Jmw"
      decimals="4"
      id="Tc_X6zzcAHIdEuvTK5A1Z5hrg_4_5"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.0487</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_251HtAiKnEG6Q7qnPV5dYA"
      decimals="4"
      id="Tc_Xdo0s_oFHESasqvLGbkGww_5_5"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.6990</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_QVm3W7ty10eUY0pOqxsecQ"
      decimals="4"
      id="Tc_O4irCzpCNUCH5qQ3FuYJnQ_6_5"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.1157</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_Z4ddAzOdL0qDbLCAWLIrow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;12&#160;&#x2013; NET EARNINGS (LOSS) PER SHARE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,582)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,312&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,168)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,582)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,140,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,472,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,512,527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,335,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,576,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,140,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,472,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,424,016&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted loss per share do not include 28,502,017 and 34,097,716 shares of Common Stock underlying outstanding stock options, warrants and convertible notes of the Company for the years ended December&#160;31, 2021 and December&#160;31, 2022, respectively, because the effect would be anti-dilutive. In the year ended December&#160;31, 2023, the diluted earnings per share do not include 18,254,264 shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_EFUdxDwvXE2vqXmtRUUymw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,582)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,312&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,168)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,582)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,140,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,472,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,512,527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,335,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,576,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,140,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,472,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,424,016&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc__XzdTH2QXkOaVHZep8uujA_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-27582000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_EUj32fI3_0uEJeJ6I26ArQ_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_0W8kxDU0uUOPA80yIHICTA_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_FMcluxMtNkagMemanaCRHA_6_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-1168000</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_6UalptuBUEaB-34fut3eRw_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-27582000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_5pwJk5wTqUWRESz0RPllmg_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-14927000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_uT68nmZKDkCrlAY6kEAwbA_7_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7144000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="0"
      id="Tc_Q4OMiSVuM0C3irEgvQGgfA_9_3"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">44140233</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="0"
      id="Tc_93zpxM44J0mCwv3IvIHiaQ_9_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">48472159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="0"
      id="Tc_yWhs_eR2o0mQWyegIDDrWg_9_9"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">67512527</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="INF"
      id="Tc_8-mikr3Gy0uGz70mJ0UqxA_10_9"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">13335430</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="INF"
      id="Tc_4bpZG7ndWUGvkHdvoXlu-g_11_9"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">1576059</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="0"
      id="Tc_J4L1FiB8BEKTEZbrZP_JWg_12_3"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">44140233</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="0"
      id="Tc_Ucc-ojLc8kSBHVcq2gW_Hw_12_6"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">48472159</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="0"
      id="Tc_soVidT04GEO-jwuoKRoLHQ_12_9"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">82424016</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_sxPvfKZ4_E6nZxOZsSDnVw"
      decimals="INF"
      id="Narr_waYeq28qg0Sr-j3vmoXGcQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">28502017</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_p8gLt_bw0EKb2iCn7NXpJg"
      decimals="INF"
      id="Narr_GQWJUpyXd0yTcBkwGk76ww"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">34097716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_eCN7L55gSkWPyF5sZKKtCw"
      decimals="INF"
      id="Narr_OOxGPrub-Eajqs9ydrkPFw"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">18254264</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_yQxhUgVseUe5U51Gs1clIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;13&#160;- TAXES ON INCOME&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Company&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#x2019;s income is taxed in the United States at a rate of up to 21%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,092)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company had an effective tax rate of 3% for the year ended December&#160;31, 2023, compared to an effective tax rate of (4)% for the year ended December&#160;31, 2022. For the year ended December&#160;31, 2023, the difference between the Company&#x2019;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted into law in December 2017 (the &#x201c;TCJA&#x201d;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $20.0&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released the valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $3.1&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The TCJA represents fundamental and dramatic modifications to the U.S. tax system. It contains several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the TCJA includes, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of NOL deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The TCJA also repealed the corporate alternative minimum tax for tax years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the TCJA included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Modification of interest expense limitation rules under the TCJA provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 30% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Section&#160;174 of the TCJA requires taxpayers to capitalize and amortize research and development expenses for tax years beginning after December&#160;31, 2021. This rule became effective for the Company during the year ended December&#160;31, 2022, and resulted in the capitalization of research and development costs of approximately $28.5&#160;million and $14.4&#160;million in 2022 and 2023, respectively. The Company will amortize these costs for tax purposes over 15 years for research and development performed outside the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company believes that all future profits of its subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company as a &#x201c;foreign-investment company&#x201d; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Tax rates&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The income of the Israeli Subsidiary, other than income from &#x201c;Approved Enterprises,&#x201d; is taxed in Israel at the regular corporate tax rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The corporate tax rate was 23% for 2018 and thereafter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Law for the Encouragement of Capital Investments, 1959 (the &#x201c;Encouragement of Capital Investments Law&#x201d;)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#x201c;Approved Enterprise&#x201d; or &#x201c;Benefited Enterprise&#x201d; status the Israeli Subsidiary is entitled to various tax benefits as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;a.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Reduced tax rates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary has an &#x201c;Approved Enterprise&#x201d; plan since 2004 and &#x201c;Benefited Enterprise&#x201d; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expired in 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#x201c;Approved Enterprise&#x201d; or &#x201c;Benefited Enterprise&#x201d; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;b.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Accelerated depreciation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;c.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Conditions for entitlement to the benefits&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary&#x2019;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#x201c;Approved Enterprise&#x201d; from the Investment Center.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;d.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Amendment of the Law for the Encouragement of Capital Investments, 1959&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#x201c;Preferred Technological Enterprise&#x201d; and &#x201c;Special Preferred Technological Enterprise&#x201d; (the &#x201c;Capital Investments Law Amendment&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2023 and 2022, the Company had aggregate NOL carry-forwards equal to approximately $234.8&#160;million and $247.4&#160;million, respectively, that are available to reduce future taxable income as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Company&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company&#x2019;s carry-forward NOLs, equal to approximately $24.4&#160;million and $26.7&#160;million as of December&#160;31, 2023 and 2022, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#x201c;IRC&#x201d;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Protalix&#160;Ltd.&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;At December&#160;31, 2023 and 2022, the Israeli Subsidiary had approximately $210.4&#160;million and $220.7&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Deferred income taxes:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The components of the Company&#x2019;s net deferred tax assets at December&#160;31, 2022 and 2023 were as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In respect of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,568&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other timing differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,115)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,387)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,097&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,092&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A reconciliation of the statutory U.S. federal income tax rate of 21% in 2023, 2022 and 2021 to the effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.49%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax computed at the statutory U.S. income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,792)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,023)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Differences in tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,512&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (899)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutorily non-deductible expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in Valuation allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,970)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,932)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Utilization of carry-forward losses and other temporary items without deferred taxes recognition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Withholding tax &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Valuation allowance roll-forward&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table presents the change in the Company&#x2019;s valuation allowance during the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (61,520)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reductions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,550)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,550)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (728)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reductions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;g.&#160;&#160;&#160;&#160;Uncertain tax position&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Provisions of ASC 740-10, Income Taxes, clarify whether to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase for tax position related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase for tax position related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;h.&#160;&#160;&#160;&#160;Tax assessments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In accordance with the Income Tax Ordinance, as of December&#160;31, 2023, all of Protalix&#160;Ltd.&#x2019;s tax assessments through tax&#160;year 2018 are considered final.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A summary of open tax&#160;years by major jurisdiction is presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Jurisdiction:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2019-2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United States (*)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020-2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;(*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_MJT48I74nkqfkLgGf8DWVg"
      decimals="2"
      id="Narr_9gI6w47G002ztUd8cdOyPw"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_BqvfZ5a8YECLflWCc8eLaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,092)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_2XIkKs6-MEO_K-ypHBTP3w_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">530000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_XvEW-q41wUKmWkB-99Hcjw_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3346000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_ZIyAO3FOdESZHLxtIQzGOQ_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-3092000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_UjFwWJqEVkCU33tSpjNRTQ_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">530000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_MkJ5BAS7vEq1txGo2MNmgA_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="2"
      id="Narr_3TnuhJs0ok2olY0m26zLXA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="2"
      id="Narr_IYhuVC1GzEq-kLZOklFcMw"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">-0.04</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="2"
      id="Narr_2AP-elCK8Um84ybNCyBt1A"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <plx:MilestonePaymentReceived
      contextRef="Duration_5_1_2023_To_5_31_2023_wxdHXaWGJUe-pHkKaGr9qA"
      decimals="-5"
      id="Narr_iNKLkm3VJEqqNUe3FRaKTg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">20000000.0</plx:MilestonePaymentReceived>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_5_1_2023_To_5_31_2023_wxdHXaWGJUe-pHkKaGr9qA"
      decimals="-5"
      id="Narr_Sx0LbPIvg0WbvGHfwBBXQA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-3100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-5"
      id="Narr_8Z7BkdbSbkyfYMg9y63C6Q"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">28500000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-5"
      id="Narr_Z2Vl2AnfjEaRXgnpa_gJDg"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">14400000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <plx:CapitalizedResearchAndDevelopmentCostAmortizationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Narr_y4va3ve5sEWRJkIMEQB6Aw">P15Y</plx:CapitalizedResearchAndDevelopmentCostAmortizationPeriod>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_iZ27SMRREEmvpe0JdqEXIQ"
      decimals="2"
      id="Narr_srW2NfqaI06yxfYKYpVpjA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_jJGc7jy940K8Qw9jBJ_iPg"
      decimals="2"
      id="Narr_3iETRsetBEWCyNE429-sAA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_XzqK5SZYk0uC0x8Ph1LJBg"
      decimals="2"
      id="Narr_hTIH5tmLekulhfOeUD1sug"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_Rc3FfJee6ka0ZRjX--HI1A"
      decimals="2"
      id="Narr_6ISbjkGU40yQNgC32Th--A"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_OISz_geoOEqDePVi3rhqJw"
      decimals="2"
      id="Narr_OEJEX2HFOEeTKFUExVdgLA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_SkKeGJpZk0ix9VIXIl82bA"
      decimals="2"
      id="Narr_tgmGrFPgt0-5A7FJcZ-blw"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-5"
      id="Narr_q2PnT7sINkCsoYAXSjbSRA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">234800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-5"
      id="Narr_QDSs9iVyGEe0ReTVU06VvQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">247400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_vtfaP8TfsEyMcbIsM1oBkQ"
      decimals="-5"
      id="Narr_zZBVrsYqr0edtD97q9XD0g"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">24400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_u3-UCxFuAUOj3iNBJvmi2w"
      decimals="-5"
      id="Narr_W6jaTs5EBU-ymb5qLFMJeQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">26700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_EyG0dq2VUECJScHNcRo4pQ"
      decimals="-5"
      id="Narr_q0_wxotGV0yMbhTaGzClyA"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">210400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_HOk8TyvPSkmZaIMc922oBA"
      decimals="-5"
      id="Narr_vc5p7R-ZlUakwNLpwl_O1A"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">220700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_ilxCZJyZY0Wvj70HiETfBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The components of the Company&#x2019;s net deferred tax assets at December&#160;31, 2022 and 2023 were as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In respect of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,568&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other timing differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,115)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,387)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,097&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,092&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_3-bE3_NzYEqm9H3O_077LA_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">6568000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_E1hBPOU8AEK_OolmEMKMxA_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4625000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <plx:DeferredTaxAssetsOtherTimingDifferences
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_wWHzremR50CgLgzLgP9O1g_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-2115000</plx:DeferredTaxAssetsOtherTimingDifferences>
    <plx:DeferredTaxAssetsOtherTimingDifferences
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_1y5NVToygUKnHf8tZrxQhg_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-1387000</plx:DeferredTaxAssetsOtherTimingDifferences>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_4ibJmK8wNE-a_1WjyICmew_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">54097000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_fN4maw_SAkaIjuAjOtUo7A_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">51472000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_Qbl-8jvyR0C7Qs57iDWiHg_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">58550000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_7eMhfhkpXkihLWKCBwRXrw_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">51618000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_Hu20NN9IrkWRaodKW7K7pQ_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_HJeB8_4bHEGW1Q7OMpVYbg_8_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3092000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="2"
      id="Narr_WdwNmryT9kKce2KEe_08hw"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="2"
      id="Narr_-jd-OMpimk2hD4eJGg8QKA"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="2"
      id="Narr_FNW37cJMQUqz1qpxkcYbdQ"
      unitRef="Unit_Standard_pure_gTTJPp7ZSkipkb-zUl5YPA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_IyHhmjSHt0y3KaBK124Pwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.49%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax computed at the statutory U.S. income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,792)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,023)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Differences in tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,512&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (899)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutorily non-deductible expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in Valuation allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,970)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,932)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Utilization of carry-forward losses and other temporary items without deferred taxes recognition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Withholding tax &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_pT_tSNdmpUaj4q8U7iFpFg_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-5792000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_bqImAUIaakuu-tANp7Se7w_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-3023000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_jiD7_3kDrUuxzvx2mP2LPg_3_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1799000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_1eDBrx04hk-m6iQ52V288w_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1512000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_RinmPaeVgkS7jkmCCjV6LA_4_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-899000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_g6yEQDHzxku0k_Oba2M6iQ_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2979000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_c2lNgfl7DEiGBpH5fexicw_5_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1684000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_7bnSLXuzf0-1WzESHJdv-A"
      decimals="-3"
      id="Tc_QzmPCgkYtU2mCjs5EDCn6g_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">5792000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_ggI9Ll1fOkybh1QJFcIXkg_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-2970000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_mx4ji9p2wk-nb20jGu394Q_6_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-6932000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_DNkgdA7Lv0Sf2T3tFqtGPQ_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2032000</plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition>
    <plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_Vn8E9GQoDEeTZFVTUX3CVQ_7_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">3602000</plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition>
    <plx:EffectiveIncomeTaxRateReconciliationWithholdingTax
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_GrLJVqod_0abHi08lGvmyw_8_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">-1000000</plx:EffectiveIncomeTaxRateReconciliationWithholdingTax>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_2WU3rzfbFkG7pY69aMkEGQ_9_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">530000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_Ld5IUckErkqq4Wjz8hIB3w_9_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_NHzEbXY0E0-wsaYxMw89og">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (61,520)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reductions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,550)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,550)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (728)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reductions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_xczCZo0kKEuGAy1qhvBKew"
      decimals="-3"
      id="Tc_qF-MVvMDDUS_bdkgf4UO_w_2_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">61520000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_fxWPVhUU2UO5aDySV9WoTg_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2970000</plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_BE4n6eHMLkq8-XBNEbmH6Q_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">58550000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_K1xhFs2XckOBxw5-Q2gvpw_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">58550000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <plx:DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_TvIRSkpe2ki50z4L8CXkag_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">728000</plx:DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod>
    <plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_orLjeXKpMk2OC2AXPwnWqA_9_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7660000</plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_RNcV7IL4e02ex_rLTvctlw_10_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">51618000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_KVWCqItcykqYDUws-F_z9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase for tax position related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase for tax position related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_tLrU-__fq0irVuklTTFohA"
      decimals="-3"
      id="Tc_LHgptcxhnUmd0gzWftCvyA_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">530000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_NRQwQMkvpESzYYCfjjHvqA_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">530000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_ovamEFkJ0kylm_x5mHF7hQ_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">530000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      decimals="-3"
      id="Tc_B_Wi9JeKt0i2WOgqokWQCA_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">275000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_x42eA-eqP0WSoiLVr-GkJw_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">805000</us-gaap:UnrecognizedTaxBenefits>
    <plx:ScheduleOfOpenTaxYearsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_orMxtRJFK0SK_XtEEy--GQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Jurisdiction:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2019-2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United States (*)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020-2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;(*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfOpenTaxYearsTableTextBlock>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_rYb5LIKYEU-DUI4F45twMw"
      id="Narr_mVc_KCfwqUW6mwUadyL1AA">2019</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_o34DNclg302qjFkTJ9TCVw"
      id="Narr_XSOIDRM4rEet2tGr1-eSRQ">2023</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_Uh0a4pl7bU-2Tnjx_lqtJg"
      id="Narr_wT4QaUxwm0upMbWDyElhpw">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_96dVppJwckClqojVBy1Ycw"
      id="Narr_1X01TmQtK0-cx2fCTXMkLQ">2023</us-gaap:OpenTaxYear>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_A0liS0PnhUSLBa13G1BOww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;14&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 54pt;"&gt;Balance sheets:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&#160;&#160;&#160;&#160;&#160;Other assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sundry&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_LOu1lrcjrkm9WyCPL8mhlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&#160;&#160;&#160;&#160;&#160;Other assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sundry&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 129&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <plx:OtherAssetsInstitutionsCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_8vEwkWlhIkG61L0rZwiSGA_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">364000</plx:OtherAssetsInstitutionsCurrent>
    <plx:OtherAssetsInstitutionsCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc__rrQDhXCGEKHwH_EtsC6RA_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">482000</plx:OtherAssetsInstitutionsCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_xIEEvnSL5EGZI8PkhEOzNA_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">774000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_qheD33-6lk6sEd-QvDcrgw_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">444000</us-gaap:PrepaidExpenseCurrent>
    <plx:OtherAssetsSundryCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_i7F01kJL9ESeQP832GgPLA_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">172000</plx:OtherAssetsSundryCurrent>
    <plx:OtherAssetsSundryCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_DY-sGBz0AUCNoTu113A7sQ_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">129000</plx:OtherAssetsSundryCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_ripBgmG2BUCsW6CiYMsJ2w_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1310000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_PgBSzj1d102Rzhp560E9Ng_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1055000</us-gaap:OtherAssetsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_dqJ0OcowpU-vUS1viYiUnw_4_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1216000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_XVdc2vStzUW4gx4zTsNusA_4_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1437000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_bJmMndFm2EOsgldZgT6I8A_5_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">719000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_fWlJT9mIUU2Bxzx-lKQYpg_5_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">511000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_McxobQ3ahkOWVzXMJ324vg_6_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1404000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_60ahLgKVPEulqZDIlD6vyg_6_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">1605000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_nXLQq3CrzkakzoZrK9cq7w_7_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">7478000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_N2Lg_oG_zUyRoHZZof-8Ww_7_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">9009000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_z4XA4JSqOkGCW6aA1Worrg_8_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">781000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_es8KDT5EwUG15ljxG3m06A_8_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">637000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_Z_tg1xxSzkyKM0NcwL1Fpw_9_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">530000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_2J5kKrMSaEiQ9yKvQVF9kQ_9_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2876000</us-gaap:TaxesPayableCurrent>
    <plx:ReserveForDeductionsFromRevenueCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_OWkLjcijjEii2Huv3D7sBg_10_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">2861000</plx:ReserveForDeductionsFromRevenueCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_BDYKpXfl2EK17GiUvz9-LQ_11_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">143000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_YGsuHyG_r0CCWrXP4A0xEA_11_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">614000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_Mp1vzpR1NECno5x7glL0zA"
      decimals="-3"
      id="Tc_5RjcJku31kWv_8Es9OU35A_12_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">12271000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_jVhpE8u9Mkez2xdS-VElHA"
      decimals="-3"
      id="Tc_PG7MTXC5jkKR2JXsaV-eYQ_12_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">19550000</us-gaap:AccountsPayableCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_esWkCau8s0ONAwf83LkAeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;15&#160;- RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Non-Executive Director Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation (including share-based compensation) to the non-executive directors&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In September 2023, with the consent of the Audit Committee of the Board of Directors, the Company engaged one of its non-executive directors to advise the Company regarding business development and licensing efforts on a consultancy basis. For the year ended December&#160;31, 2023, the director earned a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$35,475&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in consulting fees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_QGABpAgxokaOC5v_8cDRAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation (including share-based compensation) to the non-executive directors&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_bJsWGX3NvUKW3gZlGPknpw"
      decimals="-3"
      id="Tc_Qqj9fDmZnk6VmvDwESRvGQ_3_3"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">475000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_H8gaQjdU40-YdEqUm0lstA"
      decimals="-3"
      id="Tc_ZHujAMHOk0G5g2s_BqAsgg_3_6"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">368000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vv13STm1FEiXvwnu0lUpEA"
      decimals="-3"
      id="Tc_Mjzkq2ymPkCHXIBDkd5Whg_3_9"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">429000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_9_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_b6xXIxG3uUumtk0da2OG_g"
      decimals="0"
      id="Narr_zzCR2o9bgEy-IZQl-h8IAw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">35475</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_35v6GsxU1UWKbvSV7j_l4w"
      id="Tb_7ekptLDg206nXWYIKRVDUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;16&#160;- SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Since December&#160;31, 2023, the Company has collected approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.3&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from expense reimbursements in connection with its collaboration with Chiesi, and approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$4.6&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from sales to Pfizer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In January 2024, the Company granted, with the approval of the Company&#x2019;s compensation committee, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;100,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of restricted Common Stock, in the aggregate, to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of the Company&#x2019;s employees under the Plan. The restricted stock vests over a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; period in &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;12&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$161,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <plx:ProceedsFromExpenseReimbursements
      contextRef="Duration_3_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_IuM681TIWk-KXTzBvFq0cA"
      decimals="-5"
      id="Narr_X2MU_Fn2S0CyZWSQos2Imw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">300000</plx:ProceedsFromExpenseReimbursements>
    <plx:ProceedsFromExpenseReimbursements
      contextRef="Duration_1_1_2024_To_2_29_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_w5_kliyzhkCBaXvHO4GYkA"
      decimals="-5"
      id="Narr_4e80kC6BjUa22rIjWWyBbw"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">300000</plx:ProceedsFromExpenseReimbursements>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_1_1_2024_To_3_14_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_nqKCRd69hEOEP6D4HvRrJQ"
      decimals="-5"
      id="Narr_vfUi2810WEiFNERtKV58YQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">4600000</plx:ProceedsFromSaleOfProducts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A"
      decimals="INF"
      id="Narr_KnmtJ5iwKEauWLVFJfPcWQ"
      unitRef="Unit_Standard_shares_cVWTCR7EtUSuuCI47U_mdw">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A"
      decimals="INF"
      id="Narr_cmFBVxdEHEau5WzQJyxnFw"
      unitRef="Unit_Standard_employee_EpjUeGM08kCkStcWvhYgyg">2</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesReceivingGrantUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A"
      id="Narr_Ow99Bsimi02ZXYS-PrI0Vg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5p_snOVsAkuR8vBzPLJB0A"
      decimals="INF"
      id="Narr_ZpCEy0yQekeE8Duow0KNcA"
      unitRef="Unit_Standard_item_xV9JezTpmEyWleuLBVqPtg">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_1_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y7utRnms1UOqtqZVB3Km0A"
      decimals="0"
      id="Narr_HQyXpq1-Gk-SG4rMlrO9oQ"
      unitRef="Unit_Standard_USD_ttVeExB9RkqdPFKnB_0qdw">161000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
